data_5kvp_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5kvp _Structure_validation_residue.Date_analyzed 2016-10-28 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.603 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.4 Cg_exo . . . . . 0 N--CA 1.484 0.95 0 N-CA-C 113.047 0.364 . . . . 0.0 113.047 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.804 HD13 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.95 -171.96 3.07 Favored 'General case' 0 CA--C 1.508 -0.662 0 CA-C-O 122.509 1.147 . . . . 0.0 110.316 -179.695 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.529 ' H ' HD12 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -127.58 -25.12 3.2 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 112.253 -2.248 . . . . 0.0 108.797 177.267 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.804 ' O ' HD13 ' A' ' 19' ' ' LEU . 7.2 t -168.77 -168.83 0.92 Allowed 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.332 -1.304 . . . . 0.0 111.671 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.66 111.62 0.3 Allowed Glycine 0 C--N 1.32 -0.345 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.633 177.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.48 124.85 8.84 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-O 121.582 0.706 . . . . 0.0 112.578 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.557 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.97 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.476 0 CA-C-N 113.672 -1.604 . . . . 0.0 109.216 179.387 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.8 t -106.64 -27.87 10.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 112.781 -2.009 . . . . 0.0 110.929 178.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.63 -67.41 1.0 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.881 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.06 122.55 1.02 Allowed Glycine 0 N--CA 1.459 0.185 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.28 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.533 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -78.31 157.57 29.14 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -179.073 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 63.7 m-80 -56.94 32.04 0.0 OUTLIER 'General case' 0 C--O 1.24 0.556 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -177.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.676 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.98 1.31 48.66 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -102.18 85.3 0.7 Allowed Pre-proline 0 CA--C 1.545 0.788 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.8 Cg_exo -77.6 139.76 18.34 Favored 'Trans proline' 0 C--N 1.372 1.813 0 C-N-CA 122.81 2.34 . . . . 0.0 113.245 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.24 4.49 81.04 Favored Glycine 0 C--N 1.34 0.762 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.986 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -71.86 129.99 39.96 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.083 0.953 . . . . 0.0 111.089 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.63 6.15 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.351 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.91 -150.01 5.14 Favored Glycine 0 C--N 1.337 0.62 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.52 HG13 ' OH ' ' A' ' 39' ' ' TYR . 8.8 p -131.93 150.12 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.725 0 C-N-CA 122.788 0.435 . . . . 0.0 110.23 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.726 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 84.7 m-20 -126.18 135.28 51.44 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.21 0.528 . . . . 0.0 111.977 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.603 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -126.39 108.11 10.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.541 -178.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.68 104.83 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.264 179.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.63 127.97 6.81 Favored Pre-proline 0 CA--C 1.551 0.989 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.908 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -49.48 141.84 24.76 Favored 'Trans proline' 0 C--N 1.369 1.608 0 C-N-CA 123.385 2.723 . . . . 0.0 115.375 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.494 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.3 140.81 18.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 111.891 -2.413 . . . . 0.0 113.401 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.38 2.62 53.79 Favored Glycine 0 N--CA 1.442 -0.952 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.09 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' THR . . . . . 0.542 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.3 m -85.96 126.12 66.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.028 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.37 126.79 23.11 Favored 'Trans proline' 0 C--N 1.372 1.802 0 C-N-CA 122.226 1.951 . . . . 0.0 113.15 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 107' ' ' ILE . 10.2 t -100.95 122.35 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.848 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.647 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 41.2 mtt180 -101.86 154.06 19.27 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 113.044 -1.889 . . . . 0.0 111.881 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 102' ' ' LYS . . . -73.27 119.62 17.76 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.578 -1.192 . . . . 0.0 110.57 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -65.9 -15.96 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.615 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.44 143.74 1.85 Allowed 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 123.411 0.684 . . . . 0.0 110.403 179.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.415 ' ND2' ' HB1' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.86 155.74 18.93 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.32 179.358 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.627 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.66 -127.17 1.52 Allowed Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.691 -0.686 . . . . 0.0 113.766 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.4 m -148.67 141.09 24.24 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 123.583 0.753 . . . . 0.0 109.875 -178.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 99' ' ' SER . 11.8 t -84.33 112.65 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 C-N-CA 123.78 0.832 . . . . 0.0 109.027 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -95.13 -15.03 23.67 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.684 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -155.85 139.67 16.19 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.766 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.69 92.36 1.99 Allowed 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.227 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -92.14 90.3 1.48 Allowed Glycine 0 C--O 1.24 0.524 0 CA-C-N 114.28 -1.327 . . . . 0.0 111.985 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.564 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.11 121.02 17.52 Favored 'General case' 0 C--N 1.344 0.369 0 O-C-N 124.818 0.952 . . . . 0.0 112.811 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.59 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.47 -0.77 87.8 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-N 113.318 -1.764 . . . . 0.0 113.459 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -33.11 58.01 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.56 22.32 2.71 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.22 -178.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.59 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.52 116.38 58.88 Favored Pre-proline 0 N--CA 1.435 -1.217 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -178.36 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.833 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 38.7 Cg_exo -67.61 162.87 37.3 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 123.577 2.851 . . . . 0.0 111.381 177.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 60.0 m95 -97.64 10.72 39.21 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.87 -44.97 30.0 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.544 -1.207 . . . . 0.0 110.194 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.52 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -120.3 11.42 11.51 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.714 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.833 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.1 m95 -128.66 141.9 51.2 Favored 'General case' 0 C--N 1.361 1.08 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.35 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.5 mmt -144.52 -28.22 0.49 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.202 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.74 -24.62 26.84 Favored 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.391 0.432 . . . . 0.0 112.075 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.624 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.27 -128.27 9.52 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 115.743 -0.662 . . . . 0.0 114.082 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.455 ' HB2' ' O ' ' A' ' 90' ' ' LEU . 8.6 m-80 -84.92 136.68 33.52 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.243 0.617 . . . . 0.0 112.067 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -150.33 147.05 27.14 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.16 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.64 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -140.14 120.63 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.467 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.36 128.21 54.81 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 177.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.5 mt -138.97 150.81 23.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 112.741 -2.027 . . . . 0.0 110.512 -176.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.627 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.3 tt0 -99.67 116.57 32.07 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.348 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.671 ' CD2' ' HG1' ' A' ' 85' ' ' THR . 3.0 m-70 -68.31 -176.09 0.7 Allowed 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.536 -1.211 . . . . 0.0 114.215 -178.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.415 ' HB1' ' ND2' ' A' ' 52' ' ' ASN . . . -66.22 -17.78 64.95 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 114.055 -1.43 . . . . 0.0 114.398 -177.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.52 -9.06 21.37 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.881 0.372 . . . . 0.0 111.067 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.6 -6.68 45.23 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.057 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.526 ' HE3' ' HH ' ' A' ' 145' ' ' TYR . 1.8 ptt? -67.77 168.71 10.92 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 123.469 0.708 . . . . 0.0 111.367 179.067 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 -113.43 145.31 41.36 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.075 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.671 ' HG1' ' CD2' ' A' ' 79' ' ' HIS . 0.0 OUTLIER -140.94 127.28 19.81 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-O 120.973 0.416 . . . . 0.0 110.29 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.64 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.96 154.97 16.9 Favored Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.546 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.433 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.9 m-85 -134.36 99.29 4.33 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 105.361 -2.089 . . . . 0.0 105.361 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.69 166.77 11.05 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 73.3 m80 65.74 41.25 4.0 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-N 114.628 -1.169 . . . . 0.0 111.743 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.507 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 9.3 mt -101.3 166.46 10.75 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.079 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.4 t -101.04 -14.88 17.64 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -168.26 160.47 11.55 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.727 0.775 . . . . 0.0 111.901 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.684 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.3 148.65 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 113.613 -1.631 . . . . 0.0 110.757 178.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 t -112.42 -5.96 14.05 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 114.517 -1.219 . . . . 0.0 110.071 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.684 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -104.44 -175.23 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.983 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.512 -177.134 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.2 m -155.46 144.07 20.43 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.009 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.534 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 4.2 m -55.23 129.22 37.47 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.62 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.43 -5.18 0.74 Allowed 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.63 1.172 . . . . 0.0 112.026 179.314 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.45 ' O ' HG22 ' A' ' 55' ' ' VAL . 29.6 m -81.3 148.8 29.24 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.51 145.63 28.01 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.425 178.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.49 167.69 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.248 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.36 -179.216 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.404 ' O ' ' HB1' ' A' ' 49' ' ' ALA . 43.9 tttm -140.36 147.39 39.72 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.821 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.757 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.23 137.93 55.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.226 -1.352 . . . . 0.0 111.483 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.647 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.8 -4.43 52.48 Favored Glycine 0 CA--C 1.517 0.175 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.078 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.9 tt0 -74.36 139.0 43.81 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.183 0.516 . . . . 0.0 110.004 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 54.5 mt -71.35 101.53 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.118 0 CA-C-N 114.717 -1.128 . . . . 0.0 109.512 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.44 -4.74 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.149 -178.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.92 -160.82 34.6 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 112.302 -0.319 . . . . 0.0 112.302 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.507 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 30.3 m-85 -139.45 139.1 36.95 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 124.478 1.111 . . . . 0.0 108.327 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.542 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -60.37 152.57 24.99 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.472 0.709 . . . . 0.0 112.117 -179.136 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.494 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -158.06 -163.33 12.62 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.961 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.33 48.16 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 114.632 -0.784 . . . . 0.0 109.074 178.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.624 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 33.6 p . . . . . 0 CA--C 1.54 0.564 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.9 0 CA-C-O 118.832 -0.982 . . . . 0.0 111.808 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.55 144.67 45.4 Favored 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.593 2.196 . . . . 0.0 112.098 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -160.77 -172.99 3.71 Favored 'General case' 0 C--N 1.349 0.565 0 CA-C-O 121.515 0.674 . . . . 0.0 111.636 179.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.726 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.8 tp -125.51 136.25 53.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.779 -178.395 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.446 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 31.8 t60 -116.36 122.96 46.4 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.43 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -127.25 107.57 10.11 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.264 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' THR . 13.4 pt-20 -115.33 127.37 55.38 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.548 178.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.452 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.4 tpt -121.17 136.73 54.92 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.726 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.612 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -142.26 164.99 30.06 Favored Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 113.394 -1.73 . . . . 0.0 110.381 -178.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -64.09 -178.43 0.61 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.994 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.16 -27.26 62.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.004 176.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.34 102.54 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.784 0 CA-C-N 114.09 -1.414 . . . . 0.0 108.869 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.26 163.18 39.45 Favored 'Trans proline' 0 N--CA 1.445 -1.349 0 C-N-CA 122.671 2.248 . . . . 0.0 116.937 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.586 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.96 70.76 0.81 Allowed 'General case' 0 N--CA 1.425 -1.702 0 CA-C-N 112.229 -2.26 . . . . 0.0 107.392 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.45 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -62.9 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 114.291 -1.322 . . . . 0.0 112.435 -178.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.586 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 33.72 0.38 Allowed 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 124.209 1.003 . . . . 0.0 112.783 -178.487 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 11.0 m-80 71.95 128.2 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.627 0 C-N-CA 125.571 1.548 . . . . 0.0 110.666 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.33 -48.49 0.6 Allowed Glycine 0 N--CA 1.438 -1.178 0 CA-C-N 115.104 -0.953 . . . . 0.0 113.068 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.78 -19.58 0.22 Allowed 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 37.9 m 65.67 18.01 11.07 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-O 122.778 1.275 . . . . 0.0 108.108 -178.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.612 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 78.26 -11.57 23.05 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 112.237 -2.256 . . . . 0.0 112.47 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 125' ' ' MET . 0.4 OUTLIER -85.07 124.43 31.75 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 112.056 -179.24 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.441 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -127.19 -172.87 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . 0.441 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.8 m-20 -72.47 131.8 84.35 Favored Pre-proline 0 CA--C 1.547 0.844 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -176.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.605 ' O ' HG12 ' A' ' 146' ' ' ILE . 4.5 Cg_exo -77.58 -1.63 11.8 Favored 'Trans proline' 0 C--N 1.379 2.148 0 C-N-CA 123.265 2.643 . . . . 0.0 113.492 177.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.1 p -51.48 -24.25 4.89 Favored 'General case' 0 C--N 1.349 0.58 0 N-CA-C 114.134 1.161 . . . . 0.0 114.134 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.94 -24.56 75.75 Favored Glycine 0 CA--C 1.521 0.431 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.927 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . 0.526 ' HH ' ' HE3' ' A' ' 83' ' ' MET . 4.3 m-85 -103.56 -10.33 18.55 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 123.465 0.706 . . . . 0.0 111.343 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.605 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -99.81 -10.96 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.454 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.247 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.699 178.028 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.685 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.6 Cg_exo . . . . . 0 N--CA 1.479 0.626 0 N-CA-C 112.667 0.218 . . . . 0.0 112.667 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.804 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.77 -171.92 3.04 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.699 1.238 . . . . 0.0 110.335 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.528 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.26 -24.78 2.8 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 112.082 -2.326 . . . . 0.0 108.625 177.292 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.804 ' O ' HD12 ' A' ' 19' ' ' LEU . 9.3 t -168.21 -168.94 1.01 Allowed 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.162 -178.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.26 112.25 0.28 Allowed Glycine 0 C--N 1.32 -0.342 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.036 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.21 125.49 9.38 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 113.328 0.862 . . . . 0.0 113.328 -177.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.593 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.56 58.31 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.455 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.066 179.197 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.6 t -102.7 -28.13 12.3 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 112.89 -1.959 . . . . 0.0 110.829 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -115.14 -67.2 1.01 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.606 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.3 123.18 1.06 Allowed Glycine 0 C--O 1.235 0.196 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.371 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.534 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -75.11 157.44 34.7 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -55.7 31.92 0.0 OUTLIER 'General case' 0 C--O 1.241 0.618 0 N-CA-C 115.816 1.784 . . . . 0.0 115.816 -177.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.697 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 0.09 48.93 Favored Glycine 0 CA--C 1.505 -0.551 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -101.72 85.43 0.66 Allowed Pre-proline 0 CA--C 1.545 0.763 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.697 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.7 Cg_exo -77.03 138.88 18.72 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.655 2.236 . . . . 0.0 113.239 -178.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.77 4.11 70.14 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-N 115.873 -0.603 . . . . 0.0 113.12 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.471 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.4 t-80 -75.51 128.41 35.24 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 123.927 0.891 . . . . 0.0 110.743 -179.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -99.74 -14.14 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.239 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -126.04 -150.28 7.6 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.369 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.479 HG12 ' OH ' ' A' ' 39' ' ' TYR . 7.2 p -128.71 151.86 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-N 115.025 -0.588 . . . . 0.0 109.775 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.639 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -125.39 130.64 52.31 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.263 0.554 . . . . 0.0 112.409 -178.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.685 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.7 m-85 -122.89 109.78 14.59 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.102 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.92 104.93 0.41 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.243 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.45 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.0 p -145.55 124.43 6.66 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.01 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -48.95 141.79 21.13 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.386 2.724 . . . . 0.0 115.528 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.5 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 3.1 p -61.62 141.11 18.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 111.935 -2.393 . . . . 0.0 113.473 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.02 2.49 55.99 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.393 -0.821 . . . . 0.0 114.253 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' THR . . . . . 0.415 ' HB ' ' HG1' ' A' ' 110' ' ' THR . 1.7 m -88.98 126.22 59.88 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-O 119.066 -0.492 . . . . 0.0 109.808 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.14 126.67 23.14 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.209 1.939 . . . . 0.0 113.074 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 107' ' ' ILE . 4.3 t -98.28 121.51 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.083 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.64 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.9 mtp180 -102.02 151.23 22.39 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 113.088 -1.869 . . . . 0.0 111.584 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.76 122.02 19.08 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.232 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.2 t -69.08 -14.16 18.17 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.592 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.55 144.17 1.86 Allowed 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 123.447 0.699 . . . . 0.0 110.603 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.59 156.86 22.05 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.835 -1.075 . . . . 0.0 112.386 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.617 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.32 -128.14 1.68 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.725 -0.67 . . . . 0.0 113.652 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 11.9 m -148.24 140.89 24.52 Favored 'General case' 0 N--CA 1.439 -0.975 0 C-N-CA 123.759 0.824 . . . . 0.0 109.668 -178.116 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.44 HG21 ' O ' ' A' ' 99' ' ' SER . 12.1 t -83.78 112.58 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 123.721 0.809 . . . . 0.0 109.034 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.407 ' HD3' ' O ' ' A' ' 54' ' ' THR . 6.6 mmmt -95.09 -14.72 23.99 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.844 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -156.09 141.8 17.89 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.01 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.24 92.22 2.16 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.406 -1.27 . . . . 0.0 109.074 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.447 ' O ' HD11 ' A' ' 93' ' ' ILE . . . -92.02 89.98 1.46 Allowed Glycine 0 C--O 1.239 0.447 0 CA-C-N 113.955 -1.475 . . . . 0.0 112.862 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.564 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -70.41 122.97 20.63 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.925 0.89 . . . . 0.0 112.866 -179.689 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.572 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.93 -0.59 88.8 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-N 113.253 -1.794 . . . . 0.0 113.626 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.54 -33.2 54.25 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -138.44 30.18 2.39 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.467 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.572 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.66 111.83 24.33 Favored Pre-proline 0 N--CA 1.437 -1.091 0 N-CA-C 113.907 1.077 . . . . 0.0 113.907 -178.265 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 35.4 Cg_exo -68.71 162.62 40.38 Favored 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.738 2.958 . . . . 0.0 111.563 177.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -96.74 9.76 40.75 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 175.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 61.2 mtm -76.91 -43.56 35.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.342 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.533 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.8 11.24 11.1 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.857 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.1 151.24 50.0 Favored 'General case' 0 C--N 1.361 1.089 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.738 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 36.2 mtt -145.68 -36.88 0.27 Allowed 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.621 179.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -86.43 -23.46 26.05 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.45 0.469 . . . . 0.0 111.881 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.598 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.25 -118.65 6.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.69 -0.686 . . . . 0.0 114.045 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.58 ' H ' ' HG1' ' A' ' 113' ' ' THR . 7.3 m-80 -82.57 135.64 35.03 Favored 'General case' 0 C--O 1.236 0.384 0 C-N-CA 123.225 0.61 . . . . 0.0 112.49 -178.532 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.01 146.56 26.3 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.983 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.608 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -139.2 121.02 16.48 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.205 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.2 130.73 56.99 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.333 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' THR . 9.1 mt -141.01 151.02 20.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 112.587 -2.097 . . . . 0.0 110.206 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.617 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.2 tt0 -99.83 117.14 33.51 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 114.123 -1.399 . . . . 0.0 108.547 178.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.592 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 3.9 m-70 -69.99 -177.93 1.46 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.535 -1.211 . . . . 0.0 114.07 -179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.57 -17.46 64.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 113.791 -1.55 . . . . 0.0 113.752 -178.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -97.58 -13.27 21.7 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 123.38 0.425 . . . . 0.0 110.749 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.51 -5.98 44.89 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.811 179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.553 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 16.5 ptp -70.65 165.53 22.68 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 122.866 0.466 . . . . 0.0 111.416 179.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -109.09 140.02 43.2 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.719 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.554 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -135.82 127.1 28.3 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-O 121.033 0.444 . . . . 0.0 110.391 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.608 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -103.85 155.31 17.74 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 114.839 -1.073 . . . . 0.0 111.63 178.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.548 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 6.4 m-85 -132.11 99.24 4.65 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.79 167.54 10.41 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 65.62 41.49 4.02 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.591 -178.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.541 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.6 mt -101.4 170.36 8.27 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.822 177.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.2 t -105.27 -15.67 14.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 122.952 0.157 . . . . 0.0 111.37 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -168.95 160.44 10.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.658 0.742 . . . . 0.0 111.85 -178.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.607 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.37 149.64 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.638 -1.619 . . . . 0.0 110.949 179.329 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.91 -5.38 13.21 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.247 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.607 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -107.22 -175.42 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.387 -176.921 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.6 m -154.31 144.54 22.04 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.908 -1.042 . . . . 0.0 109.101 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.63 128.9 36.87 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.741 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 87.47 -4.97 0.61 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.778 1.231 . . . . 0.0 111.837 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.44 ' O ' HG21 ' A' ' 55' ' ' VAL . 8.7 t -81.67 148.13 29.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 110.44 -0.208 . . . . 0.0 110.44 178.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -83.9 145.85 28.37 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.385 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.82 168.38 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.449 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -142.18 148.55 38.4 Favored 'General case' 0 N--CA 1.427 -1.61 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.872 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.75 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.6 138.52 55.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.305 -179.771 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.64 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.78 -4.6 51.7 Favored Glycine 0 CA--C 1.516 0.117 0 CA-C-N 114.431 -1.259 . . . . 0.0 114.166 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.476 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -75.33 140.67 43.23 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.086 0.469 . . . . 0.0 109.933 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.36 100.86 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.586 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.476 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.7 -5.4 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 113.706 -1.588 . . . . 0.0 113.257 -178.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 -159.83 32.69 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 121.515 -0.374 . . . . 0.0 112.427 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.541 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 33.9 m-85 -140.37 138.48 34.85 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.572 1.149 . . . . 0.0 108.378 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.415 ' HG1' ' HB ' ' A' ' 45' ' ' THR . 0.7 OUTLIER -62.65 150.09 41.76 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.659 0.784 . . . . 0.0 112.46 -178.821 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.5 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -157.35 -164.95 14.33 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 119.884 -1.151 . . . . 0.0 114.153 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.3 52.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 178.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.598 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 38.8 p . . . . . 0 CA--C 1.54 0.565 0 CA-C-N 115.248 -0.887 . . . . 0.0 113.355 -177.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.976 0 CA-C-O 119.395 -0.669 . . . . 0.0 113.252 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.43 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 6.0 Cg_exo -79.42 146.77 19.69 Favored 'Trans proline' 0 C--N 1.373 1.854 0 C-N-CA 123.291 2.661 . . . . 0.0 112.529 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.45 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 38.1 p-80 -160.72 -166.69 1.67 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.528 0.68 . . . . 0.0 111.851 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.639 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 15.9 tp -129.47 137.92 51.12 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.064 -1.425 . . . . 0.0 110.313 -178.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 23.9 t60 -121.59 114.93 21.88 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.284 -1.326 . . . . 0.0 110.184 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -119.01 107.79 13.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.182 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.554 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.0 pt-20 -112.82 127.52 56.19 Favored 'General case' 0 N--CA 1.432 -1.327 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.57 179.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.44 ' HE3' ' SD ' ' A' ' 83' ' ' MET . 6.7 ttt -122.76 134.51 54.44 Favored 'General case' 0 N--CA 1.434 -1.255 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.152 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.608 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -141.69 164.73 32.73 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 113.271 -1.786 . . . . 0.0 110.113 -177.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -63.16 -178.57 0.45 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 122.889 2.393 . . . . 0.0 113.277 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -69.09 -28.92 66.93 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.975 176.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.429 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.0 OUTLIER -157.84 103.45 1.77 Allowed Pre-proline 0 CA--C 1.503 -0.841 0 CA-C-N 114.008 -1.451 . . . . 0.0 108.798 179.798 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 4.0 Cg_exo -72.03 163.22 39.46 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.612 2.208 . . . . 0.0 116.971 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.583 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.5 69.62 0.77 Allowed 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 112.332 -2.213 . . . . 0.0 107.581 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.19 12.3 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 114.319 -1.31 . . . . 0.0 112.412 -178.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.583 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 33.15 0.37 Allowed 'General case' 0 N--CA 1.444 -0.77 0 C-N-CA 124.306 1.043 . . . . 0.0 112.811 -178.462 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 73.11 128.79 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 113.729 -1.578 . . . . 0.0 110.745 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.26 -48.41 0.6 Allowed Glycine 0 N--CA 1.439 -1.135 0 CA-C-N 114.971 -1.013 . . . . 0.0 112.964 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.582 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -152.21 -18.96 0.18 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 179.161 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.8 m 66.12 17.74 10.83 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 122.59 1.186 . . . . 0.0 108.224 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.608 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.3 -11.32 9.0 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 112.547 -2.115 . . . . 0.0 112.673 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.582 ' HG3' ' O ' ' A' ' 136' ' ' PHE . 0.0 OUTLIER -79.64 121.7 25.61 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 111.737 0.273 . . . . 0.0 111.737 -179.012 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.93 -172.93 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.441 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -79.34 128.64 74.86 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.641 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.7 Cg_exo -76.76 -3.21 13.52 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 122.934 2.423 . . . . 0.0 113.445 178.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.86 -23.49 2.84 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.69 -30.25 70.79 Favored Glycine 0 N--CA 1.461 0.342 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.472 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -104.24 -11.35 17.27 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 122.902 0.481 . . . . 0.0 111.685 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.641 HG12 ' O ' ' A' ' 142' ' ' PRO . 18.8 mm -96.34 -8.79 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.815 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.279 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.173 177.592 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.642 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.0 Cg_exo . . . . . 0 N--CA 1.482 0.829 0 CA-C-O 120.825 0.261 . . . . 0.0 112.607 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.83 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.47 -171.95 2.89 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-O 122.402 1.096 . . . . 0.0 109.961 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.503 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.99 -25.41 3.04 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 112.452 -2.158 . . . . 0.0 108.532 177.091 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.83 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.5 t -169.39 -168.84 0.85 Allowed 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.593 -178.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.92 110.77 0.29 Allowed Glycine 0 C--N 1.317 -0.487 0 CA-C-N 114.513 -1.221 . . . . 0.0 111.171 176.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.16 124.84 8.4 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 112.829 0.677 . . . . 0.0 112.829 -178.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.524 HD11 ' H ' ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.99 58.58 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.995 -1.457 . . . . 0.0 109.097 178.551 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.3 t -104.54 -28.05 11.52 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 112.729 -2.032 . . . . 0.0 111.123 179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -116.19 -66.7 1.06 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.648 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.29 122.98 1.04 Allowed Glycine 0 N--CA 1.459 0.201 0 CA-C-N 115.011 -0.995 . . . . 0.0 112.011 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.522 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -73.49 157.26 37.12 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -178.504 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -57.86 31.89 0.0 OUTLIER 'General case' 0 C--O 1.239 0.538 0 N-CA-C 115.821 1.786 . . . . 0.0 115.821 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.678 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -1.66 48.83 Favored Glycine 0 CA--C 1.504 -0.634 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.94 85.31 0.67 Allowed Pre-proline 0 CA--C 1.548 0.866 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.678 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.6 Cg_exo -77.97 139.2 17.14 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 122.823 2.349 . . . . 0.0 113.352 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.14 4.17 69.1 Favored Glycine 0 C--N 1.339 0.727 0 O-C-N 123.685 0.615 . . . . 0.0 112.997 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.437 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.0 t-80 -78.24 135.43 37.57 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.047 0.939 . . . . 0.0 110.497 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.439 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.32 -12.53 9.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.242 -179.35 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -125.87 -149.77 7.51 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.431 HG13 ' OH ' ' A' ' 39' ' ' TYR . 14.4 p -129.82 152.88 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 O-C-N 123.892 0.407 . . . . 0.0 110.133 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.697 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 93.1 m-20 -129.32 131.97 47.03 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.24 0.543 . . . . 0.0 112.242 -178.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.642 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.5 m-85 -122.86 109.48 14.23 Favored 'General case' 0 C--O 1.238 0.5 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.165 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.86 104.26 0.18 Allowed 'General case' 0 CA--C 1.541 0.633 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.339 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.462 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.4 p -144.84 123.91 6.9 Favored Pre-proline 0 CA--C 1.549 0.934 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.855 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -49.02 142.7 19.54 Favored 'Trans proline' 0 C--N 1.371 1.737 0 C-N-CA 123.307 2.671 . . . . 0.0 115.423 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.462 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.09 141.01 17.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 111.582 -2.554 . . . . 0.0 113.619 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.53 2.73 55.45 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.552 -0.749 . . . . 0.0 114.341 177.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' THR . . . . . 0.502 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.1 m -88.01 123.46 68.78 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-O 119.146 -0.454 . . . . 0.0 109.932 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.24 127.11 24.9 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.328 2.019 . . . . 0.0 113.449 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.495 ' O ' HG13 ' A' ' 107' ' ' ILE . 4.8 t -99.68 121.82 50.79 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.138 179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.504 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 2.3 mpt_? -103.19 152.49 21.4 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 113.331 -1.759 . . . . 0.0 111.481 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 102' ' ' LYS . . . -71.69 121.46 18.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.441 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.03 -15.64 19.96 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 112.775 0.658 . . . . 0.0 112.775 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.582 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.46 144.46 1.94 Allowed 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 123.462 0.705 . . . . 0.0 110.346 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.78 157.07 18.85 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 115.077 -0.965 . . . . 0.0 112.331 179.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.638 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.01 -127.15 1.54 Allowed Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.744 -0.662 . . . . 0.0 113.849 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.9 m -148.09 141.3 25.08 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 123.678 0.791 . . . . 0.0 109.683 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.452 HG21 ' O ' ' A' ' 99' ' ' SER . 11.3 t -83.49 111.66 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 123.719 0.808 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.7 mmmt -94.35 -15.72 24.13 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.726 -1.125 . . . . 0.0 110.643 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -153.9 140.01 18.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.041 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.53 92.33 2.15 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.906 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.494 ' O ' HD12 ' A' ' 93' ' ' ILE . . . -95.05 89.87 1.23 Allowed Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.953 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.566 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.46 125.54 27.66 Favored 'General case' 0 C--N 1.346 0.418 0 C-N-CA 123.795 0.838 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.651 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -79.93 -0.66 85.94 Favored Glycine 0 CA--C 1.52 0.392 0 CA-C-N 113.354 -1.748 . . . . 0.0 113.389 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.11 -32.05 39.1 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 24.86 2.68 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.144 -178.392 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.651 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -79.45 113.88 40.59 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.418 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.813 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.4 Cg_exo -67.69 163.23 36.01 Favored 'Trans proline' 0 C--N 1.37 1.688 0 C-N-CA 123.729 2.953 . . . . 0.0 111.556 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 62.1 m95 -98.2 10.54 40.33 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 14.7 mmt -75.58 -44.55 42.6 Favored 'General case' 0 C--N 1.349 0.552 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.057 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.542 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -120.92 11.51 11.07 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.783 177.439 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.813 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.05 145.92 51.14 Favored 'General case' 0 C--N 1.359 1.005 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.701 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.9 tpt -145.56 -31.02 0.4 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.488 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.78 -23.44 24.08 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.542 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 101.71 -128.68 9.64 Favored Glycine 0 CA--C 1.522 0.48 0 O-C-N 123.543 0.527 . . . . 0.0 114.025 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.797 ' H ' ' HG1' ' A' ' 113' ' ' THR . 11.8 m-80 -78.8 138.84 38.39 Favored 'General case' 0 C--N 1.347 0.458 0 C-N-CA 123.381 0.672 . . . . 0.0 112.586 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.33 145.23 23.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.008 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.593 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.1 t -138.55 120.58 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.158 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.03 131.22 56.99 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.412 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 9.3 mt -141.02 150.91 20.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 112.695 -2.048 . . . . 0.0 110.2 -176.62 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.638 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.5 tt0 -97.72 116.49 30.03 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 113.984 -1.462 . . . . 0.0 108.294 178.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.582 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 2.2 m-70 -69.17 -175.85 0.82 Allowed 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.561 -1.199 . . . . 0.0 114.159 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -64.97 -17.78 64.69 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 113.867 -1.515 . . . . 0.0 114.485 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.79 -9.86 20.43 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-O 120.826 0.346 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.78 -6.09 43.92 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.061 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.4 ptt? -68.92 168.4 13.7 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 123.712 0.805 . . . . 0.0 111.456 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.419 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 55.6 m-70 -112.55 142.7 44.81 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.024 -179.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.26 127.06 25.54 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-O 121.041 0.448 . . . . 0.0 110.022 179.706 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.593 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.49 154.59 17.1 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.629 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.1 m-85 -135.1 99.17 4.19 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.11 168.8 9.5 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 65.28 41.86 4.2 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 124.159 0.984 . . . . 0.0 111.44 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.528 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.0 mt -102.94 169.41 8.6 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.037 178.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.4 t -103.88 -16.47 15.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -167.32 162.37 14.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.801 0.81 . . . . 0.0 112.018 -178.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.663 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.9 OUTLIER -127.83 147.82 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.643 179.298 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -110.47 -6.8 14.84 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 114.402 -1.272 . . . . 0.0 109.899 178.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.663 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.73 -175.12 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.073 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.733 -176.89 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 6.9 t -154.18 148.44 25.95 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.79 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 m -58.5 128.98 39.88 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.622 -179.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 t70 86.96 -5.71 0.67 Allowed 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 124.634 1.174 . . . . 0.0 111.722 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.452 ' O ' HG21 ' A' ' 55' ' ' VAL . 31.7 m -79.82 149.63 30.96 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 122.272 0.229 . . . . 0.0 110.711 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -84.94 145.0 27.98 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.382 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.01 168.14 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.437 -179.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.407 ' O ' ' HB2' ' A' ' 49' ' ' ALA . 42.9 tttm -140.5 149.58 42.66 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.844 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.754 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.17 138.59 56.07 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.383 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.504 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.64 -4.55 50.82 Favored Glycine 0 CA--C 1.517 0.185 0 CA-C-N 114.387 -1.278 . . . . 0.0 114.076 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.459 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.0 tt0 -75.2 140.57 43.38 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-O 121.086 0.47 . . . . 0.0 110.026 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 52.4 mt -72.11 101.46 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.64 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.59 -5.01 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-N 113.512 -1.676 . . . . 0.0 113.17 -178.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.65 -161.9 35.64 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.363 0.424 . . . . 0.0 112.571 178.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.528 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.2 m-85 -139.88 138.06 35.37 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 124.561 1.144 . . . . 0.0 108.339 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.502 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.6 OUTLIER -62.3 150.53 39.05 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 123.913 0.758 . . . . 0.0 112.572 -178.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.471 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -160.23 -161.54 11.51 Favored Glycine 0 C--N 1.348 1.232 0 C-N-CA 119.844 -1.17 . . . . 0.0 114.119 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.1 50.78 0.91 Allowed 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.632 -0.784 . . . . 0.0 108.99 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.797 ' HG1' ' H ' ' A' ' 73' ' ' ASN . 32.6 p . . . . . 0 CA--C 1.54 0.582 0 CA-C-N 115.137 -0.938 . . . . 0.0 113.094 -177.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.12 0 CA-C-O 119.352 -0.693 . . . . 0.0 113.351 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -77.71 145.67 23.18 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 123.111 2.54 . . . . 0.0 112.414 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.462 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 47.6 p-80 -159.71 -164.91 1.41 Allowed 'General case' 0 C--N 1.351 0.667 0 CA-C-O 121.68 0.753 . . . . 0.0 112.259 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.697 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 16.9 tp -129.7 133.41 47.04 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.433 -178.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.413 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 18.4 t60 -118.18 113.39 21.46 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.288 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -119.04 108.94 15.34 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.303 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 85' ' ' THR . 20.3 tt0 -117.3 127.15 53.79 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.197 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.413 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 1.9 tpt -118.13 139.81 50.7 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.646 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.546 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -143.98 165.46 24.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 CA-C-N 113.426 -1.715 . . . . 0.0 110.619 -177.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.419 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 14.1 Cg_endo -63.62 -178.68 0.55 Allowed 'Trans proline' 0 C--N 1.37 1.67 0 C-N-CA 122.842 2.361 . . . . 0.0 112.948 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.16 -27.33 63.47 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.085 176.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.411 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 0.7 OUTLIER -157.44 101.95 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.77 0 CA-C-N 114.03 -1.441 . . . . 0.0 108.871 179.786 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 3.0 Cg_exo -71.71 163.39 39.07 Favored 'Trans proline' 0 N--CA 1.446 -1.314 0 C-N-CA 122.711 2.274 . . . . 0.0 116.874 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.585 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -117.23 70.33 0.78 Allowed 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 112.532 -2.122 . . . . 0.0 107.649 177.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.448 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.25 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 114.298 -1.319 . . . . 0.0 112.54 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.585 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.63 33.35 0.36 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.122 0.969 . . . . 0.0 112.996 -178.15 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 73.26 127.46 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.583 0 C-N-CA 125.663 1.585 . . . . 0.0 110.598 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.31 -50.04 0.56 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.343 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.45 -18.92 0.24 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 179.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 39.5 m 66.01 17.74 10.87 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 122.473 1.13 . . . . 0.0 108.157 -178.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.546 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.07 -9.63 18.11 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 112.6 -2.091 . . . . 0.0 112.734 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.536 ' HD2' ' O ' ' A' ' 139' ' ' ARG . 3.2 ppt_? -82.9 127.35 33.42 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 119.854 -0.738 . . . . 0.0 112.362 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.427 HG23 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -128.07 -173.14 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.629 179.179 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . 0.427 ' H ' HG23 ' A' ' 140' ' ' ILE . 1.4 m-20 -73.28 129.8 85.4 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.571 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.3 0.22 9.96 Favored 'Trans proline' 0 C--N 1.38 2.226 0 C-N-CA 122.954 2.436 . . . . 0.0 113.341 177.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.411 ' H ' ' HG1' ' A' ' 143' ' ' THR . 0.8 OUTLIER -52.31 -23.78 6.39 Favored 'General case' 0 C--N 1.349 0.548 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.22 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.86 -25.59 74.56 Favored Glycine 0 CA--C 1.52 0.362 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.92 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -101.99 -11.67 18.75 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 123.248 0.619 . . . . 0.0 111.16 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.571 HG12 ' O ' ' A' ' 142' ' ' PRO . 20.8 mm -100.16 -9.76 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.286 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.739 178.095 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.651 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 20.1 Cg_exo . . . . . 0 N--CA 1.482 0.81 0 CA-C-O 120.742 0.226 . . . . 0.0 112.344 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.803 HD11 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -138.72 -171.97 3.2 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.482 1.134 . . . . 0.0 110.104 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.524 ' H ' HD13 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.69 -25.25 3.15 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 112.332 -2.213 . . . . 0.0 108.699 177.237 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.803 ' O ' HD11 ' A' ' 19' ' ' LEU . 8.5 t -168.99 -168.64 0.87 Allowed 'General case' 0 CA--C 1.546 0.808 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.525 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 177.4 111.18 0.29 Allowed Glycine 0 C--N 1.321 -0.281 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.483 177.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.57 124.41 8.56 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.472 0.653 . . . . 0.0 112.632 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.502 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.11 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.502 0 CA-C-N 113.949 -1.478 . . . . 0.0 109.255 178.79 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.9 t -106.46 -27.68 10.77 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 113.134 -1.848 . . . . 0.0 110.873 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.2 -67.26 1.01 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.721 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.51 123.94 1.14 Allowed Glycine 0 C--O 1.234 0.151 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.14 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.529 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -76.94 157.5 31.26 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.641 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -58.02 31.67 0.0 OUTLIER 'General case' 0 C--O 1.24 0.558 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -177.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.685 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 -0.88 48.61 Favored Glycine 0 CA--C 1.506 -0.484 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -101.6 85.55 0.67 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.685 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.07 137.89 15.86 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.807 2.338 . . . . 0.0 113.225 -178.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.41 4.07 71.29 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.149 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-80 -76.12 135.12 39.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.975 0.91 . . . . 0.0 110.37 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.559 HG11 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.68 -16.35 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.342 -179.021 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.54 -149.71 8.14 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.444 HG11 ' OH ' ' A' ' 39' ' ' TYR . 10.6 p -131.33 151.03 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 124.031 0.489 . . . . 0.0 110.042 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.688 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 89.1 m-20 -125.96 134.19 51.59 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.323 0.582 . . . . 0.0 112.046 -178.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.651 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -124.71 110.07 13.91 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 114.244 -1.344 . . . . 0.0 110.251 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.49 104.64 0.23 Allowed 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.544 178.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.469 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 12.5 p -145.98 124.78 6.53 Favored Pre-proline 0 CA--C 1.551 0.996 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.887 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.01 142.02 20.94 Favored 'Trans proline' 0 C--N 1.37 1.694 0 C-N-CA 123.346 2.697 . . . . 0.0 115.261 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.456 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -61.39 140.15 19.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 111.848 -2.433 . . . . 0.0 113.615 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.64 54.61 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.418 -0.81 . . . . 0.0 114.36 177.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' THR . . . . . 0.45 ' HB ' ' HG1' ' A' ' 110' ' ' THR . 1.9 m -87.32 125.37 65.99 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.257 -0.401 . . . . 0.0 109.952 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.34 127.69 26.57 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.291 1.994 . . . . 0.0 113.468 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 107' ' ' ILE . 9.8 t -99.96 123.36 52.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.154 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.643 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 13.6 mtp180 -101.91 152.15 21.26 Favored 'General case' 0 N--CA 1.433 -1.302 0 CA-C-N 112.963 -1.926 . . . . 0.0 111.659 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.48 120.96 18.82 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.846 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.1 t -66.68 -15.78 19.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.881 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.626 ' HB2' ' CE1' ' A' ' 79' ' ' HIS . . . -171.82 143.59 1.67 Allowed 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.546 0.738 . . . . 0.0 110.355 179.111 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.36 155.42 18.04 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.234 -0.894 . . . . 0.0 112.206 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.622 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 170.32 -128.63 1.67 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.891 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 m -148.16 136.35 21.24 Favored 'General case' 0 N--CA 1.44 -0.968 0 C-N-CA 123.446 0.698 . . . . 0.0 110.33 -178.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.433 HG22 ' O ' ' A' ' 99' ' ' SER . 11.1 t -83.89 112.44 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.697 ' HZ1' ' HB2' ' A' ' 78' ' ' GLN . 0.2 OUTLIER -98.09 -16.63 19.48 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.841 179.846 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -148.54 138.52 22.33 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.737 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.9 92.17 2.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.494 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -93.17 89.85 1.37 Allowed Glycine 0 C--O 1.24 0.478 0 CA-C-N 114.128 -1.396 . . . . 0.0 112.802 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.558 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.56 125.71 27.77 Favored 'General case' 0 C--N 1.345 0.395 0 C-N-CA 123.964 0.905 . . . . 0.0 112.517 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.639 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.26 -0.74 87.12 Favored Glycine 0 CA--C 1.52 0.349 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.375 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.69 -31.85 52.69 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.45 25.51 2.65 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.069 -178.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.639 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -80.6 112.93 35.62 Favored Pre-proline 0 N--CA 1.435 -1.2 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.16 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.836 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.0 Cg_exo -67.81 163.45 35.36 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.987 3.125 . . . . 0.0 111.821 177.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.0 m95 -96.79 8.82 43.44 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -75.2 -44.48 46.21 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.398 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.536 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.84 10.9 11.01 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.714 177.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.836 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -128.83 145.92 51.07 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.537 -178.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 32.8 mtt -146.19 -29.18 0.41 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.421 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.44 -24.79 24.05 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.677 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.616 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.6 -123.98 8.09 Favored Glycine 0 CA--C 1.519 0.315 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.753 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.505 HD22 ' HA3' ' A' ' 61' ' ' GLY . 17.2 m-80 -81.17 138.21 35.87 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 123.237 0.615 . . . . 0.0 111.95 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.55 148.16 27.67 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.343 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.607 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.4 t -140.23 122.13 15.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.065 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.34 127.6 53.85 Favored 'General case' 0 CA--C 1.494 -1.188 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.19 150.96 22.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 112.548 -2.115 . . . . 0.0 110.404 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.697 ' HB2' ' HZ1' ' A' ' 56' ' ' LYS . 1.4 tt0 -99.3 117.04 32.88 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.944 -1.48 . . . . 0.0 108.603 178.011 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.626 ' CE1' ' HB2' ' A' ' 51' ' ' ALA . 2.0 m-70 -67.27 -176.37 0.56 Allowed 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.48 -17.67 64.93 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 114.107 -1.406 . . . . 0.0 114.313 -177.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.72 -10.19 21.07 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.905 0.383 . . . . 0.0 110.956 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.76 -4.78 42.75 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.192 179.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.448 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.7 ptt? -69.04 171.1 8.68 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 123.512 0.725 . . . . 0.0 111.683 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.3 m170 -108.96 147.04 32.86 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.011 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -141.5 126.63 18.45 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.947 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.607 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -108.96 154.57 16.43 Favored Glycine 0 N--CA 1.439 -1.146 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.401 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.469 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.1 m-85 -136.77 99.35 4.02 Favored 'General case' 0 N--CA 1.437 -1.075 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.453 ' HB2' ' CG ' ' A' ' 122' ' ' HIS . . . -113.32 167.93 10.16 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 38.7 m80 65.75 40.69 4.22 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.779 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.514 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 12.1 mt -100.93 169.98 8.6 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.76 177.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.5 t -106.38 -15.51 14.8 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 111.457 0.169 . . . . 0.0 111.457 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 6.8 tttt -167.95 156.87 9.4 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.618 0.723 . . . . 0.0 111.99 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.665 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -120.84 148.83 23.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 113.844 -1.526 . . . . 0.0 110.72 178.917 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -112.01 -5.98 14.24 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.209 178.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.665 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.67 -175.1 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.088 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.683 -177.067 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.4 m -153.33 143.94 22.61 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 114.867 -1.061 . . . . 0.0 109.002 -178.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -56.47 126.61 27.26 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.184 -0.917 . . . . 0.0 111.785 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 t70 89.15 -4.77 0.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 124.807 1.243 . . . . 0.0 111.587 178.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' HG22 ' A' ' 55' ' ' VAL . 50.7 m -81.7 146.05 30.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 122.176 0.191 . . . . 0.0 110.588 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -82.64 145.83 29.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.215 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.93 167.9 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.48 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -140.09 147.38 40.19 Favored 'General case' 0 N--CA 1.428 -1.574 0 CA-C-N 114.417 -1.265 . . . . 0.0 109.836 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.753 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.1 138.8 54.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.128 -1.397 . . . . 0.0 111.693 -179.717 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.643 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.69 -6.78 37.29 Favored Glycine 0 CA--C 1.517 0.156 0 CA-C-N 114.361 -1.291 . . . . 0.0 114.129 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -73.11 140.23 46.98 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-O 121.104 0.478 . . . . 0.0 110.013 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.05 101.19 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.401 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.464 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.8 -5.44 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.88 0 CA-C-N 113.739 -1.573 . . . . 0.0 113.101 -178.867 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.3 -162.14 34.76 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-O 121.272 0.374 . . . . 0.0 112.683 178.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.514 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 24.6 m-85 -141.37 137.12 32.1 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 124.816 1.246 . . . . 0.0 108.272 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.45 ' HG1' ' HB ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -61.35 151.46 32.12 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.615 0.766 . . . . 0.0 112.654 -178.724 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.469 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -157.38 -162.17 11.41 Favored Glycine 0 C--N 1.347 1.185 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.798 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.37 47.72 0.89 Allowed 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -0.7 . . . . 0.0 109.261 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.616 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 34.4 p . . . . . 0 CA--C 1.541 0.629 0 CA-C-N 115.213 -0.903 . . . . 0.0 113.292 -177.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.873 0 CA-C-O 118.599 -1.112 . . . . 0.0 111.54 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.416 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 10.0 Cg_exo -69.8 141.95 46.43 Favored 'Trans proline' 0 C--N 1.374 1.912 0 CA-C-N 120.251 2.025 . . . . 0.0 111.725 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.469 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 53.2 p-80 -157.77 -171.56 3.59 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.495 0.664 . . . . 0.0 111.774 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.688 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 9.1 tp -125.23 139.85 53.36 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.099 -1.409 . . . . 0.0 110.565 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.523 ' HE2' ' HB2' ' A' ' 124' ' ' GLU . 29.1 t60 -118.32 128.54 54.75 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 113.706 -1.588 . . . . 0.0 107.845 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -133.0 111.26 10.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.847 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.523 ' HB2' ' HE2' ' A' ' 122' ' ' HIS . 18.0 tt0 -120.31 127.18 52.11 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.238 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.456 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.8 tpt -120.26 138.01 53.91 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.666 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.1 mp -143.6 164.68 29.13 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 113.439 -1.709 . . . . 0.0 110.298 -178.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -62.83 -178.81 0.43 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.943 2.429 . . . . 0.0 112.669 177.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -68.57 -27.82 66.41 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.206 176.195 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -157.35 107.93 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.781 0 CA-C-N 113.903 -1.498 . . . . 0.0 108.232 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -71.15 163.12 40.26 Favored 'Trans proline' 0 N--CA 1.445 -1.326 0 C-N-CA 122.347 2.031 . . . . 0.0 116.926 -176.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.581 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.89 70.82 0.8 Allowed 'General case' 0 N--CA 1.423 -1.805 0 CA-C-N 112.349 -2.205 . . . . 0.0 107.395 177.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.447 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.29 13.99 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.168 -1.378 . . . . 0.0 112.376 -178.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.581 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.23 32.3 0.33 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.269 1.027 . . . . 0.0 112.902 -178.361 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . 0.405 ' H ' ' C ' ' A' ' 132' ' ' TRP . 9.9 m-80 72.21 127.96 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 125.737 1.615 . . . . 0.0 110.997 178.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.11 -48.08 0.61 Allowed Glycine 0 N--CA 1.437 -1.278 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.341 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.68 -19.52 0.16 Allowed 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.43 18.22 10.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 122.624 1.202 . . . . 0.0 108.19 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.571 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 79.77 -11.66 32.75 Favored Glycine 0 N--CA 1.434 -1.449 0 CA-C-N 112.252 -2.249 . . . . 0.0 112.648 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.559 ' HG2' HG11 ' A' ' 35' ' ' VAL . 0.8 OUTLIER -83.98 125.02 31.65 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.301 -179.434 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.425 HG21 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -125.24 -172.96 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.585 -0.734 . . . . 0.0 112.441 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . 0.425 ' H ' HG21 ' A' ' 140' ' ' ILE . 2.9 t70 -75.82 134.77 71.63 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -176.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.585 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.9 Cg_endo -77.16 0.62 9.54 Favored 'Trans proline' 0 C--N 1.381 2.277 0 C-N-CA 123.082 2.521 . . . . 0.0 113.546 177.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -51.34 -24.08 4.32 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.69 -28.95 66.24 Favored Glycine 0 CA--C 1.521 0.45 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.912 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -99.71 -11.86 20.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 123.347 0.659 . . . . 0.0 111.194 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.585 HG12 ' O ' ' A' ' 142' ' ' PRO . 31.2 mm -98.8 -10.47 8.78 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.372 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.357 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.656 178.021 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.635 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 21.3 Cg_exo . . . . . 0 N--CA 1.482 0.842 0 N-CA-C 112.951 0.327 . . . . 0.0 112.951 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.809 HD13 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.56 -172.0 3.05 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 122.671 1.224 . . . . 0.0 110.375 -179.894 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.539 ' H ' HD12 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -128.14 -25.22 3.03 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 112.144 -2.298 . . . . 0.0 108.742 177.213 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.809 ' O ' HD13 ' A' ' 19' ' ' LEU . 7.3 t -168.62 -168.64 0.92 Allowed 'General case' 0 CA--C 1.548 0.87 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.781 -178.302 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 171.99 111.74 0.26 Allowed Glycine 0 C--N 1.318 -0.431 0 CA-C-N 114.661 -1.154 . . . . 0.0 111.441 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.16 124.97 9.12 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.729 0.776 . . . . 0.0 112.973 -178.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.515 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.75 58.34 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-N 113.393 -1.731 . . . . 0.0 109.122 179.38 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.9 t -105.15 -28.2 11.13 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 112.969 -1.923 . . . . 0.0 111.007 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.52 -67.15 1.02 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.774 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.73 122.64 1.03 Allowed Glycine 0 C--N 1.322 -0.196 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.144 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.529 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -76.17 157.6 32.57 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -178.795 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -57.14 32.12 0.0 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -177.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.695 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -0.02 49.06 Favored Glycine 0 CA--C 1.504 -0.624 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -102.16 85.42 0.72 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.695 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.5 Cg_exo -76.95 141.99 21.73 Favored 'Trans proline' 0 C--N 1.373 1.848 0 C-N-CA 122.826 2.351 . . . . 0.0 113.425 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.51 4.02 83.57 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.803 -0.635 . . . . 0.0 113.06 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' HG22 ' A' ' 24' ' ' ILE . 3.3 t-80 -74.29 127.33 32.72 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.098 0.959 . . . . 0.0 110.697 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -102.72 5.45 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.656 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.86 -150.03 5.14 Favored Glycine 0 C--N 1.337 0.603 0 C-N-CA 121.526 -0.368 . . . . 0.0 112.257 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.475 HG13 ' OH ' ' A' ' 39' ' ' TYR . 9.7 p -130.52 154.69 40.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 C-N-CA 122.97 0.508 . . . . 0.0 110.244 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.686 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -129.16 130.07 45.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.258 0.552 . . . . 0.0 111.914 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.635 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 3.4 m-85 -120.54 109.99 15.93 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.273 -178.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.3 104.15 0.15 Allowed 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.275 178.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.447 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.6 p -146.79 124.07 5.89 Favored Pre-proline 0 CA--C 1.55 0.974 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.76 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -49.0 142.97 18.81 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 123.4 2.733 . . . . 0.0 115.528 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.49 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.47 140.77 18.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 111.766 -2.47 . . . . 0.0 113.454 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.45 2.53 55.55 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 115.441 -0.8 . . . . 0.0 114.036 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -87.53 124.0 68.55 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-O 119.153 -0.451 . . . . 0.0 109.88 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.7 126.7 23.32 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.342 2.028 . . . . 0.0 113.272 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.478 ' O ' HG13 ' A' ' 107' ' ' ILE . 5.8 t -99.55 121.12 49.83 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 CA-C-N 115.107 -0.951 . . . . 0.0 108.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 3.9 mpt_? -102.21 152.41 21.06 Favored 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 113.301 -1.772 . . . . 0.0 111.434 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.71 122.63 20.97 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.689 -1.141 . . . . 0.0 111.435 -178.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 24.6 t -69.42 -14.53 18.52 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.553 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.633 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.24 143.86 1.95 Allowed 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 123.491 0.716 . . . . 0.0 110.641 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -62.68 156.04 24.67 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 114.943 -1.026 . . . . 0.0 112.477 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.617 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.32 -127.61 1.57 Allowed Glycine 0 C--N 1.334 0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.551 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.7 m -148.08 141.45 25.26 Favored 'General case' 0 N--CA 1.436 -1.148 0 C-N-CA 123.598 0.759 . . . . 0.0 109.532 -178.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 99' ' ' SER . 10.6 t -83.63 112.81 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 O-C-N 123.907 0.755 . . . . 0.0 108.995 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.44 ' N ' ' HD2' ' A' ' 56' ' ' LYS . 10.0 mmmt -94.93 -14.72 24.2 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.666 -1.152 . . . . 0.0 110.819 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -156.69 141.2 16.75 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.896 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.04 92.44 2.05 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.805 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.415 ' O ' HD12 ' A' ' 93' ' ' ILE . . . -94.96 92.03 1.46 Allowed Glycine 0 C--O 1.241 0.533 0 CA-C-N 114.35 -1.295 . . . . 0.0 112.658 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.569 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.65 123.7 23.78 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.134 0.974 . . . . 0.0 112.744 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.607 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.62 -0.76 88.21 Favored Glycine 0 CA--C 1.519 0.342 0 CA-C-N 113.369 -1.741 . . . . 0.0 113.59 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -32.31 57.54 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.54 24.79 2.66 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.027 -178.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.607 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -81.08 114.05 45.81 Favored Pre-proline 0 N--CA 1.435 -1.211 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -178.182 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.835 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.4 Cg_exo -67.81 162.12 40.95 Favored 'Trans proline' 0 C--N 1.37 1.685 0 C-N-CA 123.727 2.952 . . . . 0.0 111.804 177.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 63.3 m95 -96.1 13.01 28.64 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 176.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 81.9 mtp -80.07 -42.51 23.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.785 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.538 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.4 pp -125.76 15.44 8.08 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.795 177.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.835 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.4 OUTLIER -137.29 108.59 6.85 Favored 'General case' 0 C--N 1.369 1.416 0 C-N-CA 120.022 -0.671 . . . . 0.0 112.612 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 16.8 ttm -113.05 -20.3 11.56 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.416 178.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -91.54 -26.5 18.73 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.568 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 102.78 -128.57 9.59 Favored Glycine 0 CA--C 1.519 0.335 0 O-C-N 123.703 0.627 . . . . 0.0 113.704 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.587 HD22 ' HA3' ' A' ' 61' ' ' GLY . 17.5 m-80 -83.25 138.55 33.54 Favored 'General case' 0 C--N 1.346 0.43 0 C-N-CA 123.113 0.565 . . . . 0.0 112.138 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -152.27 145.96 25.03 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.3 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.625 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.15 120.34 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.164 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.7 129.6 56.54 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -139.19 150.81 22.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.328 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.617 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -100.24 117.27 34.11 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.904 -1.498 . . . . 0.0 108.504 178.037 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.633 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 2.9 m-70 -68.74 -175.91 0.75 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.489 -1.232 . . . . 0.0 114.092 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.92 65.03 Favored 'General case' 0 N--CA 1.452 -0.369 0 CA-C-N 114.037 -1.438 . . . . 0.0 114.457 -177.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.65 -9.02 21.29 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 120.876 0.369 . . . . 0.0 110.99 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.71 -6.74 44.85 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.122 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.511 ' HE2' ' HH ' ' A' ' 145' ' ' TYR . 2.2 ptt? -67.09 170.48 6.85 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 123.461 0.704 . . . . 0.0 111.465 179.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.439 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 70.5 m-70 -114.68 145.42 42.06 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 120.609 -0.436 . . . . 0.0 111.218 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.68 127.34 20.27 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.051 179.68 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.625 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.63 155.4 16.52 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.698 178.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.493 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.8 m-85 -134.54 99.46 4.36 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.438 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -112.38 168.02 9.97 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 112.689 0.625 . . . . 0.0 112.689 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 65.68 41.0 4.16 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.449 1.099 . . . . 0.0 111.736 -178.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.517 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.9 mt -102.14 167.93 9.7 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.039 178.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.7 t -104.57 -14.47 15.63 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.57 160.56 13.05 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.697 0.761 . . . . 0.0 111.861 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.648 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.16 149.17 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 113.563 -1.653 . . . . 0.0 110.83 179.045 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -112.56 -6.03 13.97 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.173 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.648 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.12 -175.28 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.006 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.642 -176.932 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.9 t -153.17 150.42 29.03 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.835 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.1 m -60.2 128.41 36.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.377 -179.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 85.49 -4.06 0.86 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.627 1.171 . . . . 0.0 111.674 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.458 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -79.83 148.88 31.2 Favored 'General case' 0 C--N 1.347 0.493 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.45 145.34 29.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.66 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.81 166.38 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.264 -179.271 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.7 tttp -141.5 148.48 39.5 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.916 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.761 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.65 138.23 55.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -179.595 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.88 -5.45 47.93 Favored Glycine 0 CA--C 1.518 0.242 0 CA-C-N 114.252 -1.34 . . . . 0.0 114.238 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.5 tt0 -74.5 140.35 44.48 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.024 0.44 . . . . 0.0 110.184 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 49.0 mt -71.54 101.65 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.668 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.478 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.58 -4.87 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.035 -179.02 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.11 -160.52 34.11 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-O 121.137 0.298 . . . . 0.0 112.47 178.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 28.5 m-85 -140.93 138.53 33.91 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.535 1.134 . . . . 0.0 108.377 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.11 151.9 29.83 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.625 0.77 . . . . 0.0 112.483 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.497 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -157.71 -164.1 13.46 Favored Glycine 0 C--N 1.346 1.124 0 C-N-CA 120.036 -1.078 . . . . 0.0 114.079 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.37 49.67 0.89 Allowed 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.734 -0.733 . . . . 0.0 109.076 178.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.568 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 25.5 p . . . . . 0 CA--C 1.54 0.563 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -177.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.021 0 CA-C-O 119.096 -0.835 . . . . 0.0 113.176 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.81 146.58 20.97 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.882 2.388 . . . . 0.0 112.087 179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.447 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 54.3 p-80 -159.79 -167.24 1.93 Allowed 'General case' 0 C--N 1.347 0.459 0 CA-C-O 121.467 0.651 . . . . 0.0 111.851 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.686 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 11.1 tp -126.18 137.64 53.58 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.228 -1.351 . . . . 0.0 110.339 -178.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.441 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.5 t60 -117.44 126.35 52.49 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 113.895 -1.502 . . . . 0.0 108.287 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -131.61 108.62 9.65 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.973 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.516 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.1 pt-20 -116.62 128.38 55.33 Favored 'General case' 0 N--CA 1.429 -1.49 0 CA-C-N 115.276 -0.874 . . . . 0.0 109.476 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' MET . . . . . . . . . . . . . 3.4 tpt -121.08 136.9 54.88 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.837 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.61 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.11 165.52 25.47 Favored Pre-proline 0 C--N 1.309 -1.169 0 CA-C-N 113.352 -1.749 . . . . 0.0 110.3 -177.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.439 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.8 Cg_endo -63.57 -178.25 0.5 Allowed 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 123.055 2.503 . . . . 0.0 112.9 176.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.44 -28.3 63.88 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.01 176.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.426 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 29.4 m120 -157.03 102.61 1.92 Allowed Pre-proline 0 CA--C 1.503 -0.828 0 CA-C-N 114.218 -1.355 . . . . 0.0 108.771 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 2.8 Cg_exo -73.73 163.34 37.47 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.555 2.17 . . . . 0.0 116.603 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.41 71.51 0.84 Allowed 'General case' 0 N--CA 1.425 -1.693 0 CA-C-N 112.344 -2.207 . . . . 0.0 107.095 177.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.446 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.44 14.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 114.239 -1.346 . . . . 0.0 112.463 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -82.05 35.52 0.43 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.042 0.937 . . . . 0.0 112.951 -178.197 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 73.06 127.11 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.488 0 C-N-CA 125.53 1.532 . . . . 0.0 110.52 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.41 -50.08 0.56 Allowed Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.396 -0.907 . . . . 0.0 113.353 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.595 ' CE1' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -151.87 -19.86 0.19 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.027 0.414 . . . . 0.0 111.527 179.177 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.5 m 65.78 18.01 11.02 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.885 1.274 . . . . 0.0 108.283 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.61 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.11 -11.19 12.45 Favored Glycine 0 N--CA 1.436 -1.305 0 CA-C-N 112.465 -2.152 . . . . 0.0 112.782 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.501 ' HD2' ' O ' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -82.48 121.8 27.22 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.1 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.403 HG21 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -124.64 -172.79 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.355 179.416 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . 0.403 ' H ' HG21 ' A' ' 140' ' ' ILE . 1.9 p30 -79.76 132.05 62.28 Favored Pre-proline 0 CA--C 1.552 1.038 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -176.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.513 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.71 0.04 10.19 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.233 2.622 . . . . 0.0 114.204 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.36 -24.23 7.29 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -178.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -74.5 -23.25 75.92 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.899 179.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . 0.511 ' HH ' ' HE2' ' A' ' 83' ' ' MET . 12.6 m-85 -101.12 -12.27 18.93 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 123.62 0.768 . . . . 0.0 111.169 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.513 HG12 ' O ' ' A' ' 142' ' ' PRO . 26.6 mm -101.72 -10.68 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.688 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.84 178.091 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.606 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.7 Cg_exo . . . . . 0 N--CA 1.481 0.761 0 CA-C-O 120.774 0.239 . . . . 0.0 112.27 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.844 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -139.57 -171.84 3.23 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 122.614 1.197 . . . . 0.0 110.213 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.54 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.02 -25.17 2.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 112.241 -2.254 . . . . 0.0 108.792 177.219 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.844 ' O ' HD12 ' A' ' 19' ' ' LEU . 7.4 t -168.95 -168.48 0.86 Allowed 'General case' 0 CA--C 1.546 0.802 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.619 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.04 111.9 0.35 Allowed Glycine 0 C--N 1.319 -0.371 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.336 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.67 124.63 9.96 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 121.888 0.852 . . . . 0.0 112.8 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.583 HD11 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.05 58.57 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 113.173 -1.83 . . . . 0.0 108.965 178.944 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.8 t -102.47 -28.98 11.88 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.838 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -113.42 -67.91 0.97 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.6 125.03 1.2 Allowed Glycine 0 C--N 1.323 -0.172 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.037 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.539 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -77.08 157.32 31.14 Favored 'General case' 0 C--N 1.343 0.298 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -178.956 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -55.97 32.19 0.0 OUTLIER 'General case' 0 C--O 1.239 0.526 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.69 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.74 0.94 49.33 Favored Glycine 0 CA--C 1.504 -0.647 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -101.64 85.34 0.64 Allowed Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.69 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.0 Cg_exo -77.42 139.66 18.61 Favored 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.748 2.299 . . . . 0.0 113.247 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.19 4.22 78.06 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.007 179.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.436 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.1 t-80 -75.36 131.4 40.22 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 123.997 0.919 . . . . 0.0 110.458 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.469 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.46 -1.98 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.488 -179.315 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.98 -150.21 5.89 Favored Glycine 0 C--N 1.338 0.661 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.537 HG13 ' OH ' ' A' ' 39' ' ' TYR . 11.9 p -132.05 149.19 32.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 O-C-N 123.864 0.391 . . . . 0.0 110.618 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.76 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.72 134.0 51.92 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 121.322 0.582 . . . . 0.0 112.074 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.606 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -124.57 110.44 14.45 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.354 -1.294 . . . . 0.0 110.131 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.06 107.31 0.29 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 115.813 -0.63 . . . . 0.0 112.117 178.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.481 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.2 p -146.36 127.12 7.16 Favored Pre-proline 0 CA--C 1.549 0.929 0 CA-C-N 115.021 -0.99 . . . . 0.0 109.172 -179.343 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -55.78 143.6 80.15 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.259 2.639 . . . . 0.0 115.583 -178.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.504 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -62.63 139.26 21.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 111.79 -2.459 . . . . 0.0 113.472 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.9 2.66 55.08 Favored Glycine 0 N--CA 1.442 -0.942 0 CA-C-N 115.366 -0.834 . . . . 0.0 114.063 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.12 120.83 70.74 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.2 126.1 21.39 Favored 'Trans proline' 0 C--N 1.376 1.985 0 C-N-CA 122.431 2.087 . . . . 0.0 113.104 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 107' ' ' ILE . 4.9 t -98.51 121.15 48.75 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.978 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.455 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 4.5 mpt_? -102.93 152.54 21.18 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 113.264 -1.789 . . . . 0.0 111.443 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -72.42 123.52 23.26 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.7 -1.136 . . . . 0.0 111.587 -178.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.9 t -65.83 -21.57 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 CA-C-N 115.597 -0.729 . . . . 0.0 112.613 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.561 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -167.69 143.99 4.13 Favored 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 123.184 0.593 . . . . 0.0 110.653 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.451 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -59.94 155.51 16.46 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.191 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.621 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.17 -126.37 1.4 Allowed Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.777 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.4 m -148.26 142.01 25.64 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 123.537 0.735 . . . . 0.0 109.971 -177.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.444 HG21 ' O ' ' A' ' 99' ' ' SER . 11.6 t -85.95 112.84 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 O-C-N 124.028 0.83 . . . . 0.0 108.921 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.6 mmmt -95.15 -14.79 23.84 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.596 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -154.21 140.09 18.19 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.243 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.13 92.37 2.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.781 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.453 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.18 89.87 1.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 114.141 -1.39 . . . . 0.0 113.368 -179.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.559 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -69.99 124.05 23.09 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.907 0.883 . . . . 0.0 112.552 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.564 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.39 -0.63 87.22 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-N 113.334 -1.757 . . . . 0.0 113.645 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.81 -32.14 46.18 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 26.93 2.57 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.978 -178.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.564 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.86 115.87 57.03 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -178.28 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.848 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.1 Cg_exo -69.49 162.89 40.14 Favored 'Trans proline' 0 C--N 1.37 1.704 0 C-N-CA 123.765 2.976 . . . . 0.0 111.469 177.028 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -98.73 12.36 35.77 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.2 mtt -78.36 -44.08 25.98 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.539 -1.209 . . . . 0.0 110.149 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.515 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -119.88 10.69 11.63 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.793 177.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.848 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.48 146.31 50.85 Favored 'General case' 0 C--N 1.362 1.151 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.782 -179.01 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 46.1 mtt -139.37 -36.17 0.53 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.443 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -88.79 -21.02 23.99 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.413 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.627 ' HA3' ' HG1' ' A' ' 113' ' ' THR . . . 95.12 -112.81 4.46 Favored Glycine 0 C--N 1.335 0.488 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.12 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.548 HD22 ' HA3' ' A' ' 61' ' ' GLY . 13.7 m-80 -80.37 135.7 36.23 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.182 0.593 . . . . 0.0 112.528 -178.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -149.18 146.31 27.58 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.228 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.592 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.32 122.01 17.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.094 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.434 HD23 ' HD1' ' A' ' 84' ' ' HIS . 0.1 OUTLIER -119.5 129.92 54.95 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 177.509 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.401 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -141.08 150.87 20.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 CA-C-N 112.942 -1.935 . . . . 0.0 110.497 -176.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.621 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.48 116.05 30.74 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.277 177.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.561 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.3 m-70 -68.6 -177.76 1.01 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.528 -1.215 . . . . 0.0 114.121 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.451 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -65.59 -17.37 64.53 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.824 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.58 -12.21 21.4 Favored 'General case' 0 C--O 1.236 0.388 0 O-C-N 123.415 0.447 . . . . 0.0 110.732 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.63 -6.57 45.02 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.118 -0.947 . . . . 0.0 112.035 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.423 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 12.1 ptt? -71.45 164.69 25.31 Favored 'General case' 0 N--CA 1.436 -1.154 0 C-N-CA 123.135 0.574 . . . . 0.0 111.772 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.455 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 53.0 m-70 -105.61 142.78 34.75 Favored 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.121 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.07 127.17 26.07 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.592 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.41 154.45 16.82 Favored Glycine 0 N--CA 1.442 -0.967 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.699 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -137.23 98.65 3.78 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.468 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . . . -116.11 170.42 8.52 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 54.9 m80 65.59 38.1 5.62 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.339 1.056 . . . . 0.0 111.137 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.564 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.3 mt -97.94 170.11 9.17 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.966 178.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 17.3 t -104.14 -15.28 15.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 111.465 0.172 . . . . 0.0 111.465 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 9.0 tttt -168.46 159.55 10.44 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.696 0.76 . . . . 0.0 112.204 -178.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.757 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -124.38 148.98 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 113.541 -1.663 . . . . 0.0 110.862 178.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.53 -5.05 13.45 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.213 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.757 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.08 -175.33 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.074 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.553 -177.049 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.6 t -152.23 149.45 28.73 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.841 -179.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -60.32 127.9 34.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.496 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 85.39 -3.61 0.86 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.508 1.123 . . . . 0.0 111.673 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.444 ' O ' HG21 ' A' ' 55' ' ' VAL . 40.1 m -79.98 148.95 30.96 Favored 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 122.299 0.24 . . . . 0.0 110.415 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.6 p -83.19 145.68 29.04 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.491 178.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.21 167.66 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.297 0 CA-C-N 115.302 -0.863 . . . . 0.0 112.324 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.403 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.0 tttm -141.33 147.98 38.97 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.957 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.746 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.81 137.49 56.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.378 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.409 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.94 -5.64 47.07 Favored Glycine 0 CA--C 1.519 0.334 0 CA-C-N 114.285 -1.325 . . . . 0.0 114.112 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.4 tt0 -73.87 139.66 45.17 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.108 0.48 . . . . 0.0 110.143 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 57.8 mt -70.94 101.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.62 -179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.552 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.8 OUTLIER -93.72 -4.12 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.61 -1.632 . . . . 0.0 112.937 -179.125 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.49 -161.3 35.11 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-O 121.228 0.349 . . . . 0.0 112.737 178.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.564 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.0 m-85 -141.5 136.92 31.69 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 124.834 1.253 . . . . 0.0 108.341 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.1 p -60.43 152.73 24.83 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.423 0.689 . . . . 0.0 112.08 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.504 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -155.82 -165.44 14.44 Favored Glycine 0 C--N 1.345 1.048 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.915 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -149.77 45.13 0.93 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.565 -0.818 . . . . 0.0 108.953 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.627 ' HG1' ' HA3' ' A' ' 72' ' ' GLY . 22.3 p . . . . . 0 N--CA 1.47 0.538 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.636 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.935 0 CA-C-O 119.125 -0.82 . . . . 0.0 112.682 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -73.88 146.35 37.52 Favored 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 122.93 2.42 . . . . 0.0 111.916 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.481 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 46.9 p-80 -157.66 -169.7 2.95 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-O 121.547 0.689 . . . . 0.0 112.401 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.76 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.0 tp -126.4 131.81 51.66 Favored 'General case' 0 N--CA 1.432 -1.34 0 CA-C-N 114.049 -1.432 . . . . 0.0 111.166 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.468 ' CD2' ' HB3' ' A' ' 88' ' ' ALA . 24.8 t60 -114.01 110.08 19.48 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.088 177.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -117.08 109.23 16.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.364 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.483 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.1 tt0 -116.22 127.06 54.44 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.208 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.403 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 2.5 ttt -118.62 134.7 54.91 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.679 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.458 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.4 mp -142.31 166.6 20.21 Favored Pre-proline 0 C--N 1.31 -1.14 0 CA-C-N 113.297 -1.774 . . . . 0.0 111.004 -177.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.455 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.5 Cg_endo -63.32 -178.44 0.47 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 123.027 2.484 . . . . 0.0 112.851 176.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.62 -27.06 61.92 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.194 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.41 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.3 m-80 -157.29 98.84 1.96 Allowed Pre-proline 0 CA--C 1.503 -0.835 0 CA-C-N 114.206 -1.361 . . . . 0.0 109.314 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 6.5 Cg_exo -71.1 163.37 39.44 Favored 'Trans proline' 0 N--CA 1.445 -1.377 0 C-N-CA 122.868 2.379 . . . . 0.0 116.532 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.605 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.2 t-20 -116.76 70.56 0.77 Allowed 'General case' 0 N--CA 1.425 -1.691 0 CA-C-N 112.579 -2.101 . . . . 0.0 107.24 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.99 13.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 114.351 -1.295 . . . . 0.0 112.412 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.605 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 35.27 0.41 Allowed 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 124.196 0.998 . . . . 0.0 113.083 -178.109 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 73.32 126.29 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 125.509 1.523 . . . . 0.0 110.727 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.5 -50.18 0.56 Allowed Glycine 0 N--CA 1.442 -0.902 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.482 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.554 ' CE2' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -152.43 -19.73 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 117.102 0.451 . . . . 0.0 111.432 179.257 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 30.1 t 66.45 18.13 10.78 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.034 1.334 . . . . 0.0 108.411 -178.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.554 ' HA2' ' CE2' ' A' ' 136' ' ' PHE . . . 77.7 -11.04 21.43 Favored Glycine 0 N--CA 1.436 -1.334 0 CA-C-N 112.66 -2.063 . . . . 0.0 112.8 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.469 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -81.45 127.18 32.52 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 120.081 -0.648 . . . . 0.0 112.117 -179.19 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -126.93 -174.34 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.337 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.033 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -70.34 134.7 86.84 Favored Pre-proline 0 CA--C 1.544 0.731 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.618 -178.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.56 ' O ' HG12 ' A' ' 146' ' ' ILE . 95.4 Cg_endo -76.7 21.64 0.56 Allowed 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 123.162 2.575 . . . . 0.0 114.081 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.442 ' H ' ' HG1' ' A' ' 143' ' ' THR . 1.9 p -56.04 -24.63 40.69 Favored 'General case' 0 C--N 1.344 0.349 0 C-N-CA 124.228 1.011 . . . . 0.0 113.308 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.52 -23.78 77.35 Favored Glycine 0 N--CA 1.462 0.427 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -96.2 -9.7 29.85 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.655 1.182 . . . . 0.0 110.43 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.56 HG12 ' O ' ' A' ' 142' ' ' PRO . 21.1 mm -104.93 -12.47 9.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.841 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.261 0 C-N-CA 123.133 0.573 . . . . 0.0 112.271 -179.961 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.714 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.7 Cg_exo . . . . . 0 N--CA 1.478 0.613 0 N-CA-C 113.192 0.42 . . . . 0.0 113.192 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.791 HD11 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.42 -171.81 2.86 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-O 122.736 1.255 . . . . 0.0 110.781 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.548 ' H ' HD13 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.49 -25.09 2.96 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 111.98 -2.373 . . . . 0.0 108.691 177.512 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.791 ' O ' HD11 ' A' ' 19' ' ' LEU . 6.8 t -168.58 -169.11 0.99 Allowed 'General case' 0 CA--C 1.55 0.949 0 CA-C-N 114.405 -1.271 . . . . 0.0 111.996 -178.107 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.12 110.66 0.25 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 114.504 -1.226 . . . . 0.0 111.251 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.39 124.72 8.19 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.521 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.37 58.4 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 114.201 -1.363 . . . . 0.0 108.949 178.191 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.7 t -103.27 -28.69 11.72 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.066 -1.879 . . . . 0.0 110.852 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -113.45 -66.8 1.05 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.489 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.17 124.48 1.17 Allowed Glycine 0 C--N 1.323 -0.182 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.865 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.525 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -74.55 157.39 35.57 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -178.829 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -58.95 32.02 0.01 OUTLIER 'General case' 0 C--O 1.24 0.559 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.696 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.71 -1.56 48.9 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 111.429 -0.669 . . . . 0.0 111.429 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.467 ' HB2' ' HD2' ' A' ' 28' ' ' PHE . 7.7 m-85 -102.19 85.37 0.71 Allowed Pre-proline 0 CA--C 1.548 0.868 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.696 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.71 140.21 16.38 Favored 'Trans proline' 0 C--N 1.376 1.998 0 C-N-CA 122.836 2.358 . . . . 0.0 113.585 -178.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.57 4.27 70.56 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.743 -0.662 . . . . 0.0 113.181 179.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.425 ' O ' HG12 ' A' ' 24' ' ' ILE . 4.1 t-80 -79.79 133.0 36.28 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 124.209 1.004 . . . . 0.0 110.032 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.571 HG13 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.07 -10.51 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 123.64 0.588 . . . . 0.0 111.779 -178.845 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -129.93 -149.79 6.79 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 112.063 -0.415 . . . . 0.0 112.063 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 123' ' ' PHE . 12.4 p -130.52 151.66 36.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.844 0.379 . . . . 0.0 110.522 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.704 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -127.08 132.03 50.73 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.265 0.555 . . . . 0.0 111.408 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.714 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 6.5 m-85 -118.24 111.7 19.14 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.475 -1.239 . . . . 0.0 111.227 -177.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.42 99.76 0.09 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.548 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.449 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 14.2 p -142.87 129.02 10.47 Favored Pre-proline 0 CA--C 1.547 0.859 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.168 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . 0.4 ' HA ' ' HG2' ' A' ' 119' ' ' PRO . 87.8 Cg_exo -48.82 139.83 24.16 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 123.472 2.782 . . . . 0.0 115.844 -179.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.436 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -66.57 137.34 25.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 111.764 -2.471 . . . . 0.0 113.345 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.27 2.71 51.11 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.908 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' THR . . . . . 0.436 ' H ' ' HG1' ' A' ' 110' ' ' THR . 1.8 m -87.76 131.57 43.03 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.238 -0.41 . . . . 0.0 109.976 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.64 128.32 25.45 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.214 1.942 . . . . 0.0 113.004 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.574 ' O ' HG13 ' A' ' 107' ' ' ILE . 8.1 t -100.14 123.15 52.82 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.885 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.653 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 19.5 mtt180 -101.95 152.02 21.43 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 112.929 -1.941 . . . . 0.0 111.752 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.06 123.67 24.01 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.098 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.02 -15.94 20.36 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.716 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.604 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.64 143.02 1.66 Allowed 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 123.349 0.66 . . . . 0.0 110.497 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.66 155.49 22.42 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.052 -0.976 . . . . 0.0 112.307 179.193 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.569 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.99 -126.26 1.36 Allowed Glycine 0 C--N 1.331 0.302 0 O-C-N 123.792 0.683 . . . . 0.0 113.45 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 7.9 m -147.1 141.52 26.4 Favored 'General case' 0 N--CA 1.436 -1.127 0 C-N-CA 123.576 0.75 . . . . 0.0 109.613 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.494 HG21 ' O ' ' A' ' 99' ' ' SER . 12.2 t -85.04 113.24 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 123.764 0.826 . . . . 0.0 108.783 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.42 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 7.0 mmmt -95.35 -14.9 23.49 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.675 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -156.17 140.27 16.44 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.198 179.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.01 92.12 1.93 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.147 -1.388 . . . . 0.0 108.934 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.402 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.76 91.27 1.46 Allowed Glycine 0 C--O 1.238 0.386 0 CA-C-N 114.362 -1.29 . . . . 0.0 112.214 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.57 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -70.27 122.34 19.35 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 122.006 0.908 . . . . 0.0 112.857 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.626 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.77 -0.86 88.82 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 113.201 -1.818 . . . . 0.0 113.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.46 -32.91 62.75 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.92 26.69 2.46 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.927 -178.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.626 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -82.59 114.13 49.65 Favored Pre-proline 0 N--CA 1.435 -1.192 0 N-CA-C 114.006 1.113 . . . . 0.0 114.006 -178.083 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.824 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.8 Cg_exo -67.72 162.31 39.95 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 123.987 3.125 . . . . 0.0 112.239 177.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -95.76 12.23 30.72 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 58.9 mtt -78.42 -42.8 29.07 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.774 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.529 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -126.08 14.82 7.89 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.862 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.824 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.2 OUTLIER -137.33 113.24 9.7 Favored 'General case' 0 C--N 1.367 1.331 0 C-N-CA 120.188 -0.605 . . . . 0.0 112.581 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -110.83 -33.81 6.43 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.91 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.07 -18.68 33.57 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.505 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.52 -126.68 9.0 Favored Glycine 0 CA--C 1.52 0.394 0 O-C-N 123.515 0.51 . . . . 0.0 113.946 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.545 HD22 ' HA3' ' A' ' 61' ' ' GLY . 17.4 m-80 -81.21 145.98 30.71 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.738 0.815 . . . . 0.0 112.555 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -152.31 144.85 24.14 Favored 'General case' 0 CA--C 1.519 -0.243 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.438 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.606 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -139.46 120.86 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.539 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.46 128.01 51.67 Favored 'General case' 0 CA--C 1.492 -1.28 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -138.92 151.07 23.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 112.785 -2.007 . . . . 0.0 110.679 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.569 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -100.2 117.43 34.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.903 177.859 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.604 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 3.2 m-70 -70.04 -176.23 1.09 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 114.137 -1.392 . . . . 0.0 114.196 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.54 -18.05 65.03 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 113.806 -1.543 . . . . 0.0 114.42 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -9.67 20.35 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.913 0.387 . . . . 0.0 111.016 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.86 -6.49 43.99 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.221 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.423 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 6.5 ptt? -69.36 163.66 24.65 Favored 'General case' 0 N--CA 1.439 -1.007 0 C-N-CA 123.182 0.593 . . . . 0.0 111.621 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.446 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 60.2 m-70 -107.51 144.81 33.97 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.892 -178.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.43 HG22 ' HE2' ' A' ' 79' ' ' HIS . 0.0 OUTLIER -137.96 127.31 24.68 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.606 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -107.29 154.47 16.61 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.339 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.435 ' HA ' ' O ' ' A' ' 122' ' ' HIS . 2.0 m-85 -138.44 98.44 3.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 104.221 -2.511 . . . . 0.0 104.221 179.362 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.411 ' HB2' ' HB3' ' A' ' 122' ' ' HIS . . . -116.72 173.59 6.55 Favored 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 10.7 m80 66.05 20.18 11.22 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.505 1.122 . . . . 0.0 112.121 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.529 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 12.1 mt -79.66 172.43 13.79 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 123.708 0.803 . . . . 0.0 111.14 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.4 t -104.99 -15.69 15.04 Favored 'General case' 0 N--CA 1.447 -0.607 0 O-C-N 123.139 0.275 . . . . 0.0 111.555 -179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -168.71 157.52 8.51 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.809 0.814 . . . . 0.0 112.464 -178.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.746 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.5 150.3 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 CA-C-N 113.467 -1.697 . . . . 0.0 110.97 179.187 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -114.03 -6.51 13.12 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.508 -1.224 . . . . 0.0 110.181 177.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.746 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.1 OUTLIER -103.36 -175.02 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-N 115.361 -0.836 . . . . 0.0 112.765 -177.064 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 58.8 m -152.89 144.66 23.56 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.62 -1.173 . . . . 0.0 108.985 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.528 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.1 m -57.24 127.93 34.43 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.301 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.528 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.71 -3.55 0.68 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.606 1.162 . . . . 0.0 111.884 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.494 ' O ' HG21 ' A' ' 55' ' ' VAL . 50.8 m -81.08 149.19 29.32 Favored 'General case' 0 C--N 1.346 0.456 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 178.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.26 145.28 29.21 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.184 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 166.15 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.346 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 62.9 tttt -140.09 148.56 41.91 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.064 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.76 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.1 138.37 56.14 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.132 -1.394 . . . . 0.0 111.332 -179.751 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.653 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.47 -5.89 41.65 Favored Glycine 0 CA--C 1.516 0.145 0 CA-C-N 114.3 -1.318 . . . . 0.0 114.134 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.1 tt0 -73.28 143.79 46.87 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 122.989 0.515 . . . . 0.0 109.991 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 25.6 mt -74.17 101.65 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 CA-C-N 115.074 -0.967 . . . . 0.0 109.612 -179.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.574 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -93.59 -3.68 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 113.393 -1.73 . . . . 0.0 112.55 -179.236 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.31 -160.84 34.62 Favored Glycine 0 N--CA 1.439 -1.113 0 CA-C-O 121.307 0.393 . . . . 0.0 112.696 178.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.529 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 20.9 m-85 -142.25 137.35 30.63 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 124.875 1.27 . . . . 0.0 108.061 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.436 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -58.94 151.88 20.87 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 123.556 0.743 . . . . 0.0 112.356 -178.62 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.436 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -147.58 -170.79 16.03 Favored Glycine 0 C--N 1.347 1.187 0 C-N-CA 119.834 -1.174 . . . . 0.0 113.655 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -144.83 44.46 1.36 Allowed 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.779 -0.71 . . . . 0.0 109.173 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.505 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 37.5 p . . . . . 0 CA--C 1.541 0.627 0 N-CA-C 113.62 0.971 . . . . 0.0 113.62 -177.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.683 0 CA-C-O 119.798 -0.445 . . . . 0.0 112.92 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.449 ' HB2' ' O ' ' A' ' 41' ' ' VAL . 21.4 Cg_exo -70.84 147.26 55.56 Favored 'Trans proline' 0 C--N 1.365 1.445 0 C-N-CA 123.558 2.839 . . . . 0.0 111.956 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -152.0 156.29 39.69 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 122.3 1.048 . . . . 0.0 112.82 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.704 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -117.01 127.96 54.69 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 112.566 -2.107 . . . . 0.0 108.297 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.435 ' O ' ' HA ' ' A' ' 87' ' ' TYR . 23.3 t60 -112.36 109.57 19.27 Favored 'General case' 0 N--CA 1.434 -1.258 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.255 179.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.556 ' O ' HG13 ' A' ' 37' ' ' VAL . 40.4 t80 -115.73 108.52 16.47 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.931 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.461 ' OE1' HD12 ' A' ' 126' ' ' LEU . 21.5 tt0 -120.55 125.86 48.88 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.621 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.635 ' SD ' ' HA ' ' A' ' 142' ' ' PRO . 19.4 ptm -111.74 135.36 52.45 Favored 'General case' 0 N--CA 1.419 -2.011 0 C-N-CA 124.012 0.925 . . . . 0.0 109.579 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.461 HD12 ' OE1' ' A' ' 124' ' ' GLU . 2.8 mp -138.56 165.92 29.27 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.697 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.446 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.7 Cg_endo -63.2 -178.5 0.46 Allowed 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.969 2.446 . . . . 0.0 112.703 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.99 -27.21 62.6 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.214 176.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.422 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.1 m-80 -157.46 101.21 1.87 Allowed Pre-proline 0 CA--C 1.503 -0.851 0 CA-C-N 114.182 -1.372 . . . . 0.0 109.019 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 3.0 Cg_exo -72.89 163.66 37.75 Favored 'Trans proline' 0 N--CA 1.446 -1.284 0 C-N-CA 122.722 2.281 . . . . 0.0 116.592 -177.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.592 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -118.01 70.73 0.81 Allowed 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 112.482 -2.145 . . . . 0.0 107.339 177.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.442 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.3 m-90 -63.54 14.71 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.317 -1.311 . . . . 0.0 112.696 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.592 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.24 35.49 0.39 Allowed 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 122.121 0.963 . . . . 0.0 112.897 -178.353 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 70.72 127.59 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 125.73 1.612 . . . . 0.0 110.883 178.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 148.98 -49.9 0.57 Allowed Glycine 0 N--CA 1.437 -1.254 0 CA-C-N 114.979 -1.009 . . . . 0.0 113.031 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.5 -21.5 0.23 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 122.37 0.268 . . . . 0.0 111.43 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 26.9 m 66.19 17.94 10.85 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.672 1.189 . . . . 0.0 108.454 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.93 -9.73 23.05 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 112.497 -2.138 . . . . 0.0 112.672 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.571 ' HG2' HG13 ' A' ' 35' ' ' VAL . 2.1 ppt_? -83.18 126.16 32.33 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.42 -174.34 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.89 178.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . 0.426 ' O ' ' SD ' ' A' ' 125' ' ' MET . 1.8 p30 -79.25 135.58 57.69 Favored Pre-proline 0 CA--C 1.549 0.939 0 N-CA-C 114.06 1.133 . . . . 0.0 114.06 -176.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.635 ' HA ' ' SD ' ' A' ' 125' ' ' MET . 1.0 OUTLIER -76.46 1.4 8.45 Favored 'Trans proline' 0 C--N 1.383 2.39 0 C-N-CA 123.003 2.469 . . . . 0.0 113.244 178.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.67 -23.7 7.1 Favored 'General case' 0 C--N 1.351 0.664 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -178.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.41 -31.62 74.32 Favored Glycine 0 C--N 1.333 0.387 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . 0.446 ' HE1' ' SD ' ' A' ' 125' ' ' MET . 32.1 m-85 -94.35 -13.49 26.32 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 122.978 0.511 . . . . 0.0 111.53 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.563 HG12 ' O ' ' A' ' 142' ' ' PRO . 14.6 mm -100.98 -9.06 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.434 -178.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.32 0 CA-C-O 121.238 0.542 . . . . 0.0 111.429 179.037 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.654 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.1 Cg_exo . . . . . 0 N--CA 1.484 0.92 0 N-CA-C 113.286 0.456 . . . . 0.0 113.286 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.77 HD11 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.41 -172.16 2.88 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 122.682 1.229 . . . . 0.0 110.722 -179.765 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.521 ' H ' HD13 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -129.08 -24.75 2.85 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 111.862 -2.426 . . . . 0.0 108.797 177.407 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.77 ' O ' HD11 ' A' ' 19' ' ' LEU . 7.5 t -168.58 -168.74 0.94 Allowed 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 114.55 -1.205 . . . . 0.0 112.185 -177.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.75 111.43 0.26 Allowed Glycine 0 C--N 1.319 -0.37 0 CA-C-N 114.268 -1.333 . . . . 0.0 111.415 177.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.55 124.69 8.71 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.588 0.709 . . . . 0.0 112.764 -178.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.564 HD11 ' H ' ' A' ' 24' ' ' ILE . 0.0 OUTLIER -103.04 58.74 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-N 113.692 -1.595 . . . . 0.0 108.663 178.674 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.0 t -100.05 -28.56 12.99 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 112.879 -1.964 . . . . 0.0 110.826 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.8 m -116.93 -66.28 1.1 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.434 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.96 125.74 1.3 Allowed Glycine 0 C--N 1.322 -0.199 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.824 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.523 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -73.54 157.36 36.87 Favored 'General case' 0 C--N 1.342 0.278 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.56 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -57.15 31.99 0.0 OUTLIER 'General case' 0 C--O 1.238 0.494 0 N-CA-C 115.778 1.77 . . . . 0.0 115.778 -177.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.674 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 103.12 0.74 48.03 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -102.06 85.4 0.7 Allowed Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.674 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.0 Cg_exo -76.73 141.25 21.63 Favored 'Trans proline' 0 C--N 1.374 1.884 0 C-N-CA 122.831 2.354 . . . . 0.0 113.388 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.25 4.06 78.05 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 123.694 0.621 . . . . 0.0 113.091 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.444 ' O ' HG12 ' A' ' 24' ' ' ILE . 2.6 t-80 -79.58 129.54 34.56 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 123.886 0.874 . . . . 0.0 110.659 -179.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -5.25 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.227 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -131.01 -150.15 6.69 Favored Glycine 0 C--N 1.337 0.602 0 N-CA-C 111.868 -0.493 . . . . 0.0 111.868 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.463 HG11 ' OH ' ' A' ' 39' ' ' TYR . 11.4 p -131.69 151.5 35.46 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.701 0 C-N-CA 122.824 0.449 . . . . 0.0 110.044 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.726 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -127.23 137.89 52.98 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.222 0.534 . . . . 0.0 111.715 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.654 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.3 m-85 -125.4 107.6 10.83 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 114.534 -1.212 . . . . 0.0 110.574 -178.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -59.31 104.9 0.29 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.494 179.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 p -149.25 129.04 6.5 Favored Pre-proline 0 CA--C 1.549 0.919 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.192 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.82 144.18 56.15 Favored 'Trans proline' 0 C--N 1.365 1.441 0 C-N-CA 123.298 2.665 . . . . 0.0 115.149 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.471 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.92 142.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 111.796 -2.456 . . . . 0.0 113.362 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.17 2.53 59.16 Favored Glycine 0 N--CA 1.442 -0.963 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.984 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' THR . . . . . 0.55 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.4 m -88.83 129.45 48.52 Favored Pre-proline 0 N--CA 1.447 -0.623 0 CA-C-O 119.134 -0.46 . . . . 0.0 109.791 179.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.58 126.91 22.69 Favored 'Trans proline' 0 C--N 1.371 1.742 0 C-N-CA 122.152 1.901 . . . . 0.0 112.965 -179.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.44 ' O ' HG13 ' A' ' 107' ' ' ILE . 6.2 t -99.93 124.29 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.863 179.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.624 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.1 mtp-105 -101.55 153.57 19.62 Favored 'General case' 0 N--CA 1.433 -1.309 0 CA-C-N 113.18 -1.827 . . . . 0.0 111.843 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.33 121.47 20.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.61 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 30.4 t -67.76 -14.98 19.03 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.571 ' HB1' ' ND1' ' A' ' 79' ' ' HIS . . . -170.75 143.51 2.13 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 123.376 0.67 . . . . 0.0 110.482 179.001 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.434 ' ND2' ' HB3' ' A' ' 80' ' ' ALA . 0.4 OUTLIER -61.74 156.17 21.0 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.078 -0.965 . . . . 0.0 112.156 179.199 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.677 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.61 -127.35 1.52 Allowed Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.806 -0.712 . . . . 0.0 113.996 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.4 m -149.48 137.08 20.18 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 99' ' ' SER . 10.4 t -83.26 113.82 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 123.763 0.825 . . . . 0.0 108.956 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.494 ' HZ3' ' HB2' ' A' ' 78' ' ' GLN . 0.3 OUTLIER -98.84 -17.08 18.62 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.827 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -148.78 139.57 22.83 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.435 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.95 92.34 1.96 Allowed 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.904 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.56 91.27 1.4 Allowed Glycine 0 C--O 1.24 0.482 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.269 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.578 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -73.52 122.85 22.84 Favored 'General case' 0 C--N 1.344 0.358 0 C-N-CA 123.924 0.89 . . . . 0.0 112.57 -179.358 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.588 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.34 -0.73 87.32 Favored Glycine 0 C--N 1.32 -0.349 0 CA-C-N 113.265 -1.789 . . . . 0.0 113.378 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.89 -32.91 57.77 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.67 22.58 2.69 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-N 115.894 -0.593 . . . . 0.0 112.233 -178.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.588 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.5 113.45 34.5 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -178.619 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.829 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.3 Cg_exo -66.98 162.88 36.07 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 123.675 2.917 . . . . 0.0 111.705 177.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -95.63 8.1 44.37 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 176.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.0 mtt -74.81 -44.76 47.61 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.308 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.52 11.74 10.67 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.824 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.829 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -130.65 143.21 50.59 Favored 'General case' 0 C--N 1.361 1.096 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.412 -179.319 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 5.0 ttt -147.22 -19.78 0.39 Allowed 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.212 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -90.85 -29.17 17.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -179.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.623 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 106.48 -127.38 8.87 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.8 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.526 HD22 ' HA3' ' A' ' 61' ' ' GLY . 14.8 m-80 -88.61 139.33 30.58 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 122.894 0.478 . . . . 0.0 111.928 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.48 145.67 23.81 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.143 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.56 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.34 121.24 19.31 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.174 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.121 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.1 126.87 53.51 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.402 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -139.95 150.69 21.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-N 112.579 -2.1 . . . . 0.0 110.643 -176.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.677 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.7 tt0 -97.23 116.76 30.02 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 113.921 -1.49 . . . . 0.0 108.33 177.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.571 ' ND1' ' HB1' ' A' ' 51' ' ' ALA . 3.4 m-70 -69.55 -176.91 1.08 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HB3' ' ND2' ' A' ' 52' ' ' ASN . . . -64.97 -17.55 64.5 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 113.69 -1.595 . . . . 0.0 113.966 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.61 -12.9 20.67 Favored 'General case' 0 C--O 1.236 0.345 0 O-C-N 123.449 0.468 . . . . 0.0 110.986 -179.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.59 -6.77 45.38 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.685 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.68 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 18.5 ptp -70.55 168.23 16.76 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 123.352 0.661 . . . . 0.0 110.364 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.469 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 19.0 p80 -118.16 142.11 47.79 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.142 -1.023 . . . . 0.0 111.203 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.2 OUTLIER -133.85 128.39 34.57 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.255 -177.347 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.56 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -101.15 154.8 19.13 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 114.719 -1.128 . . . . 0.0 111.471 177.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.497 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.4 m-85 -133.44 99.22 4.45 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -111.32 168.92 9.15 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.925 -0.58 . . . . 0.0 112.556 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 22.1 m80 65.99 37.24 5.44 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 114.836 -1.074 . . . . 0.0 112.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.487 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.5 mt -98.43 169.58 9.44 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.745 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.3 t -107.83 -14.69 14.72 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 111.623 0.231 . . . . 0.0 111.623 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -167.66 157.95 10.75 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.595 0.712 . . . . 0.0 111.87 -178.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.722 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -123.37 149.42 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.844 179.25 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -113.34 -6.83 13.53 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.837 177.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.722 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -101.54 -175.04 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.02 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.28 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.5 m -152.64 145.16 24.13 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.256 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.55 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.3 m -57.02 126.14 25.85 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.599 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.55 ' HB2' ' O ' ' A' ' 97' ' ' THR . 1.6 m-20 85.37 -2.19 0.83 Allowed 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.75 1.22 . . . . 0.0 111.939 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.436 ' O ' HG22 ' A' ' 55' ' ' VAL . 8.7 t -80.74 149.28 29.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -82.86 145.17 29.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.294 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.52 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.334 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.401 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 70.2 tttt -142.03 148.93 39.28 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.824 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.747 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.36 137.95 56.85 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.422 -1.263 . . . . 0.0 111.253 -179.75 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.624 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.81 -4.55 52.11 Favored Glycine 0 C--N 1.328 0.089 0 CA-C-N 114.477 -1.238 . . . . 0.0 114.083 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.46 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.8 tt0 -74.2 141.94 45.42 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.108 0.48 . . . . 0.0 110.086 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.7 mt -72.37 101.44 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.525 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.44 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.2 pt -93.57 -6.16 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.88 -179.061 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.83 -159.88 33.15 Favored Glycine 0 N--CA 1.44 -1.067 0 C-N-CA 121.435 -0.412 . . . . 0.0 112.702 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.487 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 31.9 m-85 -140.24 138.07 34.76 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 124.674 1.19 . . . . 0.0 108.355 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.55 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.7 OUTLIER -60.24 150.17 30.98 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.567 0.747 . . . . 0.0 112.85 -178.654 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.486 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -148.47 -163.71 10.99 Favored Glycine 0 C--N 1.345 1.06 0 C-N-CA 120.616 -0.802 . . . . 0.0 113.02 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.33 44.4 0.87 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.415 0.626 . . . . 0.0 109.81 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.623 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 67.4 p . . . . . 0 CA--C 1.54 0.558 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.953 -178.162 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.025 0 CA-C-O 118.987 -0.896 . . . . 0.0 112.803 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.416 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 5.0 Cg_exo -73.45 142.95 33.92 Favored 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 122.495 2.13 . . . . 0.0 112.202 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 51.9 p-80 -163.29 -171.09 2.47 Favored 'General case' 0 C--N 1.347 0.499 0 CA-C-O 121.371 0.605 . . . . 0.0 111.414 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.726 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -124.75 131.08 53.48 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.487 -178.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 23.8 t60 -112.76 109.92 19.7 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.405 -1.271 . . . . 0.0 109.436 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -114.43 110.16 19.43 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.015 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.544 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -115.01 127.13 55.47 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' MET . . . . . . . . . . . . . 2.2 ttt -121.87 134.68 54.87 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 114.354 -1.294 . . . . 0.0 109.023 -178.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.68 ' O ' ' HB2' ' A' ' 83' ' ' MET . 2.1 mp -143.46 164.77 28.94 Favored Pre-proline 0 C--N 1.313 -1.022 0 CA-C-N 113.355 -1.748 . . . . 0.0 110.358 -177.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.469 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -61.91 -178.5 0.32 Allowed 'Trans proline' 0 C--N 1.369 1.644 0 C-N-CA 123.291 2.661 . . . . 0.0 113.473 177.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.99 -28.97 67.09 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.077 176.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.43 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.4 m-80 -158.01 103.93 1.74 Allowed Pre-proline 0 CA--C 1.503 -0.839 0 CA-C-N 113.896 -1.502 . . . . 0.0 108.607 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 2.8 Cg_exo -73.5 163.13 38.37 Favored 'Trans proline' 0 N--CA 1.444 -1.44 0 C-N-CA 122.511 2.141 . . . . 0.0 116.746 -176.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.569 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -118.2 70.53 0.81 Allowed 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 112.281 -2.236 . . . . 0.0 107.412 177.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.444 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.4 m-90 -62.83 12.5 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.427 -178.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.569 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -82.17 34.18 0.41 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 124.224 1.01 . . . . 0.0 112.74 -178.565 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 72.54 128.77 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.62 0 C-N-CA 125.692 1.597 . . . . 0.0 110.748 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.27 -48.6 0.59 Allowed Glycine 0 N--CA 1.439 -1.161 0 CA-C-N 115.135 -0.939 . . . . 0.0 113.043 -179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.55 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -150.48 -20.72 0.23 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 111.756 0.28 . . . . 0.0 111.756 179.301 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.23 17.71 10.78 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.081 1.352 . . . . 0.0 107.989 -178.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.635 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.29 -11.31 8.95 Favored Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 112.262 -2.245 . . . . 0.0 112.609 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.55 ' HG3' ' O ' ' A' ' 136' ' ' PHE . 0.0 OUTLIER -79.11 125.72 29.79 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.321 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -129.84 -175.35 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.004 179.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -79.74 132.96 59.65 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.573 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.1 Cg_exo -76.68 -1.89 12.05 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.667 2.245 . . . . 0.0 112.932 178.016 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.75 -23.24 6.41 Favored 'General case' 0 C--N 1.35 0.627 0 N-CA-C 114.278 1.214 . . . . 0.0 114.278 -178.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -67.67 -31.12 75.46 Favored Glycine 0 CA--C 1.518 0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.334 -179.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -103.39 -11.99 17.5 Favored 'General case' 0 C--O 1.236 0.37 0 O-C-N 123.861 0.389 . . . . 0.0 111.919 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.573 HG12 ' O ' ' A' ' 142' ' ' PRO . 24.5 mm -96.2 -8.71 9.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.684 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.267 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.412 178.125 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.637 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.5 Cg_exo . . . . . 0 N--CA 1.481 0.787 0 CA-C-O 120.75 0.229 . . . . 0.0 112.273 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.803 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.41 -172.02 3.04 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-O 122.561 1.172 . . . . 0.0 110.509 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.534 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.52 -24.83 2.99 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 112.221 -2.263 . . . . 0.0 108.772 177.233 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.803 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.3 t -168.42 -168.51 0.93 Allowed 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.654 -178.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 179.17 110.99 0.29 Allowed Glycine 0 C--N 1.32 -0.356 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.386 177.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.416 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.09 124.65 8.35 Favored 'General case' 0 CA--C 1.506 -0.739 0 CA-C-O 121.531 0.682 . . . . 0.0 112.337 -178.434 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.5 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.93 58.77 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.533 0 CA-C-N 113.924 -1.489 . . . . 0.0 108.978 178.536 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.6 t -105.05 -28.64 10.92 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 112.815 -1.993 . . . . 0.0 111.111 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.42 -66.79 1.05 Allowed 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.981 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.05 121.4 0.94 Allowed Glycine 0 C--N 1.321 -0.257 0 CA-C-N 115.131 -0.94 . . . . 0.0 112.15 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.527 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -74.72 157.49 35.18 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -178.849 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -57.43 31.71 0.0 OUTLIER 'General case' 0 C--O 1.24 0.561 0 N-CA-C 115.87 1.804 . . . . 0.0 115.87 -177.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.676 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.56 -2.05 49.52 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -101.76 85.47 0.67 Allowed Pre-proline 0 CA--C 1.547 0.861 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.8 Cg_exo -78.12 138.11 15.94 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.785 2.323 . . . . 0.0 113.317 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 92.41 4.31 66.27 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.225 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -76.52 135.89 39.31 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 123.79 0.836 . . . . 0.0 110.2 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.498 HG13 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.19 -18.93 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.444 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.22 -149.85 8.22 Favored Glycine 0 C--N 1.337 0.624 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.2 p -131.08 148.54 32.98 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 O-C-N 123.855 0.385 . . . . 0.0 110.11 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.775 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.21 135.12 52.26 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.456 0.646 . . . . 0.0 112.148 -178.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.637 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 2.1 m-85 -124.56 110.26 14.23 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 114.231 -1.35 . . . . 0.0 109.803 -178.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.31 104.25 0.12 Allowed 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.649 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.438 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.7 p -144.88 120.75 6.0 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.563 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -49.16 144.68 16.11 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.191 2.594 . . . . 0.0 115.525 -179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.458 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -61.03 139.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 111.628 -2.533 . . . . 0.0 113.437 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.52 2.56 55.47 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.358 -0.837 . . . . 0.0 114.181 177.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' THR . . . . . 0.416 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.4 m -87.41 127.57 58.29 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-O 119.148 -0.453 . . . . 0.0 109.951 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -59.36 127.27 23.31 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.181 1.921 . . . . 0.0 113.378 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 107' ' ' ILE . 11.4 t -99.05 123.8 51.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.28 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.588 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 5.9 mtt180 -102.39 152.42 21.13 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.913 -1.949 . . . . 0.0 111.597 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 102' ' ' LYS . . . -73.47 120.82 19.61 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.771 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.3 t -65.51 -16.77 20.89 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.585 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.27 144.63 2.05 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 123.479 0.711 . . . . 0.0 110.391 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.15 156.02 19.27 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.071 -0.968 . . . . 0.0 112.512 179.492 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.644 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.71 -125.88 1.38 Allowed Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.72 -0.673 . . . . 0.0 113.701 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.3 m -148.22 142.95 26.67 Favored 'General case' 0 N--CA 1.439 -1.025 0 C-N-CA 123.624 0.77 . . . . 0.0 109.706 -178.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 99' ' ' SER . 9.4 t -84.89 112.1 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 123.805 0.842 . . . . 0.0 108.881 179.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.457 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -95.14 -14.96 23.71 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.751 -179.861 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -154.38 140.37 18.31 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.045 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -147.85 92.31 2.05 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.394 -1.275 . . . . 0.0 108.952 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.63 89.99 1.27 Allowed Glycine 0 C--O 1.24 0.499 0 CA-C-N 114.251 -1.341 . . . . 0.0 112.454 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.568 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.09 122.13 20.43 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.951 0.881 . . . . 0.0 112.822 -179.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.612 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.63 -0.94 88.59 Favored Glycine 0 N--CA 1.461 0.301 0 CA-C-N 113.197 -1.82 . . . . 0.0 113.693 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.09 -33.44 59.51 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -138.62 26.91 2.52 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.925 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.612 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.9 115.26 50.92 Favored Pre-proline 0 N--CA 1.437 -1.119 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -178.372 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.822 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 37.4 Cg_exo -68.05 162.95 37.76 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 123.845 3.03 . . . . 0.0 111.789 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -96.25 8.58 43.53 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -74.66 -44.6 49.54 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.312 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.527 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -121.97 11.76 10.35 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.913 177.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.822 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.0 OUTLIER -129.03 144.39 51.17 Favored 'General case' 0 C--N 1.361 1.093 0 C-N-CA 120.159 -0.616 . . . . 0.0 112.237 -178.854 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.61 -31.16 0.35 Allowed 'General case' 0 N--CA 1.47 0.525 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.689 178.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.62 -19.34 31.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.511 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 96.3 -130.28 10.21 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.967 -0.561 . . . . 0.0 114.112 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.558 HD22 ' HA3' ' A' ' 61' ' ' GLY . 10.1 m-80 -81.11 140.95 34.75 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.558 0.743 . . . . 0.0 112.35 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.23 146.56 24.83 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.345 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.568 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.93 121.35 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.265 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.401 HD23 ' HD1' ' A' ' 84' ' ' HIS . 0.1 OUTLIER -117.89 130.55 56.31 Favored 'General case' 0 CA--C 1.492 -1.273 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 177.561 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.4 mt -139.4 150.82 22.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-N 112.909 -1.951 . . . . 0.0 110.403 -176.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.644 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.68 116.18 31.2 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 113.865 -1.516 . . . . 0.0 108.281 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.585 ' CE1' ' HB3' ' A' ' 51' ' ' ALA . 3.8 m-70 -69.21 -175.47 0.77 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.27 -18.1 65.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 113.982 -1.463 . . . . 0.0 114.619 -177.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.22 -9.18 20.66 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.81 -6.14 43.83 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.154 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.544 ' HE1' ' HH ' ' A' ' 145' ' ' TYR . 4.0 ptt? -67.43 165.76 15.98 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 123.595 0.758 . . . . 0.0 111.353 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.497 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 61.9 m-70 -111.41 144.37 40.72 Favored 'General case' 0 N--CA 1.44 -0.929 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.826 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.7 127.06 22.96 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 120.99 0.424 . . . . 0.0 110.345 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.568 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -104.24 154.73 17.61 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.628 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.486 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.0 m-85 -136.08 99.06 4.03 Favored 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -113.66 167.78 10.32 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -177.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 65.5 42.28 3.82 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.283 1.033 . . . . 0.0 111.383 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.517 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.2 mt -103.22 168.58 9.08 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.103 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 8.1 t -102.63 -17.81 15.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.16 163.64 15.6 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.722 0.772 . . . . 0.0 111.927 -177.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.696 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -127.56 148.18 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.509 -1.678 . . . . 0.0 110.893 179.06 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 t -111.51 -6.6 14.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.886 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.696 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -103.35 -175.24 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.099 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.792 -177.118 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.7 m -153.22 143.42 22.35 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.674 -1.148 . . . . 0.0 108.936 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.76 127.88 32.23 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 86.02 -4.43 0.79 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.692 1.197 . . . . 0.0 111.719 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.466 ' O ' HG21 ' A' ' 55' ' ' VAL . 39.5 m -80.44 151.61 29.22 Favored 'General case' 0 C--N 1.347 0.463 0 CA-C-O 120.571 0.224 . . . . 0.0 110.552 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.7 145.52 27.91 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.608 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.89 169.71 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.314 0 CA-C-N 115.197 -0.91 . . . . 0.0 112.196 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' HB1' ' A' ' 49' ' ' ALA . 1.9 tttt -142.42 148.51 37.93 Favored 'General case' 0 N--CA 1.432 -1.361 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.716 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.756 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.34 138.41 56.49 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.361 -179.796 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.588 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 77.03 -8.44 30.58 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 114.38 -1.282 . . . . 0.0 114.135 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.1 tt0 -70.75 141.29 51.48 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.078 0.466 . . . . 0.0 110.214 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.8 mt -72.72 102.05 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.559 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.481 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.5 -4.97 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 CA-C-N 113.564 -1.653 . . . . 0.0 113.117 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.66 -160.74 34.44 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 121.472 -0.394 . . . . 0.0 112.749 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 35.4 m-85 -140.16 138.35 35.12 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.669 1.188 . . . . 0.0 108.522 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.416 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -62.71 150.93 39.84 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 123.631 0.773 . . . . 0.0 112.552 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.468 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -161.37 -160.98 11.23 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 119.877 -1.154 . . . . 0.0 114.034 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.43 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.2 51.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 114.48 -0.86 . . . . 0.0 108.684 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.511 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 21.6 p . . . . . 0 CA--C 1.539 0.55 0 CA-C-N 115.196 -0.911 . . . . 0.0 113.33 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.972 0 CA-C-O 119.384 -0.675 . . . . 0.0 113.634 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.43 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 6.2 Cg_exo -80.25 139.21 13.07 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 123.302 2.668 . . . . 0.0 112.419 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.438 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 24.0 p-80 -160.94 -166.34 1.57 Allowed 'General case' 0 C--N 1.348 0.5 0 CA-C-O 121.256 0.551 . . . . 0.0 111.411 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.775 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 13.3 tp -123.03 130.04 52.28 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.64 -1.163 . . . . 0.0 111.261 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.6 t60 -112.81 113.0 24.9 Favored 'General case' 0 N--CA 1.434 -1.225 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.815 177.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 45.2 t80 -118.53 111.31 18.45 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.138 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -118.55 127.21 53.4 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.163 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.488 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.0 tpt -117.61 138.41 51.97 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.7 mp -143.65 166.62 18.72 Favored Pre-proline 0 C--N 1.308 -1.237 0 CA-C-N 113.465 -1.698 . . . . 0.0 111.103 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.497 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -62.52 -178.48 0.38 Allowed 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 123.35 2.7 . . . . 0.0 112.703 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -69.98 -28.05 65.22 Favored 'General case' 0 N--CA 1.439 -0.989 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.247 176.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.432 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 29.7 m120 -156.94 101.28 1.95 Allowed Pre-proline 0 CA--C 1.504 -0.793 0 CA-C-N 114.334 -1.303 . . . . 0.0 108.829 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 4.4 Cg_exo -72.26 163.18 39.46 Favored 'Trans proline' 0 N--CA 1.444 -1.432 0 C-N-CA 122.698 2.265 . . . . 0.0 116.542 -177.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.582 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -117.08 70.7 0.78 Allowed 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.491 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.454 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.07 12.54 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 114.29 -1.323 . . . . 0.0 112.313 -178.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.582 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -81.61 32.29 0.36 Allowed 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.378 1.071 . . . . 0.0 112.815 -178.534 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 73.74 129.1 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.582 0 C-N-CA 125.825 1.65 . . . . 0.0 110.789 178.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.34 -48.6 0.59 Allowed Glycine 0 N--CA 1.44 -1.085 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.121 -179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.2 -19.77 0.18 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.762 0.315 . . . . 0.0 111.757 179.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.6 t 66.34 18.03 10.81 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.975 1.31 . . . . 0.0 108.213 -178.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.578 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 74.59 -9.71 10.12 Favored Glycine 0 N--CA 1.437 -1.26 0 CA-C-N 112.582 -2.099 . . . . 0.0 112.904 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.561 ' HD2' ' O ' ' A' ' 139' ' ' ARG . 1.5 ppt_? -82.73 127.25 33.25 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.437 HG23 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -129.37 -172.86 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.855 -0.612 . . . . 0.0 112.413 178.478 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . 0.437 ' H ' HG23 ' A' ' 140' ' ' ILE . 1.3 m-20 -71.65 134.86 83.83 Favored Pre-proline 0 CA--C 1.549 0.906 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -176.278 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.619 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.6 Cg_endo -77.7 2.03 8.24 Favored 'Trans proline' 0 C--N 1.381 2.265 0 C-N-CA 123.296 2.664 . . . . 0.0 113.297 177.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.5 p -51.17 -24.04 3.85 Favored 'General case' 0 C--N 1.347 0.467 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -178.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.52 -28.04 71.69 Favored Glycine 0 CA--C 1.52 0.383 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.867 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . 0.544 ' HH ' ' HE1' ' A' ' 83' ' ' MET . 6.0 m-85 -102.4 -9.28 20.44 Favored 'General case' 0 C--O 1.237 0.445 0 O-C-N 124.085 0.52 . . . . 0.0 111.496 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.619 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -98.53 -11.29 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.854 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.019 178.149 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.615 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 45.6 Cg_exo . . . . . 0 N--CA 1.483 0.87 0 N-CA-C 113.147 0.403 . . . . 0.0 113.147 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.871 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.37 -172.12 2.87 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-O 122.5 1.143 . . . . 0.0 110.379 -179.985 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.466 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.78 -25.71 2.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 112.4 -2.182 . . . . 0.0 108.755 177.288 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.871 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -169.61 -168.32 0.78 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 114.02 -1.445 . . . . 0.0 111.234 -178.045 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.24 110.97 0.3 Allowed Glycine 0 C--N 1.316 -0.574 0 CA-C-N 114.793 -1.094 . . . . 0.0 111.289 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.52 124.98 8.88 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.851 0.834 . . . . 0.0 113.053 -177.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.525 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.85 58.8 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.38 -1.736 . . . . 0.0 108.522 178.373 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 4.9 t -100.94 -28.73 12.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 112.595 -2.093 . . . . 0.0 110.856 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.6 m -115.55 -66.58 1.07 Allowed 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.422 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.46 122.15 0.98 Allowed Glycine 0 C--N 1.323 -0.173 0 CA-C-N 115.084 -0.962 . . . . 0.0 112.037 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.526 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -70.89 157.35 38.29 Favored 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -178.909 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 -58.67 31.75 0.01 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.66 1.726 . . . . 0.0 115.66 -177.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.687 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.81 -2.03 48.58 Favored Glycine 0 CA--C 1.505 -0.59 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.545 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -102.52 85.35 0.75 Allowed Pre-proline 0 CA--C 1.547 0.864 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.687 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 6.2 Cg_exo -78.6 138.98 15.71 Favored 'Trans proline' 0 C--N 1.374 1.898 0 C-N-CA 122.881 2.388 . . . . 0.0 113.497 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.34 3.93 62.89 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.375 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.509 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.3 t-80 -80.62 135.06 35.98 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 123.724 0.81 . . . . 0.0 109.83 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.488 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.74 -20.1 5.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.144 -179.383 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.35 -149.59 8.33 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.441 HG13 ' OH ' ' A' ' 39' ' ' TYR . 14.7 p -131.69 151.92 36.17 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 O-C-N 123.939 0.435 . . . . 0.0 110.274 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASP . . . . . 0.747 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 82.8 m-20 -128.25 131.71 48.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.172 0.51 . . . . 0.0 111.603 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' TYR . . . . . 0.615 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -119.76 111.17 17.66 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.648 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.21 102.04 0.15 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.227 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.465 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 13.8 p -143.34 133.48 12.06 Favored Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.853 -178.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -48.51 139.35 23.3 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 123.486 2.791 . . . . 0.0 115.653 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.44 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -67.57 143.75 15.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 111.793 -2.458 . . . . 0.0 113.222 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.26 2.78 58.98 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.791 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -86.89 126.86 61.91 Favored Pre-proline 0 N--CA 1.447 -0.611 0 CA-C-O 119.253 -0.403 . . . . 0.0 109.978 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.13 126.18 19.53 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.022 1.815 . . . . 0.0 112.974 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 107' ' ' ILE . 5.4 t -99.86 122.34 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.467 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 2.2 mpt_? -101.7 154.78 18.58 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 113.389 -1.732 . . . . 0.0 112.052 -178.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.35 124.32 25.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.265 -178.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.29 -18.45 24.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.568 ' HB2' ' ND1' ' A' ' 79' ' ' HIS . . . -170.26 144.2 2.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 110.388 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.453 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.03 157.45 12.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.978 179.159 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.667 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.13 -124.59 1.25 Allowed Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.781 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.2 m -147.83 143.37 27.42 Favored 'General case' 0 N--CA 1.436 -1.141 0 C-N-CA 123.594 0.758 . . . . 0.0 109.938 -177.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.477 HG22 ' O ' ' A' ' 99' ' ' SER . 9.8 t -86.94 113.06 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.819 0.848 . . . . 0.0 108.826 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -95.06 -15.02 23.76 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.621 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -154.48 139.6 17.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.221 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.29 92.33 1.94 Allowed 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.894 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . 0.43 ' O ' HD11 ' A' ' 93' ' ' ILE . . . -96.36 92.36 1.38 Allowed Glycine 0 C--O 1.239 0.443 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.488 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.592 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -71.49 122.57 20.67 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 123.914 0.886 . . . . 0.0 112.796 -179.301 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.565 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.59 -0.7 88.01 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-N 113.352 -1.749 . . . . 0.0 113.358 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.41 -32.7 48.81 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.32 27.62 2.56 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.744 -178.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.565 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.58 113.85 40.62 Favored Pre-proline 0 N--CA 1.435 -1.177 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -178.69 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.811 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.9 Cg_exo -66.74 162.59 36.71 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 123.371 2.714 . . . . 0.0 111.166 177.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.1 m95 -96.41 9.54 40.95 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.5 mtt -76.31 -44.66 35.88 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.239 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.535 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.19 11.46 10.86 Favored 'General case' 0 N--CA 1.441 -0.891 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.895 177.619 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' TRP . . . . . 0.811 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.53 138.03 52.05 Favored 'General case' 0 C--N 1.359 0.994 0 C-N-CA 120.359 -0.536 . . . . 0.0 110.842 -179.317 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 11.6 mmt -143.16 -21.21 0.63 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.769 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -96.32 -28.9 14.28 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.97 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.426 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 109.01 -131.02 10.32 Favored Glycine 0 CA--C 1.52 0.387 0 O-C-N 123.767 0.667 . . . . 0.0 113.895 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.556 HD22 ' HA3' ' A' ' 61' ' ' GLY . 12.2 m-80 -79.23 144.13 34.65 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.613 0.765 . . . . 0.0 112.448 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -151.22 144.82 24.96 Favored 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.475 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.556 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -140.46 121.55 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.975 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.86 129.02 52.26 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.421 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 11.1 mt -141.02 151.18 20.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 113.145 -1.843 . . . . 0.0 110.863 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLN . . . . . 0.667 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 2.0 tt0 -100.37 115.76 30.75 Favored 'General case' 0 N--CA 1.436 -1.128 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.996 177.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.647 ' CD2' ' HG1' ' A' ' 85' ' ' THR . 2.2 m-70 -70.08 -177.46 1.37 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 114.347 1.24 . . . . 0.0 114.347 -178.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.453 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -63.45 -17.97 63.26 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 113.744 -1.571 . . . . 0.0 114.179 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.31 -11.78 20.92 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 123.444 0.465 . . . . 0.0 110.728 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.417 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.58 -7.43 46.18 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.81 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 9.2 ptt? -69.0 163.55 24.37 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 123.286 0.635 . . . . 0.0 111.715 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.491 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 63.4 m-70 -105.68 144.78 31.94 Favored 'General case' 0 N--CA 1.437 -1.084 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.986 -179.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.647 ' HG1' ' CD2' ' A' ' 79' ' ' HIS . 0.0 OUTLIER -138.22 126.84 23.52 Favored 'General case' 0 N--CA 1.441 -0.916 0 O-C-N 123.633 0.583 . . . . 0.0 109.815 -179.519 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . 0.556 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.38 154.27 16.86 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.531 178.618 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -140.94 98.48 3.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 104.338 -2.467 . . . . 0.0 104.338 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 173.68 6.79 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 86.3 m-70 65.68 24.35 11.58 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.577 1.151 . . . . 0.0 111.642 -178.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . 0.568 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.2 mt -84.01 170.96 13.4 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.577 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.3 t -105.19 -13.82 15.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.7 tttp -166.82 158.15 12.56 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.749 0.785 . . . . 0.0 112.551 -178.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.706 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -126.06 147.43 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 113.602 -1.635 . . . . 0.0 110.87 179.014 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 t -111.26 -6.63 14.51 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.936 177.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.706 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -102.6 -175.24 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.035 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.736 -177.13 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.1 m -151.88 140.48 20.74 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.938 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -55.07 128.99 36.3 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.412 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 85.68 -4.92 0.84 Allowed 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.594 1.158 . . . . 0.0 112.001 179.07 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG22 ' A' ' 55' ' ' VAL . 46.0 m -80.48 152.72 28.59 Favored 'General case' 0 C--N 1.347 0.457 0 CA-C-O 120.514 0.197 . . . . 0.0 110.739 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 p -85.06 145.1 27.84 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 178.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.7 168.2 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.333 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 74.5 tttt -139.64 148.98 43.2 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-N 114.493 -1.23 . . . . 0.0 109.803 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . 0.757 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.94 138.89 55.42 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.231 -1.349 . . . . 0.0 111.421 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 76.78 -7.29 34.89 Favored Glycine 0 CA--C 1.517 0.165 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.093 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' GLN . . . . . 0.467 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.4 tt0 -71.89 142.92 49.52 Favored 'General case' 0 CA--C 1.51 -0.593 0 C-N-CA 122.971 0.508 . . . . 0.0 110.131 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 32.9 mt -72.65 100.86 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.49 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -94.25 -3.99 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.952 -178.902 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 170.71 -168.37 41.46 Favored Glycine 0 N--CA 1.438 -1.212 0 CA-C-O 121.353 0.418 . . . . 0.0 112.752 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.568 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 34.0 m-85 -139.59 134.29 31.92 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 124.718 1.207 . . . . 0.0 108.023 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.48 ' H ' ' HG1' ' A' ' 110' ' ' THR . 0.1 OUTLIER -56.61 150.49 15.5 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.477 0.711 . . . . 0.0 112.459 -178.533 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.455 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -146.11 -171.11 15.26 Favored Glycine 0 C--N 1.347 1.152 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.526 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -143.86 43.1 1.46 Allowed 'General case' 0 N--CA 1.441 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 109.302 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.426 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 36.5 p . . . . . 0 CA--C 1.54 0.573 0 CA-C-N 115.109 -0.95 . . . . 0.0 112.868 -178.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.874 0 CA-C-O 119.617 -0.546 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' PRO . . . . . 0.465 ' HB2' ' O ' ' A' ' 41' ' ' VAL . 23.0 Cg_exo -68.84 147.34 68.55 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.526 2.817 . . . . 0.0 112.268 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -149.45 158.44 44.18 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-O 122.313 1.054 . . . . 0.0 113.144 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.747 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 12.0 tp -120.47 125.09 47.02 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-N 112.51 -2.132 . . . . 0.0 109.402 179.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 19.1 t60 -110.88 111.01 21.85 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 114.854 -1.066 . . . . 0.0 109.832 178.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -115.49 112.59 22.48 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.635 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.45 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.0 tt0 -119.26 140.04 50.91 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.349 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' MET . . . . . 0.43 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 17.0 tpp -132.72 136.92 46.69 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.819 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.562 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.98 165.47 24.03 Favored Pre-proline 0 C--N 1.312 -1.048 0 CA-C-N 113.714 -1.585 . . . . 0.0 110.419 -178.213 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.491 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.6 Cg_endo -63.53 -178.55 0.52 Allowed 'Trans proline' 0 C--N 1.367 1.511 0 C-N-CA 122.949 2.433 . . . . 0.0 112.746 176.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -71.92 -27.46 62.84 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.205 176.245 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ASN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 29.8 m120 -156.75 101.38 1.99 Allowed Pre-proline 0 CA--C 1.504 -0.802 0 CA-C-N 114.25 -1.341 . . . . 0.0 108.741 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 2.9 Cg_exo -72.34 163.43 38.67 Favored 'Trans proline' 0 N--CA 1.443 -1.441 0 C-N-CA 122.625 2.217 . . . . 0.0 116.633 -177.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.18 71.53 0.83 Allowed 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 112.421 -2.172 . . . . 0.0 107.275 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.443 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.47 14.91 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 114.266 -1.334 . . . . 0.0 112.421 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 32.94 0.37 Allowed 'General case' 0 N--CA 1.445 -0.71 0 CA-C-O 122.13 0.967 . . . . 0.0 112.833 -178.456 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . 0.4 ' H ' ' C ' ' A' ' 132' ' ' TRP . 9.0 m-80 72.41 128.76 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 125.792 1.637 . . . . 0.0 110.96 178.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.07 -48.7 0.6 Allowed Glycine 0 N--CA 1.437 -1.287 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.109 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.57 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.1 OUTLIER -150.51 -21.09 0.23 Allowed 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 179.558 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t 66.42 18.01 10.77 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.806 1.243 . . . . 0.0 108.121 -178.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.562 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.97 -11.56 14.63 Favored Glycine 0 N--CA 1.436 -1.315 0 CA-C-N 112.439 -2.164 . . . . 0.0 112.683 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ARG . . . . . 0.57 ' HG3' ' O ' ' A' ' 136' ' ' PHE . 0.0 OUTLIER -80.62 125.59 30.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.34 -175.79 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.029 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 5.0 p30 -76.65 137.85 66.81 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . 0.552 ' O ' HG12 ' A' ' 146' ' ' ILE . 76.5 Cg_endo -76.21 20.43 0.57 Allowed 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.21 2.606 . . . . 0.0 114.559 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 5.6 p -56.95 -24.99 56.98 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.154 0.982 . . . . 0.0 113.579 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -75.12 -23.71 73.51 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -95.53 -10.56 29.33 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.607 1.163 . . . . 0.0 110.668 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.552 HG12 ' O ' ' A' ' 142' ' ' PRO . 30.0 mm -107.16 -12.27 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.771 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.899 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.5 mtt . . . . . 0 N--CA 1.487 1.39 0 CA-C-O 120.608 0.242 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -91.54 139.83 30.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -137.08 135.49 7.7 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.575 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.7 p -98.36 145.49 26.65 Favored 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.703 0.296 . . . . 0.0 110.768 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -120.82 -42.13 2.53 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.37 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -108.58 143.62 37.37 Favored 'General case' 0 N--CA 1.464 0.266 0 O-C-N 123.332 0.395 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -108.74 163.75 12.99 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.068 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -85.87 158.07 20.04 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.276 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -89.26 -42.33 11.67 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.632 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 67.1 m80 -87.92 -45.82 9.92 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 123.241 0.338 . . . . 0.0 111.56 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.88 133.26 6.75 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.39 0.431 . . . . 0.0 112.837 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.28 161.6 14.34 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.879 0.371 . . . . 0.0 111.986 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.82 109.86 2.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.899 177.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.8 t -90.81 -0.83 57.83 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.365 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -94.58 137.86 33.17 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.637 0.732 . . . . 0.0 111.872 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 20.9 p -89.44 162.41 15.76 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.646 -1.615 . . . . 0.0 112.789 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.466 HH11 HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -81.38 112.57 34.63 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.649 0.78 . . . . 0.0 111.64 -179.748 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.603 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.4 Cg_exo -66.16 -22.97 53.36 Favored 'Trans proline' 0 C--N 1.366 1.494 0 C-N-CA 122.8 2.333 . . . . 0.0 113.047 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.804 HD13 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.95 -171.96 3.07 Favored 'General case' 0 CA--C 1.508 -0.662 0 CA-C-O 122.509 1.147 . . . . 0.0 110.316 -179.695 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.529 ' H ' HD12 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -127.58 -25.12 3.2 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 112.253 -2.248 . . . . 0.0 108.797 177.267 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.804 ' O ' HD13 ' A' ' 19' ' ' LEU . 7.2 t -168.77 -168.83 0.92 Allowed 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.332 -1.304 . . . . 0.0 111.671 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.422 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.66 111.62 0.3 Allowed Glycine 0 C--N 1.32 -0.345 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.633 177.64 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.48 124.85 8.84 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-O 121.582 0.706 . . . . 0.0 112.578 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.557 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.97 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.476 0 CA-C-N 113.672 -1.604 . . . . 0.0 109.216 179.387 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.8 t -106.64 -27.87 10.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 112.781 -2.009 . . . . 0.0 110.929 178.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.63 -67.41 1.0 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.881 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.06 122.55 1.02 Allowed Glycine 0 N--CA 1.459 0.185 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.28 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.533 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -78.31 157.57 29.14 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -179.073 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 63.7 m-80 -56.94 32.04 0.0 OUTLIER 'General case' 0 C--O 1.24 0.556 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -177.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.676 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.98 1.31 48.66 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -102.18 85.3 0.7 Allowed Pre-proline 0 CA--C 1.545 0.788 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.8 Cg_exo -77.6 139.76 18.34 Favored 'Trans proline' 0 C--N 1.372 1.813 0 C-N-CA 122.81 2.34 . . . . 0.0 113.245 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.24 4.49 81.04 Favored Glycine 0 C--N 1.34 0.762 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.986 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -71.86 129.99 39.96 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.083 0.953 . . . . 0.0 111.089 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.63 6.15 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.351 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.91 -150.01 5.14 Favored Glycine 0 C--N 1.337 0.62 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.52 HG13 ' OH ' ' A' ' 39' ' ' TYR . 8.8 p -131.93 150.12 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.725 0 C-N-CA 122.788 0.435 . . . . 0.0 110.23 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.726 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 84.7 m-20 -126.18 135.28 51.44 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.21 0.528 . . . . 0.0 111.977 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.603 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -126.39 108.11 10.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.541 -178.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.68 104.83 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.264 179.076 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.63 127.97 6.81 Favored Pre-proline 0 CA--C 1.551 0.989 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.908 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -49.48 141.84 24.76 Favored 'Trans proline' 0 C--N 1.369 1.608 0 C-N-CA 123.385 2.723 . . . . 0.0 115.375 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.494 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.3 140.81 18.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 111.891 -2.413 . . . . 0.0 113.401 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.38 2.62 53.79 Favored Glycine 0 N--CA 1.442 -0.952 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.09 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' THR . . . . . 0.542 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.3 m -85.96 126.12 66.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.028 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.37 126.79 23.11 Favored 'Trans proline' 0 C--N 1.372 1.802 0 C-N-CA 122.226 1.951 . . . . 0.0 113.15 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 107' ' ' ILE . 10.2 t -100.95 122.35 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.848 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.647 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 41.2 mtt180 -101.86 154.06 19.27 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 113.044 -1.889 . . . . 0.0 111.881 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.404 ' HB1' ' O ' ' A' ' 102' ' ' LYS . . . -73.27 119.62 17.76 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.578 -1.192 . . . . 0.0 110.57 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -65.9 -15.96 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.615 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.44 143.74 1.85 Allowed 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 123.411 0.684 . . . . 0.0 110.403 179.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.415 ' ND2' ' HB1' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.86 155.74 18.93 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.32 179.358 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.627 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.66 -127.17 1.52 Allowed Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.691 -0.686 . . . . 0.0 113.766 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.4 m -148.67 141.09 24.24 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 123.583 0.753 . . . . 0.0 109.875 -178.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 99' ' ' SER . 11.8 t -84.33 112.65 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 C-N-CA 123.78 0.832 . . . . 0.0 109.027 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -95.13 -15.03 23.67 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.684 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -155.85 139.67 16.19 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.766 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.69 92.36 1.99 Allowed 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.227 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -92.14 90.3 1.48 Allowed Glycine 0 C--O 1.24 0.524 0 CA-C-N 114.28 -1.327 . . . . 0.0 111.985 179.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.564 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.11 121.02 17.52 Favored 'General case' 0 C--N 1.344 0.369 0 O-C-N 124.818 0.952 . . . . 0.0 112.811 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.59 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.47 -0.77 87.8 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-N 113.318 -1.764 . . . . 0.0 113.459 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -33.11 58.01 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.56 22.32 2.71 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.22 -178.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.59 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.52 116.38 58.88 Favored Pre-proline 0 N--CA 1.435 -1.217 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -178.36 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.833 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 38.7 Cg_exo -67.61 162.87 37.3 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 123.577 2.851 . . . . 0.0 111.381 177.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 60.0 m95 -97.64 10.72 39.21 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.87 -44.97 30.0 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.544 -1.207 . . . . 0.0 110.194 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.52 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -120.3 11.42 11.51 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.714 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.833 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.1 m95 -128.66 141.9 51.2 Favored 'General case' 0 C--N 1.361 1.08 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.35 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.5 mmt -144.52 -28.22 0.49 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.202 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.74 -24.62 26.84 Favored 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.391 0.432 . . . . 0.0 112.075 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.624 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.27 -128.27 9.52 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 115.743 -0.662 . . . . 0.0 114.082 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.455 ' HB2' ' O ' ' A' ' 90' ' ' LEU . 8.6 m-80 -84.92 136.68 33.52 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.243 0.617 . . . . 0.0 112.067 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.433 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -150.33 147.05 27.14 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.16 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.64 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -140.14 120.63 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.467 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.36 128.21 54.81 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 177.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.5 mt -138.97 150.81 23.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 112.741 -2.027 . . . . 0.0 110.512 -176.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.627 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.3 tt0 -99.67 116.57 32.07 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.348 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.671 ' CD2' ' HG1' ' A' ' 85' ' ' THR . 3.0 m-70 -68.31 -176.09 0.7 Allowed 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.536 -1.211 . . . . 0.0 114.215 -178.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.415 ' HB1' ' ND2' ' A' ' 52' ' ' ASN . . . -66.22 -17.78 64.95 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 114.055 -1.43 . . . . 0.0 114.398 -177.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.52 -9.06 21.37 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.881 0.372 . . . . 0.0 111.067 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.6 -6.68 45.23 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.057 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.526 ' HE3' ' HH ' ' A' ' 145' ' ' TYR . 1.8 ptt? -67.77 168.71 10.92 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 123.469 0.708 . . . . 0.0 111.367 179.067 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 -113.43 145.31 41.36 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.075 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.671 ' HG1' ' CD2' ' A' ' 79' ' ' HIS . 0.0 OUTLIER -140.94 127.28 19.81 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-O 120.973 0.416 . . . . 0.0 110.29 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.64 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.96 154.97 16.9 Favored Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.546 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.433 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.9 m-85 -134.36 99.29 4.33 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 105.361 -2.089 . . . . 0.0 105.361 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.69 166.77 11.05 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 73.3 m80 65.74 41.25 4.0 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-N 114.628 -1.169 . . . . 0.0 111.743 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.507 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 9.3 mt -101.3 166.46 10.75 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.079 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.4 t -101.04 -14.88 17.64 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -168.26 160.47 11.55 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.727 0.775 . . . . 0.0 111.901 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.684 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.3 148.65 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 113.613 -1.631 . . . . 0.0 110.757 178.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 t -112.42 -5.96 14.05 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 114.517 -1.219 . . . . 0.0 110.071 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.684 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -104.44 -175.23 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.983 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.512 -177.134 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.2 m -155.46 144.07 20.43 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.009 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.534 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 4.2 m -55.23 129.22 37.47 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.62 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.43 -5.18 0.74 Allowed 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.63 1.172 . . . . 0.0 112.026 179.314 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.45 ' O ' HG22 ' A' ' 55' ' ' VAL . 29.6 m -81.3 148.8 29.24 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.51 145.63 28.01 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.425 178.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.49 167.69 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.248 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.36 -179.216 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.404 ' O ' ' HB1' ' A' ' 49' ' ' ALA . 43.9 tttm -140.36 147.39 39.72 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.821 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.757 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.23 137.93 55.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.226 -1.352 . . . . 0.0 111.483 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.647 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.8 -4.43 52.48 Favored Glycine 0 CA--C 1.517 0.175 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.078 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.441 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.9 tt0 -74.36 139.0 43.81 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.183 0.516 . . . . 0.0 110.004 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 54.5 mt -71.35 101.53 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.118 0 CA-C-N 114.717 -1.128 . . . . 0.0 109.512 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.499 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.44 -4.74 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.149 -178.925 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.92 -160.82 34.6 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 112.302 -0.319 . . . . 0.0 112.302 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.507 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 30.3 m-85 -139.45 139.1 36.95 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 124.478 1.111 . . . . 0.0 108.327 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.542 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -60.37 152.57 24.99 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.472 0.709 . . . . 0.0 112.117 -179.136 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.494 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -158.06 -163.33 12.62 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.961 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.33 48.16 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 114.632 -0.784 . . . . 0.0 109.074 178.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.624 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 33.6 p -78.48 2.5 18.77 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -89.18 -97.49 1.04 Allowed Glycine 0 C--N 1.34 0.759 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.9 mt-30 -101.89 147.0 27.04 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.6 m -89.01 97.42 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 112.029 -178.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 36.0 p -146.78 -52.98 0.23 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.084 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.24 142.92 7.49 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.832 -0.982 . . . . 0.0 111.808 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.55 144.67 45.4 Favored 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.593 2.196 . . . . 0.0 112.098 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -160.77 -172.99 3.71 Favored 'General case' 0 C--N 1.349 0.565 0 CA-C-O 121.515 0.674 . . . . 0.0 111.636 179.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.726 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.8 tp -125.51 136.25 53.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.779 -178.395 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.446 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 31.8 t60 -116.36 122.96 46.4 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.43 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -127.25 107.57 10.11 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.264 178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' THR . 13.4 pt-20 -115.33 127.37 55.38 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.548 178.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.452 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.4 tpt -121.17 136.73 54.92 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.726 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.612 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -142.26 164.99 30.06 Favored Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 113.394 -1.73 . . . . 0.0 110.381 -178.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -64.09 -178.43 0.61 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.994 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.16 -27.26 62.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.004 176.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.34 102.54 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.784 0 CA-C-N 114.09 -1.414 . . . . 0.0 108.869 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.26 163.18 39.45 Favored 'Trans proline' 0 N--CA 1.445 -1.349 0 C-N-CA 122.671 2.248 . . . . 0.0 116.937 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.586 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.96 70.76 0.81 Allowed 'General case' 0 N--CA 1.425 -1.702 0 CA-C-N 112.229 -2.26 . . . . 0.0 107.392 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.45 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -62.9 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 114.291 -1.322 . . . . 0.0 112.435 -178.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.586 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 33.72 0.38 Allowed 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 124.209 1.003 . . . . 0.0 112.783 -178.487 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 11.0 m-80 71.95 128.2 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.627 0 C-N-CA 125.571 1.548 . . . . 0.0 110.666 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.33 -48.49 0.6 Allowed Glycine 0 N--CA 1.438 -1.178 0 CA-C-N 115.104 -0.953 . . . . 0.0 113.068 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.78 -19.58 0.22 Allowed 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 37.9 m 65.67 18.01 11.07 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-O 122.778 1.275 . . . . 0.0 108.108 -178.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.612 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 78.26 -11.57 23.05 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 112.237 -2.256 . . . . 0.0 112.47 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 125' ' ' MET . 0.4 OUTLIER -85.07 124.43 31.75 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 112.056 -179.24 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.441 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -127.19 -172.87 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.441 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.8 m-20 -72.47 131.8 84.35 Favored Pre-proline 0 CA--C 1.547 0.844 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -176.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.605 ' O ' HG12 ' A' ' 146' ' ' ILE . 4.5 Cg_exo -77.58 -1.63 11.8 Favored 'Trans proline' 0 C--N 1.379 2.148 0 C-N-CA 123.265 2.643 . . . . 0.0 113.492 177.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.1 p -51.48 -24.25 4.89 Favored 'General case' 0 C--N 1.349 0.58 0 N-CA-C 114.134 1.161 . . . . 0.0 114.134 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.94 -24.56 75.75 Favored Glycine 0 CA--C 1.521 0.431 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.927 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . 0.526 ' HH ' ' HE3' ' A' ' 83' ' ' MET . 4.3 m-85 -103.56 -10.33 18.55 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 123.465 0.706 . . . . 0.0 111.343 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.605 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -99.81 -10.96 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.454 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -74.18 -26.45 60.29 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.699 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 16.62 25.46 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.313 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.546 ' HB2' ' O ' ' A' ' 146' ' ' ILE . . . -94.88 167.99 12.02 Favored Pre-proline 0 N--CA 1.419 -2.005 0 CA-C-N 113.694 -1.593 . . . . 0.0 112.432 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -54.93 178.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 124.43 3.42 . . . . 0.0 113.872 179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.82 132.76 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.279 -177.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.403 ' C ' ' H ' ' A' ' 154' ' ' GLY . 37.9 t80 -101.67 97.72 8.1 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 113.733 -1.576 . . . . 0.0 109.057 178.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 68.52 -37.83 0.36 Allowed 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 124.149 0.98 . . . . 0.0 113.095 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 117.2 92.02 1.61 Allowed Glycine 0 C--N 1.338 0.687 0 N-CA-C 112.053 -0.419 . . . . 0.0 112.053 -179.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 17.4 p -95.0 105.39 17.31 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 123.18 0.592 . . . . 0.0 110.936 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 18.0 p -95.35 143.36 25.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.201 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -83.51 -37.46 0.16 Allowed 'Trans proline' 0 C--N 1.374 1.885 0 C-N-CA 122.485 2.123 . . . . 0.0 113.11 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.505 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 8.8 t -163.26 -62.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.812 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.505 ' H ' ' CG2' ' A' ' 158' ' ' THR . 31.3 mt-10 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 114.161 -1.381 . . . . 0.0 111.368 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.8 mtm . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.539 0.209 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 61.7 mtt180 -86.75 147.69 25.74 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.31 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -140.34 -58.57 0.04 OUTLIER Glycine 0 C--N 1.337 0.623 0 O-C-N 123.648 0.592 . . . . 0.0 112.672 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.0 m -95.94 150.4 20.49 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 122.423 0.289 . . . . 0.0 111.078 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.7 t-80 -123.57 -44.87 2.09 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 71.3 m-70 -118.46 147.87 43.17 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.417 0.448 . . . . 0.0 110.765 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -110.18 139.38 45.39 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.304 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -113.76 -44.68 3.16 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.242 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -116.98 145.49 43.62 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.389 0.431 . . . . 0.0 110.996 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 5.5 m80 -104.84 148.8 26.25 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.32 2.28 Favored Glycine 0 C--N 1.338 0.668 0 CA-C-N 116.036 -0.529 . . . . 0.0 113.26 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.12 161.14 13.79 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 120.894 0.378 . . . . 0.0 111.944 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -160.17 108.26 1.67 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.752 176.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.5 t -91.0 -13.75 32.72 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.18 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.42 ' HH ' HG22 ' A' ' 45' ' ' THR . 0.6 OUTLIER -96.91 122.57 40.02 Favored 'General case' 0 CA--C 1.503 -0.829 0 CA-C-O 121.644 0.735 . . . . 0.0 112.039 -179.157 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 27.3 p -98.37 155.15 17.36 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.922 -178.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.24 111.82 39.21 Favored Pre-proline 0 CA--C 1.54 0.593 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.685 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.6 Cg_exo -70.66 -21.54 29.18 Favored 'Trans proline' 0 C--N 1.366 1.456 0 C-N-CA 122.531 2.154 . . . . 0.0 112.667 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.804 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.77 -171.92 3.04 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.699 1.238 . . . . 0.0 110.335 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.528 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.26 -24.78 2.8 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 112.082 -2.326 . . . . 0.0 108.625 177.292 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.804 ' O ' HD12 ' A' ' 19' ' ' LEU . 9.3 t -168.21 -168.94 1.01 Allowed 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.162 -178.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.26 112.25 0.28 Allowed Glycine 0 C--N 1.32 -0.342 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.036 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.21 125.49 9.38 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 113.328 0.862 . . . . 0.0 113.328 -177.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.593 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.56 58.31 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.455 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.066 179.197 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.6 t -102.7 -28.13 12.3 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 112.89 -1.959 . . . . 0.0 110.829 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -115.14 -67.2 1.01 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.606 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.3 123.18 1.06 Allowed Glycine 0 C--O 1.235 0.196 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.371 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.534 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -75.11 157.44 34.7 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -55.7 31.92 0.0 OUTLIER 'General case' 0 C--O 1.241 0.618 0 N-CA-C 115.816 1.784 . . . . 0.0 115.816 -177.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.697 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 0.09 48.93 Favored Glycine 0 CA--C 1.505 -0.551 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -101.72 85.43 0.66 Allowed Pre-proline 0 CA--C 1.545 0.763 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.697 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.7 Cg_exo -77.03 138.88 18.72 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.655 2.236 . . . . 0.0 113.239 -178.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.77 4.11 70.14 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-N 115.873 -0.603 . . . . 0.0 113.12 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.471 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.4 t-80 -75.51 128.41 35.24 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 123.927 0.891 . . . . 0.0 110.743 -179.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -99.74 -14.14 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.239 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -126.04 -150.28 7.6 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.369 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.479 HG12 ' OH ' ' A' ' 39' ' ' TYR . 7.2 p -128.71 151.86 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-N 115.025 -0.588 . . . . 0.0 109.775 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.639 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -125.39 130.64 52.31 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.263 0.554 . . . . 0.0 112.409 -178.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.685 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.7 m-85 -122.89 109.78 14.59 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.102 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.92 104.93 0.41 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.243 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.45 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.0 p -145.55 124.43 6.66 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.01 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -48.95 141.79 21.13 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.386 2.724 . . . . 0.0 115.528 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.5 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 3.1 p -61.62 141.11 18.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 111.935 -2.393 . . . . 0.0 113.473 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.02 2.49 55.99 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.393 -0.821 . . . . 0.0 114.253 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' THR . . . . . 0.42 HG22 ' HH ' ' A' ' 15' ' ' TYR . 1.7 m -88.98 126.22 59.88 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-O 119.066 -0.492 . . . . 0.0 109.808 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.14 126.67 23.14 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.209 1.939 . . . . 0.0 113.074 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 107' ' ' ILE . 4.3 t -98.28 121.51 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.083 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.64 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.9 mtp180 -102.02 151.23 22.39 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 113.088 -1.869 . . . . 0.0 111.584 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -70.76 122.02 19.08 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.232 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.2 t -69.08 -14.16 18.17 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.592 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.55 144.17 1.86 Allowed 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 123.447 0.699 . . . . 0.0 110.603 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -62.59 156.86 22.05 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.835 -1.075 . . . . 0.0 112.386 179.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.617 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.32 -128.14 1.68 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.725 -0.67 . . . . 0.0 113.652 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 11.9 m -148.24 140.89 24.52 Favored 'General case' 0 N--CA 1.439 -0.975 0 C-N-CA 123.759 0.824 . . . . 0.0 109.668 -178.116 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.44 HG21 ' O ' ' A' ' 99' ' ' SER . 12.1 t -83.78 112.58 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 123.721 0.809 . . . . 0.0 109.034 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.407 ' HD3' ' O ' ' A' ' 54' ' ' THR . 6.6 mmmt -95.09 -14.72 23.99 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.844 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -156.09 141.8 17.89 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.01 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.24 92.22 2.16 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.406 -1.27 . . . . 0.0 109.074 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.447 ' O ' HD11 ' A' ' 93' ' ' ILE . . . -92.02 89.98 1.46 Allowed Glycine 0 C--O 1.239 0.447 0 CA-C-N 113.955 -1.475 . . . . 0.0 112.862 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.564 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -70.41 122.97 20.63 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.925 0.89 . . . . 0.0 112.866 -179.689 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.572 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.93 -0.59 88.8 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-N 113.253 -1.794 . . . . 0.0 113.626 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.54 -33.2 54.25 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -138.44 30.18 2.39 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.467 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.572 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.66 111.83 24.33 Favored Pre-proline 0 N--CA 1.437 -1.091 0 N-CA-C 113.907 1.077 . . . . 0.0 113.907 -178.265 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 35.4 Cg_exo -68.71 162.62 40.38 Favored 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.738 2.958 . . . . 0.0 111.563 177.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -96.74 9.76 40.75 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 175.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 61.2 mtm -76.91 -43.56 35.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.342 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.533 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.8 11.24 11.1 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.857 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.1 151.24 50.0 Favored 'General case' 0 C--N 1.361 1.089 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.738 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 36.2 mtt -145.68 -36.88 0.27 Allowed 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.621 179.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -86.43 -23.46 26.05 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.45 0.469 . . . . 0.0 111.881 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.598 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.25 -118.65 6.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.69 -0.686 . . . . 0.0 114.045 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.58 ' H ' ' HG1' ' A' ' 113' ' ' THR . 7.3 m-80 -82.57 135.64 35.03 Favored 'General case' 0 C--O 1.236 0.384 0 C-N-CA 123.225 0.61 . . . . 0.0 112.49 -178.532 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.01 146.56 26.3 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.983 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.608 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -139.2 121.02 16.48 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.205 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.2 130.73 56.99 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.333 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' THR . 9.1 mt -141.01 151.02 20.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 112.587 -2.097 . . . . 0.0 110.206 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.617 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.2 tt0 -99.83 117.14 33.51 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 114.123 -1.399 . . . . 0.0 108.547 178.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.592 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 3.9 m-70 -69.99 -177.93 1.46 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.535 -1.211 . . . . 0.0 114.07 -179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.57 -17.46 64.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 113.791 -1.55 . . . . 0.0 113.752 -178.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -97.58 -13.27 21.7 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 123.38 0.425 . . . . 0.0 110.749 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.51 -5.98 44.89 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.811 179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.553 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 16.5 ptp -70.65 165.53 22.68 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 122.866 0.466 . . . . 0.0 111.416 179.447 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -109.09 140.02 43.2 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.719 -179.164 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.554 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -135.82 127.1 28.3 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-O 121.033 0.444 . . . . 0.0 110.391 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.608 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -103.85 155.31 17.74 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 114.839 -1.073 . . . . 0.0 111.63 178.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.548 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 6.4 m-85 -132.11 99.24 4.65 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.79 167.54 10.41 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 65.62 41.49 4.02 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.591 -178.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.541 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.6 mt -101.4 170.36 8.27 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.822 177.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.2 t -105.27 -15.67 14.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 122.952 0.157 . . . . 0.0 111.37 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -168.95 160.44 10.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.658 0.742 . . . . 0.0 111.85 -178.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.607 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.37 149.64 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.638 -1.619 . . . . 0.0 110.949 179.329 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.91 -5.38 13.21 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.247 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.607 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -107.22 -175.42 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.387 -176.921 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.6 m -154.31 144.54 22.04 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.908 -1.042 . . . . 0.0 109.101 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.63 128.9 36.87 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.741 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 87.47 -4.97 0.61 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.778 1.231 . . . . 0.0 111.837 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.44 ' O ' HG21 ' A' ' 55' ' ' VAL . 8.7 t -81.67 148.13 29.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 110.44 -0.208 . . . . 0.0 110.44 178.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -83.9 145.85 28.37 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.385 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.82 168.38 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.449 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -142.18 148.55 38.4 Favored 'General case' 0 N--CA 1.427 -1.61 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.872 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.75 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.6 138.52 55.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.305 -179.771 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.64 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.78 -4.6 51.7 Favored Glycine 0 CA--C 1.516 0.117 0 CA-C-N 114.431 -1.259 . . . . 0.0 114.166 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.476 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -75.33 140.67 43.23 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.086 0.469 . . . . 0.0 109.933 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.36 100.86 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.586 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.476 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.7 -5.4 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 113.706 -1.588 . . . . 0.0 113.257 -178.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 -159.83 32.69 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 121.515 -0.374 . . . . 0.0 112.427 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.541 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 33.9 m-85 -140.37 138.48 34.85 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.572 1.149 . . . . 0.0 108.378 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.415 ' HG1' ' HB ' ' A' ' 45' ' ' THR . 0.7 OUTLIER -62.65 150.09 41.76 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.659 0.784 . . . . 0.0 112.46 -178.821 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.5 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -157.35 -164.95 14.33 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 119.884 -1.151 . . . . 0.0 114.153 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.3 52.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 178.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.598 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 38.8 p -80.88 1.49 30.58 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.248 -0.887 . . . . 0.0 113.355 -177.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.16 -162.89 23.77 Favored Glycine 0 C--N 1.337 0.59 0 C-N-CA 121.314 -0.469 . . . . 0.0 112.22 179.318 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.9 mt-30 -92.66 91.52 7.57 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-O 121.23 0.538 . . . . 0.0 110.885 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.4 m -152.01 167.44 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.97 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 p -89.69 -10.68 44.87 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.144 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -159.18 170.02 35.47 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.395 -0.669 . . . . 0.0 113.252 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.43 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 6.0 Cg_exo -79.42 146.77 19.69 Favored 'Trans proline' 0 C--N 1.373 1.854 0 C-N-CA 123.291 2.661 . . . . 0.0 112.529 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.45 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 38.1 p-80 -160.72 -166.69 1.67 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.528 0.68 . . . . 0.0 111.851 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.639 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 15.9 tp -129.47 137.92 51.12 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.064 -1.425 . . . . 0.0 110.313 -178.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.427 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 23.9 t60 -121.59 114.93 21.88 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.284 -1.326 . . . . 0.0 110.184 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -119.01 107.79 13.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.182 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.554 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.0 pt-20 -112.82 127.52 56.19 Favored 'General case' 0 N--CA 1.432 -1.327 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.57 179.085 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.44 ' HE3' ' SD ' ' A' ' 83' ' ' MET . 6.7 ttt -122.76 134.51 54.44 Favored 'General case' 0 N--CA 1.434 -1.255 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.152 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.608 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -141.69 164.73 32.73 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 113.271 -1.786 . . . . 0.0 110.113 -177.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -63.16 -178.57 0.45 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 122.889 2.393 . . . . 0.0 113.277 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -69.09 -28.92 66.93 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.975 176.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.429 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.0 OUTLIER -157.84 103.45 1.77 Allowed Pre-proline 0 CA--C 1.503 -0.841 0 CA-C-N 114.008 -1.451 . . . . 0.0 108.798 179.798 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 4.0 Cg_exo -72.03 163.22 39.46 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.612 2.208 . . . . 0.0 116.971 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.583 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.5 69.62 0.77 Allowed 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 112.332 -2.213 . . . . 0.0 107.581 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.19 12.3 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 114.319 -1.31 . . . . 0.0 112.412 -178.638 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.583 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 33.15 0.37 Allowed 'General case' 0 N--CA 1.444 -0.77 0 C-N-CA 124.306 1.043 . . . . 0.0 112.811 -178.462 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 73.11 128.79 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 113.729 -1.578 . . . . 0.0 110.745 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.26 -48.41 0.6 Allowed Glycine 0 N--CA 1.439 -1.135 0 CA-C-N 114.971 -1.013 . . . . 0.0 112.964 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.582 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -152.21 -18.96 0.18 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 179.161 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.8 m 66.12 17.74 10.83 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 122.59 1.186 . . . . 0.0 108.224 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.608 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.3 -11.32 9.0 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 112.547 -2.115 . . . . 0.0 112.673 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.582 ' HG3' ' O ' ' A' ' 136' ' ' PHE . 0.0 OUTLIER -79.64 121.7 25.61 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 111.737 0.273 . . . . 0.0 111.737 -179.012 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.93 -172.93 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.441 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -79.34 128.64 74.86 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.641 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.7 Cg_exo -76.76 -3.21 13.52 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 122.934 2.423 . . . . 0.0 113.445 178.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.86 -23.49 2.84 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.69 -30.25 70.79 Favored Glycine 0 N--CA 1.461 0.342 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.472 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -104.24 -11.35 17.27 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 122.902 0.481 . . . . 0.0 111.685 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.641 HG12 ' O ' ' A' ' 142' ' ' PRO . 18.8 mm -96.34 -8.79 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.815 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -77.0 -21.0 55.35 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.173 177.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -102.23 15.3 29.54 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.384 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.582 ' HB2' ' O ' ' A' ' 146' ' ' ILE . . . -89.7 168.94 13.64 Favored Pre-proline 0 N--CA 1.417 -2.086 0 CA-C-N 113.69 -1.596 . . . . 0.0 112.552 -179.179 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.421 ' HD2' ' CB ' ' A' ' 149' ' ' ALA . 13.0 Cg_endo -54.89 178.77 0.08 OUTLIER 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 124.478 3.452 . . . . 0.0 114.261 179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.3 t -107.32 132.22 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 121.731 0.777 . . . . 0.0 111.473 -177.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -102.44 98.41 8.51 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.146 178.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 69.32 -38.58 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 124.118 0.967 . . . . 0.0 113.067 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 147.3 81.79 0.04 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.1 p -91.09 105.21 17.65 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-O 121.512 0.673 . . . . 0.0 111.239 -179.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.6 p -98.83 127.15 36.21 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.442 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -81.79 -43.75 0.09 OUTLIER 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 122.271 1.981 . . . . 0.0 113.413 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.533 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 7.3 t -163.11 -66.42 0.04 OUTLIER 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.279 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.533 ' H ' ' CG2' ' A' ' 158' ' ' THR . 9.6 mm-40 . . . . . 0 C--O 1.252 1.197 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.546 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 mtt . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 111.642 0.238 . . . . 0.0 111.642 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 50.5 mtt180 -105.71 -39.02 6.2 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 123.277 0.361 . . . . 0.0 111.411 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 104.47 51.75 0.9 Allowed Glycine 0 C--N 1.338 0.682 0 O-C-N 123.445 0.466 . . . . 0.0 112.808 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.2 t -123.14 136.16 54.66 Favored 'General case' 0 C--O 1.236 0.346 0 O-C-N 123.571 0.218 . . . . 0.0 110.627 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.7 p-80 -108.4 134.27 51.42 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.468 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 68.6 m-70 -124.41 -42.67 2.09 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.253 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -127.06 148.41 50.13 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.293 0.371 . . . . 0.0 111.442 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -127.98 134.0 49.23 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.602 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.3 p-80 -111.16 120.11 41.2 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.177 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 64.7 m80 -94.87 146.2 24.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.944 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 155.78 23.49 0.03 OUTLIER Glycine 0 C--N 1.337 0.634 0 CA-C-N 116.027 -0.533 . . . . 0.0 113.203 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.4 167.85 11.08 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.865 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -159.01 104.87 1.73 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.1 177.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.5 t -97.08 -25.87 15.19 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.951 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -98.98 138.44 36.08 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.437 0.637 . . . . 0.0 111.629 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 47.1 p -95.66 172.98 7.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 113.972 -1.467 . . . . 0.0 112.206 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.449 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.8 OUTLIER -83.99 112.73 42.97 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 123.791 0.836 . . . . 0.0 112.098 -179.533 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.642 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.0 Cg_exo -67.0 -24.04 45.92 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.699 2.266 . . . . 0.0 112.607 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.83 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.47 -171.95 2.89 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-O 122.402 1.096 . . . . 0.0 109.961 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.503 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.99 -25.41 3.04 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 112.452 -2.158 . . . . 0.0 108.532 177.091 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.83 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.5 t -169.39 -168.84 0.85 Allowed 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.593 -178.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.92 110.77 0.29 Allowed Glycine 0 C--N 1.317 -0.487 0 CA-C-N 114.513 -1.221 . . . . 0.0 111.171 176.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.16 124.84 8.4 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 112.829 0.677 . . . . 0.0 112.829 -178.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.524 HD11 ' H ' ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.99 58.58 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.995 -1.457 . . . . 0.0 109.097 178.551 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.3 t -104.54 -28.05 11.52 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 112.729 -2.032 . . . . 0.0 111.123 179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -116.19 -66.7 1.06 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.648 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.29 122.98 1.04 Allowed Glycine 0 N--CA 1.459 0.201 0 CA-C-N 115.011 -0.995 . . . . 0.0 112.011 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.522 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -73.49 157.26 37.12 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -178.504 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -57.86 31.89 0.0 OUTLIER 'General case' 0 C--O 1.239 0.538 0 N-CA-C 115.821 1.786 . . . . 0.0 115.821 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.678 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -1.66 48.83 Favored Glycine 0 CA--C 1.504 -0.634 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.94 85.31 0.67 Allowed Pre-proline 0 CA--C 1.548 0.866 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.678 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.6 Cg_exo -77.97 139.2 17.14 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 122.823 2.349 . . . . 0.0 113.352 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.14 4.17 69.1 Favored Glycine 0 C--N 1.339 0.727 0 O-C-N 123.685 0.615 . . . . 0.0 112.997 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.437 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.0 t-80 -78.24 135.43 37.57 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.047 0.939 . . . . 0.0 110.497 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.439 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.32 -12.53 9.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.242 -179.35 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -125.87 -149.77 7.51 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.431 HG13 ' OH ' ' A' ' 39' ' ' TYR . 14.4 p -129.82 152.88 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 O-C-N 123.892 0.407 . . . . 0.0 110.133 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.697 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 93.1 m-20 -129.32 131.97 47.03 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.24 0.543 . . . . 0.0 112.242 -178.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.642 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.5 m-85 -122.86 109.48 14.23 Favored 'General case' 0 C--O 1.238 0.5 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.165 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.86 104.26 0.18 Allowed 'General case' 0 CA--C 1.541 0.633 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.339 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.462 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.4 p -144.84 123.91 6.9 Favored Pre-proline 0 CA--C 1.549 0.934 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.855 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -49.02 142.7 19.54 Favored 'Trans proline' 0 C--N 1.371 1.737 0 C-N-CA 123.307 2.671 . . . . 0.0 115.423 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.462 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.09 141.01 17.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 111.582 -2.554 . . . . 0.0 113.619 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.53 2.73 55.45 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.552 -0.749 . . . . 0.0 114.341 177.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' THR . . . . . 0.502 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.1 m -88.01 123.46 68.78 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-O 119.146 -0.454 . . . . 0.0 109.932 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.24 127.11 24.9 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.328 2.019 . . . . 0.0 113.449 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.495 ' O ' HG13 ' A' ' 107' ' ' ILE . 4.8 t -99.68 121.82 50.79 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.138 179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.504 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 2.3 mpt_? -103.19 152.49 21.4 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 113.331 -1.759 . . . . 0.0 111.481 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.407 ' HB2' ' O ' ' A' ' 102' ' ' LYS . . . -71.69 121.46 18.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.441 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.03 -15.64 19.96 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 112.775 0.658 . . . . 0.0 112.775 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.582 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.46 144.46 1.94 Allowed 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 123.462 0.705 . . . . 0.0 110.346 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.78 157.07 18.85 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 115.077 -0.965 . . . . 0.0 112.331 179.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.638 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.01 -127.15 1.54 Allowed Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.744 -0.662 . . . . 0.0 113.849 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.9 m -148.09 141.3 25.08 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 123.678 0.791 . . . . 0.0 109.683 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.452 HG21 ' O ' ' A' ' 99' ' ' SER . 11.3 t -83.49 111.66 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 123.719 0.808 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.7 mmmt -94.35 -15.72 24.13 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.726 -1.125 . . . . 0.0 110.643 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -153.9 140.01 18.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.041 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.53 92.33 2.15 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.906 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.494 ' O ' HD12 ' A' ' 93' ' ' ILE . . . -95.05 89.87 1.23 Allowed Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.953 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.566 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.46 125.54 27.66 Favored 'General case' 0 C--N 1.346 0.418 0 C-N-CA 123.795 0.838 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.651 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -79.93 -0.66 85.94 Favored Glycine 0 CA--C 1.52 0.392 0 CA-C-N 113.354 -1.748 . . . . 0.0 113.389 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.11 -32.05 39.1 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 24.86 2.68 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.144 -178.392 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.651 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -79.45 113.88 40.59 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.418 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.813 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.4 Cg_exo -67.69 163.23 36.01 Favored 'Trans proline' 0 C--N 1.37 1.688 0 C-N-CA 123.729 2.953 . . . . 0.0 111.556 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 62.1 m95 -98.2 10.54 40.33 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 14.7 mmt -75.58 -44.55 42.6 Favored 'General case' 0 C--N 1.349 0.552 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.057 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.542 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -120.92 11.51 11.07 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.783 177.439 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.813 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.05 145.92 51.14 Favored 'General case' 0 C--N 1.359 1.005 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.701 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.9 tpt -145.56 -31.02 0.4 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.488 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.78 -23.44 24.08 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.542 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 101.71 -128.68 9.64 Favored Glycine 0 CA--C 1.522 0.48 0 O-C-N 123.543 0.527 . . . . 0.0 114.025 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.797 ' H ' ' HG1' ' A' ' 113' ' ' THR . 11.8 m-80 -78.8 138.84 38.39 Favored 'General case' 0 C--N 1.347 0.458 0 C-N-CA 123.381 0.672 . . . . 0.0 112.586 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.487 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.33 145.23 23.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.008 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.593 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.1 t -138.55 120.58 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.158 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.03 131.22 56.99 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.412 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 9.3 mt -141.02 150.91 20.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 112.695 -2.048 . . . . 0.0 110.2 -176.62 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.638 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.5 tt0 -97.72 116.49 30.03 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 113.984 -1.462 . . . . 0.0 108.294 178.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.582 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 2.2 m-70 -69.17 -175.85 0.82 Allowed 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.561 -1.199 . . . . 0.0 114.159 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -64.97 -17.78 64.69 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 113.867 -1.515 . . . . 0.0 114.485 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -101.79 -9.86 20.43 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-O 120.826 0.346 . . . . 0.0 111.128 -179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.78 -6.09 43.92 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.061 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.4 ptt? -68.92 168.4 13.7 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 123.712 0.805 . . . . 0.0 111.456 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.419 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 55.6 m-70 -112.55 142.7 44.81 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.024 -179.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.26 127.06 25.54 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-O 121.041 0.448 . . . . 0.0 110.022 179.706 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.593 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.49 154.59 17.1 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.629 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.1 m-85 -135.1 99.17 4.19 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.11 168.8 9.5 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 65.28 41.86 4.2 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 124.159 0.984 . . . . 0.0 111.44 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.528 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.0 mt -102.94 169.41 8.6 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.037 178.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.4 t -103.88 -16.47 15.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -167.32 162.37 14.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.801 0.81 . . . . 0.0 112.018 -178.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.663 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.9 OUTLIER -127.83 147.82 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.643 179.298 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -110.47 -6.8 14.84 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 114.402 -1.272 . . . . 0.0 109.899 178.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.663 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.73 -175.12 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.073 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.733 -176.89 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 6.9 t -154.18 148.44 25.95 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.79 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 m -58.5 128.98 39.88 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.622 -179.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 t70 86.96 -5.71 0.67 Allowed 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 124.634 1.174 . . . . 0.0 111.722 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.452 ' O ' HG21 ' A' ' 55' ' ' VAL . 31.7 m -79.82 149.63 30.96 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 122.272 0.229 . . . . 0.0 110.711 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -84.94 145.0 27.98 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.382 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.01 168.14 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.437 -179.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.407 ' O ' ' HB2' ' A' ' 49' ' ' ALA . 42.9 tttm -140.5 149.58 42.66 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.844 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.754 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.17 138.59 56.07 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.383 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.504 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.64 -4.55 50.82 Favored Glycine 0 CA--C 1.517 0.185 0 CA-C-N 114.387 -1.278 . . . . 0.0 114.076 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.459 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.0 tt0 -75.2 140.57 43.38 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-O 121.086 0.47 . . . . 0.0 110.026 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 52.4 mt -72.11 101.46 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.64 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.59 -5.01 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-N 113.512 -1.676 . . . . 0.0 113.17 -178.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.65 -161.9 35.64 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.363 0.424 . . . . 0.0 112.571 178.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.528 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.2 m-85 -139.88 138.06 35.37 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 124.561 1.144 . . . . 0.0 108.339 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.502 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.6 OUTLIER -62.3 150.53 39.05 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 123.913 0.758 . . . . 0.0 112.572 -178.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.471 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -160.23 -161.54 11.51 Favored Glycine 0 C--N 1.348 1.232 0 C-N-CA 119.844 -1.17 . . . . 0.0 114.119 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.1 50.78 0.91 Allowed 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.632 -0.784 . . . . 0.0 108.99 178.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.797 ' HG1' ' H ' ' A' ' 73' ' ' ASN . 32.6 p -78.99 5.96 10.47 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.137 -0.938 . . . . 0.0 113.094 -177.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -108.5 -160.6 20.14 Favored Glycine 0 C--N 1.338 0.641 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.154 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -96.95 91.46 5.62 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.309 0.576 . . . . 0.0 110.331 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.7 m -152.69 172.0 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.07 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 14.9 p -93.45 -14.22 27.0 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -179.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -155.6 166.47 32.82 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.351 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -77.71 145.67 23.18 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 123.111 2.54 . . . . 0.0 112.414 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.462 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 47.6 p-80 -159.71 -164.91 1.41 Allowed 'General case' 0 C--N 1.351 0.667 0 CA-C-O 121.68 0.753 . . . . 0.0 112.259 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.697 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 16.9 tp -129.7 133.41 47.04 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.433 -178.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.413 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 18.4 t60 -118.18 113.39 21.46 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.288 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -119.04 108.94 15.34 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.303 -179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 85' ' ' THR . 20.3 tt0 -117.3 127.15 53.79 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.197 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.413 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 1.9 tpt -118.13 139.81 50.7 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.646 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.546 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -143.98 165.46 24.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 CA-C-N 113.426 -1.715 . . . . 0.0 110.619 -177.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.419 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 14.1 Cg_endo -63.62 -178.68 0.55 Allowed 'Trans proline' 0 C--N 1.37 1.67 0 C-N-CA 122.842 2.361 . . . . 0.0 112.948 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.16 -27.33 63.47 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.085 176.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.411 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 0.7 OUTLIER -157.44 101.95 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.77 0 CA-C-N 114.03 -1.441 . . . . 0.0 108.871 179.786 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 3.0 Cg_exo -71.71 163.39 39.07 Favored 'Trans proline' 0 N--CA 1.446 -1.314 0 C-N-CA 122.711 2.274 . . . . 0.0 116.874 -177.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.585 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -117.23 70.33 0.78 Allowed 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 112.532 -2.122 . . . . 0.0 107.649 177.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.448 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.25 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 114.298 -1.319 . . . . 0.0 112.54 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.585 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.63 33.35 0.36 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.122 0.969 . . . . 0.0 112.996 -178.15 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 73.26 127.46 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.583 0 C-N-CA 125.663 1.585 . . . . 0.0 110.598 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.31 -50.04 0.56 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.343 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.45 -18.92 0.24 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 179.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 39.5 m 66.01 17.74 10.87 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 122.473 1.13 . . . . 0.0 108.157 -178.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.546 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.07 -9.63 18.11 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 112.6 -2.091 . . . . 0.0 112.734 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.536 ' HD2' ' O ' ' A' ' 139' ' ' ARG . 3.2 ppt_? -82.9 127.35 33.42 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 119.854 -0.738 . . . . 0.0 112.362 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.427 HG23 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -128.07 -173.14 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.629 179.179 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.427 ' H ' HG23 ' A' ' 140' ' ' ILE . 1.4 m-20 -73.28 129.8 85.4 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.571 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.3 0.22 9.96 Favored 'Trans proline' 0 C--N 1.38 2.226 0 C-N-CA 122.954 2.436 . . . . 0.0 113.341 177.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.411 ' H ' ' HG1' ' A' ' 143' ' ' THR . 0.8 OUTLIER -52.31 -23.78 6.39 Favored 'General case' 0 C--N 1.349 0.548 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.22 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.86 -25.59 74.56 Favored Glycine 0 CA--C 1.52 0.362 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.92 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -101.99 -11.67 18.75 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 123.248 0.619 . . . . 0.0 111.16 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.571 HG12 ' O ' ' A' ' 142' ' ' PRO . 20.8 mm -100.16 -9.76 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -75.71 -24.73 56.23 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.739 178.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -101.29 14.5 31.77 Favored 'General case' 0 N--CA 1.433 -1.28 0 CA-C-O 122.051 0.929 . . . . 0.0 109.042 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 146' ' ' ILE . . . -94.41 164.5 19.87 Favored Pre-proline 0 N--CA 1.417 -2.115 0 CA-C-N 113.538 -1.665 . . . . 0.0 112.444 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -55.51 178.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.366 1.473 0 C-N-CA 124.622 3.548 . . . . 0.0 114.08 179.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 86.8 t -109.04 127.04 66.02 Favored 'Isoleucine or valine' 0 C--N 1.341 0.237 0 CA-C-O 121.488 0.661 . . . . 0.0 111.193 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.449 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 38.2 t80 -104.27 97.92 7.8 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.022 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 68.78 -38.69 0.4 Allowed 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.315 1.046 . . . . 0.0 113.137 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 122.62 83.29 0.64 Allowed Glycine 0 C--N 1.337 0.631 0 N-CA-C 112.183 -0.367 . . . . 0.0 112.183 -179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.1 p -93.6 105.59 17.62 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 123.498 0.719 . . . . 0.0 111.226 -179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 18.6 p -91.86 132.43 32.91 Favored Pre-proline 0 CA--C 1.54 0.56 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.729 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -83.16 -43.65 0.08 OUTLIER 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 122.295 1.996 . . . . 0.0 113.457 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.516 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 6.4 t -159.94 -64.89 0.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.177 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.516 ' H ' ' CG2' ' A' ' 158' ' ' THR . 33.8 mt-10 . . . . . 0 C--O 1.249 1.049 0 CA-C-N 114.33 -1.305 . . . . 0.0 111.752 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 55.0 mtt . . . . . 0 N--CA 1.487 1.397 0 CA-C-O 120.701 0.286 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -92.64 131.86 37.38 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.216 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.34 -86.18 0.06 OUTLIER Glycine 0 C--N 1.336 0.552 0 O-C-N 123.664 0.602 . . . . 0.0 112.414 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.0 m -114.79 131.0 56.95 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.329 0.252 . . . . 0.0 110.849 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -131.11 -43.11 1.07 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.4 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.9 m-70 -121.09 -43.04 2.45 Favored 'General case' 0 C--O 1.236 0.363 0 O-C-N 123.347 0.404 . . . . 0.0 111.478 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -102.39 142.79 33.02 Favored 'General case' 0 C--O 1.235 0.316 0 O-C-N 123.329 0.393 . . . . 0.0 111.155 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.4 m80 -95.28 -43.76 7.91 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.073 179.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.9 m80 -117.08 126.56 53.03 Favored 'General case' 0 C--O 1.235 0.296 0 O-C-N 123.558 0.536 . . . . 0.0 110.464 179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -126.05 140.09 52.88 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.703 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.66 42.87 1.74 Allowed Glycine 0 C--N 1.337 0.619 0 CA-C-N 116.064 -0.516 . . . . 0.0 112.59 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.12 169.24 13.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.942 0.401 . . . . 0.0 111.831 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.78 104.47 2.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.835 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 t -89.51 6.09 42.53 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-N 115.382 -0.827 . . . . 0.0 112.068 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -94.54 144.33 25.67 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-O 121.573 0.701 . . . . 0.0 111.434 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.6 p -92.82 179.91 5.33 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.116 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.705 HH11 HG22 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -63.28 113.0 8.07 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 124.596 1.158 . . . . 0.0 112.941 -179.548 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.651 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 20.1 Cg_exo -67.47 -21.21 46.95 Favored 'Trans proline' 0 C--N 1.368 1.589 0 C-N-CA 122.662 2.241 . . . . 0.0 112.344 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.803 HD11 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -138.72 -171.97 3.2 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.482 1.134 . . . . 0.0 110.104 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.524 ' H ' HD13 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.69 -25.25 3.15 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 112.332 -2.213 . . . . 0.0 108.699 177.237 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.803 ' O ' HD11 ' A' ' 19' ' ' LEU . 8.5 t -168.99 -168.64 0.87 Allowed 'General case' 0 CA--C 1.546 0.808 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.525 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 177.4 111.18 0.29 Allowed Glycine 0 C--N 1.321 -0.281 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.483 177.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.57 124.41 8.56 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.472 0.653 . . . . 0.0 112.632 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.502 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.11 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.502 0 CA-C-N 113.949 -1.478 . . . . 0.0 109.255 178.79 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.9 t -106.46 -27.68 10.77 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 113.134 -1.848 . . . . 0.0 110.873 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.2 -67.26 1.01 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.721 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.51 123.94 1.14 Allowed Glycine 0 C--O 1.234 0.151 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.14 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.529 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -76.94 157.5 31.26 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.641 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -58.02 31.67 0.0 OUTLIER 'General case' 0 C--O 1.24 0.558 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -177.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.685 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 -0.88 48.61 Favored Glycine 0 CA--C 1.506 -0.484 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -101.6 85.55 0.67 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.685 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.07 137.89 15.86 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.807 2.338 . . . . 0.0 113.225 -178.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.41 4.07 71.29 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.149 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-80 -76.12 135.12 39.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.975 0.91 . . . . 0.0 110.37 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.559 HG11 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.68 -16.35 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.342 -179.021 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.54 -149.71 8.14 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.444 HG11 ' OH ' ' A' ' 39' ' ' TYR . 10.6 p -131.33 151.03 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 124.031 0.489 . . . . 0.0 110.042 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.688 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 89.1 m-20 -125.96 134.19 51.59 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.323 0.582 . . . . 0.0 112.046 -178.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.651 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -124.71 110.07 13.91 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 114.244 -1.344 . . . . 0.0 110.251 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.49 104.64 0.23 Allowed 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.544 178.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.469 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 12.5 p -145.98 124.78 6.53 Favored Pre-proline 0 CA--C 1.551 0.996 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.887 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.01 142.02 20.94 Favored 'Trans proline' 0 C--N 1.37 1.694 0 C-N-CA 123.346 2.697 . . . . 0.0 115.261 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.456 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -61.39 140.15 19.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 111.848 -2.433 . . . . 0.0 113.615 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.64 54.61 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.418 -0.81 . . . . 0.0 114.36 177.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' THR . . . . . 0.45 ' HB ' ' HG1' ' A' ' 110' ' ' THR . 1.9 m -87.32 125.37 65.99 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.257 -0.401 . . . . 0.0 109.952 179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.34 127.69 26.57 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.291 1.994 . . . . 0.0 113.468 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 107' ' ' ILE . 9.8 t -99.96 123.36 52.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.154 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.643 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 13.6 mtp180 -101.91 152.15 21.26 Favored 'General case' 0 N--CA 1.433 -1.302 0 CA-C-N 112.963 -1.926 . . . . 0.0 111.659 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.48 120.96 18.82 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.846 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.1 t -66.68 -15.78 19.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.881 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.626 ' HB2' ' CE1' ' A' ' 79' ' ' HIS . . . -171.82 143.59 1.67 Allowed 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.546 0.738 . . . . 0.0 110.355 179.111 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.36 155.42 18.04 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.234 -0.894 . . . . 0.0 112.206 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.622 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 170.32 -128.63 1.67 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.891 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 m -148.16 136.35 21.24 Favored 'General case' 0 N--CA 1.44 -0.968 0 C-N-CA 123.446 0.698 . . . . 0.0 110.33 -178.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.433 HG22 ' O ' ' A' ' 99' ' ' SER . 11.1 t -83.89 112.44 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.697 ' HZ1' ' HB2' ' A' ' 78' ' ' GLN . 0.2 OUTLIER -98.09 -16.63 19.48 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.841 179.846 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -148.54 138.52 22.33 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.737 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.9 92.17 2.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.494 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -93.17 89.85 1.37 Allowed Glycine 0 C--O 1.24 0.478 0 CA-C-N 114.128 -1.396 . . . . 0.0 112.802 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.558 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.56 125.71 27.77 Favored 'General case' 0 C--N 1.345 0.395 0 C-N-CA 123.964 0.905 . . . . 0.0 112.517 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.639 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.26 -0.74 87.12 Favored Glycine 0 CA--C 1.52 0.349 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.375 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.69 -31.85 52.69 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.45 25.51 2.65 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.069 -178.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.639 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -80.6 112.93 35.62 Favored Pre-proline 0 N--CA 1.435 -1.2 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.16 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.836 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.0 Cg_exo -67.81 163.45 35.36 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.987 3.125 . . . . 0.0 111.821 177.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.0 m95 -96.79 8.82 43.44 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -75.2 -44.48 46.21 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.398 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.536 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.84 10.9 11.01 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.714 177.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.836 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -128.83 145.92 51.07 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.537 -178.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 32.8 mtt -146.19 -29.18 0.41 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.421 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.44 -24.79 24.05 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.677 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.616 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.6 -123.98 8.09 Favored Glycine 0 CA--C 1.519 0.315 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.753 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.505 HD22 ' HA3' ' A' ' 61' ' ' GLY . 17.2 m-80 -81.17 138.21 35.87 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 123.237 0.615 . . . . 0.0 111.95 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.55 148.16 27.67 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.343 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.607 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.4 t -140.23 122.13 15.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.065 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.34 127.6 53.85 Favored 'General case' 0 CA--C 1.494 -1.188 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.7 mt -139.19 150.96 22.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 112.548 -2.115 . . . . 0.0 110.404 -176.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.697 ' HB2' ' HZ1' ' A' ' 56' ' ' LYS . 1.4 tt0 -99.3 117.04 32.88 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.944 -1.48 . . . . 0.0 108.603 178.011 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.626 ' CE1' ' HB2' ' A' ' 51' ' ' ALA . 2.0 m-70 -67.27 -176.37 0.56 Allowed 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.48 -17.67 64.93 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 114.107 -1.406 . . . . 0.0 114.313 -177.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.72 -10.19 21.07 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.905 0.383 . . . . 0.0 110.956 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.402 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.76 -4.78 42.75 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.192 179.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.448 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.7 ptt? -69.04 171.1 8.68 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 123.512 0.725 . . . . 0.0 111.683 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.3 m170 -108.96 147.04 32.86 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.011 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -141.5 126.63 18.45 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.947 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.607 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -108.96 154.57 16.43 Favored Glycine 0 N--CA 1.439 -1.146 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.401 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.469 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.1 m-85 -136.77 99.35 4.02 Favored 'General case' 0 N--CA 1.437 -1.075 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.453 ' HB2' ' CG ' ' A' ' 122' ' ' HIS . . . -113.32 167.93 10.16 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 38.7 m80 65.75 40.69 4.22 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.779 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.514 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 12.1 mt -100.93 169.98 8.6 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.76 177.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.5 t -106.38 -15.51 14.8 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 111.457 0.169 . . . . 0.0 111.457 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 6.8 tttt -167.95 156.87 9.4 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.618 0.723 . . . . 0.0 111.99 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.665 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -120.84 148.83 23.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 113.844 -1.526 . . . . 0.0 110.72 178.917 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -112.01 -5.98 14.24 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.209 178.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.665 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.67 -175.1 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.088 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.683 -177.067 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.4 m -153.33 143.94 22.61 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 114.867 -1.061 . . . . 0.0 109.002 -178.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -56.47 126.61 27.26 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.184 -0.917 . . . . 0.0 111.785 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 t70 89.15 -4.77 0.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 124.807 1.243 . . . . 0.0 111.587 178.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.433 ' O ' HG22 ' A' ' 55' ' ' VAL . 50.7 m -81.7 146.05 30.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 122.176 0.191 . . . . 0.0 110.588 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -82.64 145.83 29.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.215 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.93 167.9 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.48 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -140.09 147.38 40.19 Favored 'General case' 0 N--CA 1.428 -1.574 0 CA-C-N 114.417 -1.265 . . . . 0.0 109.836 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.753 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.1 138.8 54.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.128 -1.397 . . . . 0.0 111.693 -179.717 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.643 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.69 -6.78 37.29 Favored Glycine 0 CA--C 1.517 0.156 0 CA-C-N 114.361 -1.291 . . . . 0.0 114.129 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -73.11 140.23 46.98 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-O 121.104 0.478 . . . . 0.0 110.013 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.05 101.19 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.401 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.464 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.8 -5.44 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.88 0 CA-C-N 113.739 -1.573 . . . . 0.0 113.101 -178.867 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.3 -162.14 34.76 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-O 121.272 0.374 . . . . 0.0 112.683 178.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.514 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 24.6 m-85 -141.37 137.12 32.1 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 124.816 1.246 . . . . 0.0 108.272 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.45 ' HG1' ' HB ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -61.35 151.46 32.12 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.615 0.766 . . . . 0.0 112.654 -178.724 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.469 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -157.38 -162.17 11.41 Favored Glycine 0 C--N 1.347 1.185 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.798 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.37 47.72 0.89 Allowed 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -0.7 . . . . 0.0 109.261 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.616 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 34.4 p -80.21 3.17 21.61 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.213 -0.903 . . . . 0.0 113.292 -177.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -95.31 -96.35 1.72 Allowed Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -96.75 143.51 27.62 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.2 m -91.75 97.05 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.651 0.739 . . . . 0.0 111.901 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 37.6 p -147.06 -52.69 0.21 Allowed 'General case' 0 C--O 1.235 0.302 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.621 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.29 143.74 8.0 Favored Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.599 -1.112 . . . . 0.0 111.54 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.416 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 10.0 Cg_exo -69.8 141.95 46.43 Favored 'Trans proline' 0 C--N 1.374 1.912 0 CA-C-N 120.251 2.025 . . . . 0.0 111.725 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.469 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 53.2 p-80 -157.77 -171.56 3.59 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.495 0.664 . . . . 0.0 111.774 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.688 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 9.1 tp -125.23 139.85 53.36 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.099 -1.409 . . . . 0.0 110.565 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.523 ' HE2' ' HB2' ' A' ' 124' ' ' GLU . 29.1 t60 -118.32 128.54 54.75 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 113.706 -1.588 . . . . 0.0 107.845 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -133.0 111.26 10.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.847 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.523 ' HB2' ' HE2' ' A' ' 122' ' ' HIS . 18.0 tt0 -120.31 127.18 52.11 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.238 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.456 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.8 tpt -120.26 138.01 53.91 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.666 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.1 mp -143.6 164.68 29.13 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 113.439 -1.709 . . . . 0.0 110.298 -178.16 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -62.83 -178.81 0.43 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.943 2.429 . . . . 0.0 112.669 177.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -68.57 -27.82 66.41 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.206 176.195 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -157.35 107.93 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.781 0 CA-C-N 113.903 -1.498 . . . . 0.0 108.232 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -71.15 163.12 40.26 Favored 'Trans proline' 0 N--CA 1.445 -1.326 0 C-N-CA 122.347 2.031 . . . . 0.0 116.926 -176.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.581 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.89 70.82 0.8 Allowed 'General case' 0 N--CA 1.423 -1.805 0 CA-C-N 112.349 -2.205 . . . . 0.0 107.395 177.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.447 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.29 13.99 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.168 -1.378 . . . . 0.0 112.376 -178.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.581 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.23 32.3 0.33 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.269 1.027 . . . . 0.0 112.902 -178.361 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . 0.405 ' H ' ' C ' ' A' ' 132' ' ' TRP . 9.9 m-80 72.21 127.96 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 125.737 1.615 . . . . 0.0 110.997 178.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.11 -48.08 0.61 Allowed Glycine 0 N--CA 1.437 -1.278 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.341 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.68 -19.52 0.16 Allowed 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.43 18.22 10.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 122.624 1.202 . . . . 0.0 108.19 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.571 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 79.77 -11.66 32.75 Favored Glycine 0 N--CA 1.434 -1.449 0 CA-C-N 112.252 -2.249 . . . . 0.0 112.648 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.559 ' HG2' HG11 ' A' ' 35' ' ' VAL . 0.8 OUTLIER -83.98 125.02 31.65 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.301 -179.434 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.425 HG21 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -125.24 -172.96 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.585 -0.734 . . . . 0.0 112.441 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.425 ' H ' HG21 ' A' ' 140' ' ' ILE . 2.9 t70 -75.82 134.77 71.63 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -176.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.585 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.9 Cg_endo -77.16 0.62 9.54 Favored 'Trans proline' 0 C--N 1.381 2.277 0 C-N-CA 123.082 2.521 . . . . 0.0 113.546 177.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -51.34 -24.08 4.32 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.69 -28.95 66.24 Favored Glycine 0 CA--C 1.521 0.45 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.912 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -99.71 -11.86 20.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 123.347 0.659 . . . . 0.0 111.194 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.705 HG22 HH11 ' A' ' 17' ' ' ARG . 31.2 mm -98.8 -10.47 8.78 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.372 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -74.74 -23.15 58.51 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.656 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.88 12.41 37.68 Favored 'General case' 0 N--CA 1.432 -1.362 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -96.43 158.43 33.82 Favored Pre-proline 0 N--CA 1.418 -2.054 0 CA-C-N 114.077 -1.42 . . . . 0.0 112.746 -178.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -55.52 178.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.367 1.507 0 C-N-CA 124.517 3.478 . . . . 0.0 114.639 179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 88.6 t -104.43 134.92 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.791 -178.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.408 ' C ' ' H ' ' A' ' 154' ' ' GLY . 43.0 t80 -100.98 97.51 8.08 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 113.815 -1.538 . . . . 0.0 109.46 179.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 67.49 -35.43 0.26 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 124.423 1.089 . . . . 0.0 113.602 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.408 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 135.27 100.81 0.64 Allowed Glycine 0 C--N 1.339 0.711 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.111 -179.247 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 16.0 p -96.04 105.34 17.37 Favored 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 123.26 0.624 . . . . 0.0 111.23 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.9 p -94.2 152.5 40.34 Favored Pre-proline 0 CA--C 1.539 0.547 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.838 178.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_endo -84.37 -44.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.374 1.883 0 C-N-CA 122.394 2.063 . . . . 0.0 113.368 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.51 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 6.7 t -160.75 -65.7 0.06 Allowed 'General case' 0 C--O 1.236 0.381 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.208 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.51 ' H ' ' CG2' ' A' ' 158' ' ' THR . 37.3 mt-10 . . . . . 0 C--O 1.249 1.044 0 CA-C-N 114.469 -1.241 . . . . 0.0 111.594 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 47.1 mtt . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.578 0.228 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 19.9 mtp180 -91.56 143.56 26.46 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.129 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 120.0 69.37 0.3 Allowed Glycine 0 C--N 1.338 0.66 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m -127.41 -51.14 1.39 Allowed 'General case' 0 C--O 1.235 0.322 0 O-C-N 123.642 0.26 . . . . 0.0 110.986 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 60.7 m80 -141.78 124.54 16.02 Favored 'General case' 0 N--CA 1.466 0.368 0 O-C-N 123.29 0.368 . . . . 0.0 111.049 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -138.89 148.6 43.84 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.892 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 67.9 m80 -102.14 146.64 27.66 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.945 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -137.45 -41.08 0.56 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.272 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.7 m-70 -120.1 -37.28 3.1 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -76.85 147.98 36.8 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 133.92 44.34 0.12 Allowed Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.793 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -120.99 167.79 12.21 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.18 101.42 1.74 Allowed 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.329 176.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.2 t -95.92 -4.24 43.8 Favored 'General case' 0 CA--C 1.542 0.67 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -178.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . 0.497 ' HH ' ' NH1' ' A' ' 48' ' ' ARG . 0.6 OUTLIER -90.1 120.32 31.18 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 121.8 0.809 . . . . 0.0 112.495 -178.916 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.0 p -99.63 157.46 16.45 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 113.387 -1.733 . . . . 0.0 112.658 -178.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.419 HH11 HG22 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -86.75 112.55 47.77 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.255 0.622 . . . . 0.0 110.816 179.013 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.635 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 21.3 Cg_exo -66.6 -23.84 49.12 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 122.717 2.278 . . . . 0.0 112.951 178.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.809 HD13 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.56 -172.0 3.05 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 122.671 1.224 . . . . 0.0 110.375 -179.894 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.539 ' H ' HD12 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -128.14 -25.22 3.03 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 112.144 -2.298 . . . . 0.0 108.742 177.213 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.809 ' O ' HD13 ' A' ' 19' ' ' LEU . 7.3 t -168.62 -168.64 0.92 Allowed 'General case' 0 CA--C 1.548 0.87 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.781 -178.302 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 171.99 111.74 0.26 Allowed Glycine 0 C--N 1.318 -0.431 0 CA-C-N 114.661 -1.154 . . . . 0.0 111.441 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.16 124.97 9.12 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.729 0.776 . . . . 0.0 112.973 -178.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.515 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.75 58.34 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-N 113.393 -1.731 . . . . 0.0 109.122 179.38 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.9 t -105.15 -28.2 11.13 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 112.969 -1.923 . . . . 0.0 111.007 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.52 -67.15 1.02 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.774 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.73 122.64 1.03 Allowed Glycine 0 C--N 1.322 -0.196 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.144 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.529 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -76.17 157.6 32.57 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -178.795 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -57.14 32.12 0.0 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -177.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.695 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -0.02 49.06 Favored Glycine 0 CA--C 1.504 -0.624 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -102.16 85.42 0.72 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.695 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.5 Cg_exo -76.95 141.99 21.73 Favored 'Trans proline' 0 C--N 1.373 1.848 0 C-N-CA 122.826 2.351 . . . . 0.0 113.425 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.51 4.02 83.57 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.803 -0.635 . . . . 0.0 113.06 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' HG22 ' A' ' 24' ' ' ILE . 3.3 t-80 -74.29 127.33 32.72 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.098 0.959 . . . . 0.0 110.697 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -102.72 5.45 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.656 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.86 -150.03 5.14 Favored Glycine 0 C--N 1.337 0.603 0 C-N-CA 121.526 -0.368 . . . . 0.0 112.257 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.475 HG13 ' OH ' ' A' ' 39' ' ' TYR . 9.7 p -130.52 154.69 40.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 C-N-CA 122.97 0.508 . . . . 0.0 110.244 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.686 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -129.16 130.07 45.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.258 0.552 . . . . 0.0 111.914 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.635 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 3.4 m-85 -120.54 109.99 15.93 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.273 -178.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.3 104.15 0.15 Allowed 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.275 178.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.447 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.6 p -146.79 124.07 5.89 Favored Pre-proline 0 CA--C 1.55 0.974 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.76 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -49.0 142.97 18.81 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 123.4 2.733 . . . . 0.0 115.528 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.49 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.47 140.77 18.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 111.766 -2.47 . . . . 0.0 113.454 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.45 2.53 55.55 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 115.441 -0.8 . . . . 0.0 114.036 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -87.53 124.0 68.55 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-O 119.153 -0.451 . . . . 0.0 109.88 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.7 126.7 23.32 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.342 2.028 . . . . 0.0 113.272 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.478 ' O ' HG13 ' A' ' 107' ' ' ILE . 5.8 t -99.55 121.12 49.83 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 CA-C-N 115.107 -0.951 . . . . 0.0 108.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.497 ' NH1' ' HH ' ' A' ' 15' ' ' TYR . 3.9 mpt_? -102.21 152.41 21.06 Favored 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 113.301 -1.772 . . . . 0.0 111.434 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.71 122.63 20.97 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.689 -1.141 . . . . 0.0 111.435 -178.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 24.6 t -69.42 -14.53 18.52 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.553 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.633 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.24 143.86 1.95 Allowed 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 123.491 0.716 . . . . 0.0 110.641 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -62.68 156.04 24.67 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 114.943 -1.026 . . . . 0.0 112.477 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.617 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.32 -127.61 1.57 Allowed Glycine 0 C--N 1.334 0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.551 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.7 m -148.08 141.45 25.26 Favored 'General case' 0 N--CA 1.436 -1.148 0 C-N-CA 123.598 0.759 . . . . 0.0 109.532 -178.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 99' ' ' SER . 10.6 t -83.63 112.81 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 O-C-N 123.907 0.755 . . . . 0.0 108.995 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.44 ' N ' ' HD2' ' A' ' 56' ' ' LYS . 10.0 mmmt -94.93 -14.72 24.2 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.666 -1.152 . . . . 0.0 110.819 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -156.69 141.2 16.75 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.896 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.04 92.44 2.05 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.805 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.415 ' O ' HD12 ' A' ' 93' ' ' ILE . . . -94.96 92.03 1.46 Allowed Glycine 0 C--O 1.241 0.533 0 CA-C-N 114.35 -1.295 . . . . 0.0 112.658 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.569 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.65 123.7 23.78 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.134 0.974 . . . . 0.0 112.744 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.607 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.62 -0.76 88.21 Favored Glycine 0 CA--C 1.519 0.342 0 CA-C-N 113.369 -1.741 . . . . 0.0 113.59 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -32.31 57.54 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.54 24.79 2.66 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.027 -178.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.607 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -81.08 114.05 45.81 Favored Pre-proline 0 N--CA 1.435 -1.211 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -178.182 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.835 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.4 Cg_exo -67.81 162.12 40.95 Favored 'Trans proline' 0 C--N 1.37 1.685 0 C-N-CA 123.727 2.952 . . . . 0.0 111.804 177.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 63.3 m95 -96.1 13.01 28.64 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 176.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 81.9 mtp -80.07 -42.51 23.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.785 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.538 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.4 pp -125.76 15.44 8.08 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.795 177.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.835 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.4 OUTLIER -137.29 108.59 6.85 Favored 'General case' 0 C--N 1.369 1.416 0 C-N-CA 120.022 -0.671 . . . . 0.0 112.612 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 16.8 ttm -113.05 -20.3 11.56 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.416 178.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -91.54 -26.5 18.73 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.568 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 102.78 -128.57 9.59 Favored Glycine 0 CA--C 1.519 0.335 0 O-C-N 123.703 0.627 . . . . 0.0 113.704 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.587 HD22 ' HA3' ' A' ' 61' ' ' GLY . 17.5 m-80 -83.25 138.55 33.54 Favored 'General case' 0 C--N 1.346 0.43 0 C-N-CA 123.113 0.565 . . . . 0.0 112.138 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -152.27 145.96 25.03 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.3 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.625 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.15 120.34 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.164 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.7 129.6 56.54 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -139.19 150.81 22.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.328 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.617 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -100.24 117.27 34.11 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.904 -1.498 . . . . 0.0 108.504 178.037 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.633 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 2.9 m-70 -68.74 -175.91 0.75 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.489 -1.232 . . . . 0.0 114.092 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.92 65.03 Favored 'General case' 0 N--CA 1.452 -0.369 0 CA-C-N 114.037 -1.438 . . . . 0.0 114.457 -177.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.65 -9.02 21.29 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 120.876 0.369 . . . . 0.0 110.99 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.71 -6.74 44.85 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.122 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.511 ' HE2' ' HH ' ' A' ' 145' ' ' TYR . 2.2 ptt? -67.09 170.48 6.85 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 123.461 0.704 . . . . 0.0 111.465 179.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.439 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 70.5 m-70 -114.68 145.42 42.06 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 120.609 -0.436 . . . . 0.0 111.218 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.68 127.34 20.27 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.051 179.68 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.625 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.63 155.4 16.52 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.698 178.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.493 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.8 m-85 -134.54 99.46 4.36 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.438 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -112.38 168.02 9.97 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 112.689 0.625 . . . . 0.0 112.689 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 65.68 41.0 4.16 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.449 1.099 . . . . 0.0 111.736 -178.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.517 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.9 mt -102.14 167.93 9.7 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.039 178.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.7 t -104.57 -14.47 15.63 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.57 160.56 13.05 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.697 0.761 . . . . 0.0 111.861 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.648 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.16 149.17 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 113.563 -1.653 . . . . 0.0 110.83 179.045 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -112.56 -6.03 13.97 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.173 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.648 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.12 -175.28 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.006 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.642 -176.932 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.9 t -153.17 150.42 29.03 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.835 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.1 m -60.2 128.41 36.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.377 -179.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 85.49 -4.06 0.86 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.627 1.171 . . . . 0.0 111.674 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.458 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -79.83 148.88 31.2 Favored 'General case' 0 C--N 1.347 0.493 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.45 145.34 29.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.66 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.81 166.38 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.264 -179.271 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.7 tttp -141.5 148.48 39.5 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.916 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.761 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.65 138.23 55.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -179.595 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.88 -5.45 47.93 Favored Glycine 0 CA--C 1.518 0.242 0 CA-C-N 114.252 -1.34 . . . . 0.0 114.238 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.444 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.5 tt0 -74.5 140.35 44.48 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.024 0.44 . . . . 0.0 110.184 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 49.0 mt -71.54 101.65 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.668 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.478 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.58 -4.87 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.035 -179.02 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.11 -160.52 34.11 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-O 121.137 0.298 . . . . 0.0 112.47 178.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 28.5 m-85 -140.93 138.53 33.91 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.535 1.134 . . . . 0.0 108.377 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.11 151.9 29.83 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.625 0.77 . . . . 0.0 112.483 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.497 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -157.71 -164.1 13.46 Favored Glycine 0 C--N 1.346 1.124 0 C-N-CA 120.036 -1.078 . . . . 0.0 114.079 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.37 49.67 0.89 Allowed 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.734 -0.733 . . . . 0.0 109.076 178.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.568 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 25.5 p -80.48 1.38 29.57 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -102.14 -160.91 26.4 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.009 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 38.3 mt-30 -92.1 91.1 7.64 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.223 0.535 . . . . 0.0 110.657 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -159.89 165.43 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.865 -179.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 14.4 p -96.15 -15.59 22.01 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.358 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -138.68 155.99 23.95 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.096 -0.835 . . . . 0.0 113.176 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.81 146.58 20.97 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.882 2.388 . . . . 0.0 112.087 179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.447 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 54.3 p-80 -159.79 -167.24 1.93 Allowed 'General case' 0 C--N 1.347 0.459 0 CA-C-O 121.467 0.651 . . . . 0.0 111.851 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.686 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 11.1 tp -126.18 137.64 53.58 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.228 -1.351 . . . . 0.0 110.339 -178.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.441 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.5 t60 -117.44 126.35 52.49 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 113.895 -1.502 . . . . 0.0 108.287 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -131.61 108.62 9.65 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.973 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.516 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.1 pt-20 -116.62 128.38 55.33 Favored 'General case' 0 N--CA 1.429 -1.49 0 CA-C-N 115.276 -0.874 . . . . 0.0 109.476 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' MET . . . . . . . . . . . . . 3.4 tpt -121.08 136.9 54.88 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.837 -179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.61 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.11 165.52 25.47 Favored Pre-proline 0 C--N 1.309 -1.169 0 CA-C-N 113.352 -1.749 . . . . 0.0 110.3 -177.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.439 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.8 Cg_endo -63.57 -178.25 0.5 Allowed 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 123.055 2.503 . . . . 0.0 112.9 176.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.44 -28.3 63.88 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.01 176.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.426 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 29.4 m120 -157.03 102.61 1.92 Allowed Pre-proline 0 CA--C 1.503 -0.828 0 CA-C-N 114.218 -1.355 . . . . 0.0 108.771 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 2.8 Cg_exo -73.73 163.34 37.47 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.555 2.17 . . . . 0.0 116.603 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.41 71.51 0.84 Allowed 'General case' 0 N--CA 1.425 -1.693 0 CA-C-N 112.344 -2.207 . . . . 0.0 107.095 177.691 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.446 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.44 14.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 114.239 -1.346 . . . . 0.0 112.463 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -82.05 35.52 0.43 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.042 0.937 . . . . 0.0 112.951 -178.197 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 73.06 127.11 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.488 0 C-N-CA 125.53 1.532 . . . . 0.0 110.52 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.41 -50.08 0.56 Allowed Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.396 -0.907 . . . . 0.0 113.353 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.595 ' CE1' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -151.87 -19.86 0.19 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.027 0.414 . . . . 0.0 111.527 179.177 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 27.5 m 65.78 18.01 11.02 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.885 1.274 . . . . 0.0 108.283 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.61 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.11 -11.19 12.45 Favored Glycine 0 N--CA 1.436 -1.305 0 CA-C-N 112.465 -2.152 . . . . 0.0 112.782 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.501 ' HD2' ' O ' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -82.48 121.8 27.22 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.1 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.403 HG21 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -124.64 -172.79 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.355 179.416 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.403 ' H ' HG21 ' A' ' 140' ' ' ILE . 1.9 p30 -79.76 132.05 62.28 Favored Pre-proline 0 CA--C 1.552 1.038 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -176.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.513 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.71 0.04 10.19 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.233 2.622 . . . . 0.0 114.204 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.36 -24.23 7.29 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -178.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -74.5 -23.25 75.92 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.899 179.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . 0.511 ' HH ' ' HE2' ' A' ' 83' ' ' MET . 12.6 m-85 -101.12 -12.27 18.93 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 123.62 0.768 . . . . 0.0 111.169 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.513 HG12 ' O ' ' A' ' 142' ' ' PRO . 26.6 mm -101.72 -10.68 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.688 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -73.75 -24.19 59.84 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.84 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.95 14.29 32.38 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.848 0.833 . . . . 0.0 109.447 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 146' ' ' ILE . . . -95.18 169.09 9.89 Favored Pre-proline 0 N--CA 1.417 -2.114 0 CA-C-N 113.846 -1.524 . . . . 0.0 112.314 -179.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.414 ' HD2' ' CB ' ' A' ' 149' ' ' ALA . 12.5 Cg_endo -54.91 178.77 0.08 OUTLIER 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 124.352 3.368 . . . . 0.0 113.955 179.56 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 88.3 t -110.22 133.0 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.325 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.426 ' C ' ' H ' ' A' ' 154' ' ' GLY . 47.5 t80 -101.92 97.43 7.79 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.23 178.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 67.07 -35.84 0.26 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 124.342 1.057 . . . . 0.0 113.452 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.426 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 119.47 74.88 0.44 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -179.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.1 p -90.88 105.37 17.78 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 123.282 0.633 . . . . 0.0 111.376 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.7 p -94.69 150.96 38.77 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.935 179.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -83.57 -35.73 0.23 Allowed 'Trans proline' 0 C--N 1.373 1.862 0 C-N-CA 122.472 2.115 . . . . 0.0 113.311 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.458 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 10.0 t -163.07 -59.9 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.707 -1.133 . . . . 0.0 109.849 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.458 ' H ' ' CG2' ' A' ' 158' ' ' THR . 27.5 mt-10 . . . . . 0 C--O 1.249 1.066 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.575 179.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.508 0.194 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 -90.41 124.93 35.36 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.171 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 136.65 130.31 2.88 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.193 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 60.8 m -102.57 -45.37 5.07 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 111.666 0.247 . . . . 0.0 111.666 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.4 m80 -110.74 128.68 55.83 Favored 'General case' 0 C--O 1.235 0.306 0 O-C-N 123.261 0.351 . . . . 0.0 111.391 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -136.84 -46.59 0.59 Allowed 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.947 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -133.99 148.64 51.15 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.788 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -124.19 133.22 53.6 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.74 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.8 m80 -118.73 147.91 43.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.081 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -104.53 154.59 19.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.096 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.78 70.41 0.04 OUTLIER Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.101 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.07 162.14 14.81 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -179.139 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -160.98 118.46 2.37 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.03 176.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 11.3 t -89.45 -13.58 37.27 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -178.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -96.99 120.54 37.53 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.523 0.677 . . . . 0.0 111.823 -179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 31.9 p -99.66 144.52 28.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 113.988 -1.46 . . . . 0.0 112.379 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.47 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.62 111.88 26.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.401 179.442 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.606 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.7 Cg_exo -66.73 -24.36 47.55 Favored 'Trans proline' 0 C--N 1.366 1.478 0 C-N-CA 122.482 2.121 . . . . 0.0 112.27 178.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.844 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -139.57 -171.84 3.23 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 122.614 1.197 . . . . 0.0 110.213 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.54 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.02 -25.17 2.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 112.241 -2.254 . . . . 0.0 108.792 177.219 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.844 ' O ' HD12 ' A' ' 19' ' ' LEU . 7.4 t -168.95 -168.48 0.86 Allowed 'General case' 0 CA--C 1.546 0.802 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.619 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.04 111.9 0.35 Allowed Glycine 0 C--N 1.319 -0.371 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.336 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.67 124.63 9.96 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 121.888 0.852 . . . . 0.0 112.8 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.583 HD11 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.05 58.57 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 113.173 -1.83 . . . . 0.0 108.965 178.944 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.8 t -102.47 -28.98 11.88 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.838 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -113.42 -67.91 0.97 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.6 125.03 1.2 Allowed Glycine 0 C--N 1.323 -0.172 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.037 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.539 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -77.08 157.32 31.14 Favored 'General case' 0 C--N 1.343 0.298 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -178.956 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -55.97 32.19 0.0 OUTLIER 'General case' 0 C--O 1.239 0.526 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.69 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.74 0.94 49.33 Favored Glycine 0 CA--C 1.504 -0.647 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -101.64 85.34 0.64 Allowed Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.69 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.0 Cg_exo -77.42 139.66 18.61 Favored 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.748 2.299 . . . . 0.0 113.247 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.19 4.22 78.06 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.007 179.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.436 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.1 t-80 -75.36 131.4 40.22 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 123.997 0.919 . . . . 0.0 110.458 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.469 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.46 -1.98 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.488 -179.315 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.98 -150.21 5.89 Favored Glycine 0 C--N 1.338 0.661 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.537 HG13 ' OH ' ' A' ' 39' ' ' TYR . 11.9 p -132.05 149.19 32.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 O-C-N 123.864 0.391 . . . . 0.0 110.618 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.76 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.72 134.0 51.92 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 121.322 0.582 . . . . 0.0 112.074 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.606 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -124.57 110.44 14.45 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.354 -1.294 . . . . 0.0 110.131 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.06 107.31 0.29 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 115.813 -0.63 . . . . 0.0 112.117 178.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.481 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.2 p -146.36 127.12 7.16 Favored Pre-proline 0 CA--C 1.549 0.929 0 CA-C-N 115.021 -0.99 . . . . 0.0 109.172 -179.343 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -55.78 143.6 80.15 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.259 2.639 . . . . 0.0 115.583 -178.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.504 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -62.63 139.26 21.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 111.79 -2.459 . . . . 0.0 113.472 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.9 2.66 55.08 Favored Glycine 0 N--CA 1.442 -0.942 0 CA-C-N 115.366 -0.834 . . . . 0.0 114.063 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.12 120.83 70.74 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.2 126.1 21.39 Favored 'Trans proline' 0 C--N 1.376 1.985 0 C-N-CA 122.431 2.087 . . . . 0.0 113.104 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 107' ' ' ILE . 4.9 t -98.51 121.15 48.75 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.978 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.455 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 4.5 mpt_? -102.93 152.54 21.18 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 113.264 -1.789 . . . . 0.0 111.443 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -72.42 123.52 23.26 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.7 -1.136 . . . . 0.0 111.587 -178.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.9 t -65.83 -21.57 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 CA-C-N 115.597 -0.729 . . . . 0.0 112.613 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.561 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -167.69 143.99 4.13 Favored 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 123.184 0.593 . . . . 0.0 110.653 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.451 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -59.94 155.51 16.46 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.191 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.621 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.17 -126.37 1.4 Allowed Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.777 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.4 m -148.26 142.01 25.64 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 123.537 0.735 . . . . 0.0 109.971 -177.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.444 HG21 ' O ' ' A' ' 99' ' ' SER . 11.6 t -85.95 112.84 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 O-C-N 124.028 0.83 . . . . 0.0 108.921 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.6 mmmt -95.15 -14.79 23.84 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.596 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -154.21 140.09 18.19 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.243 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.13 92.37 2.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.781 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.453 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.18 89.87 1.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 114.141 -1.39 . . . . 0.0 113.368 -179.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.559 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -69.99 124.05 23.09 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.907 0.883 . . . . 0.0 112.552 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.564 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.39 -0.63 87.22 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-N 113.334 -1.757 . . . . 0.0 113.645 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.81 -32.14 46.18 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 26.93 2.57 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.978 -178.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.564 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.86 115.87 57.03 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -178.28 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.848 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.1 Cg_exo -69.49 162.89 40.14 Favored 'Trans proline' 0 C--N 1.37 1.704 0 C-N-CA 123.765 2.976 . . . . 0.0 111.469 177.028 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -98.73 12.36 35.77 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.2 mtt -78.36 -44.08 25.98 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.539 -1.209 . . . . 0.0 110.149 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.515 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -119.88 10.69 11.63 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.793 177.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.848 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.48 146.31 50.85 Favored 'General case' 0 C--N 1.362 1.151 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.782 -179.01 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 46.1 mtt -139.37 -36.17 0.53 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.443 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -88.79 -21.02 23.99 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.413 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.627 ' HA3' ' HG1' ' A' ' 113' ' ' THR . . . 95.12 -112.81 4.46 Favored Glycine 0 C--N 1.335 0.488 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.12 179.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.548 HD22 ' HA3' ' A' ' 61' ' ' GLY . 13.7 m-80 -80.37 135.7 36.23 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.182 0.593 . . . . 0.0 112.528 -178.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -149.18 146.31 27.58 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.228 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.592 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.32 122.01 17.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.094 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.434 HD23 ' HD1' ' A' ' 84' ' ' HIS . 0.1 OUTLIER -119.5 129.92 54.95 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 177.509 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.401 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -141.08 150.87 20.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 CA-C-N 112.942 -1.935 . . . . 0.0 110.497 -176.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.621 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.48 116.05 30.74 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.277 177.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.561 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.3 m-70 -68.6 -177.76 1.01 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.528 -1.215 . . . . 0.0 114.121 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.451 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -65.59 -17.37 64.53 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.824 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.58 -12.21 21.4 Favored 'General case' 0 C--O 1.236 0.388 0 O-C-N 123.415 0.447 . . . . 0.0 110.732 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.63 -6.57 45.02 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.118 -0.947 . . . . 0.0 112.035 178.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.423 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 12.1 ptt? -71.45 164.69 25.31 Favored 'General case' 0 N--CA 1.436 -1.154 0 C-N-CA 123.135 0.574 . . . . 0.0 111.772 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.455 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 53.0 m-70 -105.61 142.78 34.75 Favored 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.121 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.483 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.07 127.17 26.07 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.592 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.41 154.45 16.82 Favored Glycine 0 N--CA 1.442 -0.967 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.699 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -137.23 98.65 3.78 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.468 ' HB3' ' CD2' ' A' ' 122' ' ' HIS . . . -116.11 170.42 8.52 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 54.9 m80 65.59 38.1 5.62 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.339 1.056 . . . . 0.0 111.137 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.564 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.3 mt -97.94 170.11 9.17 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.966 178.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 17.3 t -104.14 -15.28 15.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 111.465 0.172 . . . . 0.0 111.465 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 9.0 tttt -168.46 159.55 10.44 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.696 0.76 . . . . 0.0 112.204 -178.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.757 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -124.38 148.98 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 113.541 -1.663 . . . . 0.0 110.862 178.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.53 -5.05 13.45 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.213 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.757 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.08 -175.33 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.074 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.553 -177.049 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.6 t -152.23 149.45 28.73 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.841 -179.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -60.32 127.9 34.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.496 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 85.39 -3.61 0.86 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.508 1.123 . . . . 0.0 111.673 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.444 ' O ' HG21 ' A' ' 55' ' ' VAL . 40.1 m -79.98 148.95 30.96 Favored 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 122.299 0.24 . . . . 0.0 110.415 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.6 p -83.19 145.68 29.04 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.491 178.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.21 167.66 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.297 0 CA-C-N 115.302 -0.863 . . . . 0.0 112.324 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.403 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.0 tttm -141.33 147.98 38.97 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.957 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.746 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.81 137.49 56.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.378 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.409 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.94 -5.64 47.07 Favored Glycine 0 CA--C 1.519 0.334 0 CA-C-N 114.285 -1.325 . . . . 0.0 114.112 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.4 tt0 -73.87 139.66 45.17 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.108 0.48 . . . . 0.0 110.143 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 57.8 mt -70.94 101.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.62 -179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.552 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.8 OUTLIER -93.72 -4.12 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.61 -1.632 . . . . 0.0 112.937 -179.125 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.49 -161.3 35.11 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-O 121.228 0.349 . . . . 0.0 112.737 178.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.564 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.0 m-85 -141.5 136.92 31.69 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 124.834 1.253 . . . . 0.0 108.341 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.1 p -60.43 152.73 24.83 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.423 0.689 . . . . 0.0 112.08 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.504 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -155.82 -165.44 14.44 Favored Glycine 0 C--N 1.345 1.048 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.915 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -149.77 45.13 0.93 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.565 -0.818 . . . . 0.0 108.953 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.627 ' HG1' ' HA3' ' A' ' 72' ' ' GLY . 22.3 p -77.88 2.74 16.37 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.636 -177.476 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -106.3 -165.48 22.89 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.134 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -87.82 91.71 8.85 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-O 121.445 0.64 . . . . 0.0 110.046 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.43 HG22 ' H ' ' A' ' 118' ' ' GLY . 9.6 p -158.47 161.86 1.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.25 -178.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 19.0 p -90.92 -16.33 28.3 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.962 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . 0.43 ' H ' HG22 ' A' ' 116' ' ' VAL . . . -144.93 159.2 27.82 Favored Glycine 0 CA--C 1.529 0.935 0 CA-C-O 119.125 -0.82 . . . . 0.0 112.682 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -73.88 146.35 37.52 Favored 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 122.93 2.42 . . . . 0.0 111.916 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.481 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 46.9 p-80 -157.66 -169.7 2.95 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-O 121.547 0.689 . . . . 0.0 112.401 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.76 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.0 tp -126.4 131.81 51.66 Favored 'General case' 0 N--CA 1.432 -1.34 0 CA-C-N 114.049 -1.432 . . . . 0.0 111.166 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.468 ' CD2' ' HB3' ' A' ' 88' ' ' ALA . 24.8 t60 -114.01 110.08 19.48 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.088 177.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -117.08 109.23 16.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.364 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.483 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.1 tt0 -116.22 127.06 54.44 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.208 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.403 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 2.5 ttt -118.62 134.7 54.91 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.679 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.458 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.4 mp -142.31 166.6 20.21 Favored Pre-proline 0 C--N 1.31 -1.14 0 CA-C-N 113.297 -1.774 . . . . 0.0 111.004 -177.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.455 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.5 Cg_endo -63.32 -178.44 0.47 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 123.027 2.484 . . . . 0.0 112.851 176.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.62 -27.06 61.92 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.194 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.41 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.3 m-80 -157.29 98.84 1.96 Allowed Pre-proline 0 CA--C 1.503 -0.835 0 CA-C-N 114.206 -1.361 . . . . 0.0 109.314 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 6.5 Cg_exo -71.1 163.37 39.44 Favored 'Trans proline' 0 N--CA 1.445 -1.377 0 C-N-CA 122.868 2.379 . . . . 0.0 116.532 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.605 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.2 t-20 -116.76 70.56 0.77 Allowed 'General case' 0 N--CA 1.425 -1.691 0 CA-C-N 112.579 -2.101 . . . . 0.0 107.24 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.99 13.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 114.351 -1.295 . . . . 0.0 112.412 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.605 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 35.27 0.41 Allowed 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 124.196 0.998 . . . . 0.0 113.083 -178.109 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 73.32 126.29 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 125.509 1.523 . . . . 0.0 110.727 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.5 -50.18 0.56 Allowed Glycine 0 N--CA 1.442 -0.902 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.482 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.554 ' CE2' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -152.43 -19.73 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 117.102 0.451 . . . . 0.0 111.432 179.257 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 30.1 t 66.45 18.13 10.78 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.034 1.334 . . . . 0.0 108.411 -178.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.554 ' HA2' ' CE2' ' A' ' 136' ' ' PHE . . . 77.7 -11.04 21.43 Favored Glycine 0 N--CA 1.436 -1.334 0 CA-C-N 112.66 -2.063 . . . . 0.0 112.8 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.469 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -81.45 127.18 32.52 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 120.081 -0.648 . . . . 0.0 112.117 -179.19 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -126.93 -174.34 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.337 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.033 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -70.34 134.7 86.84 Favored Pre-proline 0 CA--C 1.544 0.731 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.618 -178.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.56 ' O ' HG12 ' A' ' 146' ' ' ILE . 95.4 Cg_endo -76.7 21.64 0.56 Allowed 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 123.162 2.575 . . . . 0.0 114.081 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.442 ' H ' ' HG1' ' A' ' 143' ' ' THR . 1.9 p -56.04 -24.63 40.69 Favored 'General case' 0 C--N 1.344 0.349 0 C-N-CA 124.228 1.011 . . . . 0.0 113.308 -179.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.52 -23.78 77.35 Favored Glycine 0 N--CA 1.462 0.427 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -96.2 -9.7 29.85 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.655 1.182 . . . . 0.0 110.43 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.56 HG12 ' O ' ' A' ' 142' ' ' PRO . 21.1 mm -104.93 -12.47 9.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.841 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -78.36 -27.96 47.03 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 123.133 0.573 . . . . 0.0 112.271 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . 0.525 ' H ' ' ND2' ' A' ' 148' ' ' ASN . 0.0 OUTLIER -109.54 17.54 21.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 114.546 -1.207 . . . . 0.0 109.108 -179.379 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -94.34 144.78 28.56 Favored Pre-proline 0 N--CA 1.417 -2.1 0 CA-C-N 113.706 -1.588 . . . . 0.0 112.85 -178.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -57.8 178.93 0.16 Allowed 'Trans proline' 0 C--N 1.362 1.256 0 C-N-CA 124.661 3.574 . . . . 0.0 114.464 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.6 t -97.09 132.46 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 123.872 0.869 . . . . 0.0 111.786 -177.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.429 ' C ' ' H ' ' A' ' 154' ' ' GLY . 42.6 t80 -101.11 97.36 7.91 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.288 -1.778 . . . . 0.0 109.126 178.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 7.6 m-80 66.41 -33.13 0.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 124.221 1.009 . . . . 0.0 113.628 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.429 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 141.11 71.2 0.03 OUTLIER Glycine 0 C--N 1.338 0.68 0 N-CA-C 111.616 -0.593 . . . . 0.0 111.616 -179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.412 ' H ' ' HG1' ' A' ' 155' ' ' THR . 11.8 p -91.39 104.87 17.34 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 123.244 0.618 . . . . 0.0 111.622 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.6 p -113.98 139.95 24.24 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 114.567 -1.197 . . . . 0.0 110.472 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -82.58 -45.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.22 1.947 . . . . 0.0 113.302 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.522 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 5.3 t -162.72 -67.97 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.163 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.522 ' H ' ' CG2' ' A' ' 158' ' ' THR . 7.1 mm-40 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.487 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.6 mtt . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 120.604 0.24 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -94.33 125.59 39.06 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.102 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -167.9 87.81 0.1 OUTLIER Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.122 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 11.8 t -129.89 -34.99 1.67 Allowed 'General case' 0 N--CA 1.466 0.339 0 O-C-N 123.708 0.299 . . . . 0.0 111.602 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -89.48 -39.61 13.23 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.0 t-80 -97.33 134.47 40.56 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 123.303 0.377 . . . . 0.0 111.411 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -133.94 150.73 51.31 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.65 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -99.79 -47.46 5.05 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.661 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.3 m80 -130.81 145.26 51.92 Favored 'General case' 0 C--O 1.234 0.281 0 O-C-N 123.245 0.341 . . . . 0.0 111.276 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 4.5 t60 -137.77 -41.89 0.54 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.983 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.85 80.45 0.85 Allowed Glycine 0 C--N 1.341 0.855 0 O-C-N 123.334 0.396 . . . . 0.0 112.388 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -95.52 160.33 14.56 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.17 120.38 1.89 Allowed 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.423 176.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.5 t -89.44 -9.97 48.19 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.565 -179.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.71 128.67 49.33 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-O 121.524 0.678 . . . . 0.0 112.125 -179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.516 ' HB ' ' HD1' ' A' ' 152' ' ' PHE . 20.9 p -95.21 158.13 15.59 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 113.844 -1.526 . . . . 0.0 112.644 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.55 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.0 OUTLIER -97.83 114.34 64.88 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.656 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.714 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.7 Cg_exo -71.61 -20.61 26.64 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.65 2.233 . . . . 0.0 113.192 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.791 HD11 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.42 -171.81 2.86 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-O 122.736 1.255 . . . . 0.0 110.781 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.548 ' H ' HD13 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.49 -25.09 2.96 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 111.98 -2.373 . . . . 0.0 108.691 177.512 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.791 ' O ' HD11 ' A' ' 19' ' ' LEU . 6.8 t -168.58 -169.11 0.99 Allowed 'General case' 0 CA--C 1.55 0.949 0 CA-C-N 114.405 -1.271 . . . . 0.0 111.996 -178.107 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.12 110.66 0.25 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 114.504 -1.226 . . . . 0.0 111.251 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.39 124.72 8.19 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.521 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.37 58.4 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 114.201 -1.363 . . . . 0.0 108.949 178.191 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.7 t -103.27 -28.69 11.72 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.066 -1.879 . . . . 0.0 110.852 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -113.45 -66.8 1.05 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.489 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.17 124.48 1.17 Allowed Glycine 0 C--N 1.323 -0.182 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.865 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.525 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -74.55 157.39 35.57 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -178.829 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -58.95 32.02 0.01 OUTLIER 'General case' 0 C--O 1.24 0.559 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.696 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.71 -1.56 48.9 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 111.429 -0.669 . . . . 0.0 111.429 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.467 ' HB2' ' HD2' ' A' ' 28' ' ' PHE . 7.7 m-85 -102.19 85.37 0.71 Allowed Pre-proline 0 CA--C 1.548 0.868 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.696 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.71 140.21 16.38 Favored 'Trans proline' 0 C--N 1.376 1.998 0 C-N-CA 122.836 2.358 . . . . 0.0 113.585 -178.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.57 4.27 70.56 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.743 -0.662 . . . . 0.0 113.181 179.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.425 ' O ' HG12 ' A' ' 24' ' ' ILE . 4.1 t-80 -79.79 133.0 36.28 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 124.209 1.004 . . . . 0.0 110.032 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.571 HG13 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.07 -10.51 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 123.64 0.588 . . . . 0.0 111.779 -178.845 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -129.93 -149.79 6.79 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 112.063 -0.415 . . . . 0.0 112.063 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 123' ' ' PHE . 12.4 p -130.52 151.66 36.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.844 0.379 . . . . 0.0 110.522 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.704 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -127.08 132.03 50.73 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.265 0.555 . . . . 0.0 111.408 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.714 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 6.5 m-85 -118.24 111.7 19.14 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.475 -1.239 . . . . 0.0 111.227 -177.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.42 99.76 0.09 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.548 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.449 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 14.2 p -142.87 129.02 10.47 Favored Pre-proline 0 CA--C 1.547 0.859 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.168 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . 0.4 ' HA ' ' HG2' ' A' ' 119' ' ' PRO . 87.8 Cg_exo -48.82 139.83 24.16 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 123.472 2.782 . . . . 0.0 115.844 -179.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.436 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -66.57 137.34 25.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 111.764 -2.471 . . . . 0.0 113.345 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.27 2.71 51.11 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.908 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' THR . . . . . 0.436 ' H ' ' HG1' ' A' ' 110' ' ' THR . 1.8 m -87.76 131.57 43.03 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.238 -0.41 . . . . 0.0 109.976 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.64 128.32 25.45 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.214 1.942 . . . . 0.0 113.004 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.574 ' O ' HG13 ' A' ' 107' ' ' ILE . 8.1 t -100.14 123.15 52.82 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.885 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.653 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 19.5 mtt180 -101.95 152.02 21.43 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 112.929 -1.941 . . . . 0.0 111.752 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.06 123.67 24.01 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.098 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.02 -15.94 20.36 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.716 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.604 ' HB1' ' CE1' ' A' ' 79' ' ' HIS . . . -171.64 143.02 1.66 Allowed 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 123.349 0.66 . . . . 0.0 110.497 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.66 155.49 22.42 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.052 -0.976 . . . . 0.0 112.307 179.193 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.569 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.99 -126.26 1.36 Allowed Glycine 0 C--N 1.331 0.302 0 O-C-N 123.792 0.683 . . . . 0.0 113.45 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 7.9 m -147.1 141.52 26.4 Favored 'General case' 0 N--CA 1.436 -1.127 0 C-N-CA 123.576 0.75 . . . . 0.0 109.613 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.494 HG21 ' O ' ' A' ' 99' ' ' SER . 12.2 t -85.04 113.24 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 123.764 0.826 . . . . 0.0 108.783 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.42 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 7.0 mmmt -95.35 -14.9 23.49 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.675 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -156.17 140.27 16.44 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.198 179.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.01 92.12 1.93 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.147 -1.388 . . . . 0.0 108.934 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.402 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.76 91.27 1.46 Allowed Glycine 0 C--O 1.238 0.386 0 CA-C-N 114.362 -1.29 . . . . 0.0 112.214 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.57 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -70.27 122.34 19.35 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 122.006 0.908 . . . . 0.0 112.857 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.626 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.77 -0.86 88.82 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 113.201 -1.818 . . . . 0.0 113.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.46 -32.91 62.75 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.92 26.69 2.46 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.927 -178.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.626 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -82.59 114.13 49.65 Favored Pre-proline 0 N--CA 1.435 -1.192 0 N-CA-C 114.006 1.113 . . . . 0.0 114.006 -178.083 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.824 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.8 Cg_exo -67.72 162.31 39.95 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 123.987 3.125 . . . . 0.0 112.239 177.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.8 m95 -95.76 12.23 30.72 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 58.9 mtt -78.42 -42.8 29.07 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.774 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.529 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -126.08 14.82 7.89 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.862 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.824 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.2 OUTLIER -137.33 113.24 9.7 Favored 'General case' 0 C--N 1.367 1.331 0 C-N-CA 120.188 -0.605 . . . . 0.0 112.581 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -110.83 -33.81 6.43 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.91 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.07 -18.68 33.57 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.505 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.52 -126.68 9.0 Favored Glycine 0 CA--C 1.52 0.394 0 O-C-N 123.515 0.51 . . . . 0.0 113.946 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.545 HD22 ' HA3' ' A' ' 61' ' ' GLY . 17.4 m-80 -81.21 145.98 30.71 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.738 0.815 . . . . 0.0 112.555 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -152.31 144.85 24.14 Favored 'General case' 0 CA--C 1.519 -0.243 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.438 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.606 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -139.46 120.86 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.539 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.46 128.01 51.67 Favored 'General case' 0 CA--C 1.492 -1.28 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -138.92 151.07 23.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 112.785 -2.007 . . . . 0.0 110.679 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.569 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -100.2 117.43 34.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.903 177.859 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.604 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 3.2 m-70 -70.04 -176.23 1.09 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 114.137 -1.392 . . . . 0.0 114.196 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.54 -18.05 65.03 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 113.806 -1.543 . . . . 0.0 114.42 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -9.67 20.35 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.913 0.387 . . . . 0.0 111.016 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.86 -6.49 43.99 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.221 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.423 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 6.5 ptt? -69.36 163.66 24.65 Favored 'General case' 0 N--CA 1.439 -1.007 0 C-N-CA 123.182 0.593 . . . . 0.0 111.621 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.446 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 60.2 m-70 -107.51 144.81 33.97 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.892 -178.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.43 HG22 ' HE2' ' A' ' 79' ' ' HIS . 0.0 OUTLIER -137.96 127.31 24.68 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.606 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -107.29 154.47 16.61 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.339 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.435 ' HA ' ' O ' ' A' ' 122' ' ' HIS . 2.0 m-85 -138.44 98.44 3.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 104.221 -2.511 . . . . 0.0 104.221 179.362 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.411 ' HB2' ' HB3' ' A' ' 122' ' ' HIS . . . -116.72 173.59 6.55 Favored 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . 0.425 ' CD2' ' HA3' ' A' ' 114' ' ' GLY . 10.7 m80 66.05 20.18 11.22 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.505 1.122 . . . . 0.0 112.121 -179.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.529 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 12.1 mt -79.66 172.43 13.79 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 123.708 0.803 . . . . 0.0 111.14 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.4 t -104.99 -15.69 15.04 Favored 'General case' 0 N--CA 1.447 -0.607 0 O-C-N 123.139 0.275 . . . . 0.0 111.555 -179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 12.3 tttt -168.71 157.52 8.51 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.809 0.814 . . . . 0.0 112.464 -178.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.746 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.5 150.3 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 CA-C-N 113.467 -1.697 . . . . 0.0 110.97 179.187 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -114.03 -6.51 13.12 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.508 -1.224 . . . . 0.0 110.181 177.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.746 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.1 OUTLIER -103.36 -175.02 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-N 115.361 -0.836 . . . . 0.0 112.765 -177.064 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 58.8 m -152.89 144.66 23.56 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.62 -1.173 . . . . 0.0 108.985 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.528 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.1 m -57.24 127.93 34.43 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.301 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.528 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.71 -3.55 0.68 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.606 1.162 . . . . 0.0 111.884 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.494 ' O ' HG21 ' A' ' 55' ' ' VAL . 50.8 m -81.08 149.19 29.32 Favored 'General case' 0 C--N 1.346 0.456 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 178.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.26 145.28 29.21 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.184 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 166.15 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.346 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 62.9 tttt -140.09 148.56 41.91 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.064 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.76 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.1 138.37 56.14 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.132 -1.394 . . . . 0.0 111.332 -179.751 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.653 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.47 -5.89 41.65 Favored Glycine 0 CA--C 1.516 0.145 0 CA-C-N 114.3 -1.318 . . . . 0.0 114.134 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.493 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.1 tt0 -73.28 143.79 46.87 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 122.989 0.515 . . . . 0.0 109.991 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 25.6 mt -74.17 101.65 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 CA-C-N 115.074 -0.967 . . . . 0.0 109.612 -179.313 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.574 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -93.59 -3.68 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 113.393 -1.73 . . . . 0.0 112.55 -179.236 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.31 -160.84 34.62 Favored Glycine 0 N--CA 1.439 -1.113 0 CA-C-O 121.307 0.393 . . . . 0.0 112.696 178.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.529 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 20.9 m-85 -142.25 137.35 30.63 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 124.875 1.27 . . . . 0.0 108.061 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.436 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -58.94 151.88 20.87 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 123.556 0.743 . . . . 0.0 112.356 -178.62 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.436 ' HA2' ' CG2' ' A' ' 43' ' ' VAL . . . -147.58 -170.79 16.03 Favored Glycine 0 C--N 1.347 1.187 0 C-N-CA 119.834 -1.174 . . . . 0.0 113.655 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -144.83 44.46 1.36 Allowed 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.779 -0.71 . . . . 0.0 109.173 179.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.505 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 37.5 p -81.96 -0.44 44.04 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 113.62 0.971 . . . . 0.0 113.62 -177.338 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.425 ' HA3' ' CD2' ' A' ' 89' ' ' HIS . . . -101.9 -168.63 27.3 Favored Glycine 0 C--N 1.338 0.691 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.636 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -93.46 92.4 7.6 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.317 0.58 . . . . 0.0 110.983 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.71 165.61 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.606 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.6 p -79.71 -6.54 57.41 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -162.98 -170.58 28.06 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.92 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.449 ' HB2' ' O ' ' A' ' 41' ' ' VAL . 21.4 Cg_exo -70.84 147.26 55.56 Favored 'Trans proline' 0 C--N 1.365 1.445 0 C-N-CA 123.558 2.839 . . . . 0.0 111.956 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -152.0 156.29 39.69 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 122.3 1.048 . . . . 0.0 112.82 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.704 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -117.01 127.96 54.69 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 112.566 -2.107 . . . . 0.0 108.297 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.435 ' O ' ' HA ' ' A' ' 87' ' ' TYR . 23.3 t60 -112.36 109.57 19.27 Favored 'General case' 0 N--CA 1.434 -1.258 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.255 179.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.556 ' O ' HG13 ' A' ' 37' ' ' VAL . 40.4 t80 -115.73 108.52 16.47 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.931 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.461 ' OE1' HD12 ' A' ' 126' ' ' LEU . 21.5 tt0 -120.55 125.86 48.88 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.621 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.635 ' SD ' ' HA ' ' A' ' 142' ' ' PRO . 19.4 ptm -111.74 135.36 52.45 Favored 'General case' 0 N--CA 1.419 -2.011 0 C-N-CA 124.012 0.925 . . . . 0.0 109.579 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.461 HD12 ' OE1' ' A' ' 124' ' ' GLU . 2.8 mp -138.56 165.92 29.27 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.697 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.446 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.7 Cg_endo -63.2 -178.5 0.46 Allowed 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.969 2.446 . . . . 0.0 112.703 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.99 -27.21 62.6 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.214 176.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.422 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.1 m-80 -157.46 101.21 1.87 Allowed Pre-proline 0 CA--C 1.503 -0.851 0 CA-C-N 114.182 -1.372 . . . . 0.0 109.019 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 3.0 Cg_exo -72.89 163.66 37.75 Favored 'Trans proline' 0 N--CA 1.446 -1.284 0 C-N-CA 122.722 2.281 . . . . 0.0 116.592 -177.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.592 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -118.01 70.73 0.81 Allowed 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 112.482 -2.145 . . . . 0.0 107.339 177.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.442 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.3 m-90 -63.54 14.71 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.317 -1.311 . . . . 0.0 112.696 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.592 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.24 35.49 0.39 Allowed 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 122.121 0.963 . . . . 0.0 112.897 -178.353 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 70.72 127.59 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 125.73 1.612 . . . . 0.0 110.883 178.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 148.98 -49.9 0.57 Allowed Glycine 0 N--CA 1.437 -1.254 0 CA-C-N 114.979 -1.009 . . . . 0.0 113.031 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.5 -21.5 0.23 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 122.37 0.268 . . . . 0.0 111.43 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 26.9 m 66.19 17.94 10.85 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.672 1.189 . . . . 0.0 108.454 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.438 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.93 -9.73 23.05 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 112.497 -2.138 . . . . 0.0 112.672 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.571 ' HG2' HG13 ' A' ' 35' ' ' VAL . 2.1 ppt_? -83.18 126.16 32.33 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.42 -174.34 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.89 178.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.426 ' O ' ' SD ' ' A' ' 125' ' ' MET . 1.8 p30 -79.25 135.58 57.69 Favored Pre-proline 0 CA--C 1.549 0.939 0 N-CA-C 114.06 1.133 . . . . 0.0 114.06 -176.335 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.635 ' HA ' ' SD ' ' A' ' 125' ' ' MET . 1.0 OUTLIER -76.46 1.4 8.45 Favored 'Trans proline' 0 C--N 1.383 2.39 0 C-N-CA 123.003 2.469 . . . . 0.0 113.244 178.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.67 -23.7 7.1 Favored 'General case' 0 C--N 1.351 0.664 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -178.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.41 -31.62 74.32 Favored Glycine 0 C--N 1.333 0.387 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . 0.446 ' HE1' ' SD ' ' A' ' 125' ' ' MET . 32.1 m-85 -94.35 -13.49 26.32 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 122.978 0.511 . . . . 0.0 111.53 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.563 HG12 ' O ' ' A' ' 142' ' ' PRO . 14.6 mm -100.98 -9.06 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.434 -178.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -78.37 -31.51 48.52 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.238 0.542 . . . . 0.0 111.429 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . 0.555 ' H ' ' ND2' ' A' ' 148' ' ' ASN . 0.0 OUTLIER -103.12 14.46 31.74 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-N 114.649 -1.16 . . . . 0.0 109.656 179.789 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.409 ' HB3' ' NH1' ' A' ' 17' ' ' ARG . . . -101.01 157.71 33.15 Favored Pre-proline 0 N--CA 1.418 -2.057 0 CA-C-N 113.923 -1.49 . . . . 0.0 112.434 -178.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.439 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 16.4 Cg_endo -55.6 178.6 0.1 Allowed 'Trans proline' 0 C--N 1.367 1.5 0 C-N-CA 124.832 3.688 . . . . 0.0 115.02 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.8 t -113.86 134.68 55.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 C-N-CA 124.102 0.961 . . . . 0.0 111.365 -177.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.55 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 50.6 t80 -100.72 97.17 7.85 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 113.985 -1.461 . . . . 0.0 109.894 178.236 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 64.78 -26.26 0.09 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.43 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 122.16 75.71 0.36 Allowed Glycine 0 C--N 1.338 0.665 0 N-CA-C 112.066 -0.414 . . . . 0.0 112.066 -179.5 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.41 ' H ' ' HG1' ' A' ' 155' ' ' THR . 10.1 p -92.93 105.04 17.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 123.34 0.656 . . . . 0.0 111.393 -179.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 12.6 p -121.46 122.06 28.18 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.889 178.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -81.6 -39.91 0.17 Allowed 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.286 1.991 . . . . 0.0 112.731 179.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.495 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 8.3 t -161.84 -62.46 0.05 Allowed 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.691 -1.141 . . . . 0.0 109.686 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.495 ' H ' ' CG2' ' A' ' 158' ' ' THR . 9.1 tt0 . . . . . 0 C--O 1.252 1.186 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.127 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.9 mtt . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.576 0.227 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -133.67 -42.7 0.83 Allowed 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.055 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.95 48.9 0.92 Allowed Glycine 0 C--N 1.34 0.765 0 O-C-N 123.427 0.454 . . . . 0.0 112.679 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 67.2 m -104.96 140.06 38.73 Favored 'General case' 0 C--O 1.234 0.253 0 O-C-N 123.58 0.224 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -124.8 152.85 43.36 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.003 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.1 m80 -96.19 -41.5 8.66 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.653 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 6.7 t-80 -112.81 136.42 52.45 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.352 0.408 . . . . 0.0 111.066 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -124.4 131.54 53.5 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.577 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.01 114.06 27.1 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.731 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -147.52 135.24 21.04 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.218 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.84 -130.73 7.75 Favored Glycine 0 C--N 1.337 0.607 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.636 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.46 163.89 13.04 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -179.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.8 109.94 2.11 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.726 176.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.0 t -93.79 -19.45 21.02 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -178.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -100.06 121.67 41.75 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 121.642 0.734 . . . . 0.0 112.522 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 18.0 p -102.76 137.1 41.42 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.727 -1.579 . . . . 0.0 113.648 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.488 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.0 OUTLIER -95.88 113.87 62.96 Favored Pre-proline 0 CA--C 1.54 0.579 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.508 177.71 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.654 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.1 Cg_exo -65.68 -26.52 53.33 Favored 'Trans proline' 0 C--N 1.368 1.554 0 C-N-CA 122.699 2.266 . . . . 0.0 113.286 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.77 HD11 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.41 -172.16 2.88 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 122.682 1.229 . . . . 0.0 110.722 -179.765 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.521 ' H ' HD13 ' A' ' 19' ' ' LEU . 0.2 OUTLIER -129.08 -24.75 2.85 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 111.862 -2.426 . . . . 0.0 108.797 177.407 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.77 ' O ' HD11 ' A' ' 19' ' ' LEU . 7.5 t -168.58 -168.74 0.94 Allowed 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 114.55 -1.205 . . . . 0.0 112.185 -177.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.75 111.43 0.26 Allowed Glycine 0 C--N 1.319 -0.37 0 CA-C-N 114.268 -1.333 . . . . 0.0 111.415 177.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.55 124.69 8.71 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.588 0.709 . . . . 0.0 112.764 -178.347 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.564 HD11 ' H ' ' A' ' 24' ' ' ILE . 0.0 OUTLIER -103.04 58.74 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-N 113.692 -1.595 . . . . 0.0 108.663 178.674 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.0 t -100.05 -28.56 12.99 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 112.879 -1.964 . . . . 0.0 110.826 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.8 m -116.93 -66.28 1.1 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.434 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.96 125.74 1.3 Allowed Glycine 0 C--N 1.322 -0.199 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.824 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.523 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.1 OUTLIER -73.54 157.36 36.87 Favored 'General case' 0 C--N 1.342 0.278 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.56 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -57.15 31.99 0.0 OUTLIER 'General case' 0 C--O 1.238 0.494 0 N-CA-C 115.778 1.77 . . . . 0.0 115.778 -177.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.674 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 103.12 0.74 48.03 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -102.06 85.4 0.7 Allowed Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.674 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.0 Cg_exo -76.73 141.25 21.63 Favored 'Trans proline' 0 C--N 1.374 1.884 0 C-N-CA 122.831 2.354 . . . . 0.0 113.388 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.25 4.06 78.05 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 123.694 0.621 . . . . 0.0 113.091 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.444 ' O ' HG12 ' A' ' 24' ' ' ILE . 2.6 t-80 -79.58 129.54 34.56 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 123.886 0.874 . . . . 0.0 110.659 -179.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -5.25 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.227 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -131.01 -150.15 6.69 Favored Glycine 0 C--N 1.337 0.602 0 N-CA-C 111.868 -0.493 . . . . 0.0 111.868 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.463 HG11 ' OH ' ' A' ' 39' ' ' TYR . 11.4 p -131.69 151.5 35.46 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.701 0 C-N-CA 122.824 0.449 . . . . 0.0 110.044 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.726 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -127.23 137.89 52.98 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.222 0.534 . . . . 0.0 111.715 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.654 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.3 m-85 -125.4 107.6 10.83 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 114.534 -1.212 . . . . 0.0 110.574 -178.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -59.31 104.9 0.29 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.494 179.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 p -149.25 129.04 6.5 Favored Pre-proline 0 CA--C 1.549 0.919 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.192 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.82 144.18 56.15 Favored 'Trans proline' 0 C--N 1.365 1.441 0 C-N-CA 123.298 2.665 . . . . 0.0 115.149 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.471 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.92 142.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 111.796 -2.456 . . . . 0.0 113.362 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.17 2.53 59.16 Favored Glycine 0 N--CA 1.442 -0.963 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.984 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' THR . . . . . 0.55 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.4 m -88.83 129.45 48.52 Favored Pre-proline 0 N--CA 1.447 -0.623 0 CA-C-O 119.134 -0.46 . . . . 0.0 109.791 179.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.58 126.91 22.69 Favored 'Trans proline' 0 C--N 1.371 1.742 0 C-N-CA 122.152 1.901 . . . . 0.0 112.965 -179.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.44 ' O ' HG13 ' A' ' 107' ' ' ILE . 6.2 t -99.93 124.29 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.863 179.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.624 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.1 mtp-105 -101.55 153.57 19.62 Favored 'General case' 0 N--CA 1.433 -1.309 0 CA-C-N 113.18 -1.827 . . . . 0.0 111.843 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.33 121.47 20.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.61 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 30.4 t -67.76 -14.98 19.03 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.571 ' HB1' ' ND1' ' A' ' 79' ' ' HIS . . . -170.75 143.51 2.13 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 123.376 0.67 . . . . 0.0 110.482 179.001 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.434 ' ND2' ' HB3' ' A' ' 80' ' ' ALA . 0.4 OUTLIER -61.74 156.17 21.0 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.078 -0.965 . . . . 0.0 112.156 179.199 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.677 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.61 -127.35 1.52 Allowed Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.806 -0.712 . . . . 0.0 113.996 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.4 m -149.48 137.08 20.18 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 -177.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.436 HG22 ' O ' ' A' ' 99' ' ' SER . 10.4 t -83.26 113.82 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 123.763 0.825 . . . . 0.0 108.956 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.494 ' HZ3' ' HB2' ' A' ' 78' ' ' GLN . 0.3 OUTLIER -98.84 -17.08 18.62 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.827 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -148.78 139.57 22.83 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.435 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.95 92.34 1.96 Allowed 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.904 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.56 91.27 1.4 Allowed Glycine 0 C--O 1.24 0.482 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.269 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.578 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -73.52 122.85 22.84 Favored 'General case' 0 C--N 1.344 0.358 0 C-N-CA 123.924 0.89 . . . . 0.0 112.57 -179.358 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.588 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.34 -0.73 87.32 Favored Glycine 0 C--N 1.32 -0.349 0 CA-C-N 113.265 -1.789 . . . . 0.0 113.378 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.89 -32.91 57.77 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.67 22.58 2.69 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-N 115.894 -0.593 . . . . 0.0 112.233 -178.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.588 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.5 113.45 34.5 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -178.619 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.829 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.3 Cg_exo -66.98 162.88 36.07 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 123.675 2.917 . . . . 0.0 111.705 177.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -95.63 8.1 44.37 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 176.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.0 mtt -74.81 -44.76 47.61 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.308 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.52 11.74 10.67 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.824 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.829 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -130.65 143.21 50.59 Favored 'General case' 0 C--N 1.361 1.096 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.412 -179.319 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 5.0 ttt -147.22 -19.78 0.39 Allowed 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.212 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -90.85 -29.17 17.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -179.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.623 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 106.48 -127.38 8.87 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.8 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.526 HD22 ' HA3' ' A' ' 61' ' ' GLY . 14.8 m-80 -88.61 139.33 30.58 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 122.894 0.478 . . . . 0.0 111.928 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.48 145.67 23.81 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.143 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.56 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.34 121.24 19.31 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.174 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.121 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.1 126.87 53.51 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.402 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -139.95 150.69 21.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-N 112.579 -2.1 . . . . 0.0 110.643 -176.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.677 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.7 tt0 -97.23 116.76 30.02 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 113.921 -1.49 . . . . 0.0 108.33 177.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.571 ' ND1' ' HB1' ' A' ' 51' ' ' ALA . 3.4 m-70 -69.55 -176.91 1.08 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HB3' ' ND2' ' A' ' 52' ' ' ASN . . . -64.97 -17.55 64.5 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 113.69 -1.595 . . . . 0.0 113.966 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.61 -12.9 20.67 Favored 'General case' 0 C--O 1.236 0.345 0 O-C-N 123.449 0.468 . . . . 0.0 110.986 -179.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.59 -6.77 45.38 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.685 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.68 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 18.5 ptp -70.55 168.23 16.76 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 123.352 0.661 . . . . 0.0 110.364 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.469 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 19.0 p80 -118.16 142.11 47.79 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.142 -1.023 . . . . 0.0 111.203 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.2 OUTLIER -133.85 128.39 34.57 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.255 -177.347 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.56 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -101.15 154.8 19.13 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 114.719 -1.128 . . . . 0.0 111.471 177.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.497 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.4 m-85 -133.44 99.22 4.45 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -111.32 168.92 9.15 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.925 -0.58 . . . . 0.0 112.556 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . 0.551 ' CD2' ' HA3' ' A' ' 114' ' ' GLY . 22.1 m80 65.99 37.24 5.44 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 114.836 -1.074 . . . . 0.0 112.042 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.487 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.5 mt -98.43 169.58 9.44 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.745 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.3 t -107.83 -14.69 14.72 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 111.623 0.231 . . . . 0.0 111.623 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -167.66 157.95 10.75 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.595 0.712 . . . . 0.0 111.87 -178.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.722 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -123.37 149.42 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.844 179.25 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -113.34 -6.83 13.53 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.837 177.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.722 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -101.54 -175.04 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.02 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.28 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.5 m -152.64 145.16 24.13 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.256 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.55 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.3 m -57.02 126.14 25.85 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.599 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.55 ' HB2' ' O ' ' A' ' 97' ' ' THR . 1.6 m-20 85.37 -2.19 0.83 Allowed 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.75 1.22 . . . . 0.0 111.939 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.436 ' O ' HG22 ' A' ' 55' ' ' VAL . 8.7 t -80.74 149.28 29.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -82.86 145.17 29.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.294 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.52 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.334 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.401 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 70.2 tttt -142.03 148.93 39.28 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.824 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.747 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.36 137.95 56.85 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.422 -1.263 . . . . 0.0 111.253 -179.75 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.624 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.81 -4.55 52.11 Favored Glycine 0 C--N 1.328 0.089 0 CA-C-N 114.477 -1.238 . . . . 0.0 114.083 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.46 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.8 tt0 -74.2 141.94 45.42 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.108 0.48 . . . . 0.0 110.086 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.7 mt -72.37 101.44 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.525 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.44 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.2 pt -93.57 -6.16 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.88 -179.061 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.83 -159.88 33.15 Favored Glycine 0 N--CA 1.44 -1.067 0 C-N-CA 121.435 -0.412 . . . . 0.0 112.702 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.487 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 31.9 m-85 -140.24 138.07 34.76 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 124.674 1.19 . . . . 0.0 108.355 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.55 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.7 OUTLIER -60.24 150.17 30.98 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.567 0.747 . . . . 0.0 112.85 -178.654 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.486 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -148.47 -163.71 10.99 Favored Glycine 0 C--N 1.345 1.06 0 C-N-CA 120.616 -0.802 . . . . 0.0 113.02 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -150.33 44.4 0.87 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.415 0.626 . . . . 0.0 109.81 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.623 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 67.4 p -83.88 -1.1 53.78 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.953 -178.162 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.551 ' HA3' ' CD2' ' A' ' 89' ' ' HIS . . . -92.56 -120.23 2.75 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.396 -0.43 . . . . 0.0 112.326 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -90.92 154.54 19.39 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 122.301 0.24 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 20.0 m 49.79 167.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 124.99 1.316 . . . . 0.0 114.073 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.4 p -83.92 4.68 28.47 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.913 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -88.37 116.1 4.54 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.987 -0.896 . . . . 0.0 112.803 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.416 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 5.0 Cg_exo -73.45 142.95 33.92 Favored 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 122.495 2.13 . . . . 0.0 112.202 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 51.9 p-80 -163.29 -171.09 2.47 Favored 'General case' 0 C--N 1.347 0.499 0 CA-C-O 121.371 0.605 . . . . 0.0 111.414 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.726 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -124.75 131.08 53.48 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.487 -178.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 23.8 t60 -112.76 109.92 19.7 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.405 -1.271 . . . . 0.0 109.436 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -114.43 110.16 19.43 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.015 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.544 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -115.01 127.13 55.47 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' MET . . . . . . . . . . . . . 2.2 ttt -121.87 134.68 54.87 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 114.354 -1.294 . . . . 0.0 109.023 -178.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.68 ' O ' ' HB2' ' A' ' 83' ' ' MET . 2.1 mp -143.46 164.77 28.94 Favored Pre-proline 0 C--N 1.313 -1.022 0 CA-C-N 113.355 -1.748 . . . . 0.0 110.358 -177.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.469 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -61.91 -178.5 0.32 Allowed 'Trans proline' 0 C--N 1.369 1.644 0 C-N-CA 123.291 2.661 . . . . 0.0 113.473 177.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.99 -28.97 67.09 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.077 176.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.43 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 1.4 m-80 -158.01 103.93 1.74 Allowed Pre-proline 0 CA--C 1.503 -0.839 0 CA-C-N 113.896 -1.502 . . . . 0.0 108.607 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 2.8 Cg_exo -73.5 163.13 38.37 Favored 'Trans proline' 0 N--CA 1.444 -1.44 0 C-N-CA 122.511 2.141 . . . . 0.0 116.746 -176.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.569 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -118.2 70.53 0.81 Allowed 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 112.281 -2.236 . . . . 0.0 107.412 177.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.444 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.4 m-90 -62.83 12.5 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.427 -178.55 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.569 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -82.17 34.18 0.41 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 124.224 1.01 . . . . 0.0 112.74 -178.565 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 72.54 128.77 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.62 0 C-N-CA 125.692 1.597 . . . . 0.0 110.748 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.27 -48.6 0.59 Allowed Glycine 0 N--CA 1.439 -1.161 0 CA-C-N 115.135 -0.939 . . . . 0.0 113.043 -179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.55 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -150.48 -20.72 0.23 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 111.756 0.28 . . . . 0.0 111.756 179.301 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.23 17.71 10.78 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.081 1.352 . . . . 0.0 107.989 -178.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.635 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.29 -11.31 8.95 Favored Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 112.262 -2.245 . . . . 0.0 112.609 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.55 ' HG3' ' O ' ' A' ' 136' ' ' PHE . 0.0 OUTLIER -79.11 125.72 29.79 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.321 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -129.84 -175.35 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.004 179.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -79.74 132.96 59.65 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.573 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.1 Cg_exo -76.68 -1.89 12.05 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.667 2.245 . . . . 0.0 112.932 178.016 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.75 -23.24 6.41 Favored 'General case' 0 C--N 1.35 0.627 0 N-CA-C 114.278 1.214 . . . . 0.0 114.278 -178.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -67.67 -31.12 75.46 Favored Glycine 0 CA--C 1.518 0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.334 -179.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -103.39 -11.99 17.5 Favored 'General case' 0 C--O 1.236 0.37 0 O-C-N 123.861 0.389 . . . . 0.0 111.919 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.573 HG12 ' O ' ' A' ' 142' ' ' PRO . 24.5 mm -96.2 -8.71 9.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.684 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -76.77 -23.87 52.92 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.412 178.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.92 13.6 34.59 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.013 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . 0.417 ' HB1' ' NH1' ' A' ' 17' ' ' ARG . . . -98.52 158.7 32.1 Favored Pre-proline 0 N--CA 1.415 -2.209 0 CA-C-N 113.422 -1.717 . . . . 0.0 112.548 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.432 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 10.1 Cg_endo -55.02 178.74 0.08 OUTLIER 'Trans proline' 0 C--N 1.365 1.434 0 C-N-CA 124.527 3.485 . . . . 0.0 113.977 179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.1 132.87 63.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 C-N-CA 123.43 0.692 . . . . 0.0 111.61 -177.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . 0.498 ' C ' ' H ' ' A' ' 154' ' ' GLY . 82.4 t80 -98.96 96.69 8.0 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.042 -1.435 . . . . 0.0 109.914 178.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 63.24 -30.97 0.1 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 124.312 1.045 . . . . 0.0 113.724 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . 0.498 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 111.94 64.67 0.49 Allowed Glycine 0 C--N 1.336 0.577 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.0 p -95.38 105.64 17.62 Favored 'General case' 0 N--CA 1.442 -0.829 0 C-N-CA 123.523 0.729 . . . . 0.0 111.55 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.9 p -94.04 125.39 52.98 Favored Pre-proline 0 CA--C 1.54 0.581 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.762 178.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.06 -42.09 0.11 Allowed 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.368 2.046 . . . . 0.0 113.321 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.517 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 7.9 t -160.78 -63.98 0.06 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.152 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.517 ' H ' ' CG2' ' A' ' 158' ' ' THR . 35.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-N 114.385 -1.28 . . . . 0.0 111.778 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 mtt . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 120.596 0.236 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.28 -45.31 4.13 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.263 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 118.89 154.03 9.53 Favored Glycine 0 C--N 1.34 0.776 0 O-C-N 123.433 0.458 . . . . 0.0 112.671 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.4 m -116.5 132.24 56.73 Favored 'General case' 0 C--O 1.235 0.32 0 O-C-N 123.663 0.272 . . . . 0.0 110.751 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -110.99 121.31 45.04 Favored 'General case' 0 C--O 1.235 0.335 0 O-C-N 123.647 0.592 . . . . 0.0 111.306 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 -133.7 141.89 47.76 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.831 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 78.7 m-70 -127.95 115.71 18.96 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.619 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -137.06 -43.17 0.57 Allowed 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.363 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -117.93 148.69 41.93 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 123.382 0.426 . . . . 0.0 111.475 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -101.5 140.56 35.62 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.656 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 146.9 59.83 0.01 OUTLIER Glycine 0 C--N 1.338 0.687 0 O-C-N 123.475 0.485 . . . . 0.0 112.585 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.44 164.48 12.99 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -159.16 113.16 2.36 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.444 176.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.3 t -89.93 5.69 45.3 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.5 -179.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -101.59 136.02 42.13 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.48 0.657 . . . . 0.0 111.454 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.0 p -94.5 -179.08 4.78 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 113.936 -1.484 . . . . 0.0 112.523 -178.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 1.1 ttp180 -78.04 112.23 23.86 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.949 0.9 . . . . 0.0 112.451 -179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.637 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.5 Cg_exo -67.41 -23.22 44.37 Favored 'Trans proline' 0 C--N 1.368 1.569 0 C-N-CA 122.617 2.211 . . . . 0.0 112.273 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.803 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.41 -172.02 3.04 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-O 122.561 1.172 . . . . 0.0 110.509 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.534 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.52 -24.83 2.99 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 112.221 -2.263 . . . . 0.0 108.772 177.233 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.803 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.3 t -168.42 -168.51 0.93 Allowed 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.654 -178.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 179.17 110.99 0.29 Allowed Glycine 0 C--N 1.32 -0.356 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.386 177.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.416 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.09 124.65 8.35 Favored 'General case' 0 CA--C 1.506 -0.739 0 CA-C-O 121.531 0.682 . . . . 0.0 112.337 -178.434 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.5 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.93 58.77 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.533 0 CA-C-N 113.924 -1.489 . . . . 0.0 108.978 178.536 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.6 t -105.05 -28.64 10.92 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 112.815 -1.993 . . . . 0.0 111.111 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.42 -66.79 1.05 Allowed 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.981 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.05 121.4 0.94 Allowed Glycine 0 C--N 1.321 -0.257 0 CA-C-N 115.131 -0.94 . . . . 0.0 112.15 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.527 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -74.72 157.49 35.18 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -178.849 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -57.43 31.71 0.0 OUTLIER 'General case' 0 C--O 1.24 0.561 0 N-CA-C 115.87 1.804 . . . . 0.0 115.87 -177.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.676 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.56 -2.05 49.52 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -101.76 85.47 0.67 Allowed Pre-proline 0 CA--C 1.547 0.861 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.676 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.8 Cg_exo -78.12 138.11 15.94 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.785 2.323 . . . . 0.0 113.317 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 92.41 4.31 66.27 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.225 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -76.52 135.89 39.31 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 123.79 0.836 . . . . 0.0 110.2 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.498 HG13 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.19 -18.93 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.444 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.22 -149.85 8.22 Favored Glycine 0 C--N 1.337 0.624 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.2 p -131.08 148.54 32.98 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 O-C-N 123.855 0.385 . . . . 0.0 110.11 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.775 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.21 135.12 52.26 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.456 0.646 . . . . 0.0 112.148 -178.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.637 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 2.1 m-85 -124.56 110.26 14.23 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 114.231 -1.35 . . . . 0.0 109.803 -178.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.31 104.25 0.12 Allowed 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.649 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.438 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.7 p -144.88 120.75 6.0 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.563 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -49.16 144.68 16.11 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.191 2.594 . . . . 0.0 115.525 -179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.458 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -61.03 139.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 111.628 -2.533 . . . . 0.0 113.437 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.52 2.56 55.47 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.358 -0.837 . . . . 0.0 114.181 177.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' THR . . . . . 0.416 ' H ' ' HG1' ' A' ' 110' ' ' THR . 2.4 m -87.41 127.57 58.29 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-O 119.148 -0.453 . . . . 0.0 109.951 179.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -59.36 127.27 23.31 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.181 1.921 . . . . 0.0 113.378 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.481 ' O ' HG13 ' A' ' 107' ' ' ILE . 11.4 t -99.05 123.8 51.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.28 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.588 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 5.9 mtt180 -102.39 152.42 21.13 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.913 -1.949 . . . . 0.0 111.597 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 102' ' ' LYS . . . -73.47 120.82 19.61 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.771 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.3 t -65.51 -16.77 20.89 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.585 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.27 144.63 2.05 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 123.479 0.711 . . . . 0.0 110.391 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.15 156.02 19.27 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.071 -0.968 . . . . 0.0 112.512 179.492 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.644 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.71 -125.88 1.38 Allowed Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.72 -0.673 . . . . 0.0 113.701 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 14.3 m -148.22 142.95 26.67 Favored 'General case' 0 N--CA 1.439 -1.025 0 C-N-CA 123.624 0.77 . . . . 0.0 109.706 -178.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 99' ' ' SER . 9.4 t -84.89 112.1 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 123.805 0.842 . . . . 0.0 108.881 179.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.457 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -95.14 -14.96 23.71 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.751 -179.861 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -154.38 140.37 18.31 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.045 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -147.85 92.31 2.05 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.394 -1.275 . . . . 0.0 108.952 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.63 89.99 1.27 Allowed Glycine 0 C--O 1.24 0.499 0 CA-C-N 114.251 -1.341 . . . . 0.0 112.454 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.568 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.09 122.13 20.43 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.951 0.881 . . . . 0.0 112.822 -179.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.612 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.63 -0.94 88.59 Favored Glycine 0 N--CA 1.461 0.301 0 CA-C-N 113.197 -1.82 . . . . 0.0 113.693 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.09 -33.44 59.51 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -138.62 26.91 2.52 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.925 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.612 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.9 115.26 50.92 Favored Pre-proline 0 N--CA 1.437 -1.119 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -178.372 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.822 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 37.4 Cg_exo -68.05 162.95 37.76 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 123.845 3.03 . . . . 0.0 111.789 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -96.25 8.58 43.53 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -74.66 -44.6 49.54 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.312 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.527 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -121.97 11.76 10.35 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.913 177.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.822 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.0 OUTLIER -129.03 144.39 51.17 Favored 'General case' 0 C--N 1.361 1.093 0 C-N-CA 120.159 -0.616 . . . . 0.0 112.237 -178.854 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.61 -31.16 0.35 Allowed 'General case' 0 N--CA 1.47 0.525 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.689 178.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.62 -19.34 31.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.511 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 96.3 -130.28 10.21 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.967 -0.561 . . . . 0.0 114.112 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.558 HD22 ' HA3' ' A' ' 61' ' ' GLY . 10.1 m-80 -81.11 140.95 34.75 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.558 0.743 . . . . 0.0 112.35 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.23 146.56 24.83 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.345 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.568 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.93 121.35 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.265 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.401 HD23 ' HD1' ' A' ' 84' ' ' HIS . 0.1 OUTLIER -117.89 130.55 56.31 Favored 'General case' 0 CA--C 1.492 -1.273 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 177.561 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 8.4 mt -139.4 150.82 22.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-N 112.909 -1.951 . . . . 0.0 110.403 -176.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.644 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.68 116.18 31.2 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 113.865 -1.516 . . . . 0.0 108.281 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.585 ' CE1' ' HB3' ' A' ' 51' ' ' ALA . 3.8 m-70 -69.21 -175.47 0.77 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.27 -18.1 65.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 113.982 -1.463 . . . . 0.0 114.619 -177.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.22 -9.18 20.66 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.81 -6.14 43.83 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.154 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.544 ' HE1' ' HH ' ' A' ' 145' ' ' TYR . 4.0 ptt? -67.43 165.76 15.98 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 123.595 0.758 . . . . 0.0 111.353 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.497 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 61.9 m-70 -111.41 144.37 40.72 Favored 'General case' 0 N--CA 1.44 -0.929 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.826 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.7 127.06 22.96 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 120.99 0.424 . . . . 0.0 110.345 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.568 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -104.24 154.73 17.61 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.628 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.486 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.0 m-85 -136.08 99.06 4.03 Favored 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -113.66 167.78 10.32 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -177.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 65.5 42.28 3.82 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.283 1.033 . . . . 0.0 111.383 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.517 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.2 mt -103.22 168.58 9.08 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.103 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 8.1 t -102.63 -17.81 15.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.16 163.64 15.6 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.722 0.772 . . . . 0.0 111.927 -177.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.696 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -127.56 148.18 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.509 -1.678 . . . . 0.0 110.893 179.06 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 t -111.51 -6.6 14.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.886 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.696 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -103.35 -175.24 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.099 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.792 -177.118 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.7 m -153.22 143.42 22.35 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.674 -1.148 . . . . 0.0 108.936 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.76 127.88 32.23 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 86.02 -4.43 0.79 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.692 1.197 . . . . 0.0 111.719 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.466 ' O ' HG21 ' A' ' 55' ' ' VAL . 39.5 m -80.44 151.61 29.22 Favored 'General case' 0 C--N 1.347 0.463 0 CA-C-O 120.571 0.224 . . . . 0.0 110.552 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.7 145.52 27.91 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.608 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.89 169.71 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.314 0 CA-C-N 115.197 -0.91 . . . . 0.0 112.196 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' HB1' ' A' ' 49' ' ' ALA . 1.9 tttt -142.42 148.51 37.93 Favored 'General case' 0 N--CA 1.432 -1.361 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.716 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.756 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.34 138.41 56.49 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.361 -179.796 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.588 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 77.03 -8.44 30.58 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 114.38 -1.282 . . . . 0.0 114.135 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.473 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.1 tt0 -70.75 141.29 51.48 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.078 0.466 . . . . 0.0 110.214 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.8 mt -72.72 102.05 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.559 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.481 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.5 -4.97 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 CA-C-N 113.564 -1.653 . . . . 0.0 113.117 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.66 -160.74 34.44 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 121.472 -0.394 . . . . 0.0 112.749 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 35.4 m-85 -140.16 138.35 35.12 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.669 1.188 . . . . 0.0 108.522 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.416 ' HG1' ' H ' ' A' ' 45' ' ' THR . 0.8 OUTLIER -62.71 150.93 39.84 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 123.631 0.773 . . . . 0.0 112.552 -179.224 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.468 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -161.37 -160.98 11.23 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 119.877 -1.154 . . . . 0.0 114.034 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.43 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.2 51.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 114.48 -0.86 . . . . 0.0 108.684 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.511 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 21.6 p -80.67 2.76 24.53 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.196 -0.911 . . . . 0.0 113.33 -177.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -110.6 -162.26 18.25 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 111.857 -0.497 . . . . 0.0 111.857 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . 0.502 ' O ' HG11 ' A' ' 116' ' ' VAL . 52.6 mt-30 -91.57 91.07 7.88 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.301 0.572 . . . . 0.0 110.234 179.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.502 HG11 ' O ' ' A' ' 115' ' ' GLN . 3.4 m -151.66 159.01 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.746 -179.5 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.2 t -85.57 -4.21 59.09 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -166.5 164.04 37.37 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.634 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.43 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 6.2 Cg_exo -80.25 139.21 13.07 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 123.302 2.668 . . . . 0.0 112.419 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.438 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 24.0 p-80 -160.94 -166.34 1.57 Allowed 'General case' 0 C--N 1.348 0.5 0 CA-C-O 121.256 0.551 . . . . 0.0 111.411 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.775 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 13.3 tp -123.03 130.04 52.28 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.64 -1.163 . . . . 0.0 111.261 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.6 t60 -112.81 113.0 24.9 Favored 'General case' 0 N--CA 1.434 -1.225 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.815 177.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 45.2 t80 -118.53 111.31 18.45 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.138 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -118.55 127.21 53.4 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.163 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.488 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.0 tpt -117.61 138.41 51.97 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.7 mp -143.65 166.62 18.72 Favored Pre-proline 0 C--N 1.308 -1.237 0 CA-C-N 113.465 -1.698 . . . . 0.0 111.103 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.497 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -62.52 -178.48 0.38 Allowed 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 123.35 2.7 . . . . 0.0 112.703 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -69.98 -28.05 65.22 Favored 'General case' 0 N--CA 1.439 -0.989 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.247 176.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.432 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 29.7 m120 -156.94 101.28 1.95 Allowed Pre-proline 0 CA--C 1.504 -0.793 0 CA-C-N 114.334 -1.303 . . . . 0.0 108.829 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 4.4 Cg_exo -72.26 163.18 39.46 Favored 'Trans proline' 0 N--CA 1.444 -1.432 0 C-N-CA 122.698 2.265 . . . . 0.0 116.542 -177.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.582 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -117.08 70.7 0.78 Allowed 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.491 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.454 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.07 12.54 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 114.29 -1.323 . . . . 0.0 112.313 -178.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.582 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -81.61 32.29 0.36 Allowed 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.378 1.071 . . . . 0.0 112.815 -178.534 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 73.74 129.1 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.582 0 C-N-CA 125.825 1.65 . . . . 0.0 110.789 178.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.34 -48.6 0.59 Allowed Glycine 0 N--CA 1.44 -1.085 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.121 -179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.2 -19.77 0.18 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.762 0.315 . . . . 0.0 111.757 179.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.6 t 66.34 18.03 10.81 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.975 1.31 . . . . 0.0 108.213 -178.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.578 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 74.59 -9.71 10.12 Favored Glycine 0 N--CA 1.437 -1.26 0 CA-C-N 112.582 -2.099 . . . . 0.0 112.904 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.561 ' HD2' ' O ' ' A' ' 139' ' ' ARG . 1.5 ppt_? -82.73 127.25 33.25 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.561 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.437 HG23 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -129.37 -172.86 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.855 -0.612 . . . . 0.0 112.413 178.478 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.437 ' H ' HG23 ' A' ' 140' ' ' ILE . 1.3 m-20 -71.65 134.86 83.83 Favored Pre-proline 0 CA--C 1.549 0.906 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -176.278 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.619 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.6 Cg_endo -77.7 2.03 8.24 Favored 'Trans proline' 0 C--N 1.381 2.265 0 C-N-CA 123.296 2.664 . . . . 0.0 113.297 177.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.5 p -51.17 -24.04 3.85 Favored 'General case' 0 C--N 1.347 0.467 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -178.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.52 -28.04 71.69 Favored Glycine 0 CA--C 1.52 0.383 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.867 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . 0.544 ' HH ' ' HE1' ' A' ' 83' ' ' MET . 6.0 m-85 -102.4 -9.28 20.44 Favored 'General case' 0 C--O 1.237 0.445 0 O-C-N 124.085 0.52 . . . . 0.0 111.496 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.619 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -98.53 -11.29 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.854 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -75.7 -25.51 56.75 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.019 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.29 16.04 27.02 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -94.55 157.58 36.92 Favored Pre-proline 0 N--CA 1.419 -2.011 0 CA-C-N 114.109 -1.405 . . . . 0.0 113.121 -178.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_exo -55.54 178.87 0.09 OUTLIER 'Trans proline' 0 C--N 1.367 1.551 0 C-N-CA 124.548 3.498 . . . . 0.0 114.904 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.2 t -99.84 130.7 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 114.559 -1.2 . . . . 0.0 111.152 -178.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -107.4 102.35 11.64 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 113.636 -1.62 . . . . 0.0 108.883 178.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 72.74 -40.08 0.46 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 124.517 1.127 . . . . 0.0 112.63 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 124.09 88.75 0.83 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.151 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.415 ' H ' ' HG1' ' A' ' 155' ' ' THR . 14.2 p -95.3 105.09 17.01 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-O 121.337 0.589 . . . . 0.0 111.292 -179.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 12.6 p -103.2 137.72 19.34 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.506 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.63 -41.57 0.11 Allowed 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.335 2.023 . . . . 0.0 113.231 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.505 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 8.5 t -161.67 -63.59 0.05 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.986 -1.007 . . . . 0.0 110.204 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.505 ' H ' ' CG2' ' A' ' 158' ' ' THR . 31.7 mt-10 . . . . . 0 C--O 1.25 1.094 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.609 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 58.9 mtt . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.659 0.266 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -91.35 140.32 29.89 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.357 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 171.99 80.54 0.05 OUTLIER Glycine 0 C--N 1.336 0.536 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.116 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.1 p -112.66 147.73 36.14 Favored 'General case' 0 C--O 1.235 0.293 0 O-C-N 123.624 0.249 . . . . 0.0 111.305 -179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 89.0 m-70 -102.73 -43.63 5.53 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.882 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -106.86 149.17 27.7 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -105.57 149.34 26.36 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.158 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 65.9 m80 -129.51 151.38 50.19 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.752 179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -96.96 146.81 24.61 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.3 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -136.73 152.59 50.52 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.482 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -99.59 57.38 0.85 Allowed Glycine 0 C--N 1.338 0.673 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.719 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.55 163.63 13.74 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.87 102.78 1.67 Allowed 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.732 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.6 t -92.04 -4.21 54.75 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.569 -179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -94.33 134.42 36.84 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-O 121.793 0.806 . . . . 0.0 112.67 -178.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 10.1 p -88.27 150.85 23.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.276 -1.784 . . . . 0.0 112.466 -178.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.543 ' HD2' ' O ' ' A' ' 150' ' ' PRO . 0.0 OUTLIER -94.64 113.05 60.14 Favored Pre-proline 0 CA--C 1.538 0.49 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.706 179.742 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.615 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 45.6 Cg_exo -58.08 -31.1 92.31 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.948 2.432 . . . . 0.0 113.147 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.871 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.37 -172.12 2.87 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-O 122.5 1.143 . . . . 0.0 110.379 -179.985 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.466 ' H ' HD11 ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.78 -25.71 2.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 112.4 -2.182 . . . . 0.0 108.755 177.288 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.871 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -169.61 -168.32 0.78 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 114.02 -1.445 . . . . 0.0 111.234 -178.045 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.24 110.97 0.3 Allowed Glycine 0 C--N 1.316 -0.574 0 CA-C-N 114.793 -1.094 . . . . 0.0 111.289 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.52 124.98 8.88 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.851 0.834 . . . . 0.0 113.053 -177.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.525 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.85 58.8 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.38 -1.736 . . . . 0.0 108.522 178.373 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 4.9 t -100.94 -28.73 12.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 112.595 -2.093 . . . . 0.0 110.856 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.6 m -115.55 -66.58 1.07 Allowed 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.422 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.46 122.15 0.98 Allowed Glycine 0 C--N 1.323 -0.173 0 CA-C-N 115.084 -0.962 . . . . 0.0 112.037 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.526 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -70.89 157.35 38.29 Favored 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -178.909 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 -58.67 31.75 0.01 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.66 1.726 . . . . 0.0 115.66 -177.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.687 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.81 -2.03 48.58 Favored Glycine 0 CA--C 1.505 -0.59 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.545 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -102.52 85.35 0.75 Allowed Pre-proline 0 CA--C 1.547 0.864 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.687 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 6.2 Cg_exo -78.6 138.98 15.71 Favored 'Trans proline' 0 C--N 1.374 1.898 0 C-N-CA 122.881 2.388 . . . . 0.0 113.497 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.34 3.93 62.89 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.375 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.509 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.3 t-80 -80.62 135.06 35.98 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 123.724 0.81 . . . . 0.0 109.83 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.488 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.74 -20.1 5.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.144 -179.383 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.35 -149.59 8.33 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.441 HG13 ' OH ' ' A' ' 39' ' ' TYR . 14.7 p -131.69 151.92 36.17 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 O-C-N 123.939 0.435 . . . . 0.0 110.274 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASP . . . . . 0.747 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 82.8 m-20 -128.25 131.71 48.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.172 0.51 . . . . 0.0 111.603 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' TYR . . . . . 0.615 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -119.76 111.17 17.66 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.648 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.21 102.04 0.15 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.227 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.465 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 13.8 p -143.34 133.48 12.06 Favored Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.853 -178.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -48.51 139.35 23.3 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 123.486 2.791 . . . . 0.0 115.653 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.44 ' CG2' ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -67.57 143.75 15.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 111.793 -2.458 . . . . 0.0 113.222 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.26 2.78 58.98 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.791 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -86.89 126.86 61.91 Favored Pre-proline 0 N--CA 1.447 -0.611 0 CA-C-O 119.253 -0.403 . . . . 0.0 109.978 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.13 126.18 19.53 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.022 1.815 . . . . 0.0 112.974 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 107' ' ' ILE . 5.4 t -99.86 122.34 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.467 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 2.2 mpt_? -101.7 154.78 18.58 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 113.389 -1.732 . . . . 0.0 112.052 -178.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.35 124.32 25.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.265 -178.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.29 -18.45 24.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.568 ' HB2' ' ND1' ' A' ' 79' ' ' HIS . . . -170.26 144.2 2.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 110.388 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.453 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.03 157.45 12.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.978 179.159 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.667 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.13 -124.59 1.25 Allowed Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.781 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.2 m -147.83 143.37 27.42 Favored 'General case' 0 N--CA 1.436 -1.141 0 C-N-CA 123.594 0.758 . . . . 0.0 109.938 -177.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.477 HG22 ' O ' ' A' ' 99' ' ' SER . 9.8 t -86.94 113.06 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.819 0.848 . . . . 0.0 108.826 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -95.06 -15.02 23.76 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.621 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -154.48 139.6 17.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.221 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.29 92.33 1.94 Allowed 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.894 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . 0.43 ' O ' HD11 ' A' ' 93' ' ' ILE . . . -96.36 92.36 1.38 Allowed Glycine 0 C--O 1.239 0.443 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.488 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.592 ' N ' HD21 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -71.49 122.57 20.67 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 123.914 0.886 . . . . 0.0 112.796 -179.301 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.565 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.59 -0.7 88.01 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-N 113.352 -1.749 . . . . 0.0 113.358 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.41 -32.7 48.81 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.32 27.62 2.56 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.744 -178.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.565 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.58 113.85 40.62 Favored Pre-proline 0 N--CA 1.435 -1.177 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -178.69 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.811 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.9 Cg_exo -66.74 162.59 36.71 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 123.371 2.714 . . . . 0.0 111.166 177.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.1 m95 -96.41 9.54 40.95 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.5 mtt -76.31 -44.66 35.88 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.239 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.535 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.19 11.46 10.86 Favored 'General case' 0 N--CA 1.441 -0.891 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.895 177.619 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' TRP . . . . . 0.811 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.53 138.03 52.05 Favored 'General case' 0 C--N 1.359 0.994 0 C-N-CA 120.359 -0.536 . . . . 0.0 110.842 -179.317 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 11.6 mmt -143.16 -21.21 0.63 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.769 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -96.32 -28.9 14.28 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.97 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.426 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 109.01 -131.02 10.32 Favored Glycine 0 CA--C 1.52 0.387 0 O-C-N 123.767 0.667 . . . . 0.0 113.895 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.556 HD22 ' HA3' ' A' ' 61' ' ' GLY . 12.2 m-80 -79.23 144.13 34.65 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.613 0.765 . . . . 0.0 112.448 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -151.22 144.82 24.96 Favored 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.475 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.556 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -140.46 121.55 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.975 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.86 129.02 52.26 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.421 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 11.1 mt -141.02 151.18 20.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 113.145 -1.843 . . . . 0.0 110.863 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLN . . . . . 0.667 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 2.0 tt0 -100.37 115.76 30.75 Favored 'General case' 0 N--CA 1.436 -1.128 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.996 177.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.647 ' CD2' ' HG1' ' A' ' 85' ' ' THR . 2.2 m-70 -70.08 -177.46 1.37 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 114.347 1.24 . . . . 0.0 114.347 -178.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.453 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -63.45 -17.97 63.26 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 113.744 -1.571 . . . . 0.0 114.179 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.31 -11.78 20.92 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 123.444 0.465 . . . . 0.0 110.728 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.417 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.58 -7.43 46.18 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.81 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.446 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 9.2 ptt? -69.0 163.55 24.37 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 123.286 0.635 . . . . 0.0 111.715 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.491 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 63.4 m-70 -105.68 144.78 31.94 Favored 'General case' 0 N--CA 1.437 -1.084 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.986 -179.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.647 ' HG1' ' CD2' ' A' ' 79' ' ' HIS . 0.0 OUTLIER -138.22 126.84 23.52 Favored 'General case' 0 N--CA 1.441 -0.916 0 O-C-N 123.633 0.583 . . . . 0.0 109.815 -179.519 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . 0.556 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.38 154.27 16.86 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.531 178.618 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -140.94 98.48 3.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 104.338 -2.467 . . . . 0.0 104.338 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 173.68 6.79 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' HIS . . . . . 0.493 ' CE1' ' HA3' ' A' ' 114' ' ' GLY . 86.3 m-70 65.68 24.35 11.58 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.577 1.151 . . . . 0.0 111.642 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . 0.568 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.2 mt -84.01 170.96 13.4 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.577 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.3 t -105.19 -13.82 15.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.7 tttp -166.82 158.15 12.56 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.749 0.785 . . . . 0.0 112.551 -178.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.706 HG21 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -126.06 147.43 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 113.602 -1.635 . . . . 0.0 110.87 179.014 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 t -111.26 -6.63 14.51 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.936 177.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.706 ' H ' HG21 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -102.6 -175.24 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.035 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.736 -177.13 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.1 m -151.88 140.48 20.74 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.938 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -55.07 128.99 36.3 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.412 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 85.68 -4.92 0.84 Allowed 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.594 1.158 . . . . 0.0 112.001 179.07 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG22 ' A' ' 55' ' ' VAL . 46.0 m -80.48 152.72 28.59 Favored 'General case' 0 C--N 1.347 0.457 0 CA-C-O 120.514 0.197 . . . . 0.0 110.739 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 p -85.06 145.1 27.84 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 178.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.7 168.2 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.333 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 74.5 tttt -139.64 148.98 43.2 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-N 114.493 -1.23 . . . . 0.0 109.803 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . 0.757 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.94 138.89 55.42 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.231 -1.349 . . . . 0.0 111.421 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 76.78 -7.29 34.89 Favored Glycine 0 CA--C 1.517 0.165 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.093 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLN . . . . . 0.467 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.4 tt0 -71.89 142.92 49.52 Favored 'General case' 0 CA--C 1.51 -0.593 0 C-N-CA 122.971 0.508 . . . . 0.0 110.131 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 32.9 mt -72.65 100.86 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.49 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -94.25 -3.99 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.952 -178.902 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 170.71 -168.37 41.46 Favored Glycine 0 N--CA 1.438 -1.212 0 CA-C-O 121.353 0.418 . . . . 0.0 112.752 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.568 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 34.0 m-85 -139.59 134.29 31.92 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 124.718 1.207 . . . . 0.0 108.023 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.48 ' H ' ' HG1' ' A' ' 110' ' ' THR . 0.1 OUTLIER -56.61 150.49 15.5 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.477 0.711 . . . . 0.0 112.459 -178.533 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.455 ' N ' ' HA ' ' A' ' 90' ' ' LEU . . . -146.11 -171.11 15.26 Favored Glycine 0 C--N 1.347 1.152 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.526 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -143.86 43.1 1.46 Allowed 'General case' 0 N--CA 1.441 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 109.302 179.273 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.426 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 36.5 p -81.72 -0.3 42.26 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.109 -0.95 . . . . 0.0 112.868 -178.053 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.493 ' HA3' ' CE1' ' A' ' 89' ' ' HIS . . . -100.87 179.19 28.78 Favored Glycine 0 C--N 1.338 0.67 0 C-N-CA 121.394 -0.431 . . . . 0.0 112.485 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -85.01 91.76 8.17 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 121.626 0.727 . . . . 0.0 110.685 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.11 166.12 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.706 -178.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.2 p -78.14 -3.78 44.2 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.26 -168.16 31.71 Favored Glycine 0 CA--C 1.528 0.874 0 CA-C-O 119.617 -0.546 . . . . 0.0 113.133 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' PRO . . . . . 0.465 ' HB2' ' O ' ' A' ' 41' ' ' VAL . 23.0 Cg_exo -68.84 147.34 68.55 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.526 2.817 . . . . 0.0 112.268 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -149.45 158.44 44.18 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-O 122.313 1.054 . . . . 0.0 113.144 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.747 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 12.0 tp -120.47 125.09 47.02 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-N 112.51 -2.132 . . . . 0.0 109.402 179.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 19.1 t60 -110.88 111.01 21.85 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 114.854 -1.066 . . . . 0.0 109.832 178.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -115.49 112.59 22.48 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.635 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.45 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.0 tt0 -119.26 140.04 50.91 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.349 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' MET . . . . . 0.43 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 17.0 tpp -132.72 136.92 46.69 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.819 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.562 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.98 165.47 24.03 Favored Pre-proline 0 C--N 1.312 -1.048 0 CA-C-N 113.714 -1.585 . . . . 0.0 110.419 -178.213 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.491 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.6 Cg_endo -63.53 -178.55 0.52 Allowed 'Trans proline' 0 C--N 1.367 1.511 0 C-N-CA 122.949 2.433 . . . . 0.0 112.746 176.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -71.92 -27.46 62.84 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.205 176.245 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ASN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 130' ' ' PRO . 29.8 m120 -156.75 101.38 1.99 Allowed Pre-proline 0 CA--C 1.504 -0.802 0 CA-C-N 114.25 -1.341 . . . . 0.0 108.741 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 129' ' ' ASN . 2.9 Cg_exo -72.34 163.43 38.67 Favored 'Trans proline' 0 N--CA 1.443 -1.441 0 C-N-CA 122.625 2.217 . . . . 0.0 116.633 -177.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.18 71.53 0.83 Allowed 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 112.421 -2.172 . . . . 0.0 107.275 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.443 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.47 14.91 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 114.266 -1.334 . . . . 0.0 112.421 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 32.94 0.37 Allowed 'General case' 0 N--CA 1.445 -0.71 0 CA-C-O 122.13 0.967 . . . . 0.0 112.833 -178.456 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . 0.4 ' H ' ' C ' ' A' ' 132' ' ' TRP . 9.0 m-80 72.41 128.76 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 125.792 1.637 . . . . 0.0 110.96 178.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.07 -48.7 0.6 Allowed Glycine 0 N--CA 1.437 -1.287 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.109 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.57 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.1 OUTLIER -150.51 -21.09 0.23 Allowed 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 179.558 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t 66.42 18.01 10.77 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.806 1.243 . . . . 0.0 108.121 -178.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.562 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.97 -11.56 14.63 Favored Glycine 0 N--CA 1.436 -1.315 0 CA-C-N 112.439 -2.164 . . . . 0.0 112.683 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ARG . . . . . 0.57 ' HG3' ' O ' ' A' ' 136' ' ' PHE . 0.0 OUTLIER -80.62 125.59 30.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.34 -175.79 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.029 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 5.0 p30 -76.65 137.85 66.81 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . 0.552 ' O ' HG12 ' A' ' 146' ' ' ILE . 76.5 Cg_endo -76.21 20.43 0.57 Allowed 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.21 2.606 . . . . 0.0 114.559 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 5.6 p -56.95 -24.99 56.98 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.154 0.982 . . . . 0.0 113.579 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -75.12 -23.71 73.51 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -95.53 -10.56 29.33 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.607 1.163 . . . . 0.0 110.668 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.552 HG12 ' O ' ' A' ' 142' ' ' PRO . 30.0 mm -107.16 -12.27 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.771 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -76.13 -29.27 57.75 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.899 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ASN . . . . . 0.552 ' H ' ' ND2' ' A' ' 148' ' ' ASN . 0.0 OUTLIER -104.1 9.39 36.37 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 114.637 -1.165 . . . . 0.0 109.387 179.648 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -103.23 152.96 38.72 Favored Pre-proline 0 N--CA 1.416 -2.173 0 CA-C-N 114.169 -1.378 . . . . 0.0 112.212 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.543 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 77.7 Cg_exo -55.03 178.91 0.08 OUTLIER 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 124.605 3.537 . . . . 0.0 114.824 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 93.7 t -110.16 129.75 64.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.7 -178.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 81.4 t80 -105.15 98.15 7.89 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.79 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 53.85 20.67 2.42 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -112.83 63.79 0.28 Allowed Glycine 0 C--N 1.339 0.704 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 22.3 p -102.15 105.14 15.79 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 123.224 0.61 . . . . 0.0 111.609 -179.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.5 p -109.34 140.43 22.03 Favored Pre-proline 0 CA--C 1.537 0.451 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.289 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -82.82 -43.0 0.09 OUTLIER 'Trans proline' 0 C--N 1.373 1.855 0 C-N-CA 122.278 1.985 . . . . 0.0 113.108 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.516 ' CG2' ' H ' ' A' ' 159' ' ' GLU . 9.2 t -160.55 -64.02 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.12 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' GLU . . . . . 0.516 ' H ' ' CG2' ' A' ' 158' ' ' THR . 31.4 mt-10 . . . . . 0 C--O 1.249 1.078 0 CA-C-N 114.461 -1.245 . . . . 0.0 111.637 179.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.652 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.4 Cg_exo . . . . . 0 N--CA 1.484 0.95 0 N-CA-C 113.047 0.364 . . . . 0.0 113.047 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.739 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.95 -171.96 3.07 Favored 'General case' 0 CA--C 1.508 -0.662 0 CA-C-O 122.509 1.147 . . . . 0.0 110.316 -179.695 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -127.58 -25.12 3.2 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 112.253 -2.248 . . . . 0.0 108.797 177.267 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.739 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.2 t -168.77 -168.83 0.92 Allowed 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.332 -1.304 . . . . 0.0 111.671 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.66 111.62 0.3 Allowed Glycine 0 C--N 1.32 -0.345 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.633 177.64 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.48 124.85 8.84 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-O 121.582 0.706 . . . . 0.0 112.578 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.718 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.97 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.476 0 CA-C-N 113.672 -1.604 . . . . 0.0 109.216 179.387 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.8 t -106.64 -27.87 10.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 112.781 -2.009 . . . . 0.0 110.929 178.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.63 -67.41 1.0 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.881 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.06 122.55 1.02 Allowed Glycine 0 N--CA 1.459 0.185 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.28 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.495 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -78.31 157.57 29.14 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -179.073 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 63.7 m-80 -56.94 32.04 0.0 OUTLIER 'General case' 0 C--O 1.24 0.556 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -177.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.98 1.31 48.66 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -102.18 85.3 0.7 Allowed Pre-proline 0 CA--C 1.545 0.788 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.8 Cg_exo -77.6 139.76 18.34 Favored 'Trans proline' 0 C--N 1.372 1.813 0 C-N-CA 122.81 2.34 . . . . 0.0 113.245 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.24 4.49 81.04 Favored Glycine 0 C--N 1.34 0.762 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.986 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -71.86 129.99 39.96 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.083 0.953 . . . . 0.0 111.089 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.684 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.63 6.15 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.351 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.91 -150.01 5.14 Favored Glycine 0 C--N 1.337 0.62 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.565 HG12 ' O ' ' A' ' 123' ' ' PHE . 8.8 p -131.93 150.12 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.725 0 C-N-CA 122.788 0.435 . . . . 0.0 110.23 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.741 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 84.7 m-20 -126.18 135.28 51.44 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.21 0.528 . . . . 0.0 111.977 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.652 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -126.39 108.11 10.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.541 -178.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.68 104.83 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.264 179.076 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.441 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 11.0 p -147.63 127.97 6.81 Favored Pre-proline 0 CA--C 1.551 0.989 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.908 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -49.48 141.84 24.76 Favored 'Trans proline' 0 C--N 1.369 1.608 0 C-N-CA 123.385 2.723 . . . . 0.0 115.375 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.768 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.3 140.81 18.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 111.891 -2.413 . . . . 0.0 113.401 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.38 2.62 53.79 Favored Glycine 0 N--CA 1.442 -0.952 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.09 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.3 m -85.96 126.12 66.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.37 126.79 23.11 Favored 'Trans proline' 0 C--N 1.372 1.802 0 C-N-CA 122.226 1.951 . . . . 0.0 113.15 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.599 HG21 HD22 ' A' ' 90' ' ' LEU . 10.2 t -100.95 122.35 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.848 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 41.2 mtt180 -101.86 154.06 19.27 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 113.044 -1.889 . . . . 0.0 111.881 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.27 119.62 17.76 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.578 -1.192 . . . . 0.0 110.57 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -65.9 -15.96 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.44 143.74 1.85 Allowed 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 123.411 0.684 . . . . 0.0 110.403 179.09 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -60.86 155.74 18.93 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.32 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.64 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.66 -127.17 1.52 Allowed Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.691 -0.686 . . . . 0.0 113.766 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 16.4 m -148.67 141.09 24.24 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 123.583 0.753 . . . . 0.0 109.875 -178.021 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 99' ' ' SER . 11.8 t -84.33 112.65 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 C-N-CA 123.78 0.832 . . . . 0.0 109.027 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -95.13 -15.03 23.67 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.684 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -155.85 139.67 16.19 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.766 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.69 92.36 1.99 Allowed 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.227 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.438 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.14 90.3 1.48 Allowed Glycine 0 C--O 1.24 0.524 0 CA-C-N 114.28 -1.327 . . . . 0.0 111.985 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.552 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.8 m120 -71.11 121.02 17.52 Favored 'General case' 0 C--N 1.344 0.369 0 O-C-N 124.818 0.952 . . . . 0.0 112.811 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.47 -0.77 87.8 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-N 113.318 -1.764 . . . . 0.0 113.459 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -33.11 58.01 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.56 22.32 2.71 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.22 -178.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.596 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.52 116.38 58.88 Favored Pre-proline 0 N--CA 1.435 -1.217 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -178.36 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.832 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 38.7 Cg_exo -67.61 162.87 37.3 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 123.577 2.851 . . . . 0.0 111.381 177.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 60.0 m95 -97.64 10.72 39.21 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.87 -44.97 30.0 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.544 -1.207 . . . . 0.0 110.194 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.525 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -120.3 11.42 11.51 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.714 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.832 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.1 m95 -128.66 141.9 51.2 Favored 'General case' 0 C--N 1.361 1.08 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.35 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.5 mmt -144.52 -28.22 0.49 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.202 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.74 -24.62 26.84 Favored 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.391 0.432 . . . . 0.0 112.075 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.636 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.27 -128.27 9.52 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 115.743 -0.662 . . . . 0.0 114.082 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 90' ' ' LEU . 8.6 m-80 -84.92 136.68 33.52 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.243 0.617 . . . . 0.0 112.067 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -150.33 147.05 27.14 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.16 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.646 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -140.14 120.63 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.467 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.36 128.21 54.81 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 177.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.5 mt -138.97 150.81 23.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 112.741 -2.027 . . . . 0.0 110.512 -176.252 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.64 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.3 tt0 -99.67 116.57 32.07 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.348 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.65 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.0 m-70 -68.31 -176.09 0.7 Allowed 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.536 -1.211 . . . . 0.0 114.215 -178.702 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.78 64.95 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 114.055 -1.43 . . . . 0.0 114.398 -177.456 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.438 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.1 OUTLIER -101.52 -9.06 21.37 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.881 0.372 . . . . 0.0 111.067 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.6 -6.68 45.23 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.057 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.8 ptt? -67.77 168.71 10.92 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 123.469 0.708 . . . . 0.0 111.367 179.067 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 -113.43 145.31 41.36 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.075 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.497 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.94 127.28 19.81 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-O 120.973 0.416 . . . . 0.0 110.29 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.646 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.96 154.97 16.9 Favored Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.546 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.457 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.9 m-85 -134.36 99.29 4.33 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 105.361 -2.089 . . . . 0.0 105.361 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.69 166.77 11.05 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 73.3 m80 65.74 41.25 4.0 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-N 114.628 -1.169 . . . . 0.0 111.743 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.599 HD22 HG21 ' A' ' 47' ' ' VAL . 9.3 mt -101.3 166.46 10.75 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.079 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.401 ' HB2' HG23 ' A' ' 43' ' ' VAL . 12.4 t -101.04 -14.88 17.64 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -168.26 160.47 11.55 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.727 0.775 . . . . 0.0 111.901 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.837 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.3 148.65 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 113.613 -1.631 . . . . 0.0 110.757 178.83 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 t -112.42 -5.96 14.05 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 114.517 -1.219 . . . . 0.0 110.071 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.837 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -104.44 -175.23 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.983 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.512 -177.134 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.2 m -155.46 144.07 20.43 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.009 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.537 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 4.2 m -55.23 129.22 37.47 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.62 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.43 -5.18 0.74 Allowed 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.63 1.172 . . . . 0.0 112.026 179.314 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 55' ' ' VAL . 29.6 m -81.3 148.8 29.24 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.51 145.63 28.01 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.425 178.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.49 167.69 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.248 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.36 -179.216 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.9 tttm -140.36 147.39 39.72 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.821 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.23 137.93 55.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.226 -1.352 . . . . 0.0 111.483 -179.491 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.8 -4.43 52.48 Favored Glycine 0 CA--C 1.517 0.175 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.078 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.6 tt0 -74.36 139.0 43.81 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.183 0.516 . . . . 0.0 110.004 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 54.5 mt -71.35 101.53 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.118 0 CA-C-N 114.717 -1.128 . . . . 0.0 109.512 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.44 -4.74 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.149 -178.925 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.92 -160.82 34.6 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 112.302 -0.319 . . . . 0.0 112.302 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 30.3 m-85 -139.45 139.1 36.95 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 124.478 1.111 . . . . 0.0 108.327 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.402 HG23 HG22 ' A' ' 47' ' ' VAL . 0.8 OUTLIER -60.37 152.57 24.99 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.472 0.709 . . . . 0.0 112.117 -179.136 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.768 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -158.06 -163.33 12.62 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.961 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.642 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 48.16 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 114.632 -0.784 . . . . 0.0 109.074 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.636 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 33.6 p . . . . . 0 CA--C 1.54 0.564 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.9 0 CA-C-O 118.832 -0.982 . . . . 0.0 111.808 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.642 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.6 Cg_exo -71.55 144.67 45.4 Favored 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.593 2.196 . . . . 0.0 112.098 179.585 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.441 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 56.1 p-80 -160.77 -172.99 3.71 Favored 'General case' 0 C--N 1.349 0.565 0 CA-C-O 121.515 0.674 . . . . 0.0 111.636 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.741 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.8 tp -125.51 136.25 53.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.779 -178.395 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 31.8 t60 -116.36 122.96 46.4 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.43 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.565 ' O ' HG12 ' A' ' 37' ' ' VAL . 50.0 t80 -127.25 107.57 10.11 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.264 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' THR . 13.4 pt-20 -115.33 127.37 55.38 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.548 178.773 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.4 tpt -121.17 136.73 54.92 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.726 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.633 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -142.26 164.99 30.06 Favored Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 113.394 -1.73 . . . . 0.0 110.381 -178.039 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -64.09 -178.43 0.61 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.994 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.16 -27.26 62.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.004 176.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.34 102.54 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.784 0 CA-C-N 114.09 -1.414 . . . . 0.0 108.869 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.26 163.18 39.45 Favored 'Trans proline' 0 N--CA 1.445 -1.349 0 C-N-CA 122.671 2.248 . . . . 0.0 116.937 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.577 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.96 70.76 0.81 Allowed 'General case' 0 N--CA 1.425 -1.702 0 CA-C-N 112.229 -2.26 . . . . 0.0 107.392 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.5 m-90 -62.9 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 114.291 -1.322 . . . . 0.0 112.435 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.577 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.81 33.72 0.38 Allowed 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 124.209 1.003 . . . . 0.0 112.783 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 11.0 m-80 71.95 128.2 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.627 0 C-N-CA 125.571 1.548 . . . . 0.0 110.666 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.33 -48.49 0.6 Allowed Glycine 0 N--CA 1.438 -1.178 0 CA-C-N 115.104 -0.953 . . . . 0.0 113.068 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.78 -19.58 0.22 Allowed 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 37.9 m 65.67 18.01 11.07 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-O 122.778 1.275 . . . . 0.0 108.108 -178.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.633 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 78.26 -11.57 23.05 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 112.237 -2.256 . . . . 0.0 112.47 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.684 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -85.07 124.43 31.75 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 112.056 -179.24 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.456 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -127.19 -172.87 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.8 m-20 -72.47 131.8 84.35 Favored Pre-proline 0 CA--C 1.547 0.844 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -176.397 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.619 ' O ' HG12 ' A' ' 146' ' ' ILE . 4.5 Cg_exo -77.58 -1.63 11.8 Favored 'Trans proline' 0 C--N 1.379 2.148 0 C-N-CA 123.265 2.643 . . . . 0.0 113.492 177.708 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.1 p -51.48 -24.25 4.89 Favored 'General case' 0 C--N 1.349 0.58 0 N-CA-C 114.134 1.161 . . . . 0.0 114.134 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.94 -24.56 75.75 Favored Glycine 0 CA--C 1.521 0.431 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.927 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -103.56 -10.33 18.55 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 123.465 0.706 . . . . 0.0 111.343 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.619 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -99.81 -10.96 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.454 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.247 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.699 178.028 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.736 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.6 Cg_exo . . . . . 0 N--CA 1.479 0.626 0 N-CA-C 112.667 0.218 . . . . 0.0 112.667 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.76 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.77 -171.92 3.04 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.699 1.238 . . . . 0.0 110.335 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.457 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.26 -24.78 2.8 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 112.082 -2.326 . . . . 0.0 108.625 177.292 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.76 ' H ' HD12 ' A' ' 19' ' ' LEU . 9.3 t -168.21 -168.94 1.01 Allowed 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.162 -178.054 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.26 112.25 0.28 Allowed Glycine 0 C--N 1.32 -0.342 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.036 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.21 125.49 9.38 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 113.328 0.862 . . . . 0.0 113.328 -177.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.751 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.56 58.31 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.455 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.066 179.197 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.6 t -102.7 -28.13 12.3 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 112.89 -1.959 . . . . 0.0 110.829 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -115.14 -67.2 1.01 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.606 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.3 123.18 1.06 Allowed Glycine 0 C--O 1.235 0.196 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.371 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.487 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -75.11 157.44 34.7 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -55.7 31.92 0.0 OUTLIER 'General case' 0 C--O 1.241 0.618 0 N-CA-C 115.816 1.784 . . . . 0.0 115.816 -177.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.71 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 0.09 48.93 Favored Glycine 0 CA--C 1.505 -0.551 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -101.72 85.43 0.66 Allowed Pre-proline 0 CA--C 1.545 0.763 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.71 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.7 Cg_exo -77.03 138.88 18.72 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.655 2.236 . . . . 0.0 113.239 -178.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.77 4.11 70.14 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-N 115.873 -0.603 . . . . 0.0 113.12 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.475 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.4 t-80 -75.51 128.41 35.24 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 123.927 0.891 . . . . 0.0 110.743 -179.381 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.644 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -99.74 -14.14 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.239 -179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -126.04 -150.28 7.6 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.369 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 123' ' ' PHE . 7.2 p -128.71 151.86 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-N 115.025 -0.588 . . . . 0.0 109.775 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.662 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -125.39 130.64 52.31 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.263 0.554 . . . . 0.0 112.409 -178.444 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.736 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.7 m-85 -122.89 109.78 14.59 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.102 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.92 104.93 0.41 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.243 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.541 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.0 p -145.55 124.43 6.66 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.01 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -48.95 141.79 21.13 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.386 2.724 . . . . 0.0 115.528 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.751 HG23 ' HA2' ' A' ' 111' ' ' GLY . 3.1 p -61.62 141.11 18.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 111.935 -2.393 . . . . 0.0 113.473 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.02 2.49 55.99 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.393 -0.821 . . . . 0.0 114.253 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.7 m -88.98 126.22 59.88 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-O 119.066 -0.492 . . . . 0.0 109.808 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.14 126.67 23.14 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.209 1.939 . . . . 0.0 113.074 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.641 HG21 HD22 ' A' ' 90' ' ' LEU . 4.3 t -98.28 121.51 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.083 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.623 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.9 mtp180 -102.02 151.23 22.39 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 113.088 -1.869 . . . . 0.0 111.584 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -70.76 122.02 19.08 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.232 -178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.2 t -69.08 -14.16 18.17 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.603 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.55 144.17 1.86 Allowed 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 123.447 0.699 . . . . 0.0 110.603 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -62.59 156.86 22.05 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.835 -1.075 . . . . 0.0 112.386 179.368 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.632 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.32 -128.14 1.68 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.725 -0.67 . . . . 0.0 113.652 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.449 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 11.9 m -148.24 140.89 24.52 Favored 'General case' 0 N--CA 1.439 -0.975 0 C-N-CA 123.759 0.824 . . . . 0.0 109.668 -178.116 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 99' ' ' SER . 12.1 t -83.78 112.58 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 123.721 0.809 . . . . 0.0 109.034 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 54' ' ' THR . 6.6 mmmt -95.09 -14.72 23.99 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.844 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -156.09 141.8 17.89 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.01 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.24 92.22 2.16 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.406 -1.27 . . . . 0.0 109.074 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.02 89.98 1.46 Allowed Glycine 0 C--O 1.239 0.447 0 CA-C-N 113.955 -1.475 . . . . 0.0 112.862 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.503 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -70.41 122.97 20.63 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.925 0.89 . . . . 0.0 112.866 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.578 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.93 -0.59 88.8 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-N 113.253 -1.794 . . . . 0.0 113.626 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.54 -33.2 54.25 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -138.44 30.18 2.39 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.467 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.578 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.66 111.83 24.33 Favored Pre-proline 0 N--CA 1.437 -1.091 0 N-CA-C 113.907 1.077 . . . . 0.0 113.907 -178.265 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 35.4 Cg_exo -68.71 162.62 40.38 Favored 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.738 2.958 . . . . 0.0 111.563 177.133 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -96.74 9.76 40.75 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 175.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 61.2 mtm -76.91 -43.56 35.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.342 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.539 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.8 11.24 11.1 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.857 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.1 151.24 50.0 Favored 'General case' 0 C--N 1.361 1.089 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.738 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 36.2 mtt -145.68 -36.88 0.27 Allowed 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.621 179.142 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -86.43 -23.46 26.05 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.45 0.469 . . . . 0.0 111.881 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.606 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.25 -118.65 6.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.69 -0.686 . . . . 0.0 114.045 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.536 HD21 ' HA3' ' A' ' 61' ' ' GLY . 7.3 m-80 -82.57 135.64 35.03 Favored 'General case' 0 C--O 1.236 0.384 0 C-N-CA 123.225 0.61 . . . . 0.0 112.49 -178.532 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.01 146.56 26.3 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.983 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.616 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -139.2 121.02 16.48 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.205 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.2 130.73 56.99 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.333 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 54' ' ' THR . 9.1 mt -141.01 151.02 20.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 112.587 -2.097 . . . . 0.0 110.206 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.632 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.2 tt0 -99.83 117.14 33.51 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 114.123 -1.399 . . . . 0.0 108.547 178.034 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.603 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.9 m-70 -69.99 -177.93 1.46 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.535 -1.211 . . . . 0.0 114.07 -179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.57 -17.46 64.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 113.791 -1.55 . . . . 0.0 113.752 -178.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -97.58 -13.27 21.7 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 123.38 0.425 . . . . 0.0 110.749 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.51 -5.98 44.89 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.811 179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.588 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 16.5 ptp -70.65 165.53 22.68 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 122.866 0.466 . . . . 0.0 111.416 179.447 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.431 ' O ' ' HA ' ' A' ' 125' ' ' MET . 65.6 m-70 -109.09 140.02 43.2 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.719 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -135.82 127.1 28.3 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-O 121.033 0.444 . . . . 0.0 110.391 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.616 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -103.85 155.31 17.74 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 114.839 -1.073 . . . . 0.0 111.63 178.569 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.568 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 6.4 m-85 -132.11 99.24 4.65 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.79 167.54 10.41 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 43.5 m80 65.62 41.49 4.02 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.591 -178.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.641 HD22 HG21 ' A' ' 47' ' ' VAL . 11.6 mt -101.4 170.36 8.27 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.822 177.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.2 t -105.27 -15.67 14.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 122.952 0.157 . . . . 0.0 111.37 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -168.95 160.44 10.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.658 0.742 . . . . 0.0 111.85 -178.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.833 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.37 149.64 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.638 -1.619 . . . . 0.0 110.949 179.329 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.91 -5.38 13.21 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.247 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.833 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -107.22 -175.42 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.387 -176.921 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.6 m -154.31 144.54 22.04 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.908 -1.042 . . . . 0.0 109.101 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.63 128.9 36.87 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.741 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 87.47 -4.97 0.61 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.778 1.231 . . . . 0.0 111.837 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.466 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -81.67 148.13 29.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 110.44 -0.208 . . . . 0.0 110.44 178.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -83.9 145.85 28.37 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.385 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.82 168.38 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.449 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 73.6 tttt -142.18 148.55 38.4 Favored 'General case' 0 N--CA 1.427 -1.61 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.872 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.6 138.52 55.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.305 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.623 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.78 -4.6 51.7 Favored Glycine 0 CA--C 1.516 0.117 0 CA-C-N 114.431 -1.259 . . . . 0.0 114.166 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.7 tt0 -75.33 140.67 43.23 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.086 0.469 . . . . 0.0 109.933 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.36 100.86 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.586 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.7 -5.4 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 113.706 -1.588 . . . . 0.0 113.257 -178.982 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 -159.83 32.69 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 121.515 -0.374 . . . . 0.0 112.427 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.547 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 33.9 m-85 -140.37 138.48 34.85 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.572 1.149 . . . . 0.0 108.378 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.445 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -62.65 150.09 41.76 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.659 0.784 . . . . 0.0 112.46 -178.821 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.751 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.35 -164.95 14.33 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 119.884 -1.151 . . . . 0.0 114.153 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.3 52.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.606 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 38.8 p . . . . . 0 CA--C 1.54 0.565 0 CA-C-N 115.248 -0.887 . . . . 0.0 113.355 -177.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.976 0 CA-C-O 119.395 -0.669 . . . . 0.0 113.252 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.716 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 6.0 Cg_exo -79.42 146.77 19.69 Favored 'Trans proline' 0 C--N 1.373 1.854 0 C-N-CA 123.291 2.661 . . . . 0.0 112.529 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.541 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 38.1 p-80 -160.72 -166.69 1.67 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.528 0.68 . . . . 0.0 111.851 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.662 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 15.9 tp -129.47 137.92 51.12 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.064 -1.425 . . . . 0.0 110.313 -178.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.458 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 23.9 t60 -121.59 114.93 21.88 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.284 -1.326 . . . . 0.0 110.184 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 37' ' ' VAL . 22.7 t80 -119.01 107.79 13.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.182 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.559 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.0 pt-20 -112.82 127.52 56.19 Favored 'General case' 0 N--CA 1.432 -1.327 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.57 179.085 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.431 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 6.7 ttt -122.76 134.51 54.44 Favored 'General case' 0 N--CA 1.434 -1.255 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.152 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.625 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -141.69 164.73 32.73 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 113.271 -1.786 . . . . 0.0 110.113 -177.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -63.16 -178.57 0.45 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 122.889 2.393 . . . . 0.0 113.277 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -69.09 -28.92 66.93 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.975 176.171 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -157.84 103.45 1.77 Allowed Pre-proline 0 CA--C 1.503 -0.841 0 CA-C-N 114.008 -1.451 . . . . 0.0 108.798 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -72.03 163.22 39.46 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.612 2.208 . . . . 0.0 116.971 -176.569 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.573 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.5 69.62 0.77 Allowed 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 112.332 -2.213 . . . . 0.0 107.581 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -62.19 12.3 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 114.319 -1.31 . . . . 0.0 112.412 -178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.573 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.8 mp0 -81.76 33.15 0.37 Allowed 'General case' 0 N--CA 1.444 -0.77 0 C-N-CA 124.306 1.043 . . . . 0.0 112.811 -178.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 73.11 128.79 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 113.729 -1.578 . . . . 0.0 110.745 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.26 -48.41 0.6 Allowed Glycine 0 N--CA 1.439 -1.135 0 CA-C-N 114.971 -1.013 . . . . 0.0 112.964 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.588 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -152.21 -18.96 0.18 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 179.161 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.8 m 66.12 17.74 10.83 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 122.59 1.186 . . . . 0.0 108.224 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.625 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.3 -11.32 9.0 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 112.547 -2.115 . . . . 0.0 112.673 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.644 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.64 121.7 25.61 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 111.737 0.273 . . . . 0.0 111.737 -179.012 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.93 -172.93 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.441 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -79.34 128.64 74.86 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.656 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.7 Cg_exo -76.76 -3.21 13.52 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 122.934 2.423 . . . . 0.0 113.445 178.281 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.86 -23.49 2.84 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.617 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.69 -30.25 70.79 Favored Glycine 0 N--CA 1.461 0.342 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.472 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -104.24 -11.35 17.27 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 122.902 0.481 . . . . 0.0 111.685 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.656 HG12 ' O ' ' A' ' 142' ' ' PRO . 18.8 mm -96.34 -8.79 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.815 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.279 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.173 177.592 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.693 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.0 Cg_exo . . . . . 0 N--CA 1.482 0.829 0 CA-C-O 120.825 0.261 . . . . 0.0 112.607 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.726 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.47 -171.95 2.89 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-O 122.402 1.096 . . . . 0.0 109.961 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.99 -25.41 3.04 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 112.452 -2.158 . . . . 0.0 108.532 177.091 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.726 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.5 t -169.39 -168.84 0.85 Allowed 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.593 -178.318 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.92 110.77 0.29 Allowed Glycine 0 C--N 1.317 -0.487 0 CA-C-N 114.513 -1.221 . . . . 0.0 111.171 176.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.41 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.16 124.84 8.4 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 112.829 0.677 . . . . 0.0 112.829 -178.313 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.99 58.58 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.995 -1.457 . . . . 0.0 109.097 178.551 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.3 t -104.54 -28.05 11.52 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 112.729 -2.032 . . . . 0.0 111.123 179.267 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -116.19 -66.7 1.06 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.648 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.29 122.98 1.04 Allowed Glycine 0 N--CA 1.459 0.201 0 CA-C-N 115.011 -0.995 . . . . 0.0 112.011 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.532 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -73.49 157.26 37.12 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -178.504 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -57.86 31.89 0.0 OUTLIER 'General case' 0 C--O 1.239 0.538 0 N-CA-C 115.821 1.786 . . . . 0.0 115.821 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -1.66 48.83 Favored Glycine 0 CA--C 1.504 -0.634 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.94 85.31 0.67 Allowed Pre-proline 0 CA--C 1.548 0.866 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.6 Cg_exo -77.97 139.2 17.14 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 122.823 2.349 . . . . 0.0 113.352 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.14 4.17 69.1 Favored Glycine 0 C--N 1.339 0.727 0 O-C-N 123.685 0.615 . . . . 0.0 112.997 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.44 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.0 t-80 -78.24 135.43 37.57 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.047 0.939 . . . . 0.0 110.497 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.595 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.32 -12.53 9.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.242 -179.35 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -125.87 -149.77 7.51 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 123' ' ' PHE . 14.4 p -129.82 152.88 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 O-C-N 123.892 0.407 . . . . 0.0 110.133 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.714 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 93.1 m-20 -129.32 131.97 47.03 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.24 0.543 . . . . 0.0 112.242 -178.483 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.693 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.5 m-85 -122.86 109.48 14.23 Favored 'General case' 0 C--O 1.238 0.5 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.165 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.86 104.26 0.18 Allowed 'General case' 0 CA--C 1.541 0.633 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.339 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.552 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.4 p -144.84 123.91 6.9 Favored Pre-proline 0 CA--C 1.549 0.934 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.855 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -49.02 142.7 19.54 Favored 'Trans proline' 0 C--N 1.371 1.737 0 C-N-CA 123.307 2.671 . . . . 0.0 115.423 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.676 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.09 141.01 17.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 111.582 -2.554 . . . . 0.0 113.619 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.53 2.73 55.45 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.552 -0.749 . . . . 0.0 114.341 177.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.1 m -88.01 123.46 68.78 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-O 119.146 -0.454 . . . . 0.0 109.932 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.24 127.11 24.9 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.328 2.019 . . . . 0.0 113.449 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.55 HG21 HD22 ' A' ' 90' ' ' LEU . 4.8 t -99.68 121.82 50.79 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.138 179.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.511 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 2.3 mpt_? -103.19 152.49 21.4 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 113.331 -1.759 . . . . 0.0 111.481 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -71.69 121.46 18.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.441 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.03 -15.64 19.96 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 112.775 0.658 . . . . 0.0 112.775 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.652 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.46 144.46 1.94 Allowed 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 123.462 0.705 . . . . 0.0 110.346 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -61.78 157.07 18.85 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 115.077 -0.965 . . . . 0.0 112.331 179.494 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.653 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.01 -127.15 1.54 Allowed Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.744 -0.662 . . . . 0.0 113.849 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.9 m -148.09 141.3 25.08 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 123.678 0.791 . . . . 0.0 109.683 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 99' ' ' SER . 11.3 t -83.49 111.66 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 123.719 0.808 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.7 mmmt -94.35 -15.72 24.13 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.726 -1.125 . . . . 0.0 110.643 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -153.9 140.01 18.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.041 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.53 92.33 2.15 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.906 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -95.05 89.87 1.23 Allowed Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.953 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.533 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.8 m120 -72.46 125.54 27.66 Favored 'General case' 0 C--N 1.346 0.418 0 C-N-CA 123.795 0.838 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.664 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -79.93 -0.66 85.94 Favored Glycine 0 CA--C 1.52 0.392 0 CA-C-N 113.354 -1.748 . . . . 0.0 113.389 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.11 -32.05 39.1 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 24.86 2.68 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.144 -178.392 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.664 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -79.45 113.88 40.59 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.418 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.808 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.4 Cg_exo -67.69 163.23 36.01 Favored 'Trans proline' 0 C--N 1.37 1.688 0 C-N-CA 123.729 2.953 . . . . 0.0 111.556 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 62.1 m95 -98.2 10.54 40.33 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 14.7 mmt -75.58 -44.55 42.6 Favored 'General case' 0 C--N 1.349 0.552 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.057 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.547 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -120.92 11.51 11.07 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.783 177.439 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.808 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.05 145.92 51.14 Favored 'General case' 0 C--N 1.359 1.005 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.701 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.9 tpt -145.56 -31.02 0.4 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.488 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.78 -23.44 24.08 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.551 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 101.71 -128.68 9.64 Favored Glycine 0 CA--C 1.522 0.48 0 O-C-N 123.543 0.527 . . . . 0.0 114.025 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.596 HD21 ' HA3' ' A' ' 61' ' ' GLY . 11.8 m-80 -78.8 138.84 38.39 Favored 'General case' 0 C--N 1.347 0.458 0 C-N-CA 123.381 0.672 . . . . 0.0 112.586 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.33 145.23 23.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.008 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.1 t -138.55 120.58 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.158 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.03 131.22 56.99 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.423 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 9.3 mt -141.02 150.91 20.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 112.695 -2.048 . . . . 0.0 110.2 -176.62 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.653 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.5 tt0 -97.72 116.49 30.03 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 113.984 -1.462 . . . . 0.0 108.294 178.06 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.652 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -69.17 -175.85 0.82 Allowed 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.561 -1.199 . . . . 0.0 114.159 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -64.97 -17.78 64.69 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 113.867 -1.515 . . . . 0.0 114.485 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.458 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.2 OUTLIER -101.79 -9.86 20.43 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-O 120.826 0.346 . . . . 0.0 111.128 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.78 -6.09 43.92 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.061 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.521 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.4 ptt? -68.92 168.4 13.7 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 123.712 0.805 . . . . 0.0 111.456 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.418 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 55.6 m-70 -112.55 142.7 44.81 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.024 -179.102 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.26 127.06 25.54 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-O 121.041 0.448 . . . . 0.0 110.022 179.706 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.49 154.59 17.1 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.629 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.506 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.1 m-85 -135.1 99.17 4.19 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.401 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -114.11 168.8 9.5 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.294 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 38.6 m80 65.28 41.86 4.2 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 124.159 0.984 . . . . 0.0 111.44 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.55 HD22 HG21 ' A' ' 47' ' ' VAL . 11.0 mt -102.94 169.41 8.6 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.037 178.287 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.4 t -103.88 -16.47 15.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -167.32 162.37 14.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.801 0.81 . . . . 0.0 112.018 -178.132 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.825 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.9 OUTLIER -127.83 147.82 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.643 179.298 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -110.47 -6.8 14.84 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 114.402 -1.272 . . . . 0.0 109.899 178.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.825 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.73 -175.12 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.073 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.733 -176.89 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 6.9 t -154.18 148.44 25.95 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.79 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 m -58.5 128.98 39.88 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.622 -179.24 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 t70 86.96 -5.71 0.67 Allowed 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 124.634 1.174 . . . . 0.0 111.722 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.479 ' O ' HG23 ' A' ' 55' ' ' VAL . 31.7 m -79.82 149.63 30.96 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 122.272 0.229 . . . . 0.0 110.711 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -84.94 145.0 27.98 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.382 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.01 168.14 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.437 -179.22 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 42.9 tttm -140.5 149.58 42.66 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.844 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -58.17 138.59 56.07 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.383 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.511 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.64 -4.55 50.82 Favored Glycine 0 CA--C 1.517 0.185 0 CA-C-N 114.387 -1.278 . . . . 0.0 114.076 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.4 tt0 -75.2 140.57 43.38 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-O 121.086 0.47 . . . . 0.0 110.026 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 52.4 mt -72.11 101.46 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.64 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.59 -5.01 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-N 113.512 -1.676 . . . . 0.0 113.17 -178.86 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.65 -161.9 35.64 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.363 0.424 . . . . 0.0 112.571 178.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.2 m-85 -139.88 138.06 35.37 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 124.561 1.144 . . . . 0.0 108.339 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.3 150.53 39.05 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 123.913 0.758 . . . . 0.0 112.572 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.676 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -160.23 -161.54 11.51 Favored Glycine 0 C--N 1.348 1.232 0 C-N-CA 119.844 -1.17 . . . . 0.0 114.119 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.1 50.78 0.91 Allowed 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.632 -0.784 . . . . 0.0 108.99 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.551 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 32.6 p . . . . . 0 CA--C 1.54 0.582 0 CA-C-N 115.137 -0.938 . . . . 0.0 113.094 -177.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.12 0 CA-C-O 119.352 -0.693 . . . . 0.0 113.351 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.637 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -77.71 145.67 23.18 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 123.111 2.54 . . . . 0.0 112.414 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.552 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 47.6 p-80 -159.71 -164.91 1.41 Allowed 'General case' 0 C--N 1.351 0.667 0 CA-C-O 121.68 0.753 . . . . 0.0 112.259 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.714 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 16.9 tp -129.7 133.41 47.04 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.433 -178.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.452 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 18.4 t60 -118.18 113.39 21.46 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.288 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.563 ' O ' HG12 ' A' ' 37' ' ' VAL . 37.9 t80 -119.04 108.94 15.34 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.303 -179.711 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 85' ' ' THR . 20.3 tt0 -117.3 127.15 53.79 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.197 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.426 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 1.9 tpt -118.13 139.81 50.7 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.646 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -143.98 165.46 24.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 CA-C-N 113.426 -1.715 . . . . 0.0 110.619 -177.579 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 14.1 Cg_endo -63.62 -178.68 0.55 Allowed 'Trans proline' 0 C--N 1.37 1.67 0 C-N-CA 122.842 2.361 . . . . 0.0 112.948 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.16 -27.33 63.47 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.085 176.341 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -157.44 101.95 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.77 0 CA-C-N 114.03 -1.441 . . . . 0.0 108.871 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -71.71 163.39 39.07 Favored 'Trans proline' 0 N--CA 1.446 -1.314 0 C-N-CA 122.711 2.274 . . . . 0.0 116.874 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.552 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -117.23 70.33 0.78 Allowed 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 112.532 -2.122 . . . . 0.0 107.649 177.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.5 m-90 -63.25 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 114.298 -1.319 . . . . 0.0 112.54 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.552 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.63 33.35 0.36 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.122 0.969 . . . . 0.0 112.996 -178.15 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 73.26 127.46 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.583 0 C-N-CA 125.663 1.585 . . . . 0.0 110.598 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.31 -50.04 0.56 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.343 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.45 -18.92 0.24 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 179.655 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 39.5 m 66.01 17.74 10.87 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 122.473 1.13 . . . . 0.0 108.157 -178.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.564 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.07 -9.63 18.11 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 112.6 -2.091 . . . . 0.0 112.734 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.595 ' HG2' HG12 ' A' ' 35' ' ' VAL . 3.2 ppt_? -82.9 127.35 33.42 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 119.854 -0.738 . . . . 0.0 112.362 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -128.07 -173.14 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.629 179.179 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.4 m-20 -73.28 129.8 85.4 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.581 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.3 0.22 9.96 Favored 'Trans proline' 0 C--N 1.38 2.226 0 C-N-CA 122.954 2.436 . . . . 0.0 113.341 177.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.31 -23.78 6.39 Favored 'General case' 0 C--N 1.349 0.548 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.22 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.86 -25.59 74.56 Favored Glycine 0 CA--C 1.52 0.362 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.92 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -101.99 -11.67 18.75 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 123.248 0.619 . . . . 0.0 111.16 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.581 HG12 ' O ' ' A' ' 142' ' ' PRO . 20.8 mm -100.16 -9.76 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.286 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.739 178.095 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.701 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 20.1 Cg_exo . . . . . 0 N--CA 1.482 0.81 0 CA-C-O 120.742 0.226 . . . . 0.0 112.344 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -138.72 -171.97 3.2 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.482 1.134 . . . . 0.0 110.104 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.69 -25.25 3.15 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 112.332 -2.213 . . . . 0.0 108.699 177.237 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.737 ' H ' HD12 ' A' ' 19' ' ' LEU . 8.5 t -168.99 -168.64 0.87 Allowed 'General case' 0 CA--C 1.546 0.808 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.525 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.401 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.4 111.18 0.29 Allowed Glycine 0 C--N 1.321 -0.281 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.483 177.116 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.57 124.41 8.56 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.472 0.653 . . . . 0.0 112.632 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.11 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.502 0 CA-C-N 113.949 -1.478 . . . . 0.0 109.255 178.79 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.9 t -106.46 -27.68 10.77 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 113.134 -1.848 . . . . 0.0 110.873 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.2 -67.26 1.01 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.721 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.51 123.94 1.14 Allowed Glycine 0 C--O 1.234 0.151 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.14 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.514 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.94 157.5 31.26 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.641 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -58.02 31.67 0.0 OUTLIER 'General case' 0 C--O 1.24 0.558 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -177.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.699 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 -0.88 48.61 Favored Glycine 0 CA--C 1.506 -0.484 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -101.6 85.55 0.67 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.699 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.07 137.89 15.86 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.807 2.338 . . . . 0.0 113.225 -178.589 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.41 4.07 71.29 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.149 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-80 -76.12 135.12 39.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.975 0.91 . . . . 0.0 110.37 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.678 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.68 -16.35 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.342 -179.021 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.54 -149.71 8.14 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 123' ' ' PHE . 10.6 p -131.33 151.03 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 124.031 0.489 . . . . 0.0 110.042 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.706 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 89.1 m-20 -125.96 134.19 51.59 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.323 0.582 . . . . 0.0 112.046 -178.634 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.701 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -124.71 110.07 13.91 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 114.244 -1.344 . . . . 0.0 110.251 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.49 104.64 0.23 Allowed 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.544 178.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.556 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 12.5 p -145.98 124.78 6.53 Favored Pre-proline 0 CA--C 1.551 0.996 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.887 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.01 142.02 20.94 Favored 'Trans proline' 0 C--N 1.37 1.694 0 C-N-CA 123.346 2.697 . . . . 0.0 115.261 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.726 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -61.39 140.15 19.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 111.848 -2.433 . . . . 0.0 113.615 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.64 54.61 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.418 -0.81 . . . . 0.0 114.36 177.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.9 m -87.32 125.37 65.99 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.257 -0.401 . . . . 0.0 109.952 179.132 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.34 127.69 26.57 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.291 1.994 . . . . 0.0 113.468 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.531 HG21 HD22 ' A' ' 90' ' ' LEU . 9.8 t -99.96 123.36 52.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.154 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 13.6 mtp180 -101.91 152.15 21.26 Favored 'General case' 0 N--CA 1.433 -1.302 0 CA-C-N 112.963 -1.926 . . . . 0.0 111.659 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.48 120.96 18.82 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.846 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.1 t -66.68 -15.78 19.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.881 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.617 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.82 143.59 1.67 Allowed 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.546 0.738 . . . . 0.0 110.355 179.111 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -60.36 155.42 18.04 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.234 -0.894 . . . . 0.0 112.206 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 170.32 -128.63 1.67 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.891 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.3 m -148.16 136.35 21.24 Favored 'General case' 0 N--CA 1.44 -0.968 0 C-N-CA 123.446 0.698 . . . . 0.0 110.33 -178.086 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 11.1 t -83.89 112.44 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.43 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.2 OUTLIER -98.09 -16.63 19.48 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.841 179.846 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -148.54 138.52 22.33 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.737 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.9 92.17 2.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.494 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.422 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.17 89.85 1.37 Allowed Glycine 0 C--O 1.24 0.478 0 CA-C-N 114.128 -1.396 . . . . 0.0 112.802 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.502 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -71.56 125.71 27.77 Favored 'General case' 0 C--N 1.345 0.395 0 C-N-CA 123.964 0.905 . . . . 0.0 112.517 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.655 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.26 -0.74 87.12 Favored Glycine 0 CA--C 1.52 0.349 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.375 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.69 -31.85 52.69 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.45 25.51 2.65 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.069 -178.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.655 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -80.6 112.93 35.62 Favored Pre-proline 0 N--CA 1.435 -1.2 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.16 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.833 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.0 Cg_exo -67.81 163.45 35.36 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.987 3.125 . . . . 0.0 111.821 177.395 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.0 m95 -96.79 8.82 43.44 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -75.2 -44.48 46.21 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.398 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.541 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.84 10.9 11.01 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.714 177.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.833 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -128.83 145.92 51.07 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.537 -178.92 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 32.8 mtt -146.19 -29.18 0.41 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.421 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.44 -24.79 24.05 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.677 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.626 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.6 -123.98 8.09 Favored Glycine 0 CA--C 1.519 0.315 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.753 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.526 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.2 m-80 -81.17 138.21 35.87 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 123.237 0.615 . . . . 0.0 111.95 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.55 148.16 27.67 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.343 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.61 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.4 t -140.23 122.13 15.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.065 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.34 127.6 53.85 Favored 'General case' 0 CA--C 1.494 -1.188 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.7 mt -139.19 150.96 22.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 112.548 -2.115 . . . . 0.0 110.404 -176.14 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.3 117.04 32.88 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.944 -1.48 . . . . 0.0 108.603 178.011 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.617 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.0 m-70 -67.27 -176.37 0.56 Allowed 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.48 -17.67 64.93 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 114.107 -1.406 . . . . 0.0 114.313 -177.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.72 -10.19 21.07 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.905 0.383 . . . . 0.0 110.956 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.76 -4.78 42.75 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.192 179.03 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.7 ptt? -69.04 171.1 8.68 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 123.512 0.725 . . . . 0.0 111.683 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.3 m170 -108.96 147.04 32.86 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.011 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -141.5 126.63 18.45 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.947 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.61 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -108.96 154.57 16.43 Favored Glycine 0 N--CA 1.439 -1.146 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.401 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.1 m-85 -136.77 99.35 4.02 Favored 'General case' 0 N--CA 1.437 -1.075 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.51 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.32 167.93 10.16 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 38.7 m80 65.75 40.69 4.22 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.779 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.531 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -100.93 169.98 8.6 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.76 177.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.5 t -106.38 -15.51 14.8 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 111.457 0.169 . . . . 0.0 111.457 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 6.8 tttt -167.95 156.87 9.4 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.618 0.723 . . . . 0.0 111.99 -178.037 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -120.84 148.83 23.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 113.844 -1.526 . . . . 0.0 110.72 178.917 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -112.01 -5.98 14.24 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.209 178.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.67 -175.1 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.088 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.683 -177.067 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.4 m -153.33 143.94 22.61 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 114.867 -1.061 . . . . 0.0 109.002 -178.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -56.47 126.61 27.26 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.184 -0.917 . . . . 0.0 111.785 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 t70 89.15 -4.77 0.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 124.807 1.243 . . . . 0.0 111.587 178.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.7 m -81.7 146.05 30.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 122.176 0.191 . . . . 0.0 110.588 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -82.64 145.83 29.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.215 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.93 167.9 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.48 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -140.09 147.38 40.19 Favored 'General case' 0 N--CA 1.428 -1.574 0 CA-C-N 114.417 -1.265 . . . . 0.0 109.836 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.1 138.8 54.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.128 -1.397 . . . . 0.0 111.693 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.69 -6.78 37.29 Favored Glycine 0 CA--C 1.517 0.156 0 CA-C-N 114.361 -1.291 . . . . 0.0 114.129 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.494 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 41.3 tt0 -73.11 140.23 46.98 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-O 121.104 0.478 . . . . 0.0 110.013 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.05 101.19 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.401 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.8 -5.44 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.88 0 CA-C-N 113.739 -1.573 . . . . 0.0 113.101 -178.867 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.3 -162.14 34.76 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-O 121.272 0.374 . . . . 0.0 112.683 178.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 24.6 m-85 -141.37 137.12 32.1 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 124.816 1.246 . . . . 0.0 108.272 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -61.35 151.46 32.12 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.615 0.766 . . . . 0.0 112.654 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.726 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.38 -162.17 11.41 Favored Glycine 0 C--N 1.347 1.185 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.798 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.619 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 47.72 0.89 Allowed 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -0.7 . . . . 0.0 109.261 178.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.626 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 34.4 p . . . . . 0 CA--C 1.541 0.629 0 CA-C-N 115.213 -0.903 . . . . 0.0 113.292 -177.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.873 0 CA-C-O 118.599 -1.112 . . . . 0.0 111.54 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.619 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.0 Cg_exo -69.8 141.95 46.43 Favored 'Trans proline' 0 C--N 1.374 1.912 0 CA-C-N 120.251 2.025 . . . . 0.0 111.725 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.556 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 53.2 p-80 -157.77 -171.56 3.59 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.495 0.664 . . . . 0.0 111.774 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.706 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 9.1 tp -125.23 139.85 53.36 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.099 -1.409 . . . . 0.0 110.565 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.51 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 29.1 t60 -118.32 128.54 54.75 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 113.706 -1.588 . . . . 0.0 107.845 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.528 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.5 t80 -133.0 111.26 10.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.48 ' HB2' ' NE2' ' A' ' 122' ' ' HIS . 18.0 tt0 -120.31 127.18 52.11 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.238 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.8 tpt -120.26 138.01 53.91 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.666 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.591 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.1 mp -143.6 164.68 29.13 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 113.439 -1.709 . . . . 0.0 110.298 -178.16 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -62.83 -178.81 0.43 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.943 2.429 . . . . 0.0 112.669 177.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -68.57 -27.82 66.41 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.206 176.195 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -157.35 107.93 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.781 0 CA-C-N 113.903 -1.498 . . . . 0.0 108.232 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -71.15 163.12 40.26 Favored 'Trans proline' 0 N--CA 1.445 -1.326 0 C-N-CA 122.347 2.031 . . . . 0.0 116.926 -176.725 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.568 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.89 70.82 0.8 Allowed 'General case' 0 N--CA 1.423 -1.805 0 CA-C-N 112.349 -2.205 . . . . 0.0 107.395 177.799 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -63.29 13.99 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.168 -1.378 . . . . 0.0 112.376 -178.439 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.568 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.23 32.3 0.33 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.269 1.027 . . . . 0.0 112.902 -178.361 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 72.21 127.96 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 125.737 1.615 . . . . 0.0 110.997 178.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.11 -48.08 0.61 Allowed Glycine 0 N--CA 1.437 -1.278 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.341 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.68 -19.52 0.16 Allowed 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.43 18.22 10.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 122.624 1.202 . . . . 0.0 108.19 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 79.77 -11.66 32.75 Favored Glycine 0 N--CA 1.434 -1.449 0 CA-C-N 112.252 -2.249 . . . . 0.0 112.648 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.678 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.8 OUTLIER -83.98 125.02 31.65 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.301 -179.434 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.439 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -125.24 -172.96 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.585 -0.734 . . . . 0.0 112.441 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 140' ' ' ILE . 2.9 t70 -75.82 134.77 71.63 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -176.391 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.596 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.9 Cg_endo -77.16 0.62 9.54 Favored 'Trans proline' 0 C--N 1.381 2.277 0 C-N-CA 123.082 2.521 . . . . 0.0 113.546 177.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -51.34 -24.08 4.32 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.69 -28.95 66.24 Favored Glycine 0 CA--C 1.521 0.45 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.912 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -99.71 -11.86 20.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 123.347 0.659 . . . . 0.0 111.194 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.596 HG12 ' O ' ' A' ' 142' ' ' PRO . 31.2 mm -98.8 -10.47 8.78 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.372 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.357 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.656 178.021 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.685 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 21.3 Cg_exo . . . . . 0 N--CA 1.482 0.842 0 N-CA-C 112.951 0.327 . . . . 0.0 112.951 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.753 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.56 -172.0 3.05 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 122.671 1.224 . . . . 0.0 110.375 -179.894 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -128.14 -25.22 3.03 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 112.144 -2.298 . . . . 0.0 108.742 177.213 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.753 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.3 t -168.62 -168.64 0.92 Allowed 'General case' 0 CA--C 1.548 0.87 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.781 -178.302 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 171.99 111.74 0.26 Allowed Glycine 0 C--N 1.318 -0.431 0 CA-C-N 114.661 -1.154 . . . . 0.0 111.441 178.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.16 124.97 9.12 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.729 0.776 . . . . 0.0 112.973 -178.496 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.763 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.75 58.34 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-N 113.393 -1.731 . . . . 0.0 109.122 179.38 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.9 t -105.15 -28.2 11.13 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 112.969 -1.923 . . . . 0.0 111.007 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.52 -67.15 1.02 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.774 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.73 122.64 1.03 Allowed Glycine 0 C--N 1.322 -0.196 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.144 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.51 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.17 157.6 32.57 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -178.795 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -57.14 32.12 0.0 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -177.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.706 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -0.02 49.06 Favored Glycine 0 CA--C 1.504 -0.624 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -102.16 85.42 0.72 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.706 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.5 Cg_exo -76.95 141.99 21.73 Favored 'Trans proline' 0 C--N 1.373 1.848 0 C-N-CA 122.826 2.351 . . . . 0.0 113.425 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.51 4.02 83.57 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.803 -0.635 . . . . 0.0 113.06 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.416 ' O ' HG21 ' A' ' 24' ' ' ILE . 3.3 t-80 -74.29 127.33 32.72 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.098 0.959 . . . . 0.0 110.697 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.753 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -102.72 5.45 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.656 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.86 -150.03 5.14 Favored Glycine 0 C--N 1.337 0.603 0 C-N-CA 121.526 -0.368 . . . . 0.0 112.257 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 123' ' ' PHE . 9.7 p -130.52 154.69 40.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 C-N-CA 122.97 0.508 . . . . 0.0 110.244 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.702 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -129.16 130.07 45.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.258 0.552 . . . . 0.0 111.914 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.685 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 3.4 m-85 -120.54 109.99 15.93 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.273 -178.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.3 104.15 0.15 Allowed 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.275 178.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.531 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.6 p -146.79 124.07 5.89 Favored Pre-proline 0 CA--C 1.55 0.974 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.76 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -49.0 142.97 18.81 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 123.4 2.733 . . . . 0.0 115.528 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.748 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.47 140.77 18.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 111.766 -2.47 . . . . 0.0 113.454 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.45 2.53 55.55 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 115.441 -0.8 . . . . 0.0 114.036 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -87.53 124.0 68.55 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-O 119.153 -0.451 . . . . 0.0 109.88 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.7 126.7 23.32 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.342 2.028 . . . . 0.0 113.272 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.602 HG21 HD22 ' A' ' 90' ' ' LEU . 5.8 t -99.55 121.12 49.83 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 CA-C-N 115.107 -0.951 . . . . 0.0 108.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.506 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 3.9 mpt_? -102.21 152.41 21.06 Favored 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 113.301 -1.772 . . . . 0.0 111.434 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.71 122.63 20.97 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.689 -1.141 . . . . 0.0 111.435 -178.408 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 24.6 t -69.42 -14.53 18.52 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.553 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.631 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.24 143.86 1.95 Allowed 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 123.491 0.716 . . . . 0.0 110.641 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -62.68 156.04 24.67 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 114.943 -1.026 . . . . 0.0 112.477 179.464 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.63 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.32 -127.61 1.57 Allowed Glycine 0 C--N 1.334 0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.551 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.7 m -148.08 141.45 25.26 Favored 'General case' 0 N--CA 1.436 -1.148 0 C-N-CA 123.598 0.759 . . . . 0.0 109.532 -178.272 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 10.6 t -83.63 112.81 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 O-C-N 123.907 0.755 . . . . 0.0 108.995 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 10.0 mmmt -94.93 -14.72 24.2 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.666 -1.152 . . . . 0.0 110.819 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -156.69 141.2 16.75 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.896 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.04 92.44 2.05 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.805 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.426 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.96 92.03 1.46 Allowed Glycine 0 C--O 1.241 0.533 0 CA-C-N 114.35 -1.295 . . . . 0.0 112.658 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -72.65 123.7 23.78 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.134 0.974 . . . . 0.0 112.744 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.623 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.62 -0.76 88.21 Favored Glycine 0 CA--C 1.519 0.342 0 CA-C-N 113.369 -1.741 . . . . 0.0 113.59 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -32.31 57.54 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.54 24.79 2.66 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.027 -178.268 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.623 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -81.08 114.05 45.81 Favored Pre-proline 0 N--CA 1.435 -1.211 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -178.182 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.837 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.4 Cg_exo -67.81 162.12 40.95 Favored 'Trans proline' 0 C--N 1.37 1.685 0 C-N-CA 123.727 2.952 . . . . 0.0 111.804 177.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 63.3 m95 -96.1 13.01 28.64 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 176.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 81.9 mtp -80.07 -42.51 23.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.785 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.537 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.4 pp -125.76 15.44 8.08 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.795 177.544 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.837 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.4 OUTLIER -137.29 108.59 6.85 Favored 'General case' 0 C--N 1.369 1.416 0 C-N-CA 120.022 -0.671 . . . . 0.0 112.612 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 16.8 ttm -113.05 -20.3 11.56 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.416 178.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -91.54 -26.5 18.73 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.581 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 102.78 -128.57 9.59 Favored Glycine 0 CA--C 1.519 0.335 0 O-C-N 123.703 0.627 . . . . 0.0 113.704 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.614 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.5 m-80 -83.25 138.55 33.54 Favored 'General case' 0 C--N 1.346 0.43 0 C-N-CA 123.113 0.565 . . . . 0.0 112.138 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -152.27 145.96 25.03 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.3 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.63 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.15 120.34 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.164 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.7 129.6 56.54 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.107 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' THR . 7.7 mt -139.19 150.81 22.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.328 -176.549 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.63 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -100.24 117.27 34.11 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.904 -1.498 . . . . 0.0 108.504 178.037 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.631 ' CE1' ' HB3' ' A' ' 51' ' ' ALA . 2.9 m-70 -68.74 -175.91 0.75 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.489 -1.232 . . . . 0.0 114.092 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.92 65.03 Favored 'General case' 0 N--CA 1.452 -0.369 0 CA-C-N 114.037 -1.438 . . . . 0.0 114.457 -177.493 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.65 -9.02 21.29 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 120.876 0.369 . . . . 0.0 110.99 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.71 -6.74 44.85 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.122 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.2 ptt? -67.09 170.48 6.85 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 123.461 0.704 . . . . 0.0 111.465 179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.437 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 70.5 m-70 -114.68 145.42 42.06 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 120.609 -0.436 . . . . 0.0 111.218 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.68 127.34 20.27 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.051 179.68 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.63 155.4 16.52 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.698 178.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.8 m-85 -134.54 99.46 4.36 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.478 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -112.38 168.02 9.97 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 112.689 0.625 . . . . 0.0 112.689 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 41.1 m80 65.68 41.0 4.16 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.449 1.099 . . . . 0.0 111.736 -178.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.602 HD22 HG21 ' A' ' 47' ' ' VAL . 10.9 mt -102.14 167.93 9.7 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.039 178.061 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.7 t -104.57 -14.47 15.63 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.57 160.56 13.05 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.697 0.761 . . . . 0.0 111.861 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.836 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.16 149.17 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 113.563 -1.653 . . . . 0.0 110.83 179.045 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -112.56 -6.03 13.97 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.173 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.836 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.12 -175.28 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.006 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.642 -176.932 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.9 t -153.17 150.42 29.03 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.835 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.1 m -60.2 128.41 36.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.377 -179.102 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 85.49 -4.06 0.86 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.627 1.171 . . . . 0.0 111.674 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -79.83 148.88 31.2 Favored 'General case' 0 C--N 1.347 0.493 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.45 145.34 29.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.66 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.81 166.38 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.264 -179.271 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.7 tttp -141.5 148.48 39.5 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.916 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.65 138.23 55.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.506 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.88 -5.45 47.93 Favored Glycine 0 CA--C 1.518 0.242 0 CA-C-N 114.252 -1.34 . . . . 0.0 114.238 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 42.0 tt0 -74.5 140.35 44.48 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.024 0.44 . . . . 0.0 110.184 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 49.0 mt -71.54 101.65 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.668 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.58 -4.87 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.035 -179.02 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.11 -160.52 34.11 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-O 121.137 0.298 . . . . 0.0 112.47 178.578 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 28.5 m-85 -140.93 138.53 33.91 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.535 1.134 . . . . 0.0 108.377 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.11 151.9 29.83 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.625 0.77 . . . . 0.0 112.483 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.748 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.71 -164.1 13.46 Favored Glycine 0 C--N 1.346 1.124 0 C-N-CA 120.036 -1.078 . . . . 0.0 114.079 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.624 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 49.67 0.89 Allowed 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.734 -0.733 . . . . 0.0 109.076 178.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.581 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 25.5 p . . . . . 0 CA--C 1.54 0.563 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -177.434 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.021 0 CA-C-O 119.096 -0.835 . . . . 0.0 113.176 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.624 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.8 Cg_exo -78.81 146.58 20.97 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.882 2.388 . . . . 0.0 112.087 179.152 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.531 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 54.3 p-80 -159.79 -167.24 1.93 Allowed 'General case' 0 C--N 1.347 0.459 0 CA-C-O 121.467 0.651 . . . . 0.0 111.851 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.702 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 11.1 tp -126.18 137.64 53.58 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.228 -1.351 . . . . 0.0 110.339 -178.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.478 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 28.5 t60 -117.44 126.35 52.49 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 113.895 -1.502 . . . . 0.0 108.287 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.532 ' O ' HG12 ' A' ' 37' ' ' VAL . 32.2 t80 -131.61 108.62 9.65 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.973 178.255 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.516 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.1 pt-20 -116.62 128.38 55.33 Favored 'General case' 0 N--CA 1.429 -1.49 0 CA-C-N 115.276 -0.874 . . . . 0.0 109.476 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.417 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 3.4 tpt -121.08 136.9 54.88 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.837 -179.415 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.628 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.11 165.52 25.47 Favored Pre-proline 0 C--N 1.309 -1.169 0 CA-C-N 113.352 -1.749 . . . . 0.0 110.3 -177.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.8 Cg_endo -63.57 -178.25 0.5 Allowed 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 123.055 2.503 . . . . 0.0 112.9 176.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.44 -28.3 63.88 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.01 176.15 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -157.03 102.61 1.92 Allowed Pre-proline 0 CA--C 1.503 -0.828 0 CA-C-N 114.218 -1.355 . . . . 0.0 108.771 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.73 163.34 37.47 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.555 2.17 . . . . 0.0 116.603 -177.077 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.565 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.41 71.51 0.84 Allowed 'General case' 0 N--CA 1.425 -1.693 0 CA-C-N 112.344 -2.207 . . . . 0.0 107.095 177.691 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.5 m-90 -63.44 14.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 114.239 -1.346 . . . . 0.0 112.463 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.565 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -82.05 35.52 0.43 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.042 0.937 . . . . 0.0 112.951 -178.197 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 73.06 127.11 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.488 0 C-N-CA 125.53 1.532 . . . . 0.0 110.52 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.41 -50.08 0.56 Allowed Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.396 -0.907 . . . . 0.0 113.353 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.598 ' CE1' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -151.87 -19.86 0.19 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.027 0.414 . . . . 0.0 111.527 179.177 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 137' ' ' SER . . . . . 0.402 ' H ' ' H ' ' A' ' 136' ' ' PHE . 27.5 m 65.78 18.01 11.02 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.885 1.274 . . . . 0.0 108.283 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.628 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.11 -11.19 12.45 Favored Glycine 0 N--CA 1.436 -1.305 0 CA-C-N 112.465 -2.152 . . . . 0.0 112.782 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.753 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -82.48 121.8 27.22 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.1 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.418 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -124.64 -172.79 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.355 179.416 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ASP . . . . . 0.418 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.9 p30 -79.76 132.05 62.28 Favored Pre-proline 0 CA--C 1.552 1.038 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -176.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.527 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.71 0.04 10.19 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.233 2.622 . . . . 0.0 114.204 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.36 -24.23 7.29 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -178.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -74.5 -23.25 75.92 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.899 179.391 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -101.12 -12.27 18.93 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 123.62 0.768 . . . . 0.0 111.169 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.527 HG12 ' O ' ' A' ' 142' ' ' PRO . 26.6 mm -101.72 -10.68 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.688 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.84 178.091 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.66 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.7 Cg_exo . . . . . 0 N--CA 1.481 0.761 0 CA-C-O 120.774 0.239 . . . . 0.0 112.27 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.749 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -139.57 -171.84 3.23 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 122.614 1.197 . . . . 0.0 110.213 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.466 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.02 -25.17 2.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 112.241 -2.254 . . . . 0.0 108.792 177.219 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.749 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.4 t -168.95 -168.48 0.86 Allowed 'General case' 0 CA--C 1.546 0.802 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.619 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.04 111.9 0.35 Allowed Glycine 0 C--N 1.319 -0.371 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.336 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.67 124.63 9.96 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 121.888 0.852 . . . . 0.0 112.8 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.733 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.05 58.57 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 113.173 -1.83 . . . . 0.0 108.965 178.944 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.8 t -102.47 -28.98 11.88 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.838 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -113.42 -67.91 0.97 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.6 125.03 1.2 Allowed Glycine 0 C--N 1.323 -0.172 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.037 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.5 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -77.08 157.32 31.14 Favored 'General case' 0 C--N 1.343 0.298 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -178.956 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -55.97 32.19 0.0 OUTLIER 'General case' 0 C--O 1.239 0.526 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.702 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.74 0.94 49.33 Favored Glycine 0 CA--C 1.504 -0.647 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -101.64 85.34 0.64 Allowed Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.0 Cg_exo -77.42 139.66 18.61 Favored 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.748 2.299 . . . . 0.0 113.247 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.19 4.22 78.06 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.007 179.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.437 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.1 t-80 -75.36 131.4 40.22 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 123.997 0.919 . . . . 0.0 110.458 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.642 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.46 -1.98 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.488 -179.315 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.98 -150.21 5.89 Favored Glycine 0 C--N 1.338 0.661 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.685 HG11 ' HG3' ' A' ' 142' ' ' PRO . 11.9 p -132.05 149.19 32.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 O-C-N 123.864 0.391 . . . . 0.0 110.618 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.777 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.72 134.0 51.92 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 121.322 0.582 . . . . 0.0 112.074 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.66 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -124.57 110.44 14.45 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.354 -1.294 . . . . 0.0 110.131 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.06 107.31 0.29 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 115.813 -0.63 . . . . 0.0 112.117 178.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.563 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.2 p -146.36 127.12 7.16 Favored Pre-proline 0 CA--C 1.549 0.929 0 CA-C-N 115.021 -0.99 . . . . 0.0 109.172 -179.343 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -55.78 143.6 80.15 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.259 2.639 . . . . 0.0 115.583 -178.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.756 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -62.63 139.26 21.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 111.79 -2.459 . . . . 0.0 113.472 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.9 2.66 55.08 Favored Glycine 0 N--CA 1.442 -0.942 0 CA-C-N 115.366 -0.834 . . . . 0.0 114.063 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.12 120.83 70.74 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.143 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.2 126.1 21.39 Favored 'Trans proline' 0 C--N 1.376 1.985 0 C-N-CA 122.431 2.087 . . . . 0.0 113.104 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.594 HG21 HD22 ' A' ' 90' ' ' LEU . 4.9 t -98.51 121.15 48.75 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.978 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 4.5 mpt_? -102.93 152.54 21.18 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 113.264 -1.789 . . . . 0.0 111.443 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -72.42 123.52 23.26 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.7 -1.136 . . . . 0.0 111.587 -178.063 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.9 t -65.83 -21.57 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 CA-C-N 115.597 -0.729 . . . . 0.0 112.613 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.646 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -167.69 143.99 4.13 Favored 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 123.184 0.593 . . . . 0.0 110.653 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -59.94 155.51 16.46 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.191 179.227 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.17 -126.37 1.4 Allowed Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.777 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.4 m -148.26 142.01 25.64 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 123.537 0.735 . . . . 0.0 109.971 -177.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 99' ' ' SER . 11.6 t -85.95 112.84 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 O-C-N 124.028 0.83 . . . . 0.0 108.921 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.6 mmmt -95.15 -14.79 23.84 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.596 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -154.21 140.09 18.19 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.243 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.13 92.37 2.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.781 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.463 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.18 89.87 1.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 114.141 -1.39 . . . . 0.0 113.368 -179.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.479 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -69.99 124.05 23.09 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.907 0.883 . . . . 0.0 112.552 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.574 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.39 -0.63 87.22 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-N 113.334 -1.757 . . . . 0.0 113.645 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.81 -32.14 46.18 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 26.93 2.57 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.978 -178.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.57 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.86 115.87 57.03 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -178.28 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.1 Cg_exo -69.49 162.89 40.14 Favored 'Trans proline' 0 C--N 1.37 1.704 0 C-N-CA 123.765 2.976 . . . . 0.0 111.469 177.028 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -98.73 12.36 35.77 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.072 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.2 mtt -78.36 -44.08 25.98 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.539 -1.209 . . . . 0.0 110.149 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.518 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -119.88 10.69 11.63 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.793 177.411 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.48 146.31 50.85 Favored 'General case' 0 C--N 1.362 1.151 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.782 -179.01 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 46.1 mtt -139.37 -36.17 0.53 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.443 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -88.79 -21.02 23.99 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.413 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 95.12 -112.81 4.46 Favored Glycine 0 C--N 1.335 0.488 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.12 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.574 HD21 ' HA3' ' A' ' 61' ' ' GLY . 13.7 m-80 -80.37 135.7 36.23 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.182 0.593 . . . . 0.0 112.528 -178.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -149.18 146.31 27.58 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.228 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.32 122.01 17.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.094 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.5 129.92 54.95 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 177.509 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -141.08 150.87 20.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 CA-C-N 112.942 -1.935 . . . . 0.0 110.497 -176.187 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.48 116.05 30.74 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.277 177.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.646 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.3 m-70 -68.6 -177.76 1.01 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.528 -1.215 . . . . 0.0 114.121 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.59 -17.37 64.53 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.824 -178.319 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.58 -12.21 21.4 Favored 'General case' 0 C--O 1.236 0.388 0 O-C-N 123.415 0.447 . . . . 0.0 110.732 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.63 -6.57 45.02 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.118 -0.947 . . . . 0.0 112.035 178.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.455 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 12.1 ptt? -71.45 164.69 25.31 Favored 'General case' 0 N--CA 1.436 -1.154 0 C-N-CA 123.135 0.574 . . . . 0.0 111.772 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.455 ' O ' ' HA ' ' A' ' 125' ' ' MET . 53.0 m-70 -105.61 142.78 34.75 Favored 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.121 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.07 127.17 26.07 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.41 154.45 16.82 Favored Glycine 0 N--CA 1.442 -0.967 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.699 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -137.23 98.65 3.78 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.442 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -116.11 170.42 8.52 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 54.9 m80 65.59 38.1 5.62 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.339 1.056 . . . . 0.0 111.137 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.594 HD22 HG21 ' A' ' 47' ' ' VAL . 11.3 mt -97.94 170.11 9.17 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.966 178.133 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 17.3 t -104.14 -15.28 15.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 111.465 0.172 . . . . 0.0 111.465 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 9.0 tttt -168.46 159.55 10.44 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.696 0.76 . . . . 0.0 112.204 -178.339 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.821 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -124.38 148.98 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 113.541 -1.663 . . . . 0.0 110.862 178.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.53 -5.05 13.45 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.213 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.821 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.08 -175.33 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.074 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.553 -177.049 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.6 t -152.23 149.45 28.73 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.841 -179.209 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -60.32 127.9 34.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.496 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 85.39 -3.61 0.86 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.508 1.123 . . . . 0.0 111.673 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.478 ' O ' HG23 ' A' ' 55' ' ' VAL . 40.1 m -79.98 148.95 30.96 Favored 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 122.299 0.24 . . . . 0.0 110.415 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.6 p -83.19 145.68 29.04 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.491 178.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.21 167.66 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.297 0 CA-C-N 115.302 -0.863 . . . . 0.0 112.324 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.418 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.0 tttm -141.33 147.98 38.97 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.957 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.81 137.49 56.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.378 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.94 -5.64 47.07 Favored Glycine 0 CA--C 1.519 0.334 0 CA-C-N 114.285 -1.325 . . . . 0.0 114.112 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.498 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 41.4 tt0 -73.87 139.66 45.17 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.108 0.48 . . . . 0.0 110.143 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 57.8 mt -70.94 101.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.62 -179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.8 OUTLIER -93.72 -4.12 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.61 -1.632 . . . . 0.0 112.937 -179.125 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.49 -161.3 35.11 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-O 121.228 0.349 . . . . 0.0 112.737 178.627 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.572 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.0 m-85 -141.5 136.92 31.69 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 124.834 1.253 . . . . 0.0 108.341 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.408 HG23 HG22 ' A' ' 47' ' ' VAL . 2.1 p -60.43 152.73 24.83 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.423 0.689 . . . . 0.0 112.08 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.756 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -155.82 -165.44 14.44 Favored Glycine 0 C--N 1.345 1.048 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.915 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -149.77 45.13 0.93 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.565 -0.818 . . . . 0.0 108.953 178.5 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.47 0.538 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.636 -177.476 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.935 0 CA-C-O 119.125 -0.82 . . . . 0.0 112.682 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.584 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -73.88 146.35 37.52 Favored 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 122.93 2.42 . . . . 0.0 111.916 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.563 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 46.9 p-80 -157.66 -169.7 2.95 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-O 121.547 0.689 . . . . 0.0 112.401 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.777 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.0 tp -126.4 131.81 51.66 Favored 'General case' 0 N--CA 1.432 -1.34 0 CA-C-N 114.049 -1.432 . . . . 0.0 111.166 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 24.8 t60 -114.01 110.08 19.48 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.088 177.829 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.54 ' O ' HG12 ' A' ' 37' ' ' VAL . 23.1 t80 -117.08 109.23 16.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.364 -179.388 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.1 tt0 -116.22 127.06 54.44 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.208 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.455 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 2.5 ttt -118.62 134.7 54.91 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.679 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.4 mp -142.31 166.6 20.21 Favored Pre-proline 0 C--N 1.31 -1.14 0 CA-C-N 113.297 -1.774 . . . . 0.0 111.004 -177.125 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.5 Cg_endo -63.32 -178.44 0.47 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 123.027 2.484 . . . . 0.0 112.851 176.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -72.62 -27.06 61.92 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.194 176.315 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.29 98.84 1.96 Allowed Pre-proline 0 CA--C 1.503 -0.835 0 CA-C-N 114.206 -1.361 . . . . 0.0 109.314 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -71.1 163.37 39.44 Favored 'Trans proline' 0 N--CA 1.445 -1.377 0 C-N-CA 122.868 2.379 . . . . 0.0 116.532 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.2 t-20 -116.76 70.56 0.77 Allowed 'General case' 0 N--CA 1.425 -1.691 0 CA-C-N 112.579 -2.101 . . . . 0.0 107.24 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -62.99 13.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 114.351 -1.295 . . . . 0.0 112.412 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.8 mp0 -81.76 35.27 0.41 Allowed 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 124.196 0.998 . . . . 0.0 113.083 -178.109 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 73.32 126.29 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 125.509 1.523 . . . . 0.0 110.727 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.5 -50.18 0.56 Allowed Glycine 0 N--CA 1.442 -0.902 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.482 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.559 ' CE2' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -152.43 -19.73 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 117.102 0.451 . . . . 0.0 111.432 179.257 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 30.1 t 66.45 18.13 10.78 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.034 1.334 . . . . 0.0 108.411 -178.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.559 ' HA2' ' CE2' ' A' ' 136' ' ' PHE . . . 77.7 -11.04 21.43 Favored Glycine 0 N--CA 1.436 -1.334 0 CA-C-N 112.66 -2.063 . . . . 0.0 112.8 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.642 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -81.45 127.18 32.52 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 120.081 -0.648 . . . . 0.0 112.117 -179.19 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -126.93 -174.34 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.337 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.033 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -70.34 134.7 86.84 Favored Pre-proline 0 CA--C 1.544 0.731 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.618 -178.126 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.685 ' HG3' HG11 ' A' ' 37' ' ' VAL . 95.4 Cg_endo -76.7 21.64 0.56 Allowed 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 123.162 2.575 . . . . 0.0 114.081 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.9 p -56.04 -24.63 40.69 Favored 'General case' 0 C--N 1.344 0.349 0 C-N-CA 124.228 1.011 . . . . 0.0 113.308 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.52 -23.78 77.35 Favored Glycine 0 N--CA 1.462 0.427 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -96.2 -9.7 29.85 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.655 1.182 . . . . 0.0 110.43 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 142' ' ' PRO . 21.1 mm -104.93 -12.47 9.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.841 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.261 0 C-N-CA 123.133 0.573 . . . . 0.0 112.271 -179.961 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.762 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.7 Cg_exo . . . . . 0 N--CA 1.478 0.613 0 N-CA-C 113.192 0.42 . . . . 0.0 113.192 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.42 -171.81 2.86 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-O 122.736 1.255 . . . . 0.0 110.781 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.477 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.49 -25.09 2.96 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 111.98 -2.373 . . . . 0.0 108.691 177.512 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.764 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -168.58 -169.11 0.99 Allowed 'General case' 0 CA--C 1.55 0.949 0 CA-C-N 114.405 -1.271 . . . . 0.0 111.996 -178.107 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.12 110.66 0.25 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 114.504 -1.226 . . . . 0.0 111.251 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.39 124.72 8.19 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.714 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.37 58.4 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 114.201 -1.363 . . . . 0.0 108.949 178.191 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.7 t -103.27 -28.69 11.72 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.066 -1.879 . . . . 0.0 110.852 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -113.45 -66.8 1.05 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.489 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.17 124.48 1.17 Allowed Glycine 0 C--N 1.323 -0.182 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.865 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.484 ' HD2' ' HB2' ' A' ' 31' ' ' TYR . 0.1 OUTLIER -74.55 157.39 35.57 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -178.829 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -58.95 32.02 0.01 OUTLIER 'General case' 0 C--O 1.24 0.559 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.709 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.71 -1.56 48.9 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 111.429 -0.669 . . . . 0.0 111.429 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.484 ' HB2' ' HD2' ' A' ' 28' ' ' PHE . 7.7 m-85 -102.19 85.37 0.71 Allowed Pre-proline 0 CA--C 1.548 0.868 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.71 140.21 16.38 Favored 'Trans proline' 0 C--N 1.376 1.998 0 C-N-CA 122.836 2.358 . . . . 0.0 113.585 -178.467 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.57 4.27 70.56 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.743 -0.662 . . . . 0.0 113.181 179.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.423 ' O ' HG12 ' A' ' 24' ' ' ILE . 4.1 t-80 -79.79 133.0 36.28 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 124.209 1.004 . . . . 0.0 110.032 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.637 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.07 -10.51 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 123.64 0.588 . . . . 0.0 111.779 -178.845 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -129.93 -149.79 6.79 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 112.063 -0.415 . . . . 0.0 112.063 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.558 HG12 ' O ' ' A' ' 123' ' ' PHE . 12.4 p -130.52 151.66 36.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.844 0.379 . . . . 0.0 110.522 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.719 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -127.08 132.03 50.73 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.265 0.555 . . . . 0.0 111.408 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.762 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 6.5 m-85 -118.24 111.7 19.14 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.475 -1.239 . . . . 0.0 111.227 -177.874 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.42 99.76 0.09 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.548 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.46 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 14.2 p -142.87 129.02 10.47 Favored Pre-proline 0 CA--C 1.547 0.859 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.168 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 119' ' ' PRO . 87.8 Cg_exo -48.82 139.83 24.16 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 123.472 2.782 . . . . 0.0 115.844 -179.343 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.846 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -66.57 137.34 25.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 111.764 -2.471 . . . . 0.0 113.345 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.27 2.71 51.11 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.908 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.8 m -87.76 131.57 43.03 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.238 -0.41 . . . . 0.0 109.976 179.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.64 128.32 25.45 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.214 1.942 . . . . 0.0 113.004 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.621 HG21 HD22 ' A' ' 90' ' ' LEU . 8.1 t -100.14 123.15 52.82 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.885 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.64 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 19.5 mtt180 -101.95 152.02 21.43 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 112.929 -1.941 . . . . 0.0 111.752 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.06 123.67 24.01 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.098 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.02 -15.94 20.36 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.716 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.639 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.64 143.02 1.66 Allowed 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 123.349 0.66 . . . . 0.0 110.497 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.435 ' HB3' ' HA ' ' A' ' 102' ' ' LYS . 8.1 p30 -61.66 155.49 22.42 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.052 -0.976 . . . . 0.0 112.307 179.193 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.581 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.99 -126.26 1.36 Allowed Glycine 0 C--N 1.331 0.302 0 O-C-N 123.792 0.683 . . . . 0.0 113.45 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 7.9 m -147.1 141.52 26.4 Favored 'General case' 0 N--CA 1.436 -1.127 0 C-N-CA 123.576 0.75 . . . . 0.0 109.613 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 99' ' ' SER . 12.2 t -85.04 113.24 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 123.764 0.826 . . . . 0.0 108.783 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.408 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 7.0 mmmt -95.35 -14.9 23.49 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.675 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -156.17 140.27 16.44 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.198 179.363 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.01 92.12 1.93 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.147 -1.388 . . . . 0.0 108.934 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.41 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.76 91.27 1.46 Allowed Glycine 0 C--O 1.238 0.386 0 CA-C-N 114.362 -1.29 . . . . 0.0 112.214 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.517 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -70.27 122.34 19.35 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 122.006 0.908 . . . . 0.0 112.857 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.632 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.77 -0.86 88.82 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 113.201 -1.818 . . . . 0.0 113.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.46 -32.91 62.75 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.92 26.69 2.46 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.927 -178.479 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.632 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -82.59 114.13 49.65 Favored Pre-proline 0 N--CA 1.435 -1.192 0 N-CA-C 114.006 1.113 . . . . 0.0 114.006 -178.083 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.823 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.8 Cg_exo -67.72 162.31 39.95 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 123.987 3.125 . . . . 0.0 112.239 177.4 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TRP . . . . . 0.401 ' HA ' ' O ' ' A' ' 69' ' ' TRP . 59.8 m95 -95.76 12.23 30.72 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.24 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 58.9 mtt -78.42 -42.8 29.07 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.774 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.53 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -126.08 14.82 7.89 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.862 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.823 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.2 OUTLIER -137.33 113.24 9.7 Favored 'General case' 0 C--N 1.367 1.331 0 C-N-CA 120.188 -0.605 . . . . 0.0 112.581 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -110.83 -33.81 6.43 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.91 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.07 -18.68 33.57 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.513 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.52 -126.68 9.0 Favored Glycine 0 CA--C 1.52 0.394 0 O-C-N 123.515 0.51 . . . . 0.0 113.946 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.568 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.4 m-80 -81.21 145.98 30.71 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.738 0.815 . . . . 0.0 112.555 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -152.31 144.85 24.14 Favored 'General case' 0 CA--C 1.519 -0.243 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.438 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.612 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -139.46 120.86 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.539 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.46 128.01 51.67 Favored 'General case' 0 CA--C 1.492 -1.28 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.214 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -138.92 151.07 23.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 112.785 -2.007 . . . . 0.0 110.679 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.581 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -100.2 117.43 34.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.903 177.859 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.639 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.2 m-70 -70.04 -176.23 1.09 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 114.137 -1.392 . . . . 0.0 114.196 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.54 -18.05 65.03 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 113.806 -1.543 . . . . 0.0 114.42 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -9.67 20.35 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.913 0.387 . . . . 0.0 111.016 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.86 -6.49 43.99 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.221 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.456 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 6.5 ptt? -69.36 163.66 24.65 Favored 'General case' 0 N--CA 1.439 -1.007 0 C-N-CA 123.182 0.593 . . . . 0.0 111.621 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.444 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 60.2 m-70 -107.51 144.81 33.97 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.892 -178.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.96 127.31 24.68 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.612 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -107.29 154.47 16.61 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.339 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -138.44 98.44 3.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 104.221 -2.511 . . . . 0.0 104.221 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB3' ' HB3' ' A' ' 122' ' ' HIS . . . -116.72 173.59 6.55 Favored 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 10.7 m80 66.05 20.18 11.22 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.505 1.122 . . . . 0.0 112.121 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.621 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -79.66 172.43 13.79 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 123.708 0.803 . . . . 0.0 111.14 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.4 t -104.99 -15.69 15.04 Favored 'General case' 0 N--CA 1.447 -0.607 0 O-C-N 123.139 0.275 . . . . 0.0 111.555 -179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.432 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 12.3 tttt -168.71 157.52 8.51 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.809 0.814 . . . . 0.0 112.464 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.5 150.3 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 CA-C-N 113.467 -1.697 . . . . 0.0 110.97 179.187 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -114.03 -6.51 13.12 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.508 -1.224 . . . . 0.0 110.181 177.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.1 OUTLIER -103.36 -175.02 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-N 115.361 -0.836 . . . . 0.0 112.765 -177.064 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 58.8 m -152.89 144.66 23.56 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.62 -1.173 . . . . 0.0 108.985 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.534 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.1 m -57.24 127.93 34.43 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.301 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.71 -3.55 0.68 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.606 1.162 . . . . 0.0 111.884 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.498 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.8 m -81.08 149.19 29.32 Favored 'General case' 0 C--N 1.346 0.456 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 178.456 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.26 145.28 29.21 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.184 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 166.15 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.346 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.435 ' HA ' ' HB3' ' A' ' 52' ' ' ASN . 62.9 tttt -140.09 148.56 41.91 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.064 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -58.1 138.37 56.14 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.132 -1.394 . . . . 0.0 111.332 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.64 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.47 -5.89 41.65 Favored Glycine 0 CA--C 1.516 0.145 0 CA-C-N 114.3 -1.318 . . . . 0.0 114.134 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.534 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.1 tt0 -73.28 143.79 46.87 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 122.989 0.515 . . . . 0.0 109.991 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 25.6 mt -74.17 101.65 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 CA-C-N 115.074 -0.967 . . . . 0.0 109.612 -179.313 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.59 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -93.59 -3.68 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 113.393 -1.73 . . . . 0.0 112.55 -179.236 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.31 -160.84 34.62 Favored Glycine 0 N--CA 1.439 -1.113 0 CA-C-O 121.307 0.393 . . . . 0.0 112.696 178.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 20.9 m-85 -142.25 137.35 30.63 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 124.875 1.27 . . . . 0.0 108.061 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -58.94 151.88 20.87 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 123.556 0.743 . . . . 0.0 112.356 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.846 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -147.58 -170.79 16.03 Favored Glycine 0 C--N 1.347 1.187 0 C-N-CA 119.834 -1.174 . . . . 0.0 113.655 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -144.83 44.46 1.36 Allowed 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.779 -0.71 . . . . 0.0 109.173 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.513 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 37.5 p . . . . . 0 CA--C 1.541 0.627 0 N-CA-C 113.62 0.971 . . . . 0.0 113.62 -177.338 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.683 0 CA-C-O 119.798 -0.445 . . . . 0.0 112.92 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.612 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 21.4 Cg_exo -70.84 147.26 55.56 Favored 'Trans proline' 0 C--N 1.365 1.445 0 C-N-CA 123.558 2.839 . . . . 0.0 111.956 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -152.0 156.29 39.69 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 122.3 1.048 . . . . 0.0 112.82 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -117.01 127.96 54.69 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 112.566 -2.107 . . . . 0.0 108.297 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 88' ' ' ALA . 23.3 t60 -112.36 109.57 19.27 Favored 'General case' 0 N--CA 1.434 -1.258 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.255 179.48 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.558 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.73 108.52 16.47 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.931 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.475 ' OE1' HD11 ' A' ' 126' ' ' LEU . 21.5 tt0 -120.55 125.86 48.88 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.621 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.653 ' SD ' ' HA ' ' A' ' 142' ' ' PRO . 19.4 ptm -111.74 135.36 52.45 Favored 'General case' 0 N--CA 1.419 -2.011 0 C-N-CA 124.012 0.925 . . . . 0.0 109.579 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.475 HD11 ' OE1' ' A' ' 124' ' ' GLU . 2.8 mp -138.56 165.92 29.27 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.697 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.444 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.7 Cg_endo -63.2 -178.5 0.46 Allowed 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.969 2.446 . . . . 0.0 112.703 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.99 -27.21 62.6 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.214 176.176 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -157.46 101.21 1.87 Allowed Pre-proline 0 CA--C 1.503 -0.851 0 CA-C-N 114.182 -1.372 . . . . 0.0 109.019 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HB3' ' HA3' ' A' ' 138' ' ' GLY . 3.0 Cg_exo -72.89 163.66 37.75 Favored 'Trans proline' 0 N--CA 1.446 -1.284 0 C-N-CA 122.722 2.281 . . . . 0.0 116.592 -177.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.559 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -118.01 70.73 0.81 Allowed 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 112.482 -2.145 . . . . 0.0 107.339 177.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.3 m-90 -63.54 14.71 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.317 -1.311 . . . . 0.0 112.696 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.559 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.24 35.49 0.39 Allowed 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 122.121 0.963 . . . . 0.0 112.897 -178.353 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 70.72 127.59 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 125.73 1.612 . . . . 0.0 110.883 178.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 148.98 -49.9 0.57 Allowed Glycine 0 N--CA 1.437 -1.254 0 CA-C-N 114.979 -1.009 . . . . 0.0 113.031 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.5 -21.5 0.23 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 122.37 0.268 . . . . 0.0 111.43 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 26.9 m 66.19 17.94 10.85 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.672 1.189 . . . . 0.0 108.454 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.93 -9.73 23.05 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 112.497 -2.138 . . . . 0.0 112.672 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.637 ' HG2' HG12 ' A' ' 35' ' ' VAL . 2.1 ppt_? -83.18 126.16 32.33 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.42 -174.34 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.89 178.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ASP . . . . . 0.426 ' O ' ' SD ' ' A' ' 125' ' ' MET . 1.8 p30 -79.25 135.58 57.69 Favored Pre-proline 0 CA--C 1.549 0.939 0 N-CA-C 114.06 1.133 . . . . 0.0 114.06 -176.335 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.653 ' HA ' ' SD ' ' A' ' 125' ' ' MET . 1.0 OUTLIER -76.46 1.4 8.45 Favored 'Trans proline' 0 C--N 1.383 2.39 0 C-N-CA 123.003 2.469 . . . . 0.0 113.244 178.963 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.67 -23.7 7.1 Favored 'General case' 0 C--N 1.351 0.664 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -178.201 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.41 -31.62 74.32 Favored Glycine 0 C--N 1.333 0.387 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' TYR . . . . . 0.446 ' HE1' ' SD ' ' A' ' 125' ' ' MET . 32.1 m-85 -94.35 -13.49 26.32 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 122.978 0.511 . . . . 0.0 111.53 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.571 HG12 ' O ' ' A' ' 142' ' ' PRO . 14.6 mm -100.98 -9.06 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.434 -178.354 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.32 0 CA-C-O 121.238 0.542 . . . . 0.0 111.429 179.037 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.705 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.1 Cg_exo . . . . . 0 N--CA 1.484 0.92 0 N-CA-C 113.286 0.456 . . . . 0.0 113.286 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.768 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.41 -172.16 2.88 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 122.682 1.229 . . . . 0.0 110.722 -179.765 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -129.08 -24.75 2.85 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 111.862 -2.426 . . . . 0.0 108.797 177.407 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.768 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.5 t -168.58 -168.74 0.94 Allowed 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 114.55 -1.205 . . . . 0.0 112.185 -177.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.411 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 172.75 111.43 0.26 Allowed Glycine 0 C--N 1.319 -0.37 0 CA-C-N 114.268 -1.333 . . . . 0.0 111.415 177.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.55 124.69 8.71 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.588 0.709 . . . . 0.0 112.764 -178.347 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.796 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -103.04 58.74 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-N 113.692 -1.595 . . . . 0.0 108.663 178.674 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.0 t -100.05 -28.56 12.99 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 112.879 -1.964 . . . . 0.0 110.826 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.8 m -116.93 -66.28 1.1 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.434 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.96 125.74 1.3 Allowed Glycine 0 C--N 1.322 -0.199 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.824 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.537 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -73.54 157.36 36.87 Favored 'General case' 0 C--N 1.342 0.278 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.56 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -57.15 31.99 0.0 OUTLIER 'General case' 0 C--O 1.238 0.494 0 N-CA-C 115.778 1.77 . . . . 0.0 115.778 -177.47 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.689 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 103.12 0.74 48.03 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -102.06 85.4 0.7 Allowed Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.689 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.0 Cg_exo -76.73 141.25 21.63 Favored 'Trans proline' 0 C--N 1.374 1.884 0 C-N-CA 122.831 2.354 . . . . 0.0 113.388 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.25 4.06 78.05 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 123.694 0.621 . . . . 0.0 113.091 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.453 ' O ' HG12 ' A' ' 24' ' ' ILE . 2.6 t-80 -79.58 129.54 34.56 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 123.886 0.874 . . . . 0.0 110.659 -179.314 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.671 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.17 -5.25 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.227 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -131.01 -150.15 6.69 Favored Glycine 0 C--N 1.337 0.602 0 N-CA-C 111.868 -0.493 . . . . 0.0 111.868 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.4 p -131.69 151.5 35.46 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.701 0 C-N-CA 122.824 0.449 . . . . 0.0 110.044 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.743 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -127.23 137.89 52.98 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.222 0.534 . . . . 0.0 111.715 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.705 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.3 m-85 -125.4 107.6 10.83 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 114.534 -1.212 . . . . 0.0 110.574 -178.122 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -59.31 104.9 0.29 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.494 179.107 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 p -149.25 129.04 6.5 Favored Pre-proline 0 CA--C 1.549 0.919 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.192 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.82 144.18 56.15 Favored 'Trans proline' 0 C--N 1.365 1.441 0 C-N-CA 123.298 2.665 . . . . 0.0 115.149 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.769 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.92 142.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 111.796 -2.456 . . . . 0.0 113.362 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.17 2.53 59.16 Favored Glycine 0 N--CA 1.442 -0.963 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.984 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.83 129.45 48.52 Favored Pre-proline 0 N--CA 1.447 -0.623 0 CA-C-O 119.134 -0.46 . . . . 0.0 109.791 179.128 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.58 126.91 22.69 Favored 'Trans proline' 0 C--N 1.371 1.742 0 C-N-CA 122.152 1.901 . . . . 0.0 112.965 -179.393 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.595 HG21 HD22 ' A' ' 90' ' ' LEU . 6.2 t -99.93 124.29 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.863 179.62 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.601 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.1 mtp-105 -101.55 153.57 19.62 Favored 'General case' 0 N--CA 1.433 -1.309 0 CA-C-N 113.18 -1.827 . . . . 0.0 111.843 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.33 121.47 20.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.61 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 30.4 t -67.76 -14.98 19.03 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.672 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.75 143.51 2.13 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 123.376 0.67 . . . . 0.0 110.482 179.001 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.412 ' OD1' ' HB2' ' A' ' 80' ' ' ALA . 7.8 p30 -61.74 156.17 21.0 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.078 -0.965 . . . . 0.0 112.156 179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.689 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.61 -127.35 1.52 Allowed Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.806 -0.712 . . . . 0.0 113.996 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 20.4 m -149.48 137.08 20.18 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 -177.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 99' ' ' SER . 10.4 t -83.26 113.82 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 123.763 0.825 . . . . 0.0 108.956 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.401 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.3 OUTLIER -98.84 -17.08 18.62 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.827 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -148.78 139.57 22.83 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.435 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.95 92.34 1.96 Allowed 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.904 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.56 91.27 1.4 Allowed Glycine 0 C--O 1.24 0.482 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.269 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.52 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -73.52 122.85 22.84 Favored 'General case' 0 C--N 1.344 0.358 0 C-N-CA 123.924 0.89 . . . . 0.0 112.57 -179.358 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.604 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.34 -0.73 87.32 Favored Glycine 0 C--N 1.32 -0.349 0 CA-C-N 113.265 -1.789 . . . . 0.0 113.378 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.89 -32.91 57.77 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.67 22.58 2.69 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-N 115.894 -0.593 . . . . 0.0 112.233 -178.296 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.604 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.5 113.45 34.5 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -178.619 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.83 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.3 Cg_exo -66.98 162.88 36.07 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 123.675 2.917 . . . . 0.0 111.705 177.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -95.63 8.1 44.37 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 176.134 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.0 mtt -74.81 -44.76 47.61 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.308 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.536 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.52 11.74 10.67 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.824 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.83 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -130.65 143.21 50.59 Favored 'General case' 0 C--N 1.361 1.096 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.412 -179.319 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 5.0 ttt -147.22 -19.78 0.39 Allowed 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.212 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -90.85 -29.17 17.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -179.095 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.63 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 106.48 -127.38 8.87 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.8 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.549 HD21 ' HA3' ' A' ' 61' ' ' GLY . 14.8 m-80 -88.61 139.33 30.58 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 122.894 0.478 . . . . 0.0 111.928 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.48 145.67 23.81 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.143 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.567 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.34 121.24 19.31 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.174 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.121 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.1 126.87 53.51 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -139.95 150.69 21.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-N 112.579 -2.1 . . . . 0.0 110.643 -176.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.689 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.7 tt0 -97.23 116.76 30.02 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 113.921 -1.49 . . . . 0.0 108.33 177.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.672 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.4 m-70 -69.55 -176.91 1.08 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.412 ' HB2' ' OD1' ' A' ' 52' ' ' ASN . . . -64.97 -17.55 64.5 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 113.69 -1.595 . . . . 0.0 113.966 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.61 -12.9 20.67 Favored 'General case' 0 C--O 1.236 0.345 0 O-C-N 123.449 0.468 . . . . 0.0 110.986 -179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.59 -6.77 45.38 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.685 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.717 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 18.5 ptp -70.55 168.23 16.76 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 123.352 0.661 . . . . 0.0 110.364 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.463 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 19.0 p80 -118.16 142.11 47.79 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.142 -1.023 . . . . 0.0 111.203 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.2 OUTLIER -133.85 128.39 34.57 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.255 -177.347 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -101.15 154.8 19.13 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 114.719 -1.128 . . . . 0.0 111.471 177.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.4 m-85 -133.44 99.22 4.45 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -111.32 168.92 9.15 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.925 -0.58 . . . . 0.0 112.556 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 22.1 m80 65.99 37.24 5.44 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 114.836 -1.074 . . . . 0.0 112.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.595 HD22 HG21 ' A' ' 47' ' ' VAL . 11.5 mt -98.43 169.58 9.44 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.745 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.3 t -107.83 -14.69 14.72 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 111.623 0.231 . . . . 0.0 111.623 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.408 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 0.7 OUTLIER -167.66 157.95 10.75 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.595 0.712 . . . . 0.0 111.87 -178.544 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.82 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -123.37 149.42 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.844 179.25 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -113.34 -6.83 13.53 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.837 177.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.82 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -101.54 -175.04 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.02 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.28 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.5 m -152.64 145.16 24.13 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.256 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.553 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.3 m -57.02 126.14 25.85 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.599 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.553 ' HB2' ' O ' ' A' ' 97' ' ' THR . 1.6 m-20 85.37 -2.19 0.83 Allowed 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.75 1.22 . . . . 0.0 111.939 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.469 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -80.74 149.28 29.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -82.86 145.17 29.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.294 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.52 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.334 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 70.2 tttt -142.03 148.93 39.28 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.824 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -58.36 137.95 56.85 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.422 -1.263 . . . . 0.0 111.253 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.601 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.81 -4.55 52.11 Favored Glycine 0 C--N 1.328 0.089 0 CA-C-N 114.477 -1.238 . . . . 0.0 114.083 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 39.3 tt0 -74.2 141.94 45.42 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.108 0.48 . . . . 0.0 110.086 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.7 mt -72.37 101.44 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.525 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.2 pt -93.57 -6.16 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.88 -179.061 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.83 -159.88 33.15 Favored Glycine 0 N--CA 1.44 -1.067 0 C-N-CA 121.435 -0.412 . . . . 0.0 112.702 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.496 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 31.9 m-85 -140.24 138.07 34.76 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 124.674 1.19 . . . . 0.0 108.355 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.421 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -60.24 150.17 30.98 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.567 0.747 . . . . 0.0 112.85 -178.654 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.769 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -148.47 -163.71 10.99 Favored Glycine 0 C--N 1.345 1.06 0 C-N-CA 120.616 -0.802 . . . . 0.0 113.02 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.481 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 44.4 0.87 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.415 0.626 . . . . 0.0 109.81 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.63 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 67.4 p . . . . . 0 CA--C 1.54 0.558 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.953 -178.162 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.025 0 CA-C-O 118.987 -0.896 . . . . 0.0 112.803 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.481 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.0 Cg_exo -73.45 142.95 33.92 Favored 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 122.495 2.13 . . . . 0.0 112.202 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 51.9 p-80 -163.29 -171.09 2.47 Favored 'General case' 0 C--N 1.347 0.499 0 CA-C-O 121.371 0.605 . . . . 0.0 111.414 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.743 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -124.75 131.08 53.48 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.487 -178.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 23.8 t60 -112.76 109.92 19.7 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.405 -1.271 . . . . 0.0 109.436 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.539 ' O ' HG12 ' A' ' 37' ' ' VAL . 30.1 t80 -114.43 110.16 19.43 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.015 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.544 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -115.01 127.13 55.47 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.4 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.2 ttt -121.87 134.68 54.87 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 114.354 -1.294 . . . . 0.0 109.023 -178.118 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.717 ' O ' ' HB2' ' A' ' 83' ' ' MET . 2.1 mp -143.46 164.77 28.94 Favored Pre-proline 0 C--N 1.313 -1.022 0 CA-C-N 113.355 -1.748 . . . . 0.0 110.358 -177.521 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.463 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -61.91 -178.5 0.32 Allowed 'Trans proline' 0 C--N 1.369 1.644 0 C-N-CA 123.291 2.661 . . . . 0.0 113.473 177.744 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.99 -28.97 67.09 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.077 176.252 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -158.01 103.93 1.74 Allowed Pre-proline 0 CA--C 1.503 -0.839 0 CA-C-N 113.896 -1.502 . . . . 0.0 108.607 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.5 163.13 38.37 Favored 'Trans proline' 0 N--CA 1.444 -1.44 0 C-N-CA 122.511 2.141 . . . . 0.0 116.746 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.558 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -118.2 70.53 0.81 Allowed 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 112.281 -2.236 . . . . 0.0 107.412 177.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.4 m-90 -62.83 12.5 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.427 -178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.558 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.7 mp0 -82.17 34.18 0.41 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 124.224 1.01 . . . . 0.0 112.74 -178.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 72.54 128.77 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.62 0 C-N-CA 125.692 1.597 . . . . 0.0 110.748 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.27 -48.6 0.59 Allowed Glycine 0 N--CA 1.439 -1.161 0 CA-C-N 115.135 -0.939 . . . . 0.0 113.043 -179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.55 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -150.48 -20.72 0.23 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 111.756 0.28 . . . . 0.0 111.756 179.301 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.23 17.71 10.78 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.081 1.352 . . . . 0.0 107.989 -178.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.651 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.29 -11.31 8.95 Favored Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 112.262 -2.245 . . . . 0.0 112.609 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.671 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.11 125.72 29.79 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.321 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -129.84 -175.35 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.004 179.301 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ASP . . . . . 0.431 ' HA ' ' HD3' ' A' ' 142' ' ' PRO . 1.9 p30 -79.74 132.96 59.65 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.01 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.591 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.1 Cg_exo -76.68 -1.89 12.05 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.667 2.245 . . . . 0.0 112.932 178.016 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.75 -23.24 6.41 Favored 'General case' 0 C--N 1.35 0.627 0 N-CA-C 114.278 1.214 . . . . 0.0 114.278 -178.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -67.67 -31.12 75.46 Favored Glycine 0 CA--C 1.518 0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.334 -179.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -103.39 -11.99 17.5 Favored 'General case' 0 C--O 1.236 0.37 0 O-C-N 123.861 0.389 . . . . 0.0 111.919 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.591 HG12 ' O ' ' A' ' 142' ' ' PRO . 24.5 mm -96.2 -8.71 9.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.684 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.267 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.412 178.125 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.689 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.5 Cg_exo . . . . . 0 N--CA 1.481 0.787 0 CA-C-O 120.75 0.229 . . . . 0.0 112.273 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.746 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.41 -172.02 3.04 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-O 122.561 1.172 . . . . 0.0 110.509 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.52 -24.83 2.99 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 112.221 -2.263 . . . . 0.0 108.772 177.233 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.746 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.3 t -168.42 -168.51 0.93 Allowed 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.654 -178.254 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.428 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 179.17 110.99 0.29 Allowed Glycine 0 C--N 1.32 -0.356 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.386 177.415 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.426 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.09 124.65 8.35 Favored 'General case' 0 CA--C 1.506 -0.739 0 CA-C-O 121.531 0.682 . . . . 0.0 112.337 -178.434 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.93 58.77 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.533 0 CA-C-N 113.924 -1.489 . . . . 0.0 108.978 178.536 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.6 t -105.05 -28.64 10.92 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 112.815 -1.993 . . . . 0.0 111.111 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.42 -66.79 1.05 Allowed 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.981 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.05 121.4 0.94 Allowed Glycine 0 C--N 1.321 -0.257 0 CA-C-N 115.131 -0.94 . . . . 0.0 112.15 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.483 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -74.72 157.49 35.18 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -178.849 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -57.43 31.71 0.0 OUTLIER 'General case' 0 C--O 1.24 0.561 0 N-CA-C 115.87 1.804 . . . . 0.0 115.87 -177.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.56 -2.05 49.52 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -101.76 85.47 0.67 Allowed Pre-proline 0 CA--C 1.547 0.861 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.8 Cg_exo -78.12 138.11 15.94 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.785 2.323 . . . . 0.0 113.317 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 92.41 4.31 66.27 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.225 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -76.52 135.89 39.31 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 123.79 0.836 . . . . 0.0 110.2 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.611 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.19 -18.93 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.444 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.22 -149.85 8.22 Favored Glycine 0 C--N 1.337 0.624 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.2 p -131.08 148.54 32.98 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 O-C-N 123.855 0.385 . . . . 0.0 110.11 179.242 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.788 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.21 135.12 52.26 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.456 0.646 . . . . 0.0 112.148 -178.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.689 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 2.1 m-85 -124.56 110.26 14.23 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 114.231 -1.35 . . . . 0.0 109.803 -178.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.31 104.25 0.12 Allowed 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.649 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.522 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.7 p -144.88 120.75 6.0 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.563 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -49.16 144.68 16.11 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.191 2.594 . . . . 0.0 115.525 -179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.706 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -61.03 139.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 111.628 -2.533 . . . . 0.0 113.437 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.52 2.56 55.47 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.358 -0.837 . . . . 0.0 114.181 177.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -87.41 127.57 58.29 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-O 119.148 -0.453 . . . . 0.0 109.951 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -59.36 127.27 23.31 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.181 1.921 . . . . 0.0 113.378 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.524 HG21 HD22 ' A' ' 90' ' ' LEU . 11.4 t -99.05 123.8 51.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.28 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 5.9 mtt180 -102.39 152.42 21.13 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.913 -1.949 . . . . 0.0 111.597 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.47 120.82 19.61 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.771 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.3 t -65.51 -16.77 20.89 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.671 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.27 144.63 2.05 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 123.479 0.711 . . . . 0.0 110.391 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -61.15 156.02 19.27 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.071 -0.968 . . . . 0.0 112.512 179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.657 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.71 -125.88 1.38 Allowed Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.72 -0.673 . . . . 0.0 113.701 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 14.3 m -148.22 142.95 26.67 Favored 'General case' 0 N--CA 1.439 -1.025 0 C-N-CA 123.624 0.77 . . . . 0.0 109.706 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 99' ' ' SER . 9.4 t -84.89 112.1 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 123.805 0.842 . . . . 0.0 108.881 179.597 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.444 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -95.14 -14.96 23.71 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.751 -179.861 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -154.38 140.37 18.31 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.045 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -147.85 92.31 2.05 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.394 -1.275 . . . . 0.0 108.952 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.412 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.63 89.99 1.27 Allowed Glycine 0 C--O 1.24 0.499 0 CA-C-N 114.251 -1.341 . . . . 0.0 112.454 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.546 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -72.09 122.13 20.43 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.951 0.881 . . . . 0.0 112.822 -179.409 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.627 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.63 -0.94 88.59 Favored Glycine 0 N--CA 1.461 0.301 0 CA-C-N 113.197 -1.82 . . . . 0.0 113.693 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.09 -33.44 59.51 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -138.62 26.91 2.52 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.925 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.627 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.9 115.26 50.92 Favored Pre-proline 0 N--CA 1.437 -1.119 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -178.372 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 37.4 Cg_exo -68.05 162.95 37.76 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 123.845 3.03 . . . . 0.0 111.789 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -96.25 8.58 43.53 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -74.66 -44.6 49.54 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.312 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.528 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -121.97 11.76 10.35 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.913 177.694 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.0 OUTLIER -129.03 144.39 51.17 Favored 'General case' 0 C--N 1.361 1.093 0 C-N-CA 120.159 -0.616 . . . . 0.0 112.237 -178.854 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.61 -31.16 0.35 Allowed 'General case' 0 N--CA 1.47 0.525 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.689 178.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.62 -19.34 31.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.522 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 96.3 -130.28 10.21 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.967 -0.561 . . . . 0.0 114.112 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.579 HD21 ' HA3' ' A' ' 61' ' ' GLY . 10.1 m-80 -81.11 140.95 34.75 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.558 0.743 . . . . 0.0 112.35 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.23 146.56 24.83 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.345 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.572 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.93 121.35 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.265 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.89 130.55 56.31 Favored 'General case' 0 CA--C 1.492 -1.273 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 177.561 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.4 mt -139.4 150.82 22.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-N 112.909 -1.951 . . . . 0.0 110.403 -176.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.657 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.68 116.18 31.2 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 113.865 -1.516 . . . . 0.0 108.281 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.671 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.8 m-70 -69.21 -175.47 0.77 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.27 -18.1 65.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 113.982 -1.463 . . . . 0.0 114.619 -177.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.22 -9.18 20.66 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.81 -6.14 43.83 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.154 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.507 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 4.0 ptt? -67.43 165.76 15.98 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 123.595 0.758 . . . . 0.0 111.353 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.496 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 61.9 m-70 -111.41 144.37 40.72 Favored 'General case' 0 N--CA 1.44 -0.929 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.826 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.7 127.06 22.96 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 120.99 0.424 . . . . 0.0 110.345 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -104.24 154.73 17.61 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.628 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.507 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.0 m-85 -136.08 99.06 4.03 Favored 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.409 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.66 167.78 10.32 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -177.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 65.5 42.28 3.82 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.283 1.033 . . . . 0.0 111.383 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.2 mt -103.22 168.58 9.08 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.103 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 8.1 t -102.63 -17.81 15.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.16 163.64 15.6 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.722 0.772 . . . . 0.0 111.927 -177.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.829 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -127.56 148.18 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.509 -1.678 . . . . 0.0 110.893 179.06 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 t -111.51 -6.6 14.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.886 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.829 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -103.35 -175.24 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.099 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.792 -177.118 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.7 m -153.22 143.42 22.35 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.674 -1.148 . . . . 0.0 108.936 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.76 127.88 32.23 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 86.02 -4.43 0.79 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.692 1.197 . . . . 0.0 111.719 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.476 ' O ' HG23 ' A' ' 55' ' ' VAL . 39.5 m -80.44 151.61 29.22 Favored 'General case' 0 C--N 1.347 0.463 0 CA-C-O 120.571 0.224 . . . . 0.0 110.552 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.7 145.52 27.91 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.608 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.89 169.71 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.314 0 CA-C-N 115.197 -0.91 . . . . 0.0 112.196 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.438 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 1.9 tttt -142.42 148.51 37.93 Favored 'General case' 0 N--CA 1.432 -1.361 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.716 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -58.34 138.41 56.49 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.361 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.584 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 77.03 -8.44 30.58 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 114.38 -1.282 . . . . 0.0 114.135 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 41.1 tt0 -70.75 141.29 51.48 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.078 0.466 . . . . 0.0 110.214 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.8 mt -72.72 102.05 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.559 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.5 -4.97 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 CA-C-N 113.564 -1.653 . . . . 0.0 113.117 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.66 -160.74 34.44 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 121.472 -0.394 . . . . 0.0 112.749 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 35.4 m-85 -140.16 138.35 35.12 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.669 1.188 . . . . 0.0 108.522 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -62.71 150.93 39.84 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 123.631 0.773 . . . . 0.0 112.552 -179.224 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.706 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -161.37 -160.98 11.23 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 119.877 -1.154 . . . . 0.0 114.034 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.416 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.2 51.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 114.48 -0.86 . . . . 0.0 108.684 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.522 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 21.6 p . . . . . 0 CA--C 1.539 0.55 0 CA-C-N 115.196 -0.911 . . . . 0.0 113.33 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.972 0 CA-C-O 119.384 -0.675 . . . . 0.0 113.634 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.417 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 6.2 Cg_exo -80.25 139.21 13.07 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 123.302 2.668 . . . . 0.0 112.419 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.522 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 31.5 p80 -160.94 -166.34 1.57 Allowed 'General case' 0 C--N 1.348 0.5 0 CA-C-O 121.256 0.551 . . . . 0.0 111.411 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.788 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 13.3 tp -123.03 130.04 52.28 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.64 -1.163 . . . . 0.0 111.261 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.409 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 22.6 t60 -112.81 113.0 24.9 Favored 'General case' 0 N--CA 1.434 -1.225 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.815 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.527 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.2 t80 -118.53 111.31 18.45 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.138 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -118.55 127.21 53.4 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.163 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.0 tpt -117.61 138.41 51.97 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.7 mp -143.65 166.62 18.72 Favored Pre-proline 0 C--N 1.308 -1.237 0 CA-C-N 113.465 -1.698 . . . . 0.0 111.103 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -62.52 -178.48 0.38 Allowed 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 123.35 2.7 . . . . 0.0 112.703 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -69.98 -28.05 65.22 Favored 'General case' 0 N--CA 1.439 -0.989 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.247 176.251 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -156.94 101.28 1.95 Allowed Pre-proline 0 CA--C 1.504 -0.793 0 CA-C-N 114.334 -1.303 . . . . 0.0 108.829 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -72.26 163.18 39.46 Favored 'Trans proline' 0 N--CA 1.444 -1.432 0 C-N-CA 122.698 2.265 . . . . 0.0 116.542 -177.254 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.579 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -117.08 70.7 0.78 Allowed 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.491 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -63.07 12.54 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 114.29 -1.323 . . . . 0.0 112.313 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.579 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.8 mp0 -81.61 32.29 0.36 Allowed 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.378 1.071 . . . . 0.0 112.815 -178.534 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 73.74 129.1 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.582 0 C-N-CA 125.825 1.65 . . . . 0.0 110.789 178.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.34 -48.6 0.59 Allowed Glycine 0 N--CA 1.44 -1.085 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.121 -179.585 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.2 -19.77 0.18 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.762 0.315 . . . . 0.0 111.757 179.247 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.6 t 66.34 18.03 10.81 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.975 1.31 . . . . 0.0 108.213 -178.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 74.59 -9.71 10.12 Favored Glycine 0 N--CA 1.437 -1.26 0 CA-C-N 112.582 -2.099 . . . . 0.0 112.904 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.611 ' HG2' HG12 ' A' ' 35' ' ' VAL . 1.5 ppt_? -82.73 127.25 33.25 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.561 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.452 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -129.37 -172.86 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.855 -0.612 . . . . 0.0 112.413 178.478 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ASP . . . . . 0.452 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.3 m-20 -71.65 134.86 83.83 Favored Pre-proline 0 CA--C 1.549 0.906 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -176.278 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.629 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.6 Cg_endo -77.7 2.03 8.24 Favored 'Trans proline' 0 C--N 1.381 2.265 0 C-N-CA 123.296 2.664 . . . . 0.0 113.297 177.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.5 p -51.17 -24.04 3.85 Favored 'General case' 0 C--N 1.347 0.467 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -178.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.52 -28.04 71.69 Favored Glycine 0 CA--C 1.52 0.383 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.867 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -102.4 -9.28 20.44 Favored 'General case' 0 C--O 1.237 0.445 0 O-C-N 124.085 0.52 . . . . 0.0 111.496 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.629 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -98.53 -11.29 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.854 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.019 178.149 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.667 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 45.6 Cg_exo . . . . . 0 N--CA 1.483 0.87 0 N-CA-C 113.147 0.403 . . . . 0.0 113.147 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.754 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.37 -172.12 2.87 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-O 122.5 1.143 . . . . 0.0 110.379 -179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.459 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.78 -25.71 2.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 112.4 -2.182 . . . . 0.0 108.755 177.288 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.754 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -169.61 -168.32 0.78 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 114.02 -1.445 . . . . 0.0 111.234 -178.045 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.24 110.97 0.3 Allowed Glycine 0 C--N 1.316 -0.574 0 CA-C-N 114.793 -1.094 . . . . 0.0 111.289 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.52 124.98 8.88 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.851 0.834 . . . . 0.0 113.053 -177.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.808 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.85 58.8 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.38 -1.736 . . . . 0.0 108.522 178.373 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 4.9 t -100.94 -28.73 12.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 112.595 -2.093 . . . . 0.0 110.856 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.6 m -115.55 -66.58 1.07 Allowed 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.422 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.46 122.15 0.98 Allowed Glycine 0 C--N 1.323 -0.173 0 CA-C-N 115.084 -0.962 . . . . 0.0 112.037 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.547 ' CD2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -70.89 157.35 38.29 Favored 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -178.909 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 -58.67 31.75 0.01 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.66 1.726 . . . . 0.0 115.66 -177.483 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.698 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.81 -2.03 48.58 Favored Glycine 0 CA--C 1.505 -0.59 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.545 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -102.52 85.35 0.75 Allowed Pre-proline 0 CA--C 1.547 0.864 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.698 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 6.2 Cg_exo -78.6 138.98 15.71 Favored 'Trans proline' 0 C--N 1.374 1.898 0 C-N-CA 122.881 2.388 . . . . 0.0 113.497 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.34 3.93 62.89 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.375 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.507 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.3 t-80 -80.62 135.06 35.98 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 123.724 0.81 . . . . 0.0 109.83 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.658 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.74 -20.1 5.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.144 -179.383 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.35 -149.59 8.33 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 142' ' ' PRO . 14.7 p -131.69 151.92 36.17 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 O-C-N 123.939 0.435 . . . . 0.0 110.274 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASP . . . . . 0.763 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 82.8 m-20 -128.25 131.71 48.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.172 0.51 . . . . 0.0 111.603 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' TYR . . . . . 0.667 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -119.76 111.17 17.66 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.648 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.21 102.04 0.15 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.227 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 13.8 p -143.34 133.48 12.06 Favored Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.853 -178.597 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -48.51 139.35 23.3 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 123.486 2.791 . . . . 0.0 115.653 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.789 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -67.57 143.75 15.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 111.793 -2.458 . . . . 0.0 113.222 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.26 2.78 58.98 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.791 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -86.89 126.86 61.91 Favored Pre-proline 0 N--CA 1.447 -0.611 0 CA-C-O 119.253 -0.403 . . . . 0.0 109.978 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.13 126.18 19.53 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.022 1.815 . . . . 0.0 112.974 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.508 HG21 HD22 ' A' ' 90' ' ' LEU . 5.4 t -99.86 122.34 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.505 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 2.2 mpt_? -101.7 154.78 18.58 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 113.389 -1.732 . . . . 0.0 112.052 -178.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.35 124.32 25.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.265 -178.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.29 -18.45 24.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.66 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.26 144.2 2.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 110.388 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.466 ' OD1' ' HB2' ' A' ' 80' ' ' ALA . 7.6 p30 -60.03 157.45 12.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.978 179.159 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.13 -124.59 1.25 Allowed Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.781 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.2 m -147.83 143.37 27.42 Favored 'General case' 0 N--CA 1.436 -1.141 0 C-N-CA 123.594 0.758 . . . . 0.0 109.938 -177.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 99' ' ' SER . 9.8 t -86.94 113.06 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.819 0.848 . . . . 0.0 108.826 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -95.06 -15.02 23.76 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.621 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -154.48 139.6 17.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.221 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.29 92.33 1.94 Allowed 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.894 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . 0.485 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -96.36 92.36 1.38 Allowed Glycine 0 C--O 1.239 0.443 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.488 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.512 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.6 m120 -71.49 122.57 20.67 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 123.914 0.886 . . . . 0.0 112.796 -179.301 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.582 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.59 -0.7 88.01 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-N 113.352 -1.749 . . . . 0.0 113.358 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.41 -32.7 48.81 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.32 27.62 2.56 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.744 -178.526 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.573 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.58 113.85 40.62 Favored Pre-proline 0 N--CA 1.435 -1.177 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -178.69 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.9 Cg_exo -66.74 162.59 36.71 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 123.371 2.714 . . . . 0.0 111.166 177.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.1 m95 -96.41 9.54 40.95 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.5 mtt -76.31 -44.66 35.88 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.239 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.538 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.19 11.46 10.86 Favored 'General case' 0 N--CA 1.441 -0.891 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.895 177.619 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.53 138.03 52.05 Favored 'General case' 0 C--N 1.359 0.994 0 C-N-CA 120.359 -0.536 . . . . 0.0 110.842 -179.317 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 11.6 mmt -143.16 -21.21 0.63 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.769 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -96.32 -28.9 14.28 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.97 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.434 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 109.01 -131.02 10.32 Favored Glycine 0 CA--C 1.52 0.387 0 O-C-N 123.767 0.667 . . . . 0.0 113.895 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.582 HD21 ' HA3' ' A' ' 61' ' ' GLY . 12.2 m-80 -79.23 144.13 34.65 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.613 0.765 . . . . 0.0 112.448 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -151.22 144.82 24.96 Favored 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.475 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.562 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -140.46 121.55 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.975 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.86 129.02 52.26 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.435 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 11.1 mt -141.02 151.18 20.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 113.145 -1.843 . . . . 0.0 110.863 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLN . . . . . 0.679 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 2.0 tt0 -100.37 115.76 30.75 Favored 'General case' 0 N--CA 1.436 -1.128 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.996 177.535 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.66 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -70.08 -177.46 1.37 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 114.347 1.24 . . . . 0.0 114.347 -178.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.466 ' HB2' ' OD1' ' A' ' 52' ' ' ASN . . . -63.45 -17.97 63.26 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 113.744 -1.571 . . . . 0.0 114.179 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.31 -11.78 20.92 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 123.444 0.465 . . . . 0.0 110.728 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.58 -7.43 46.18 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.81 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.477 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 9.2 ptt? -69.0 163.55 24.37 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 123.286 0.635 . . . . 0.0 111.715 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.489 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 63.4 m-70 -105.68 144.78 31.94 Favored 'General case' 0 N--CA 1.437 -1.084 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.986 -179.272 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.22 126.84 23.52 Favored 'General case' 0 N--CA 1.441 -0.916 0 O-C-N 123.633 0.583 . . . . 0.0 109.815 -179.519 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.38 154.27 16.86 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.531 178.618 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -140.94 98.48 3.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 104.338 -2.467 . . . . 0.0 104.338 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 173.68 6.79 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 86.3 m-70 65.68 24.35 11.58 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.577 1.151 . . . . 0.0 111.642 -178.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.575 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.2 mt -84.01 170.96 13.4 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.577 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.3 t -105.19 -13.82 15.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.7 tttp -166.82 158.15 12.56 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.749 0.785 . . . . 0.0 112.551 -178.321 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.822 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -126.06 147.43 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 113.602 -1.635 . . . . 0.0 110.87 179.014 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 t -111.26 -6.63 14.51 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.936 177.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.822 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -102.6 -175.24 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.035 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.736 -177.13 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.1 m -151.88 140.48 20.74 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.938 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -55.07 128.99 36.3 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.412 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 85.68 -4.92 0.84 Allowed 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.594 1.158 . . . . 0.0 112.001 179.07 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.481 ' O ' HG23 ' A' ' 55' ' ' VAL . 46.0 m -80.48 152.72 28.59 Favored 'General case' 0 C--N 1.347 0.457 0 CA-C-O 120.514 0.197 . . . . 0.0 110.739 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 p -85.06 145.1 27.84 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 178.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.7 168.2 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.333 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 74.5 tttt -139.64 148.98 43.2 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-N 114.493 -1.23 . . . . 0.0 109.803 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -57.94 138.89 55.42 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.231 -1.349 . . . . 0.0 111.421 -179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 76.78 -7.29 34.89 Favored Glycine 0 CA--C 1.517 0.165 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.093 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 38.9 tt0 -71.89 142.92 49.52 Favored 'General case' 0 CA--C 1.51 -0.593 0 C-N-CA 122.971 0.508 . . . . 0.0 110.131 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 32.9 mt -72.65 100.86 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.49 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.491 ' H ' HG13 ' A' ' 107' ' ' ILE . 1.0 OUTLIER -94.25 -3.99 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.952 -178.902 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 170.71 -168.37 41.46 Favored Glycine 0 N--CA 1.438 -1.212 0 CA-C-O 121.353 0.418 . . . . 0.0 112.752 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.575 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 34.0 m-85 -139.59 134.29 31.92 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 124.718 1.207 . . . . 0.0 108.023 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -56.61 150.49 15.5 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.477 0.711 . . . . 0.0 112.459 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.789 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -146.11 -171.11 15.26 Favored Glycine 0 C--N 1.347 1.152 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.526 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -143.86 43.1 1.46 Allowed 'General case' 0 N--CA 1.441 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 109.302 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.434 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 36.5 p . . . . . 0 CA--C 1.54 0.573 0 CA-C-N 115.109 -0.95 . . . . 0.0 112.868 -178.053 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.874 0 CA-C-O 119.617 -0.546 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 119' ' ' PRO . . . . . 0.594 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 23.0 Cg_exo -68.84 147.34 68.55 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.526 2.817 . . . . 0.0 112.268 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -149.45 158.44 44.18 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-O 122.313 1.054 . . . . 0.0 113.144 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.763 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 12.0 tp -120.47 125.09 47.02 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-N 112.51 -2.132 . . . . 0.0 109.402 179.359 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 19.1 t60 -110.88 111.01 21.85 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 114.854 -1.066 . . . . 0.0 109.832 178.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.53 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.49 112.59 22.48 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.635 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.0 tt0 -119.26 140.04 50.91 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.349 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' MET . . . . . 0.447 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 17.0 tpp -132.72 136.92 46.69 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.819 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.581 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.98 165.47 24.03 Favored Pre-proline 0 C--N 1.312 -1.048 0 CA-C-N 113.714 -1.585 . . . . 0.0 110.419 -178.213 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.6 Cg_endo -63.53 -178.55 0.52 Allowed 'Trans proline' 0 C--N 1.367 1.511 0 C-N-CA 122.949 2.433 . . . . 0.0 112.746 176.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ALA . . . . . 0.444 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -71.92 -27.46 62.84 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.205 176.245 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -156.75 101.38 1.99 Allowed Pre-proline 0 CA--C 1.504 -0.802 0 CA-C-N 114.25 -1.341 . . . . 0.0 108.741 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -72.34 163.43 38.67 Favored 'Trans proline' 0 N--CA 1.443 -1.441 0 C-N-CA 122.625 2.217 . . . . 0.0 116.633 -177.252 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.574 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.18 71.53 0.83 Allowed 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 112.421 -2.172 . . . . 0.0 107.275 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -63.47 14.91 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 114.266 -1.334 . . . . 0.0 112.421 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.574 ' H ' ' C ' ' A' ' 131' ' ' ASN . 2.0 mp0 -81.81 32.94 0.37 Allowed 'General case' 0 N--CA 1.445 -0.71 0 CA-C-O 122.13 0.967 . . . . 0.0 112.833 -178.456 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 72.41 128.76 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 125.792 1.637 . . . . 0.0 110.96 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.07 -48.7 0.6 Allowed Glycine 0 N--CA 1.437 -1.287 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.109 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.572 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.1 OUTLIER -150.51 -21.09 0.23 Allowed 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 179.558 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t 66.42 18.01 10.77 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.806 1.243 . . . . 0.0 108.121 -178.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.97 -11.56 14.63 Favored Glycine 0 N--CA 1.436 -1.315 0 CA-C-N 112.439 -2.164 . . . . 0.0 112.683 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ARG . . . . . 0.658 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -80.62 125.59 30.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.34 -175.79 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.029 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 5.0 p30 -76.65 137.85 66.81 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.584 ' HG3' HG11 ' A' ' 37' ' ' VAL . 76.5 Cg_endo -76.21 20.43 0.57 Allowed 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.21 2.606 . . . . 0.0 114.559 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 5.6 p -56.95 -24.99 56.98 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.154 0.982 . . . . 0.0 113.579 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -75.12 -23.71 73.51 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -95.53 -10.56 29.33 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.607 1.163 . . . . 0.0 110.668 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 142' ' ' PRO . 30.0 mm -107.16 -12.27 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.771 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.899 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.5 mtt . . . . . 0 N--CA 1.487 1.39 0 CA-C-O 120.608 0.242 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -91.54 139.83 30.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -137.08 135.49 7.7 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.575 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.7 p -98.36 145.49 26.65 Favored 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.703 0.296 . . . . 0.0 110.768 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -120.82 -42.13 2.53 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.37 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -108.58 143.62 37.37 Favored 'General case' 0 N--CA 1.464 0.266 0 O-C-N 123.332 0.395 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -108.74 163.75 12.99 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.068 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -85.87 158.07 20.04 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.276 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -89.26 -42.33 11.67 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.632 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 67.1 m80 -87.92 -45.82 9.92 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 123.241 0.338 . . . . 0.0 111.56 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.88 133.26 6.75 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.39 0.431 . . . . 0.0 112.837 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.28 161.6 14.34 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.879 0.371 . . . . 0.0 111.986 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.82 109.86 2.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.899 177.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.8 t -90.81 -0.83 57.83 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.365 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -94.58 137.86 33.17 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.637 0.732 . . . . 0.0 111.872 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 20.9 p -89.44 162.41 15.76 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.646 -1.615 . . . . 0.0 112.789 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.532 HH11 HG22 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -81.38 112.57 34.63 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.649 0.78 . . . . 0.0 111.64 -179.748 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.652 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.4 Cg_exo -66.16 -22.97 53.36 Favored 'Trans proline' 0 C--N 1.366 1.494 0 C-N-CA 122.8 2.333 . . . . 0.0 113.047 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.739 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.95 -171.96 3.07 Favored 'General case' 0 CA--C 1.508 -0.662 0 CA-C-O 122.509 1.147 . . . . 0.0 110.316 -179.695 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -127.58 -25.12 3.2 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 112.253 -2.248 . . . . 0.0 108.797 177.267 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.739 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.2 t -168.77 -168.83 0.92 Allowed 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.332 -1.304 . . . . 0.0 111.671 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.66 111.62 0.3 Allowed Glycine 0 C--N 1.32 -0.345 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.633 177.64 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.48 124.85 8.84 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-O 121.582 0.706 . . . . 0.0 112.578 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.718 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.97 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.476 0 CA-C-N 113.672 -1.604 . . . . 0.0 109.216 179.387 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.8 t -106.64 -27.87 10.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 112.781 -2.009 . . . . 0.0 110.929 178.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.63 -67.41 1.0 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.881 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.06 122.55 1.02 Allowed Glycine 0 N--CA 1.459 0.185 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.28 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.495 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -78.31 157.57 29.14 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -179.073 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 63.7 m-80 -56.94 32.04 0.0 OUTLIER 'General case' 0 C--O 1.24 0.556 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -177.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.98 1.31 48.66 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -102.18 85.3 0.7 Allowed Pre-proline 0 CA--C 1.545 0.788 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.8 Cg_exo -77.6 139.76 18.34 Favored 'Trans proline' 0 C--N 1.372 1.813 0 C-N-CA 122.81 2.34 . . . . 0.0 113.245 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.24 4.49 81.04 Favored Glycine 0 C--N 1.34 0.762 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.986 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -71.86 129.99 39.96 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.083 0.953 . . . . 0.0 111.089 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.684 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.63 6.15 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.351 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.91 -150.01 5.14 Favored Glycine 0 C--N 1.337 0.62 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.565 HG12 ' O ' ' A' ' 123' ' ' PHE . 8.8 p -131.93 150.12 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.725 0 C-N-CA 122.788 0.435 . . . . 0.0 110.23 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.741 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 84.7 m-20 -126.18 135.28 51.44 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.21 0.528 . . . . 0.0 111.977 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.652 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -126.39 108.11 10.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.541 -178.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.68 104.83 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.264 179.076 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.441 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 11.0 p -147.63 127.97 6.81 Favored Pre-proline 0 CA--C 1.551 0.989 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.908 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -49.48 141.84 24.76 Favored 'Trans proline' 0 C--N 1.369 1.608 0 C-N-CA 123.385 2.723 . . . . 0.0 115.375 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.768 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.3 140.81 18.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 111.891 -2.413 . . . . 0.0 113.401 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.38 2.62 53.79 Favored Glycine 0 N--CA 1.442 -0.952 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.09 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.3 m -85.96 126.12 66.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.37 126.79 23.11 Favored 'Trans proline' 0 C--N 1.372 1.802 0 C-N-CA 122.226 1.951 . . . . 0.0 113.15 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.599 HG21 HD22 ' A' ' 90' ' ' LEU . 10.2 t -100.95 122.35 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.848 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 41.2 mtt180 -101.86 154.06 19.27 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 113.044 -1.889 . . . . 0.0 111.881 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.27 119.62 17.76 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.578 -1.192 . . . . 0.0 110.57 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -65.9 -15.96 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.44 143.74 1.85 Allowed 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 123.411 0.684 . . . . 0.0 110.403 179.09 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -60.86 155.74 18.93 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.32 179.358 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.64 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.66 -127.17 1.52 Allowed Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.691 -0.686 . . . . 0.0 113.766 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 16.4 m -148.67 141.09 24.24 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 123.583 0.753 . . . . 0.0 109.875 -178.021 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 99' ' ' SER . 11.8 t -84.33 112.65 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 C-N-CA 123.78 0.832 . . . . 0.0 109.027 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -95.13 -15.03 23.67 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.684 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -155.85 139.67 16.19 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.766 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.69 92.36 1.99 Allowed 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.227 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.438 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.14 90.3 1.48 Allowed Glycine 0 C--O 1.24 0.524 0 CA-C-N 114.28 -1.327 . . . . 0.0 111.985 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.552 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.8 m120 -71.11 121.02 17.52 Favored 'General case' 0 C--N 1.344 0.369 0 O-C-N 124.818 0.952 . . . . 0.0 112.811 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.47 -0.77 87.8 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-N 113.318 -1.764 . . . . 0.0 113.459 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -33.11 58.01 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.56 22.32 2.71 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.22 -178.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.596 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.52 116.38 58.88 Favored Pre-proline 0 N--CA 1.435 -1.217 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -178.36 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.832 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 38.7 Cg_exo -67.61 162.87 37.3 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 123.577 2.851 . . . . 0.0 111.381 177.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 60.0 m95 -97.64 10.72 39.21 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.87 -44.97 30.0 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.544 -1.207 . . . . 0.0 110.194 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.525 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -120.3 11.42 11.51 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.714 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.832 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.1 m95 -128.66 141.9 51.2 Favored 'General case' 0 C--N 1.361 1.08 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.35 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.5 mmt -144.52 -28.22 0.49 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.202 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.74 -24.62 26.84 Favored 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.391 0.432 . . . . 0.0 112.075 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.636 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.27 -128.27 9.52 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 115.743 -0.662 . . . . 0.0 114.082 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 90' ' ' LEU . 8.6 m-80 -84.92 136.68 33.52 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.243 0.617 . . . . 0.0 112.067 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -150.33 147.05 27.14 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.16 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.646 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -140.14 120.63 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.467 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.36 128.21 54.81 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 177.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.5 mt -138.97 150.81 23.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 112.741 -2.027 . . . . 0.0 110.512 -176.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.64 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.3 tt0 -99.67 116.57 32.07 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.348 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.65 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.0 m-70 -68.31 -176.09 0.7 Allowed 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.536 -1.211 . . . . 0.0 114.215 -178.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.78 64.95 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 114.055 -1.43 . . . . 0.0 114.398 -177.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.438 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.1 OUTLIER -101.52 -9.06 21.37 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.881 0.372 . . . . 0.0 111.067 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.6 -6.68 45.23 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.057 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.8 ptt? -67.77 168.71 10.92 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 123.469 0.708 . . . . 0.0 111.367 179.067 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 -113.43 145.31 41.36 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.075 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.497 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.94 127.28 19.81 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-O 120.973 0.416 . . . . 0.0 110.29 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.646 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.96 154.97 16.9 Favored Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.546 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.457 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.9 m-85 -134.36 99.29 4.33 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 105.361 -2.089 . . . . 0.0 105.361 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.69 166.77 11.05 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 73.3 m80 65.74 41.25 4.0 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-N 114.628 -1.169 . . . . 0.0 111.743 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.599 HD22 HG21 ' A' ' 47' ' ' VAL . 9.3 mt -101.3 166.46 10.75 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.079 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.401 ' HB2' HG23 ' A' ' 43' ' ' VAL . 12.4 t -101.04 -14.88 17.64 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -168.26 160.47 11.55 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.727 0.775 . . . . 0.0 111.901 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.837 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.3 148.65 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 113.613 -1.631 . . . . 0.0 110.757 178.83 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 t -112.42 -5.96 14.05 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 114.517 -1.219 . . . . 0.0 110.071 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.837 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -104.44 -175.23 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.983 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.512 -177.134 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.2 m -155.46 144.07 20.43 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.009 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.537 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 4.2 m -55.23 129.22 37.47 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.62 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.43 -5.18 0.74 Allowed 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.63 1.172 . . . . 0.0 112.026 179.314 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 55' ' ' VAL . 29.6 m -81.3 148.8 29.24 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.51 145.63 28.01 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.425 178.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.49 167.69 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.248 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.36 -179.216 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.9 tttm -140.36 147.39 39.72 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.821 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.23 137.93 55.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.226 -1.352 . . . . 0.0 111.483 -179.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.8 -4.43 52.48 Favored Glycine 0 CA--C 1.517 0.175 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.078 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.6 tt0 -74.36 139.0 43.81 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.183 0.516 . . . . 0.0 110.004 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 54.5 mt -71.35 101.53 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.118 0 CA-C-N 114.717 -1.128 . . . . 0.0 109.512 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.44 -4.74 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.149 -178.925 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.92 -160.82 34.6 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 112.302 -0.319 . . . . 0.0 112.302 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 30.3 m-85 -139.45 139.1 36.95 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 124.478 1.111 . . . . 0.0 108.327 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.402 HG23 HG22 ' A' ' 47' ' ' VAL . 0.8 OUTLIER -60.37 152.57 24.99 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.472 0.709 . . . . 0.0 112.117 -179.136 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.768 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -158.06 -163.33 12.62 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.961 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.642 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 48.16 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 114.632 -0.784 . . . . 0.0 109.074 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.636 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 33.6 p -78.48 2.5 18.77 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -89.18 -97.49 1.04 Allowed Glycine 0 C--N 1.34 0.759 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.9 mt-30 -101.89 147.0 27.04 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.6 m -89.01 97.42 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 112.029 -178.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 36.0 p -146.78 -52.98 0.23 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.084 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.24 142.92 7.49 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.832 -0.982 . . . . 0.0 111.808 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.642 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.6 Cg_exo -71.55 144.67 45.4 Favored 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.593 2.196 . . . . 0.0 112.098 179.585 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.441 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 56.1 p-80 -160.77 -172.99 3.71 Favored 'General case' 0 C--N 1.349 0.565 0 CA-C-O 121.515 0.674 . . . . 0.0 111.636 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.741 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.8 tp -125.51 136.25 53.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.779 -178.395 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 31.8 t60 -116.36 122.96 46.4 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.43 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.565 ' O ' HG12 ' A' ' 37' ' ' VAL . 50.0 t80 -127.25 107.57 10.11 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.264 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' THR . 13.4 pt-20 -115.33 127.37 55.38 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.548 178.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.4 tpt -121.17 136.73 54.92 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.726 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.633 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -142.26 164.99 30.06 Favored Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 113.394 -1.73 . . . . 0.0 110.381 -178.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -64.09 -178.43 0.61 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.994 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.16 -27.26 62.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.004 176.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.34 102.54 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.784 0 CA-C-N 114.09 -1.414 . . . . 0.0 108.869 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.26 163.18 39.45 Favored 'Trans proline' 0 N--CA 1.445 -1.349 0 C-N-CA 122.671 2.248 . . . . 0.0 116.937 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.577 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.96 70.76 0.81 Allowed 'General case' 0 N--CA 1.425 -1.702 0 CA-C-N 112.229 -2.26 . . . . 0.0 107.392 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.5 m-90 -62.9 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 114.291 -1.322 . . . . 0.0 112.435 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.577 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.81 33.72 0.38 Allowed 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 124.209 1.003 . . . . 0.0 112.783 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 11.0 m-80 71.95 128.2 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.627 0 C-N-CA 125.571 1.548 . . . . 0.0 110.666 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.33 -48.49 0.6 Allowed Glycine 0 N--CA 1.438 -1.178 0 CA-C-N 115.104 -0.953 . . . . 0.0 113.068 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.78 -19.58 0.22 Allowed 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 37.9 m 65.67 18.01 11.07 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-O 122.778 1.275 . . . . 0.0 108.108 -178.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.633 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 78.26 -11.57 23.05 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 112.237 -2.256 . . . . 0.0 112.47 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.684 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -85.07 124.43 31.75 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 112.056 -179.24 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.456 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -127.19 -172.87 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.8 m-20 -72.47 131.8 84.35 Favored Pre-proline 0 CA--C 1.547 0.844 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -176.397 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.619 ' O ' HG12 ' A' ' 146' ' ' ILE . 4.5 Cg_exo -77.58 -1.63 11.8 Favored 'Trans proline' 0 C--N 1.379 2.148 0 C-N-CA 123.265 2.643 . . . . 0.0 113.492 177.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.1 p -51.48 -24.25 4.89 Favored 'General case' 0 C--N 1.349 0.58 0 N-CA-C 114.134 1.161 . . . . 0.0 114.134 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.94 -24.56 75.75 Favored Glycine 0 CA--C 1.521 0.431 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.927 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -103.56 -10.33 18.55 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 123.465 0.706 . . . . 0.0 111.343 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.619 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -99.81 -10.96 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.454 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -74.18 -26.45 60.29 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.699 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 16.62 25.46 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.313 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.638 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -94.88 167.99 12.02 Favored Pre-proline 0 N--CA 1.419 -2.005 0 CA-C-N 113.694 -1.593 . . . . 0.0 112.432 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.638 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 13.1 Cg_endo -54.93 178.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 124.43 3.42 . . . . 0.0 113.872 179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.82 132.76 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.279 -177.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -101.67 97.72 8.1 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 113.733 -1.576 . . . . 0.0 109.057 178.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 68.52 -37.83 0.36 Allowed 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 124.149 0.98 . . . . 0.0 113.095 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 117.2 92.02 1.61 Allowed Glycine 0 C--N 1.338 0.687 0 N-CA-C 112.053 -0.419 . . . . 0.0 112.053 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 17.4 p -95.0 105.39 17.31 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 123.18 0.592 . . . . 0.0 110.936 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 18.0 p -95.35 143.36 25.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.201 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -83.51 -37.46 0.16 Allowed 'Trans proline' 0 C--N 1.374 1.885 0 C-N-CA 122.485 2.123 . . . . 0.0 113.11 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.603 HG23 ' H ' ' A' ' 159' ' ' GLU . 8.8 t -163.26 -62.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.812 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.603 ' H ' HG23 ' A' ' 158' ' ' THR . 31.3 mt-10 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 114.161 -1.381 . . . . 0.0 111.368 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.8 mtm . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.539 0.209 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 61.7 mtt180 -86.75 147.69 25.74 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.31 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -140.34 -58.57 0.04 OUTLIER Glycine 0 C--N 1.337 0.623 0 O-C-N 123.648 0.592 . . . . 0.0 112.672 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.0 m -95.94 150.4 20.49 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 122.423 0.289 . . . . 0.0 111.078 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.7 t-80 -123.57 -44.87 2.09 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 71.3 m-70 -118.46 147.87 43.17 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.417 0.448 . . . . 0.0 110.765 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -110.18 139.38 45.39 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.304 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -113.76 -44.68 3.16 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.242 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -116.98 145.49 43.62 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.389 0.431 . . . . 0.0 110.996 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 5.5 m80 -104.84 148.8 26.25 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.32 2.28 Favored Glycine 0 C--N 1.338 0.668 0 CA-C-N 116.036 -0.529 . . . . 0.0 113.26 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.12 161.14 13.79 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 120.894 0.378 . . . . 0.0 111.944 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -160.17 108.26 1.67 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.752 176.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.5 t -91.0 -13.75 32.72 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.18 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -96.91 122.57 40.02 Favored 'General case' 0 CA--C 1.503 -0.829 0 CA-C-O 121.644 0.735 . . . . 0.0 112.039 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 27.3 p -98.37 155.15 17.36 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.922 -178.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.24 111.82 39.21 Favored Pre-proline 0 CA--C 1.54 0.593 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.736 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.6 Cg_exo -70.66 -21.54 29.18 Favored 'Trans proline' 0 C--N 1.366 1.456 0 C-N-CA 122.531 2.154 . . . . 0.0 112.667 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.76 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.77 -171.92 3.04 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.699 1.238 . . . . 0.0 110.335 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.457 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.26 -24.78 2.8 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 112.082 -2.326 . . . . 0.0 108.625 177.292 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.76 ' H ' HD12 ' A' ' 19' ' ' LEU . 9.3 t -168.21 -168.94 1.01 Allowed 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.162 -178.054 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.26 112.25 0.28 Allowed Glycine 0 C--N 1.32 -0.342 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.036 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.21 125.49 9.38 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 113.328 0.862 . . . . 0.0 113.328 -177.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.751 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.56 58.31 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.455 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.066 179.197 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.6 t -102.7 -28.13 12.3 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 112.89 -1.959 . . . . 0.0 110.829 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -115.14 -67.2 1.01 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.606 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.3 123.18 1.06 Allowed Glycine 0 C--O 1.235 0.196 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.371 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.487 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -75.11 157.44 34.7 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -55.7 31.92 0.0 OUTLIER 'General case' 0 C--O 1.241 0.618 0 N-CA-C 115.816 1.784 . . . . 0.0 115.816 -177.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.71 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 0.09 48.93 Favored Glycine 0 CA--C 1.505 -0.551 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -101.72 85.43 0.66 Allowed Pre-proline 0 CA--C 1.545 0.763 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.71 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.7 Cg_exo -77.03 138.88 18.72 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.655 2.236 . . . . 0.0 113.239 -178.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.77 4.11 70.14 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-N 115.873 -0.603 . . . . 0.0 113.12 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.475 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.4 t-80 -75.51 128.41 35.24 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 123.927 0.891 . . . . 0.0 110.743 -179.381 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.644 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -99.74 -14.14 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.239 -179.923 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -126.04 -150.28 7.6 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.369 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 123' ' ' PHE . 7.2 p -128.71 151.86 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-N 115.025 -0.588 . . . . 0.0 109.775 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.662 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -125.39 130.64 52.31 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.263 0.554 . . . . 0.0 112.409 -178.444 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.736 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.7 m-85 -122.89 109.78 14.59 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.102 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.92 104.93 0.41 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.243 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.541 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.0 p -145.55 124.43 6.66 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.01 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -48.95 141.79 21.13 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.386 2.724 . . . . 0.0 115.528 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.751 HG23 ' HA2' ' A' ' 111' ' ' GLY . 3.1 p -61.62 141.11 18.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 111.935 -2.393 . . . . 0.0 113.473 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.02 2.49 55.99 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.393 -0.821 . . . . 0.0 114.253 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.7 m -88.98 126.22 59.88 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-O 119.066 -0.492 . . . . 0.0 109.808 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.14 126.67 23.14 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.209 1.939 . . . . 0.0 113.074 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.641 HG21 HD22 ' A' ' 90' ' ' LEU . 4.3 t -98.28 121.51 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.083 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.623 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.9 mtp180 -102.02 151.23 22.39 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 113.088 -1.869 . . . . 0.0 111.584 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -70.76 122.02 19.08 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.232 -178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.2 t -69.08 -14.16 18.17 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.603 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.55 144.17 1.86 Allowed 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 123.447 0.699 . . . . 0.0 110.603 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -62.59 156.86 22.05 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.835 -1.075 . . . . 0.0 112.386 179.368 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.632 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.32 -128.14 1.68 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.725 -0.67 . . . . 0.0 113.652 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.449 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 11.9 m -148.24 140.89 24.52 Favored 'General case' 0 N--CA 1.439 -0.975 0 C-N-CA 123.759 0.824 . . . . 0.0 109.668 -178.116 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 99' ' ' SER . 12.1 t -83.78 112.58 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 123.721 0.809 . . . . 0.0 109.034 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 54' ' ' THR . 6.6 mmmt -95.09 -14.72 23.99 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.844 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -156.09 141.8 17.89 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.01 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.24 92.22 2.16 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.406 -1.27 . . . . 0.0 109.074 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.02 89.98 1.46 Allowed Glycine 0 C--O 1.239 0.447 0 CA-C-N 113.955 -1.475 . . . . 0.0 112.862 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.503 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -70.41 122.97 20.63 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.925 0.89 . . . . 0.0 112.866 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.578 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.93 -0.59 88.8 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-N 113.253 -1.794 . . . . 0.0 113.626 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.54 -33.2 54.25 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -138.44 30.18 2.39 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.467 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.578 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.66 111.83 24.33 Favored Pre-proline 0 N--CA 1.437 -1.091 0 N-CA-C 113.907 1.077 . . . . 0.0 113.907 -178.265 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 35.4 Cg_exo -68.71 162.62 40.38 Favored 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.738 2.958 . . . . 0.0 111.563 177.133 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -96.74 9.76 40.75 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 175.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 61.2 mtm -76.91 -43.56 35.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.342 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.539 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.8 11.24 11.1 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.857 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.1 151.24 50.0 Favored 'General case' 0 C--N 1.361 1.089 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.738 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 36.2 mtt -145.68 -36.88 0.27 Allowed 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.621 179.142 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -86.43 -23.46 26.05 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.45 0.469 . . . . 0.0 111.881 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.606 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.25 -118.65 6.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.69 -0.686 . . . . 0.0 114.045 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.536 HD21 ' HA3' ' A' ' 61' ' ' GLY . 7.3 m-80 -82.57 135.64 35.03 Favored 'General case' 0 C--O 1.236 0.384 0 C-N-CA 123.225 0.61 . . . . 0.0 112.49 -178.532 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.01 146.56 26.3 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.983 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.616 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -139.2 121.02 16.48 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.205 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.2 130.73 56.99 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.333 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 54' ' ' THR . 9.1 mt -141.01 151.02 20.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 112.587 -2.097 . . . . 0.0 110.206 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.632 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.2 tt0 -99.83 117.14 33.51 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 114.123 -1.399 . . . . 0.0 108.547 178.034 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.603 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.9 m-70 -69.99 -177.93 1.46 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.535 -1.211 . . . . 0.0 114.07 -179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.57 -17.46 64.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 113.791 -1.55 . . . . 0.0 113.752 -178.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -97.58 -13.27 21.7 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 123.38 0.425 . . . . 0.0 110.749 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.51 -5.98 44.89 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.811 179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.588 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 16.5 ptp -70.65 165.53 22.68 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 122.866 0.466 . . . . 0.0 111.416 179.447 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.431 ' O ' ' HA ' ' A' ' 125' ' ' MET . 65.6 m-70 -109.09 140.02 43.2 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.719 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -135.82 127.1 28.3 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-O 121.033 0.444 . . . . 0.0 110.391 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.616 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -103.85 155.31 17.74 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 114.839 -1.073 . . . . 0.0 111.63 178.569 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.568 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 6.4 m-85 -132.11 99.24 4.65 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.79 167.54 10.41 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 65.62 41.49 4.02 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.591 -178.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.641 HD22 HG21 ' A' ' 47' ' ' VAL . 11.6 mt -101.4 170.36 8.27 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.822 177.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.2 t -105.27 -15.67 14.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 122.952 0.157 . . . . 0.0 111.37 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -168.95 160.44 10.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.658 0.742 . . . . 0.0 111.85 -178.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.833 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.37 149.64 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.638 -1.619 . . . . 0.0 110.949 179.329 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.91 -5.38 13.21 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.247 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.833 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -107.22 -175.42 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.387 -176.921 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.6 m -154.31 144.54 22.04 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.908 -1.042 . . . . 0.0 109.101 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.63 128.9 36.87 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.741 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 87.47 -4.97 0.61 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.778 1.231 . . . . 0.0 111.837 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.466 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -81.67 148.13 29.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 110.44 -0.208 . . . . 0.0 110.44 178.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -83.9 145.85 28.37 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.385 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.82 168.38 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.449 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 73.6 tttt -142.18 148.55 38.4 Favored 'General case' 0 N--CA 1.427 -1.61 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.872 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.6 138.52 55.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.305 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.623 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.78 -4.6 51.7 Favored Glycine 0 CA--C 1.516 0.117 0 CA-C-N 114.431 -1.259 . . . . 0.0 114.166 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.7 tt0 -75.33 140.67 43.23 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.086 0.469 . . . . 0.0 109.933 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.36 100.86 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.586 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.7 -5.4 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 113.706 -1.588 . . . . 0.0 113.257 -178.982 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 -159.83 32.69 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 121.515 -0.374 . . . . 0.0 112.427 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.547 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 33.9 m-85 -140.37 138.48 34.85 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.572 1.149 . . . . 0.0 108.378 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.445 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -62.65 150.09 41.76 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.659 0.784 . . . . 0.0 112.46 -178.821 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.751 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.35 -164.95 14.33 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 119.884 -1.151 . . . . 0.0 114.153 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.3 52.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.606 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 38.8 p -80.88 1.49 30.58 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.248 -0.887 . . . . 0.0 113.355 -177.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.16 -162.89 23.77 Favored Glycine 0 C--N 1.337 0.59 0 C-N-CA 121.314 -0.469 . . . . 0.0 112.22 179.318 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.9 mt-30 -92.66 91.52 7.57 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-O 121.23 0.538 . . . . 0.0 110.885 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.4 m -152.01 167.44 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.97 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 p -89.69 -10.68 44.87 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.144 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -159.18 170.02 35.47 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.395 -0.669 . . . . 0.0 113.252 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.716 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 6.0 Cg_exo -79.42 146.77 19.69 Favored 'Trans proline' 0 C--N 1.373 1.854 0 C-N-CA 123.291 2.661 . . . . 0.0 112.529 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.541 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 38.1 p-80 -160.72 -166.69 1.67 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.528 0.68 . . . . 0.0 111.851 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.662 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 15.9 tp -129.47 137.92 51.12 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.064 -1.425 . . . . 0.0 110.313 -178.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.458 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 23.9 t60 -121.59 114.93 21.88 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.284 -1.326 . . . . 0.0 110.184 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 37' ' ' VAL . 22.7 t80 -119.01 107.79 13.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.182 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.559 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.0 pt-20 -112.82 127.52 56.19 Favored 'General case' 0 N--CA 1.432 -1.327 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.57 179.085 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.431 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 6.7 ttt -122.76 134.51 54.44 Favored 'General case' 0 N--CA 1.434 -1.255 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.152 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.625 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -141.69 164.73 32.73 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 113.271 -1.786 . . . . 0.0 110.113 -177.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -63.16 -178.57 0.45 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 122.889 2.393 . . . . 0.0 113.277 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -69.09 -28.92 66.93 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.975 176.171 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -157.84 103.45 1.77 Allowed Pre-proline 0 CA--C 1.503 -0.841 0 CA-C-N 114.008 -1.451 . . . . 0.0 108.798 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -72.03 163.22 39.46 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.612 2.208 . . . . 0.0 116.971 -176.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.573 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.5 69.62 0.77 Allowed 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 112.332 -2.213 . . . . 0.0 107.581 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -62.19 12.3 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 114.319 -1.31 . . . . 0.0 112.412 -178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.573 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.8 mp0 -81.76 33.15 0.37 Allowed 'General case' 0 N--CA 1.444 -0.77 0 C-N-CA 124.306 1.043 . . . . 0.0 112.811 -178.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 73.11 128.79 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 113.729 -1.578 . . . . 0.0 110.745 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.26 -48.41 0.6 Allowed Glycine 0 N--CA 1.439 -1.135 0 CA-C-N 114.971 -1.013 . . . . 0.0 112.964 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.588 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -152.21 -18.96 0.18 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 179.161 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.8 m 66.12 17.74 10.83 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 122.59 1.186 . . . . 0.0 108.224 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.625 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.3 -11.32 9.0 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 112.547 -2.115 . . . . 0.0 112.673 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.644 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.64 121.7 25.61 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 111.737 0.273 . . . . 0.0 111.737 -179.012 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.93 -172.93 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.441 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -79.34 128.64 74.86 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.656 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.7 Cg_exo -76.76 -3.21 13.52 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 122.934 2.423 . . . . 0.0 113.445 178.281 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.86 -23.49 2.84 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.69 -30.25 70.79 Favored Glycine 0 N--CA 1.461 0.342 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.472 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -104.24 -11.35 17.27 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 122.902 0.481 . . . . 0.0 111.685 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.656 HG12 ' O ' ' A' ' 142' ' ' PRO . 18.8 mm -96.34 -8.79 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.815 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -77.0 -21.0 55.35 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.173 177.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -102.23 15.3 29.54 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.384 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.686 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -89.7 168.94 13.64 Favored Pre-proline 0 N--CA 1.417 -2.086 0 CA-C-N 113.69 -1.596 . . . . 0.0 112.552 -179.179 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.686 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 13.0 Cg_endo -54.89 178.77 0.08 OUTLIER 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 124.478 3.452 . . . . 0.0 114.261 179.816 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.444 HG13 ' H ' ' A' ' 155' ' ' THR . 99.3 t -107.32 132.22 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 121.731 0.777 . . . . 0.0 111.473 -177.191 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -102.44 98.41 8.51 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.146 178.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 69.32 -38.58 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 124.118 0.967 . . . . 0.0 113.067 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 147.3 81.79 0.04 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.444 ' H ' HG13 ' A' ' 151' ' ' VAL . 11.1 p -91.09 105.21 17.65 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-O 121.512 0.673 . . . . 0.0 111.239 -179.31 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.6 p -98.83 127.15 36.21 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.442 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -81.79 -43.75 0.09 OUTLIER 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 122.271 1.981 . . . . 0.0 113.413 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.701 HG23 ' H ' ' A' ' 159' ' ' GLU . 7.3 t -163.11 -66.42 0.04 OUTLIER 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.279 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.701 ' H ' HG23 ' A' ' 158' ' ' THR . 9.6 mm-40 . . . . . 0 C--O 1.252 1.197 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.546 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 mtt . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 111.642 0.238 . . . . 0.0 111.642 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 50.5 mtt180 -105.71 -39.02 6.2 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 123.277 0.361 . . . . 0.0 111.411 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 104.47 51.75 0.9 Allowed Glycine 0 C--N 1.338 0.682 0 O-C-N 123.445 0.466 . . . . 0.0 112.808 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.2 t -123.14 136.16 54.66 Favored 'General case' 0 C--O 1.236 0.346 0 O-C-N 123.571 0.218 . . . . 0.0 110.627 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.7 p-80 -108.4 134.27 51.42 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.468 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 68.6 m-70 -124.41 -42.67 2.09 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.253 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -127.06 148.41 50.13 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.293 0.371 . . . . 0.0 111.442 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -127.98 134.0 49.23 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.602 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.3 p-80 -111.16 120.11 41.2 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.177 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 64.7 m80 -94.87 146.2 24.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.944 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 155.78 23.49 0.03 OUTLIER Glycine 0 C--N 1.337 0.634 0 CA-C-N 116.027 -0.533 . . . . 0.0 113.203 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.4 167.85 11.08 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.865 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -159.01 104.87 1.73 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.1 177.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.5 t -97.08 -25.87 15.19 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.951 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -98.98 138.44 36.08 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.437 0.637 . . . . 0.0 111.629 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 47.1 p -95.66 172.98 7.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 113.972 -1.467 . . . . 0.0 112.206 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.55 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.8 OUTLIER -83.99 112.73 42.97 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 123.791 0.836 . . . . 0.0 112.098 -179.533 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.693 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.0 Cg_exo -67.0 -24.04 45.92 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.699 2.266 . . . . 0.0 112.607 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.726 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.47 -171.95 2.89 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-O 122.402 1.096 . . . . 0.0 109.961 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.99 -25.41 3.04 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 112.452 -2.158 . . . . 0.0 108.532 177.091 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.726 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.5 t -169.39 -168.84 0.85 Allowed 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.593 -178.318 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.92 110.77 0.29 Allowed Glycine 0 C--N 1.317 -0.487 0 CA-C-N 114.513 -1.221 . . . . 0.0 111.171 176.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.41 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.16 124.84 8.4 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 112.829 0.677 . . . . 0.0 112.829 -178.313 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.99 58.58 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.995 -1.457 . . . . 0.0 109.097 178.551 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.3 t -104.54 -28.05 11.52 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 112.729 -2.032 . . . . 0.0 111.123 179.267 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -116.19 -66.7 1.06 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.648 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.29 122.98 1.04 Allowed Glycine 0 N--CA 1.459 0.201 0 CA-C-N 115.011 -0.995 . . . . 0.0 112.011 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.532 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -73.49 157.26 37.12 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -178.504 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -57.86 31.89 0.0 OUTLIER 'General case' 0 C--O 1.239 0.538 0 N-CA-C 115.821 1.786 . . . . 0.0 115.821 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -1.66 48.83 Favored Glycine 0 CA--C 1.504 -0.634 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.94 85.31 0.67 Allowed Pre-proline 0 CA--C 1.548 0.866 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.6 Cg_exo -77.97 139.2 17.14 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 122.823 2.349 . . . . 0.0 113.352 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.14 4.17 69.1 Favored Glycine 0 C--N 1.339 0.727 0 O-C-N 123.685 0.615 . . . . 0.0 112.997 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.44 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.0 t-80 -78.24 135.43 37.57 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.047 0.939 . . . . 0.0 110.497 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.595 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.32 -12.53 9.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.242 -179.35 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -125.87 -149.77 7.51 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 123' ' ' PHE . 14.4 p -129.82 152.88 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 O-C-N 123.892 0.407 . . . . 0.0 110.133 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.714 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 93.1 m-20 -129.32 131.97 47.03 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.24 0.543 . . . . 0.0 112.242 -178.483 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.693 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.5 m-85 -122.86 109.48 14.23 Favored 'General case' 0 C--O 1.238 0.5 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.165 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.86 104.26 0.18 Allowed 'General case' 0 CA--C 1.541 0.633 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.339 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.552 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.4 p -144.84 123.91 6.9 Favored Pre-proline 0 CA--C 1.549 0.934 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.855 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -49.02 142.7 19.54 Favored 'Trans proline' 0 C--N 1.371 1.737 0 C-N-CA 123.307 2.671 . . . . 0.0 115.423 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.676 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.09 141.01 17.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 111.582 -2.554 . . . . 0.0 113.619 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.53 2.73 55.45 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.552 -0.749 . . . . 0.0 114.341 177.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.1 m -88.01 123.46 68.78 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-O 119.146 -0.454 . . . . 0.0 109.932 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.24 127.11 24.9 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.328 2.019 . . . . 0.0 113.449 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.55 HG21 HD22 ' A' ' 90' ' ' LEU . 4.8 t -99.68 121.82 50.79 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.138 179.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.511 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 2.3 mpt_? -103.19 152.49 21.4 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 113.331 -1.759 . . . . 0.0 111.481 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -71.69 121.46 18.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.441 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.03 -15.64 19.96 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 112.775 0.658 . . . . 0.0 112.775 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.652 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.46 144.46 1.94 Allowed 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 123.462 0.705 . . . . 0.0 110.346 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -61.78 157.07 18.85 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 115.077 -0.965 . . . . 0.0 112.331 179.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.653 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.01 -127.15 1.54 Allowed Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.744 -0.662 . . . . 0.0 113.849 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.9 m -148.09 141.3 25.08 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 123.678 0.791 . . . . 0.0 109.683 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 99' ' ' SER . 11.3 t -83.49 111.66 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 123.719 0.808 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.7 mmmt -94.35 -15.72 24.13 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.726 -1.125 . . . . 0.0 110.643 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -153.9 140.01 18.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.041 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.53 92.33 2.15 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.906 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -95.05 89.87 1.23 Allowed Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.953 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.533 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.8 m120 -72.46 125.54 27.66 Favored 'General case' 0 C--N 1.346 0.418 0 C-N-CA 123.795 0.838 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.664 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -79.93 -0.66 85.94 Favored Glycine 0 CA--C 1.52 0.392 0 CA-C-N 113.354 -1.748 . . . . 0.0 113.389 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.11 -32.05 39.1 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 24.86 2.68 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.144 -178.392 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.664 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -79.45 113.88 40.59 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.418 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.808 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.4 Cg_exo -67.69 163.23 36.01 Favored 'Trans proline' 0 C--N 1.37 1.688 0 C-N-CA 123.729 2.953 . . . . 0.0 111.556 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 62.1 m95 -98.2 10.54 40.33 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 14.7 mmt -75.58 -44.55 42.6 Favored 'General case' 0 C--N 1.349 0.552 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.057 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.547 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -120.92 11.51 11.07 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.783 177.439 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.808 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.05 145.92 51.14 Favored 'General case' 0 C--N 1.359 1.005 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.701 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.9 tpt -145.56 -31.02 0.4 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.488 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.78 -23.44 24.08 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.551 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 101.71 -128.68 9.64 Favored Glycine 0 CA--C 1.522 0.48 0 O-C-N 123.543 0.527 . . . . 0.0 114.025 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.596 HD21 ' HA3' ' A' ' 61' ' ' GLY . 11.8 m-80 -78.8 138.84 38.39 Favored 'General case' 0 C--N 1.347 0.458 0 C-N-CA 123.381 0.672 . . . . 0.0 112.586 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.33 145.23 23.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.008 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.1 t -138.55 120.58 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.158 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.03 131.22 56.99 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.423 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 9.3 mt -141.02 150.91 20.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 112.695 -2.048 . . . . 0.0 110.2 -176.62 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.653 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.5 tt0 -97.72 116.49 30.03 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 113.984 -1.462 . . . . 0.0 108.294 178.06 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.652 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -69.17 -175.85 0.82 Allowed 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.561 -1.199 . . . . 0.0 114.159 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -64.97 -17.78 64.69 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 113.867 -1.515 . . . . 0.0 114.485 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.458 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.2 OUTLIER -101.79 -9.86 20.43 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-O 120.826 0.346 . . . . 0.0 111.128 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.78 -6.09 43.92 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.061 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.521 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.4 ptt? -68.92 168.4 13.7 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 123.712 0.805 . . . . 0.0 111.456 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.418 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 55.6 m-70 -112.55 142.7 44.81 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.024 -179.102 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.26 127.06 25.54 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-O 121.041 0.448 . . . . 0.0 110.022 179.706 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.49 154.59 17.1 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.629 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.506 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.1 m-85 -135.1 99.17 4.19 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.401 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -114.11 168.8 9.5 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.294 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 65.28 41.86 4.2 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 124.159 0.984 . . . . 0.0 111.44 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.55 HD22 HG21 ' A' ' 47' ' ' VAL . 11.0 mt -102.94 169.41 8.6 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.037 178.287 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.4 t -103.88 -16.47 15.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -167.32 162.37 14.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.801 0.81 . . . . 0.0 112.018 -178.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.825 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.9 OUTLIER -127.83 147.82 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.643 179.298 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -110.47 -6.8 14.84 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 114.402 -1.272 . . . . 0.0 109.899 178.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.825 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.73 -175.12 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.073 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.733 -176.89 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 6.9 t -154.18 148.44 25.95 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.79 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 m -58.5 128.98 39.88 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.622 -179.24 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 t70 86.96 -5.71 0.67 Allowed 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 124.634 1.174 . . . . 0.0 111.722 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.479 ' O ' HG23 ' A' ' 55' ' ' VAL . 31.7 m -79.82 149.63 30.96 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 122.272 0.229 . . . . 0.0 110.711 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -84.94 145.0 27.98 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.382 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -127.01 168.14 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.437 -179.22 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 42.9 tttm -140.5 149.58 42.66 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.844 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -58.17 138.59 56.07 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.383 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.511 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.64 -4.55 50.82 Favored Glycine 0 CA--C 1.517 0.185 0 CA-C-N 114.387 -1.278 . . . . 0.0 114.076 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.4 tt0 -75.2 140.57 43.38 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-O 121.086 0.47 . . . . 0.0 110.026 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 52.4 mt -72.11 101.46 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.64 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.59 -5.01 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-N 113.512 -1.676 . . . . 0.0 113.17 -178.86 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.65 -161.9 35.64 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.363 0.424 . . . . 0.0 112.571 178.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.2 m-85 -139.88 138.06 35.37 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 124.561 1.144 . . . . 0.0 108.339 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.3 150.53 39.05 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 123.913 0.758 . . . . 0.0 112.572 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.676 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -160.23 -161.54 11.51 Favored Glycine 0 C--N 1.348 1.232 0 C-N-CA 119.844 -1.17 . . . . 0.0 114.119 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.1 50.78 0.91 Allowed 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.632 -0.784 . . . . 0.0 108.99 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.551 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 32.6 p -78.99 5.96 10.47 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.137 -0.938 . . . . 0.0 113.094 -177.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -108.5 -160.6 20.14 Favored Glycine 0 C--N 1.338 0.641 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.154 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -96.95 91.46 5.62 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.309 0.576 . . . . 0.0 110.331 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.7 m -152.69 172.0 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.07 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 14.9 p -93.45 -14.22 27.0 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -179.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -155.6 166.47 32.82 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.351 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.637 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -77.71 145.67 23.18 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 123.111 2.54 . . . . 0.0 112.414 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.552 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 47.6 p-80 -159.71 -164.91 1.41 Allowed 'General case' 0 C--N 1.351 0.667 0 CA-C-O 121.68 0.753 . . . . 0.0 112.259 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.714 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 16.9 tp -129.7 133.41 47.04 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.433 -178.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.452 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 18.4 t60 -118.18 113.39 21.46 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.288 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.563 ' O ' HG12 ' A' ' 37' ' ' VAL . 37.9 t80 -119.04 108.94 15.34 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.303 -179.711 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 85' ' ' THR . 20.3 tt0 -117.3 127.15 53.79 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.197 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.426 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 1.9 tpt -118.13 139.81 50.7 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.646 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -143.98 165.46 24.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 CA-C-N 113.426 -1.715 . . . . 0.0 110.619 -177.579 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 14.1 Cg_endo -63.62 -178.68 0.55 Allowed 'Trans proline' 0 C--N 1.37 1.67 0 C-N-CA 122.842 2.361 . . . . 0.0 112.948 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.16 -27.33 63.47 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.085 176.341 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -157.44 101.95 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.77 0 CA-C-N 114.03 -1.441 . . . . 0.0 108.871 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -71.71 163.39 39.07 Favored 'Trans proline' 0 N--CA 1.446 -1.314 0 C-N-CA 122.711 2.274 . . . . 0.0 116.874 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.552 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -117.23 70.33 0.78 Allowed 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 112.532 -2.122 . . . . 0.0 107.649 177.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.5 m-90 -63.25 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 114.298 -1.319 . . . . 0.0 112.54 -178.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.552 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.63 33.35 0.36 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.122 0.969 . . . . 0.0 112.996 -178.15 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 73.26 127.46 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.583 0 C-N-CA 125.663 1.585 . . . . 0.0 110.598 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.31 -50.04 0.56 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.343 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.45 -18.92 0.24 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 179.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 39.5 m 66.01 17.74 10.87 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 122.473 1.13 . . . . 0.0 108.157 -178.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.564 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.07 -9.63 18.11 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 112.6 -2.091 . . . . 0.0 112.734 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.595 ' HG2' HG12 ' A' ' 35' ' ' VAL . 3.2 ppt_? -82.9 127.35 33.42 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 119.854 -0.738 . . . . 0.0 112.362 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -128.07 -173.14 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.629 179.179 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.4 m-20 -73.28 129.8 85.4 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.581 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.3 0.22 9.96 Favored 'Trans proline' 0 C--N 1.38 2.226 0 C-N-CA 122.954 2.436 . . . . 0.0 113.341 177.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.31 -23.78 6.39 Favored 'General case' 0 C--N 1.349 0.548 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.22 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.86 -25.59 74.56 Favored Glycine 0 CA--C 1.52 0.362 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.92 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -101.99 -11.67 18.75 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 123.248 0.619 . . . . 0.0 111.16 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.581 HG12 ' O ' ' A' ' 142' ' ' PRO . 20.8 mm -100.16 -9.76 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -75.71 -24.73 56.23 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.739 178.095 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -101.29 14.5 31.77 Favored 'General case' 0 N--CA 1.433 -1.28 0 CA-C-O 122.051 0.929 . . . . 0.0 109.042 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.555 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -94.41 164.5 19.87 Favored Pre-proline 0 N--CA 1.417 -2.115 0 CA-C-N 113.538 -1.665 . . . . 0.0 112.444 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.555 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 16.8 Cg_endo -55.51 178.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.366 1.473 0 C-N-CA 124.622 3.548 . . . . 0.0 114.08 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 86.8 t -109.04 127.04 66.02 Favored 'Isoleucine or valine' 0 C--N 1.341 0.237 0 CA-C-O 121.488 0.661 . . . . 0.0 111.193 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.55 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 38.2 t80 -104.27 97.92 7.8 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.022 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 68.78 -38.69 0.4 Allowed 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.315 1.046 . . . . 0.0 113.137 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 122.62 83.29 0.64 Allowed Glycine 0 C--N 1.337 0.631 0 N-CA-C 112.183 -0.367 . . . . 0.0 112.183 -179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.1 p -93.6 105.59 17.62 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 123.498 0.719 . . . . 0.0 111.226 -179.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 18.6 p -91.86 132.43 32.91 Favored Pre-proline 0 CA--C 1.54 0.56 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.729 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -83.16 -43.65 0.08 OUTLIER 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 122.295 1.996 . . . . 0.0 113.457 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.682 HG23 ' H ' ' A' ' 159' ' ' GLU . 6.4 t -159.94 -64.89 0.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.177 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.682 ' H ' HG23 ' A' ' 158' ' ' THR . 33.8 mt-10 . . . . . 0 C--O 1.249 1.049 0 CA-C-N 114.33 -1.305 . . . . 0.0 111.752 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 55.0 mtt . . . . . 0 N--CA 1.487 1.397 0 CA-C-O 120.701 0.286 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -92.64 131.86 37.38 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.216 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.34 -86.18 0.06 OUTLIER Glycine 0 C--N 1.336 0.552 0 O-C-N 123.664 0.602 . . . . 0.0 112.414 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.0 m -114.79 131.0 56.95 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.329 0.252 . . . . 0.0 110.849 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -131.11 -43.11 1.07 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.4 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.9 m-70 -121.09 -43.04 2.45 Favored 'General case' 0 C--O 1.236 0.363 0 O-C-N 123.347 0.404 . . . . 0.0 111.478 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -102.39 142.79 33.02 Favored 'General case' 0 C--O 1.235 0.316 0 O-C-N 123.329 0.393 . . . . 0.0 111.155 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.4 m80 -95.28 -43.76 7.91 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.073 179.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.9 m80 -117.08 126.56 53.03 Favored 'General case' 0 C--O 1.235 0.296 0 O-C-N 123.558 0.536 . . . . 0.0 110.464 179.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -126.05 140.09 52.88 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.703 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.66 42.87 1.74 Allowed Glycine 0 C--N 1.337 0.619 0 CA-C-N 116.064 -0.516 . . . . 0.0 112.59 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.12 169.24 13.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.942 0.401 . . . . 0.0 111.831 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.78 104.47 2.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.835 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 t -89.51 6.09 42.53 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-N 115.382 -0.827 . . . . 0.0 112.068 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -94.54 144.33 25.67 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-O 121.573 0.701 . . . . 0.0 111.434 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.6 p -92.82 179.91 5.33 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.116 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.716 HH11 HG22 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -63.28 113.0 8.07 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 124.596 1.158 . . . . 0.0 112.941 -179.548 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.701 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 20.1 Cg_exo -67.47 -21.21 46.95 Favored 'Trans proline' 0 C--N 1.368 1.589 0 C-N-CA 122.662 2.241 . . . . 0.0 112.344 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -138.72 -171.97 3.2 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.482 1.134 . . . . 0.0 110.104 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.69 -25.25 3.15 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 112.332 -2.213 . . . . 0.0 108.699 177.237 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.737 ' H ' HD12 ' A' ' 19' ' ' LEU . 8.5 t -168.99 -168.64 0.87 Allowed 'General case' 0 CA--C 1.546 0.808 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.525 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.401 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.4 111.18 0.29 Allowed Glycine 0 C--N 1.321 -0.281 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.483 177.116 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.57 124.41 8.56 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.472 0.653 . . . . 0.0 112.632 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.11 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.502 0 CA-C-N 113.949 -1.478 . . . . 0.0 109.255 178.79 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.9 t -106.46 -27.68 10.77 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 113.134 -1.848 . . . . 0.0 110.873 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.2 -67.26 1.01 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.721 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.51 123.94 1.14 Allowed Glycine 0 C--O 1.234 0.151 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.14 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.514 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.94 157.5 31.26 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.641 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -58.02 31.67 0.0 OUTLIER 'General case' 0 C--O 1.24 0.558 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -177.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.699 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 -0.88 48.61 Favored Glycine 0 CA--C 1.506 -0.484 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -101.6 85.55 0.67 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.699 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.07 137.89 15.86 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.807 2.338 . . . . 0.0 113.225 -178.589 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.41 4.07 71.29 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.149 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-80 -76.12 135.12 39.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.975 0.91 . . . . 0.0 110.37 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.678 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.68 -16.35 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.342 -179.021 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.54 -149.71 8.14 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 123' ' ' PHE . 10.6 p -131.33 151.03 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 124.031 0.489 . . . . 0.0 110.042 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.706 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 89.1 m-20 -125.96 134.19 51.59 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.323 0.582 . . . . 0.0 112.046 -178.634 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.701 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -124.71 110.07 13.91 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 114.244 -1.344 . . . . 0.0 110.251 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.49 104.64 0.23 Allowed 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.544 178.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.556 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 12.5 p -145.98 124.78 6.53 Favored Pre-proline 0 CA--C 1.551 0.996 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.887 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.01 142.02 20.94 Favored 'Trans proline' 0 C--N 1.37 1.694 0 C-N-CA 123.346 2.697 . . . . 0.0 115.261 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.726 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -61.39 140.15 19.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 111.848 -2.433 . . . . 0.0 113.615 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.64 54.61 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.418 -0.81 . . . . 0.0 114.36 177.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.9 m -87.32 125.37 65.99 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.257 -0.401 . . . . 0.0 109.952 179.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.34 127.69 26.57 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.291 1.994 . . . . 0.0 113.468 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.531 HG21 HD22 ' A' ' 90' ' ' LEU . 9.8 t -99.96 123.36 52.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.154 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 13.6 mtp180 -101.91 152.15 21.26 Favored 'General case' 0 N--CA 1.433 -1.302 0 CA-C-N 112.963 -1.926 . . . . 0.0 111.659 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.48 120.96 18.82 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.846 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.1 t -66.68 -15.78 19.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.881 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.617 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.82 143.59 1.67 Allowed 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.546 0.738 . . . . 0.0 110.355 179.111 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -60.36 155.42 18.04 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.234 -0.894 . . . . 0.0 112.206 179.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 170.32 -128.63 1.67 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.891 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.3 m -148.16 136.35 21.24 Favored 'General case' 0 N--CA 1.44 -0.968 0 C-N-CA 123.446 0.698 . . . . 0.0 110.33 -178.086 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 11.1 t -83.89 112.44 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.43 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.2 OUTLIER -98.09 -16.63 19.48 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.841 179.846 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -148.54 138.52 22.33 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.737 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.9 92.17 2.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.494 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.422 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.17 89.85 1.37 Allowed Glycine 0 C--O 1.24 0.478 0 CA-C-N 114.128 -1.396 . . . . 0.0 112.802 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.502 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -71.56 125.71 27.77 Favored 'General case' 0 C--N 1.345 0.395 0 C-N-CA 123.964 0.905 . . . . 0.0 112.517 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.655 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.26 -0.74 87.12 Favored Glycine 0 CA--C 1.52 0.349 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.375 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.69 -31.85 52.69 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.45 25.51 2.65 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.069 -178.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.655 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -80.6 112.93 35.62 Favored Pre-proline 0 N--CA 1.435 -1.2 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.16 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.833 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.0 Cg_exo -67.81 163.45 35.36 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.987 3.125 . . . . 0.0 111.821 177.395 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.0 m95 -96.79 8.82 43.44 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -75.2 -44.48 46.21 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.398 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.541 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.84 10.9 11.01 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.714 177.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.833 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -128.83 145.92 51.07 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.537 -178.92 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 32.8 mtt -146.19 -29.18 0.41 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.421 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.44 -24.79 24.05 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.677 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.626 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.6 -123.98 8.09 Favored Glycine 0 CA--C 1.519 0.315 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.753 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.526 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.2 m-80 -81.17 138.21 35.87 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 123.237 0.615 . . . . 0.0 111.95 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.55 148.16 27.67 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.343 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.61 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.4 t -140.23 122.13 15.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.065 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.34 127.6 53.85 Favored 'General case' 0 CA--C 1.494 -1.188 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.7 mt -139.19 150.96 22.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 112.548 -2.115 . . . . 0.0 110.404 -176.14 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.3 117.04 32.88 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.944 -1.48 . . . . 0.0 108.603 178.011 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.617 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.0 m-70 -67.27 -176.37 0.56 Allowed 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.48 -17.67 64.93 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 114.107 -1.406 . . . . 0.0 114.313 -177.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.72 -10.19 21.07 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.905 0.383 . . . . 0.0 110.956 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.76 -4.78 42.75 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.192 179.03 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.7 ptt? -69.04 171.1 8.68 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 123.512 0.725 . . . . 0.0 111.683 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.3 m170 -108.96 147.04 32.86 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.011 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -141.5 126.63 18.45 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.947 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.61 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -108.96 154.57 16.43 Favored Glycine 0 N--CA 1.439 -1.146 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.401 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.1 m-85 -136.77 99.35 4.02 Favored 'General case' 0 N--CA 1.437 -1.075 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.51 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.32 167.93 10.16 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 38.7 m80 65.75 40.69 4.22 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.779 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.531 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -100.93 169.98 8.6 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.76 177.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.5 t -106.38 -15.51 14.8 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 111.457 0.169 . . . . 0.0 111.457 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 6.8 tttt -167.95 156.87 9.4 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.618 0.723 . . . . 0.0 111.99 -178.037 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -120.84 148.83 23.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 113.844 -1.526 . . . . 0.0 110.72 178.917 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -112.01 -5.98 14.24 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.209 178.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.67 -175.1 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.088 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.683 -177.067 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.4 m -153.33 143.94 22.61 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 114.867 -1.061 . . . . 0.0 109.002 -178.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -56.47 126.61 27.26 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.184 -0.917 . . . . 0.0 111.785 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 t70 89.15 -4.77 0.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 124.807 1.243 . . . . 0.0 111.587 178.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.7 m -81.7 146.05 30.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 122.176 0.191 . . . . 0.0 110.588 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -82.64 145.83 29.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.215 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.93 167.9 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.48 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -140.09 147.38 40.19 Favored 'General case' 0 N--CA 1.428 -1.574 0 CA-C-N 114.417 -1.265 . . . . 0.0 109.836 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.1 138.8 54.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.128 -1.397 . . . . 0.0 111.693 -179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.69 -6.78 37.29 Favored Glycine 0 CA--C 1.517 0.156 0 CA-C-N 114.361 -1.291 . . . . 0.0 114.129 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.494 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 41.3 tt0 -73.11 140.23 46.98 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-O 121.104 0.478 . . . . 0.0 110.013 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.05 101.19 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.401 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.8 -5.44 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.88 0 CA-C-N 113.739 -1.573 . . . . 0.0 113.101 -178.867 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.3 -162.14 34.76 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-O 121.272 0.374 . . . . 0.0 112.683 178.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 24.6 m-85 -141.37 137.12 32.1 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 124.816 1.246 . . . . 0.0 108.272 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -61.35 151.46 32.12 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.615 0.766 . . . . 0.0 112.654 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.726 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.38 -162.17 11.41 Favored Glycine 0 C--N 1.347 1.185 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.798 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.619 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 47.72 0.89 Allowed 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -0.7 . . . . 0.0 109.261 178.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.626 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 34.4 p -80.21 3.17 21.61 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.213 -0.903 . . . . 0.0 113.292 -177.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -95.31 -96.35 1.72 Allowed Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -96.75 143.51 27.62 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.2 m -91.75 97.05 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.651 0.739 . . . . 0.0 111.901 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 37.6 p -147.06 -52.69 0.21 Allowed 'General case' 0 C--O 1.235 0.302 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.621 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.29 143.74 8.0 Favored Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.599 -1.112 . . . . 0.0 111.54 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.619 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.0 Cg_exo -69.8 141.95 46.43 Favored 'Trans proline' 0 C--N 1.374 1.912 0 CA-C-N 120.251 2.025 . . . . 0.0 111.725 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.556 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 53.2 p-80 -157.77 -171.56 3.59 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.495 0.664 . . . . 0.0 111.774 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.706 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 9.1 tp -125.23 139.85 53.36 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.099 -1.409 . . . . 0.0 110.565 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.571 ' HE2' ' HB2' ' A' ' 124' ' ' GLU . 29.1 t60 -118.32 128.54 54.75 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 113.706 -1.588 . . . . 0.0 107.845 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.528 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.5 t80 -133.0 111.26 10.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.571 ' HB2' ' HE2' ' A' ' 122' ' ' HIS . 18.0 tt0 -120.31 127.18 52.11 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.238 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.8 tpt -120.26 138.01 53.91 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.666 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.591 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.1 mp -143.6 164.68 29.13 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 113.439 -1.709 . . . . 0.0 110.298 -178.16 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -62.83 -178.81 0.43 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.943 2.429 . . . . 0.0 112.669 177.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -68.57 -27.82 66.41 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.206 176.195 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -157.35 107.93 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.781 0 CA-C-N 113.903 -1.498 . . . . 0.0 108.232 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -71.15 163.12 40.26 Favored 'Trans proline' 0 N--CA 1.445 -1.326 0 C-N-CA 122.347 2.031 . . . . 0.0 116.926 -176.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.568 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.89 70.82 0.8 Allowed 'General case' 0 N--CA 1.423 -1.805 0 CA-C-N 112.349 -2.205 . . . . 0.0 107.395 177.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -63.29 13.99 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.168 -1.378 . . . . 0.0 112.376 -178.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.568 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.23 32.3 0.33 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.269 1.027 . . . . 0.0 112.902 -178.361 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 72.21 127.96 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 125.737 1.615 . . . . 0.0 110.997 178.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.11 -48.08 0.61 Allowed Glycine 0 N--CA 1.437 -1.278 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.341 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.68 -19.52 0.16 Allowed 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.43 18.22 10.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 122.624 1.202 . . . . 0.0 108.19 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 79.77 -11.66 32.75 Favored Glycine 0 N--CA 1.434 -1.449 0 CA-C-N 112.252 -2.249 . . . . 0.0 112.648 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.678 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.8 OUTLIER -83.98 125.02 31.65 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.301 -179.434 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.439 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -125.24 -172.96 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.585 -0.734 . . . . 0.0 112.441 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 140' ' ' ILE . 2.9 t70 -75.82 134.77 71.63 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -176.391 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.596 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.9 Cg_endo -77.16 0.62 9.54 Favored 'Trans proline' 0 C--N 1.381 2.277 0 C-N-CA 123.082 2.521 . . . . 0.0 113.546 177.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -51.34 -24.08 4.32 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.69 -28.95 66.24 Favored Glycine 0 CA--C 1.521 0.45 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.912 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -99.71 -11.86 20.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 123.347 0.659 . . . . 0.0 111.194 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.716 HG22 HH11 ' A' ' 17' ' ' ARG . 31.2 mm -98.8 -10.47 8.78 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.372 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -74.74 -23.15 58.51 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.656 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.88 12.41 37.68 Favored 'General case' 0 N--CA 1.432 -1.362 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 146' ' ' ILE . . . -96.43 158.43 33.82 Favored Pre-proline 0 N--CA 1.418 -2.054 0 CA-C-N 114.077 -1.42 . . . . 0.0 112.746 -178.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -55.52 178.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.367 1.507 0 C-N-CA 124.517 3.478 . . . . 0.0 114.639 179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 88.6 t -104.43 134.92 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.791 -178.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.0 t80 -100.98 97.51 8.08 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 113.815 -1.538 . . . . 0.0 109.46 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 67.49 -35.43 0.26 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 124.423 1.089 . . . . 0.0 113.602 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 135.27 100.81 0.64 Allowed Glycine 0 C--N 1.339 0.711 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.111 -179.247 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 16.0 p -96.04 105.34 17.37 Favored 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 123.26 0.624 . . . . 0.0 111.23 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.9 p -94.2 152.5 40.34 Favored Pre-proline 0 CA--C 1.539 0.547 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.838 178.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_endo -84.37 -44.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.374 1.883 0 C-N-CA 122.394 2.063 . . . . 0.0 113.368 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.687 HG23 ' H ' ' A' ' 159' ' ' GLU . 6.7 t -160.75 -65.7 0.06 Allowed 'General case' 0 C--O 1.236 0.381 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.208 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.687 ' H ' HG23 ' A' ' 158' ' ' THR . 37.3 mt-10 . . . . . 0 C--O 1.249 1.044 0 CA-C-N 114.469 -1.241 . . . . 0.0 111.594 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 47.1 mtt . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.578 0.228 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 19.9 mtp180 -91.56 143.56 26.46 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.129 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 120.0 69.37 0.3 Allowed Glycine 0 C--N 1.338 0.66 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m -127.41 -51.14 1.39 Allowed 'General case' 0 C--O 1.235 0.322 0 O-C-N 123.642 0.26 . . . . 0.0 110.986 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 60.7 m80 -141.78 124.54 16.02 Favored 'General case' 0 N--CA 1.466 0.368 0 O-C-N 123.29 0.368 . . . . 0.0 111.049 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -138.89 148.6 43.84 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.892 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 67.9 m80 -102.14 146.64 27.66 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.945 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -137.45 -41.08 0.56 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.272 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.7 m-70 -120.1 -37.28 3.1 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -76.85 147.98 36.8 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 133.92 44.34 0.12 Allowed Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.793 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -120.99 167.79 12.21 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.18 101.42 1.74 Allowed 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.329 176.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.2 t -95.92 -4.24 43.8 Favored 'General case' 0 CA--C 1.542 0.67 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -178.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -90.1 120.32 31.18 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 121.8 0.809 . . . . 0.0 112.495 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.0 p -99.63 157.46 16.45 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 113.387 -1.733 . . . . 0.0 112.658 -178.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.491 HH11 HG22 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -86.75 112.55 47.77 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.255 0.622 . . . . 0.0 110.816 179.013 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.685 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 21.3 Cg_exo -66.6 -23.84 49.12 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 122.717 2.278 . . . . 0.0 112.951 178.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.753 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.56 -172.0 3.05 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 122.671 1.224 . . . . 0.0 110.375 -179.894 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -128.14 -25.22 3.03 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 112.144 -2.298 . . . . 0.0 108.742 177.213 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.753 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.3 t -168.62 -168.64 0.92 Allowed 'General case' 0 CA--C 1.548 0.87 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.781 -178.302 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 171.99 111.74 0.26 Allowed Glycine 0 C--N 1.318 -0.431 0 CA-C-N 114.661 -1.154 . . . . 0.0 111.441 178.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.16 124.97 9.12 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.729 0.776 . . . . 0.0 112.973 -178.496 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.763 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.75 58.34 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-N 113.393 -1.731 . . . . 0.0 109.122 179.38 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.9 t -105.15 -28.2 11.13 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 112.969 -1.923 . . . . 0.0 111.007 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.52 -67.15 1.02 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.774 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.73 122.64 1.03 Allowed Glycine 0 C--N 1.322 -0.196 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.144 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.51 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.17 157.6 32.57 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -178.795 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -57.14 32.12 0.0 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -177.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.706 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -0.02 49.06 Favored Glycine 0 CA--C 1.504 -0.624 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -102.16 85.42 0.72 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.706 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.5 Cg_exo -76.95 141.99 21.73 Favored 'Trans proline' 0 C--N 1.373 1.848 0 C-N-CA 122.826 2.351 . . . . 0.0 113.425 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.51 4.02 83.57 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.803 -0.635 . . . . 0.0 113.06 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.416 ' O ' HG21 ' A' ' 24' ' ' ILE . 3.3 t-80 -74.29 127.33 32.72 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.098 0.959 . . . . 0.0 110.697 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.753 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -102.72 5.45 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.656 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.86 -150.03 5.14 Favored Glycine 0 C--N 1.337 0.603 0 C-N-CA 121.526 -0.368 . . . . 0.0 112.257 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 123' ' ' PHE . 9.7 p -130.52 154.69 40.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 C-N-CA 122.97 0.508 . . . . 0.0 110.244 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.702 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -129.16 130.07 45.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.258 0.552 . . . . 0.0 111.914 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.685 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 3.4 m-85 -120.54 109.99 15.93 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.273 -178.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.3 104.15 0.15 Allowed 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.275 178.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.531 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.6 p -146.79 124.07 5.89 Favored Pre-proline 0 CA--C 1.55 0.974 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.76 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -49.0 142.97 18.81 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 123.4 2.733 . . . . 0.0 115.528 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.748 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.47 140.77 18.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 111.766 -2.47 . . . . 0.0 113.454 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.45 2.53 55.55 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 115.441 -0.8 . . . . 0.0 114.036 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -87.53 124.0 68.55 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-O 119.153 -0.451 . . . . 0.0 109.88 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.7 126.7 23.32 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.342 2.028 . . . . 0.0 113.272 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.602 HG21 HD22 ' A' ' 90' ' ' LEU . 5.8 t -99.55 121.12 49.83 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 CA-C-N 115.107 -0.951 . . . . 0.0 108.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.506 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 3.9 mpt_? -102.21 152.41 21.06 Favored 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 113.301 -1.772 . . . . 0.0 111.434 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.71 122.63 20.97 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.689 -1.141 . . . . 0.0 111.435 -178.408 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 24.6 t -69.42 -14.53 18.52 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.553 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.631 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.24 143.86 1.95 Allowed 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 123.491 0.716 . . . . 0.0 110.641 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -62.68 156.04 24.67 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 114.943 -1.026 . . . . 0.0 112.477 179.464 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.63 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.32 -127.61 1.57 Allowed Glycine 0 C--N 1.334 0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.551 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.7 m -148.08 141.45 25.26 Favored 'General case' 0 N--CA 1.436 -1.148 0 C-N-CA 123.598 0.759 . . . . 0.0 109.532 -178.272 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 10.6 t -83.63 112.81 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 O-C-N 123.907 0.755 . . . . 0.0 108.995 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 10.0 mmmt -94.93 -14.72 24.2 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.666 -1.152 . . . . 0.0 110.819 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -156.69 141.2 16.75 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.896 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.04 92.44 2.05 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.805 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.426 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.96 92.03 1.46 Allowed Glycine 0 C--O 1.241 0.533 0 CA-C-N 114.35 -1.295 . . . . 0.0 112.658 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.536 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -72.65 123.7 23.78 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.134 0.974 . . . . 0.0 112.744 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.623 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.62 -0.76 88.21 Favored Glycine 0 CA--C 1.519 0.342 0 CA-C-N 113.369 -1.741 . . . . 0.0 113.59 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -32.31 57.54 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.54 24.79 2.66 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.027 -178.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.623 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -81.08 114.05 45.81 Favored Pre-proline 0 N--CA 1.435 -1.211 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -178.182 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.837 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.4 Cg_exo -67.81 162.12 40.95 Favored 'Trans proline' 0 C--N 1.37 1.685 0 C-N-CA 123.727 2.952 . . . . 0.0 111.804 177.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 63.3 m95 -96.1 13.01 28.64 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 176.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 81.9 mtp -80.07 -42.51 23.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.785 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.537 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.4 pp -125.76 15.44 8.08 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.795 177.544 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.837 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.4 OUTLIER -137.29 108.59 6.85 Favored 'General case' 0 C--N 1.369 1.416 0 C-N-CA 120.022 -0.671 . . . . 0.0 112.612 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 16.8 ttm -113.05 -20.3 11.56 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.416 178.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -91.54 -26.5 18.73 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.581 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 102.78 -128.57 9.59 Favored Glycine 0 CA--C 1.519 0.335 0 O-C-N 123.703 0.627 . . . . 0.0 113.704 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.614 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.5 m-80 -83.25 138.55 33.54 Favored 'General case' 0 C--N 1.346 0.43 0 C-N-CA 123.113 0.565 . . . . 0.0 112.138 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -152.27 145.96 25.03 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.3 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.63 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.15 120.34 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.164 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.7 129.6 56.54 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.107 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' THR . 7.7 mt -139.19 150.81 22.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.328 -176.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.63 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -100.24 117.27 34.11 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.904 -1.498 . . . . 0.0 108.504 178.037 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.631 ' CE1' ' HB3' ' A' ' 51' ' ' ALA . 2.9 m-70 -68.74 -175.91 0.75 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.489 -1.232 . . . . 0.0 114.092 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.92 65.03 Favored 'General case' 0 N--CA 1.452 -0.369 0 CA-C-N 114.037 -1.438 . . . . 0.0 114.457 -177.493 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.65 -9.02 21.29 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 120.876 0.369 . . . . 0.0 110.99 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.71 -6.74 44.85 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.122 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.2 ptt? -67.09 170.48 6.85 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 123.461 0.704 . . . . 0.0 111.465 179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.437 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 70.5 m-70 -114.68 145.42 42.06 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 120.609 -0.436 . . . . 0.0 111.218 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.68 127.34 20.27 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.051 179.68 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.63 155.4 16.52 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.698 178.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.8 m-85 -134.54 99.46 4.36 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.478 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -112.38 168.02 9.97 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 112.689 0.625 . . . . 0.0 112.689 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 65.68 41.0 4.16 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.449 1.099 . . . . 0.0 111.736 -178.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.602 HD22 HG21 ' A' ' 47' ' ' VAL . 10.9 mt -102.14 167.93 9.7 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.039 178.061 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.7 t -104.57 -14.47 15.63 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.57 160.56 13.05 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.697 0.761 . . . . 0.0 111.861 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.836 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.16 149.17 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 113.563 -1.653 . . . . 0.0 110.83 179.045 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -112.56 -6.03 13.97 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.173 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.836 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.12 -175.28 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.006 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.642 -176.932 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.9 t -153.17 150.42 29.03 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.835 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.1 m -60.2 128.41 36.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.377 -179.102 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 85.49 -4.06 0.86 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.627 1.171 . . . . 0.0 111.674 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -79.83 148.88 31.2 Favored 'General case' 0 C--N 1.347 0.493 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.45 145.34 29.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.66 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.81 166.38 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.264 -179.271 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.7 tttp -141.5 148.48 39.5 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.916 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.65 138.23 55.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -179.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.506 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.88 -5.45 47.93 Favored Glycine 0 CA--C 1.518 0.242 0 CA-C-N 114.252 -1.34 . . . . 0.0 114.238 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 42.0 tt0 -74.5 140.35 44.48 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.024 0.44 . . . . 0.0 110.184 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 49.0 mt -71.54 101.65 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.668 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.58 -4.87 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.035 -179.02 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.11 -160.52 34.11 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-O 121.137 0.298 . . . . 0.0 112.47 178.578 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 28.5 m-85 -140.93 138.53 33.91 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.535 1.134 . . . . 0.0 108.377 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.11 151.9 29.83 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.625 0.77 . . . . 0.0 112.483 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.748 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.71 -164.1 13.46 Favored Glycine 0 C--N 1.346 1.124 0 C-N-CA 120.036 -1.078 . . . . 0.0 114.079 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.624 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 49.67 0.89 Allowed 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.734 -0.733 . . . . 0.0 109.076 178.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.581 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 25.5 p -80.48 1.38 29.57 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -102.14 -160.91 26.4 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.009 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLN . . . . . 0.408 ' O ' HG13 ' A' ' 116' ' ' VAL . 38.3 mt-30 -92.1 91.1 7.64 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.223 0.535 . . . . 0.0 110.657 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 115' ' ' GLN . 0.5 OUTLIER -159.89 165.43 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.865 -179.495 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 14.4 p -96.15 -15.59 22.01 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.358 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -138.68 155.99 23.95 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.096 -0.835 . . . . 0.0 113.176 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.624 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.8 Cg_exo -78.81 146.58 20.97 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.882 2.388 . . . . 0.0 112.087 179.152 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.531 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 54.3 p-80 -159.79 -167.24 1.93 Allowed 'General case' 0 C--N 1.347 0.459 0 CA-C-O 121.467 0.651 . . . . 0.0 111.851 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.702 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 11.1 tp -126.18 137.64 53.58 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.228 -1.351 . . . . 0.0 110.339 -178.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.478 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 28.5 t60 -117.44 126.35 52.49 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 113.895 -1.502 . . . . 0.0 108.287 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.532 ' O ' HG12 ' A' ' 37' ' ' VAL . 32.2 t80 -131.61 108.62 9.65 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.973 178.255 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.516 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.1 pt-20 -116.62 128.38 55.33 Favored 'General case' 0 N--CA 1.429 -1.49 0 CA-C-N 115.276 -0.874 . . . . 0.0 109.476 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.417 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 3.4 tpt -121.08 136.9 54.88 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.837 -179.415 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.628 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.11 165.52 25.47 Favored Pre-proline 0 C--N 1.309 -1.169 0 CA-C-N 113.352 -1.749 . . . . 0.0 110.3 -177.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.8 Cg_endo -63.57 -178.25 0.5 Allowed 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 123.055 2.503 . . . . 0.0 112.9 176.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.44 -28.3 63.88 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.01 176.15 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -157.03 102.61 1.92 Allowed Pre-proline 0 CA--C 1.503 -0.828 0 CA-C-N 114.218 -1.355 . . . . 0.0 108.771 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.73 163.34 37.47 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.555 2.17 . . . . 0.0 116.603 -177.077 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.565 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.41 71.51 0.84 Allowed 'General case' 0 N--CA 1.425 -1.693 0 CA-C-N 112.344 -2.207 . . . . 0.0 107.095 177.691 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.5 m-90 -63.44 14.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 114.239 -1.346 . . . . 0.0 112.463 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.565 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -82.05 35.52 0.43 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.042 0.937 . . . . 0.0 112.951 -178.197 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 73.06 127.11 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.488 0 C-N-CA 125.53 1.532 . . . . 0.0 110.52 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.41 -50.08 0.56 Allowed Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.396 -0.907 . . . . 0.0 113.353 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.598 ' CE1' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -151.87 -19.86 0.19 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.027 0.414 . . . . 0.0 111.527 179.177 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 137' ' ' SER . . . . . 0.402 ' H ' ' H ' ' A' ' 136' ' ' PHE . 27.5 m 65.78 18.01 11.02 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.885 1.274 . . . . 0.0 108.283 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.628 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.11 -11.19 12.45 Favored Glycine 0 N--CA 1.436 -1.305 0 CA-C-N 112.465 -2.152 . . . . 0.0 112.782 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.753 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -82.48 121.8 27.22 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.1 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.418 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -124.64 -172.79 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.355 179.416 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.418 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.9 p30 -79.76 132.05 62.28 Favored Pre-proline 0 CA--C 1.552 1.038 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -176.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.527 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.71 0.04 10.19 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.233 2.622 . . . . 0.0 114.204 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.36 -24.23 7.29 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -178.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -74.5 -23.25 75.92 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.899 179.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -101.12 -12.27 18.93 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 123.62 0.768 . . . . 0.0 111.169 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.527 HG12 ' O ' ' A' ' 142' ' ' PRO . 26.6 mm -101.72 -10.68 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.688 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -73.75 -24.19 59.84 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.84 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.95 14.29 32.38 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.848 0.833 . . . . 0.0 109.447 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.668 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -95.18 169.09 9.89 Favored Pre-proline 0 N--CA 1.417 -2.114 0 CA-C-N 113.846 -1.524 . . . . 0.0 112.314 -179.043 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.668 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 12.5 Cg_endo -54.91 178.77 0.08 OUTLIER 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 124.352 3.368 . . . . 0.0 113.955 179.56 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 88.3 t -110.22 133.0 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.325 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.433 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 47.5 t80 -101.92 97.43 7.79 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.23 178.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 67.07 -35.84 0.26 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 124.342 1.057 . . . . 0.0 113.452 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 119.47 74.88 0.44 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.1 p -90.88 105.37 17.78 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 123.282 0.633 . . . . 0.0 111.376 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.7 p -94.69 150.96 38.77 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.935 179.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -83.57 -35.73 0.23 Allowed 'Trans proline' 0 C--N 1.373 1.862 0 C-N-CA 122.472 2.115 . . . . 0.0 113.311 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.525 HG23 ' H ' ' A' ' 159' ' ' GLU . 10.0 t -163.07 -59.9 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.707 -1.133 . . . . 0.0 109.849 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.525 ' H ' HG23 ' A' ' 158' ' ' THR . 27.5 mt-10 . . . . . 0 C--O 1.249 1.066 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.575 179.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.508 0.194 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 -90.41 124.93 35.36 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.171 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 136.65 130.31 2.88 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.193 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 60.8 m -102.57 -45.37 5.07 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 111.666 0.247 . . . . 0.0 111.666 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.4 m80 -110.74 128.68 55.83 Favored 'General case' 0 C--O 1.235 0.306 0 O-C-N 123.261 0.351 . . . . 0.0 111.391 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -136.84 -46.59 0.59 Allowed 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.947 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -133.99 148.64 51.15 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.788 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -124.19 133.22 53.6 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.74 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.8 m80 -118.73 147.91 43.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.081 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -104.53 154.59 19.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.096 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.78 70.41 0.04 OUTLIER Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.101 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.07 162.14 14.81 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -179.139 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -160.98 118.46 2.37 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.03 176.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 11.3 t -89.45 -13.58 37.27 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -178.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -96.99 120.54 37.53 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.523 0.677 . . . . 0.0 111.823 -179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 31.9 p -99.66 144.52 28.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 113.988 -1.46 . . . . 0.0 112.379 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.62 111.88 26.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.401 179.442 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.66 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.7 Cg_exo -66.73 -24.36 47.55 Favored 'Trans proline' 0 C--N 1.366 1.478 0 C-N-CA 122.482 2.121 . . . . 0.0 112.27 178.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.749 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -139.57 -171.84 3.23 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 122.614 1.197 . . . . 0.0 110.213 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.466 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.02 -25.17 2.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 112.241 -2.254 . . . . 0.0 108.792 177.219 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.749 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.4 t -168.95 -168.48 0.86 Allowed 'General case' 0 CA--C 1.546 0.802 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.619 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.04 111.9 0.35 Allowed Glycine 0 C--N 1.319 -0.371 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.336 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.67 124.63 9.96 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 121.888 0.852 . . . . 0.0 112.8 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.733 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.05 58.57 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 113.173 -1.83 . . . . 0.0 108.965 178.944 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.8 t -102.47 -28.98 11.88 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.838 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -113.42 -67.91 0.97 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.6 125.03 1.2 Allowed Glycine 0 C--N 1.323 -0.172 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.037 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.5 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -77.08 157.32 31.14 Favored 'General case' 0 C--N 1.343 0.298 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -178.956 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -55.97 32.19 0.0 OUTLIER 'General case' 0 C--O 1.239 0.526 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.702 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.74 0.94 49.33 Favored Glycine 0 CA--C 1.504 -0.647 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -101.64 85.34 0.64 Allowed Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.0 Cg_exo -77.42 139.66 18.61 Favored 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.748 2.299 . . . . 0.0 113.247 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.19 4.22 78.06 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.007 179.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.437 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.1 t-80 -75.36 131.4 40.22 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 123.997 0.919 . . . . 0.0 110.458 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.642 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.46 -1.98 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.488 -179.315 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.98 -150.21 5.89 Favored Glycine 0 C--N 1.338 0.661 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.685 HG11 ' HG3' ' A' ' 142' ' ' PRO . 11.9 p -132.05 149.19 32.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 O-C-N 123.864 0.391 . . . . 0.0 110.618 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.777 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.72 134.0 51.92 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 121.322 0.582 . . . . 0.0 112.074 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.66 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -124.57 110.44 14.45 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.354 -1.294 . . . . 0.0 110.131 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.06 107.31 0.29 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 115.813 -0.63 . . . . 0.0 112.117 178.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.563 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.2 p -146.36 127.12 7.16 Favored Pre-proline 0 CA--C 1.549 0.929 0 CA-C-N 115.021 -0.99 . . . . 0.0 109.172 -179.343 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -55.78 143.6 80.15 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.259 2.639 . . . . 0.0 115.583 -178.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.756 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -62.63 139.26 21.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 111.79 -2.459 . . . . 0.0 113.472 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.9 2.66 55.08 Favored Glycine 0 N--CA 1.442 -0.942 0 CA-C-N 115.366 -0.834 . . . . 0.0 114.063 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.12 120.83 70.74 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.143 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.2 126.1 21.39 Favored 'Trans proline' 0 C--N 1.376 1.985 0 C-N-CA 122.431 2.087 . . . . 0.0 113.104 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.594 HG21 HD22 ' A' ' 90' ' ' LEU . 4.9 t -98.51 121.15 48.75 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.978 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 4.5 mpt_? -102.93 152.54 21.18 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 113.264 -1.789 . . . . 0.0 111.443 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -72.42 123.52 23.26 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.7 -1.136 . . . . 0.0 111.587 -178.063 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.9 t -65.83 -21.57 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 CA-C-N 115.597 -0.729 . . . . 0.0 112.613 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.646 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -167.69 143.99 4.13 Favored 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 123.184 0.593 . . . . 0.0 110.653 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -59.94 155.51 16.46 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.191 179.227 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.17 -126.37 1.4 Allowed Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.777 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.4 m -148.26 142.01 25.64 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 123.537 0.735 . . . . 0.0 109.971 -177.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 99' ' ' SER . 11.6 t -85.95 112.84 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 O-C-N 124.028 0.83 . . . . 0.0 108.921 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.6 mmmt -95.15 -14.79 23.84 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.596 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -154.21 140.09 18.19 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.243 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.13 92.37 2.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.781 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.463 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.18 89.87 1.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 114.141 -1.39 . . . . 0.0 113.368 -179.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.479 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -69.99 124.05 23.09 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.907 0.883 . . . . 0.0 112.552 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.574 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.39 -0.63 87.22 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-N 113.334 -1.757 . . . . 0.0 113.645 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.81 -32.14 46.18 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 26.93 2.57 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.978 -178.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.57 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.86 115.87 57.03 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -178.28 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.1 Cg_exo -69.49 162.89 40.14 Favored 'Trans proline' 0 C--N 1.37 1.704 0 C-N-CA 123.765 2.976 . . . . 0.0 111.469 177.028 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -98.73 12.36 35.77 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.072 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.2 mtt -78.36 -44.08 25.98 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.539 -1.209 . . . . 0.0 110.149 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.518 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -119.88 10.69 11.63 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.793 177.411 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.48 146.31 50.85 Favored 'General case' 0 C--N 1.362 1.151 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.782 -179.01 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 46.1 mtt -139.37 -36.17 0.53 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.443 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -88.79 -21.02 23.99 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.413 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 95.12 -112.81 4.46 Favored Glycine 0 C--N 1.335 0.488 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.12 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.574 HD21 ' HA3' ' A' ' 61' ' ' GLY . 13.7 m-80 -80.37 135.7 36.23 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.182 0.593 . . . . 0.0 112.528 -178.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -149.18 146.31 27.58 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.228 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.32 122.01 17.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.094 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.5 129.92 54.95 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 177.509 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -141.08 150.87 20.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 CA-C-N 112.942 -1.935 . . . . 0.0 110.497 -176.187 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.48 116.05 30.74 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.277 177.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.646 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.3 m-70 -68.6 -177.76 1.01 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.528 -1.215 . . . . 0.0 114.121 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.59 -17.37 64.53 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.824 -178.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.58 -12.21 21.4 Favored 'General case' 0 C--O 1.236 0.388 0 O-C-N 123.415 0.447 . . . . 0.0 110.732 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.63 -6.57 45.02 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.118 -0.947 . . . . 0.0 112.035 178.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.455 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 12.1 ptt? -71.45 164.69 25.31 Favored 'General case' 0 N--CA 1.436 -1.154 0 C-N-CA 123.135 0.574 . . . . 0.0 111.772 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.455 ' O ' ' HA ' ' A' ' 125' ' ' MET . 53.0 m-70 -105.61 142.78 34.75 Favored 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.121 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.07 127.17 26.07 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.41 154.45 16.82 Favored Glycine 0 N--CA 1.442 -0.967 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.699 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -137.23 98.65 3.78 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.442 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -116.11 170.42 8.52 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 65.59 38.1 5.62 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.339 1.056 . . . . 0.0 111.137 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.594 HD22 HG21 ' A' ' 47' ' ' VAL . 11.3 mt -97.94 170.11 9.17 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.966 178.133 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 17.3 t -104.14 -15.28 15.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 111.465 0.172 . . . . 0.0 111.465 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 9.0 tttt -168.46 159.55 10.44 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.696 0.76 . . . . 0.0 112.204 -178.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.821 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -124.38 148.98 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 113.541 -1.663 . . . . 0.0 110.862 178.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.53 -5.05 13.45 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.213 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.821 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.08 -175.33 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.074 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.553 -177.049 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.6 t -152.23 149.45 28.73 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.841 -179.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -60.32 127.9 34.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.496 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 85.39 -3.61 0.86 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.508 1.123 . . . . 0.0 111.673 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.478 ' O ' HG23 ' A' ' 55' ' ' VAL . 40.1 m -79.98 148.95 30.96 Favored 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 122.299 0.24 . . . . 0.0 110.415 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.6 p -83.19 145.68 29.04 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.491 178.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.21 167.66 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.297 0 CA-C-N 115.302 -0.863 . . . . 0.0 112.324 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.418 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.0 tttm -141.33 147.98 38.97 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.957 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.81 137.49 56.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.378 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.94 -5.64 47.07 Favored Glycine 0 CA--C 1.519 0.334 0 CA-C-N 114.285 -1.325 . . . . 0.0 114.112 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.498 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 41.4 tt0 -73.87 139.66 45.17 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.108 0.48 . . . . 0.0 110.143 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 57.8 mt -70.94 101.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.62 -179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.8 OUTLIER -93.72 -4.12 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.61 -1.632 . . . . 0.0 112.937 -179.125 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.49 -161.3 35.11 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-O 121.228 0.349 . . . . 0.0 112.737 178.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.572 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.0 m-85 -141.5 136.92 31.69 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 124.834 1.253 . . . . 0.0 108.341 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.408 HG23 HG22 ' A' ' 47' ' ' VAL . 2.1 p -60.43 152.73 24.83 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.423 0.689 . . . . 0.0 112.08 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.756 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -155.82 -165.44 14.44 Favored Glycine 0 C--N 1.345 1.048 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.915 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -149.77 45.13 0.93 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.565 -0.818 . . . . 0.0 108.953 178.5 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.3 p -77.88 2.74 16.37 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.636 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -106.3 -165.48 22.89 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.134 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -87.82 91.71 8.85 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-O 121.445 0.64 . . . . 0.0 110.046 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.488 HG22 ' H ' ' A' ' 118' ' ' GLY . 9.6 p -158.47 161.86 1.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.25 -178.674 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 19.0 p -90.92 -16.33 28.3 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.962 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.488 ' H ' HG22 ' A' ' 116' ' ' VAL . . . -144.93 159.2 27.82 Favored Glycine 0 CA--C 1.529 0.935 0 CA-C-O 119.125 -0.82 . . . . 0.0 112.682 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.584 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -73.88 146.35 37.52 Favored 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 122.93 2.42 . . . . 0.0 111.916 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.563 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 26.4 p80 -157.66 -169.7 2.95 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-O 121.547 0.689 . . . . 0.0 112.401 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.777 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.0 tp -126.4 131.81 51.66 Favored 'General case' 0 N--CA 1.432 -1.34 0 CA-C-N 114.049 -1.432 . . . . 0.0 111.166 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 24.8 t60 -114.01 110.08 19.48 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.088 177.829 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.54 ' O ' HG12 ' A' ' 37' ' ' VAL . 23.1 t80 -117.08 109.23 16.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.364 -179.388 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.1 tt0 -116.22 127.06 54.44 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.208 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.455 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 2.5 ttt -118.62 134.7 54.91 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.679 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.4 mp -142.31 166.6 20.21 Favored Pre-proline 0 C--N 1.31 -1.14 0 CA-C-N 113.297 -1.774 . . . . 0.0 111.004 -177.125 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.5 Cg_endo -63.32 -178.44 0.47 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 123.027 2.484 . . . . 0.0 112.851 176.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -72.62 -27.06 61.92 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.194 176.315 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.29 98.84 1.96 Allowed Pre-proline 0 CA--C 1.503 -0.835 0 CA-C-N 114.206 -1.361 . . . . 0.0 109.314 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -71.1 163.37 39.44 Favored 'Trans proline' 0 N--CA 1.445 -1.377 0 C-N-CA 122.868 2.379 . . . . 0.0 116.532 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.2 t-20 -116.76 70.56 0.77 Allowed 'General case' 0 N--CA 1.425 -1.691 0 CA-C-N 112.579 -2.101 . . . . 0.0 107.24 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -62.99 13.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 114.351 -1.295 . . . . 0.0 112.412 -178.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.8 mp0 -81.76 35.27 0.41 Allowed 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 124.196 0.998 . . . . 0.0 113.083 -178.109 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 73.32 126.29 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 125.509 1.523 . . . . 0.0 110.727 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.5 -50.18 0.56 Allowed Glycine 0 N--CA 1.442 -0.902 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.482 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.559 ' CE2' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -152.43 -19.73 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 117.102 0.451 . . . . 0.0 111.432 179.257 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 30.1 t 66.45 18.13 10.78 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.034 1.334 . . . . 0.0 108.411 -178.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.559 ' HA2' ' CE2' ' A' ' 136' ' ' PHE . . . 77.7 -11.04 21.43 Favored Glycine 0 N--CA 1.436 -1.334 0 CA-C-N 112.66 -2.063 . . . . 0.0 112.8 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.642 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -81.45 127.18 32.52 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 120.081 -0.648 . . . . 0.0 112.117 -179.19 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -126.93 -174.34 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.337 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.033 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -70.34 134.7 86.84 Favored Pre-proline 0 CA--C 1.544 0.731 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.618 -178.126 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.685 ' HG3' HG11 ' A' ' 37' ' ' VAL . 95.4 Cg_endo -76.7 21.64 0.56 Allowed 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 123.162 2.575 . . . . 0.0 114.081 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.9 p -56.04 -24.63 40.69 Favored 'General case' 0 C--N 1.344 0.349 0 C-N-CA 124.228 1.011 . . . . 0.0 113.308 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.52 -23.78 77.35 Favored Glycine 0 N--CA 1.462 0.427 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -96.2 -9.7 29.85 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.655 1.182 . . . . 0.0 110.43 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 142' ' ' PRO . 21.1 mm -104.93 -12.47 9.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.841 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -78.36 -27.96 47.03 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 123.133 0.573 . . . . 0.0 112.271 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -109.54 17.54 21.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 114.546 -1.207 . . . . 0.0 109.108 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -94.34 144.78 28.56 Favored Pre-proline 0 N--CA 1.417 -2.1 0 CA-C-N 113.706 -1.588 . . . . 0.0 112.85 -178.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -57.8 178.93 0.16 Allowed 'Trans proline' 0 C--N 1.362 1.256 0 C-N-CA 124.661 3.574 . . . . 0.0 114.464 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.6 t -97.09 132.46 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 123.872 0.869 . . . . 0.0 111.786 -177.223 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -101.11 97.36 7.91 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.288 -1.778 . . . . 0.0 109.126 178.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 7.6 m-80 66.41 -33.13 0.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 124.221 1.009 . . . . 0.0 113.628 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 141.11 71.2 0.03 OUTLIER Glycine 0 C--N 1.338 0.68 0 N-CA-C 111.616 -0.593 . . . . 0.0 111.616 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.8 p -91.39 104.87 17.34 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 123.244 0.618 . . . . 0.0 111.622 -178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.6 p -113.98 139.95 24.24 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 114.567 -1.197 . . . . 0.0 110.472 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -82.58 -45.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.22 1.947 . . . . 0.0 113.302 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.744 HG23 ' H ' ' A' ' 159' ' ' GLU . 5.3 t -162.72 -67.97 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.163 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.744 ' H ' HG23 ' A' ' 158' ' ' THR . 7.1 mm-40 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.487 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.6 mtt . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 120.604 0.24 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -94.33 125.59 39.06 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.102 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -167.9 87.81 0.1 OUTLIER Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.122 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 11.8 t -129.89 -34.99 1.67 Allowed 'General case' 0 N--CA 1.466 0.339 0 O-C-N 123.708 0.299 . . . . 0.0 111.602 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -89.48 -39.61 13.23 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.0 t-80 -97.33 134.47 40.56 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 123.303 0.377 . . . . 0.0 111.411 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -133.94 150.73 51.31 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.65 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -99.79 -47.46 5.05 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.661 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.3 m80 -130.81 145.26 51.92 Favored 'General case' 0 C--O 1.234 0.281 0 O-C-N 123.245 0.341 . . . . 0.0 111.276 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 4.5 t60 -137.77 -41.89 0.54 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.983 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.85 80.45 0.85 Allowed Glycine 0 C--N 1.341 0.855 0 O-C-N 123.334 0.396 . . . . 0.0 112.388 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -95.52 160.33 14.56 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.17 120.38 1.89 Allowed 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.423 176.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.5 t -89.44 -9.97 48.19 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.565 -179.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.71 128.67 49.33 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-O 121.524 0.678 . . . . 0.0 112.125 -179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.542 ' HB ' ' HD1' ' A' ' 152' ' ' PHE . 20.9 p -95.21 158.13 15.59 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 113.844 -1.526 . . . . 0.0 112.644 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.65 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.0 OUTLIER -97.83 114.34 64.88 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.656 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.762 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.7 Cg_exo -71.61 -20.61 26.64 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.65 2.233 . . . . 0.0 113.192 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.42 -171.81 2.86 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-O 122.736 1.255 . . . . 0.0 110.781 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.477 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.49 -25.09 2.96 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 111.98 -2.373 . . . . 0.0 108.691 177.512 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.764 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -168.58 -169.11 0.99 Allowed 'General case' 0 CA--C 1.55 0.949 0 CA-C-N 114.405 -1.271 . . . . 0.0 111.996 -178.107 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.12 110.66 0.25 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 114.504 -1.226 . . . . 0.0 111.251 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.39 124.72 8.19 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.714 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.37 58.4 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 114.201 -1.363 . . . . 0.0 108.949 178.191 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.7 t -103.27 -28.69 11.72 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.066 -1.879 . . . . 0.0 110.852 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -113.45 -66.8 1.05 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.489 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.17 124.48 1.17 Allowed Glycine 0 C--N 1.323 -0.182 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.865 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.484 ' HD2' ' HB2' ' A' ' 31' ' ' TYR . 0.1 OUTLIER -74.55 157.39 35.57 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -178.829 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -58.95 32.02 0.01 OUTLIER 'General case' 0 C--O 1.24 0.559 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.709 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.71 -1.56 48.9 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 111.429 -0.669 . . . . 0.0 111.429 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.484 ' HB2' ' HD2' ' A' ' 28' ' ' PHE . 7.7 m-85 -102.19 85.37 0.71 Allowed Pre-proline 0 CA--C 1.548 0.868 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.71 140.21 16.38 Favored 'Trans proline' 0 C--N 1.376 1.998 0 C-N-CA 122.836 2.358 . . . . 0.0 113.585 -178.467 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.57 4.27 70.56 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.743 -0.662 . . . . 0.0 113.181 179.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.423 ' O ' HG12 ' A' ' 24' ' ' ILE . 4.1 t-80 -79.79 133.0 36.28 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 124.209 1.004 . . . . 0.0 110.032 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.637 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.07 -10.51 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 123.64 0.588 . . . . 0.0 111.779 -178.845 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -129.93 -149.79 6.79 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 112.063 -0.415 . . . . 0.0 112.063 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.558 HG12 ' O ' ' A' ' 123' ' ' PHE . 12.4 p -130.52 151.66 36.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.844 0.379 . . . . 0.0 110.522 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.719 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -127.08 132.03 50.73 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.265 0.555 . . . . 0.0 111.408 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.762 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 6.5 m-85 -118.24 111.7 19.14 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.475 -1.239 . . . . 0.0 111.227 -177.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.42 99.76 0.09 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.548 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.46 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 14.2 p -142.87 129.02 10.47 Favored Pre-proline 0 CA--C 1.547 0.859 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.168 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 119' ' ' PRO . 87.8 Cg_exo -48.82 139.83 24.16 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 123.472 2.782 . . . . 0.0 115.844 -179.343 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.846 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -66.57 137.34 25.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 111.764 -2.471 . . . . 0.0 113.345 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.27 2.71 51.11 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.908 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.8 m -87.76 131.57 43.03 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.238 -0.41 . . . . 0.0 109.976 179.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.64 128.32 25.45 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.214 1.942 . . . . 0.0 113.004 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.621 HG21 HD22 ' A' ' 90' ' ' LEU . 8.1 t -100.14 123.15 52.82 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.885 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.64 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 19.5 mtt180 -101.95 152.02 21.43 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 112.929 -1.941 . . . . 0.0 111.752 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.06 123.67 24.01 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.098 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.02 -15.94 20.36 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.716 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.639 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.64 143.02 1.66 Allowed 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 123.349 0.66 . . . . 0.0 110.497 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.435 ' HB3' ' HA ' ' A' ' 102' ' ' LYS . 8.1 p30 -61.66 155.49 22.42 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.052 -0.976 . . . . 0.0 112.307 179.193 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.581 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.99 -126.26 1.36 Allowed Glycine 0 C--N 1.331 0.302 0 O-C-N 123.792 0.683 . . . . 0.0 113.45 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 7.9 m -147.1 141.52 26.4 Favored 'General case' 0 N--CA 1.436 -1.127 0 C-N-CA 123.576 0.75 . . . . 0.0 109.613 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 99' ' ' SER . 12.2 t -85.04 113.24 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 123.764 0.826 . . . . 0.0 108.783 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.408 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 7.0 mmmt -95.35 -14.9 23.49 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.675 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -156.17 140.27 16.44 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.198 179.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.01 92.12 1.93 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.147 -1.388 . . . . 0.0 108.934 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.41 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.76 91.27 1.46 Allowed Glycine 0 C--O 1.238 0.386 0 CA-C-N 114.362 -1.29 . . . . 0.0 112.214 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.517 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -70.27 122.34 19.35 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 122.006 0.908 . . . . 0.0 112.857 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.632 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.77 -0.86 88.82 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 113.201 -1.818 . . . . 0.0 113.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.46 -32.91 62.75 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.92 26.69 2.46 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.927 -178.479 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.632 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -82.59 114.13 49.65 Favored Pre-proline 0 N--CA 1.435 -1.192 0 N-CA-C 114.006 1.113 . . . . 0.0 114.006 -178.083 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.823 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.8 Cg_exo -67.72 162.31 39.95 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 123.987 3.125 . . . . 0.0 112.239 177.4 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TRP . . . . . 0.401 ' HA ' ' O ' ' A' ' 69' ' ' TRP . 59.8 m95 -95.76 12.23 30.72 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.24 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 58.9 mtt -78.42 -42.8 29.07 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.774 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.53 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -126.08 14.82 7.89 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.862 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.823 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.2 OUTLIER -137.33 113.24 9.7 Favored 'General case' 0 C--N 1.367 1.331 0 C-N-CA 120.188 -0.605 . . . . 0.0 112.581 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -110.83 -33.81 6.43 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.91 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.07 -18.68 33.57 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.513 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.52 -126.68 9.0 Favored Glycine 0 CA--C 1.52 0.394 0 O-C-N 123.515 0.51 . . . . 0.0 113.946 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.568 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.4 m-80 -81.21 145.98 30.71 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.738 0.815 . . . . 0.0 112.555 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -152.31 144.85 24.14 Favored 'General case' 0 CA--C 1.519 -0.243 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.438 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.612 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -139.46 120.86 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.539 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.46 128.01 51.67 Favored 'General case' 0 CA--C 1.492 -1.28 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.214 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -138.92 151.07 23.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 112.785 -2.007 . . . . 0.0 110.679 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.581 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -100.2 117.43 34.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.903 177.859 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.639 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.2 m-70 -70.04 -176.23 1.09 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 114.137 -1.392 . . . . 0.0 114.196 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.54 -18.05 65.03 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 113.806 -1.543 . . . . 0.0 114.42 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -9.67 20.35 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.913 0.387 . . . . 0.0 111.016 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.86 -6.49 43.99 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.221 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.456 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 6.5 ptt? -69.36 163.66 24.65 Favored 'General case' 0 N--CA 1.439 -1.007 0 C-N-CA 123.182 0.593 . . . . 0.0 111.621 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.444 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 60.2 m-70 -107.51 144.81 33.97 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.892 -178.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.96 127.31 24.68 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.612 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -107.29 154.47 16.61 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.339 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -138.44 98.44 3.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 104.221 -2.511 . . . . 0.0 104.221 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB3' ' HB3' ' A' ' 122' ' ' HIS . . . -116.72 173.59 6.55 Favored 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 15.8 m-70 66.05 20.18 11.22 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.505 1.122 . . . . 0.0 112.121 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.621 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -79.66 172.43 13.79 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 123.708 0.803 . . . . 0.0 111.14 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.4 t -104.99 -15.69 15.04 Favored 'General case' 0 N--CA 1.447 -0.607 0 O-C-N 123.139 0.275 . . . . 0.0 111.555 -179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.432 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 12.3 tttt -168.71 157.52 8.51 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.809 0.814 . . . . 0.0 112.464 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.5 150.3 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 CA-C-N 113.467 -1.697 . . . . 0.0 110.97 179.187 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -114.03 -6.51 13.12 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.508 -1.224 . . . . 0.0 110.181 177.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.1 OUTLIER -103.36 -175.02 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-N 115.361 -0.836 . . . . 0.0 112.765 -177.064 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 58.8 m -152.89 144.66 23.56 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.62 -1.173 . . . . 0.0 108.985 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.534 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.1 m -57.24 127.93 34.43 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.301 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.71 -3.55 0.68 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.606 1.162 . . . . 0.0 111.884 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.498 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.8 m -81.08 149.19 29.32 Favored 'General case' 0 C--N 1.346 0.456 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 178.456 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.26 145.28 29.21 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.184 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 166.15 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.346 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.435 ' HA ' ' HB3' ' A' ' 52' ' ' ASN . 62.9 tttt -140.09 148.56 41.91 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.064 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -58.1 138.37 56.14 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.132 -1.394 . . . . 0.0 111.332 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.64 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.47 -5.89 41.65 Favored Glycine 0 CA--C 1.516 0.145 0 CA-C-N 114.3 -1.318 . . . . 0.0 114.134 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.534 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 40.1 tt0 -73.28 143.79 46.87 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 122.989 0.515 . . . . 0.0 109.991 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 25.6 mt -74.17 101.65 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 CA-C-N 115.074 -0.967 . . . . 0.0 109.612 -179.313 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.59 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -93.59 -3.68 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 113.393 -1.73 . . . . 0.0 112.55 -179.236 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.31 -160.84 34.62 Favored Glycine 0 N--CA 1.439 -1.113 0 CA-C-O 121.307 0.393 . . . . 0.0 112.696 178.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 20.9 m-85 -142.25 137.35 30.63 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 124.875 1.27 . . . . 0.0 108.061 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -58.94 151.88 20.87 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 123.556 0.743 . . . . 0.0 112.356 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.846 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -147.58 -170.79 16.03 Favored Glycine 0 C--N 1.347 1.187 0 C-N-CA 119.834 -1.174 . . . . 0.0 113.655 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -144.83 44.46 1.36 Allowed 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.779 -0.71 . . . . 0.0 109.173 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.513 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 37.5 p -81.96 -0.44 44.04 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 113.62 0.971 . . . . 0.0 113.62 -177.338 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -101.9 -168.63 27.3 Favored Glycine 0 C--N 1.338 0.691 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.636 179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -93.46 92.4 7.6 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.317 0.58 . . . . 0.0 110.983 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.71 165.61 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.606 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.6 p -79.71 -6.54 57.41 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -162.98 -170.58 28.06 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.92 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.612 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 21.4 Cg_exo -70.84 147.26 55.56 Favored 'Trans proline' 0 C--N 1.365 1.445 0 C-N-CA 123.558 2.839 . . . . 0.0 111.956 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -152.0 156.29 39.69 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 122.3 1.048 . . . . 0.0 112.82 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -117.01 127.96 54.69 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 112.566 -2.107 . . . . 0.0 108.297 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 88' ' ' ALA . 23.3 t60 -112.36 109.57 19.27 Favored 'General case' 0 N--CA 1.434 -1.258 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.255 179.48 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.558 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.73 108.52 16.47 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.931 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.475 ' OE1' HD11 ' A' ' 126' ' ' LEU . 21.5 tt0 -120.55 125.86 48.88 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.621 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.653 ' SD ' ' HA ' ' A' ' 142' ' ' PRO . 19.4 ptm -111.74 135.36 52.45 Favored 'General case' 0 N--CA 1.419 -2.011 0 C-N-CA 124.012 0.925 . . . . 0.0 109.579 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.475 HD11 ' OE1' ' A' ' 124' ' ' GLU . 2.8 mp -138.56 165.92 29.27 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.697 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.444 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.7 Cg_endo -63.2 -178.5 0.46 Allowed 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.969 2.446 . . . . 0.0 112.703 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.99 -27.21 62.6 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.214 176.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -157.46 101.21 1.87 Allowed Pre-proline 0 CA--C 1.503 -0.851 0 CA-C-N 114.182 -1.372 . . . . 0.0 109.019 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HB3' ' HA3' ' A' ' 138' ' ' GLY . 3.0 Cg_exo -72.89 163.66 37.75 Favored 'Trans proline' 0 N--CA 1.446 -1.284 0 C-N-CA 122.722 2.281 . . . . 0.0 116.592 -177.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.559 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -118.01 70.73 0.81 Allowed 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 112.482 -2.145 . . . . 0.0 107.339 177.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.3 m-90 -63.54 14.71 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.317 -1.311 . . . . 0.0 112.696 -178.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.559 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.9 mp0 -81.24 35.49 0.39 Allowed 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 122.121 0.963 . . . . 0.0 112.897 -178.353 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 70.72 127.59 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 125.73 1.612 . . . . 0.0 110.883 178.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 148.98 -49.9 0.57 Allowed Glycine 0 N--CA 1.437 -1.254 0 CA-C-N 114.979 -1.009 . . . . 0.0 113.031 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.5 -21.5 0.23 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 122.37 0.268 . . . . 0.0 111.43 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 26.9 m 66.19 17.94 10.85 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.672 1.189 . . . . 0.0 108.454 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.93 -9.73 23.05 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 112.497 -2.138 . . . . 0.0 112.672 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.637 ' HG2' HG12 ' A' ' 35' ' ' VAL . 2.1 ppt_? -83.18 126.16 32.33 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.42 -174.34 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.89 178.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.426 ' O ' ' SD ' ' A' ' 125' ' ' MET . 1.8 p30 -79.25 135.58 57.69 Favored Pre-proline 0 CA--C 1.549 0.939 0 N-CA-C 114.06 1.133 . . . . 0.0 114.06 -176.335 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.653 ' HA ' ' SD ' ' A' ' 125' ' ' MET . 1.0 OUTLIER -76.46 1.4 8.45 Favored 'Trans proline' 0 C--N 1.383 2.39 0 C-N-CA 123.003 2.469 . . . . 0.0 113.244 178.963 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.67 -23.7 7.1 Favored 'General case' 0 C--N 1.351 0.664 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -178.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.41 -31.62 74.32 Favored Glycine 0 C--N 1.333 0.387 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' TYR . . . . . 0.446 ' HE1' ' SD ' ' A' ' 125' ' ' MET . 32.1 m-85 -94.35 -13.49 26.32 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 122.978 0.511 . . . . 0.0 111.53 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.571 HG12 ' O ' ' A' ' 142' ' ' PRO . 14.6 mm -100.98 -9.06 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.434 -178.354 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -78.37 -31.51 48.52 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.238 0.542 . . . . 0.0 111.429 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -103.12 14.46 31.74 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-N 114.649 -1.16 . . . . 0.0 109.656 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -101.01 157.71 33.15 Favored Pre-proline 0 N--CA 1.418 -2.057 0 CA-C-N 113.923 -1.49 . . . . 0.0 112.434 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.45 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 16.4 Cg_endo -55.6 178.6 0.1 Allowed 'Trans proline' 0 C--N 1.367 1.5 0 C-N-CA 124.832 3.688 . . . . 0.0 115.02 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.8 t -113.86 134.68 55.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 C-N-CA 124.102 0.961 . . . . 0.0 111.365 -177.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.65 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 50.6 t80 -100.72 97.17 7.85 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 113.985 -1.461 . . . . 0.0 109.894 178.236 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 64.78 -26.26 0.09 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.407 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 122.16 75.71 0.36 Allowed Glycine 0 C--N 1.338 0.665 0 N-CA-C 112.066 -0.414 . . . . 0.0 112.066 -179.5 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 10.1 p -92.93 105.04 17.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 123.34 0.656 . . . . 0.0 111.393 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 12.6 p -121.46 122.06 28.18 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.889 178.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -81.6 -39.91 0.17 Allowed 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.286 1.991 . . . . 0.0 112.731 179.155 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.588 HG23 ' H ' ' A' ' 159' ' ' GLU . 8.3 t -161.84 -62.46 0.05 Allowed 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.691 -1.141 . . . . 0.0 109.686 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.588 ' H ' HG23 ' A' ' 158' ' ' THR . 9.1 tt0 . . . . . 0 C--O 1.252 1.186 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.127 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.9 mtt . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.576 0.227 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -133.67 -42.7 0.83 Allowed 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.055 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.95 48.9 0.92 Allowed Glycine 0 C--N 1.34 0.765 0 O-C-N 123.427 0.454 . . . . 0.0 112.679 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 67.2 m -104.96 140.06 38.73 Favored 'General case' 0 C--O 1.234 0.253 0 O-C-N 123.58 0.224 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -124.8 152.85 43.36 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.003 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.1 m80 -96.19 -41.5 8.66 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.653 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 6.7 t-80 -112.81 136.42 52.45 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.352 0.408 . . . . 0.0 111.066 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -124.4 131.54 53.5 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.577 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.01 114.06 27.1 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.731 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -147.52 135.24 21.04 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.218 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.84 -130.73 7.75 Favored Glycine 0 C--N 1.337 0.607 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.636 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.46 163.89 13.04 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -179.47 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.8 109.94 2.11 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.726 176.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.0 t -93.79 -19.45 21.02 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -178.003 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -100.06 121.67 41.75 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 121.642 0.734 . . . . 0.0 112.522 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 18.0 p -102.76 137.1 41.42 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.727 -1.579 . . . . 0.0 113.648 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.59 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.0 OUTLIER -95.88 113.87 62.96 Favored Pre-proline 0 CA--C 1.54 0.579 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.508 177.71 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.705 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.1 Cg_exo -65.68 -26.52 53.33 Favored 'Trans proline' 0 C--N 1.368 1.554 0 C-N-CA 122.699 2.266 . . . . 0.0 113.286 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.768 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.41 -172.16 2.88 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 122.682 1.229 . . . . 0.0 110.722 -179.765 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -129.08 -24.75 2.85 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 111.862 -2.426 . . . . 0.0 108.797 177.407 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.768 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.5 t -168.58 -168.74 0.94 Allowed 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 114.55 -1.205 . . . . 0.0 112.185 -177.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.411 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 172.75 111.43 0.26 Allowed Glycine 0 C--N 1.319 -0.37 0 CA-C-N 114.268 -1.333 . . . . 0.0 111.415 177.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.55 124.69 8.71 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.588 0.709 . . . . 0.0 112.764 -178.347 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.796 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -103.04 58.74 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-N 113.692 -1.595 . . . . 0.0 108.663 178.674 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.0 t -100.05 -28.56 12.99 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 112.879 -1.964 . . . . 0.0 110.826 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.8 m -116.93 -66.28 1.1 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.434 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.96 125.74 1.3 Allowed Glycine 0 C--N 1.322 -0.199 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.824 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.537 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -73.54 157.36 36.87 Favored 'General case' 0 C--N 1.342 0.278 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.56 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -57.15 31.99 0.0 OUTLIER 'General case' 0 C--O 1.238 0.494 0 N-CA-C 115.778 1.77 . . . . 0.0 115.778 -177.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.689 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 103.12 0.74 48.03 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -102.06 85.4 0.7 Allowed Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.689 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.0 Cg_exo -76.73 141.25 21.63 Favored 'Trans proline' 0 C--N 1.374 1.884 0 C-N-CA 122.831 2.354 . . . . 0.0 113.388 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.25 4.06 78.05 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 123.694 0.621 . . . . 0.0 113.091 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.453 ' O ' HG12 ' A' ' 24' ' ' ILE . 2.6 t-80 -79.58 129.54 34.56 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 123.886 0.874 . . . . 0.0 110.659 -179.314 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.671 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.17 -5.25 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.227 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -131.01 -150.15 6.69 Favored Glycine 0 C--N 1.337 0.602 0 N-CA-C 111.868 -0.493 . . . . 0.0 111.868 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.4 p -131.69 151.5 35.46 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.701 0 C-N-CA 122.824 0.449 . . . . 0.0 110.044 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.743 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -127.23 137.89 52.98 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.222 0.534 . . . . 0.0 111.715 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.705 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.3 m-85 -125.4 107.6 10.83 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 114.534 -1.212 . . . . 0.0 110.574 -178.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -59.31 104.9 0.29 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.494 179.107 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 p -149.25 129.04 6.5 Favored Pre-proline 0 CA--C 1.549 0.919 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.192 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.82 144.18 56.15 Favored 'Trans proline' 0 C--N 1.365 1.441 0 C-N-CA 123.298 2.665 . . . . 0.0 115.149 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.769 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.92 142.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 111.796 -2.456 . . . . 0.0 113.362 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.17 2.53 59.16 Favored Glycine 0 N--CA 1.442 -0.963 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.984 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.83 129.45 48.52 Favored Pre-proline 0 N--CA 1.447 -0.623 0 CA-C-O 119.134 -0.46 . . . . 0.0 109.791 179.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.58 126.91 22.69 Favored 'Trans proline' 0 C--N 1.371 1.742 0 C-N-CA 122.152 1.901 . . . . 0.0 112.965 -179.393 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.595 HG21 HD22 ' A' ' 90' ' ' LEU . 6.2 t -99.93 124.29 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.863 179.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.601 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.1 mtp-105 -101.55 153.57 19.62 Favored 'General case' 0 N--CA 1.433 -1.309 0 CA-C-N 113.18 -1.827 . . . . 0.0 111.843 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.33 121.47 20.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.61 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 30.4 t -67.76 -14.98 19.03 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.672 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.75 143.51 2.13 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 123.376 0.67 . . . . 0.0 110.482 179.001 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.412 ' OD1' ' HB2' ' A' ' 80' ' ' ALA . 7.8 p30 -61.74 156.17 21.0 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.078 -0.965 . . . . 0.0 112.156 179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.689 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.61 -127.35 1.52 Allowed Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.806 -0.712 . . . . 0.0 113.996 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 20.4 m -149.48 137.08 20.18 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 -177.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 99' ' ' SER . 10.4 t -83.26 113.82 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 123.763 0.825 . . . . 0.0 108.956 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.401 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.3 OUTLIER -98.84 -17.08 18.62 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.827 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -148.78 139.57 22.83 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.435 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.95 92.34 1.96 Allowed 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.904 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.56 91.27 1.4 Allowed Glycine 0 C--O 1.24 0.482 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.269 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.52 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -73.52 122.85 22.84 Favored 'General case' 0 C--N 1.344 0.358 0 C-N-CA 123.924 0.89 . . . . 0.0 112.57 -179.358 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.604 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.34 -0.73 87.32 Favored Glycine 0 C--N 1.32 -0.349 0 CA-C-N 113.265 -1.789 . . . . 0.0 113.378 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.89 -32.91 57.77 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.67 22.58 2.69 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-N 115.894 -0.593 . . . . 0.0 112.233 -178.296 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.604 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.5 113.45 34.5 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -178.619 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.83 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.3 Cg_exo -66.98 162.88 36.07 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 123.675 2.917 . . . . 0.0 111.705 177.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -95.63 8.1 44.37 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 176.134 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.0 mtt -74.81 -44.76 47.61 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.308 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.536 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.52 11.74 10.67 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.824 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.83 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -130.65 143.21 50.59 Favored 'General case' 0 C--N 1.361 1.096 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.412 -179.319 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 5.0 ttt -147.22 -19.78 0.39 Allowed 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.212 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -90.85 -29.17 17.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -179.095 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.63 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 106.48 -127.38 8.87 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.8 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.549 HD21 ' HA3' ' A' ' 61' ' ' GLY . 14.8 m-80 -88.61 139.33 30.58 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 122.894 0.478 . . . . 0.0 111.928 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.48 145.67 23.81 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.143 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.567 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.34 121.24 19.31 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.174 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.121 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.1 126.87 53.51 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -139.95 150.69 21.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-N 112.579 -2.1 . . . . 0.0 110.643 -176.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.689 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.7 tt0 -97.23 116.76 30.02 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 113.921 -1.49 . . . . 0.0 108.33 177.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.672 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.4 m-70 -69.55 -176.91 1.08 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.412 ' HB2' ' OD1' ' A' ' 52' ' ' ASN . . . -64.97 -17.55 64.5 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 113.69 -1.595 . . . . 0.0 113.966 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.61 -12.9 20.67 Favored 'General case' 0 C--O 1.236 0.345 0 O-C-N 123.449 0.468 . . . . 0.0 110.986 -179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.59 -6.77 45.38 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.685 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.717 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 18.5 ptp -70.55 168.23 16.76 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 123.352 0.661 . . . . 0.0 110.364 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.463 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 19.0 p80 -118.16 142.11 47.79 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.142 -1.023 . . . . 0.0 111.203 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.2 OUTLIER -133.85 128.39 34.57 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.255 -177.347 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -101.15 154.8 19.13 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 114.719 -1.128 . . . . 0.0 111.471 177.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.4 m-85 -133.44 99.22 4.45 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -111.32 168.92 9.15 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.925 -0.58 . . . . 0.0 112.556 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' HIS . . . . . 0.554 ' CD2' ' HA3' ' A' ' 114' ' ' GLY . 22.1 m80 65.99 37.24 5.44 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 114.836 -1.074 . . . . 0.0 112.042 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.595 HD22 HG21 ' A' ' 47' ' ' VAL . 11.5 mt -98.43 169.58 9.44 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.745 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.3 t -107.83 -14.69 14.72 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 111.623 0.231 . . . . 0.0 111.623 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.408 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 0.7 OUTLIER -167.66 157.95 10.75 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.595 0.712 . . . . 0.0 111.87 -178.544 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.82 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -123.37 149.42 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.844 179.25 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -113.34 -6.83 13.53 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.837 177.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.82 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -101.54 -175.04 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.02 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.28 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.5 m -152.64 145.16 24.13 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.256 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.553 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.3 m -57.02 126.14 25.85 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.599 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.553 ' HB2' ' O ' ' A' ' 97' ' ' THR . 1.6 m-20 85.37 -2.19 0.83 Allowed 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.75 1.22 . . . . 0.0 111.939 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.469 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -80.74 149.28 29.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -82.86 145.17 29.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.294 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.52 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.334 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 70.2 tttt -142.03 148.93 39.28 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.824 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -58.36 137.95 56.85 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.422 -1.263 . . . . 0.0 111.253 -179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.601 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.81 -4.55 52.11 Favored Glycine 0 C--N 1.328 0.089 0 CA-C-N 114.477 -1.238 . . . . 0.0 114.083 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 39.3 tt0 -74.2 141.94 45.42 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.108 0.48 . . . . 0.0 110.086 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.7 mt -72.37 101.44 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.525 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.2 pt -93.57 -6.16 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.88 -179.061 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.83 -159.88 33.15 Favored Glycine 0 N--CA 1.44 -1.067 0 C-N-CA 121.435 -0.412 . . . . 0.0 112.702 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.496 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 31.9 m-85 -140.24 138.07 34.76 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 124.674 1.19 . . . . 0.0 108.355 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.421 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -60.24 150.17 30.98 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.567 0.747 . . . . 0.0 112.85 -178.654 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.769 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -148.47 -163.71 10.99 Favored Glycine 0 C--N 1.345 1.06 0 C-N-CA 120.616 -0.802 . . . . 0.0 113.02 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.481 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 44.4 0.87 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.415 0.626 . . . . 0.0 109.81 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.63 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 67.4 p -83.88 -1.1 53.78 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.953 -178.162 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.554 ' HA3' ' CD2' ' A' ' 89' ' ' HIS . . . -92.56 -120.23 2.75 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.396 -0.43 . . . . 0.0 112.326 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -90.92 154.54 19.39 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 122.301 0.24 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 20.0 m 49.79 167.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 124.99 1.316 . . . . 0.0 114.073 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.4 p -83.92 4.68 28.47 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.913 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -88.37 116.1 4.54 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.987 -0.896 . . . . 0.0 112.803 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.481 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.0 Cg_exo -73.45 142.95 33.92 Favored 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 122.495 2.13 . . . . 0.0 112.202 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 51.9 p-80 -163.29 -171.09 2.47 Favored 'General case' 0 C--N 1.347 0.499 0 CA-C-O 121.371 0.605 . . . . 0.0 111.414 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.743 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -124.75 131.08 53.48 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.487 -178.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 23.8 t60 -112.76 109.92 19.7 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.405 -1.271 . . . . 0.0 109.436 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.539 ' O ' HG12 ' A' ' 37' ' ' VAL . 30.1 t80 -114.43 110.16 19.43 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.015 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.544 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -115.01 127.13 55.47 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.4 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.2 ttt -121.87 134.68 54.87 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 114.354 -1.294 . . . . 0.0 109.023 -178.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.717 ' O ' ' HB2' ' A' ' 83' ' ' MET . 2.1 mp -143.46 164.77 28.94 Favored Pre-proline 0 C--N 1.313 -1.022 0 CA-C-N 113.355 -1.748 . . . . 0.0 110.358 -177.521 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.463 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -61.91 -178.5 0.32 Allowed 'Trans proline' 0 C--N 1.369 1.644 0 C-N-CA 123.291 2.661 . . . . 0.0 113.473 177.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.99 -28.97 67.09 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.077 176.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -158.01 103.93 1.74 Allowed Pre-proline 0 CA--C 1.503 -0.839 0 CA-C-N 113.896 -1.502 . . . . 0.0 108.607 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.5 163.13 38.37 Favored 'Trans proline' 0 N--CA 1.444 -1.44 0 C-N-CA 122.511 2.141 . . . . 0.0 116.746 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.558 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -118.2 70.53 0.81 Allowed 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 112.281 -2.236 . . . . 0.0 107.412 177.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.4 m-90 -62.83 12.5 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.427 -178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.558 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.7 mp0 -82.17 34.18 0.41 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 124.224 1.01 . . . . 0.0 112.74 -178.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 72.54 128.77 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.62 0 C-N-CA 125.692 1.597 . . . . 0.0 110.748 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.27 -48.6 0.59 Allowed Glycine 0 N--CA 1.439 -1.161 0 CA-C-N 115.135 -0.939 . . . . 0.0 113.043 -179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.55 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -150.48 -20.72 0.23 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 111.756 0.28 . . . . 0.0 111.756 179.301 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.23 17.71 10.78 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.081 1.352 . . . . 0.0 107.989 -178.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.651 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.29 -11.31 8.95 Favored Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 112.262 -2.245 . . . . 0.0 112.609 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.671 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.11 125.72 29.79 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.321 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -129.84 -175.35 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.004 179.301 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.431 ' HA ' ' HD3' ' A' ' 142' ' ' PRO . 1.9 p30 -79.74 132.96 59.65 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.01 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.591 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.1 Cg_exo -76.68 -1.89 12.05 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.667 2.245 . . . . 0.0 112.932 178.016 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.75 -23.24 6.41 Favored 'General case' 0 C--N 1.35 0.627 0 N-CA-C 114.278 1.214 . . . . 0.0 114.278 -178.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -67.67 -31.12 75.46 Favored Glycine 0 CA--C 1.518 0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.334 -179.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -103.39 -11.99 17.5 Favored 'General case' 0 C--O 1.236 0.37 0 O-C-N 123.861 0.389 . . . . 0.0 111.919 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.591 HG12 ' O ' ' A' ' 142' ' ' PRO . 24.5 mm -96.2 -8.71 9.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.684 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -76.77 -23.87 52.92 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.412 178.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.92 13.6 34.59 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.013 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.489 ' HB3' ' O ' ' A' ' 146' ' ' ILE . . . -98.52 158.7 32.1 Favored Pre-proline 0 N--CA 1.415 -2.209 0 CA-C-N 113.422 -1.717 . . . . 0.0 112.548 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.446 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 10.1 Cg_endo -55.02 178.74 0.08 OUTLIER 'Trans proline' 0 C--N 1.365 1.434 0 C-N-CA 124.527 3.485 . . . . 0.0 113.977 179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.1 132.87 63.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 C-N-CA 123.43 0.692 . . . . 0.0 111.61 -177.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.59 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 82.4 t80 -98.96 96.69 8.0 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.042 -1.435 . . . . 0.0 109.914 178.267 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 63.24 -30.97 0.1 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 124.312 1.045 . . . . 0.0 113.724 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 111.94 64.67 0.49 Allowed Glycine 0 C--N 1.336 0.577 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.0 p -95.38 105.64 17.62 Favored 'General case' 0 N--CA 1.442 -0.829 0 C-N-CA 123.523 0.729 . . . . 0.0 111.55 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.9 p -94.04 125.39 52.98 Favored Pre-proline 0 CA--C 1.54 0.581 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.762 178.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.06 -42.09 0.11 Allowed 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.368 2.046 . . . . 0.0 113.321 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.64 HG23 ' H ' ' A' ' 159' ' ' GLU . 7.9 t -160.78 -63.98 0.06 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.152 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.64 ' H ' HG23 ' A' ' 158' ' ' THR . 35.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-N 114.385 -1.28 . . . . 0.0 111.778 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 mtt . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 120.596 0.236 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.28 -45.31 4.13 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.263 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 118.89 154.03 9.53 Favored Glycine 0 C--N 1.34 0.776 0 O-C-N 123.433 0.458 . . . . 0.0 112.671 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.4 m -116.5 132.24 56.73 Favored 'General case' 0 C--O 1.235 0.32 0 O-C-N 123.663 0.272 . . . . 0.0 110.751 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -110.99 121.31 45.04 Favored 'General case' 0 C--O 1.235 0.335 0 O-C-N 123.647 0.592 . . . . 0.0 111.306 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 -133.7 141.89 47.76 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.831 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 78.7 m-70 -127.95 115.71 18.96 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.619 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -137.06 -43.17 0.57 Allowed 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.363 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -117.93 148.69 41.93 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 123.382 0.426 . . . . 0.0 111.475 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -101.5 140.56 35.62 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.656 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 146.9 59.83 0.01 OUTLIER Glycine 0 C--N 1.338 0.687 0 O-C-N 123.475 0.485 . . . . 0.0 112.585 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.44 164.48 12.99 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -159.16 113.16 2.36 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.444 176.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.3 t -89.93 5.69 45.3 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.5 -179.182 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -101.59 136.02 42.13 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.48 0.657 . . . . 0.0 111.454 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.0 p -94.5 -179.08 4.78 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 113.936 -1.484 . . . . 0.0 112.523 -178.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.4 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 1.1 ttp180 -78.04 112.23 23.86 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.949 0.9 . . . . 0.0 112.451 -179.276 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.689 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.5 Cg_exo -67.41 -23.22 44.37 Favored 'Trans proline' 0 C--N 1.368 1.569 0 C-N-CA 122.617 2.211 . . . . 0.0 112.273 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.746 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.41 -172.02 3.04 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-O 122.561 1.172 . . . . 0.0 110.509 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.52 -24.83 2.99 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 112.221 -2.263 . . . . 0.0 108.772 177.233 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.746 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.3 t -168.42 -168.51 0.93 Allowed 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.654 -178.254 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.428 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 179.17 110.99 0.29 Allowed Glycine 0 C--N 1.32 -0.356 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.386 177.415 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.426 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.09 124.65 8.35 Favored 'General case' 0 CA--C 1.506 -0.739 0 CA-C-O 121.531 0.682 . . . . 0.0 112.337 -178.434 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.93 58.77 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.533 0 CA-C-N 113.924 -1.489 . . . . 0.0 108.978 178.536 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.6 t -105.05 -28.64 10.92 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 112.815 -1.993 . . . . 0.0 111.111 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.42 -66.79 1.05 Allowed 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.981 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.05 121.4 0.94 Allowed Glycine 0 C--N 1.321 -0.257 0 CA-C-N 115.131 -0.94 . . . . 0.0 112.15 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.483 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -74.72 157.49 35.18 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -178.849 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -57.43 31.71 0.0 OUTLIER 'General case' 0 C--O 1.24 0.561 0 N-CA-C 115.87 1.804 . . . . 0.0 115.87 -177.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.56 -2.05 49.52 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -101.76 85.47 0.67 Allowed Pre-proline 0 CA--C 1.547 0.861 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.8 Cg_exo -78.12 138.11 15.94 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.785 2.323 . . . . 0.0 113.317 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 92.41 4.31 66.27 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.225 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -76.52 135.89 39.31 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 123.79 0.836 . . . . 0.0 110.2 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.611 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.19 -18.93 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.444 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.22 -149.85 8.22 Favored Glycine 0 C--N 1.337 0.624 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.2 p -131.08 148.54 32.98 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 O-C-N 123.855 0.385 . . . . 0.0 110.11 179.242 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.788 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.21 135.12 52.26 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.456 0.646 . . . . 0.0 112.148 -178.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.689 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 2.1 m-85 -124.56 110.26 14.23 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 114.231 -1.35 . . . . 0.0 109.803 -178.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.31 104.25 0.12 Allowed 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.649 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.522 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.7 p -144.88 120.75 6.0 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.563 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -49.16 144.68 16.11 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.191 2.594 . . . . 0.0 115.525 -179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.706 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -61.03 139.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 111.628 -2.533 . . . . 0.0 113.437 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.52 2.56 55.47 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.358 -0.837 . . . . 0.0 114.181 177.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -87.41 127.57 58.29 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-O 119.148 -0.453 . . . . 0.0 109.951 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -59.36 127.27 23.31 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.181 1.921 . . . . 0.0 113.378 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.524 HG21 HD22 ' A' ' 90' ' ' LEU . 11.4 t -99.05 123.8 51.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.28 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 5.9 mtt180 -102.39 152.42 21.13 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.913 -1.949 . . . . 0.0 111.597 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.47 120.82 19.61 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.771 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.3 t -65.51 -16.77 20.89 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.671 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.27 144.63 2.05 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 123.479 0.711 . . . . 0.0 110.391 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -61.15 156.02 19.27 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.071 -0.968 . . . . 0.0 112.512 179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.657 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.71 -125.88 1.38 Allowed Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.72 -0.673 . . . . 0.0 113.701 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 14.3 m -148.22 142.95 26.67 Favored 'General case' 0 N--CA 1.439 -1.025 0 C-N-CA 123.624 0.77 . . . . 0.0 109.706 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 99' ' ' SER . 9.4 t -84.89 112.1 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 123.805 0.842 . . . . 0.0 108.881 179.597 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.444 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -95.14 -14.96 23.71 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.751 -179.861 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -154.38 140.37 18.31 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.045 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -147.85 92.31 2.05 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.394 -1.275 . . . . 0.0 108.952 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.412 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.63 89.99 1.27 Allowed Glycine 0 C--O 1.24 0.499 0 CA-C-N 114.251 -1.341 . . . . 0.0 112.454 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.546 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.7 m120 -72.09 122.13 20.43 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.951 0.881 . . . . 0.0 112.822 -179.409 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.627 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.63 -0.94 88.59 Favored Glycine 0 N--CA 1.461 0.301 0 CA-C-N 113.197 -1.82 . . . . 0.0 113.693 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.09 -33.44 59.51 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -138.62 26.91 2.52 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.925 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.627 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.9 115.26 50.92 Favored Pre-proline 0 N--CA 1.437 -1.119 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -178.372 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 37.4 Cg_exo -68.05 162.95 37.76 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 123.845 3.03 . . . . 0.0 111.789 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -96.25 8.58 43.53 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -74.66 -44.6 49.54 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.312 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.528 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -121.97 11.76 10.35 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.913 177.694 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.0 OUTLIER -129.03 144.39 51.17 Favored 'General case' 0 C--N 1.361 1.093 0 C-N-CA 120.159 -0.616 . . . . 0.0 112.237 -178.854 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.61 -31.16 0.35 Allowed 'General case' 0 N--CA 1.47 0.525 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.689 178.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.62 -19.34 31.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.522 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 96.3 -130.28 10.21 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.967 -0.561 . . . . 0.0 114.112 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.579 HD21 ' HA3' ' A' ' 61' ' ' GLY . 10.1 m-80 -81.11 140.95 34.75 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.558 0.743 . . . . 0.0 112.35 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.23 146.56 24.83 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.345 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.572 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.93 121.35 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.265 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.89 130.55 56.31 Favored 'General case' 0 CA--C 1.492 -1.273 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 177.561 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.4 mt -139.4 150.82 22.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-N 112.909 -1.951 . . . . 0.0 110.403 -176.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.657 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.68 116.18 31.2 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 113.865 -1.516 . . . . 0.0 108.281 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.671 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.8 m-70 -69.21 -175.47 0.77 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.27 -18.1 65.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 113.982 -1.463 . . . . 0.0 114.619 -177.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.22 -9.18 20.66 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.81 -6.14 43.83 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.154 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.507 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 4.0 ptt? -67.43 165.76 15.98 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 123.595 0.758 . . . . 0.0 111.353 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.496 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 61.9 m-70 -111.41 144.37 40.72 Favored 'General case' 0 N--CA 1.44 -0.929 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.826 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.7 127.06 22.96 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 120.99 0.424 . . . . 0.0 110.345 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -104.24 154.73 17.61 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.628 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.507 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.0 m-85 -136.08 99.06 4.03 Favored 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.409 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.66 167.78 10.32 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -177.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 65.5 42.28 3.82 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.283 1.033 . . . . 0.0 111.383 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.2 mt -103.22 168.58 9.08 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.103 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 8.1 t -102.63 -17.81 15.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.16 163.64 15.6 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.722 0.772 . . . . 0.0 111.927 -177.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.829 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -127.56 148.18 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.509 -1.678 . . . . 0.0 110.893 179.06 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 t -111.51 -6.6 14.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.886 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.829 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -103.35 -175.24 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.099 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.792 -177.118 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.7 m -153.22 143.42 22.35 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.674 -1.148 . . . . 0.0 108.936 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.76 127.88 32.23 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 86.02 -4.43 0.79 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.692 1.197 . . . . 0.0 111.719 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.476 ' O ' HG23 ' A' ' 55' ' ' VAL . 39.5 m -80.44 151.61 29.22 Favored 'General case' 0 C--N 1.347 0.463 0 CA-C-O 120.571 0.224 . . . . 0.0 110.552 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.7 145.52 27.91 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.608 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.89 169.71 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.314 0 CA-C-N 115.197 -0.91 . . . . 0.0 112.196 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.438 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 1.9 tttt -142.42 148.51 37.93 Favored 'General case' 0 N--CA 1.432 -1.361 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.716 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -58.34 138.41 56.49 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.361 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.584 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 77.03 -8.44 30.58 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 114.38 -1.282 . . . . 0.0 114.135 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 41.1 tt0 -70.75 141.29 51.48 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.078 0.466 . . . . 0.0 110.214 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.8 mt -72.72 102.05 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.559 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.5 -4.97 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 CA-C-N 113.564 -1.653 . . . . 0.0 113.117 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.66 -160.74 34.44 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 121.472 -0.394 . . . . 0.0 112.749 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 35.4 m-85 -140.16 138.35 35.12 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.669 1.188 . . . . 0.0 108.522 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -62.71 150.93 39.84 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 123.631 0.773 . . . . 0.0 112.552 -179.224 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.706 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -161.37 -160.98 11.23 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 119.877 -1.154 . . . . 0.0 114.034 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.416 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.2 51.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 114.48 -0.86 . . . . 0.0 108.684 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.522 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 21.6 p -80.67 2.76 24.53 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.196 -0.911 . . . . 0.0 113.33 -177.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -110.6 -162.26 18.25 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 111.857 -0.497 . . . . 0.0 111.857 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 52.6 mt-30 -91.57 91.07 7.88 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.301 0.572 . . . . 0.0 110.234 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.4 m -151.66 159.01 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.746 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.2 t -85.57 -4.21 59.09 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -166.5 164.04 37.37 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.634 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.417 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 6.2 Cg_exo -80.25 139.21 13.07 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 123.302 2.668 . . . . 0.0 112.419 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.522 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 31.5 p80 -160.94 -166.34 1.57 Allowed 'General case' 0 C--N 1.348 0.5 0 CA-C-O 121.256 0.551 . . . . 0.0 111.411 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.788 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 13.3 tp -123.03 130.04 52.28 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.64 -1.163 . . . . 0.0 111.261 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.409 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 22.6 t60 -112.81 113.0 24.9 Favored 'General case' 0 N--CA 1.434 -1.225 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.815 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.527 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.2 t80 -118.53 111.31 18.45 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.138 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -118.55 127.21 53.4 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.163 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.0 tpt -117.61 138.41 51.97 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.7 mp -143.65 166.62 18.72 Favored Pre-proline 0 C--N 1.308 -1.237 0 CA-C-N 113.465 -1.698 . . . . 0.0 111.103 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -62.52 -178.48 0.38 Allowed 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 123.35 2.7 . . . . 0.0 112.703 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -69.98 -28.05 65.22 Favored 'General case' 0 N--CA 1.439 -0.989 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.247 176.251 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -156.94 101.28 1.95 Allowed Pre-proline 0 CA--C 1.504 -0.793 0 CA-C-N 114.334 -1.303 . . . . 0.0 108.829 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -72.26 163.18 39.46 Favored 'Trans proline' 0 N--CA 1.444 -1.432 0 C-N-CA 122.698 2.265 . . . . 0.0 116.542 -177.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.579 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -117.08 70.7 0.78 Allowed 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.491 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -63.07 12.54 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 114.29 -1.323 . . . . 0.0 112.313 -178.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.579 ' H ' ' C ' ' A' ' 131' ' ' ASN . 1.8 mp0 -81.61 32.29 0.36 Allowed 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.378 1.071 . . . . 0.0 112.815 -178.534 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 73.74 129.1 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.582 0 C-N-CA 125.825 1.65 . . . . 0.0 110.789 178.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.34 -48.6 0.59 Allowed Glycine 0 N--CA 1.44 -1.085 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.121 -179.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.2 -19.77 0.18 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.762 0.315 . . . . 0.0 111.757 179.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.6 t 66.34 18.03 10.81 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.975 1.31 . . . . 0.0 108.213 -178.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 74.59 -9.71 10.12 Favored Glycine 0 N--CA 1.437 -1.26 0 CA-C-N 112.582 -2.099 . . . . 0.0 112.904 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.611 ' HG2' HG12 ' A' ' 35' ' ' VAL . 1.5 ppt_? -82.73 127.25 33.25 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.561 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.452 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -129.37 -172.86 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.855 -0.612 . . . . 0.0 112.413 178.478 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.452 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.3 m-20 -71.65 134.86 83.83 Favored Pre-proline 0 CA--C 1.549 0.906 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -176.278 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.629 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.6 Cg_endo -77.7 2.03 8.24 Favored 'Trans proline' 0 C--N 1.381 2.265 0 C-N-CA 123.296 2.664 . . . . 0.0 113.297 177.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.5 p -51.17 -24.04 3.85 Favored 'General case' 0 C--N 1.347 0.467 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -178.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.52 -28.04 71.69 Favored Glycine 0 CA--C 1.52 0.383 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.867 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -102.4 -9.28 20.44 Favored 'General case' 0 C--O 1.237 0.445 0 O-C-N 124.085 0.52 . . . . 0.0 111.496 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.629 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -98.53 -11.29 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.854 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -75.7 -25.51 56.75 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.019 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.29 16.04 27.02 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -94.55 157.58 36.92 Favored Pre-proline 0 N--CA 1.419 -2.011 0 CA-C-N 114.109 -1.405 . . . . 0.0 113.121 -178.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_exo -55.54 178.87 0.09 OUTLIER 'Trans proline' 0 C--N 1.367 1.551 0 C-N-CA 124.548 3.498 . . . . 0.0 114.904 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.2 t -99.84 130.7 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 114.559 -1.2 . . . . 0.0 111.152 -178.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' PHE . . . . . 0.4 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 41.1 t80 -107.4 102.35 11.64 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 113.636 -1.62 . . . . 0.0 108.883 178.198 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 72.74 -40.08 0.46 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 124.517 1.127 . . . . 0.0 112.63 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 124.09 88.75 0.83 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.151 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.2 p -95.3 105.09 17.01 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-O 121.337 0.589 . . . . 0.0 111.292 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 12.6 p -103.2 137.72 19.34 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.506 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.63 -41.57 0.11 Allowed 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.335 2.023 . . . . 0.0 113.231 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.62 HG23 ' H ' ' A' ' 159' ' ' GLU . 8.5 t -161.67 -63.59 0.05 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.986 -1.007 . . . . 0.0 110.204 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.62 ' H ' HG23 ' A' ' 158' ' ' THR . 31.7 mt-10 . . . . . 0 C--O 1.25 1.094 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.609 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 58.9 mtt . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.659 0.266 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -91.35 140.32 29.89 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.357 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 171.99 80.54 0.05 OUTLIER Glycine 0 C--N 1.336 0.536 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.116 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.1 p -112.66 147.73 36.14 Favored 'General case' 0 C--O 1.235 0.293 0 O-C-N 123.624 0.249 . . . . 0.0 111.305 -179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 89.0 m-70 -102.73 -43.63 5.53 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.882 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -106.86 149.17 27.7 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -105.57 149.34 26.36 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.158 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 65.9 m80 -129.51 151.38 50.19 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.752 179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -96.96 146.81 24.61 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.3 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -136.73 152.59 50.52 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.482 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -99.59 57.38 0.85 Allowed Glycine 0 C--N 1.338 0.673 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.719 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.55 163.63 13.74 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.87 102.78 1.67 Allowed 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.732 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.6 t -92.04 -4.21 54.75 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.569 -179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -94.33 134.42 36.84 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-O 121.793 0.806 . . . . 0.0 112.67 -178.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 10.1 p -88.27 150.85 23.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.276 -1.784 . . . . 0.0 112.466 -178.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.734 ' HD3' ' HB1' ' A' ' 149' ' ' ALA . 0.0 OUTLIER -94.64 113.05 60.14 Favored Pre-proline 0 CA--C 1.538 0.49 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.706 179.742 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.667 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 45.6 Cg_exo -58.08 -31.1 92.31 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.948 2.432 . . . . 0.0 113.147 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.754 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.37 -172.12 2.87 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-O 122.5 1.143 . . . . 0.0 110.379 -179.985 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.459 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.78 -25.71 2.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 112.4 -2.182 . . . . 0.0 108.755 177.288 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.754 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -169.61 -168.32 0.78 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 114.02 -1.445 . . . . 0.0 111.234 -178.045 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.24 110.97 0.3 Allowed Glycine 0 C--N 1.316 -0.574 0 CA-C-N 114.793 -1.094 . . . . 0.0 111.289 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.52 124.98 8.88 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.851 0.834 . . . . 0.0 113.053 -177.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.808 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.85 58.8 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.38 -1.736 . . . . 0.0 108.522 178.373 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 4.9 t -100.94 -28.73 12.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 112.595 -2.093 . . . . 0.0 110.856 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.6 m -115.55 -66.58 1.07 Allowed 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.422 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.46 122.15 0.98 Allowed Glycine 0 C--N 1.323 -0.173 0 CA-C-N 115.084 -0.962 . . . . 0.0 112.037 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.547 ' CD2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -70.89 157.35 38.29 Favored 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -178.909 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 -58.67 31.75 0.01 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.66 1.726 . . . . 0.0 115.66 -177.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.698 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.81 -2.03 48.58 Favored Glycine 0 CA--C 1.505 -0.59 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.545 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -102.52 85.35 0.75 Allowed Pre-proline 0 CA--C 1.547 0.864 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.698 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 6.2 Cg_exo -78.6 138.98 15.71 Favored 'Trans proline' 0 C--N 1.374 1.898 0 C-N-CA 122.881 2.388 . . . . 0.0 113.497 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.34 3.93 62.89 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.375 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.507 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.3 t-80 -80.62 135.06 35.98 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 123.724 0.81 . . . . 0.0 109.83 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.658 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.74 -20.1 5.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.144 -179.383 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.35 -149.59 8.33 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 142' ' ' PRO . 14.7 p -131.69 151.92 36.17 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 O-C-N 123.939 0.435 . . . . 0.0 110.274 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASP . . . . . 0.763 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 82.8 m-20 -128.25 131.71 48.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.172 0.51 . . . . 0.0 111.603 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' TYR . . . . . 0.667 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -119.76 111.17 17.66 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.648 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.21 102.04 0.15 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.227 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 13.8 p -143.34 133.48 12.06 Favored Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.853 -178.597 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -48.51 139.35 23.3 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 123.486 2.791 . . . . 0.0 115.653 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.789 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -67.57 143.75 15.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 111.793 -2.458 . . . . 0.0 113.222 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.26 2.78 58.98 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.791 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -86.89 126.86 61.91 Favored Pre-proline 0 N--CA 1.447 -0.611 0 CA-C-O 119.253 -0.403 . . . . 0.0 109.978 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.13 126.18 19.53 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.022 1.815 . . . . 0.0 112.974 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.508 HG21 HD22 ' A' ' 90' ' ' LEU . 5.4 t -99.86 122.34 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.505 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 2.2 mpt_? -101.7 154.78 18.58 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 113.389 -1.732 . . . . 0.0 112.052 -178.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.35 124.32 25.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.265 -178.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.29 -18.45 24.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.66 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.26 144.2 2.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 110.388 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.466 ' OD1' ' HB2' ' A' ' 80' ' ' ALA . 7.6 p30 -60.03 157.45 12.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.978 179.159 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.13 -124.59 1.25 Allowed Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.781 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.2 m -147.83 143.37 27.42 Favored 'General case' 0 N--CA 1.436 -1.141 0 C-N-CA 123.594 0.758 . . . . 0.0 109.938 -177.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 99' ' ' SER . 9.8 t -86.94 113.06 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.819 0.848 . . . . 0.0 108.826 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -95.06 -15.02 23.76 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.621 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -154.48 139.6 17.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.221 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.29 92.33 1.94 Allowed 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.894 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . 0.485 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -96.36 92.36 1.38 Allowed Glycine 0 C--O 1.239 0.443 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.488 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.512 ' O ' ' HB3' ' A' ' 64' ' ' HIS . 2.6 m120 -71.49 122.57 20.67 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 123.914 0.886 . . . . 0.0 112.796 -179.301 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.582 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.59 -0.7 88.01 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-N 113.352 -1.749 . . . . 0.0 113.358 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.41 -32.7 48.81 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.32 27.62 2.56 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.744 -178.526 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.573 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.58 113.85 40.62 Favored Pre-proline 0 N--CA 1.435 -1.177 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -178.69 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.9 Cg_exo -66.74 162.59 36.71 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 123.371 2.714 . . . . 0.0 111.166 177.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.1 m95 -96.41 9.54 40.95 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.5 mtt -76.31 -44.66 35.88 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.239 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.538 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.19 11.46 10.86 Favored 'General case' 0 N--CA 1.441 -0.891 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.895 177.619 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.53 138.03 52.05 Favored 'General case' 0 C--N 1.359 0.994 0 C-N-CA 120.359 -0.536 . . . . 0.0 110.842 -179.317 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 11.6 mmt -143.16 -21.21 0.63 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.769 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -96.32 -28.9 14.28 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.97 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.434 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 109.01 -131.02 10.32 Favored Glycine 0 CA--C 1.52 0.387 0 O-C-N 123.767 0.667 . . . . 0.0 113.895 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.582 HD21 ' HA3' ' A' ' 61' ' ' GLY . 12.2 m-80 -79.23 144.13 34.65 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.613 0.765 . . . . 0.0 112.448 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -151.22 144.82 24.96 Favored 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.475 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.562 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -140.46 121.55 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.975 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.86 129.02 52.26 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.435 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 11.1 mt -141.02 151.18 20.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 113.145 -1.843 . . . . 0.0 110.863 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLN . . . . . 0.679 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 2.0 tt0 -100.37 115.76 30.75 Favored 'General case' 0 N--CA 1.436 -1.128 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.996 177.535 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.66 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -70.08 -177.46 1.37 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 114.347 1.24 . . . . 0.0 114.347 -178.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.466 ' HB2' ' OD1' ' A' ' 52' ' ' ASN . . . -63.45 -17.97 63.26 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 113.744 -1.571 . . . . 0.0 114.179 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.31 -11.78 20.92 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 123.444 0.465 . . . . 0.0 110.728 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.58 -7.43 46.18 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.81 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.477 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 9.2 ptt? -69.0 163.55 24.37 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 123.286 0.635 . . . . 0.0 111.715 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.489 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 63.4 m-70 -105.68 144.78 31.94 Favored 'General case' 0 N--CA 1.437 -1.084 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.986 -179.272 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.22 126.84 23.52 Favored 'General case' 0 N--CA 1.441 -0.916 0 O-C-N 123.633 0.583 . . . . 0.0 109.815 -179.519 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.38 154.27 16.86 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.531 178.618 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -140.94 98.48 3.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 104.338 -2.467 . . . . 0.0 104.338 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 173.68 6.79 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' HIS . . . . . 0.513 ' CE1' ' HA3' ' A' ' 114' ' ' GLY . 86.3 m-70 65.68 24.35 11.58 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.577 1.151 . . . . 0.0 111.642 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.575 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.2 mt -84.01 170.96 13.4 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.577 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.3 t -105.19 -13.82 15.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.7 tttp -166.82 158.15 12.56 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.749 0.785 . . . . 0.0 112.551 -178.321 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.822 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -126.06 147.43 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 113.602 -1.635 . . . . 0.0 110.87 179.014 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 t -111.26 -6.63 14.51 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.936 177.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.822 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -102.6 -175.24 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.035 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.736 -177.13 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.1 m -151.88 140.48 20.74 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.938 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -55.07 128.99 36.3 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.412 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 85.68 -4.92 0.84 Allowed 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.594 1.158 . . . . 0.0 112.001 179.07 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.481 ' O ' HG23 ' A' ' 55' ' ' VAL . 46.0 m -80.48 152.72 28.59 Favored 'General case' 0 C--N 1.347 0.457 0 CA-C-O 120.514 0.197 . . . . 0.0 110.739 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 p -85.06 145.1 27.84 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 178.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.7 168.2 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.333 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 74.5 tttt -139.64 148.98 43.2 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-N 114.493 -1.23 . . . . 0.0 109.803 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -57.94 138.89 55.42 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.231 -1.349 . . . . 0.0 111.421 -179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 76.78 -7.29 34.89 Favored Glycine 0 CA--C 1.517 0.165 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.093 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 38.9 tt0 -71.89 142.92 49.52 Favored 'General case' 0 CA--C 1.51 -0.593 0 C-N-CA 122.971 0.508 . . . . 0.0 110.131 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 32.9 mt -72.65 100.86 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.49 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.491 ' H ' HG13 ' A' ' 107' ' ' ILE . 1.0 OUTLIER -94.25 -3.99 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.952 -178.902 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 170.71 -168.37 41.46 Favored Glycine 0 N--CA 1.438 -1.212 0 CA-C-O 121.353 0.418 . . . . 0.0 112.752 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.575 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 34.0 m-85 -139.59 134.29 31.92 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 124.718 1.207 . . . . 0.0 108.023 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -56.61 150.49 15.5 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.477 0.711 . . . . 0.0 112.459 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.789 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -146.11 -171.11 15.26 Favored Glycine 0 C--N 1.347 1.152 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.526 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -143.86 43.1 1.46 Allowed 'General case' 0 N--CA 1.441 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 109.302 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.434 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 36.5 p -81.72 -0.3 42.26 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.109 -0.95 . . . . 0.0 112.868 -178.053 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 89' ' ' HIS . . . -100.87 179.19 28.78 Favored Glycine 0 C--N 1.338 0.67 0 C-N-CA 121.394 -0.431 . . . . 0.0 112.485 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -85.01 91.76 8.17 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 121.626 0.727 . . . . 0.0 110.685 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.11 166.12 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.706 -178.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.2 p -78.14 -3.78 44.2 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.26 -168.16 31.71 Favored Glycine 0 CA--C 1.528 0.874 0 CA-C-O 119.617 -0.546 . . . . 0.0 113.133 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' PRO . . . . . 0.594 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 23.0 Cg_exo -68.84 147.34 68.55 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.526 2.817 . . . . 0.0 112.268 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -149.45 158.44 44.18 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-O 122.313 1.054 . . . . 0.0 113.144 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.763 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 12.0 tp -120.47 125.09 47.02 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-N 112.51 -2.132 . . . . 0.0 109.402 179.359 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 19.1 t60 -110.88 111.01 21.85 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 114.854 -1.066 . . . . 0.0 109.832 178.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.53 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.49 112.59 22.48 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.635 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.0 tt0 -119.26 140.04 50.91 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.349 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' MET . . . . . 0.447 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 17.0 tpp -132.72 136.92 46.69 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.819 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.581 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.98 165.47 24.03 Favored Pre-proline 0 C--N 1.312 -1.048 0 CA-C-N 113.714 -1.585 . . . . 0.0 110.419 -178.213 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.6 Cg_endo -63.53 -178.55 0.52 Allowed 'Trans proline' 0 C--N 1.367 1.511 0 C-N-CA 122.949 2.433 . . . . 0.0 112.746 176.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ALA . . . . . 0.444 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -71.92 -27.46 62.84 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.205 176.245 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -156.75 101.38 1.99 Allowed Pre-proline 0 CA--C 1.504 -0.802 0 CA-C-N 114.25 -1.341 . . . . 0.0 108.741 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -72.34 163.43 38.67 Favored 'Trans proline' 0 N--CA 1.443 -1.441 0 C-N-CA 122.625 2.217 . . . . 0.0 116.633 -177.252 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.574 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.18 71.53 0.83 Allowed 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 112.421 -2.172 . . . . 0.0 107.275 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' TRP . . . . . . . . . . . . . 2.6 m-90 -63.47 14.91 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 114.266 -1.334 . . . . 0.0 112.421 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.574 ' H ' ' C ' ' A' ' 131' ' ' ASN . 2.0 mp0 -81.81 32.94 0.37 Allowed 'General case' 0 N--CA 1.445 -0.71 0 CA-C-O 122.13 0.967 . . . . 0.0 112.833 -178.456 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 72.41 128.76 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 125.792 1.637 . . . . 0.0 110.96 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.07 -48.7 0.6 Allowed Glycine 0 N--CA 1.437 -1.287 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.109 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.572 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.1 OUTLIER -150.51 -21.09 0.23 Allowed 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 179.558 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t 66.42 18.01 10.77 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.806 1.243 . . . . 0.0 108.121 -178.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.97 -11.56 14.63 Favored Glycine 0 N--CA 1.436 -1.315 0 CA-C-N 112.439 -2.164 . . . . 0.0 112.683 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ARG . . . . . 0.658 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -80.62 125.59 30.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.34 -175.79 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.029 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 5.0 p30 -76.65 137.85 66.81 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.584 ' HG3' HG11 ' A' ' 37' ' ' VAL . 76.5 Cg_endo -76.21 20.43 0.57 Allowed 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.21 2.606 . . . . 0.0 114.559 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 5.6 p -56.95 -24.99 56.98 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.154 0.982 . . . . 0.0 113.579 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -75.12 -23.71 73.51 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -95.53 -10.56 29.33 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.607 1.163 . . . . 0.0 110.668 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 142' ' ' PRO . 30.0 mm -107.16 -12.27 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.771 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -76.13 -29.27 57.75 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.899 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -104.1 9.39 36.37 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 114.637 -1.165 . . . . 0.0 109.387 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ALA . . . . . 0.734 ' HB1' ' HD3' ' A' ' 17' ' ' ARG . . . -103.23 152.96 38.72 Favored Pre-proline 0 N--CA 1.416 -2.173 0 CA-C-N 114.169 -1.378 . . . . 0.0 112.212 -179.033 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.559 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 77.7 Cg_exo -55.03 178.91 0.08 OUTLIER 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 124.605 3.537 . . . . 0.0 114.824 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 93.7 t -110.16 129.75 64.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.7 -178.164 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 81.4 t80 -105.15 98.15 7.89 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.79 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 53.85 20.67 2.42 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -112.83 63.79 0.28 Allowed Glycine 0 C--N 1.339 0.704 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 22.3 p -102.15 105.14 15.79 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 123.224 0.61 . . . . 0.0 111.609 -179.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.5 p -109.34 140.43 22.03 Favored Pre-proline 0 CA--C 1.537 0.451 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.289 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -82.82 -43.0 0.09 OUTLIER 'Trans proline' 0 C--N 1.373 1.855 0 C-N-CA 122.278 1.985 . . . . 0.0 113.108 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.639 HG23 ' H ' ' A' ' 159' ' ' GLU . 9.2 t -160.55 -64.02 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.12 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' GLU . . . . . 0.639 ' H ' HG23 ' A' ' 158' ' ' THR . 31.4 mt-10 . . . . . 0 C--O 1.249 1.078 0 CA-C-N 114.461 -1.245 . . . . 0.0 111.637 179.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.652 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.4 Cg_exo . . . . . 0 N--CA 1.484 0.95 0 N-CA-C 113.047 0.364 . . . . 0.0 113.047 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.739 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.95 -171.96 3.07 Favored 'General case' 0 CA--C 1.508 -0.662 0 CA-C-O 122.509 1.147 . . . . 0.0 110.316 -179.695 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -127.58 -25.12 3.2 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 112.253 -2.248 . . . . 0.0 108.797 177.267 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.739 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.2 t -168.77 -168.83 0.92 Allowed 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.332 -1.304 . . . . 0.0 111.671 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.66 111.62 0.3 Allowed Glycine 0 C--N 1.32 -0.345 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.633 177.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.48 124.85 8.84 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-O 121.582 0.706 . . . . 0.0 112.578 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.718 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.97 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.476 0 CA-C-N 113.672 -1.604 . . . . 0.0 109.216 179.387 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.8 t -106.64 -27.87 10.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 112.781 -2.009 . . . . 0.0 110.929 178.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.63 -67.41 1.0 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.881 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.06 122.55 1.02 Allowed Glycine 0 N--CA 1.459 0.185 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.28 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.495 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -78.31 157.57 29.14 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -179.073 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 63.7 m-80 -56.94 32.04 0.0 OUTLIER 'General case' 0 C--O 1.24 0.556 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -177.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.98 1.31 48.66 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -102.18 85.3 0.7 Allowed Pre-proline 0 CA--C 1.545 0.788 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.8 Cg_exo -77.6 139.76 18.34 Favored 'Trans proline' 0 C--N 1.372 1.813 0 C-N-CA 122.81 2.34 . . . . 0.0 113.245 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.24 4.49 81.04 Favored Glycine 0 C--N 1.34 0.762 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.986 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -71.86 129.99 39.96 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.083 0.953 . . . . 0.0 111.089 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.684 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.63 6.15 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.351 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.91 -150.01 5.14 Favored Glycine 0 C--N 1.337 0.62 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.565 HG12 ' O ' ' A' ' 123' ' ' PHE . 8.8 p -131.93 150.12 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.725 0 C-N-CA 122.788 0.435 . . . . 0.0 110.23 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.741 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 84.7 m-20 -126.18 135.28 51.44 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.21 0.528 . . . . 0.0 111.977 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.652 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -126.39 108.11 10.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.541 -178.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.68 104.83 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.264 179.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.441 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 11.0 p -147.63 127.97 6.81 Favored Pre-proline 0 CA--C 1.551 0.989 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.908 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -49.48 141.84 24.76 Favored 'Trans proline' 0 C--N 1.369 1.608 0 C-N-CA 123.385 2.723 . . . . 0.0 115.375 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.768 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.3 140.81 18.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 111.891 -2.413 . . . . 0.0 113.401 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.38 2.62 53.79 Favored Glycine 0 N--CA 1.442 -0.952 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.09 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.3 m -85.96 126.12 66.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.37 126.79 23.11 Favored 'Trans proline' 0 C--N 1.372 1.802 0 C-N-CA 122.226 1.951 . . . . 0.0 113.15 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.599 HG21 HD22 ' A' ' 90' ' ' LEU . 10.2 t -100.95 122.35 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.848 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 41.2 mtt180 -101.86 154.06 19.27 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 113.044 -1.889 . . . . 0.0 111.881 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.27 119.62 17.76 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.578 -1.192 . . . . 0.0 110.57 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -65.9 -15.96 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.44 143.74 1.85 Allowed 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 123.411 0.684 . . . . 0.0 110.403 179.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.538 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.86 155.74 18.93 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.32 179.358 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.64 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.66 -127.17 1.52 Allowed Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.691 -0.686 . . . . 0.0 113.766 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 16.4 m -148.67 141.09 24.24 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 123.583 0.753 . . . . 0.0 109.875 -178.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 99' ' ' SER . 11.8 t -84.33 112.65 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 C-N-CA 123.78 0.832 . . . . 0.0 109.027 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -95.13 -15.03 23.67 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.684 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -155.85 139.67 16.19 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.766 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.69 92.36 1.99 Allowed 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.227 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.438 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.14 90.3 1.48 Allowed Glycine 0 C--O 1.24 0.524 0 CA-C-N 114.28 -1.327 . . . . 0.0 111.985 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.576 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.11 121.02 17.52 Favored 'General case' 0 C--N 1.344 0.369 0 O-C-N 124.818 0.952 . . . . 0.0 112.811 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.47 -0.77 87.8 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-N 113.318 -1.764 . . . . 0.0 113.459 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -33.11 58.01 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.56 22.32 2.71 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.22 -178.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.596 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.52 116.38 58.88 Favored Pre-proline 0 N--CA 1.435 -1.217 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -178.36 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.832 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 38.7 Cg_exo -67.61 162.87 37.3 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 123.577 2.851 . . . . 0.0 111.381 177.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 60.0 m95 -97.64 10.72 39.21 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.87 -44.97 30.0 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.544 -1.207 . . . . 0.0 110.194 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.525 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -120.3 11.42 11.51 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.714 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.832 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.1 m95 -128.66 141.9 51.2 Favored 'General case' 0 C--N 1.361 1.08 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.35 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.5 mmt -144.52 -28.22 0.49 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.202 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.74 -24.62 26.84 Favored 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.391 0.432 . . . . 0.0 112.075 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.636 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.27 -128.27 9.52 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 115.743 -0.662 . . . . 0.0 114.082 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 90' ' ' LEU . 8.6 m-80 -84.92 136.68 33.52 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.243 0.617 . . . . 0.0 112.067 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -150.33 147.05 27.14 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.16 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.646 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -140.14 120.63 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.467 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.36 128.21 54.81 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 177.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.5 mt -138.97 150.81 23.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 112.741 -2.027 . . . . 0.0 110.512 -176.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.64 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.3 tt0 -99.67 116.57 32.07 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.348 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.65 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.0 m-70 -68.31 -176.09 0.7 Allowed 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.536 -1.211 . . . . 0.0 114.215 -178.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.538 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -66.22 -17.78 64.95 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 114.055 -1.43 . . . . 0.0 114.398 -177.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.438 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.1 OUTLIER -101.52 -9.06 21.37 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.881 0.372 . . . . 0.0 111.067 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.6 -6.68 45.23 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.057 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.8 ptt? -67.77 168.71 10.92 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 123.469 0.708 . . . . 0.0 111.367 179.067 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 -113.43 145.31 41.36 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.075 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.497 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.94 127.28 19.81 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-O 120.973 0.416 . . . . 0.0 110.29 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.646 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.96 154.97 16.9 Favored Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.546 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.457 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.9 m-85 -134.36 99.29 4.33 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 105.361 -2.089 . . . . 0.0 105.361 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.69 166.77 11.05 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 73.3 m80 65.74 41.25 4.0 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-N 114.628 -1.169 . . . . 0.0 111.743 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.599 HD22 HG21 ' A' ' 47' ' ' VAL . 9.3 mt -101.3 166.46 10.75 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.079 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.401 ' HB2' HG23 ' A' ' 43' ' ' VAL . 12.4 t -101.04 -14.88 17.64 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -168.26 160.47 11.55 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.727 0.775 . . . . 0.0 111.901 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.837 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.3 148.65 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 113.613 -1.631 . . . . 0.0 110.757 178.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 t -112.42 -5.96 14.05 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 114.517 -1.219 . . . . 0.0 110.071 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.837 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -104.44 -175.23 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.983 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.512 -177.134 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.2 m -155.46 144.07 20.43 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.009 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.537 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 4.2 m -55.23 129.22 37.47 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.62 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.43 -5.18 0.74 Allowed 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.63 1.172 . . . . 0.0 112.026 179.314 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 55' ' ' VAL . 29.6 m -81.3 148.8 29.24 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.51 145.63 28.01 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.425 178.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.401 HG12 HE21 ' A' ' 105' ' ' GLN . 0.0 OUTLIER -125.49 167.69 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.248 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.36 -179.216 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.9 tttm -140.36 147.39 39.72 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.821 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.793 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.23 137.93 55.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.226 -1.352 . . . . 0.0 111.483 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.8 -4.43 52.48 Favored Glycine 0 CA--C 1.517 0.175 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.078 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.9 tt0 -74.36 139.0 43.81 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.183 0.516 . . . . 0.0 110.004 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 54.5 mt -71.35 101.53 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.118 0 CA-C-N 114.717 -1.128 . . . . 0.0 109.512 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.44 -4.74 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.149 -178.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.92 -160.82 34.6 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 112.302 -0.319 . . . . 0.0 112.302 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 30.3 m-85 -139.45 139.1 36.95 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 124.478 1.111 . . . . 0.0 108.327 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.402 HG23 HG22 ' A' ' 47' ' ' VAL . 0.8 OUTLIER -60.37 152.57 24.99 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.472 0.709 . . . . 0.0 112.117 -179.136 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.768 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -158.06 -163.33 12.62 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.961 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.642 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 48.16 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 114.632 -0.784 . . . . 0.0 109.074 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.636 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 33.6 p . . . . . 0 CA--C 1.54 0.564 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.9 0 CA-C-O 118.832 -0.982 . . . . 0.0 111.808 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.642 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.6 Cg_exo -71.55 144.67 45.4 Favored 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.593 2.196 . . . . 0.0 112.098 179.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.441 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 56.1 p-80 -160.77 -172.99 3.71 Favored 'General case' 0 C--N 1.349 0.565 0 CA-C-O 121.515 0.674 . . . . 0.0 111.636 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.741 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.8 tp -125.51 136.25 53.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.779 -178.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 31.8 t60 -116.36 122.96 46.4 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.43 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.565 ' O ' HG12 ' A' ' 37' ' ' VAL . 50.0 t80 -127.25 107.57 10.11 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.264 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' THR . 13.4 pt-20 -115.33 127.37 55.38 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.548 178.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.4 tpt -121.17 136.73 54.92 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.726 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.633 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -142.26 164.99 30.06 Favored Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 113.394 -1.73 . . . . 0.0 110.381 -178.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -64.09 -178.43 0.61 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.994 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.16 -27.26 62.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.004 176.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.34 102.54 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.784 0 CA-C-N 114.09 -1.414 . . . . 0.0 108.869 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.26 163.18 39.45 Favored 'Trans proline' 0 N--CA 1.445 -1.349 0 C-N-CA 122.671 2.248 . . . . 0.0 116.937 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.577 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.96 70.76 0.81 Allowed 'General case' 0 N--CA 1.425 -1.702 0 CA-C-N 112.229 -2.26 . . . . 0.0 107.392 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.45 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -62.9 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 114.291 -1.322 . . . . 0.0 112.435 -178.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.577 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 33.72 0.38 Allowed 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 124.209 1.003 . . . . 0.0 112.783 -178.487 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 11.0 m-80 71.95 128.2 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.627 0 C-N-CA 125.571 1.548 . . . . 0.0 110.666 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.33 -48.49 0.6 Allowed Glycine 0 N--CA 1.438 -1.178 0 CA-C-N 115.104 -0.953 . . . . 0.0 113.068 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.78 -19.58 0.22 Allowed 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 37.9 m 65.67 18.01 11.07 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-O 122.778 1.275 . . . . 0.0 108.108 -178.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.633 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 78.26 -11.57 23.05 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 112.237 -2.256 . . . . 0.0 112.47 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.684 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -85.07 124.43 31.75 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 112.056 -179.24 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.456 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -127.19 -172.87 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.8 m-20 -72.47 131.8 84.35 Favored Pre-proline 0 CA--C 1.547 0.844 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -176.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.619 ' O ' HG12 ' A' ' 146' ' ' ILE . 4.5 Cg_exo -77.58 -1.63 11.8 Favored 'Trans proline' 0 C--N 1.379 2.148 0 C-N-CA 123.265 2.643 . . . . 0.0 113.492 177.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.1 p -51.48 -24.25 4.89 Favored 'General case' 0 C--N 1.349 0.58 0 N-CA-C 114.134 1.161 . . . . 0.0 114.134 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.94 -24.56 75.75 Favored Glycine 0 CA--C 1.521 0.431 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.927 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -103.56 -10.33 18.55 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 123.465 0.706 . . . . 0.0 111.343 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.619 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -99.81 -10.96 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.454 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.247 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.699 178.028 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.736 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.6 Cg_exo . . . . . 0 N--CA 1.479 0.626 0 N-CA-C 112.667 0.218 . . . . 0.0 112.667 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.76 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.77 -171.92 3.04 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.699 1.238 . . . . 0.0 110.335 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.457 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.26 -24.78 2.8 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 112.082 -2.326 . . . . 0.0 108.625 177.292 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.76 ' H ' HD12 ' A' ' 19' ' ' LEU . 9.3 t -168.21 -168.94 1.01 Allowed 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.162 -178.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.26 112.25 0.28 Allowed Glycine 0 C--N 1.32 -0.342 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.036 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.21 125.49 9.38 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 113.328 0.862 . . . . 0.0 113.328 -177.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.751 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.56 58.31 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.455 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.066 179.197 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.6 t -102.7 -28.13 12.3 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 112.89 -1.959 . . . . 0.0 110.829 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -115.14 -67.2 1.01 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.606 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.3 123.18 1.06 Allowed Glycine 0 C--O 1.235 0.196 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.371 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.487 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -75.11 157.44 34.7 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -55.7 31.92 0.0 OUTLIER 'General case' 0 C--O 1.241 0.618 0 N-CA-C 115.816 1.784 . . . . 0.0 115.816 -177.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.71 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 0.09 48.93 Favored Glycine 0 CA--C 1.505 -0.551 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -101.72 85.43 0.66 Allowed Pre-proline 0 CA--C 1.545 0.763 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.71 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.7 Cg_exo -77.03 138.88 18.72 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.655 2.236 . . . . 0.0 113.239 -178.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.77 4.11 70.14 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-N 115.873 -0.603 . . . . 0.0 113.12 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.475 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.4 t-80 -75.51 128.41 35.24 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 123.927 0.891 . . . . 0.0 110.743 -179.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.644 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -99.74 -14.14 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.239 -179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -126.04 -150.28 7.6 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.369 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 123' ' ' PHE . 7.2 p -128.71 151.86 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-N 115.025 -0.588 . . . . 0.0 109.775 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.662 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -125.39 130.64 52.31 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.263 0.554 . . . . 0.0 112.409 -178.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.736 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.7 m-85 -122.89 109.78 14.59 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.102 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.92 104.93 0.41 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.243 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.541 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.0 p -145.55 124.43 6.66 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.01 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -48.95 141.79 21.13 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.386 2.724 . . . . 0.0 115.528 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.751 HG23 ' HA2' ' A' ' 111' ' ' GLY . 3.1 p -61.62 141.11 18.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 111.935 -2.393 . . . . 0.0 113.473 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.02 2.49 55.99 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.393 -0.821 . . . . 0.0 114.253 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.7 m -88.98 126.22 59.88 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-O 119.066 -0.492 . . . . 0.0 109.808 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.14 126.67 23.14 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.209 1.939 . . . . 0.0 113.074 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.641 HG21 HD22 ' A' ' 90' ' ' LEU . 4.3 t -98.28 121.51 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.083 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.623 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.9 mtp180 -102.02 151.23 22.39 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 113.088 -1.869 . . . . 0.0 111.584 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -70.76 122.02 19.08 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.232 -178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.2 t -69.08 -14.16 18.17 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.603 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.55 144.17 1.86 Allowed 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 123.447 0.699 . . . . 0.0 110.603 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.424 HD21 ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -62.59 156.86 22.05 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.835 -1.075 . . . . 0.0 112.386 179.368 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.632 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.32 -128.14 1.68 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.725 -0.67 . . . . 0.0 113.652 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.449 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 11.9 m -148.24 140.89 24.52 Favored 'General case' 0 N--CA 1.439 -0.975 0 C-N-CA 123.759 0.824 . . . . 0.0 109.668 -178.116 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 99' ' ' SER . 12.1 t -83.78 112.58 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 123.721 0.809 . . . . 0.0 109.034 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 54' ' ' THR . 6.6 mmmt -95.09 -14.72 23.99 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.844 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -156.09 141.8 17.89 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.01 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.24 92.22 2.16 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.406 -1.27 . . . . 0.0 109.074 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.02 89.98 1.46 Allowed Glycine 0 C--O 1.239 0.447 0 CA-C-N 113.955 -1.475 . . . . 0.0 112.862 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.575 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -70.41 122.97 20.63 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.925 0.89 . . . . 0.0 112.866 -179.689 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.578 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.93 -0.59 88.8 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-N 113.253 -1.794 . . . . 0.0 113.626 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.54 -33.2 54.25 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -138.44 30.18 2.39 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.467 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.578 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.66 111.83 24.33 Favored Pre-proline 0 N--CA 1.437 -1.091 0 N-CA-C 113.907 1.077 . . . . 0.0 113.907 -178.265 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 35.4 Cg_exo -68.71 162.62 40.38 Favored 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.738 2.958 . . . . 0.0 111.563 177.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -96.74 9.76 40.75 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 175.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 61.2 mtm -76.91 -43.56 35.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.342 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.539 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.8 11.24 11.1 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.857 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.1 151.24 50.0 Favored 'General case' 0 C--N 1.361 1.089 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.738 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 36.2 mtt -145.68 -36.88 0.27 Allowed 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.621 179.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -86.43 -23.46 26.05 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.45 0.469 . . . . 0.0 111.881 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.606 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.25 -118.65 6.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.69 -0.686 . . . . 0.0 114.045 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.536 HD21 ' HA3' ' A' ' 61' ' ' GLY . 7.3 m-80 -82.57 135.64 35.03 Favored 'General case' 0 C--O 1.236 0.384 0 C-N-CA 123.225 0.61 . . . . 0.0 112.49 -178.532 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.01 146.56 26.3 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.983 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.616 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -139.2 121.02 16.48 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.205 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.2 130.73 56.99 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.333 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 54' ' ' THR . 9.1 mt -141.01 151.02 20.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 112.587 -2.097 . . . . 0.0 110.206 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.632 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.2 tt0 -99.83 117.14 33.51 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 114.123 -1.399 . . . . 0.0 108.547 178.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.603 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.9 m-70 -69.99 -177.93 1.46 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.535 -1.211 . . . . 0.0 114.07 -179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.424 ' HB2' HD21 ' A' ' 52' ' ' ASN . . . -65.57 -17.46 64.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 113.791 -1.55 . . . . 0.0 113.752 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -97.58 -13.27 21.7 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 123.38 0.425 . . . . 0.0 110.749 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.51 -5.98 44.89 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.811 179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.588 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 16.5 ptp -70.65 165.53 22.68 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 122.866 0.466 . . . . 0.0 111.416 179.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.431 ' O ' ' HA ' ' A' ' 125' ' ' MET . 65.6 m-70 -109.09 140.02 43.2 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.719 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -135.82 127.1 28.3 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-O 121.033 0.444 . . . . 0.0 110.391 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.616 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -103.85 155.31 17.74 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 114.839 -1.073 . . . . 0.0 111.63 178.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.568 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 6.4 m-85 -132.11 99.24 4.65 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.79 167.54 10.41 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 65.62 41.49 4.02 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.591 -178.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.641 HD22 HG21 ' A' ' 47' ' ' VAL . 11.6 mt -101.4 170.36 8.27 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.822 177.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.2 t -105.27 -15.67 14.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 122.952 0.157 . . . . 0.0 111.37 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -168.95 160.44 10.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.658 0.742 . . . . 0.0 111.85 -178.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.833 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.37 149.64 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.638 -1.619 . . . . 0.0 110.949 179.329 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.91 -5.38 13.21 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.247 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.833 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -107.22 -175.42 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.387 -176.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.6 m -154.31 144.54 22.04 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.908 -1.042 . . . . 0.0 109.101 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.63 128.9 36.87 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.741 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 87.47 -4.97 0.61 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.778 1.231 . . . . 0.0 111.837 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.466 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -81.67 148.13 29.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 110.44 -0.208 . . . . 0.0 110.44 178.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -83.9 145.85 28.37 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.385 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.82 168.38 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.449 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 73.6 tttt -142.18 148.55 38.4 Favored 'General case' 0 N--CA 1.427 -1.61 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.872 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.784 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.6 138.52 55.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.305 -179.771 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.623 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.78 -4.6 51.7 Favored Glycine 0 CA--C 1.516 0.117 0 CA-C-N 114.431 -1.259 . . . . 0.0 114.166 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -75.33 140.67 43.23 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.086 0.469 . . . . 0.0 109.933 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.36 100.86 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.586 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.7 -5.4 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 113.706 -1.588 . . . . 0.0 113.257 -178.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 -159.83 32.69 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 121.515 -0.374 . . . . 0.0 112.427 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.547 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 33.9 m-85 -140.37 138.48 34.85 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.572 1.149 . . . . 0.0 108.378 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.445 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -62.65 150.09 41.76 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.659 0.784 . . . . 0.0 112.46 -178.821 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.751 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.35 -164.95 14.33 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 119.884 -1.151 . . . . 0.0 114.153 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.3 52.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.606 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 38.8 p . . . . . 0 CA--C 1.54 0.565 0 CA-C-N 115.248 -0.887 . . . . 0.0 113.355 -177.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.976 0 CA-C-O 119.395 -0.669 . . . . 0.0 113.252 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.716 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 6.0 Cg_exo -79.42 146.77 19.69 Favored 'Trans proline' 0 C--N 1.373 1.854 0 C-N-CA 123.291 2.661 . . . . 0.0 112.529 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.541 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 38.1 p-80 -160.72 -166.69 1.67 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.528 0.68 . . . . 0.0 111.851 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.662 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 15.9 tp -129.47 137.92 51.12 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.064 -1.425 . . . . 0.0 110.313 -178.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.458 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 23.9 t60 -121.59 114.93 21.88 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.284 -1.326 . . . . 0.0 110.184 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 37' ' ' VAL . 22.7 t80 -119.01 107.79 13.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.182 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.559 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.0 pt-20 -112.82 127.52 56.19 Favored 'General case' 0 N--CA 1.432 -1.327 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.57 179.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.431 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 6.7 ttt -122.76 134.51 54.44 Favored 'General case' 0 N--CA 1.434 -1.255 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.152 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.625 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -141.69 164.73 32.73 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 113.271 -1.786 . . . . 0.0 110.113 -177.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -63.16 -178.57 0.45 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 122.889 2.393 . . . . 0.0 113.277 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -69.09 -28.92 66.93 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.975 176.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -157.84 103.45 1.77 Allowed Pre-proline 0 CA--C 1.503 -0.841 0 CA-C-N 114.008 -1.451 . . . . 0.0 108.798 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -72.03 163.22 39.46 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.612 2.208 . . . . 0.0 116.971 -176.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.573 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.5 69.62 0.77 Allowed 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 112.332 -2.213 . . . . 0.0 107.581 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.19 12.3 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 114.319 -1.31 . . . . 0.0 112.412 -178.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.573 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 33.15 0.37 Allowed 'General case' 0 N--CA 1.444 -0.77 0 C-N-CA 124.306 1.043 . . . . 0.0 112.811 -178.462 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 73.11 128.79 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 113.729 -1.578 . . . . 0.0 110.745 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.26 -48.41 0.6 Allowed Glycine 0 N--CA 1.439 -1.135 0 CA-C-N 114.971 -1.013 . . . . 0.0 112.964 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.588 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -152.21 -18.96 0.18 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 179.161 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.8 m 66.12 17.74 10.83 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 122.59 1.186 . . . . 0.0 108.224 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.625 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.3 -11.32 9.0 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 112.547 -2.115 . . . . 0.0 112.673 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.644 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.64 121.7 25.61 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 111.737 0.273 . . . . 0.0 111.737 -179.012 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.93 -172.93 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.441 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -79.34 128.64 74.86 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.656 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.7 Cg_exo -76.76 -3.21 13.52 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 122.934 2.423 . . . . 0.0 113.445 178.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.86 -23.49 2.84 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.69 -30.25 70.79 Favored Glycine 0 N--CA 1.461 0.342 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.472 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -104.24 -11.35 17.27 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 122.902 0.481 . . . . 0.0 111.685 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.656 HG12 ' O ' ' A' ' 142' ' ' PRO . 18.8 mm -96.34 -8.79 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.815 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.279 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.173 177.592 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.693 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.0 Cg_exo . . . . . 0 N--CA 1.482 0.829 0 CA-C-O 120.825 0.261 . . . . 0.0 112.607 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.726 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.47 -171.95 2.89 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-O 122.402 1.096 . . . . 0.0 109.961 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.99 -25.41 3.04 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 112.452 -2.158 . . . . 0.0 108.532 177.091 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.726 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.5 t -169.39 -168.84 0.85 Allowed 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.593 -178.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.92 110.77 0.29 Allowed Glycine 0 C--N 1.317 -0.487 0 CA-C-N 114.513 -1.221 . . . . 0.0 111.171 176.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.41 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.16 124.84 8.4 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 112.829 0.677 . . . . 0.0 112.829 -178.313 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.99 58.58 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.995 -1.457 . . . . 0.0 109.097 178.551 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.3 t -104.54 -28.05 11.52 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 112.729 -2.032 . . . . 0.0 111.123 179.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -116.19 -66.7 1.06 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.648 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.29 122.98 1.04 Allowed Glycine 0 N--CA 1.459 0.201 0 CA-C-N 115.011 -0.995 . . . . 0.0 112.011 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.532 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -73.49 157.26 37.12 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -178.504 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -57.86 31.89 0.0 OUTLIER 'General case' 0 C--O 1.239 0.538 0 N-CA-C 115.821 1.786 . . . . 0.0 115.821 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -1.66 48.83 Favored Glycine 0 CA--C 1.504 -0.634 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.94 85.31 0.67 Allowed Pre-proline 0 CA--C 1.548 0.866 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.6 Cg_exo -77.97 139.2 17.14 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 122.823 2.349 . . . . 0.0 113.352 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.14 4.17 69.1 Favored Glycine 0 C--N 1.339 0.727 0 O-C-N 123.685 0.615 . . . . 0.0 112.997 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.44 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.0 t-80 -78.24 135.43 37.57 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.047 0.939 . . . . 0.0 110.497 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.595 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.32 -12.53 9.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.242 -179.35 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -125.87 -149.77 7.51 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 123' ' ' PHE . 14.4 p -129.82 152.88 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 O-C-N 123.892 0.407 . . . . 0.0 110.133 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.714 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 93.1 m-20 -129.32 131.97 47.03 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.24 0.543 . . . . 0.0 112.242 -178.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.693 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.5 m-85 -122.86 109.48 14.23 Favored 'General case' 0 C--O 1.238 0.5 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.165 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.86 104.26 0.18 Allowed 'General case' 0 CA--C 1.541 0.633 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.339 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.552 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.4 p -144.84 123.91 6.9 Favored Pre-proline 0 CA--C 1.549 0.934 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.855 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -49.02 142.7 19.54 Favored 'Trans proline' 0 C--N 1.371 1.737 0 C-N-CA 123.307 2.671 . . . . 0.0 115.423 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.676 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.09 141.01 17.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 111.582 -2.554 . . . . 0.0 113.619 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.53 2.73 55.45 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.552 -0.749 . . . . 0.0 114.341 177.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.1 m -88.01 123.46 68.78 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-O 119.146 -0.454 . . . . 0.0 109.932 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.24 127.11 24.9 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.328 2.019 . . . . 0.0 113.449 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.55 HG21 HD22 ' A' ' 90' ' ' LEU . 4.8 t -99.68 121.82 50.79 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.138 179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.511 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 2.3 mpt_? -103.19 152.49 21.4 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 113.331 -1.759 . . . . 0.0 111.481 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -71.69 121.46 18.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.441 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.03 -15.64 19.96 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 112.775 0.658 . . . . 0.0 112.775 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.652 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.46 144.46 1.94 Allowed 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 123.462 0.705 . . . . 0.0 110.346 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.78 157.07 18.85 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 115.077 -0.965 . . . . 0.0 112.331 179.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.653 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.01 -127.15 1.54 Allowed Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.744 -0.662 . . . . 0.0 113.849 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.9 m -148.09 141.3 25.08 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 123.678 0.791 . . . . 0.0 109.683 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 99' ' ' SER . 11.3 t -83.49 111.66 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 123.719 0.808 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.7 mmmt -94.35 -15.72 24.13 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.726 -1.125 . . . . 0.0 110.643 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -153.9 140.01 18.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.041 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.53 92.33 2.15 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.906 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -95.05 89.87 1.23 Allowed Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.953 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.577 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.46 125.54 27.66 Favored 'General case' 0 C--N 1.346 0.418 0 C-N-CA 123.795 0.838 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.664 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -79.93 -0.66 85.94 Favored Glycine 0 CA--C 1.52 0.392 0 CA-C-N 113.354 -1.748 . . . . 0.0 113.389 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.11 -32.05 39.1 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 24.86 2.68 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.144 -178.392 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.664 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -79.45 113.88 40.59 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.418 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.808 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.4 Cg_exo -67.69 163.23 36.01 Favored 'Trans proline' 0 C--N 1.37 1.688 0 C-N-CA 123.729 2.953 . . . . 0.0 111.556 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 62.1 m95 -98.2 10.54 40.33 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 14.7 mmt -75.58 -44.55 42.6 Favored 'General case' 0 C--N 1.349 0.552 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.057 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.547 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -120.92 11.51 11.07 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.783 177.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.808 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.05 145.92 51.14 Favored 'General case' 0 C--N 1.359 1.005 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.701 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.9 tpt -145.56 -31.02 0.4 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.488 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.78 -23.44 24.08 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.551 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 101.71 -128.68 9.64 Favored Glycine 0 CA--C 1.522 0.48 0 O-C-N 123.543 0.527 . . . . 0.0 114.025 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.596 HD21 ' HA3' ' A' ' 61' ' ' GLY . 11.8 m-80 -78.8 138.84 38.39 Favored 'General case' 0 C--N 1.347 0.458 0 C-N-CA 123.381 0.672 . . . . 0.0 112.586 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.33 145.23 23.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.008 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.1 t -138.55 120.58 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.158 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.03 131.22 56.99 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.423 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 9.3 mt -141.02 150.91 20.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 112.695 -2.048 . . . . 0.0 110.2 -176.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.653 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.5 tt0 -97.72 116.49 30.03 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 113.984 -1.462 . . . . 0.0 108.294 178.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.652 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -69.17 -175.85 0.82 Allowed 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.561 -1.199 . . . . 0.0 114.159 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -64.97 -17.78 64.69 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 113.867 -1.515 . . . . 0.0 114.485 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.458 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.2 OUTLIER -101.79 -9.86 20.43 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-O 120.826 0.346 . . . . 0.0 111.128 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.78 -6.09 43.92 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.061 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.521 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.4 ptt? -68.92 168.4 13.7 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 123.712 0.805 . . . . 0.0 111.456 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.418 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 55.6 m-70 -112.55 142.7 44.81 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.024 -179.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.26 127.06 25.54 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-O 121.041 0.448 . . . . 0.0 110.022 179.706 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.49 154.59 17.1 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.629 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.506 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.1 m-85 -135.1 99.17 4.19 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.401 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -114.11 168.8 9.5 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 65.28 41.86 4.2 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 124.159 0.984 . . . . 0.0 111.44 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.55 HD22 HG21 ' A' ' 47' ' ' VAL . 11.0 mt -102.94 169.41 8.6 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.037 178.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.4 t -103.88 -16.47 15.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -167.32 162.37 14.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.801 0.81 . . . . 0.0 112.018 -178.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.825 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.9 OUTLIER -127.83 147.82 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.643 179.298 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -110.47 -6.8 14.84 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 114.402 -1.272 . . . . 0.0 109.899 178.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.825 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.73 -175.12 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.073 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.733 -176.89 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 6.9 t -154.18 148.44 25.95 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.79 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 m -58.5 128.98 39.88 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.622 -179.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 t70 86.96 -5.71 0.67 Allowed 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 124.634 1.174 . . . . 0.0 111.722 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.479 ' O ' HG23 ' A' ' 55' ' ' VAL . 31.7 m -79.82 149.63 30.96 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 122.272 0.229 . . . . 0.0 110.711 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -84.94 145.0 27.98 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.382 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.413 HG12 HE21 ' A' ' 105' ' ' GLN . 0.0 OUTLIER -127.01 168.14 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.437 -179.22 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 42.9 tttm -140.5 149.58 42.66 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.844 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.787 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.17 138.59 56.07 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.383 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.511 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.64 -4.55 50.82 Favored Glycine 0 CA--C 1.517 0.185 0 CA-C-N 114.387 -1.278 . . . . 0.0 114.076 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.0 tt0 -75.2 140.57 43.38 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-O 121.086 0.47 . . . . 0.0 110.026 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 52.4 mt -72.11 101.46 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.64 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.59 -5.01 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-N 113.512 -1.676 . . . . 0.0 113.17 -178.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.65 -161.9 35.64 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.363 0.424 . . . . 0.0 112.571 178.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.2 m-85 -139.88 138.06 35.37 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 124.561 1.144 . . . . 0.0 108.339 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.3 150.53 39.05 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 123.913 0.758 . . . . 0.0 112.572 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.676 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -160.23 -161.54 11.51 Favored Glycine 0 C--N 1.348 1.232 0 C-N-CA 119.844 -1.17 . . . . 0.0 114.119 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.1 50.78 0.91 Allowed 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.632 -0.784 . . . . 0.0 108.99 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.551 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 32.6 p . . . . . 0 CA--C 1.54 0.582 0 CA-C-N 115.137 -0.938 . . . . 0.0 113.094 -177.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.12 0 CA-C-O 119.352 -0.693 . . . . 0.0 113.351 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.637 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -77.71 145.67 23.18 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 123.111 2.54 . . . . 0.0 112.414 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.552 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 47.6 p-80 -159.71 -164.91 1.41 Allowed 'General case' 0 C--N 1.351 0.667 0 CA-C-O 121.68 0.753 . . . . 0.0 112.259 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.714 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 16.9 tp -129.7 133.41 47.04 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.433 -178.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.452 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 18.4 t60 -118.18 113.39 21.46 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.288 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.563 ' O ' HG12 ' A' ' 37' ' ' VAL . 37.9 t80 -119.04 108.94 15.34 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.303 -179.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 85' ' ' THR . 20.3 tt0 -117.3 127.15 53.79 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.197 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.426 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 1.9 tpt -118.13 139.81 50.7 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.646 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -143.98 165.46 24.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 CA-C-N 113.426 -1.715 . . . . 0.0 110.619 -177.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 14.1 Cg_endo -63.62 -178.68 0.55 Allowed 'Trans proline' 0 C--N 1.37 1.67 0 C-N-CA 122.842 2.361 . . . . 0.0 112.948 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.16 -27.33 63.47 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.085 176.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -157.44 101.95 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.77 0 CA-C-N 114.03 -1.441 . . . . 0.0 108.871 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -71.71 163.39 39.07 Favored 'Trans proline' 0 N--CA 1.446 -1.314 0 C-N-CA 122.711 2.274 . . . . 0.0 116.874 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.552 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -117.23 70.33 0.78 Allowed 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 112.532 -2.122 . . . . 0.0 107.649 177.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.448 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.25 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 114.298 -1.319 . . . . 0.0 112.54 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.552 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.63 33.35 0.36 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.122 0.969 . . . . 0.0 112.996 -178.15 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 73.26 127.46 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.583 0 C-N-CA 125.663 1.585 . . . . 0.0 110.598 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.31 -50.04 0.56 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.343 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.45 -18.92 0.24 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 179.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 39.5 m 66.01 17.74 10.87 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 122.473 1.13 . . . . 0.0 108.157 -178.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.564 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.07 -9.63 18.11 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 112.6 -2.091 . . . . 0.0 112.734 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.595 ' HG2' HG12 ' A' ' 35' ' ' VAL . 3.2 ppt_? -82.9 127.35 33.42 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 119.854 -0.738 . . . . 0.0 112.362 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -128.07 -173.14 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.629 179.179 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.4 m-20 -73.28 129.8 85.4 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.581 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.3 0.22 9.96 Favored 'Trans proline' 0 C--N 1.38 2.226 0 C-N-CA 122.954 2.436 . . . . 0.0 113.341 177.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.31 -23.78 6.39 Favored 'General case' 0 C--N 1.349 0.548 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.86 -25.59 74.56 Favored Glycine 0 CA--C 1.52 0.362 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.92 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -101.99 -11.67 18.75 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 123.248 0.619 . . . . 0.0 111.16 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.581 HG12 ' O ' ' A' ' 142' ' ' PRO . 20.8 mm -100.16 -9.76 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.286 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.739 178.095 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.701 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 20.1 Cg_exo . . . . . 0 N--CA 1.482 0.81 0 CA-C-O 120.742 0.226 . . . . 0.0 112.344 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -138.72 -171.97 3.2 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.482 1.134 . . . . 0.0 110.104 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.69 -25.25 3.15 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 112.332 -2.213 . . . . 0.0 108.699 177.237 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.737 ' H ' HD12 ' A' ' 19' ' ' LEU . 8.5 t -168.99 -168.64 0.87 Allowed 'General case' 0 CA--C 1.546 0.808 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.525 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.401 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.4 111.18 0.29 Allowed Glycine 0 C--N 1.321 -0.281 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.483 177.116 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.57 124.41 8.56 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.472 0.653 . . . . 0.0 112.632 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.11 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.502 0 CA-C-N 113.949 -1.478 . . . . 0.0 109.255 178.79 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.9 t -106.46 -27.68 10.77 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 113.134 -1.848 . . . . 0.0 110.873 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.2 -67.26 1.01 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.721 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.51 123.94 1.14 Allowed Glycine 0 C--O 1.234 0.151 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.14 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.514 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.94 157.5 31.26 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.641 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -58.02 31.67 0.0 OUTLIER 'General case' 0 C--O 1.24 0.558 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -177.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.699 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 -0.88 48.61 Favored Glycine 0 CA--C 1.506 -0.484 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -101.6 85.55 0.67 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.699 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.07 137.89 15.86 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.807 2.338 . . . . 0.0 113.225 -178.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.41 4.07 71.29 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.149 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-80 -76.12 135.12 39.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.975 0.91 . . . . 0.0 110.37 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.678 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.68 -16.35 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.342 -179.021 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.54 -149.71 8.14 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 123' ' ' PHE . 10.6 p -131.33 151.03 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 124.031 0.489 . . . . 0.0 110.042 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.706 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 89.1 m-20 -125.96 134.19 51.59 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.323 0.582 . . . . 0.0 112.046 -178.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.701 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -124.71 110.07 13.91 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 114.244 -1.344 . . . . 0.0 110.251 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.49 104.64 0.23 Allowed 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.544 178.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.556 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 12.5 p -145.98 124.78 6.53 Favored Pre-proline 0 CA--C 1.551 0.996 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.887 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.01 142.02 20.94 Favored 'Trans proline' 0 C--N 1.37 1.694 0 C-N-CA 123.346 2.697 . . . . 0.0 115.261 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.726 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -61.39 140.15 19.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 111.848 -2.433 . . . . 0.0 113.615 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.64 54.61 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.418 -0.81 . . . . 0.0 114.36 177.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.9 m -87.32 125.37 65.99 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.257 -0.401 . . . . 0.0 109.952 179.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.34 127.69 26.57 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.291 1.994 . . . . 0.0 113.468 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.531 HG21 HD22 ' A' ' 90' ' ' LEU . 9.8 t -99.96 123.36 52.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.154 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 13.6 mtp180 -101.91 152.15 21.26 Favored 'General case' 0 N--CA 1.433 -1.302 0 CA-C-N 112.963 -1.926 . . . . 0.0 111.659 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.48 120.96 18.82 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.846 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.1 t -66.68 -15.78 19.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.881 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.617 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.82 143.59 1.67 Allowed 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.546 0.738 . . . . 0.0 110.355 179.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.434 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.4 OUTLIER -60.36 155.42 18.04 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.234 -0.894 . . . . 0.0 112.206 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 170.32 -128.63 1.67 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.891 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.3 m -148.16 136.35 21.24 Favored 'General case' 0 N--CA 1.44 -0.968 0 C-N-CA 123.446 0.698 . . . . 0.0 110.33 -178.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 11.1 t -83.89 112.44 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.43 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.2 OUTLIER -98.09 -16.63 19.48 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.841 179.846 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -148.54 138.52 22.33 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.737 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.9 92.17 2.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.494 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.422 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.17 89.85 1.37 Allowed Glycine 0 C--O 1.24 0.478 0 CA-C-N 114.128 -1.396 . . . . 0.0 112.802 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.571 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.56 125.71 27.77 Favored 'General case' 0 C--N 1.345 0.395 0 C-N-CA 123.964 0.905 . . . . 0.0 112.517 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.655 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.26 -0.74 87.12 Favored Glycine 0 CA--C 1.52 0.349 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.375 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.69 -31.85 52.69 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.45 25.51 2.65 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.069 -178.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.655 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -80.6 112.93 35.62 Favored Pre-proline 0 N--CA 1.435 -1.2 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.16 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.833 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.0 Cg_exo -67.81 163.45 35.36 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.987 3.125 . . . . 0.0 111.821 177.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.0 m95 -96.79 8.82 43.44 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -75.2 -44.48 46.21 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.398 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.541 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.84 10.9 11.01 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.714 177.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.833 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -128.83 145.92 51.07 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.537 -178.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 32.8 mtt -146.19 -29.18 0.41 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.421 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.44 -24.79 24.05 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.677 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.626 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.6 -123.98 8.09 Favored Glycine 0 CA--C 1.519 0.315 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.753 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.526 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.2 m-80 -81.17 138.21 35.87 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 123.237 0.615 . . . . 0.0 111.95 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.55 148.16 27.67 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.343 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.61 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.4 t -140.23 122.13 15.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.065 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.34 127.6 53.85 Favored 'General case' 0 CA--C 1.494 -1.188 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.7 mt -139.19 150.96 22.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 112.548 -2.115 . . . . 0.0 110.404 -176.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.3 117.04 32.88 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.944 -1.48 . . . . 0.0 108.603 178.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.617 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.0 m-70 -67.27 -176.37 0.56 Allowed 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -66.48 -17.67 64.93 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 114.107 -1.406 . . . . 0.0 114.313 -177.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.72 -10.19 21.07 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.905 0.383 . . . . 0.0 110.956 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.76 -4.78 42.75 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.192 179.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.7 ptt? -69.04 171.1 8.68 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 123.512 0.725 . . . . 0.0 111.683 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.3 m170 -108.96 147.04 32.86 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.011 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -141.5 126.63 18.45 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.947 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.61 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -108.96 154.57 16.43 Favored Glycine 0 N--CA 1.439 -1.146 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.401 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.1 m-85 -136.77 99.35 4.02 Favored 'General case' 0 N--CA 1.437 -1.075 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.51 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.32 167.93 10.16 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 38.7 m80 65.75 40.69 4.22 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.779 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.531 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -100.93 169.98 8.6 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.76 177.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.5 t -106.38 -15.51 14.8 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 111.457 0.169 . . . . 0.0 111.457 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 6.8 tttt -167.95 156.87 9.4 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.618 0.723 . . . . 0.0 111.99 -178.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -120.84 148.83 23.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 113.844 -1.526 . . . . 0.0 110.72 178.917 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -112.01 -5.98 14.24 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.209 178.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.67 -175.1 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.088 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.683 -177.067 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.4 m -153.33 143.94 22.61 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 114.867 -1.061 . . . . 0.0 109.002 -178.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -56.47 126.61 27.26 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.184 -0.917 . . . . 0.0 111.785 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 t70 89.15 -4.77 0.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 124.807 1.243 . . . . 0.0 111.587 178.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.7 m -81.7 146.05 30.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 122.176 0.191 . . . . 0.0 110.588 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -82.64 145.83 29.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.215 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.93 167.9 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.48 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -140.09 147.38 40.19 Favored 'General case' 0 N--CA 1.428 -1.574 0 CA-C-N 114.417 -1.265 . . . . 0.0 109.836 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.789 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.1 138.8 54.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.128 -1.397 . . . . 0.0 111.693 -179.717 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.69 -6.78 37.29 Favored Glycine 0 CA--C 1.517 0.156 0 CA-C-N 114.361 -1.291 . . . . 0.0 114.129 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.494 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -73.11 140.23 46.98 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-O 121.104 0.478 . . . . 0.0 110.013 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.05 101.19 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.401 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.8 -5.44 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.88 0 CA-C-N 113.739 -1.573 . . . . 0.0 113.101 -178.867 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.3 -162.14 34.76 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-O 121.272 0.374 . . . . 0.0 112.683 178.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 24.6 m-85 -141.37 137.12 32.1 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 124.816 1.246 . . . . 0.0 108.272 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -61.35 151.46 32.12 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.615 0.766 . . . . 0.0 112.654 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.726 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.38 -162.17 11.41 Favored Glycine 0 C--N 1.347 1.185 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.798 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.619 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 47.72 0.89 Allowed 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -0.7 . . . . 0.0 109.261 178.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.626 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 34.4 p . . . . . 0 CA--C 1.541 0.629 0 CA-C-N 115.213 -0.903 . . . . 0.0 113.292 -177.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.873 0 CA-C-O 118.599 -1.112 . . . . 0.0 111.54 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.619 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.0 Cg_exo -69.8 141.95 46.43 Favored 'Trans proline' 0 C--N 1.374 1.912 0 CA-C-N 120.251 2.025 . . . . 0.0 111.725 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.556 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 53.2 p-80 -157.77 -171.56 3.59 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.495 0.664 . . . . 0.0 111.774 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.706 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 9.1 tp -125.23 139.85 53.36 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.099 -1.409 . . . . 0.0 110.565 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.51 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 29.1 t60 -118.32 128.54 54.75 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 113.706 -1.588 . . . . 0.0 107.845 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.528 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.5 t80 -133.0 111.26 10.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.48 ' HB2' ' NE2' ' A' ' 122' ' ' HIS . 18.0 tt0 -120.31 127.18 52.11 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.238 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.8 tpt -120.26 138.01 53.91 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.666 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.591 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.1 mp -143.6 164.68 29.13 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 113.439 -1.709 . . . . 0.0 110.298 -178.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -62.83 -178.81 0.43 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.943 2.429 . . . . 0.0 112.669 177.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -68.57 -27.82 66.41 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.206 176.195 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -157.35 107.93 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.781 0 CA-C-N 113.903 -1.498 . . . . 0.0 108.232 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -71.15 163.12 40.26 Favored 'Trans proline' 0 N--CA 1.445 -1.326 0 C-N-CA 122.347 2.031 . . . . 0.0 116.926 -176.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.568 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.89 70.82 0.8 Allowed 'General case' 0 N--CA 1.423 -1.805 0 CA-C-N 112.349 -2.205 . . . . 0.0 107.395 177.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.447 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.29 13.99 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.168 -1.378 . . . . 0.0 112.376 -178.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.568 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.23 32.3 0.33 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.269 1.027 . . . . 0.0 112.902 -178.361 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 72.21 127.96 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 125.737 1.615 . . . . 0.0 110.997 178.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.11 -48.08 0.61 Allowed Glycine 0 N--CA 1.437 -1.278 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.341 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.68 -19.52 0.16 Allowed 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.43 18.22 10.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 122.624 1.202 . . . . 0.0 108.19 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 79.77 -11.66 32.75 Favored Glycine 0 N--CA 1.434 -1.449 0 CA-C-N 112.252 -2.249 . . . . 0.0 112.648 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.678 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.8 OUTLIER -83.98 125.02 31.65 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.301 -179.434 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.439 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -125.24 -172.96 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.585 -0.734 . . . . 0.0 112.441 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 140' ' ' ILE . 2.9 t70 -75.82 134.77 71.63 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -176.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.596 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.9 Cg_endo -77.16 0.62 9.54 Favored 'Trans proline' 0 C--N 1.381 2.277 0 C-N-CA 123.082 2.521 . . . . 0.0 113.546 177.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -51.34 -24.08 4.32 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.69 -28.95 66.24 Favored Glycine 0 CA--C 1.521 0.45 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.912 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -99.71 -11.86 20.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 123.347 0.659 . . . . 0.0 111.194 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.596 HG12 ' O ' ' A' ' 142' ' ' PRO . 31.2 mm -98.8 -10.47 8.78 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.372 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.357 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.656 178.021 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.685 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 21.3 Cg_exo . . . . . 0 N--CA 1.482 0.842 0 N-CA-C 112.951 0.327 . . . . 0.0 112.951 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.753 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.56 -172.0 3.05 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 122.671 1.224 . . . . 0.0 110.375 -179.894 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -128.14 -25.22 3.03 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 112.144 -2.298 . . . . 0.0 108.742 177.213 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.753 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.3 t -168.62 -168.64 0.92 Allowed 'General case' 0 CA--C 1.548 0.87 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.781 -178.302 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 171.99 111.74 0.26 Allowed Glycine 0 C--N 1.318 -0.431 0 CA-C-N 114.661 -1.154 . . . . 0.0 111.441 178.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.16 124.97 9.12 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.729 0.776 . . . . 0.0 112.973 -178.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.763 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.75 58.34 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-N 113.393 -1.731 . . . . 0.0 109.122 179.38 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.9 t -105.15 -28.2 11.13 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 112.969 -1.923 . . . . 0.0 111.007 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.52 -67.15 1.02 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.774 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.73 122.64 1.03 Allowed Glycine 0 C--N 1.322 -0.196 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.144 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.51 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.17 157.6 32.57 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -178.795 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -57.14 32.12 0.0 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -177.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.706 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -0.02 49.06 Favored Glycine 0 CA--C 1.504 -0.624 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -102.16 85.42 0.72 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.706 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.5 Cg_exo -76.95 141.99 21.73 Favored 'Trans proline' 0 C--N 1.373 1.848 0 C-N-CA 122.826 2.351 . . . . 0.0 113.425 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.51 4.02 83.57 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.803 -0.635 . . . . 0.0 113.06 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.416 ' O ' HG21 ' A' ' 24' ' ' ILE . 3.3 t-80 -74.29 127.33 32.72 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.098 0.959 . . . . 0.0 110.697 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.753 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -102.72 5.45 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.656 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.86 -150.03 5.14 Favored Glycine 0 C--N 1.337 0.603 0 C-N-CA 121.526 -0.368 . . . . 0.0 112.257 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 123' ' ' PHE . 9.7 p -130.52 154.69 40.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 C-N-CA 122.97 0.508 . . . . 0.0 110.244 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.702 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -129.16 130.07 45.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.258 0.552 . . . . 0.0 111.914 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.685 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 3.4 m-85 -120.54 109.99 15.93 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.273 -178.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.3 104.15 0.15 Allowed 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.275 178.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.531 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.6 p -146.79 124.07 5.89 Favored Pre-proline 0 CA--C 1.55 0.974 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.76 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -49.0 142.97 18.81 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 123.4 2.733 . . . . 0.0 115.528 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.748 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.47 140.77 18.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 111.766 -2.47 . . . . 0.0 113.454 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.45 2.53 55.55 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 115.441 -0.8 . . . . 0.0 114.036 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -87.53 124.0 68.55 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-O 119.153 -0.451 . . . . 0.0 109.88 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.7 126.7 23.32 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.342 2.028 . . . . 0.0 113.272 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.602 HG21 HD22 ' A' ' 90' ' ' LEU . 5.8 t -99.55 121.12 49.83 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 CA-C-N 115.107 -0.951 . . . . 0.0 108.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.506 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 3.9 mpt_? -102.21 152.41 21.06 Favored 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 113.301 -1.772 . . . . 0.0 111.434 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.71 122.63 20.97 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.689 -1.141 . . . . 0.0 111.435 -178.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 24.6 t -69.42 -14.53 18.52 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.553 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.631 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.24 143.86 1.95 Allowed 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 123.491 0.716 . . . . 0.0 110.641 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -62.68 156.04 24.67 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 114.943 -1.026 . . . . 0.0 112.477 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.63 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.32 -127.61 1.57 Allowed Glycine 0 C--N 1.334 0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.551 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.7 m -148.08 141.45 25.26 Favored 'General case' 0 N--CA 1.436 -1.148 0 C-N-CA 123.598 0.759 . . . . 0.0 109.532 -178.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 10.6 t -83.63 112.81 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 O-C-N 123.907 0.755 . . . . 0.0 108.995 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 10.0 mmmt -94.93 -14.72 24.2 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.666 -1.152 . . . . 0.0 110.819 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -156.69 141.2 16.75 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.896 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.04 92.44 2.05 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.805 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.426 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.96 92.03 1.46 Allowed Glycine 0 C--O 1.241 0.533 0 CA-C-N 114.35 -1.295 . . . . 0.0 112.658 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.582 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.65 123.7 23.78 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.134 0.974 . . . . 0.0 112.744 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.623 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.62 -0.76 88.21 Favored Glycine 0 CA--C 1.519 0.342 0 CA-C-N 113.369 -1.741 . . . . 0.0 113.59 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -32.31 57.54 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.54 24.79 2.66 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.027 -178.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.623 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -81.08 114.05 45.81 Favored Pre-proline 0 N--CA 1.435 -1.211 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -178.182 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.837 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.4 Cg_exo -67.81 162.12 40.95 Favored 'Trans proline' 0 C--N 1.37 1.685 0 C-N-CA 123.727 2.952 . . . . 0.0 111.804 177.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 63.3 m95 -96.1 13.01 28.64 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 176.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 81.9 mtp -80.07 -42.51 23.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.785 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.537 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.4 pp -125.76 15.44 8.08 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.795 177.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.837 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.4 OUTLIER -137.29 108.59 6.85 Favored 'General case' 0 C--N 1.369 1.416 0 C-N-CA 120.022 -0.671 . . . . 0.0 112.612 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 16.8 ttm -113.05 -20.3 11.56 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.416 178.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -91.54 -26.5 18.73 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.581 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 102.78 -128.57 9.59 Favored Glycine 0 CA--C 1.519 0.335 0 O-C-N 123.703 0.627 . . . . 0.0 113.704 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.614 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.5 m-80 -83.25 138.55 33.54 Favored 'General case' 0 C--N 1.346 0.43 0 C-N-CA 123.113 0.565 . . . . 0.0 112.138 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -152.27 145.96 25.03 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.3 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.63 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.15 120.34 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.164 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.7 129.6 56.54 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' THR . 7.7 mt -139.19 150.81 22.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.328 -176.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.63 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -100.24 117.27 34.11 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.904 -1.498 . . . . 0.0 108.504 178.037 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.631 ' CE1' ' HB3' ' A' ' 51' ' ' ALA . 2.9 m-70 -68.74 -175.91 0.75 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.489 -1.232 . . . . 0.0 114.092 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.92 65.03 Favored 'General case' 0 N--CA 1.452 -0.369 0 CA-C-N 114.037 -1.438 . . . . 0.0 114.457 -177.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.65 -9.02 21.29 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 120.876 0.369 . . . . 0.0 110.99 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.71 -6.74 44.85 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.122 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.2 ptt? -67.09 170.48 6.85 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 123.461 0.704 . . . . 0.0 111.465 179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.437 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 70.5 m-70 -114.68 145.42 42.06 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 120.609 -0.436 . . . . 0.0 111.218 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.68 127.34 20.27 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.051 179.68 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.63 155.4 16.52 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.698 178.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.8 m-85 -134.54 99.46 4.36 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.478 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -112.38 168.02 9.97 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 112.689 0.625 . . . . 0.0 112.689 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 65.68 41.0 4.16 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.449 1.099 . . . . 0.0 111.736 -178.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.602 HD22 HG21 ' A' ' 47' ' ' VAL . 10.9 mt -102.14 167.93 9.7 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.039 178.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.7 t -104.57 -14.47 15.63 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.57 160.56 13.05 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.697 0.761 . . . . 0.0 111.861 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.836 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.16 149.17 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 113.563 -1.653 . . . . 0.0 110.83 179.045 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -112.56 -6.03 13.97 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.173 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.836 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.12 -175.28 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.006 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.642 -176.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.9 t -153.17 150.42 29.03 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.835 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.1 m -60.2 128.41 36.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.377 -179.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 85.49 -4.06 0.86 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.627 1.171 . . . . 0.0 111.674 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -79.83 148.88 31.2 Favored 'General case' 0 C--N 1.347 0.493 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.45 145.34 29.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.66 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.81 166.38 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.264 -179.271 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.7 tttp -141.5 148.48 39.5 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.916 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.794 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.65 138.23 55.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -179.595 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.506 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.88 -5.45 47.93 Favored Glycine 0 CA--C 1.518 0.242 0 CA-C-N 114.252 -1.34 . . . . 0.0 114.238 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.5 tt0 -74.5 140.35 44.48 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.024 0.44 . . . . 0.0 110.184 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 49.0 mt -71.54 101.65 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.668 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.58 -4.87 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.035 -179.02 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.11 -160.52 34.11 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-O 121.137 0.298 . . . . 0.0 112.47 178.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 28.5 m-85 -140.93 138.53 33.91 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.535 1.134 . . . . 0.0 108.377 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.11 151.9 29.83 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.625 0.77 . . . . 0.0 112.483 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.748 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.71 -164.1 13.46 Favored Glycine 0 C--N 1.346 1.124 0 C-N-CA 120.036 -1.078 . . . . 0.0 114.079 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.624 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 49.67 0.89 Allowed 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.734 -0.733 . . . . 0.0 109.076 178.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.581 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 25.5 p . . . . . 0 CA--C 1.54 0.563 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -177.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.021 0 CA-C-O 119.096 -0.835 . . . . 0.0 113.176 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.624 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.8 Cg_exo -78.81 146.58 20.97 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.882 2.388 . . . . 0.0 112.087 179.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.531 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 54.3 p-80 -159.79 -167.24 1.93 Allowed 'General case' 0 C--N 1.347 0.459 0 CA-C-O 121.467 0.651 . . . . 0.0 111.851 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.702 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 11.1 tp -126.18 137.64 53.58 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.228 -1.351 . . . . 0.0 110.339 -178.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.478 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 28.5 t60 -117.44 126.35 52.49 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 113.895 -1.502 . . . . 0.0 108.287 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.532 ' O ' HG12 ' A' ' 37' ' ' VAL . 32.2 t80 -131.61 108.62 9.65 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.973 178.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.516 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.1 pt-20 -116.62 128.38 55.33 Favored 'General case' 0 N--CA 1.429 -1.49 0 CA-C-N 115.276 -0.874 . . . . 0.0 109.476 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.417 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 3.4 tpt -121.08 136.9 54.88 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.837 -179.415 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.628 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.11 165.52 25.47 Favored Pre-proline 0 C--N 1.309 -1.169 0 CA-C-N 113.352 -1.749 . . . . 0.0 110.3 -177.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.8 Cg_endo -63.57 -178.25 0.5 Allowed 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 123.055 2.503 . . . . 0.0 112.9 176.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.44 -28.3 63.88 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.01 176.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -157.03 102.61 1.92 Allowed Pre-proline 0 CA--C 1.503 -0.828 0 CA-C-N 114.218 -1.355 . . . . 0.0 108.771 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.73 163.34 37.47 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.555 2.17 . . . . 0.0 116.603 -177.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.565 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.41 71.51 0.84 Allowed 'General case' 0 N--CA 1.425 -1.693 0 CA-C-N 112.344 -2.207 . . . . 0.0 107.095 177.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.446 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.44 14.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 114.239 -1.346 . . . . 0.0 112.463 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.565 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -82.05 35.52 0.43 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.042 0.937 . . . . 0.0 112.951 -178.197 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 73.06 127.11 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.488 0 C-N-CA 125.53 1.532 . . . . 0.0 110.52 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.41 -50.08 0.56 Allowed Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.396 -0.907 . . . . 0.0 113.353 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.598 ' CE1' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -151.87 -19.86 0.19 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.027 0.414 . . . . 0.0 111.527 179.177 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . 0.402 ' H ' ' H ' ' A' ' 136' ' ' PHE . 27.5 m 65.78 18.01 11.02 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.885 1.274 . . . . 0.0 108.283 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.628 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.11 -11.19 12.45 Favored Glycine 0 N--CA 1.436 -1.305 0 CA-C-N 112.465 -2.152 . . . . 0.0 112.782 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.753 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -82.48 121.8 27.22 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.1 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.418 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -124.64 -172.79 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.355 179.416 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . 0.418 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.9 p30 -79.76 132.05 62.28 Favored Pre-proline 0 CA--C 1.552 1.038 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -176.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.527 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.71 0.04 10.19 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.233 2.622 . . . . 0.0 114.204 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.36 -24.23 7.29 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -178.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -74.5 -23.25 75.92 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.899 179.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -101.12 -12.27 18.93 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 123.62 0.768 . . . . 0.0 111.169 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.527 HG12 ' O ' ' A' ' 142' ' ' PRO . 26.6 mm -101.72 -10.68 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.688 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.236 0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.84 178.091 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.66 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.7 Cg_exo . . . . . 0 N--CA 1.481 0.761 0 CA-C-O 120.774 0.239 . . . . 0.0 112.27 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.749 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -139.57 -171.84 3.23 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 122.614 1.197 . . . . 0.0 110.213 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.466 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.02 -25.17 2.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 112.241 -2.254 . . . . 0.0 108.792 177.219 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.749 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.4 t -168.95 -168.48 0.86 Allowed 'General case' 0 CA--C 1.546 0.802 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.619 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.04 111.9 0.35 Allowed Glycine 0 C--N 1.319 -0.371 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.336 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.67 124.63 9.96 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 121.888 0.852 . . . . 0.0 112.8 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.733 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.05 58.57 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 113.173 -1.83 . . . . 0.0 108.965 178.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.8 t -102.47 -28.98 11.88 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.838 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -113.42 -67.91 0.97 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.6 125.03 1.2 Allowed Glycine 0 C--N 1.323 -0.172 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.037 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.5 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -77.08 157.32 31.14 Favored 'General case' 0 C--N 1.343 0.298 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -178.956 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -55.97 32.19 0.0 OUTLIER 'General case' 0 C--O 1.239 0.526 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.702 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.74 0.94 49.33 Favored Glycine 0 CA--C 1.504 -0.647 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -101.64 85.34 0.64 Allowed Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.0 Cg_exo -77.42 139.66 18.61 Favored 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.748 2.299 . . . . 0.0 113.247 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.19 4.22 78.06 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.007 179.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.437 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.1 t-80 -75.36 131.4 40.22 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 123.997 0.919 . . . . 0.0 110.458 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.642 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.46 -1.98 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.488 -179.315 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.98 -150.21 5.89 Favored Glycine 0 C--N 1.338 0.661 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.685 HG11 ' HG3' ' A' ' 142' ' ' PRO . 11.9 p -132.05 149.19 32.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 O-C-N 123.864 0.391 . . . . 0.0 110.618 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.777 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.72 134.0 51.92 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 121.322 0.582 . . . . 0.0 112.074 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.66 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -124.57 110.44 14.45 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.354 -1.294 . . . . 0.0 110.131 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.06 107.31 0.29 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 115.813 -0.63 . . . . 0.0 112.117 178.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.563 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.2 p -146.36 127.12 7.16 Favored Pre-proline 0 CA--C 1.549 0.929 0 CA-C-N 115.021 -0.99 . . . . 0.0 109.172 -179.343 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -55.78 143.6 80.15 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.259 2.639 . . . . 0.0 115.583 -178.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.756 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -62.63 139.26 21.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 111.79 -2.459 . . . . 0.0 113.472 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.9 2.66 55.08 Favored Glycine 0 N--CA 1.442 -0.942 0 CA-C-N 115.366 -0.834 . . . . 0.0 114.063 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.12 120.83 70.74 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.2 126.1 21.39 Favored 'Trans proline' 0 C--N 1.376 1.985 0 C-N-CA 122.431 2.087 . . . . 0.0 113.104 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.594 HG21 HD22 ' A' ' 90' ' ' LEU . 4.9 t -98.51 121.15 48.75 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.978 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 4.5 mpt_? -102.93 152.54 21.18 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 113.264 -1.789 . . . . 0.0 111.443 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -72.42 123.52 23.26 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.7 -1.136 . . . . 0.0 111.587 -178.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.9 t -65.83 -21.57 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 CA-C-N 115.597 -0.729 . . . . 0.0 112.613 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.646 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -167.69 143.99 4.13 Favored 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 123.184 0.593 . . . . 0.0 110.653 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -59.94 155.51 16.46 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.191 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.17 -126.37 1.4 Allowed Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.777 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.4 m -148.26 142.01 25.64 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 123.537 0.735 . . . . 0.0 109.971 -177.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 99' ' ' SER . 11.6 t -85.95 112.84 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 O-C-N 124.028 0.83 . . . . 0.0 108.921 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.6 mmmt -95.15 -14.79 23.84 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.596 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -154.21 140.09 18.19 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.243 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.13 92.37 2.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.781 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.463 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.18 89.87 1.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 114.141 -1.39 . . . . 0.0 113.368 -179.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.573 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -69.99 124.05 23.09 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.907 0.883 . . . . 0.0 112.552 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.574 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.39 -0.63 87.22 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-N 113.334 -1.757 . . . . 0.0 113.645 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.81 -32.14 46.18 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 26.93 2.57 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.978 -178.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.57 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.86 115.87 57.03 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -178.28 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.1 Cg_exo -69.49 162.89 40.14 Favored 'Trans proline' 0 C--N 1.37 1.704 0 C-N-CA 123.765 2.976 . . . . 0.0 111.469 177.028 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -98.73 12.36 35.77 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.2 mtt -78.36 -44.08 25.98 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.539 -1.209 . . . . 0.0 110.149 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.518 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -119.88 10.69 11.63 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.793 177.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.48 146.31 50.85 Favored 'General case' 0 C--N 1.362 1.151 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.782 -179.01 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 46.1 mtt -139.37 -36.17 0.53 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.443 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -88.79 -21.02 23.99 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.413 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 95.12 -112.81 4.46 Favored Glycine 0 C--N 1.335 0.488 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.12 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.574 HD21 ' HA3' ' A' ' 61' ' ' GLY . 13.7 m-80 -80.37 135.7 36.23 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.182 0.593 . . . . 0.0 112.528 -178.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -149.18 146.31 27.58 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.228 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.32 122.01 17.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.094 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.5 129.92 54.95 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 177.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -141.08 150.87 20.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 CA-C-N 112.942 -1.935 . . . . 0.0 110.497 -176.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.48 116.05 30.74 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.277 177.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.646 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.3 m-70 -68.6 -177.76 1.01 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.528 -1.215 . . . . 0.0 114.121 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -65.59 -17.37 64.53 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.824 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.58 -12.21 21.4 Favored 'General case' 0 C--O 1.236 0.388 0 O-C-N 123.415 0.447 . . . . 0.0 110.732 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.63 -6.57 45.02 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.118 -0.947 . . . . 0.0 112.035 178.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.455 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 12.1 ptt? -71.45 164.69 25.31 Favored 'General case' 0 N--CA 1.436 -1.154 0 C-N-CA 123.135 0.574 . . . . 0.0 111.772 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.455 ' O ' ' HA ' ' A' ' 125' ' ' MET . 53.0 m-70 -105.61 142.78 34.75 Favored 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.121 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.07 127.17 26.07 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.41 154.45 16.82 Favored Glycine 0 N--CA 1.442 -0.967 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.699 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -137.23 98.65 3.78 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.442 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -116.11 170.42 8.52 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 54.9 m80 65.59 38.1 5.62 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.339 1.056 . . . . 0.0 111.137 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.594 HD22 HG21 ' A' ' 47' ' ' VAL . 11.3 mt -97.94 170.11 9.17 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.966 178.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 17.3 t -104.14 -15.28 15.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 111.465 0.172 . . . . 0.0 111.465 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 9.0 tttt -168.46 159.55 10.44 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.696 0.76 . . . . 0.0 112.204 -178.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.821 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -124.38 148.98 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 113.541 -1.663 . . . . 0.0 110.862 178.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.53 -5.05 13.45 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.213 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.821 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.08 -175.33 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.074 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.553 -177.049 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.6 t -152.23 149.45 28.73 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.841 -179.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -60.32 127.9 34.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.496 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 85.39 -3.61 0.86 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.508 1.123 . . . . 0.0 111.673 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.478 ' O ' HG23 ' A' ' 55' ' ' VAL . 40.1 m -79.98 148.95 30.96 Favored 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 122.299 0.24 . . . . 0.0 110.415 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.6 p -83.19 145.68 29.04 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.491 178.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.21 167.66 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.297 0 CA-C-N 115.302 -0.863 . . . . 0.0 112.324 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.418 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.0 tttm -141.33 147.98 38.97 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.957 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.776 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.81 137.49 56.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.378 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.94 -5.64 47.07 Favored Glycine 0 CA--C 1.519 0.334 0 CA-C-N 114.285 -1.325 . . . . 0.0 114.112 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.498 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.4 tt0 -73.87 139.66 45.17 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.108 0.48 . . . . 0.0 110.143 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 57.8 mt -70.94 101.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.62 -179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.8 OUTLIER -93.72 -4.12 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.61 -1.632 . . . . 0.0 112.937 -179.125 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.49 -161.3 35.11 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-O 121.228 0.349 . . . . 0.0 112.737 178.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.572 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.0 m-85 -141.5 136.92 31.69 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 124.834 1.253 . . . . 0.0 108.341 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.408 HG23 HG22 ' A' ' 47' ' ' VAL . 2.1 p -60.43 152.73 24.83 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.423 0.689 . . . . 0.0 112.08 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.756 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -155.82 -165.44 14.44 Favored Glycine 0 C--N 1.345 1.048 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.915 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -149.77 45.13 0.93 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.565 -0.818 . . . . 0.0 108.953 178.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.47 0.538 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.636 -177.476 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.935 0 CA-C-O 119.125 -0.82 . . . . 0.0 112.682 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.584 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -73.88 146.35 37.52 Favored 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 122.93 2.42 . . . . 0.0 111.916 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.563 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 46.9 p-80 -157.66 -169.7 2.95 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-O 121.547 0.689 . . . . 0.0 112.401 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.777 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.0 tp -126.4 131.81 51.66 Favored 'General case' 0 N--CA 1.432 -1.34 0 CA-C-N 114.049 -1.432 . . . . 0.0 111.166 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 24.8 t60 -114.01 110.08 19.48 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.088 177.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.54 ' O ' HG12 ' A' ' 37' ' ' VAL . 23.1 t80 -117.08 109.23 16.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.364 -179.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.1 tt0 -116.22 127.06 54.44 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.208 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.455 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 2.5 ttt -118.62 134.7 54.91 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.679 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.4 mp -142.31 166.6 20.21 Favored Pre-proline 0 C--N 1.31 -1.14 0 CA-C-N 113.297 -1.774 . . . . 0.0 111.004 -177.125 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.5 Cg_endo -63.32 -178.44 0.47 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 123.027 2.484 . . . . 0.0 112.851 176.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -72.62 -27.06 61.92 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.194 176.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.29 98.84 1.96 Allowed Pre-proline 0 CA--C 1.503 -0.835 0 CA-C-N 114.206 -1.361 . . . . 0.0 109.314 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -71.1 163.37 39.44 Favored 'Trans proline' 0 N--CA 1.445 -1.377 0 C-N-CA 122.868 2.379 . . . . 0.0 116.532 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.2 t-20 -116.76 70.56 0.77 Allowed 'General case' 0 N--CA 1.425 -1.691 0 CA-C-N 112.579 -2.101 . . . . 0.0 107.24 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.99 13.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 114.351 -1.295 . . . . 0.0 112.412 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 35.27 0.41 Allowed 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 124.196 0.998 . . . . 0.0 113.083 -178.109 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 73.32 126.29 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 125.509 1.523 . . . . 0.0 110.727 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.5 -50.18 0.56 Allowed Glycine 0 N--CA 1.442 -0.902 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.482 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.559 ' CE2' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -152.43 -19.73 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 117.102 0.451 . . . . 0.0 111.432 179.257 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 30.1 t 66.45 18.13 10.78 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.034 1.334 . . . . 0.0 108.411 -178.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.559 ' HA2' ' CE2' ' A' ' 136' ' ' PHE . . . 77.7 -11.04 21.43 Favored Glycine 0 N--CA 1.436 -1.334 0 CA-C-N 112.66 -2.063 . . . . 0.0 112.8 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.642 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -81.45 127.18 32.52 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 120.081 -0.648 . . . . 0.0 112.117 -179.19 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -126.93 -174.34 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.337 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.033 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -70.34 134.7 86.84 Favored Pre-proline 0 CA--C 1.544 0.731 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.618 -178.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.685 ' HG3' HG11 ' A' ' 37' ' ' VAL . 95.4 Cg_endo -76.7 21.64 0.56 Allowed 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 123.162 2.575 . . . . 0.0 114.081 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.9 p -56.04 -24.63 40.69 Favored 'General case' 0 C--N 1.344 0.349 0 C-N-CA 124.228 1.011 . . . . 0.0 113.308 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.52 -23.78 77.35 Favored Glycine 0 N--CA 1.462 0.427 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -96.2 -9.7 29.85 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.655 1.182 . . . . 0.0 110.43 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 142' ' ' PRO . 21.1 mm -104.93 -12.47 9.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.841 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.261 0 C-N-CA 123.133 0.573 . . . . 0.0 112.271 -179.961 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.762 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.7 Cg_exo . . . . . 0 N--CA 1.478 0.613 0 N-CA-C 113.192 0.42 . . . . 0.0 113.192 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.42 -171.81 2.86 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-O 122.736 1.255 . . . . 0.0 110.781 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.477 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.49 -25.09 2.96 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 111.98 -2.373 . . . . 0.0 108.691 177.512 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.764 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -168.58 -169.11 0.99 Allowed 'General case' 0 CA--C 1.55 0.949 0 CA-C-N 114.405 -1.271 . . . . 0.0 111.996 -178.107 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.12 110.66 0.25 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 114.504 -1.226 . . . . 0.0 111.251 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.39 124.72 8.19 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.714 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.37 58.4 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 114.201 -1.363 . . . . 0.0 108.949 178.191 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.7 t -103.27 -28.69 11.72 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.066 -1.879 . . . . 0.0 110.852 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -113.45 -66.8 1.05 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.489 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.17 124.48 1.17 Allowed Glycine 0 C--N 1.323 -0.182 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.865 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.484 ' HD2' ' HB2' ' A' ' 31' ' ' TYR . 0.1 OUTLIER -74.55 157.39 35.57 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -178.829 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -58.95 32.02 0.01 OUTLIER 'General case' 0 C--O 1.24 0.559 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.709 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.71 -1.56 48.9 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 111.429 -0.669 . . . . 0.0 111.429 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.484 ' HB2' ' HD2' ' A' ' 28' ' ' PHE . 7.7 m-85 -102.19 85.37 0.71 Allowed Pre-proline 0 CA--C 1.548 0.868 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.71 140.21 16.38 Favored 'Trans proline' 0 C--N 1.376 1.998 0 C-N-CA 122.836 2.358 . . . . 0.0 113.585 -178.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.57 4.27 70.56 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.743 -0.662 . . . . 0.0 113.181 179.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.423 ' O ' HG12 ' A' ' 24' ' ' ILE . 4.1 t-80 -79.79 133.0 36.28 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 124.209 1.004 . . . . 0.0 110.032 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.637 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.07 -10.51 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 123.64 0.588 . . . . 0.0 111.779 -178.845 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -129.93 -149.79 6.79 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 112.063 -0.415 . . . . 0.0 112.063 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.558 HG12 ' O ' ' A' ' 123' ' ' PHE . 12.4 p -130.52 151.66 36.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.844 0.379 . . . . 0.0 110.522 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.719 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -127.08 132.03 50.73 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.265 0.555 . . . . 0.0 111.408 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.762 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 6.5 m-85 -118.24 111.7 19.14 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.475 -1.239 . . . . 0.0 111.227 -177.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.42 99.76 0.09 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.548 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.46 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 14.2 p -142.87 129.02 10.47 Favored Pre-proline 0 CA--C 1.547 0.859 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.168 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 119' ' ' PRO . 87.8 Cg_exo -48.82 139.83 24.16 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 123.472 2.782 . . . . 0.0 115.844 -179.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.846 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -66.57 137.34 25.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 111.764 -2.471 . . . . 0.0 113.345 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.27 2.71 51.11 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.908 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.8 m -87.76 131.57 43.03 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.238 -0.41 . . . . 0.0 109.976 179.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.64 128.32 25.45 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.214 1.942 . . . . 0.0 113.004 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.621 HG21 HD22 ' A' ' 90' ' ' LEU . 8.1 t -100.14 123.15 52.82 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.885 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.64 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 19.5 mtt180 -101.95 152.02 21.43 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 112.929 -1.941 . . . . 0.0 111.752 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.06 123.67 24.01 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.098 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.02 -15.94 20.36 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.716 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.639 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.64 143.02 1.66 Allowed 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 123.349 0.66 . . . . 0.0 110.497 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.435 ' HB3' ' HA ' ' A' ' 102' ' ' LYS . 0.4 OUTLIER -61.66 155.49 22.42 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.052 -0.976 . . . . 0.0 112.307 179.193 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.581 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.99 -126.26 1.36 Allowed Glycine 0 C--N 1.331 0.302 0 O-C-N 123.792 0.683 . . . . 0.0 113.45 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 7.9 m -147.1 141.52 26.4 Favored 'General case' 0 N--CA 1.436 -1.127 0 C-N-CA 123.576 0.75 . . . . 0.0 109.613 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 99' ' ' SER . 12.2 t -85.04 113.24 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 123.764 0.826 . . . . 0.0 108.783 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.408 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 7.0 mmmt -95.35 -14.9 23.49 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.675 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -156.17 140.27 16.44 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.198 179.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.01 92.12 1.93 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.147 -1.388 . . . . 0.0 108.934 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.41 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.76 91.27 1.46 Allowed Glycine 0 C--O 1.238 0.386 0 CA-C-N 114.362 -1.29 . . . . 0.0 112.214 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.582 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -70.27 122.34 19.35 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 122.006 0.908 . . . . 0.0 112.857 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.632 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.77 -0.86 88.82 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 113.201 -1.818 . . . . 0.0 113.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.46 -32.91 62.75 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.92 26.69 2.46 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.927 -178.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.632 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -82.59 114.13 49.65 Favored Pre-proline 0 N--CA 1.435 -1.192 0 N-CA-C 114.006 1.113 . . . . 0.0 114.006 -178.083 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.823 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.8 Cg_exo -67.72 162.31 39.95 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 123.987 3.125 . . . . 0.0 112.239 177.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . 0.401 ' HA ' ' O ' ' A' ' 69' ' ' TRP . 59.8 m95 -95.76 12.23 30.72 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.24 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 58.9 mtt -78.42 -42.8 29.07 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.774 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.53 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -126.08 14.82 7.89 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.862 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.823 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.2 OUTLIER -137.33 113.24 9.7 Favored 'General case' 0 C--N 1.367 1.331 0 C-N-CA 120.188 -0.605 . . . . 0.0 112.581 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -110.83 -33.81 6.43 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.91 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.07 -18.68 33.57 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.513 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.52 -126.68 9.0 Favored Glycine 0 CA--C 1.52 0.394 0 O-C-N 123.515 0.51 . . . . 0.0 113.946 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.568 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.4 m-80 -81.21 145.98 30.71 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.738 0.815 . . . . 0.0 112.555 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -152.31 144.85 24.14 Favored 'General case' 0 CA--C 1.519 -0.243 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.438 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.612 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -139.46 120.86 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.539 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.46 128.01 51.67 Favored 'General case' 0 CA--C 1.492 -1.28 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -138.92 151.07 23.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 112.785 -2.007 . . . . 0.0 110.679 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.581 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -100.2 117.43 34.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.903 177.859 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.639 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.2 m-70 -70.04 -176.23 1.09 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 114.137 -1.392 . . . . 0.0 114.196 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.54 -18.05 65.03 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 113.806 -1.543 . . . . 0.0 114.42 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -9.67 20.35 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.913 0.387 . . . . 0.0 111.016 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.86 -6.49 43.99 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.221 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.456 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 6.5 ptt? -69.36 163.66 24.65 Favored 'General case' 0 N--CA 1.439 -1.007 0 C-N-CA 123.182 0.593 . . . . 0.0 111.621 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.444 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 60.2 m-70 -107.51 144.81 33.97 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.892 -178.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.96 127.31 24.68 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.612 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -107.29 154.47 16.61 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.339 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -138.44 98.44 3.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 104.221 -2.511 . . . . 0.0 104.221 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB3' ' HB3' ' A' ' 122' ' ' HIS . . . -116.72 173.59 6.55 Favored 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 10.7 m80 66.05 20.18 11.22 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.505 1.122 . . . . 0.0 112.121 -179.043 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.621 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -79.66 172.43 13.79 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 123.708 0.803 . . . . 0.0 111.14 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.4 t -104.99 -15.69 15.04 Favored 'General case' 0 N--CA 1.447 -0.607 0 O-C-N 123.139 0.275 . . . . 0.0 111.555 -179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.432 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 12.3 tttt -168.71 157.52 8.51 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.809 0.814 . . . . 0.0 112.464 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.5 150.3 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 CA-C-N 113.467 -1.697 . . . . 0.0 110.97 179.187 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -114.03 -6.51 13.12 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.508 -1.224 . . . . 0.0 110.181 177.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.1 OUTLIER -103.36 -175.02 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-N 115.361 -0.836 . . . . 0.0 112.765 -177.064 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 58.8 m -152.89 144.66 23.56 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.62 -1.173 . . . . 0.0 108.985 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.534 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.1 m -57.24 127.93 34.43 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.301 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.71 -3.55 0.68 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.606 1.162 . . . . 0.0 111.884 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.498 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.8 m -81.08 149.19 29.32 Favored 'General case' 0 C--N 1.346 0.456 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 178.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.26 145.28 29.21 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.184 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 166.15 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.346 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.435 ' HA ' ' HB3' ' A' ' 52' ' ' ASN . 62.9 tttt -140.09 148.56 41.91 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.064 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.793 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.1 138.37 56.14 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.132 -1.394 . . . . 0.0 111.332 -179.751 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.64 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.47 -5.89 41.65 Favored Glycine 0 CA--C 1.516 0.145 0 CA-C-N 114.3 -1.318 . . . . 0.0 114.134 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.534 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.1 tt0 -73.28 143.79 46.87 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 122.989 0.515 . . . . 0.0 109.991 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 25.6 mt -74.17 101.65 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 CA-C-N 115.074 -0.967 . . . . 0.0 109.612 -179.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.59 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -93.59 -3.68 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 113.393 -1.73 . . . . 0.0 112.55 -179.236 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.31 -160.84 34.62 Favored Glycine 0 N--CA 1.439 -1.113 0 CA-C-O 121.307 0.393 . . . . 0.0 112.696 178.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 20.9 m-85 -142.25 137.35 30.63 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 124.875 1.27 . . . . 0.0 108.061 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -58.94 151.88 20.87 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 123.556 0.743 . . . . 0.0 112.356 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.846 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -147.58 -170.79 16.03 Favored Glycine 0 C--N 1.347 1.187 0 C-N-CA 119.834 -1.174 . . . . 0.0 113.655 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -144.83 44.46 1.36 Allowed 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.779 -0.71 . . . . 0.0 109.173 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.513 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 37.5 p . . . . . 0 CA--C 1.541 0.627 0 N-CA-C 113.62 0.971 . . . . 0.0 113.62 -177.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.683 0 CA-C-O 119.798 -0.445 . . . . 0.0 112.92 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.612 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 21.4 Cg_exo -70.84 147.26 55.56 Favored 'Trans proline' 0 C--N 1.365 1.445 0 C-N-CA 123.558 2.839 . . . . 0.0 111.956 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -152.0 156.29 39.69 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 122.3 1.048 . . . . 0.0 112.82 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -117.01 127.96 54.69 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 112.566 -2.107 . . . . 0.0 108.297 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 88' ' ' ALA . 23.3 t60 -112.36 109.57 19.27 Favored 'General case' 0 N--CA 1.434 -1.258 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.255 179.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.558 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.73 108.52 16.47 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.931 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.475 ' OE1' HD11 ' A' ' 126' ' ' LEU . 21.5 tt0 -120.55 125.86 48.88 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.621 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.653 ' SD ' ' HA ' ' A' ' 142' ' ' PRO . 19.4 ptm -111.74 135.36 52.45 Favored 'General case' 0 N--CA 1.419 -2.011 0 C-N-CA 124.012 0.925 . . . . 0.0 109.579 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.475 HD11 ' OE1' ' A' ' 124' ' ' GLU . 2.8 mp -138.56 165.92 29.27 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.697 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.444 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.7 Cg_endo -63.2 -178.5 0.46 Allowed 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.969 2.446 . . . . 0.0 112.703 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.99 -27.21 62.6 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.214 176.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -157.46 101.21 1.87 Allowed Pre-proline 0 CA--C 1.503 -0.851 0 CA-C-N 114.182 -1.372 . . . . 0.0 109.019 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HB3' ' HA3' ' A' ' 138' ' ' GLY . 3.0 Cg_exo -72.89 163.66 37.75 Favored 'Trans proline' 0 N--CA 1.446 -1.284 0 C-N-CA 122.722 2.281 . . . . 0.0 116.592 -177.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.559 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -118.01 70.73 0.81 Allowed 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 112.482 -2.145 . . . . 0.0 107.339 177.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.442 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.3 m-90 -63.54 14.71 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.317 -1.311 . . . . 0.0 112.696 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.559 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.24 35.49 0.39 Allowed 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 122.121 0.963 . . . . 0.0 112.897 -178.353 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 70.72 127.59 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 125.73 1.612 . . . . 0.0 110.883 178.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 148.98 -49.9 0.57 Allowed Glycine 0 N--CA 1.437 -1.254 0 CA-C-N 114.979 -1.009 . . . . 0.0 113.031 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.5 -21.5 0.23 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 122.37 0.268 . . . . 0.0 111.43 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 26.9 m 66.19 17.94 10.85 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.672 1.189 . . . . 0.0 108.454 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.93 -9.73 23.05 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 112.497 -2.138 . . . . 0.0 112.672 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.637 ' HG2' HG12 ' A' ' 35' ' ' VAL . 2.1 ppt_? -83.18 126.16 32.33 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.42 -174.34 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.89 178.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . 0.426 ' O ' ' SD ' ' A' ' 125' ' ' MET . 1.8 p30 -79.25 135.58 57.69 Favored Pre-proline 0 CA--C 1.549 0.939 0 N-CA-C 114.06 1.133 . . . . 0.0 114.06 -176.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.653 ' HA ' ' SD ' ' A' ' 125' ' ' MET . 1.0 OUTLIER -76.46 1.4 8.45 Favored 'Trans proline' 0 C--N 1.383 2.39 0 C-N-CA 123.003 2.469 . . . . 0.0 113.244 178.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.67 -23.7 7.1 Favored 'General case' 0 C--N 1.351 0.664 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -178.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.41 -31.62 74.32 Favored Glycine 0 C--N 1.333 0.387 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . 0.446 ' HE1' ' SD ' ' A' ' 125' ' ' MET . 32.1 m-85 -94.35 -13.49 26.32 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 122.978 0.511 . . . . 0.0 111.53 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.571 HG12 ' O ' ' A' ' 142' ' ' PRO . 14.6 mm -100.98 -9.06 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.434 -178.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.32 0 CA-C-O 121.238 0.542 . . . . 0.0 111.429 179.037 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.705 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.1 Cg_exo . . . . . 0 N--CA 1.484 0.92 0 N-CA-C 113.286 0.456 . . . . 0.0 113.286 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.768 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.41 -172.16 2.88 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 122.682 1.229 . . . . 0.0 110.722 -179.765 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -129.08 -24.75 2.85 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 111.862 -2.426 . . . . 0.0 108.797 177.407 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.768 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.5 t -168.58 -168.74 0.94 Allowed 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 114.55 -1.205 . . . . 0.0 112.185 -177.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.411 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 172.75 111.43 0.26 Allowed Glycine 0 C--N 1.319 -0.37 0 CA-C-N 114.268 -1.333 . . . . 0.0 111.415 177.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.55 124.69 8.71 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.588 0.709 . . . . 0.0 112.764 -178.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.796 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -103.04 58.74 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-N 113.692 -1.595 . . . . 0.0 108.663 178.674 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.0 t -100.05 -28.56 12.99 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 112.879 -1.964 . . . . 0.0 110.826 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.8 m -116.93 -66.28 1.1 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.434 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.96 125.74 1.3 Allowed Glycine 0 C--N 1.322 -0.199 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.824 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.537 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -73.54 157.36 36.87 Favored 'General case' 0 C--N 1.342 0.278 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.56 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -57.15 31.99 0.0 OUTLIER 'General case' 0 C--O 1.238 0.494 0 N-CA-C 115.778 1.77 . . . . 0.0 115.778 -177.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.689 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 103.12 0.74 48.03 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -102.06 85.4 0.7 Allowed Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.689 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.0 Cg_exo -76.73 141.25 21.63 Favored 'Trans proline' 0 C--N 1.374 1.884 0 C-N-CA 122.831 2.354 . . . . 0.0 113.388 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.25 4.06 78.05 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 123.694 0.621 . . . . 0.0 113.091 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.453 ' O ' HG12 ' A' ' 24' ' ' ILE . 2.6 t-80 -79.58 129.54 34.56 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 123.886 0.874 . . . . 0.0 110.659 -179.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.671 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.17 -5.25 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.227 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -131.01 -150.15 6.69 Favored Glycine 0 C--N 1.337 0.602 0 N-CA-C 111.868 -0.493 . . . . 0.0 111.868 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.4 p -131.69 151.5 35.46 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.701 0 C-N-CA 122.824 0.449 . . . . 0.0 110.044 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.743 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -127.23 137.89 52.98 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.222 0.534 . . . . 0.0 111.715 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.705 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.3 m-85 -125.4 107.6 10.83 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 114.534 -1.212 . . . . 0.0 110.574 -178.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -59.31 104.9 0.29 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.494 179.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 p -149.25 129.04 6.5 Favored Pre-proline 0 CA--C 1.549 0.919 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.192 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.82 144.18 56.15 Favored 'Trans proline' 0 C--N 1.365 1.441 0 C-N-CA 123.298 2.665 . . . . 0.0 115.149 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.769 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.92 142.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 111.796 -2.456 . . . . 0.0 113.362 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.17 2.53 59.16 Favored Glycine 0 N--CA 1.442 -0.963 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.984 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.83 129.45 48.52 Favored Pre-proline 0 N--CA 1.447 -0.623 0 CA-C-O 119.134 -0.46 . . . . 0.0 109.791 179.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.58 126.91 22.69 Favored 'Trans proline' 0 C--N 1.371 1.742 0 C-N-CA 122.152 1.901 . . . . 0.0 112.965 -179.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.595 HG21 HD22 ' A' ' 90' ' ' LEU . 6.2 t -99.93 124.29 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.863 179.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.601 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.1 mtp-105 -101.55 153.57 19.62 Favored 'General case' 0 N--CA 1.433 -1.309 0 CA-C-N 113.18 -1.827 . . . . 0.0 111.843 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.33 121.47 20.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.61 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 30.4 t -67.76 -14.98 19.03 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.672 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.75 143.51 2.13 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 123.376 0.67 . . . . 0.0 110.482 179.001 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.562 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.4 OUTLIER -61.74 156.17 21.0 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.078 -0.965 . . . . 0.0 112.156 179.199 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.689 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.61 -127.35 1.52 Allowed Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.806 -0.712 . . . . 0.0 113.996 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 20.4 m -149.48 137.08 20.18 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 -177.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 99' ' ' SER . 10.4 t -83.26 113.82 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 123.763 0.825 . . . . 0.0 108.956 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.401 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.3 OUTLIER -98.84 -17.08 18.62 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.827 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -148.78 139.57 22.83 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.435 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.95 92.34 1.96 Allowed 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.904 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.56 91.27 1.4 Allowed Glycine 0 C--O 1.24 0.482 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.269 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.591 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -73.52 122.85 22.84 Favored 'General case' 0 C--N 1.344 0.358 0 C-N-CA 123.924 0.89 . . . . 0.0 112.57 -179.358 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.604 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.34 -0.73 87.32 Favored Glycine 0 C--N 1.32 -0.349 0 CA-C-N 113.265 -1.789 . . . . 0.0 113.378 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.89 -32.91 57.77 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.67 22.58 2.69 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-N 115.894 -0.593 . . . . 0.0 112.233 -178.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.604 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.5 113.45 34.5 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -178.619 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.83 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.3 Cg_exo -66.98 162.88 36.07 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 123.675 2.917 . . . . 0.0 111.705 177.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -95.63 8.1 44.37 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 176.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.0 mtt -74.81 -44.76 47.61 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.308 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.536 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.52 11.74 10.67 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.824 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.83 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -130.65 143.21 50.59 Favored 'General case' 0 C--N 1.361 1.096 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.412 -179.319 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 5.0 ttt -147.22 -19.78 0.39 Allowed 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.212 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -90.85 -29.17 17.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -179.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.63 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 106.48 -127.38 8.87 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.8 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.549 HD21 ' HA3' ' A' ' 61' ' ' GLY . 14.8 m-80 -88.61 139.33 30.58 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 122.894 0.478 . . . . 0.0 111.928 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.48 145.67 23.81 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.143 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.567 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.34 121.24 19.31 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.174 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.121 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.1 126.87 53.51 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -139.95 150.69 21.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-N 112.579 -2.1 . . . . 0.0 110.643 -176.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.689 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.7 tt0 -97.23 116.76 30.02 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 113.921 -1.49 . . . . 0.0 108.33 177.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.672 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.4 m-70 -69.55 -176.91 1.08 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.562 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -64.97 -17.55 64.5 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 113.69 -1.595 . . . . 0.0 113.966 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.61 -12.9 20.67 Favored 'General case' 0 C--O 1.236 0.345 0 O-C-N 123.449 0.468 . . . . 0.0 110.986 -179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.59 -6.77 45.38 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.685 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.717 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 18.5 ptp -70.55 168.23 16.76 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 123.352 0.661 . . . . 0.0 110.364 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.463 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 19.0 p80 -118.16 142.11 47.79 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.142 -1.023 . . . . 0.0 111.203 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.2 OUTLIER -133.85 128.39 34.57 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.255 -177.347 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -101.15 154.8 19.13 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 114.719 -1.128 . . . . 0.0 111.471 177.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.4 m-85 -133.44 99.22 4.45 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -111.32 168.92 9.15 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.925 -0.58 . . . . 0.0 112.556 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 22.1 m80 65.99 37.24 5.44 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 114.836 -1.074 . . . . 0.0 112.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.595 HD22 HG21 ' A' ' 47' ' ' VAL . 11.5 mt -98.43 169.58 9.44 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.745 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.3 t -107.83 -14.69 14.72 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 111.623 0.231 . . . . 0.0 111.623 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.408 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 0.7 OUTLIER -167.66 157.95 10.75 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.595 0.712 . . . . 0.0 111.87 -178.544 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.82 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -123.37 149.42 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.844 179.25 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -113.34 -6.83 13.53 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.837 177.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.82 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -101.54 -175.04 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.02 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.28 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.5 m -152.64 145.16 24.13 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.256 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.553 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.3 m -57.02 126.14 25.85 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.599 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.553 ' HB2' ' O ' ' A' ' 97' ' ' THR . 1.6 m-20 85.37 -2.19 0.83 Allowed 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.75 1.22 . . . . 0.0 111.939 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.469 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -80.74 149.28 29.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -82.86 145.17 29.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.294 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.52 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.334 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 70.2 tttt -142.03 148.93 39.28 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.824 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.787 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.36 137.95 56.85 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.422 -1.263 . . . . 0.0 111.253 -179.75 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.601 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.81 -4.55 52.11 Favored Glycine 0 C--N 1.328 0.089 0 CA-C-N 114.477 -1.238 . . . . 0.0 114.083 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.8 tt0 -74.2 141.94 45.42 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.108 0.48 . . . . 0.0 110.086 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.7 mt -72.37 101.44 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.525 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.2 pt -93.57 -6.16 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.88 -179.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.83 -159.88 33.15 Favored Glycine 0 N--CA 1.44 -1.067 0 C-N-CA 121.435 -0.412 . . . . 0.0 112.702 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.496 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 31.9 m-85 -140.24 138.07 34.76 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 124.674 1.19 . . . . 0.0 108.355 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.421 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -60.24 150.17 30.98 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.567 0.747 . . . . 0.0 112.85 -178.654 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.769 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -148.47 -163.71 10.99 Favored Glycine 0 C--N 1.345 1.06 0 C-N-CA 120.616 -0.802 . . . . 0.0 113.02 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.481 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 44.4 0.87 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.415 0.626 . . . . 0.0 109.81 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.63 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 67.4 p . . . . . 0 CA--C 1.54 0.558 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.953 -178.162 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.025 0 CA-C-O 118.987 -0.896 . . . . 0.0 112.803 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.481 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.0 Cg_exo -73.45 142.95 33.92 Favored 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 122.495 2.13 . . . . 0.0 112.202 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 51.9 p-80 -163.29 -171.09 2.47 Favored 'General case' 0 C--N 1.347 0.499 0 CA-C-O 121.371 0.605 . . . . 0.0 111.414 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.743 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -124.75 131.08 53.48 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.487 -178.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 23.8 t60 -112.76 109.92 19.7 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.405 -1.271 . . . . 0.0 109.436 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.539 ' O ' HG12 ' A' ' 37' ' ' VAL . 30.1 t80 -114.43 110.16 19.43 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.015 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.544 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -115.01 127.13 55.47 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.4 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.2 ttt -121.87 134.68 54.87 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 114.354 -1.294 . . . . 0.0 109.023 -178.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.717 ' O ' ' HB2' ' A' ' 83' ' ' MET . 2.1 mp -143.46 164.77 28.94 Favored Pre-proline 0 C--N 1.313 -1.022 0 CA-C-N 113.355 -1.748 . . . . 0.0 110.358 -177.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.463 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -61.91 -178.5 0.32 Allowed 'Trans proline' 0 C--N 1.369 1.644 0 C-N-CA 123.291 2.661 . . . . 0.0 113.473 177.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.99 -28.97 67.09 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.077 176.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -158.01 103.93 1.74 Allowed Pre-proline 0 CA--C 1.503 -0.839 0 CA-C-N 113.896 -1.502 . . . . 0.0 108.607 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.5 163.13 38.37 Favored 'Trans proline' 0 N--CA 1.444 -1.44 0 C-N-CA 122.511 2.141 . . . . 0.0 116.746 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.558 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -118.2 70.53 0.81 Allowed 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 112.281 -2.236 . . . . 0.0 107.412 177.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.444 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.4 m-90 -62.83 12.5 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.427 -178.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.558 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -82.17 34.18 0.41 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 124.224 1.01 . . . . 0.0 112.74 -178.565 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 72.54 128.77 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.62 0 C-N-CA 125.692 1.597 . . . . 0.0 110.748 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.27 -48.6 0.59 Allowed Glycine 0 N--CA 1.439 -1.161 0 CA-C-N 115.135 -0.939 . . . . 0.0 113.043 -179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.55 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -150.48 -20.72 0.23 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 111.756 0.28 . . . . 0.0 111.756 179.301 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.23 17.71 10.78 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.081 1.352 . . . . 0.0 107.989 -178.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.651 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.29 -11.31 8.95 Favored Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 112.262 -2.245 . . . . 0.0 112.609 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.671 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.11 125.72 29.79 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.321 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -129.84 -175.35 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.004 179.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . 0.431 ' HA ' ' HD3' ' A' ' 142' ' ' PRO . 1.9 p30 -79.74 132.96 59.65 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.591 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.1 Cg_exo -76.68 -1.89 12.05 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.667 2.245 . . . . 0.0 112.932 178.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.75 -23.24 6.41 Favored 'General case' 0 C--N 1.35 0.627 0 N-CA-C 114.278 1.214 . . . . 0.0 114.278 -178.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -67.67 -31.12 75.46 Favored Glycine 0 CA--C 1.518 0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.334 -179.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -103.39 -11.99 17.5 Favored 'General case' 0 C--O 1.236 0.37 0 O-C-N 123.861 0.389 . . . . 0.0 111.919 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.591 HG12 ' O ' ' A' ' 142' ' ' PRO . 24.5 mm -96.2 -8.71 9.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.684 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.267 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.412 178.125 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.689 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.5 Cg_exo . . . . . 0 N--CA 1.481 0.787 0 CA-C-O 120.75 0.229 . . . . 0.0 112.273 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.746 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.41 -172.02 3.04 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-O 122.561 1.172 . . . . 0.0 110.509 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.52 -24.83 2.99 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 112.221 -2.263 . . . . 0.0 108.772 177.233 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.746 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.3 t -168.42 -168.51 0.93 Allowed 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.654 -178.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.428 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 179.17 110.99 0.29 Allowed Glycine 0 C--N 1.32 -0.356 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.386 177.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.426 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.09 124.65 8.35 Favored 'General case' 0 CA--C 1.506 -0.739 0 CA-C-O 121.531 0.682 . . . . 0.0 112.337 -178.434 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.93 58.77 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.533 0 CA-C-N 113.924 -1.489 . . . . 0.0 108.978 178.536 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.6 t -105.05 -28.64 10.92 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 112.815 -1.993 . . . . 0.0 111.111 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.42 -66.79 1.05 Allowed 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.981 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.05 121.4 0.94 Allowed Glycine 0 C--N 1.321 -0.257 0 CA-C-N 115.131 -0.94 . . . . 0.0 112.15 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.483 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -74.72 157.49 35.18 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -178.849 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -57.43 31.71 0.0 OUTLIER 'General case' 0 C--O 1.24 0.561 0 N-CA-C 115.87 1.804 . . . . 0.0 115.87 -177.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.56 -2.05 49.52 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -101.76 85.47 0.67 Allowed Pre-proline 0 CA--C 1.547 0.861 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.8 Cg_exo -78.12 138.11 15.94 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.785 2.323 . . . . 0.0 113.317 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 92.41 4.31 66.27 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.225 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -76.52 135.89 39.31 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 123.79 0.836 . . . . 0.0 110.2 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.611 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.19 -18.93 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.444 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.22 -149.85 8.22 Favored Glycine 0 C--N 1.337 0.624 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.2 p -131.08 148.54 32.98 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 O-C-N 123.855 0.385 . . . . 0.0 110.11 179.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.788 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.21 135.12 52.26 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.456 0.646 . . . . 0.0 112.148 -178.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.689 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 2.1 m-85 -124.56 110.26 14.23 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 114.231 -1.35 . . . . 0.0 109.803 -178.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.31 104.25 0.12 Allowed 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.649 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.522 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.7 p -144.88 120.75 6.0 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.563 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -49.16 144.68 16.11 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.191 2.594 . . . . 0.0 115.525 -179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.706 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -61.03 139.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 111.628 -2.533 . . . . 0.0 113.437 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.52 2.56 55.47 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.358 -0.837 . . . . 0.0 114.181 177.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -87.41 127.57 58.29 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-O 119.148 -0.453 . . . . 0.0 109.951 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -59.36 127.27 23.31 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.181 1.921 . . . . 0.0 113.378 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.524 HG21 HD22 ' A' ' 90' ' ' LEU . 11.4 t -99.05 123.8 51.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.28 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 5.9 mtt180 -102.39 152.42 21.13 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.913 -1.949 . . . . 0.0 111.597 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.47 120.82 19.61 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.771 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.3 t -65.51 -16.77 20.89 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.671 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.27 144.63 2.05 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 123.479 0.711 . . . . 0.0 110.391 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.498 HD21 ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -61.15 156.02 19.27 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.071 -0.968 . . . . 0.0 112.512 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.657 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.71 -125.88 1.38 Allowed Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.72 -0.673 . . . . 0.0 113.701 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 14.3 m -148.22 142.95 26.67 Favored 'General case' 0 N--CA 1.439 -1.025 0 C-N-CA 123.624 0.77 . . . . 0.0 109.706 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 99' ' ' SER . 9.4 t -84.89 112.1 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 123.805 0.842 . . . . 0.0 108.881 179.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.444 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -95.14 -14.96 23.71 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.751 -179.861 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -154.38 140.37 18.31 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.045 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -147.85 92.31 2.05 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.394 -1.275 . . . . 0.0 108.952 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.412 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.63 89.99 1.27 Allowed Glycine 0 C--O 1.24 0.499 0 CA-C-N 114.251 -1.341 . . . . 0.0 112.454 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.58 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.09 122.13 20.43 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.951 0.881 . . . . 0.0 112.822 -179.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.627 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.63 -0.94 88.59 Favored Glycine 0 N--CA 1.461 0.301 0 CA-C-N 113.197 -1.82 . . . . 0.0 113.693 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.09 -33.44 59.51 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -138.62 26.91 2.52 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.925 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.627 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.9 115.26 50.92 Favored Pre-proline 0 N--CA 1.437 -1.119 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -178.372 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 37.4 Cg_exo -68.05 162.95 37.76 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 123.845 3.03 . . . . 0.0 111.789 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -96.25 8.58 43.53 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -74.66 -44.6 49.54 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.312 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.528 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -121.97 11.76 10.35 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.913 177.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.0 OUTLIER -129.03 144.39 51.17 Favored 'General case' 0 C--N 1.361 1.093 0 C-N-CA 120.159 -0.616 . . . . 0.0 112.237 -178.854 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.61 -31.16 0.35 Allowed 'General case' 0 N--CA 1.47 0.525 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.689 178.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.62 -19.34 31.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.522 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 96.3 -130.28 10.21 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.967 -0.561 . . . . 0.0 114.112 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.579 HD21 ' HA3' ' A' ' 61' ' ' GLY . 10.1 m-80 -81.11 140.95 34.75 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.558 0.743 . . . . 0.0 112.35 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.23 146.56 24.83 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.345 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.572 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.93 121.35 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.265 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.89 130.55 56.31 Favored 'General case' 0 CA--C 1.492 -1.273 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 177.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.4 mt -139.4 150.82 22.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-N 112.909 -1.951 . . . . 0.0 110.403 -176.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.657 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.68 116.18 31.2 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 113.865 -1.516 . . . . 0.0 108.281 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.671 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.8 m-70 -69.21 -175.47 0.77 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.498 ' HB2' HD21 ' A' ' 52' ' ' ASN . . . -65.27 -18.1 65.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 113.982 -1.463 . . . . 0.0 114.619 -177.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.22 -9.18 20.66 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.81 -6.14 43.83 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.154 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.507 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 4.0 ptt? -67.43 165.76 15.98 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 123.595 0.758 . . . . 0.0 111.353 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.496 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 61.9 m-70 -111.41 144.37 40.72 Favored 'General case' 0 N--CA 1.44 -0.929 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.826 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.7 127.06 22.96 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 120.99 0.424 . . . . 0.0 110.345 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -104.24 154.73 17.61 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.628 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.507 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.0 m-85 -136.08 99.06 4.03 Favored 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.409 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.66 167.78 10.32 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -177.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 65.5 42.28 3.82 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.283 1.033 . . . . 0.0 111.383 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.2 mt -103.22 168.58 9.08 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.103 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 8.1 t -102.63 -17.81 15.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.16 163.64 15.6 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.722 0.772 . . . . 0.0 111.927 -177.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.829 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -127.56 148.18 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.509 -1.678 . . . . 0.0 110.893 179.06 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 t -111.51 -6.6 14.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.886 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.829 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -103.35 -175.24 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.099 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.792 -177.118 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.7 m -153.22 143.42 22.35 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.674 -1.148 . . . . 0.0 108.936 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.76 127.88 32.23 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 86.02 -4.43 0.79 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.692 1.197 . . . . 0.0 111.719 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.476 ' O ' HG23 ' A' ' 55' ' ' VAL . 39.5 m -80.44 151.61 29.22 Favored 'General case' 0 C--N 1.347 0.463 0 CA-C-O 120.571 0.224 . . . . 0.0 110.552 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.7 145.52 27.91 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.608 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.89 169.71 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.314 0 CA-C-N 115.197 -0.91 . . . . 0.0 112.196 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.438 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 1.9 tttt -142.42 148.51 37.93 Favored 'General case' 0 N--CA 1.432 -1.361 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.716 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.791 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.34 138.41 56.49 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.361 -179.796 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.584 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 77.03 -8.44 30.58 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 114.38 -1.282 . . . . 0.0 114.135 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.1 tt0 -70.75 141.29 51.48 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.078 0.466 . . . . 0.0 110.214 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.8 mt -72.72 102.05 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.559 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.5 -4.97 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 CA-C-N 113.564 -1.653 . . . . 0.0 113.117 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.66 -160.74 34.44 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 121.472 -0.394 . . . . 0.0 112.749 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 35.4 m-85 -140.16 138.35 35.12 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.669 1.188 . . . . 0.0 108.522 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -62.71 150.93 39.84 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 123.631 0.773 . . . . 0.0 112.552 -179.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.706 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -161.37 -160.98 11.23 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 119.877 -1.154 . . . . 0.0 114.034 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.416 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.2 51.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 114.48 -0.86 . . . . 0.0 108.684 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.522 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 21.6 p . . . . . 0 CA--C 1.539 0.55 0 CA-C-N 115.196 -0.911 . . . . 0.0 113.33 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.972 0 CA-C-O 119.384 -0.675 . . . . 0.0 113.634 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.417 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 6.2 Cg_exo -80.25 139.21 13.07 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 123.302 2.668 . . . . 0.0 112.419 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.522 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 24.0 p-80 -160.94 -166.34 1.57 Allowed 'General case' 0 C--N 1.348 0.5 0 CA-C-O 121.256 0.551 . . . . 0.0 111.411 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.788 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 13.3 tp -123.03 130.04 52.28 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.64 -1.163 . . . . 0.0 111.261 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.409 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 22.6 t60 -112.81 113.0 24.9 Favored 'General case' 0 N--CA 1.434 -1.225 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.815 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.527 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.2 t80 -118.53 111.31 18.45 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.138 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -118.55 127.21 53.4 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.163 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.0 tpt -117.61 138.41 51.97 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.7 mp -143.65 166.62 18.72 Favored Pre-proline 0 C--N 1.308 -1.237 0 CA-C-N 113.465 -1.698 . . . . 0.0 111.103 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -62.52 -178.48 0.38 Allowed 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 123.35 2.7 . . . . 0.0 112.703 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -69.98 -28.05 65.22 Favored 'General case' 0 N--CA 1.439 -0.989 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.247 176.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -156.94 101.28 1.95 Allowed Pre-proline 0 CA--C 1.504 -0.793 0 CA-C-N 114.334 -1.303 . . . . 0.0 108.829 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -72.26 163.18 39.46 Favored 'Trans proline' 0 N--CA 1.444 -1.432 0 C-N-CA 122.698 2.265 . . . . 0.0 116.542 -177.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.579 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -117.08 70.7 0.78 Allowed 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.491 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.454 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.07 12.54 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 114.29 -1.323 . . . . 0.0 112.313 -178.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.579 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -81.61 32.29 0.36 Allowed 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.378 1.071 . . . . 0.0 112.815 -178.534 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 73.74 129.1 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.582 0 C-N-CA 125.825 1.65 . . . . 0.0 110.789 178.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.34 -48.6 0.59 Allowed Glycine 0 N--CA 1.44 -1.085 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.121 -179.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.2 -19.77 0.18 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.762 0.315 . . . . 0.0 111.757 179.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.6 t 66.34 18.03 10.81 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.975 1.31 . . . . 0.0 108.213 -178.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 74.59 -9.71 10.12 Favored Glycine 0 N--CA 1.437 -1.26 0 CA-C-N 112.582 -2.099 . . . . 0.0 112.904 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.611 ' HG2' HG12 ' A' ' 35' ' ' VAL . 1.5 ppt_? -82.73 127.25 33.25 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.452 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -129.37 -172.86 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.855 -0.612 . . . . 0.0 112.413 178.478 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . 0.452 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.3 m-20 -71.65 134.86 83.83 Favored Pre-proline 0 CA--C 1.549 0.906 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -176.278 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.629 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.6 Cg_endo -77.7 2.03 8.24 Favored 'Trans proline' 0 C--N 1.381 2.265 0 C-N-CA 123.296 2.664 . . . . 0.0 113.297 177.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.5 p -51.17 -24.04 3.85 Favored 'General case' 0 C--N 1.347 0.467 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -178.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.52 -28.04 71.69 Favored Glycine 0 CA--C 1.52 0.383 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.867 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -102.4 -9.28 20.44 Favored 'General case' 0 C--O 1.237 0.445 0 O-C-N 124.085 0.52 . . . . 0.0 111.496 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.629 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -98.53 -11.29 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.854 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.019 178.149 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.667 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 45.6 Cg_exo . . . . . 0 N--CA 1.483 0.87 0 N-CA-C 113.147 0.403 . . . . 0.0 113.147 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.754 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.37 -172.12 2.87 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-O 122.5 1.143 . . . . 0.0 110.379 -179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.459 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.78 -25.71 2.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 112.4 -2.182 . . . . 0.0 108.755 177.288 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.754 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -169.61 -168.32 0.78 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 114.02 -1.445 . . . . 0.0 111.234 -178.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.24 110.97 0.3 Allowed Glycine 0 C--N 1.316 -0.574 0 CA-C-N 114.793 -1.094 . . . . 0.0 111.289 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.52 124.98 8.88 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.851 0.834 . . . . 0.0 113.053 -177.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.808 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.85 58.8 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.38 -1.736 . . . . 0.0 108.522 178.373 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 4.9 t -100.94 -28.73 12.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 112.595 -2.093 . . . . 0.0 110.856 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.6 m -115.55 -66.58 1.07 Allowed 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.422 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.46 122.15 0.98 Allowed Glycine 0 C--N 1.323 -0.173 0 CA-C-N 115.084 -0.962 . . . . 0.0 112.037 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.547 ' CD2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -70.89 157.35 38.29 Favored 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -178.909 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 -58.67 31.75 0.01 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.66 1.726 . . . . 0.0 115.66 -177.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.698 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.81 -2.03 48.58 Favored Glycine 0 CA--C 1.505 -0.59 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.545 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -102.52 85.35 0.75 Allowed Pre-proline 0 CA--C 1.547 0.864 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.698 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 6.2 Cg_exo -78.6 138.98 15.71 Favored 'Trans proline' 0 C--N 1.374 1.898 0 C-N-CA 122.881 2.388 . . . . 0.0 113.497 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.34 3.93 62.89 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.375 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.507 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.3 t-80 -80.62 135.06 35.98 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 123.724 0.81 . . . . 0.0 109.83 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.658 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.74 -20.1 5.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.144 -179.383 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.35 -149.59 8.33 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 142' ' ' PRO . 14.7 p -131.69 151.92 36.17 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 O-C-N 123.939 0.435 . . . . 0.0 110.274 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASP . . . . . 0.763 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 82.8 m-20 -128.25 131.71 48.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.172 0.51 . . . . 0.0 111.603 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' TYR . . . . . 0.667 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -119.76 111.17 17.66 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.648 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.21 102.04 0.15 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.227 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 13.8 p -143.34 133.48 12.06 Favored Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.853 -178.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -48.51 139.35 23.3 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 123.486 2.791 . . . . 0.0 115.653 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.789 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -67.57 143.75 15.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 111.793 -2.458 . . . . 0.0 113.222 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.26 2.78 58.98 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.791 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -86.89 126.86 61.91 Favored Pre-proline 0 N--CA 1.447 -0.611 0 CA-C-O 119.253 -0.403 . . . . 0.0 109.978 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.13 126.18 19.53 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.022 1.815 . . . . 0.0 112.974 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.508 HG21 HD22 ' A' ' 90' ' ' LEU . 5.4 t -99.86 122.34 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.505 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 2.2 mpt_? -101.7 154.78 18.58 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 113.389 -1.732 . . . . 0.0 112.052 -178.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.35 124.32 25.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.265 -178.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.29 -18.45 24.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.66 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.26 144.2 2.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 110.388 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.616 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.03 157.45 12.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.978 179.159 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.13 -124.59 1.25 Allowed Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.781 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.2 m -147.83 143.37 27.42 Favored 'General case' 0 N--CA 1.436 -1.141 0 C-N-CA 123.594 0.758 . . . . 0.0 109.938 -177.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 99' ' ' SER . 9.8 t -86.94 113.06 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.819 0.848 . . . . 0.0 108.826 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -95.06 -15.02 23.76 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.621 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -154.48 139.6 17.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.221 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.29 92.33 1.94 Allowed 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.894 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . 0.485 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -96.36 92.36 1.38 Allowed Glycine 0 C--O 1.239 0.443 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.488 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.603 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -71.49 122.57 20.67 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 123.914 0.886 . . . . 0.0 112.796 -179.301 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.582 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.59 -0.7 88.01 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-N 113.352 -1.749 . . . . 0.0 113.358 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.41 -32.7 48.81 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.32 27.62 2.56 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.744 -178.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.573 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.58 113.85 40.62 Favored Pre-proline 0 N--CA 1.435 -1.177 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -178.69 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.9 Cg_exo -66.74 162.59 36.71 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 123.371 2.714 . . . . 0.0 111.166 177.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.1 m95 -96.41 9.54 40.95 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.5 mtt -76.31 -44.66 35.88 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.239 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.538 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.19 11.46 10.86 Favored 'General case' 0 N--CA 1.441 -0.891 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.895 177.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.53 138.03 52.05 Favored 'General case' 0 C--N 1.359 0.994 0 C-N-CA 120.359 -0.536 . . . . 0.0 110.842 -179.317 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 11.6 mmt -143.16 -21.21 0.63 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.769 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -96.32 -28.9 14.28 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.97 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.434 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 109.01 -131.02 10.32 Favored Glycine 0 CA--C 1.52 0.387 0 O-C-N 123.767 0.667 . . . . 0.0 113.895 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.582 HD21 ' HA3' ' A' ' 61' ' ' GLY . 12.2 m-80 -79.23 144.13 34.65 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.613 0.765 . . . . 0.0 112.448 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -151.22 144.82 24.96 Favored 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.475 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.562 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -140.46 121.55 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.975 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.86 129.02 52.26 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.435 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 11.1 mt -141.02 151.18 20.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 113.145 -1.843 . . . . 0.0 110.863 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLN . . . . . 0.679 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 2.0 tt0 -100.37 115.76 30.75 Favored 'General case' 0 N--CA 1.436 -1.128 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.996 177.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.66 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -70.08 -177.46 1.37 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 114.347 1.24 . . . . 0.0 114.347 -178.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.616 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -63.45 -17.97 63.26 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 113.744 -1.571 . . . . 0.0 114.179 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.31 -11.78 20.92 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 123.444 0.465 . . . . 0.0 110.728 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.58 -7.43 46.18 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.81 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.477 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 9.2 ptt? -69.0 163.55 24.37 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 123.286 0.635 . . . . 0.0 111.715 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.489 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 63.4 m-70 -105.68 144.78 31.94 Favored 'General case' 0 N--CA 1.437 -1.084 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.986 -179.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.22 126.84 23.52 Favored 'General case' 0 N--CA 1.441 -0.916 0 O-C-N 123.633 0.583 . . . . 0.0 109.815 -179.519 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.38 154.27 16.86 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.531 178.618 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -140.94 98.48 3.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 104.338 -2.467 . . . . 0.0 104.338 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 173.68 6.79 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 86.3 m-70 65.68 24.35 11.58 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.577 1.151 . . . . 0.0 111.642 -178.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.575 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.2 mt -84.01 170.96 13.4 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.577 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.3 t -105.19 -13.82 15.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.7 tttp -166.82 158.15 12.56 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.749 0.785 . . . . 0.0 112.551 -178.321 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.822 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -126.06 147.43 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 113.602 -1.635 . . . . 0.0 110.87 179.014 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 t -111.26 -6.63 14.51 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.936 177.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.822 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -102.6 -175.24 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.035 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.736 -177.13 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.1 m -151.88 140.48 20.74 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.938 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -55.07 128.99 36.3 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.412 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 85.68 -4.92 0.84 Allowed 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.594 1.158 . . . . 0.0 112.001 179.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.481 ' O ' HG23 ' A' ' 55' ' ' VAL . 46.0 m -80.48 152.72 28.59 Favored 'General case' 0 C--N 1.347 0.457 0 CA-C-O 120.514 0.197 . . . . 0.0 110.739 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 p -85.06 145.1 27.84 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 178.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.7 168.2 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.333 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 74.5 tttt -139.64 148.98 43.2 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-N 114.493 -1.23 . . . . 0.0 109.803 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . 0.79 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.94 138.89 55.42 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.231 -1.349 . . . . 0.0 111.421 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 76.78 -7.29 34.89 Favored Glycine 0 CA--C 1.517 0.165 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.093 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.4 tt0 -71.89 142.92 49.52 Favored 'General case' 0 CA--C 1.51 -0.593 0 C-N-CA 122.971 0.508 . . . . 0.0 110.131 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 32.9 mt -72.65 100.86 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.49 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.491 ' H ' HG13 ' A' ' 107' ' ' ILE . 1.0 OUTLIER -94.25 -3.99 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.952 -178.902 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 170.71 -168.37 41.46 Favored Glycine 0 N--CA 1.438 -1.212 0 CA-C-O 121.353 0.418 . . . . 0.0 112.752 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.575 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 34.0 m-85 -139.59 134.29 31.92 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 124.718 1.207 . . . . 0.0 108.023 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -56.61 150.49 15.5 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.477 0.711 . . . . 0.0 112.459 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.789 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -146.11 -171.11 15.26 Favored Glycine 0 C--N 1.347 1.152 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.526 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -143.86 43.1 1.46 Allowed 'General case' 0 N--CA 1.441 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 109.302 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.434 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 36.5 p . . . . . 0 CA--C 1.54 0.573 0 CA-C-N 115.109 -0.95 . . . . 0.0 112.868 -178.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.874 0 CA-C-O 119.617 -0.546 . . . . 0.0 113.133 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' PRO . . . . . 0.594 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 23.0 Cg_exo -68.84 147.34 68.55 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.526 2.817 . . . . 0.0 112.268 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -149.45 158.44 44.18 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-O 122.313 1.054 . . . . 0.0 113.144 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.763 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 12.0 tp -120.47 125.09 47.02 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-N 112.51 -2.132 . . . . 0.0 109.402 179.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 19.1 t60 -110.88 111.01 21.85 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 114.854 -1.066 . . . . 0.0 109.832 178.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.53 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.49 112.59 22.48 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.635 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.0 tt0 -119.26 140.04 50.91 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.349 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' MET . . . . . 0.447 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 17.0 tpp -132.72 136.92 46.69 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.819 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.581 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.98 165.47 24.03 Favored Pre-proline 0 C--N 1.312 -1.048 0 CA-C-N 113.714 -1.585 . . . . 0.0 110.419 -178.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.6 Cg_endo -63.53 -178.55 0.52 Allowed 'Trans proline' 0 C--N 1.367 1.511 0 C-N-CA 122.949 2.433 . . . . 0.0 112.746 176.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ALA . . . . . 0.444 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -71.92 -27.46 62.84 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.205 176.245 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -156.75 101.38 1.99 Allowed Pre-proline 0 CA--C 1.504 -0.802 0 CA-C-N 114.25 -1.341 . . . . 0.0 108.741 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -72.34 163.43 38.67 Favored 'Trans proline' 0 N--CA 1.443 -1.441 0 C-N-CA 122.625 2.217 . . . . 0.0 116.633 -177.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.574 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.18 71.53 0.83 Allowed 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 112.421 -2.172 . . . . 0.0 107.275 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.443 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.47 14.91 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 114.266 -1.334 . . . . 0.0 112.421 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.574 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 32.94 0.37 Allowed 'General case' 0 N--CA 1.445 -0.71 0 CA-C-O 122.13 0.967 . . . . 0.0 112.833 -178.456 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 72.41 128.76 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 125.792 1.637 . . . . 0.0 110.96 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.07 -48.7 0.6 Allowed Glycine 0 N--CA 1.437 -1.287 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.109 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.572 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.1 OUTLIER -150.51 -21.09 0.23 Allowed 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 179.558 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t 66.42 18.01 10.77 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.806 1.243 . . . . 0.0 108.121 -178.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.97 -11.56 14.63 Favored Glycine 0 N--CA 1.436 -1.315 0 CA-C-N 112.439 -2.164 . . . . 0.0 112.683 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ARG . . . . . 0.658 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -80.62 125.59 30.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.34 -175.79 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.029 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 5.0 p30 -76.65 137.85 66.81 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.584 ' HG3' HG11 ' A' ' 37' ' ' VAL . 76.5 Cg_endo -76.21 20.43 0.57 Allowed 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.21 2.606 . . . . 0.0 114.559 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 5.6 p -56.95 -24.99 56.98 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.154 0.982 . . . . 0.0 113.579 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -75.12 -23.71 73.51 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -95.53 -10.56 29.33 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.607 1.163 . . . . 0.0 110.668 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 142' ' ' PRO . 30.0 mm -107.16 -12.27 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.771 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.323 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.899 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.5 mtt . . . . . 0 N--CA 1.487 1.39 0 CA-C-O 120.608 0.242 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -91.54 139.83 30.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -137.08 135.49 7.7 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.575 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.7 p -98.36 145.49 26.65 Favored 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.703 0.296 . . . . 0.0 110.768 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -120.82 -42.13 2.53 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.37 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -108.58 143.62 37.37 Favored 'General case' 0 N--CA 1.464 0.266 0 O-C-N 123.332 0.395 . . . . 0.0 111.14 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -108.74 163.75 12.99 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.068 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -85.87 158.07 20.04 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.276 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -89.26 -42.33 11.67 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.632 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 67.1 m80 -87.92 -45.82 9.92 Favored 'General case' 0 N--CA 1.469 0.507 0 O-C-N 123.241 0.338 . . . . 0.0 111.56 -179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.88 133.26 6.75 Favored Glycine 0 C--N 1.342 0.9 0 O-C-N 123.39 0.431 . . . . 0.0 112.837 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.28 161.6 14.34 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.879 0.371 . . . . 0.0 111.986 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.82 109.86 2.1 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.899 177.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.8 t -90.81 -0.83 57.83 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.365 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -94.58 137.86 33.17 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.637 0.732 . . . . 0.0 111.872 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 20.9 p -89.44 162.41 15.76 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 113.646 -1.615 . . . . 0.0 112.789 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.532 HH11 HG22 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -81.38 112.57 34.63 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 123.649 0.78 . . . . 0.0 111.64 -179.748 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.652 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.4 Cg_exo -66.16 -22.97 53.36 Favored 'Trans proline' 0 C--N 1.366 1.494 0 C-N-CA 122.8 2.333 . . . . 0.0 113.047 178.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.739 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.95 -171.96 3.07 Favored 'General case' 0 CA--C 1.508 -0.662 0 CA-C-O 122.509 1.147 . . . . 0.0 110.316 -179.695 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -127.58 -25.12 3.2 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 112.253 -2.248 . . . . 0.0 108.797 177.267 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.739 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.2 t -168.77 -168.83 0.92 Allowed 'General case' 0 CA--C 1.546 0.823 0 CA-C-N 114.332 -1.304 . . . . 0.0 111.671 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.454 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.66 111.62 0.3 Allowed Glycine 0 C--N 1.32 -0.345 0 CA-C-N 114.736 -1.12 . . . . 0.0 111.633 177.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.48 124.85 8.84 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-O 121.582 0.706 . . . . 0.0 112.578 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.718 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.97 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.476 0 CA-C-N 113.672 -1.604 . . . . 0.0 109.216 179.387 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.8 t -106.64 -27.87 10.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 112.781 -2.009 . . . . 0.0 110.929 178.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.63 -67.41 1.0 Allowed 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.881 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.06 122.55 1.02 Allowed Glycine 0 N--CA 1.459 0.185 0 CA-C-N 115.203 -0.908 . . . . 0.0 112.28 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.495 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -78.31 157.57 29.14 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -179.073 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 63.7 m-80 -56.94 32.04 0.0 OUTLIER 'General case' 0 C--O 1.24 0.556 0 N-CA-C 115.715 1.746 . . . . 0.0 115.715 -177.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.98 1.31 48.66 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -102.18 85.3 0.7 Allowed Pre-proline 0 CA--C 1.545 0.788 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.8 Cg_exo -77.6 139.76 18.34 Favored 'Trans proline' 0 C--N 1.372 1.813 0 C-N-CA 122.81 2.34 . . . . 0.0 113.245 -178.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 87.24 4.49 81.04 Favored Glycine 0 C--N 1.34 0.762 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.986 179.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -71.86 129.99 39.96 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.083 0.953 . . . . 0.0 111.089 -179.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.684 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.63 6.15 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.351 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.91 -150.01 5.14 Favored Glycine 0 C--N 1.337 0.62 0 N-CA-C 112.046 -0.422 . . . . 0.0 112.046 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.565 HG12 ' O ' ' A' ' 123' ' ' PHE . 8.8 p -131.93 150.12 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.725 0 C-N-CA 122.788 0.435 . . . . 0.0 110.23 179.419 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.741 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 84.7 m-20 -126.18 135.28 51.44 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.21 0.528 . . . . 0.0 111.977 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.652 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -126.39 108.11 10.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.541 -178.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.68 104.83 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.264 179.076 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.441 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 11.0 p -147.63 127.97 6.81 Favored Pre-proline 0 CA--C 1.551 0.989 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.908 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -49.48 141.84 24.76 Favored 'Trans proline' 0 C--N 1.369 1.608 0 C-N-CA 123.385 2.723 . . . . 0.0 115.375 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.768 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.3 140.81 18.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 111.891 -2.413 . . . . 0.0 113.401 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.38 2.62 53.79 Favored Glycine 0 N--CA 1.442 -0.952 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.09 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.3 m -85.96 126.12 66.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.37 126.79 23.11 Favored 'Trans proline' 0 C--N 1.372 1.802 0 C-N-CA 122.226 1.951 . . . . 0.0 113.15 -179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.599 HG21 HD22 ' A' ' 90' ' ' LEU . 10.2 t -100.95 122.35 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 CA-C-N 115.111 -0.949 . . . . 0.0 108.848 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 41.2 mtt180 -101.86 154.06 19.27 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 113.044 -1.889 . . . . 0.0 111.881 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.27 119.62 17.76 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 114.578 -1.192 . . . . 0.0 110.57 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.7 t -65.9 -15.96 19.74 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.65 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.44 143.74 1.85 Allowed 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 123.411 0.684 . . . . 0.0 110.403 179.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.538 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.86 155.74 18.93 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.32 179.358 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.64 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.66 -127.17 1.52 Allowed Glycine 0 C--N 1.331 0.289 0 CA-C-N 115.691 -0.686 . . . . 0.0 113.766 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 16.4 m -148.67 141.09 24.24 Favored 'General case' 0 N--CA 1.438 -1.057 0 C-N-CA 123.583 0.753 . . . . 0.0 109.875 -178.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 99' ' ' SER . 11.8 t -84.33 112.65 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 C-N-CA 123.78 0.832 . . . . 0.0 109.027 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 6.7 mmmt -95.13 -15.03 23.67 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.684 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -155.85 139.67 16.19 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 114.902 -1.045 . . . . 0.0 109.766 179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.69 92.36 1.99 Allowed 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.629 -1.169 . . . . 0.0 109.227 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.438 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.14 90.3 1.48 Allowed Glycine 0 C--O 1.24 0.524 0 CA-C-N 114.28 -1.327 . . . . 0.0 111.985 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.576 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.11 121.02 17.52 Favored 'General case' 0 C--N 1.344 0.369 0 O-C-N 124.818 0.952 . . . . 0.0 112.811 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.47 -0.77 87.8 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-N 113.318 -1.764 . . . . 0.0 113.459 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -33.11 58.01 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.56 22.32 2.71 Favored 'General case' 0 C--O 1.239 0.502 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.22 -178.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.596 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.52 116.38 58.88 Favored Pre-proline 0 N--CA 1.435 -1.217 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -178.36 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.832 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 38.7 Cg_exo -67.61 162.87 37.3 Favored 'Trans proline' 0 C--N 1.368 1.578 0 C-N-CA 123.577 2.851 . . . . 0.0 111.381 177.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 60.0 m95 -97.64 10.72 39.21 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.87 -44.97 30.0 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.544 -1.207 . . . . 0.0 110.194 -179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.525 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -120.3 11.42 11.51 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.714 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.832 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.1 m95 -128.66 141.9 51.2 Favored 'General case' 0 C--N 1.361 1.08 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.35 -179.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 8.5 mmt -144.52 -28.22 0.49 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.364 -0.835 . . . . 0.0 111.202 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.74 -24.62 26.84 Favored 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.391 0.432 . . . . 0.0 112.075 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.636 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.27 -128.27 9.52 Favored Glycine 0 C--N 1.331 0.263 0 CA-C-N 115.743 -0.662 . . . . 0.0 114.082 179.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 90' ' ' LEU . 8.6 m-80 -84.92 136.68 33.52 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.243 0.617 . . . . 0.0 112.067 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.457 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -150.33 147.05 27.14 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.16 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.646 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -140.14 120.63 13.89 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.467 -179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.36 128.21 54.81 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 177.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.5 mt -138.97 150.81 23.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 112.741 -2.027 . . . . 0.0 110.512 -176.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.64 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.3 tt0 -99.67 116.57 32.07 Favored 'General case' 0 N--CA 1.435 -1.219 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.348 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.65 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.0 m-70 -68.31 -176.09 0.7 Allowed 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.536 -1.211 . . . . 0.0 114.215 -178.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.538 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -66.22 -17.78 64.95 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 114.055 -1.43 . . . . 0.0 114.398 -177.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.438 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.1 OUTLIER -101.52 -9.06 21.37 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.881 0.372 . . . . 0.0 111.067 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.6 -6.68 45.23 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.057 179.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.8 ptt? -67.77 168.71 10.92 Favored 'General case' 0 N--CA 1.439 -0.994 0 C-N-CA 123.469 0.708 . . . . 0.0 111.367 179.067 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 64.9 m-70 -113.43 145.31 41.36 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.075 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.497 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.94 127.28 19.81 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-O 120.973 0.416 . . . . 0.0 110.29 179.752 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.646 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.96 154.97 16.9 Favored Glycine 0 N--CA 1.442 -0.964 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.546 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.457 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.9 m-85 -134.36 99.29 4.33 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 105.361 -2.089 . . . . 0.0 105.361 179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.69 166.77 11.05 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -177.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 73.3 m80 65.74 41.25 4.0 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-N 114.628 -1.169 . . . . 0.0 111.743 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.599 HD22 HG21 ' A' ' 47' ' ' VAL . 9.3 mt -101.3 166.46 10.75 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.079 177.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.401 ' HB2' HG23 ' A' ' 43' ' ' VAL . 12.4 t -101.04 -14.88 17.64 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -168.26 160.47 11.55 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.727 0.775 . . . . 0.0 111.901 -178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.837 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.3 148.65 30.97 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 113.613 -1.631 . . . . 0.0 110.757 178.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 t -112.42 -5.96 14.05 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 114.517 -1.219 . . . . 0.0 110.071 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.837 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -104.44 -175.23 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.983 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.512 -177.134 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.2 m -155.46 144.07 20.43 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.009 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.537 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 4.2 m -55.23 129.22 37.47 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.62 -179.366 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.43 -5.18 0.74 Allowed 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 124.63 1.172 . . . . 0.0 112.026 179.314 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 55' ' ' VAL . 29.6 m -81.3 148.8 29.24 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 178.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.51 145.63 28.01 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.425 178.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.401 HG12 HE21 ' A' ' 105' ' ' GLN . 0.0 OUTLIER -125.49 167.69 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.248 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.36 -179.216 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.9 tttm -140.36 147.39 39.72 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.821 179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.793 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.23 137.93 55.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.226 -1.352 . . . . 0.0 111.483 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.8 -4.43 52.48 Favored Glycine 0 CA--C 1.517 0.175 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.078 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.9 tt0 -74.36 139.0 43.81 Favored 'General case' 0 CA--C 1.507 -0.707 0 CA-C-O 121.183 0.516 . . . . 0.0 110.004 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 54.5 mt -71.35 101.53 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.118 0 CA-C-N 114.717 -1.128 . . . . 0.0 109.512 -179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.516 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.44 -4.74 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.149 -178.925 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 166.92 -160.82 34.6 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 112.302 -0.319 . . . . 0.0 112.302 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.517 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 30.3 m-85 -139.45 139.1 36.95 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 124.478 1.111 . . . . 0.0 108.327 179.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.402 HG23 HG22 ' A' ' 47' ' ' VAL . 0.8 OUTLIER -60.37 152.57 24.99 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.472 0.709 . . . . 0.0 112.117 -179.136 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.768 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -158.06 -163.33 12.62 Favored Glycine 0 C--N 1.345 1.07 0 C-N-CA 119.676 -1.249 . . . . 0.0 113.961 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.642 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 48.16 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 CA-C-N 114.632 -0.784 . . . . 0.0 109.074 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.636 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 33.6 p -78.48 2.5 18.77 Favored 'General case' 0 CA--C 1.54 0.564 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -89.18 -97.49 1.04 Allowed Glycine 0 C--N 1.34 0.759 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.9 mt-30 -101.89 147.0 27.04 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.6 m -89.01 97.42 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 112.029 -178.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 36.0 p -146.78 -52.98 0.23 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.084 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.24 142.92 7.49 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.832 -0.982 . . . . 0.0 111.808 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.642 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.6 Cg_exo -71.55 144.67 45.4 Favored 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.593 2.196 . . . . 0.0 112.098 179.585 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.441 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 56.1 p-80 -160.77 -172.99 3.71 Favored 'General case' 0 C--N 1.349 0.565 0 CA-C-O 121.515 0.674 . . . . 0.0 111.636 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.741 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.8 tp -125.51 136.25 53.15 Favored 'General case' 0 N--CA 1.43 -1.467 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.779 -178.395 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 31.8 t60 -116.36 122.96 46.4 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-N 113.883 -1.508 . . . . 0.0 108.43 177.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.565 ' O ' HG12 ' A' ' 37' ' ' VAL . 50.0 t80 -127.25 107.57 10.11 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.264 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' THR . 13.4 pt-20 -115.33 127.37 55.38 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.548 178.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.4 tpt -121.17 136.73 54.92 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.726 -179.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.633 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -142.26 164.99 30.06 Favored Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 113.394 -1.73 . . . . 0.0 110.381 -178.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo -64.09 -178.43 0.61 Allowed 'Trans proline' 0 C--N 1.366 1.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.994 177.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -72.16 -27.26 62.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.004 176.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.34 102.54 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.784 0 CA-C-N 114.09 -1.414 . . . . 0.0 108.869 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -72.26 163.18 39.45 Favored 'Trans proline' 0 N--CA 1.445 -1.349 0 C-N-CA 122.671 2.248 . . . . 0.0 116.937 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.577 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.96 70.76 0.81 Allowed 'General case' 0 N--CA 1.425 -1.702 0 CA-C-N 112.229 -2.26 . . . . 0.0 107.392 177.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.45 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -62.9 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 114.291 -1.322 . . . . 0.0 112.435 -178.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.577 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 33.72 0.38 Allowed 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 124.209 1.003 . . . . 0.0 112.783 -178.487 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 11.0 m-80 71.95 128.2 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.627 0 C-N-CA 125.571 1.548 . . . . 0.0 110.666 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.33 -48.49 0.6 Allowed Glycine 0 N--CA 1.438 -1.178 0 CA-C-N 115.104 -0.953 . . . . 0.0 113.068 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.78 -19.58 0.22 Allowed 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 37.9 m 65.67 18.01 11.07 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-O 122.778 1.275 . . . . 0.0 108.108 -178.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.633 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 78.26 -11.57 23.05 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 112.237 -2.256 . . . . 0.0 112.47 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.684 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -85.07 124.43 31.75 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 120.283 -0.567 . . . . 0.0 112.056 -179.24 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.456 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -127.19 -172.87 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.456 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.8 m-20 -72.47 131.8 84.35 Favored Pre-proline 0 CA--C 1.547 0.844 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -176.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.619 ' O ' HG12 ' A' ' 146' ' ' ILE . 4.5 Cg_exo -77.58 -1.63 11.8 Favored 'Trans proline' 0 C--N 1.379 2.148 0 C-N-CA 123.265 2.643 . . . . 0.0 113.492 177.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.1 p -51.48 -24.25 4.89 Favored 'General case' 0 C--N 1.349 0.58 0 N-CA-C 114.134 1.161 . . . . 0.0 114.134 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.94 -24.56 75.75 Favored Glycine 0 CA--C 1.521 0.431 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.927 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -103.56 -10.33 18.55 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 123.465 0.706 . . . . 0.0 111.343 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.619 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -99.81 -10.96 8.76 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.454 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -74.18 -26.45 60.29 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.699 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 16.62 25.46 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 115.153 -0.93 . . . . 0.0 109.313 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.638 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -94.88 167.99 12.02 Favored Pre-proline 0 N--CA 1.419 -2.005 0 CA-C-N 113.694 -1.593 . . . . 0.0 112.432 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.638 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 13.1 Cg_endo -54.93 178.56 0.08 OUTLIER 'Trans proline' 0 C--N 1.37 1.662 0 C-N-CA 124.43 3.42 . . . . 0.0 113.872 179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.0 t -109.82 132.76 57.16 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.365 0 CA-C-N 115.648 -0.706 . . . . 0.0 111.279 -177.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -101.67 97.72 8.1 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 113.733 -1.576 . . . . 0.0 109.057 178.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 68.52 -37.83 0.36 Allowed 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 124.149 0.98 . . . . 0.0 113.095 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 117.2 92.02 1.61 Allowed Glycine 0 C--N 1.338 0.687 0 N-CA-C 112.053 -0.419 . . . . 0.0 112.053 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 17.4 p -95.0 105.39 17.31 Favored 'General case' 0 N--CA 1.444 -0.769 0 C-N-CA 123.18 0.592 . . . . 0.0 110.936 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 18.0 p -95.35 143.36 25.98 Favored Pre-proline 0 CA--C 1.538 0.503 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.201 179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -83.51 -37.46 0.16 Allowed 'Trans proline' 0 C--N 1.374 1.885 0 C-N-CA 122.485 2.123 . . . . 0.0 113.11 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.603 HG23 ' H ' ' A' ' 159' ' ' GLU . 8.8 t -163.26 -62.61 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.812 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.603 ' H ' HG23 ' A' ' 158' ' ' THR . 31.3 mt-10 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 114.161 -1.381 . . . . 0.0 111.368 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.8 mtm . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.539 0.209 . . . . 0.0 110.867 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 61.7 mtt180 -86.75 147.69 25.74 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.31 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -140.34 -58.57 0.04 OUTLIER Glycine 0 C--N 1.337 0.623 0 O-C-N 123.648 0.592 . . . . 0.0 112.672 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.0 m -95.94 150.4 20.49 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 122.423 0.289 . . . . 0.0 111.078 -179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.7 t-80 -123.57 -44.87 2.09 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.914 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 71.3 m-70 -118.46 147.87 43.17 Favored 'General case' 0 C--O 1.234 0.286 0 O-C-N 123.417 0.448 . . . . 0.0 110.765 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -110.18 139.38 45.39 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.304 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -113.76 -44.68 3.16 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.242 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -116.98 145.49 43.62 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.389 0.431 . . . . 0.0 110.996 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 5.5 m80 -104.84 148.8 26.25 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.97 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.32 2.28 Favored Glycine 0 C--N 1.338 0.668 0 CA-C-N 116.036 -0.529 . . . . 0.0 113.26 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.12 161.14 13.79 Favored 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 120.894 0.378 . . . . 0.0 111.944 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -160.17 108.26 1.67 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.752 176.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.5 t -91.0 -13.75 32.72 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.18 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -96.91 122.57 40.02 Favored 'General case' 0 CA--C 1.503 -0.829 0 CA-C-O 121.644 0.735 . . . . 0.0 112.039 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 27.3 p -98.37 155.15 17.36 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.922 -178.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -85.24 111.82 39.21 Favored Pre-proline 0 CA--C 1.54 0.593 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.908 179.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.736 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.6 Cg_exo -70.66 -21.54 29.18 Favored 'Trans proline' 0 C--N 1.366 1.456 0 C-N-CA 122.531 2.154 . . . . 0.0 112.667 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.76 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.77 -171.92 3.04 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-O 122.699 1.238 . . . . 0.0 110.335 -179.963 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.457 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.26 -24.78 2.8 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 112.082 -2.326 . . . . 0.0 108.625 177.292 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.76 ' H ' HD12 ' A' ' 19' ' ' LEU . 9.3 t -168.21 -168.94 1.01 Allowed 'General case' 0 CA--C 1.548 0.876 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.162 -178.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 172.26 112.25 0.28 Allowed Glycine 0 C--N 1.32 -0.342 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.036 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.21 125.49 9.38 Favored 'General case' 0 CA--C 1.508 -0.656 0 N-CA-C 113.328 0.862 . . . . 0.0 113.328 -177.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.751 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.56 58.31 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.455 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.066 179.197 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.6 t -102.7 -28.13 12.3 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 112.89 -1.959 . . . . 0.0 110.829 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -115.14 -67.2 1.01 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.606 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.3 123.18 1.06 Allowed Glycine 0 C--O 1.235 0.196 0 CA-C-N 115.05 -0.977 . . . . 0.0 112.371 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.487 ' C ' ' H ' ' A' ' 30' ' ' GLY . 0.2 OUTLIER -75.11 157.44 34.7 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -55.7 31.92 0.0 OUTLIER 'General case' 0 C--O 1.241 0.618 0 N-CA-C 115.816 1.784 . . . . 0.0 115.816 -177.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.71 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 0.09 48.93 Favored Glycine 0 CA--C 1.505 -0.551 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.3 m-85 -101.72 85.43 0.66 Allowed Pre-proline 0 CA--C 1.545 0.763 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.71 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.7 Cg_exo -77.03 138.88 18.72 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.655 2.236 . . . . 0.0 113.239 -178.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.77 4.11 70.14 Favored Glycine 0 C--N 1.339 0.726 0 CA-C-N 115.873 -0.603 . . . . 0.0 113.12 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.475 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.4 t-80 -75.51 128.41 35.24 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 123.927 0.891 . . . . 0.0 110.743 -179.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.644 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -99.74 -14.14 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.239 -179.923 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -126.04 -150.28 7.6 Favored Glycine 0 C--N 1.337 0.629 0 C-N-CA 121.192 -0.528 . . . . 0.0 112.369 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 123' ' ' PHE . 7.2 p -128.71 151.86 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.692 0 CA-C-N 115.025 -0.588 . . . . 0.0 109.775 179.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.662 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -125.39 130.64 52.31 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.263 0.554 . . . . 0.0 112.409 -178.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.736 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.7 m-85 -122.89 109.78 14.59 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.102 -179.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.92 104.93 0.41 Allowed 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.243 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.541 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.0 p -145.55 124.43 6.66 Favored Pre-proline 0 CA--C 1.551 0.986 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.01 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -48.95 141.79 21.13 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.386 2.724 . . . . 0.0 115.528 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.751 HG23 ' HA2' ' A' ' 111' ' ' GLY . 3.1 p -61.62 141.11 18.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 111.935 -2.393 . . . . 0.0 113.473 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.02 2.49 55.99 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-N 115.393 -0.821 . . . . 0.0 114.253 177.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.7 m -88.98 126.22 59.88 Favored Pre-proline 0 N--CA 1.448 -0.546 0 CA-C-O 119.066 -0.492 . . . . 0.0 109.808 179.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.14 126.67 23.14 Favored 'Trans proline' 0 C--N 1.375 1.937 0 C-N-CA 122.209 1.939 . . . . 0.0 113.074 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.641 HG21 HD22 ' A' ' 90' ' ' LEU . 4.3 t -98.28 121.51 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.083 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.623 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.9 mtp180 -102.02 151.23 22.39 Favored 'General case' 0 N--CA 1.433 -1.318 0 CA-C-N 113.088 -1.869 . . . . 0.0 111.584 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -70.76 122.02 19.08 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.232 -178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.2 t -69.08 -14.16 18.17 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 CA-C-N 115.694 -0.685 . . . . 0.0 112.421 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.603 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.55 144.17 1.86 Allowed 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 123.447 0.699 . . . . 0.0 110.603 178.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.424 HD21 ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -62.59 156.86 22.05 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 114.835 -1.075 . . . . 0.0 112.386 179.368 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.632 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.32 -128.14 1.68 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.725 -0.67 . . . . 0.0 113.652 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.449 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 11.9 m -148.24 140.89 24.52 Favored 'General case' 0 N--CA 1.439 -0.975 0 C-N-CA 123.759 0.824 . . . . 0.0 109.668 -178.116 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 99' ' ' SER . 12.1 t -83.78 112.58 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 123.721 0.809 . . . . 0.0 109.034 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 54' ' ' THR . 6.6 mmmt -95.09 -14.72 23.99 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.844 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -156.09 141.8 17.89 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.01 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.24 92.22 2.16 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.406 -1.27 . . . . 0.0 109.074 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -92.02 89.98 1.46 Allowed Glycine 0 C--O 1.239 0.447 0 CA-C-N 113.955 -1.475 . . . . 0.0 112.862 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.575 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -70.41 122.97 20.63 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.925 0.89 . . . . 0.0 112.866 -179.689 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.578 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.93 -0.59 88.8 Favored Glycine 0 CA--C 1.521 0.425 0 CA-C-N 113.253 -1.794 . . . . 0.0 113.626 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.54 -33.2 54.25 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -138.44 30.18 2.39 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.467 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.578 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.66 111.83 24.33 Favored Pre-proline 0 N--CA 1.437 -1.091 0 N-CA-C 113.907 1.077 . . . . 0.0 113.907 -178.265 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 35.4 Cg_exo -68.71 162.62 40.38 Favored 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 123.738 2.958 . . . . 0.0 111.563 177.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 56.1 m95 -96.74 9.76 40.75 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.22 -1.029 . . . . 0.0 108.22 175.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 61.2 mtm -76.91 -43.56 35.15 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.342 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.539 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.8 11.24 11.1 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.857 177.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.1 151.24 50.0 Favored 'General case' 0 C--N 1.361 1.089 0 C-N-CA 120.351 -0.54 . . . . 0.0 111.738 -179.207 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 36.2 mtt -145.68 -36.88 0.27 Allowed 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.621 179.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -86.43 -23.46 26.05 Favored 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.45 0.469 . . . . 0.0 111.881 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.606 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 100.25 -118.65 6.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.69 -0.686 . . . . 0.0 114.045 179.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.536 HD21 ' HA3' ' A' ' 61' ' ' GLY . 7.3 m-80 -82.57 135.64 35.03 Favored 'General case' 0 C--O 1.236 0.384 0 C-N-CA 123.225 0.61 . . . . 0.0 112.49 -178.532 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.01 146.56 26.3 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.983 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.616 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.3 t -139.2 121.02 16.48 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.312 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.205 -179.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.2 130.73 56.99 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.333 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 54' ' ' THR . 9.1 mt -141.01 151.02 20.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 112.587 -2.097 . . . . 0.0 110.206 -176.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.632 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.2 tt0 -99.83 117.14 33.51 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 114.123 -1.399 . . . . 0.0 108.547 178.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.603 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.9 m-70 -69.99 -177.93 1.46 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 114.535 -1.211 . . . . 0.0 114.07 -179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.424 ' HB2' HD21 ' A' ' 52' ' ' ASN . . . -65.57 -17.46 64.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 113.791 -1.55 . . . . 0.0 113.752 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -97.58 -13.27 21.7 Favored 'General case' 0 C--O 1.237 0.415 0 O-C-N 123.38 0.425 . . . . 0.0 110.749 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.51 -5.98 44.89 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.811 179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.588 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 16.5 ptp -70.65 165.53 22.68 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 122.866 0.466 . . . . 0.0 111.416 179.447 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.431 ' O ' ' HA ' ' A' ' 125' ' ' MET . 65.6 m-70 -109.09 140.02 43.2 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.719 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.559 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -135.82 127.1 28.3 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-O 121.033 0.444 . . . . 0.0 110.391 -179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.616 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -103.85 155.31 17.74 Favored Glycine 0 N--CA 1.444 -0.817 0 CA-C-N 114.839 -1.073 . . . . 0.0 111.63 178.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.568 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 6.4 m-85 -132.11 99.24 4.65 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -112.79 167.54 10.41 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -177.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 65.62 41.49 4.02 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 114.709 -1.132 . . . . 0.0 111.591 -178.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.641 HD22 HG21 ' A' ' 47' ' ' VAL . 11.6 mt -101.4 170.36 8.27 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.822 177.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 12.2 t -105.27 -15.67 14.98 Favored 'General case' 0 N--CA 1.449 -0.491 0 O-C-N 122.952 0.157 . . . . 0.0 111.37 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -168.95 160.44 10.1 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.658 0.742 . . . . 0.0 111.85 -178.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.833 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.37 149.64 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 113.638 -1.619 . . . . 0.0 110.949 179.329 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.91 -5.38 13.21 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.247 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.833 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -107.22 -175.42 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -1.99 0 CA-C-N 115.369 -0.832 . . . . 0.0 112.387 -176.921 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 57.6 m -154.31 144.54 22.04 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.908 -1.042 . . . . 0.0 109.101 -178.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.63 128.9 36.87 Favored 'General case' 0 CA--C 1.538 0.485 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.741 -179.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 87.47 -4.97 0.61 Allowed 'General case' 0 N--CA 1.483 1.204 0 C-N-CA 124.778 1.231 . . . . 0.0 111.837 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.466 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -81.67 148.13 29.17 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 110.44 -0.208 . . . . 0.0 110.44 178.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -83.9 145.85 28.37 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.385 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.82 168.38 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 CA-C-N 115.314 -0.857 . . . . 0.0 112.449 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 73.6 tttt -142.18 148.55 38.4 Favored 'General case' 0 N--CA 1.427 -1.61 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.872 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.784 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.6 138.52 55.2 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.305 -179.771 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.623 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.78 -4.6 51.7 Favored Glycine 0 CA--C 1.516 0.117 0 CA-C-N 114.431 -1.259 . . . . 0.0 114.166 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.515 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -75.33 140.67 43.23 Favored 'General case' 0 CA--C 1.507 -0.703 0 CA-C-O 121.086 0.469 . . . . 0.0 109.933 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.36 100.86 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 CA-C-N 114.875 -1.057 . . . . 0.0 109.586 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.7 -5.4 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 113.706 -1.588 . . . . 0.0 113.257 -178.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 169.71 -159.83 32.69 Favored Glycine 0 N--CA 1.443 -0.867 0 C-N-CA 121.515 -0.374 . . . . 0.0 112.427 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.547 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 33.9 m-85 -140.37 138.48 34.85 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 124.572 1.149 . . . . 0.0 108.378 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.445 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -62.65 150.09 41.76 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.659 0.784 . . . . 0.0 112.46 -178.821 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.751 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.35 -164.95 14.33 Favored Glycine 0 C--N 1.347 1.145 0 C-N-CA 119.884 -1.151 . . . . 0.0 114.153 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.3 52.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 178.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.606 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 38.8 p -80.88 1.49 30.58 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.248 -0.887 . . . . 0.0 113.355 -177.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -105.16 -162.89 23.77 Favored Glycine 0 C--N 1.337 0.59 0 C-N-CA 121.314 -0.469 . . . . 0.0 112.22 179.318 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 34.9 mt-30 -92.66 91.52 7.57 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-O 121.23 0.538 . . . . 0.0 110.885 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 2.4 m -152.01 167.44 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.97 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.0 p -89.69 -10.68 44.87 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.144 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -159.18 170.02 35.47 Favored Glycine 0 CA--C 1.53 0.976 0 CA-C-O 119.395 -0.669 . . . . 0.0 113.252 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.716 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 6.0 Cg_exo -79.42 146.77 19.69 Favored 'Trans proline' 0 C--N 1.373 1.854 0 C-N-CA 123.291 2.661 . . . . 0.0 112.529 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.541 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 38.1 p-80 -160.72 -166.69 1.67 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.528 0.68 . . . . 0.0 111.851 179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.662 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 15.9 tp -129.47 137.92 51.12 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.064 -1.425 . . . . 0.0 110.313 -178.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.458 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 23.9 t60 -121.59 114.93 21.88 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.284 -1.326 . . . . 0.0 110.184 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.556 ' O ' HG12 ' A' ' 37' ' ' VAL . 22.7 t80 -119.01 107.79 13.95 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.182 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.559 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.0 pt-20 -112.82 127.52 56.19 Favored 'General case' 0 N--CA 1.432 -1.327 0 CA-C-N 115.135 -0.939 . . . . 0.0 108.57 179.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.431 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 6.7 ttt -122.76 134.51 54.44 Favored 'General case' 0 N--CA 1.434 -1.255 0 CA-C-N 114.709 -1.132 . . . . 0.0 109.152 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.625 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -141.69 164.73 32.73 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 113.271 -1.786 . . . . 0.0 110.113 -177.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -63.16 -178.57 0.45 Allowed 'Trans proline' 0 C--N 1.369 1.613 0 C-N-CA 122.889 2.393 . . . . 0.0 113.277 177.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -69.09 -28.92 66.93 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.975 176.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -157.84 103.45 1.77 Allowed Pre-proline 0 CA--C 1.503 -0.841 0 CA-C-N 114.008 -1.451 . . . . 0.0 108.798 179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -72.03 163.22 39.46 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.612 2.208 . . . . 0.0 116.971 -176.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.573 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.5 69.62 0.77 Allowed 'General case' 0 N--CA 1.426 -1.668 0 CA-C-N 112.332 -2.213 . . . . 0.0 107.581 178.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.19 12.3 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.589 0 CA-C-N 114.319 -1.31 . . . . 0.0 112.412 -178.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.573 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 33.15 0.37 Allowed 'General case' 0 N--CA 1.444 -0.77 0 C-N-CA 124.306 1.043 . . . . 0.0 112.811 -178.462 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 73.11 128.79 0.04 OUTLIER 'General case' 0 CA--C 1.508 -0.645 0 CA-C-N 113.729 -1.578 . . . . 0.0 110.745 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.26 -48.41 0.6 Allowed Glycine 0 N--CA 1.439 -1.135 0 CA-C-N 114.971 -1.013 . . . . 0.0 112.964 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.588 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -152.21 -18.96 0.18 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 179.161 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 23.8 m 66.12 17.74 10.83 Favored 'General case' 0 N--CA 1.477 0.881 0 CA-C-O 122.59 1.186 . . . . 0.0 108.224 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.625 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.3 -11.32 9.0 Favored Glycine 0 N--CA 1.436 -1.345 0 CA-C-N 112.547 -2.115 . . . . 0.0 112.673 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.644 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.64 121.7 25.61 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 111.737 0.273 . . . . 0.0 111.737 -179.012 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -127.93 -172.93 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 115.774 -0.648 . . . . 0.0 112.441 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -79.34 128.64 74.86 Favored Pre-proline 0 CA--C 1.549 0.928 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.656 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.7 Cg_exo -76.76 -3.21 13.52 Favored 'Trans proline' 0 C--N 1.378 2.095 0 C-N-CA 122.934 2.423 . . . . 0.0 113.445 178.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -50.86 -23.49 2.84 Favored 'General case' 0 C--N 1.348 0.508 0 N-CA-C 114.681 1.363 . . . . 0.0 114.681 -177.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -69.69 -30.25 70.79 Favored Glycine 0 N--CA 1.461 0.342 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.472 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -104.24 -11.35 17.27 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 122.902 0.481 . . . . 0.0 111.685 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.656 HG12 ' O ' ' A' ' 142' ' ' PRO . 18.8 mm -96.34 -8.79 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.815 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -77.0 -21.0 55.35 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.173 177.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -102.23 15.3 29.54 Favored 'General case' 0 N--CA 1.431 -1.401 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.384 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.686 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -89.7 168.94 13.64 Favored Pre-proline 0 N--CA 1.417 -2.086 0 CA-C-N 113.69 -1.596 . . . . 0.0 112.552 -179.179 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.686 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 13.0 Cg_endo -54.89 178.77 0.08 OUTLIER 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 124.478 3.452 . . . . 0.0 114.261 179.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.444 HG13 ' H ' ' A' ' 155' ' ' THR . 99.3 t -107.32 132.22 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 121.731 0.777 . . . . 0.0 111.473 -177.191 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -102.44 98.41 8.51 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.146 178.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 69.32 -38.58 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 124.118 0.967 . . . . 0.0 113.067 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 147.3 81.79 0.04 OUTLIER Glycine 0 C--N 1.339 0.7 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.444 ' H ' HG13 ' A' ' 151' ' ' VAL . 11.1 p -91.09 105.21 17.65 Favored 'General case' 0 N--CA 1.444 -0.764 0 CA-C-O 121.512 0.673 . . . . 0.0 111.239 -179.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.6 p -98.83 127.15 36.21 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.442 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -81.79 -43.75 0.09 OUTLIER 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 122.271 1.981 . . . . 0.0 113.413 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.701 HG23 ' H ' ' A' ' 159' ' ' GLU . 7.3 t -163.11 -66.42 0.04 OUTLIER 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.279 -179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.701 ' H ' HG23 ' A' ' 158' ' ' THR . 9.6 mm-40 . . . . . 0 C--O 1.252 1.197 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.546 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 mtt . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 111.642 0.238 . . . . 0.0 111.642 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 50.5 mtt180 -105.71 -39.02 6.2 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 123.277 0.361 . . . . 0.0 111.411 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 104.47 51.75 0.9 Allowed Glycine 0 C--N 1.338 0.682 0 O-C-N 123.445 0.466 . . . . 0.0 112.808 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.2 t -123.14 136.16 54.66 Favored 'General case' 0 C--O 1.236 0.346 0 O-C-N 123.571 0.218 . . . . 0.0 110.627 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.7 p-80 -108.4 134.27 51.42 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.468 -179.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 68.6 m-70 -124.41 -42.67 2.09 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.253 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -127.06 148.41 50.13 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.293 0.371 . . . . 0.0 111.442 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -127.98 134.0 49.23 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.602 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 11.3 p-80 -111.16 120.11 41.2 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.177 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 64.7 m80 -94.87 146.2 24.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.944 -179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 155.78 23.49 0.03 OUTLIER Glycine 0 C--N 1.337 0.634 0 CA-C-N 116.027 -0.533 . . . . 0.0 113.203 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.4 167.85 11.08 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.865 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -159.01 104.87 1.73 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.1 177.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.5 t -97.08 -25.87 15.19 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.951 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 2.1 m-85 -98.98 138.44 36.08 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.437 0.637 . . . . 0.0 111.629 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 47.1 p -95.66 172.98 7.71 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 113.972 -1.467 . . . . 0.0 112.206 -178.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.55 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.8 OUTLIER -83.99 112.73 42.97 Favored Pre-proline 0 CA--C 1.544 0.735 0 C-N-CA 123.791 0.836 . . . . 0.0 112.098 -179.533 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.693 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.0 Cg_exo -67.0 -24.04 45.92 Favored 'Trans proline' 0 C--N 1.37 1.683 0 C-N-CA 122.699 2.266 . . . . 0.0 112.607 177.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.726 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.47 -171.95 2.89 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-O 122.402 1.096 . . . . 0.0 109.961 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.99 -25.41 3.04 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 112.452 -2.158 . . . . 0.0 108.532 177.091 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.726 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.5 t -169.39 -168.84 0.85 Allowed 'General case' 0 CA--C 1.546 0.797 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.593 -178.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 179.92 110.77 0.29 Allowed Glycine 0 C--N 1.317 -0.487 0 CA-C-N 114.513 -1.221 . . . . 0.0 111.171 176.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.41 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.16 124.84 8.4 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 112.829 0.677 . . . . 0.0 112.829 -178.313 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.99 58.58 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.995 -1.457 . . . . 0.0 109.097 178.551 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.3 t -104.54 -28.05 11.52 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 112.729 -2.032 . . . . 0.0 111.123 179.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -116.19 -66.7 1.06 Allowed 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.648 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.29 122.98 1.04 Allowed Glycine 0 N--CA 1.459 0.201 0 CA-C-N 115.011 -0.995 . . . . 0.0 112.011 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.532 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -73.49 157.26 37.12 Favored 'General case' 0 C--N 1.342 0.277 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -178.504 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.5 m-80 -57.86 31.89 0.0 OUTLIER 'General case' 0 C--O 1.239 0.538 0 N-CA-C 115.821 1.786 . . . . 0.0 115.821 -177.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -1.66 48.83 Favored Glycine 0 CA--C 1.504 -0.634 0 N-CA-C 111.356 -0.698 . . . . 0.0 111.356 179.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -101.94 85.31 0.67 Allowed Pre-proline 0 CA--C 1.548 0.866 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.6 Cg_exo -77.97 139.2 17.14 Favored 'Trans proline' 0 C--N 1.375 1.925 0 C-N-CA 122.823 2.349 . . . . 0.0 113.352 -178.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 91.14 4.17 69.1 Favored Glycine 0 C--N 1.339 0.727 0 O-C-N 123.685 0.615 . . . . 0.0 112.997 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.44 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.0 t-80 -78.24 135.43 37.57 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.047 0.939 . . . . 0.0 110.497 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.595 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.32 -12.53 9.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.242 -179.35 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -125.87 -149.77 7.51 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 123' ' ' PHE . 14.4 p -129.82 152.88 38.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 O-C-N 123.892 0.407 . . . . 0.0 110.133 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.714 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 93.1 m-20 -129.32 131.97 47.03 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.24 0.543 . . . . 0.0 112.242 -178.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.693 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.5 m-85 -122.86 109.48 14.23 Favored 'General case' 0 C--O 1.238 0.5 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.165 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.86 104.26 0.18 Allowed 'General case' 0 CA--C 1.541 0.633 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.339 179.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.552 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.4 p -144.84 123.91 6.9 Favored Pre-proline 0 CA--C 1.549 0.934 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.855 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_exo -49.02 142.7 19.54 Favored 'Trans proline' 0 C--N 1.371 1.737 0 C-N-CA 123.307 2.671 . . . . 0.0 115.423 -179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.676 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.09 141.01 17.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 111.582 -2.554 . . . . 0.0 113.619 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.53 2.73 55.45 Favored Glycine 0 N--CA 1.44 -1.035 0 CA-C-N 115.552 -0.749 . . . . 0.0 114.341 177.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.1 m -88.01 123.46 68.78 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-O 119.146 -0.454 . . . . 0.0 109.932 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.24 127.11 24.9 Favored 'Trans proline' 0 C--N 1.374 1.896 0 C-N-CA 122.328 2.019 . . . . 0.0 113.449 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.55 HG21 HD22 ' A' ' 90' ' ' LEU . 4.8 t -99.68 121.82 50.79 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.138 179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.511 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 2.3 mpt_? -103.19 152.49 21.4 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 113.331 -1.759 . . . . 0.0 111.481 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.414 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -71.69 121.46 18.89 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.441 -178.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.03 -15.64 19.96 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 112.775 0.658 . . . . 0.0 112.775 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.652 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.46 144.46 1.94 Allowed 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 123.462 0.705 . . . . 0.0 110.346 178.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -61.78 157.07 18.85 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 115.077 -0.965 . . . . 0.0 112.331 179.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.653 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 167.01 -127.15 1.54 Allowed Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.744 -0.662 . . . . 0.0 113.849 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.9 m -148.09 141.3 25.08 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 123.678 0.791 . . . . 0.0 109.683 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 99' ' ' SER . 11.3 t -83.49 111.66 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 123.719 0.808 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.7 mmmt -94.35 -15.72 24.13 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 114.726 -1.125 . . . . 0.0 110.643 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -153.9 140.01 18.39 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.041 179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.53 92.33 2.15 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 114.305 -1.316 . . . . 0.0 108.906 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.479 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -95.05 89.87 1.23 Allowed Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 114.06 -1.427 . . . . 0.0 112.953 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.577 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.46 125.54 27.66 Favored 'General case' 0 C--N 1.346 0.418 0 C-N-CA 123.795 0.838 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.664 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -79.93 -0.66 85.94 Favored Glycine 0 CA--C 1.52 0.392 0 CA-C-N 113.354 -1.748 . . . . 0.0 113.389 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -80.11 -32.05 39.1 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 24.86 2.68 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.144 -178.392 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.664 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -79.45 113.88 40.59 Favored Pre-proline 0 N--CA 1.436 -1.138 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.418 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.808 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.4 Cg_exo -67.69 163.23 36.01 Favored 'Trans proline' 0 C--N 1.37 1.688 0 C-N-CA 123.729 2.953 . . . . 0.0 111.556 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 62.1 m95 -98.2 10.54 40.33 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 14.7 mmt -75.58 -44.55 42.6 Favored 'General case' 0 C--N 1.349 0.552 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.057 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.547 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -120.92 11.51 11.07 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.783 177.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.808 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -129.05 145.92 51.14 Favored 'General case' 0 C--N 1.359 1.005 0 C-N-CA 120.545 -0.462 . . . . 0.0 111.701 -178.925 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 2.9 tpt -145.56 -31.02 0.4 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.488 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.78 -23.44 24.08 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.551 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 101.71 -128.68 9.64 Favored Glycine 0 CA--C 1.522 0.48 0 O-C-N 123.543 0.527 . . . . 0.0 114.025 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.596 HD21 ' HA3' ' A' ' 61' ' ' GLY . 11.8 m-80 -78.8 138.84 38.39 Favored 'General case' 0 C--N 1.347 0.458 0 C-N-CA 123.381 0.672 . . . . 0.0 112.586 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.33 145.23 23.59 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.008 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.1 t -138.55 120.58 17.69 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.158 -179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.03 131.22 56.99 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.423 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 9.3 mt -141.02 150.91 20.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 112.695 -2.048 . . . . 0.0 110.2 -176.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.653 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.5 tt0 -97.72 116.49 30.03 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 113.984 -1.462 . . . . 0.0 108.294 178.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.652 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -69.17 -175.85 0.82 Allowed 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.561 -1.199 . . . . 0.0 114.159 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -64.97 -17.78 64.69 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 113.867 -1.515 . . . . 0.0 114.485 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.458 ' HB2' ' HE1' ' A' ' 83' ' ' MET . 0.2 OUTLIER -101.79 -9.86 20.43 Favored 'General case' 0 C--O 1.237 0.431 0 CA-C-O 120.826 0.346 . . . . 0.0 111.128 -179.599 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.78 -6.09 43.92 Favored Glycine 0 N--CA 1.448 -0.566 0 CA-C-N 115.447 -0.797 . . . . 0.0 112.061 179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.521 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 1.4 ptt? -68.92 168.4 13.7 Favored 'General case' 0 N--CA 1.44 -0.944 0 C-N-CA 123.712 0.805 . . . . 0.0 111.456 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.418 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 55.6 m-70 -112.55 142.7 44.81 Favored 'General case' 0 N--CA 1.441 -0.892 0 C-N-CA 120.463 -0.495 . . . . 0.0 111.024 -179.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.4 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.26 127.06 25.54 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-O 121.041 0.448 . . . . 0.0 110.022 179.706 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -105.49 154.59 17.1 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 114.882 -1.054 . . . . 0.0 111.629 178.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.506 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.1 m-85 -135.1 99.17 4.19 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 105.227 -2.138 . . . . 0.0 105.227 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.401 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -114.11 168.8 9.5 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 65.28 41.86 4.2 Favored 'General case' 0 N--CA 1.476 0.852 0 C-N-CA 124.159 0.984 . . . . 0.0 111.44 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.55 HD22 HG21 ' A' ' 47' ' ' VAL . 11.0 mt -102.94 169.41 8.6 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.037 178.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.4 t -103.88 -16.47 15.36 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 111.676 0.25 . . . . 0.0 111.676 -179.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 1.2 tttm -167.32 162.37 14.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 121.801 0.81 . . . . 0.0 112.018 -178.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.825 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.9 OUTLIER -127.83 147.82 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 113.443 -1.708 . . . . 0.0 110.643 179.298 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -110.47 -6.8 14.84 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 114.402 -1.272 . . . . 0.0 109.899 178.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.825 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.73 -175.12 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.073 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.733 -176.89 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 6.9 t -154.18 148.44 25.95 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.79 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.6 m -58.5 128.98 39.88 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.622 -179.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.3 t70 86.96 -5.71 0.67 Allowed 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 124.634 1.174 . . . . 0.0 111.722 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.479 ' O ' HG23 ' A' ' 55' ' ' VAL . 31.7 m -79.82 149.63 30.96 Favored 'General case' 0 N--CA 1.45 -0.431 0 C-N-CA 122.272 0.229 . . . . 0.0 110.711 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -84.94 145.0 27.98 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.382 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.413 HG12 HE21 ' A' ' 105' ' ' GLN . 0.0 OUTLIER -127.01 168.14 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.244 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.437 -179.22 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 42.9 tttm -140.5 149.58 42.66 Favored 'General case' 0 N--CA 1.428 -1.555 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.844 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.787 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.17 138.59 56.07 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.383 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.511 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.64 -4.55 50.82 Favored Glycine 0 CA--C 1.517 0.185 0 CA-C-N 114.387 -1.278 . . . . 0.0 114.076 179.592 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.5 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.0 tt0 -75.2 140.57 43.38 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-O 121.086 0.47 . . . . 0.0 110.026 179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 52.4 mt -72.11 101.46 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.64 -179.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.59 -5.01 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-N 113.512 -1.676 . . . . 0.0 113.17 -178.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.65 -161.9 35.64 Favored Glycine 0 N--CA 1.443 -0.851 0 CA-C-O 121.363 0.424 . . . . 0.0 112.571 178.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.2 m-85 -139.88 138.06 35.37 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 124.561 1.144 . . . . 0.0 108.339 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.3 150.53 39.05 Favored 'General case' 0 N--CA 1.469 0.485 0 O-C-N 123.913 0.758 . . . . 0.0 112.572 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.676 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -160.23 -161.54 11.51 Favored Glycine 0 C--N 1.348 1.232 0 C-N-CA 119.844 -1.17 . . . . 0.0 114.119 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.637 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.1 50.78 0.91 Allowed 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.632 -0.784 . . . . 0.0 108.99 178.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.551 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 32.6 p -78.99 5.96 10.47 Favored 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.137 -0.938 . . . . 0.0 113.094 -177.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -108.5 -160.6 20.14 Favored Glycine 0 C--N 1.338 0.641 0 C-N-CA 121.374 -0.441 . . . . 0.0 112.154 179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 6.3 tt0 -96.95 91.46 5.62 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 121.309 0.576 . . . . 0.0 110.331 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 1.7 m -152.69 172.0 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.07 -179.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 14.9 p -93.45 -14.22 27.0 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -179.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -155.6 166.47 32.82 Favored Glycine 0 CA--C 1.532 1.12 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.351 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.637 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -77.71 145.67 23.18 Favored 'Trans proline' 0 C--N 1.374 1.893 0 C-N-CA 123.111 2.54 . . . . 0.0 112.414 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.552 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 47.6 p-80 -159.71 -164.91 1.41 Allowed 'General case' 0 C--N 1.351 0.667 0 CA-C-O 121.68 0.753 . . . . 0.0 112.259 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.714 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 16.9 tp -129.7 133.41 47.04 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.433 -178.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.452 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 18.4 t60 -118.18 113.39 21.46 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.288 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.563 ' O ' HG12 ' A' ' 37' ' ' VAL . 37.9 t80 -119.04 108.94 15.34 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.303 -179.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 85' ' ' THR . 20.3 tt0 -117.3 127.15 53.79 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.197 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.426 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 1.9 tpt -118.13 139.81 50.7 Favored 'General case' 0 N--CA 1.431 -1.391 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.646 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.0 mp -143.98 165.46 24.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 CA-C-N 113.426 -1.715 . . . . 0.0 110.619 -177.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.418 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 14.1 Cg_endo -63.62 -178.68 0.55 Allowed 'Trans proline' 0 C--N 1.37 1.67 0 C-N-CA 122.842 2.361 . . . . 0.0 112.948 177.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.16 -27.33 63.47 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.085 176.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -157.44 101.95 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.77 0 CA-C-N 114.03 -1.441 . . . . 0.0 108.871 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -71.71 163.39 39.07 Favored 'Trans proline' 0 N--CA 1.446 -1.314 0 C-N-CA 122.711 2.274 . . . . 0.0 116.874 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.552 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -117.23 70.33 0.78 Allowed 'General case' 0 N--CA 1.425 -1.699 0 CA-C-N 112.532 -2.122 . . . . 0.0 107.649 177.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.448 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.25 13.67 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 114.298 -1.319 . . . . 0.0 112.54 -178.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.552 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.63 33.35 0.36 Allowed 'General case' 0 N--CA 1.446 -0.675 0 C-N-CA 124.122 0.969 . . . . 0.0 112.996 -178.15 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 73.26 127.46 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.583 0 C-N-CA 125.663 1.585 . . . . 0.0 110.598 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.31 -50.04 0.56 Allowed Glycine 0 N--CA 1.436 -1.338 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.343 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -150.45 -18.92 0.24 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 179.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 39.5 m 66.01 17.74 10.87 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 122.473 1.13 . . . . 0.0 108.157 -178.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.564 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.07 -9.63 18.11 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 112.6 -2.091 . . . . 0.0 112.734 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.595 ' HG2' HG12 ' A' ' 35' ' ' VAL . 3.2 ppt_? -82.9 127.35 33.42 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 119.854 -0.738 . . . . 0.0 112.362 -179.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -128.07 -173.14 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.629 179.179 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.438 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.4 m-20 -73.28 129.8 85.4 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -176.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.581 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.3 0.22 9.96 Favored 'Trans proline' 0 C--N 1.38 2.226 0 C-N-CA 122.954 2.436 . . . . 0.0 113.341 177.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.31 -23.78 6.39 Favored 'General case' 0 C--N 1.349 0.548 0 N-CA-C 113.963 1.098 . . . . 0.0 113.963 -178.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -71.86 -25.59 74.56 Favored Glycine 0 CA--C 1.52 0.362 0 CA-C-N 115.732 -0.667 . . . . 0.0 111.92 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -101.99 -11.67 18.75 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 123.248 0.619 . . . . 0.0 111.16 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.581 HG12 ' O ' ' A' ' 142' ' ' PRO . 20.8 mm -100.16 -9.76 8.93 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -75.71 -24.73 56.23 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.739 178.095 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -101.29 14.5 31.77 Favored 'General case' 0 N--CA 1.433 -1.28 0 CA-C-O 122.051 0.929 . . . . 0.0 109.042 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.555 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -94.41 164.5 19.87 Favored Pre-proline 0 N--CA 1.417 -2.115 0 CA-C-N 113.538 -1.665 . . . . 0.0 112.444 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.555 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 16.8 Cg_endo -55.51 178.82 0.09 OUTLIER 'Trans proline' 0 C--N 1.366 1.473 0 C-N-CA 124.622 3.548 . . . . 0.0 114.08 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 86.8 t -109.04 127.04 66.02 Favored 'Isoleucine or valine' 0 C--N 1.341 0.237 0 CA-C-O 121.488 0.661 . . . . 0.0 111.193 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.55 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 38.2 t80 -104.27 97.92 7.8 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.022 178.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 68.78 -38.69 0.4 Allowed 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.315 1.046 . . . . 0.0 113.137 179.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 122.62 83.29 0.64 Allowed Glycine 0 C--N 1.337 0.631 0 N-CA-C 112.183 -0.367 . . . . 0.0 112.183 -179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.1 p -93.6 105.59 17.62 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 123.498 0.719 . . . . 0.0 111.226 -179.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 18.6 p -91.86 132.43 32.91 Favored Pre-proline 0 CA--C 1.54 0.56 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.729 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -83.16 -43.65 0.08 OUTLIER 'Trans proline' 0 C--N 1.374 1.907 0 C-N-CA 122.295 1.996 . . . . 0.0 113.457 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.682 HG23 ' H ' ' A' ' 159' ' ' GLU . 6.4 t -159.94 -64.89 0.07 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.177 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.682 ' H ' HG23 ' A' ' 158' ' ' THR . 33.8 mt-10 . . . . . 0 C--O 1.249 1.049 0 CA-C-N 114.33 -1.305 . . . . 0.0 111.752 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 55.0 mtt . . . . . 0 N--CA 1.487 1.397 0 CA-C-O 120.701 0.286 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -92.64 131.86 37.38 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.216 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.34 -86.18 0.06 OUTLIER Glycine 0 C--N 1.336 0.552 0 O-C-N 123.664 0.602 . . . . 0.0 112.414 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.0 m -114.79 131.0 56.95 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.329 0.252 . . . . 0.0 110.849 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -131.11 -43.11 1.07 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.4 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.9 m-70 -121.09 -43.04 2.45 Favored 'General case' 0 C--O 1.236 0.363 0 O-C-N 123.347 0.404 . . . . 0.0 111.478 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -102.39 142.79 33.02 Favored 'General case' 0 C--O 1.235 0.316 0 O-C-N 123.329 0.393 . . . . 0.0 111.155 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.4 m80 -95.28 -43.76 7.91 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.777 -0.647 . . . . 0.0 111.073 179.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.9 m80 -117.08 126.56 53.03 Favored 'General case' 0 C--O 1.235 0.296 0 O-C-N 123.558 0.536 . . . . 0.0 110.464 179.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 2.5 t-80 -126.05 140.09 52.88 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.703 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.66 42.87 1.74 Allowed Glycine 0 C--N 1.337 0.619 0 CA-C-N 116.064 -0.516 . . . . 0.0 112.59 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.12 169.24 13.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 120.942 0.401 . . . . 0.0 111.831 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.78 104.47 2.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.835 177.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.4 t -89.51 6.09 42.53 Favored 'General case' 0 CA--C 1.542 0.652 0 CA-C-N 115.382 -0.827 . . . . 0.0 112.068 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -94.54 144.33 25.67 Favored 'General case' 0 N--CA 1.44 -0.958 0 CA-C-O 121.573 0.701 . . . . 0.0 111.434 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 34.6 p -92.82 179.91 5.33 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 113.806 -1.543 . . . . 0.0 113.116 -177.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.716 HH11 HG22 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -63.28 113.0 8.07 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 124.596 1.158 . . . . 0.0 112.941 -179.548 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.701 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 20.1 Cg_exo -67.47 -21.21 46.95 Favored 'Trans proline' 0 C--N 1.368 1.589 0 C-N-CA 122.662 2.241 . . . . 0.0 112.344 178.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.737 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -138.72 -171.97 3.2 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.482 1.134 . . . . 0.0 110.104 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -127.69 -25.25 3.15 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 112.332 -2.213 . . . . 0.0 108.699 177.237 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.737 ' H ' HD12 ' A' ' 19' ' ' LEU . 8.5 t -168.99 -168.64 0.87 Allowed 'General case' 0 CA--C 1.546 0.808 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.525 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.401 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 177.4 111.18 0.29 Allowed Glycine 0 C--N 1.321 -0.281 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.483 177.116 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -151.57 124.41 8.56 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 121.472 0.653 . . . . 0.0 112.632 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.756 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.11 58.19 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.502 0 CA-C-N 113.949 -1.478 . . . . 0.0 109.255 178.79 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 7.9 t -106.46 -27.68 10.77 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 113.134 -1.848 . . . . 0.0 110.873 178.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.2 -67.26 1.01 Allowed 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.721 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.51 123.94 1.14 Allowed Glycine 0 C--O 1.234 0.151 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.14 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.514 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.94 157.5 31.26 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.641 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 59.2 m-80 -58.02 31.67 0.0 OUTLIER 'General case' 0 C--O 1.24 0.558 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -177.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.699 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.78 -0.88 48.61 Favored Glycine 0 CA--C 1.506 -0.484 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -101.6 85.55 0.67 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.699 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.07 137.89 15.86 Favored 'Trans proline' 0 C--N 1.375 1.94 0 C-N-CA 122.807 2.338 . . . . 0.0 113.225 -178.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.41 4.07 71.29 Favored Glycine 0 C--N 1.34 0.758 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.149 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-80 -76.12 135.12 39.84 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 123.975 0.91 . . . . 0.0 110.37 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.678 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.68 -16.35 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.772 -0.649 . . . . 0.0 111.342 -179.021 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.54 -149.71 8.14 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 123' ' ' PHE . 10.6 p -131.33 151.03 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 O-C-N 124.031 0.489 . . . . 0.0 110.042 179.235 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.706 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 89.1 m-20 -125.96 134.19 51.59 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 121.323 0.582 . . . . 0.0 112.046 -178.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.701 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.6 m-85 -124.71 110.07 13.91 Favored 'General case' 0 C--O 1.238 0.464 0 CA-C-N 114.244 -1.344 . . . . 0.0 110.251 -178.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -58.49 104.64 0.23 Allowed 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.544 178.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.556 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 12.5 p -145.98 124.78 6.53 Favored Pre-proline 0 CA--C 1.551 0.996 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.887 -179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.01 142.02 20.94 Favored 'Trans proline' 0 C--N 1.37 1.694 0 C-N-CA 123.346 2.697 . . . . 0.0 115.261 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.726 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -61.39 140.15 19.41 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 111.848 -2.433 . . . . 0.0 113.615 -179.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.64 54.61 Favored Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.418 -0.81 . . . . 0.0 114.36 177.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.9 m -87.32 125.37 65.99 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.257 -0.401 . . . . 0.0 109.952 179.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -57.34 127.69 26.57 Favored 'Trans proline' 0 C--N 1.374 1.897 0 C-N-CA 122.291 1.994 . . . . 0.0 113.468 -179.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.531 HG21 HD22 ' A' ' 90' ' ' LEU . 9.8 t -99.96 123.36 52.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.97 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.154 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.633 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 13.6 mtp180 -101.91 152.15 21.26 Favored 'General case' 0 N--CA 1.433 -1.302 0 CA-C-N 112.963 -1.926 . . . . 0.0 111.659 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -72.48 120.96 18.82 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.846 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.1 t -66.68 -15.78 19.95 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.881 0 N-CA-C 112.777 0.658 . . . . 0.0 112.777 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.617 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.82 143.59 1.67 Allowed 'General case' 0 CA--C 1.516 -0.361 0 C-N-CA 123.546 0.738 . . . . 0.0 110.355 179.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.434 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.4 OUTLIER -60.36 155.42 18.04 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.234 -0.894 . . . . 0.0 112.206 179.137 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 170.32 -128.63 1.67 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.891 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.407 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.3 m -148.16 136.35 21.24 Favored 'General case' 0 N--CA 1.44 -0.968 0 C-N-CA 123.446 0.698 . . . . 0.0 110.33 -178.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 11.1 t -83.89 112.44 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.43 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.2 OUTLIER -98.09 -16.63 19.48 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.841 179.846 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -148.54 138.52 22.33 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.737 178.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.9 92.17 2.1 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 114.081 -1.418 . . . . 0.0 108.494 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.422 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.17 89.85 1.37 Allowed Glycine 0 C--O 1.24 0.478 0 CA-C-N 114.128 -1.396 . . . . 0.0 112.802 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.571 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -71.56 125.71 27.77 Favored 'General case' 0 C--N 1.345 0.395 0 C-N-CA 123.964 0.905 . . . . 0.0 112.517 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.655 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.26 -0.74 87.12 Favored Glycine 0 CA--C 1.52 0.349 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.375 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.69 -31.85 52.69 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.45 25.51 2.65 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.069 -178.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.655 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -80.6 112.93 35.62 Favored Pre-proline 0 N--CA 1.435 -1.2 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.16 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.833 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.0 Cg_exo -67.81 163.45 35.36 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.987 3.125 . . . . 0.0 111.821 177.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.0 m95 -96.79 8.82 43.44 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -75.2 -44.48 46.21 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.398 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.541 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -120.84 10.9 11.01 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.714 177.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.833 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -128.83 145.92 51.07 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 120.332 -0.547 . . . . 0.0 111.537 -178.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 32.8 mtt -146.19 -29.18 0.41 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.421 179.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -87.44 -24.79 24.05 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.677 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.626 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.6 -123.98 8.09 Favored Glycine 0 CA--C 1.519 0.315 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.753 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.526 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.2 m-80 -81.17 138.21 35.87 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 123.237 0.615 . . . . 0.0 111.95 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -151.55 148.16 27.67 Favored 'General case' 0 CA--C 1.52 -0.193 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.343 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.61 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.4 t -140.23 122.13 15.58 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.175 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.065 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -118.34 127.6 53.85 Favored 'General case' 0 CA--C 1.494 -1.188 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.7 mt -139.19 150.96 22.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 CA-C-N 112.548 -2.115 . . . . 0.0 110.404 -176.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.3 117.04 32.88 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 113.944 -1.48 . . . . 0.0 108.603 178.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.617 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.0 m-70 -67.27 -176.37 0.56 Allowed 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 114.11 1.152 . . . . 0.0 114.11 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.434 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -66.48 -17.67 64.93 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 114.107 -1.406 . . . . 0.0 114.313 -177.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.72 -10.19 21.07 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.905 0.383 . . . . 0.0 110.956 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.427 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.76 -4.78 42.75 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.273 -0.876 . . . . 0.0 112.192 179.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.7 ptt? -69.04 171.1 8.68 Favored 'General case' 0 N--CA 1.442 -0.874 0 C-N-CA 123.512 0.725 . . . . 0.0 111.683 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.3 m170 -108.96 147.04 32.86 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.011 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.1 OUTLIER -141.5 126.63 18.45 Favored 'General case' 0 N--CA 1.439 -0.981 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.947 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.61 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -108.96 154.57 16.43 Favored Glycine 0 N--CA 1.439 -1.146 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.401 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.492 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.1 m-85 -136.77 99.35 4.02 Favored 'General case' 0 N--CA 1.437 -1.075 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.51 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.32 167.93 10.16 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 38.7 m80 65.75 40.69 4.22 Favored 'General case' 0 N--CA 1.48 1.037 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.779 -178.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.531 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -100.93 169.98 8.6 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.76 177.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.5 t -106.38 -15.51 14.8 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 111.457 0.169 . . . . 0.0 111.457 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 6.8 tttt -167.95 156.87 9.4 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.618 0.723 . . . . 0.0 111.99 -178.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -120.84 148.83 23.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 113.844 -1.526 . . . . 0.0 110.72 178.917 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -112.01 -5.98 14.24 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.209 178.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -105.67 -175.1 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.088 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.683 -177.067 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 67.4 m -153.33 143.94 22.61 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-N 114.867 -1.061 . . . . 0.0 109.002 -178.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -56.47 126.61 27.26 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.184 -0.917 . . . . 0.0 111.785 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.2 t70 89.15 -4.77 0.42 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 124.807 1.243 . . . . 0.0 111.587 178.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.7 m -81.7 146.05 30.21 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 122.176 0.191 . . . . 0.0 110.588 178.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.4 p -82.64 145.83 29.44 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.215 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.93 167.9 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.48 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -140.09 147.38 40.19 Favored 'General case' 0 N--CA 1.428 -1.574 0 CA-C-N 114.417 -1.265 . . . . 0.0 109.836 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.789 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.1 138.8 54.01 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.128 -1.397 . . . . 0.0 111.693 -179.717 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.633 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.69 -6.78 37.29 Favored Glycine 0 CA--C 1.517 0.156 0 CA-C-N 114.361 -1.291 . . . . 0.0 114.129 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.494 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 25.8 tt0 -73.11 140.23 46.98 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-O 121.104 0.478 . . . . 0.0 110.013 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 43.0 mt -72.05 101.19 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 CA-C-N 114.705 -1.134 . . . . 0.0 109.401 -179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.8 -5.44 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.88 0 CA-C-N 113.739 -1.573 . . . . 0.0 113.101 -178.867 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 171.3 -162.14 34.76 Favored Glycine 0 N--CA 1.44 -1.054 0 CA-C-O 121.272 0.374 . . . . 0.0 112.683 178.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 24.6 m-85 -141.37 137.12 32.1 Favored 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 124.816 1.246 . . . . 0.0 108.272 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -61.35 151.46 32.12 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 123.615 0.766 . . . . 0.0 112.654 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.726 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.38 -162.17 11.41 Favored Glycine 0 C--N 1.347 1.185 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.798 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.619 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 47.72 0.89 Allowed 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -0.7 . . . . 0.0 109.261 178.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.626 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 34.4 p -80.21 3.17 21.61 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.213 -0.903 . . . . 0.0 113.292 -177.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -95.31 -96.35 1.72 Allowed Glycine 0 C--N 1.339 0.745 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 178.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -96.75 143.51 27.62 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.2 m -91.75 97.05 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.651 0.739 . . . . 0.0 111.901 -179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 37.6 p -147.06 -52.69 0.21 Allowed 'General case' 0 C--O 1.235 0.302 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.621 179.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.29 143.74 8.0 Favored Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.599 -1.112 . . . . 0.0 111.54 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.619 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 10.0 Cg_exo -69.8 141.95 46.43 Favored 'Trans proline' 0 C--N 1.374 1.912 0 CA-C-N 120.251 2.025 . . . . 0.0 111.725 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.556 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 53.2 p-80 -157.77 -171.56 3.59 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.495 0.664 . . . . 0.0 111.774 -179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.706 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 9.1 tp -125.23 139.85 53.36 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.099 -1.409 . . . . 0.0 110.565 -178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.571 ' HE2' ' HB2' ' A' ' 124' ' ' GLU . 29.1 t60 -118.32 128.54 54.75 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 113.706 -1.588 . . . . 0.0 107.845 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.528 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.5 t80 -133.0 111.26 10.86 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.847 178.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.571 ' HB2' ' HE2' ' A' ' 122' ' ' HIS . 18.0 tt0 -120.31 127.18 52.11 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.238 179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.8 tpt -120.26 138.01 53.91 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.666 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.591 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.1 mp -143.6 164.68 29.13 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 113.439 -1.709 . . . . 0.0 110.298 -178.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo -62.83 -178.81 0.43 Allowed 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.943 2.429 . . . . 0.0 112.669 177.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -68.57 -27.82 66.41 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.206 176.195 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.5 m120 -157.35 107.93 1.86 Allowed Pre-proline 0 CA--C 1.505 -0.781 0 CA-C-N 113.903 -1.498 . . . . 0.0 108.232 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -71.15 163.12 40.26 Favored 'Trans proline' 0 N--CA 1.445 -1.326 0 C-N-CA 122.347 2.031 . . . . 0.0 116.926 -176.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.568 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -117.89 70.82 0.8 Allowed 'General case' 0 N--CA 1.423 -1.805 0 CA-C-N 112.349 -2.205 . . . . 0.0 107.395 177.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.447 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.29 13.99 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.168 -1.378 . . . . 0.0 112.376 -178.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.568 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.23 32.3 0.33 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 124.269 1.027 . . . . 0.0 112.902 -178.361 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 72.21 127.96 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.64 0 C-N-CA 125.737 1.615 . . . . 0.0 110.997 178.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.11 -48.08 0.61 Allowed Glycine 0 N--CA 1.437 -1.278 0 CA-C-N 115.028 -0.987 . . . . 0.0 113.341 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.68 -19.52 0.16 Allowed 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.43 18.22 10.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 122.624 1.202 . . . . 0.0 108.19 -178.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 79.77 -11.66 32.75 Favored Glycine 0 N--CA 1.434 -1.449 0 CA-C-N 112.252 -2.249 . . . . 0.0 112.648 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.678 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.8 OUTLIER -83.98 125.02 31.65 Favored 'General case' 0 N--CA 1.464 0.273 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.301 -179.434 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.439 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -125.24 -172.96 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 CA-C-N 115.585 -0.734 . . . . 0.0 112.441 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.439 ' H ' HG22 ' A' ' 140' ' ' ILE . 2.9 t70 -75.82 134.77 71.63 Favored Pre-proline 0 CA--C 1.549 0.94 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -176.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.596 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.9 Cg_endo -77.16 0.62 9.54 Favored 'Trans proline' 0 C--N 1.381 2.277 0 C-N-CA 123.082 2.521 . . . . 0.0 113.546 177.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -51.34 -24.08 4.32 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.69 -28.95 66.24 Favored Glycine 0 CA--C 1.521 0.45 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.912 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 7.3 m-85 -99.71 -11.86 20.5 Favored 'General case' 0 C--O 1.236 0.39 0 C-N-CA 123.347 0.659 . . . . 0.0 111.194 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.716 HG22 HH11 ' A' ' 17' ' ' ARG . 31.2 mm -98.8 -10.47 8.78 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.372 -178.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -74.74 -23.15 58.51 Favored 'General case' 0 C--O 1.236 0.357 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.656 178.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.88 12.41 37.68 Favored 'General case' 0 N--CA 1.432 -1.362 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 146' ' ' ILE . . . -96.43 158.43 33.82 Favored Pre-proline 0 N--CA 1.418 -2.054 0 CA-C-N 114.077 -1.42 . . . . 0.0 112.746 -178.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -55.52 178.9 0.09 OUTLIER 'Trans proline' 0 C--N 1.367 1.507 0 C-N-CA 124.517 3.478 . . . . 0.0 114.639 179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 88.6 t -104.43 134.92 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.791 -178.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 43.0 t80 -100.98 97.51 8.08 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 113.815 -1.538 . . . . 0.0 109.46 179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 67.49 -35.43 0.26 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 124.423 1.089 . . . . 0.0 113.602 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 135.27 100.81 0.64 Allowed Glycine 0 C--N 1.339 0.711 0 C-N-CA 121.306 -0.473 . . . . 0.0 112.111 -179.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 16.0 p -96.04 105.34 17.37 Favored 'General case' 0 N--CA 1.443 -0.822 0 C-N-CA 123.26 0.624 . . . . 0.0 111.23 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.9 p -94.2 152.5 40.34 Favored Pre-proline 0 CA--C 1.539 0.547 0 CA-C-N 115.005 -0.998 . . . . 0.0 110.838 178.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_endo -84.37 -44.46 0.06 OUTLIER 'Trans proline' 0 C--N 1.374 1.883 0 C-N-CA 122.394 2.063 . . . . 0.0 113.368 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.687 HG23 ' H ' ' A' ' 159' ' ' GLU . 6.7 t -160.75 -65.7 0.06 Allowed 'General case' 0 C--O 1.236 0.381 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.208 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.687 ' H ' HG23 ' A' ' 158' ' ' THR . 37.3 mt-10 . . . . . 0 C--O 1.249 1.044 0 CA-C-N 114.469 -1.241 . . . . 0.0 111.594 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 47.1 mtt . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.578 0.228 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 19.9 mtp180 -91.56 143.56 26.46 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.129 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 120.0 69.37 0.3 Allowed Glycine 0 C--N 1.338 0.66 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.488 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 49.3 m -127.41 -51.14 1.39 Allowed 'General case' 0 C--O 1.235 0.322 0 O-C-N 123.642 0.26 . . . . 0.0 110.986 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 60.7 m80 -141.78 124.54 16.02 Favored 'General case' 0 N--CA 1.466 0.368 0 O-C-N 123.29 0.368 . . . . 0.0 111.049 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -138.89 148.6 43.84 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.892 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 67.9 m80 -102.14 146.64 27.66 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.945 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 77.4 m-70 -137.45 -41.08 0.56 Allowed 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.272 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.7 m-70 -120.1 -37.28 3.1 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -178.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -76.85 147.98 36.8 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 133.92 44.34 0.12 Allowed Glycine 0 C--N 1.341 0.846 0 CA-C-N 115.66 -0.7 . . . . 0.0 112.793 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -120.99 167.79 12.21 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.18 101.42 1.74 Allowed 'General case' 0 N--CA 1.448 -0.546 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.329 176.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.2 t -95.92 -4.24 43.8 Favored 'General case' 0 CA--C 1.542 0.67 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -178.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -90.1 120.32 31.18 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 121.8 0.809 . . . . 0.0 112.495 -178.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.0 p -99.63 157.46 16.45 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 113.387 -1.733 . . . . 0.0 112.658 -178.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.491 HH11 HG22 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -86.75 112.55 47.77 Favored Pre-proline 0 CA--C 1.544 0.722 0 C-N-CA 123.255 0.622 . . . . 0.0 110.816 179.013 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.685 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 21.3 Cg_exo -66.6 -23.84 49.12 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 122.717 2.278 . . . . 0.0 112.951 178.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.753 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.56 -172.0 3.05 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-O 122.671 1.224 . . . . 0.0 110.375 -179.894 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.471 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -128.14 -25.22 3.03 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 112.144 -2.298 . . . . 0.0 108.742 177.213 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.753 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.3 t -168.62 -168.64 0.92 Allowed 'General case' 0 CA--C 1.548 0.87 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.781 -178.302 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 171.99 111.74 0.26 Allowed Glycine 0 C--N 1.318 -0.431 0 CA-C-N 114.661 -1.154 . . . . 0.0 111.441 178.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.16 124.97 9.12 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.729 0.776 . . . . 0.0 112.973 -178.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.763 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.75 58.34 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.459 0 CA-C-N 113.393 -1.731 . . . . 0.0 109.122 179.38 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.9 t -105.15 -28.2 11.13 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 112.969 -1.923 . . . . 0.0 111.007 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.2 m -114.52 -67.15 1.02 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.774 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.73 122.64 1.03 Allowed Glycine 0 C--N 1.322 -0.196 0 CA-C-N 115.147 -0.933 . . . . 0.0 112.144 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.51 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -76.17 157.6 32.57 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -178.795 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -57.14 32.12 0.0 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.718 1.747 . . . . 0.0 115.718 -177.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.706 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.73 -0.02 49.06 Favored Glycine 0 CA--C 1.504 -0.624 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -102.16 85.42 0.72 Allowed Pre-proline 0 CA--C 1.547 0.854 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.706 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 3.5 Cg_exo -76.95 141.99 21.73 Favored 'Trans proline' 0 C--N 1.373 1.848 0 C-N-CA 122.826 2.351 . . . . 0.0 113.425 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 86.51 4.02 83.57 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-N 115.803 -0.635 . . . . 0.0 113.06 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.416 ' O ' HG21 ' A' ' 24' ' ' ILE . 3.3 t-80 -74.29 127.33 32.72 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.098 0.959 . . . . 0.0 110.697 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.753 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -102.72 5.45 10.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.656 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -144.86 -150.03 5.14 Favored Glycine 0 C--N 1.337 0.603 0 C-N-CA 121.526 -0.368 . . . . 0.0 112.257 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 123' ' ' PHE . 9.7 p -130.52 154.69 40.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.811 0 C-N-CA 122.97 0.508 . . . . 0.0 110.244 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.702 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -129.16 130.07 45.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.258 0.552 . . . . 0.0 111.914 -179.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.685 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 3.4 m-85 -120.54 109.99 15.93 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.273 -178.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -57.3 104.15 0.15 Allowed 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.275 178.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.531 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 13.6 p -146.79 124.07 5.89 Favored Pre-proline 0 CA--C 1.55 0.974 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.76 -179.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -49.0 142.97 18.81 Favored 'Trans proline' 0 C--N 1.37 1.663 0 C-N-CA 123.4 2.733 . . . . 0.0 115.528 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.748 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -62.47 140.77 18.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 111.766 -2.47 . . . . 0.0 113.454 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.45 2.53 55.55 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 115.441 -0.8 . . . . 0.0 114.036 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -87.53 124.0 68.55 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-O 119.153 -0.451 . . . . 0.0 109.88 179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.7 126.7 23.32 Favored 'Trans proline' 0 C--N 1.376 1.987 0 C-N-CA 122.342 2.028 . . . . 0.0 113.272 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.602 HG21 HD22 ' A' ' 90' ' ' LEU . 5.8 t -99.55 121.12 49.83 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.985 0 CA-C-N 115.107 -0.951 . . . . 0.0 108.903 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.506 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 3.9 mpt_? -102.21 152.41 21.06 Favored 'General case' 0 N--CA 1.433 -1.279 0 CA-C-N 113.301 -1.772 . . . . 0.0 111.434 -179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -71.71 122.63 20.97 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 114.689 -1.141 . . . . 0.0 111.435 -178.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 24.6 t -69.42 -14.53 18.52 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 CA-C-N 115.727 -0.669 . . . . 0.0 112.553 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.631 ' HB3' ' CE1' ' A' ' 79' ' ' HIS . . . -171.24 143.86 1.95 Allowed 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 123.491 0.716 . . . . 0.0 110.641 178.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -62.68 156.04 24.67 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 114.943 -1.026 . . . . 0.0 112.477 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.63 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.32 -127.61 1.57 Allowed Glycine 0 C--N 1.334 0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.551 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.7 m -148.08 141.45 25.26 Favored 'General case' 0 N--CA 1.436 -1.148 0 C-N-CA 123.598 0.759 . . . . 0.0 109.532 -178.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.477 HG23 ' O ' ' A' ' 99' ' ' SER . 10.6 t -83.63 112.81 21.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.516 0 O-C-N 123.907 0.755 . . . . 0.0 108.995 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.431 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 10.0 mmmt -94.93 -14.72 24.2 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.666 -1.152 . . . . 0.0 110.819 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.8 t80 -156.69 141.2 16.75 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 115.042 -0.981 . . . . 0.0 109.896 179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.04 92.44 2.05 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.475 -1.239 . . . . 0.0 108.805 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.426 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.96 92.03 1.46 Allowed Glycine 0 C--O 1.241 0.533 0 CA-C-N 114.35 -1.295 . . . . 0.0 112.658 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.582 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.65 123.7 23.78 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.134 0.974 . . . . 0.0 112.744 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.623 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.62 -0.76 88.21 Favored Glycine 0 CA--C 1.519 0.342 0 CA-C-N 113.369 -1.741 . . . . 0.0 113.59 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.81 -32.31 57.54 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -179.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.54 24.79 2.66 Favored 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.027 -178.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.623 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -81.08 114.05 45.81 Favored Pre-proline 0 N--CA 1.435 -1.211 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -178.182 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.837 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.4 Cg_exo -67.81 162.12 40.95 Favored 'Trans proline' 0 C--N 1.37 1.685 0 C-N-CA 123.727 2.952 . . . . 0.0 111.804 177.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 63.3 m95 -96.1 13.01 28.64 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 176.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 81.9 mtp -80.07 -42.51 23.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.785 179.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.537 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.4 pp -125.76 15.44 8.08 Favored 'General case' 0 N--CA 1.44 -0.956 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.795 177.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.837 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.4 OUTLIER -137.29 108.59 6.85 Favored 'General case' 0 C--N 1.369 1.416 0 C-N-CA 120.022 -0.671 . . . . 0.0 112.612 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 16.8 ttm -113.05 -20.3 11.56 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.416 178.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -91.54 -26.5 18.73 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.581 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 102.78 -128.57 9.59 Favored Glycine 0 CA--C 1.519 0.335 0 O-C-N 123.703 0.627 . . . . 0.0 113.704 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.614 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.5 m-80 -83.25 138.55 33.54 Favored 'General case' 0 C--N 1.346 0.43 0 C-N-CA 123.113 0.565 . . . . 0.0 112.138 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -152.27 145.96 25.03 Favored 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.3 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.63 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.15 120.34 18.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.164 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.7 129.6 56.54 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 178.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' A' ' 54' ' ' THR . 7.7 mt -139.19 150.81 22.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.328 -176.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.63 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.0 OUTLIER -100.24 117.27 34.11 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-N 113.904 -1.498 . . . . 0.0 108.504 178.037 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.631 ' CE1' ' HB3' ' A' ' 51' ' ' ALA . 2.9 m-70 -68.74 -175.91 0.75 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.489 -1.232 . . . . 0.0 114.092 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.22 -17.92 65.03 Favored 'General case' 0 N--CA 1.452 -0.369 0 CA-C-N 114.037 -1.438 . . . . 0.0 114.457 -177.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.65 -9.02 21.29 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 120.876 0.369 . . . . 0.0 110.99 -179.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.71 -6.74 44.85 Favored Glycine 0 N--CA 1.445 -0.747 0 CA-C-N 115.308 -0.86 . . . . 0.0 112.122 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.49 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 2.2 ptt? -67.09 170.48 6.85 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 123.461 0.704 . . . . 0.0 111.465 179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.437 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 70.5 m-70 -114.68 145.42 42.06 Favored 'General case' 0 N--CA 1.44 -0.972 0 C-N-CA 120.609 -0.436 . . . . 0.0 111.218 -178.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -140.68 127.34 20.27 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.051 179.68 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.63 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.63 155.4 16.52 Favored Glycine 0 N--CA 1.441 -0.973 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.698 178.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 3.8 m-85 -134.54 99.46 4.36 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 105.525 -2.028 . . . . 0.0 105.525 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.478 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -112.38 168.02 9.97 Favored 'General case' 0 C--O 1.236 0.362 0 N-CA-C 112.689 0.625 . . . . 0.0 112.689 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 65.68 41.0 4.16 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.449 1.099 . . . . 0.0 111.736 -178.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.602 HD22 HG21 ' A' ' 47' ' ' VAL . 10.9 mt -102.14 167.93 9.7 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.039 178.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.7 t -104.57 -14.47 15.63 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.57 160.56 13.05 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 121.697 0.761 . . . . 0.0 111.861 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.836 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -126.16 149.17 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 113.563 -1.653 . . . . 0.0 110.83 179.045 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -112.56 -6.03 13.97 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.426 -1.261 . . . . 0.0 110.173 178.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.836 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.12 -175.28 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.006 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.642 -176.932 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.9 t -153.17 150.42 29.03 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.835 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.1 m -60.2 128.41 36.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.377 -179.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 85.49 -4.06 0.86 Allowed 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 124.627 1.171 . . . . 0.0 111.674 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.477 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -79.83 148.88 31.2 Favored 'General case' 0 C--N 1.347 0.493 0 N-CA-C 110.254 -0.276 . . . . 0.0 110.254 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.45 145.34 29.02 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.66 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.81 166.38 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.264 -179.271 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 36.7 tttp -141.5 148.48 39.5 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.916 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.794 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.65 138.23 55.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -179.595 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.506 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.88 -5.45 47.93 Favored Glycine 0 CA--C 1.518 0.242 0 CA-C-N 114.252 -1.34 . . . . 0.0 114.238 179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.487 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.5 tt0 -74.5 140.35 44.48 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-O 121.024 0.44 . . . . 0.0 110.184 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 49.0 mt -71.54 101.65 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.034 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.668 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.0 OUTLIER -93.58 -4.87 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.035 -179.02 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.11 -160.52 34.11 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-O 121.137 0.298 . . . . 0.0 112.47 178.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 28.5 m-85 -140.93 138.53 33.91 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.535 1.134 . . . . 0.0 108.377 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -61.11 151.9 29.83 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.625 0.77 . . . . 0.0 112.483 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.748 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -157.71 -164.1 13.46 Favored Glycine 0 C--N 1.346 1.124 0 C-N-CA 120.036 -1.078 . . . . 0.0 114.079 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.624 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.37 49.67 0.89 Allowed 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 114.734 -0.733 . . . . 0.0 109.076 178.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.581 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 25.5 p -80.48 1.38 29.57 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 113.542 0.942 . . . . 0.0 113.542 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -102.14 -160.91 26.4 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.009 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . 0.408 ' O ' HG13 ' A' ' 116' ' ' VAL . 38.3 mt-30 -92.1 91.1 7.64 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.223 0.535 . . . . 0.0 110.657 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 115' ' ' GLN . 0.5 OUTLIER -159.89 165.43 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.865 -179.495 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 14.4 p -96.15 -15.59 22.01 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.358 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -138.68 155.99 23.95 Favored Glycine 0 CA--C 1.53 1.021 0 CA-C-O 119.096 -0.835 . . . . 0.0 113.176 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.624 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.8 Cg_exo -78.81 146.58 20.97 Favored 'Trans proline' 0 C--N 1.374 1.878 0 C-N-CA 122.882 2.388 . . . . 0.0 112.087 179.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.531 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 54.3 p-80 -159.79 -167.24 1.93 Allowed 'General case' 0 C--N 1.347 0.459 0 CA-C-O 121.467 0.651 . . . . 0.0 111.851 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.702 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 11.1 tp -126.18 137.64 53.58 Favored 'General case' 0 N--CA 1.428 -1.536 0 CA-C-N 114.228 -1.351 . . . . 0.0 110.339 -178.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.478 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 28.5 t60 -117.44 126.35 52.49 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 113.895 -1.502 . . . . 0.0 108.287 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.532 ' O ' HG12 ' A' ' 37' ' ' VAL . 32.2 t80 -131.61 108.62 9.65 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.973 178.255 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.516 ' O ' ' HA ' ' A' ' 85' ' ' THR . 12.1 pt-20 -116.62 128.38 55.33 Favored 'General case' 0 N--CA 1.429 -1.49 0 CA-C-N 115.276 -0.874 . . . . 0.0 109.476 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.417 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 3.4 tpt -121.08 136.9 54.88 Favored 'General case' 0 N--CA 1.431 -1.396 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.837 -179.415 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.628 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.11 165.52 25.47 Favored Pre-proline 0 C--N 1.309 -1.169 0 CA-C-N 113.352 -1.749 . . . . 0.0 110.3 -177.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.437 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.8 Cg_endo -63.57 -178.25 0.5 Allowed 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 123.055 2.503 . . . . 0.0 112.9 176.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.44 -28.3 63.88 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.01 176.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -157.03 102.61 1.92 Allowed Pre-proline 0 CA--C 1.503 -0.828 0 CA-C-N 114.218 -1.355 . . . . 0.0 108.771 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.73 163.34 37.47 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.555 2.17 . . . . 0.0 116.603 -177.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.565 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.41 71.51 0.84 Allowed 'General case' 0 N--CA 1.425 -1.693 0 CA-C-N 112.344 -2.207 . . . . 0.0 107.095 177.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.446 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.5 m-90 -63.44 14.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 114.239 -1.346 . . . . 0.0 112.463 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.565 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -82.05 35.52 0.43 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.042 0.937 . . . . 0.0 112.951 -178.197 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 73.06 127.11 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.488 0 C-N-CA 125.53 1.532 . . . . 0.0 110.52 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.41 -50.08 0.56 Allowed Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.396 -0.907 . . . . 0.0 113.353 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.598 ' CE1' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -151.87 -19.86 0.19 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.027 0.414 . . . . 0.0 111.527 179.177 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . 0.402 ' H ' ' H ' ' A' ' 136' ' ' PHE . 27.5 m 65.78 18.01 11.02 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.885 1.274 . . . . 0.0 108.283 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.628 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.11 -11.19 12.45 Favored Glycine 0 N--CA 1.436 -1.305 0 CA-C-N 112.465 -2.152 . . . . 0.0 112.782 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.753 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -82.48 121.8 27.22 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.1 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.418 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.1 OUTLIER -124.64 -172.79 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 CA-C-N 116.015 -0.539 . . . . 0.0 112.355 179.416 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.418 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.9 p30 -79.76 132.05 62.28 Favored Pre-proline 0 CA--C 1.552 1.038 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 -176.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.527 ' O ' HG12 ' A' ' 146' ' ' ILE . 2.1 Cg_endo -77.71 0.04 10.19 Favored 'Trans proline' 0 C--N 1.379 2.153 0 C-N-CA 123.233 2.622 . . . . 0.0 114.204 178.149 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.36 -24.23 7.29 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -178.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -74.5 -23.25 75.92 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.899 179.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 12.6 m-85 -101.12 -12.27 18.93 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 123.62 0.768 . . . . 0.0 111.169 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.527 HG12 ' O ' ' A' ' 142' ' ' PRO . 26.6 mm -101.72 -10.68 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.688 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -73.75 -24.19 59.84 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.84 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.95 14.29 32.38 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.848 0.833 . . . . 0.0 109.447 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.668 ' HB1' ' HD2' ' A' ' 150' ' ' PRO . . . -95.18 169.09 9.89 Favored Pre-proline 0 N--CA 1.417 -2.114 0 CA-C-N 113.846 -1.524 . . . . 0.0 112.314 -179.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.668 ' HD2' ' HB1' ' A' ' 149' ' ' ALA . 12.5 Cg_endo -54.91 178.77 0.08 OUTLIER 'Trans proline' 0 C--N 1.37 1.687 0 C-N-CA 124.352 3.368 . . . . 0.0 113.955 179.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 88.3 t -110.22 133.0 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.325 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.433 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 47.5 t80 -101.92 97.43 7.79 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.23 178.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 67.07 -35.84 0.26 Allowed 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 124.342 1.057 . . . . 0.0 113.452 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 119.47 74.88 0.44 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 111.688 -0.565 . . . . 0.0 111.688 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.1 p -90.88 105.37 17.78 Favored 'General case' 0 N--CA 1.445 -0.71 0 C-N-CA 123.282 0.633 . . . . 0.0 111.376 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.7 p -94.69 150.96 38.77 Favored Pre-proline 0 CA--C 1.54 0.59 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.935 179.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -83.57 -35.73 0.23 Allowed 'Trans proline' 0 C--N 1.373 1.862 0 C-N-CA 122.472 2.115 . . . . 0.0 113.311 179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.525 HG23 ' H ' ' A' ' 159' ' ' GLU . 10.0 t -163.07 -59.9 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 114.707 -1.133 . . . . 0.0 109.849 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.525 ' H ' HG23 ' A' ' 158' ' ' THR . 27.5 mt-10 . . . . . 0 C--O 1.249 1.066 0 CA-C-N 114.039 -1.437 . . . . 0.0 111.575 179.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.508 0.194 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 6.7 ttm180 -90.41 124.93 35.36 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.921 -0.581 . . . . 0.0 111.171 -179.542 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 136.65 130.31 2.88 Favored Glycine 0 C--N 1.339 0.706 0 CA-C-N 115.747 -0.66 . . . . 0.0 112.193 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 60.8 m -102.57 -45.37 5.07 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 111.666 0.247 . . . . 0.0 111.666 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.4 m80 -110.74 128.68 55.83 Favored 'General case' 0 C--O 1.235 0.306 0 O-C-N 123.261 0.351 . . . . 0.0 111.391 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -136.84 -46.59 0.59 Allowed 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.947 179.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -133.99 148.64 51.15 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.788 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.5 t60 -124.19 133.22 53.6 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.74 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.8 m80 -118.73 147.91 43.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.081 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -104.53 154.59 19.72 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.096 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 170.78 70.41 0.04 OUTLIER Glycine 0 C--N 1.338 0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.101 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.07 162.14 14.81 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.741 0.645 . . . . 0.0 112.741 -179.139 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -160.98 118.46 2.37 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.03 176.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 11.3 t -89.45 -13.58 37.27 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.697 0.629 . . . . 0.0 112.697 -178.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 1.1 m-85 -96.99 120.54 37.53 Favored 'General case' 0 CA--C 1.508 -0.67 0 CA-C-O 121.523 0.677 . . . . 0.0 111.823 -179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 31.9 p -99.66 144.52 28.65 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 113.988 -1.46 . . . . 0.0 112.379 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 19' ' ' LEU . 0.5 OUTLIER -80.62 111.88 26.74 Favored Pre-proline 0 CA--C 1.541 0.628 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.401 179.442 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.66 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.7 Cg_exo -66.73 -24.36 47.55 Favored 'Trans proline' 0 C--N 1.366 1.478 0 C-N-CA 122.482 2.121 . . . . 0.0 112.27 178.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.749 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -139.57 -171.84 3.23 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 122.614 1.197 . . . . 0.0 110.213 179.946 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.466 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.02 -25.17 2.8 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 112.241 -2.254 . . . . 0.0 108.792 177.219 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.749 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.4 t -168.95 -168.48 0.86 Allowed 'General case' 0 CA--C 1.546 0.802 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.619 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -178.04 111.9 0.35 Allowed Glycine 0 C--N 1.319 -0.371 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.336 177.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -149.67 124.63 9.96 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 121.888 0.852 . . . . 0.0 112.8 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.733 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.05 58.57 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 113.173 -1.83 . . . . 0.0 108.965 178.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.8 t -102.47 -28.98 11.88 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 112.778 -2.01 . . . . 0.0 110.838 178.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.1 m -113.42 -67.91 0.97 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.6 125.03 1.2 Allowed Glycine 0 C--N 1.323 -0.172 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.037 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.5 ' CE2' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -77.08 157.32 31.14 Favored 'General case' 0 C--N 1.343 0.298 0 N-CA-C 113.167 0.802 . . . . 0.0 113.167 -178.956 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 58.7 m-80 -55.97 32.19 0.0 OUTLIER 'General case' 0 C--O 1.239 0.526 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -177.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.702 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.74 0.94 49.33 Favored Glycine 0 CA--C 1.504 -0.647 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -101.64 85.34 0.64 Allowed Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.0 Cg_exo -77.42 139.66 18.61 Favored 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.748 2.299 . . . . 0.0 113.247 -178.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.19 4.22 78.06 Favored Glycine 0 C--N 1.339 0.714 0 CA-C-N 115.958 -0.565 . . . . 0.0 113.007 179.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.437 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.1 t-80 -75.36 131.4 40.22 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 123.997 0.919 . . . . 0.0 110.458 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.642 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -106.46 -1.98 9.94 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.488 -179.315 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -135.98 -150.21 5.89 Favored Glycine 0 C--N 1.338 0.661 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.685 HG11 ' HG3' ' A' ' 142' ' ' PRO . 11.9 p -132.05 149.19 32.34 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 O-C-N 123.864 0.391 . . . . 0.0 110.618 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.777 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.72 134.0 51.92 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-O 121.322 0.582 . . . . 0.0 112.074 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.66 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -124.57 110.44 14.45 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.354 -1.294 . . . . 0.0 110.131 -178.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.06 107.31 0.29 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 115.813 -0.63 . . . . 0.0 112.117 178.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.563 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.2 p -146.36 127.12 7.16 Favored Pre-proline 0 CA--C 1.549 0.929 0 CA-C-N 115.021 -0.99 . . . . 0.0 109.172 -179.343 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -55.78 143.6 80.15 Favored 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 123.259 2.639 . . . . 0.0 115.583 -178.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.756 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.9 p -62.63 139.26 21.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 111.79 -2.459 . . . . 0.0 113.472 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.9 2.66 55.08 Favored Glycine 0 N--CA 1.442 -0.942 0 CA-C-N 115.366 -0.834 . . . . 0.0 114.063 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.12 120.83 70.74 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 109.85 -0.426 . . . . 0.0 109.85 179.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.2 126.1 21.39 Favored 'Trans proline' 0 C--N 1.376 1.985 0 C-N-CA 122.431 2.087 . . . . 0.0 113.104 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.594 HG21 HD22 ' A' ' 90' ' ' LEU . 4.9 t -98.51 121.15 48.75 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.978 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.498 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 4.5 mpt_? -102.93 152.54 21.18 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 113.264 -1.789 . . . . 0.0 111.443 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -72.42 123.52 23.26 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.7 -1.136 . . . . 0.0 111.587 -178.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.9 t -65.83 -21.57 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.768 0 CA-C-N 115.597 -0.729 . . . . 0.0 112.613 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.646 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -167.69 143.99 4.13 Favored 'General case' 0 CA--C 1.515 -0.39 0 C-N-CA 123.184 0.593 . . . . 0.0 110.653 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -59.94 155.51 16.46 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.191 179.227 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.635 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.17 -126.37 1.4 Allowed Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.777 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 10.4 m -148.26 142.01 25.64 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 123.537 0.735 . . . . 0.0 109.971 -177.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' O ' ' A' ' 99' ' ' SER . 11.6 t -85.95 112.84 23.1 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.405 0 O-C-N 124.028 0.83 . . . . 0.0 108.921 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.6 mmmt -95.15 -14.79 23.84 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.596 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -154.21 140.09 18.19 Favored 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.243 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -146.13 92.37 2.18 Favored 'General case' 0 N--CA 1.448 -0.552 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.781 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.463 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.18 89.87 1.29 Allowed Glycine 0 N--CA 1.451 -0.347 0 CA-C-N 114.141 -1.39 . . . . 0.0 113.368 -179.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.573 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -69.99 124.05 23.09 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.907 0.883 . . . . 0.0 112.552 179.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.574 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.39 -0.63 87.22 Favored Glycine 0 CA--C 1.521 0.443 0 CA-C-N 113.334 -1.757 . . . . 0.0 113.645 -179.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.81 -32.14 46.18 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 113.144 0.794 . . . . 0.0 113.144 -179.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.42 26.93 2.57 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.978 -178.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.57 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.86 115.87 57.03 Favored Pre-proline 0 N--CA 1.436 -1.165 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -178.28 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.85 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.1 Cg_exo -69.49 162.89 40.14 Favored 'Trans proline' 0 C--N 1.37 1.704 0 C-N-CA 123.765 2.976 . . . . 0.0 111.469 177.028 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -98.73 12.36 35.77 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 23.2 mtt -78.36 -44.08 25.98 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 114.539 -1.209 . . . . 0.0 110.149 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.518 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -119.88 10.69 11.63 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.793 177.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.85 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.48 146.31 50.85 Favored 'General case' 0 C--N 1.362 1.151 0 C-N-CA 120.355 -0.538 . . . . 0.0 111.782 -179.01 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 46.1 mtt -139.37 -36.17 0.53 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.443 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -88.79 -21.02 23.99 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.413 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 95.12 -112.81 4.46 Favored Glycine 0 C--N 1.335 0.488 0 CA-C-N 115.587 -0.733 . . . . 0.0 114.12 179.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.574 HD21 ' HA3' ' A' ' 61' ' ' GLY . 13.7 m-80 -80.37 135.7 36.23 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.182 0.593 . . . . 0.0 112.528 -178.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -149.18 146.31 27.58 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.228 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.6 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.32 122.01 17.57 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.094 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -119.5 129.92 54.95 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 177.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -141.08 150.87 20.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 CA-C-N 112.942 -1.935 . . . . 0.0 110.497 -176.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.635 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.48 116.05 30.74 Favored 'General case' 0 N--CA 1.434 -1.251 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.277 177.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.646 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.3 m-70 -68.6 -177.76 1.01 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.528 -1.215 . . . . 0.0 114.121 -178.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -65.59 -17.37 64.53 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.824 -178.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.58 -12.21 21.4 Favored 'General case' 0 C--O 1.236 0.388 0 O-C-N 123.415 0.447 . . . . 0.0 110.732 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.63 -6.57 45.02 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.118 -0.947 . . . . 0.0 112.035 178.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.455 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 12.1 ptt? -71.45 164.69 25.31 Favored 'General case' 0 N--CA 1.436 -1.154 0 C-N-CA 123.135 0.574 . . . . 0.0 111.772 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.455 ' O ' ' HA ' ' A' ' 125' ' ' MET . 53.0 m-70 -105.61 142.78 34.75 Favored 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 120.605 -0.438 . . . . 0.0 111.121 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -137.07 127.17 26.07 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 109.765 -0.458 . . . . 0.0 109.765 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.6 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.41 154.45 16.82 Favored Glycine 0 N--CA 1.442 -0.967 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.699 178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -137.23 98.65 3.78 Favored 'General case' 0 N--CA 1.44 -0.944 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.442 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -116.11 170.42 8.52 Favored 'General case' 0 C--O 1.234 0.284 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 -177.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 54.9 m80 65.59 38.1 5.62 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 124.339 1.056 . . . . 0.0 111.137 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.594 HD22 HG21 ' A' ' 47' ' ' VAL . 11.3 mt -97.94 170.11 9.17 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.966 178.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 17.3 t -104.14 -15.28 15.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 N-CA-C 111.465 0.172 . . . . 0.0 111.465 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 9.0 tttt -168.46 159.55 10.44 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.696 0.76 . . . . 0.0 112.204 -178.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.821 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -124.38 148.98 28.51 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 113.541 -1.663 . . . . 0.0 110.862 178.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 t -113.53 -5.05 13.45 Favored 'General case' 0 N--CA 1.443 -0.792 0 CA-C-N 114.471 -1.241 . . . . 0.0 110.213 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.821 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -106.08 -175.33 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.074 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.553 -177.049 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.6 t -152.23 149.45 28.73 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.841 -179.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -60.32 127.9 34.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.496 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 85.39 -3.61 0.86 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.508 1.123 . . . . 0.0 111.673 179.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.478 ' O ' HG23 ' A' ' 55' ' ' VAL . 40.1 m -79.98 148.95 30.96 Favored 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 122.299 0.24 . . . . 0.0 110.415 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.6 p -83.19 145.68 29.04 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.491 178.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.21 167.66 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.297 0 CA-C-N 115.302 -0.863 . . . . 0.0 112.324 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.418 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 43.0 tttm -141.33 147.98 38.97 Favored 'General case' 0 N--CA 1.428 -1.526 0 CA-C-N 114.559 -1.2 . . . . 0.0 109.957 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.776 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.81 137.49 56.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.378 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.94 -5.64 47.07 Favored Glycine 0 CA--C 1.519 0.334 0 CA-C-N 114.285 -1.325 . . . . 0.0 114.112 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.498 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.4 tt0 -73.87 139.66 45.17 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.108 0.48 . . . . 0.0 110.143 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 57.8 mt -70.94 101.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.62 -179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.569 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.8 OUTLIER -93.72 -4.12 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.61 -1.632 . . . . 0.0 112.937 -179.125 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.49 -161.3 35.11 Favored Glycine 0 N--CA 1.441 -0.995 0 CA-C-O 121.228 0.349 . . . . 0.0 112.737 178.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.572 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 32.0 m-85 -141.5 136.92 31.69 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 124.834 1.253 . . . . 0.0 108.341 179.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.408 HG23 HG22 ' A' ' 47' ' ' VAL . 2.1 p -60.43 152.73 24.83 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.423 0.689 . . . . 0.0 112.08 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.756 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -155.82 -165.44 14.44 Favored Glycine 0 C--N 1.345 1.048 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.915 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.584 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -149.77 45.13 0.93 Allowed 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.565 -0.818 . . . . 0.0 108.953 178.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.3 p -77.88 2.74 16.37 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.636 -177.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -106.3 -165.48 22.89 Favored Glycine 0 C--N 1.336 0.531 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.134 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -87.82 91.71 8.85 Favored 'General case' 0 C--O 1.239 0.525 0 CA-C-O 121.445 0.64 . . . . 0.0 110.046 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.488 HG22 ' H ' ' A' ' 118' ' ' GLY . 9.6 p -158.47 161.86 1.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.25 -178.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 19.0 p -90.92 -16.33 28.3 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.962 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.488 ' H ' HG22 ' A' ' 116' ' ' VAL . . . -144.93 159.2 27.82 Favored Glycine 0 CA--C 1.529 0.935 0 CA-C-O 119.125 -0.82 . . . . 0.0 112.682 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.584 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.4 Cg_exo -73.88 146.35 37.52 Favored 'Trans proline' 0 C--N 1.372 1.794 0 C-N-CA 122.93 2.42 . . . . 0.0 111.916 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.563 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 46.9 p-80 -157.66 -169.7 2.95 Favored 'General case' 0 C--N 1.35 0.605 0 CA-C-O 121.547 0.689 . . . . 0.0 112.401 179.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.777 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.0 tp -126.4 131.81 51.66 Favored 'General case' 0 N--CA 1.432 -1.34 0 CA-C-N 114.049 -1.432 . . . . 0.0 111.166 -177.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 24.8 t60 -114.01 110.08 19.48 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.088 177.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.54 ' O ' HG12 ' A' ' 37' ' ' VAL . 23.1 t80 -117.08 109.23 16.69 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.364 -179.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.1 tt0 -116.22 127.06 54.44 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.208 179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.455 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 2.5 ttt -118.62 134.7 54.91 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 114.638 -1.165 . . . . 0.0 108.679 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.4 mp -142.31 166.6 20.21 Favored Pre-proline 0 C--N 1.31 -1.14 0 CA-C-N 113.297 -1.774 . . . . 0.0 111.004 -177.125 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.453 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.5 Cg_endo -63.32 -178.44 0.47 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 123.027 2.484 . . . . 0.0 112.851 176.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -72.62 -27.06 61.92 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.194 176.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -157.29 98.84 1.96 Allowed Pre-proline 0 CA--C 1.503 -0.835 0 CA-C-N 114.206 -1.361 . . . . 0.0 109.314 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -71.1 163.37 39.44 Favored 'Trans proline' 0 N--CA 1.445 -1.377 0 C-N-CA 122.868 2.379 . . . . 0.0 116.532 -177.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.584 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.2 t-20 -116.76 70.56 0.77 Allowed 'General case' 0 N--CA 1.425 -1.691 0 CA-C-N 112.579 -2.101 . . . . 0.0 107.24 177.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.451 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -62.99 13.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 114.351 -1.295 . . . . 0.0 112.412 -178.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.584 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.76 35.27 0.41 Allowed 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 124.196 0.998 . . . . 0.0 113.083 -178.109 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 73.32 126.29 0.04 OUTLIER 'General case' 0 CA--C 1.512 -0.482 0 C-N-CA 125.509 1.523 . . . . 0.0 110.727 178.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.5 -50.18 0.56 Allowed Glycine 0 N--CA 1.442 -0.902 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.482 -179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.559 ' CE2' ' HA2' ' A' ' 138' ' ' GLY . 0.1 OUTLIER -152.43 -19.73 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 117.102 0.451 . . . . 0.0 111.432 179.257 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 30.1 t 66.45 18.13 10.78 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 125.034 1.334 . . . . 0.0 108.411 -178.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.559 ' HA2' ' CE2' ' A' ' 136' ' ' PHE . . . 77.7 -11.04 21.43 Favored Glycine 0 N--CA 1.436 -1.334 0 CA-C-N 112.66 -2.063 . . . . 0.0 112.8 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.642 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -81.45 127.18 32.52 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 120.081 -0.648 . . . . 0.0 112.117 -179.19 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -126.93 -174.34 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.337 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.033 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -70.34 134.7 86.84 Favored Pre-proline 0 CA--C 1.544 0.731 0 CA-C-N 115.594 -0.73 . . . . 0.0 112.618 -178.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.685 ' HG3' HG11 ' A' ' 37' ' ' VAL . 95.4 Cg_endo -76.7 21.64 0.56 Allowed 'Trans proline' 0 C--N 1.369 1.619 0 C-N-CA 123.162 2.575 . . . . 0.0 114.081 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.9 p -56.04 -24.63 40.69 Favored 'General case' 0 C--N 1.344 0.349 0 C-N-CA 124.228 1.011 . . . . 0.0 113.308 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -72.52 -23.78 77.35 Favored Glycine 0 N--CA 1.462 0.427 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 177.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 3.2 t80 -96.2 -9.7 29.85 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 124.655 1.182 . . . . 0.0 110.43 178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 142' ' ' PRO . 21.1 mm -104.93 -12.47 9.38 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.841 179.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -78.36 -27.96 47.03 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 123.133 0.573 . . . . 0.0 112.271 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . 0.606 ' H ' ' ND2' ' A' ' 148' ' ' ASN . 0.0 OUTLIER -109.54 17.54 21.26 Favored 'General case' 0 N--CA 1.435 -1.216 0 CA-C-N 114.546 -1.207 . . . . 0.0 109.108 -179.379 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -94.34 144.78 28.56 Favored Pre-proline 0 N--CA 1.417 -2.1 0 CA-C-N 113.706 -1.588 . . . . 0.0 112.85 -178.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -57.8 178.93 0.16 Allowed 'Trans proline' 0 C--N 1.362 1.256 0 C-N-CA 124.661 3.574 . . . . 0.0 114.464 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 89.6 t -97.09 132.46 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 C-N-CA 123.872 0.869 . . . . 0.0 111.786 -177.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -101.11 97.36 7.91 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 113.288 -1.778 . . . . 0.0 109.126 178.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 7.6 m-80 66.41 -33.13 0.19 Allowed 'General case' 0 N--CA 1.49 1.542 0 C-N-CA 124.221 1.009 . . . . 0.0 113.628 179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 141.11 71.2 0.03 OUTLIER Glycine 0 C--N 1.338 0.68 0 N-CA-C 111.616 -0.593 . . . . 0.0 111.616 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.8 p -91.39 104.87 17.34 Favored 'General case' 0 N--CA 1.444 -0.735 0 C-N-CA 123.244 0.618 . . . . 0.0 111.622 -178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.6 p -113.98 139.95 24.24 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 114.567 -1.197 . . . . 0.0 110.472 178.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -82.58 -45.12 0.07 OUTLIER 'Trans proline' 0 C--N 1.373 1.841 0 C-N-CA 122.22 1.947 . . . . 0.0 113.302 179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.744 HG23 ' H ' ' A' ' 159' ' ' GLU . 5.3 t -162.72 -67.97 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.163 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.744 ' H ' HG23 ' A' ' 158' ' ' THR . 7.1 mm-40 . . . . . 0 C--O 1.249 1.035 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.487 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.6 mtt . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 120.604 0.24 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 56.8 mtt180 -94.33 125.59 39.06 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.102 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -167.9 87.81 0.1 OUTLIER Glycine 0 C--N 1.337 0.634 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.122 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 11.8 t -129.89 -34.99 1.67 Allowed 'General case' 0 N--CA 1.466 0.339 0 O-C-N 123.708 0.299 . . . . 0.0 111.602 -179.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 72.9 m-70 -89.48 -39.61 13.23 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.0 t-80 -97.33 134.47 40.56 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 123.303 0.377 . . . . 0.0 111.411 -179.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.8 m80 -133.94 150.73 51.31 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.65 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -99.79 -47.46 5.05 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.661 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.3 m80 -130.81 145.26 51.92 Favored 'General case' 0 C--O 1.234 0.281 0 O-C-N 123.245 0.341 . . . . 0.0 111.276 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 4.5 t60 -137.77 -41.89 0.54 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.983 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.85 80.45 0.85 Allowed Glycine 0 C--N 1.341 0.855 0 O-C-N 123.334 0.396 . . . . 0.0 112.388 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -95.52 160.33 14.56 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -163.17 120.38 1.89 Allowed 'General case' 0 N--CA 1.448 -0.558 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.423 176.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.5 t -89.44 -9.97 48.19 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.565 -179.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -102.71 128.67 49.33 Favored 'General case' 0 CA--C 1.503 -0.839 0 CA-C-O 121.524 0.678 . . . . 0.0 112.125 -179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.542 ' HB ' ' HD1' ' A' ' 152' ' ' PHE . 20.9 p -95.21 158.13 15.59 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 113.844 -1.526 . . . . 0.0 112.644 -178.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.65 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.0 OUTLIER -97.83 114.34 64.88 Favored Pre-proline 0 CA--C 1.539 0.532 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.656 179.583 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.762 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 15.7 Cg_exo -71.61 -20.61 26.64 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.65 2.233 . . . . 0.0 113.192 178.12 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.764 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -134.42 -171.81 2.86 Favored 'General case' 0 CA--C 1.508 -0.653 0 CA-C-O 122.736 1.255 . . . . 0.0 110.781 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.477 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.49 -25.09 2.96 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 111.98 -2.373 . . . . 0.0 108.691 177.512 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.764 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -168.58 -169.11 0.99 Allowed 'General case' 0 CA--C 1.55 0.949 0 CA-C-N 114.405 -1.271 . . . . 0.0 111.996 -178.107 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.12 110.66 0.25 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 114.504 -1.226 . . . . 0.0 111.251 176.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -152.39 124.72 8.19 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.714 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -103.37 58.4 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 114.201 -1.363 . . . . 0.0 108.949 178.191 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.7 t -103.27 -28.69 11.72 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 113.066 -1.879 . . . . 0.0 110.852 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.4 m -113.45 -66.8 1.05 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.489 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.17 124.48 1.17 Allowed Glycine 0 C--N 1.323 -0.182 0 CA-C-N 114.885 -1.052 . . . . 0.0 111.865 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.484 ' HD2' ' HB2' ' A' ' 31' ' ' TYR . 0.1 OUTLIER -74.55 157.39 35.57 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 113.696 0.999 . . . . 0.0 113.696 -178.829 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -58.95 32.02 0.01 OUTLIER 'General case' 0 C--O 1.24 0.559 0 N-CA-C 115.451 1.648 . . . . 0.0 115.451 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.709 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.71 -1.56 48.9 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 111.429 -0.669 . . . . 0.0 111.429 179.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.484 ' HB2' ' HD2' ' A' ' 28' ' ' PHE . 7.7 m-85 -102.19 85.37 0.71 Allowed Pre-proline 0 CA--C 1.548 0.868 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.7 Cg_exo -78.71 140.21 16.38 Favored 'Trans proline' 0 C--N 1.376 1.998 0 C-N-CA 122.836 2.358 . . . . 0.0 113.585 -178.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 90.57 4.27 70.56 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.743 -0.662 . . . . 0.0 113.181 179.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.423 ' O ' HG12 ' A' ' 24' ' ' ILE . 4.1 t-80 -79.79 133.0 36.28 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 124.209 1.004 . . . . 0.0 110.032 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.637 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.07 -10.51 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 O-C-N 123.64 0.588 . . . . 0.0 111.779 -178.845 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -129.93 -149.79 6.79 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 112.063 -0.415 . . . . 0.0 112.063 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.558 HG12 ' O ' ' A' ' 123' ' ' PHE . 12.4 p -130.52 151.66 36.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 O-C-N 123.844 0.379 . . . . 0.0 110.522 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.719 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 83.5 m-20 -127.08 132.03 50.73 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.265 0.555 . . . . 0.0 111.408 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.762 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 6.5 m-85 -118.24 111.7 19.14 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-N 114.475 -1.239 . . . . 0.0 111.227 -177.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.42 99.76 0.09 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.548 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.46 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 14.2 p -142.87 129.02 10.47 Favored Pre-proline 0 CA--C 1.547 0.859 0 CA-C-N 115.254 -0.884 . . . . 0.0 109.168 -179.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . 0.432 ' HA ' ' HG2' ' A' ' 119' ' ' PRO . 87.8 Cg_exo -48.82 139.83 24.16 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 123.472 2.782 . . . . 0.0 115.844 -179.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.846 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -66.57 137.34 25.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 111.764 -2.471 . . . . 0.0 113.345 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.27 2.71 51.11 Favored Glycine 0 N--CA 1.441 -1.003 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.908 177.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.8 m -87.76 131.57 43.03 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.238 -0.41 . . . . 0.0 109.976 179.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -60.64 128.32 25.45 Favored 'Trans proline' 0 C--N 1.373 1.864 0 C-N-CA 122.214 1.942 . . . . 0.0 113.004 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.621 HG21 HD22 ' A' ' 90' ' ' LEU . 8.1 t -100.14 123.15 52.82 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.885 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.64 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 19.5 mtt180 -101.95 152.02 21.43 Favored 'General case' 0 N--CA 1.434 -1.264 0 CA-C-N 112.929 -1.941 . . . . 0.0 111.752 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.06 123.67 24.01 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 114.573 -1.194 . . . . 0.0 111.098 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.02 -15.94 20.36 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 115.651 -0.704 . . . . 0.0 112.716 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.639 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.64 143.02 1.66 Allowed 'General case' 0 CA--C 1.517 -0.326 0 C-N-CA 123.349 0.66 . . . . 0.0 110.497 179.181 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.435 ' HB3' ' HA ' ' A' ' 102' ' ' LYS . 0.4 OUTLIER -61.66 155.49 22.42 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.052 -0.976 . . . . 0.0 112.307 179.193 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.581 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.99 -126.26 1.36 Allowed Glycine 0 C--N 1.331 0.302 0 O-C-N 123.792 0.683 . . . . 0.0 113.45 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 7.9 m -147.1 141.52 26.4 Favored 'General case' 0 N--CA 1.436 -1.127 0 C-N-CA 123.576 0.75 . . . . 0.0 109.613 -178.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 99' ' ' SER . 12.2 t -85.04 113.24 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 C-N-CA 123.764 0.826 . . . . 0.0 108.783 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.408 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 7.0 mmmt -95.35 -14.9 23.49 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.675 179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -156.17 140.27 16.44 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.198 179.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.01 92.12 1.93 Allowed 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 114.147 -1.388 . . . . 0.0 108.934 179.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.41 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -93.76 91.27 1.46 Allowed Glycine 0 C--O 1.238 0.386 0 CA-C-N 114.362 -1.29 . . . . 0.0 112.214 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.582 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -70.27 122.34 19.35 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 122.006 0.908 . . . . 0.0 112.857 -179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.632 ' HA2' ' CG ' ' A' ' 64' ' ' HIS . . . -80.77 -0.86 88.82 Favored Glycine 0 CA--C 1.52 0.396 0 CA-C-N 113.201 -1.818 . . . . 0.0 113.565 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.46 -32.91 62.75 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.92 26.69 2.46 Favored 'General case' 0 C--O 1.24 0.563 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.927 -178.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.632 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -82.59 114.13 49.65 Favored Pre-proline 0 N--CA 1.435 -1.192 0 N-CA-C 114.006 1.113 . . . . 0.0 114.006 -178.083 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.823 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 32.8 Cg_exo -67.72 162.31 39.95 Favored 'Trans proline' 0 C--N 1.373 1.825 0 C-N-CA 123.987 3.125 . . . . 0.0 112.239 177.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . 0.401 ' HA ' ' O ' ' A' ' 69' ' ' TRP . 59.8 m95 -95.76 12.23 30.72 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 176.24 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 58.9 mtt -78.42 -42.8 29.07 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.774 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.53 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.7 pp -126.08 14.82 7.89 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.862 177.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.823 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.2 OUTLIER -137.33 113.24 9.7 Favored 'General case' 0 C--N 1.367 1.331 0 C-N-CA 120.188 -0.605 . . . . 0.0 112.581 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 1.8 mpt? -110.83 -33.81 6.43 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.91 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.07 -18.68 33.57 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.513 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 99.52 -126.68 9.0 Favored Glycine 0 CA--C 1.52 0.394 0 O-C-N 123.515 0.51 . . . . 0.0 113.946 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.568 HD21 ' HA3' ' A' ' 61' ' ' GLY . 17.4 m-80 -81.21 145.98 30.71 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 123.738 0.815 . . . . 0.0 112.555 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -152.31 144.85 24.14 Favored 'General case' 0 CA--C 1.519 -0.243 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.438 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.612 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -139.46 120.86 15.72 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.328 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.539 179.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.46 128.01 51.67 Favored 'General case' 0 CA--C 1.492 -1.28 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 178.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 7.7 mt -138.92 151.07 23.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 CA-C-N 112.785 -2.007 . . . . 0.0 110.679 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.581 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -100.2 117.43 34.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 113.691 -1.595 . . . . 0.0 108.903 177.859 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.639 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.2 m-70 -70.04 -176.23 1.09 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 114.137 -1.392 . . . . 0.0 114.196 -179.121 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -65.54 -18.05 65.03 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 113.806 -1.543 . . . . 0.0 114.42 -177.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.08 -9.67 20.35 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.913 0.387 . . . . 0.0 111.016 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.86 -6.49 43.99 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.333 -0.849 . . . . 0.0 112.221 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.456 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 6.5 ptt? -69.36 163.66 24.65 Favored 'General case' 0 N--CA 1.439 -1.007 0 C-N-CA 123.182 0.593 . . . . 0.0 111.621 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.444 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 60.2 m-70 -107.51 144.81 33.97 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 120.745 -0.382 . . . . 0.0 110.892 -178.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -137.96 127.31 24.68 Favored 'General case' 0 N--CA 1.433 -1.277 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.612 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -107.29 154.47 16.61 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.339 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -138.44 98.44 3.59 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 104.221 -2.511 . . . . 0.0 104.221 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB3' ' HB3' ' A' ' 122' ' ' HIS . . . -116.72 173.59 6.55 Favored 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . 0.433 ' CD2' ' HA3' ' A' ' 114' ' ' GLY . 10.7 m80 66.05 20.18 11.22 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 124.505 1.122 . . . . 0.0 112.121 -179.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.621 HD22 HG21 ' A' ' 47' ' ' VAL . 12.1 mt -79.66 172.43 13.79 Favored 'General case' 0 C--O 1.237 0.395 0 C-N-CA 123.708 0.803 . . . . 0.0 111.14 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.4 t -104.99 -15.69 15.04 Favored 'General case' 0 N--CA 1.447 -0.607 0 O-C-N 123.139 0.275 . . . . 0.0 111.555 -179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.432 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 12.3 tttt -168.71 157.52 8.51 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.809 0.814 . . . . 0.0 112.464 -178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.832 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -123.5 150.3 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 CA-C-N 113.467 -1.697 . . . . 0.0 110.97 179.187 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.8 t -114.03 -6.51 13.12 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.508 -1.224 . . . . 0.0 110.181 177.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.832 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.1 OUTLIER -103.36 -175.02 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-N 115.361 -0.836 . . . . 0.0 112.765 -177.064 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 58.8 m -152.89 144.66 23.56 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.62 -1.173 . . . . 0.0 108.985 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.534 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.1 m -57.24 127.93 34.43 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.301 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.534 ' HB2' ' O ' ' A' ' 97' ' ' THR . 0.5 OUTLIER 86.71 -3.55 0.68 Allowed 'General case' 0 N--CA 1.484 1.25 0 C-N-CA 124.606 1.162 . . . . 0.0 111.884 179.436 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.498 ' O ' HG23 ' A' ' 55' ' ' VAL . 50.8 m -81.08 149.19 29.32 Favored 'General case' 0 C--N 1.346 0.456 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 178.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.8 p -83.26 145.28 29.21 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.184 178.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 166.15 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.41 0 CA-C-N 115.329 -0.85 . . . . 0.0 112.346 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.435 ' HA ' ' HB3' ' A' ' 52' ' ' ASN . 62.9 tttt -140.09 148.56 41.91 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.448 -1.251 . . . . 0.0 110.064 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.793 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.1 138.37 56.14 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.132 -1.394 . . . . 0.0 111.332 -179.751 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.64 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.47 -5.89 41.65 Favored Glycine 0 CA--C 1.516 0.145 0 CA-C-N 114.3 -1.318 . . . . 0.0 114.134 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.534 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.1 tt0 -73.28 143.79 46.87 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 122.989 0.515 . . . . 0.0 109.991 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 25.6 mt -74.17 101.65 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.148 0 CA-C-N 115.074 -0.967 . . . . 0.0 109.612 -179.313 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.59 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.5 OUTLIER -93.59 -3.68 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 113.393 -1.73 . . . . 0.0 112.55 -179.236 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.31 -160.84 34.62 Favored Glycine 0 N--CA 1.439 -1.113 0 CA-C-O 121.307 0.393 . . . . 0.0 112.696 178.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.535 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 20.9 m-85 -142.25 137.35 30.63 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 124.875 1.27 . . . . 0.0 108.061 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -58.94 151.88 20.87 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 123.556 0.743 . . . . 0.0 112.356 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.846 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -147.58 -170.79 16.03 Favored Glycine 0 C--N 1.347 1.187 0 C-N-CA 119.834 -1.174 . . . . 0.0 113.655 -179.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.612 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -144.83 44.46 1.36 Allowed 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.779 -0.71 . . . . 0.0 109.173 179.264 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.513 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 37.5 p -81.96 -0.44 44.04 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 113.62 0.971 . . . . 0.0 113.62 -177.338 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.433 ' HA3' ' CD2' ' A' ' 89' ' ' HIS . . . -101.9 -168.63 27.3 Favored Glycine 0 C--N 1.338 0.691 0 C-N-CA 121.112 -0.566 . . . . 0.0 112.636 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -93.46 92.4 7.6 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.317 0.58 . . . . 0.0 110.983 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.71 165.61 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.606 -179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.6 p -79.71 -6.54 57.41 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 112.347 0.499 . . . . 0.0 112.347 -179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -162.98 -170.58 28.06 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 121.19 -0.529 . . . . 0.0 112.92 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.612 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 21.4 Cg_exo -70.84 147.26 55.56 Favored 'Trans proline' 0 C--N 1.365 1.445 0 C-N-CA 123.558 2.839 . . . . 0.0 111.956 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 18.0 m80 -152.0 156.29 39.69 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 122.3 1.048 . . . . 0.0 112.82 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.719 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -117.01 127.96 54.69 Favored 'General case' 0 N--CA 1.431 -1.402 0 CA-C-N 112.566 -2.107 . . . . 0.0 108.297 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 88' ' ' ALA . 23.3 t60 -112.36 109.57 19.27 Favored 'General case' 0 N--CA 1.434 -1.258 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.255 179.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.558 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.73 108.52 16.47 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.931 -179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.475 ' OE1' HD11 ' A' ' 126' ' ' LEU . 21.5 tt0 -120.55 125.86 48.88 Favored 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.621 178.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.653 ' SD ' ' HA ' ' A' ' 142' ' ' PRO . 19.4 ptm -111.74 135.36 52.45 Favored 'General case' 0 N--CA 1.419 -2.011 0 C-N-CA 124.012 0.925 . . . . 0.0 109.579 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.475 HD11 ' OE1' ' A' ' 124' ' ' GLU . 2.8 mp -138.56 165.92 29.27 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.697 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.444 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.7 Cg_endo -63.2 -178.5 0.46 Allowed 'Trans proline' 0 C--N 1.37 1.686 0 C-N-CA 122.969 2.446 . . . . 0.0 112.703 176.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -71.99 -27.21 62.6 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.214 176.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -157.46 101.21 1.87 Allowed Pre-proline 0 CA--C 1.503 -0.851 0 CA-C-N 114.182 -1.372 . . . . 0.0 109.019 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HB3' ' HA3' ' A' ' 138' ' ' GLY . 3.0 Cg_exo -72.89 163.66 37.75 Favored 'Trans proline' 0 N--CA 1.446 -1.284 0 C-N-CA 122.722 2.281 . . . . 0.0 116.592 -177.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.559 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.3 t-20 -118.01 70.73 0.81 Allowed 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 112.482 -2.145 . . . . 0.0 107.339 177.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.442 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.3 m-90 -63.54 14.71 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.317 -1.311 . . . . 0.0 112.696 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.559 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.24 35.49 0.39 Allowed 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 122.121 0.963 . . . . 0.0 112.897 -178.353 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 70.72 127.59 0.03 OUTLIER 'General case' 0 CA--C 1.508 -0.651 0 C-N-CA 125.73 1.612 . . . . 0.0 110.883 178.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 148.98 -49.9 0.57 Allowed Glycine 0 N--CA 1.437 -1.254 0 CA-C-N 114.979 -1.009 . . . . 0.0 113.031 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -150.5 -21.5 0.23 Allowed 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 122.37 0.268 . . . . 0.0 111.43 179.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 26.9 m 66.19 17.94 10.85 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 124.672 1.189 . . . . 0.0 108.454 -178.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.93 -9.73 23.05 Favored Glycine 0 N--CA 1.437 -1.292 0 CA-C-N 112.497 -2.138 . . . . 0.0 112.672 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.637 ' HG2' HG12 ' A' ' 35' ' ' VAL . 2.1 ppt_? -83.18 126.16 32.33 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.42 -174.34 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.474 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.89 178.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.426 ' O ' ' SD ' ' A' ' 125' ' ' MET . 1.8 p30 -79.25 135.58 57.69 Favored Pre-proline 0 CA--C 1.549 0.939 0 N-CA-C 114.06 1.133 . . . . 0.0 114.06 -176.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.653 ' HA ' ' SD ' ' A' ' 125' ' ' MET . 1.0 OUTLIER -76.46 1.4 8.45 Favored 'Trans proline' 0 C--N 1.383 2.39 0 C-N-CA 123.003 2.469 . . . . 0.0 113.244 178.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.67 -23.7 7.1 Favored 'General case' 0 C--N 1.351 0.664 0 N-CA-C 113.706 1.002 . . . . 0.0 113.706 -178.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -68.41 -31.62 74.32 Favored Glycine 0 C--N 1.333 0.387 0 N-CA-C 111.405 -0.678 . . . . 0.0 111.405 179.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . 0.446 ' HE1' ' SD ' ' A' ' 125' ' ' MET . 32.1 m-85 -94.35 -13.49 26.32 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 122.978 0.511 . . . . 0.0 111.53 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.571 HG12 ' O ' ' A' ' 142' ' ' PRO . 14.6 mm -100.98 -9.06 9.04 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.434 -178.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -78.37 -31.51 48.52 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.238 0.542 . . . . 0.0 111.429 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . 0.641 ' H ' ' ND2' ' A' ' 148' ' ' ASN . 0.0 OUTLIER -103.12 14.46 31.74 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-N 114.649 -1.16 . . . . 0.0 109.656 179.789 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -101.01 157.71 33.15 Favored Pre-proline 0 N--CA 1.418 -2.057 0 CA-C-N 113.923 -1.49 . . . . 0.0 112.434 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.45 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 16.4 Cg_endo -55.6 178.6 0.1 Allowed 'Trans proline' 0 C--N 1.367 1.5 0 C-N-CA 124.832 3.688 . . . . 0.0 115.02 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 94.8 t -113.86 134.68 55.91 Favored 'Isoleucine or valine' 0 C--N 1.346 0.452 0 C-N-CA 124.102 0.961 . . . . 0.0 111.365 -177.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.65 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 50.6 t80 -100.72 97.17 7.85 Favored 'General case' 0 CA--C 1.544 0.745 0 CA-C-N 113.985 -1.461 . . . . 0.0 109.894 178.236 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 64.78 -26.26 0.09 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 114.231 1.197 . . . . 0.0 114.231 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.407 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 122.16 75.71 0.36 Allowed Glycine 0 C--N 1.338 0.665 0 N-CA-C 112.066 -0.414 . . . . 0.0 112.066 -179.5 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 10.1 p -92.93 105.04 17.22 Favored 'General case' 0 N--CA 1.445 -0.707 0 C-N-CA 123.34 0.656 . . . . 0.0 111.393 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 12.6 p -121.46 122.06 28.18 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.889 178.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -81.6 -39.91 0.17 Allowed 'Trans proline' 0 C--N 1.375 1.938 0 C-N-CA 122.286 1.991 . . . . 0.0 112.731 179.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.588 HG23 ' H ' ' A' ' 159' ' ' GLU . 8.3 t -161.84 -62.46 0.05 Allowed 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.691 -1.141 . . . . 0.0 109.686 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.588 ' H ' HG23 ' A' ' 158' ' ' THR . 9.1 tt0 . . . . . 0 C--O 1.252 1.186 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.127 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 48.9 mtt . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.576 0.227 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 -133.67 -42.7 0.83 Allowed 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.055 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.95 48.9 0.92 Allowed Glycine 0 C--N 1.34 0.765 0 O-C-N 123.427 0.454 . . . . 0.0 112.679 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 67.2 m -104.96 140.06 38.73 Favored 'General case' 0 C--O 1.234 0.253 0 O-C-N 123.58 0.224 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -124.8 152.85 43.36 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.003 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.1 m80 -96.19 -41.5 8.66 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.653 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 6.7 t-80 -112.81 136.42 52.45 Favored 'General case' 0 C--O 1.235 0.315 0 O-C-N 123.352 0.408 . . . . 0.0 111.066 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 68.2 m80 -124.4 131.54 53.5 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.577 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.01 114.06 27.1 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.731 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -147.52 135.24 21.04 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.218 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 123.84 -130.73 7.75 Favored Glycine 0 C--N 1.337 0.607 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.636 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.46 163.89 13.04 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -179.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.8 109.94 2.11 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.726 176.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.0 t -93.79 -19.45 21.02 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -178.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 2.0 m-85 -100.06 121.67 41.75 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-O 121.642 0.734 . . . . 0.0 112.522 -178.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 18.0 p -102.76 137.1 41.42 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 113.727 -1.579 . . . . 0.0 113.648 -178.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.59 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 0.0 OUTLIER -95.88 113.87 62.96 Favored Pre-proline 0 CA--C 1.54 0.579 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.508 177.71 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.705 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 23.1 Cg_exo -65.68 -26.52 53.33 Favored 'Trans proline' 0 C--N 1.368 1.554 0 C-N-CA 122.699 2.266 . . . . 0.0 113.286 178.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.768 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.41 -172.16 2.88 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 122.682 1.229 . . . . 0.0 110.722 -179.765 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.47 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.2 OUTLIER -129.08 -24.75 2.85 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 111.862 -2.426 . . . . 0.0 108.797 177.407 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.768 ' H ' HD12 ' A' ' 19' ' ' LEU . 7.5 t -168.58 -168.74 0.94 Allowed 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 114.55 -1.205 . . . . 0.0 112.185 -177.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.411 ' HA3' ' CG2' ' A' ' 37' ' ' VAL . . . 172.75 111.43 0.26 Allowed Glycine 0 C--N 1.319 -0.37 0 CA-C-N 114.268 -1.333 . . . . 0.0 111.415 177.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.55 124.69 8.71 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 121.588 0.709 . . . . 0.0 112.764 -178.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.796 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -103.04 58.74 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-N 113.692 -1.595 . . . . 0.0 108.663 178.674 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 5.0 t -100.05 -28.56 12.99 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 112.879 -1.964 . . . . 0.0 110.826 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.8 m -116.93 -66.28 1.1 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.434 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -168.96 125.74 1.3 Allowed Glycine 0 C--N 1.322 -0.199 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.824 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.537 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -73.54 157.36 36.87 Favored 'General case' 0 C--N 1.342 0.278 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.56 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -57.15 31.99 0.0 OUTLIER 'General case' 0 C--O 1.238 0.494 0 N-CA-C 115.778 1.77 . . . . 0.0 115.778 -177.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.689 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 103.12 0.74 48.03 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 111.404 -0.678 . . . . 0.0 111.404 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 3.7 m-85 -102.06 85.4 0.7 Allowed Pre-proline 0 CA--C 1.546 0.816 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.689 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 4.0 Cg_exo -76.73 141.25 21.63 Favored 'Trans proline' 0 C--N 1.374 1.884 0 C-N-CA 122.831 2.354 . . . . 0.0 113.388 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 88.25 4.06 78.05 Favored Glycine 0 C--N 1.339 0.744 0 O-C-N 123.694 0.621 . . . . 0.0 113.091 179.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.453 ' O ' HG12 ' A' ' 24' ' ' ILE . 2.6 t-80 -79.58 129.54 34.56 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 123.886 0.874 . . . . 0.0 110.659 -179.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.671 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -105.17 -5.25 9.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.227 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -131.01 -150.15 6.69 Favored Glycine 0 C--N 1.337 0.602 0 N-CA-C 111.868 -0.493 . . . . 0.0 111.868 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.4 p -131.69 151.5 35.46 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.701 0 C-N-CA 122.824 0.449 . . . . 0.0 110.044 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.743 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 88.0 m-20 -127.23 137.89 52.98 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.222 0.534 . . . . 0.0 111.715 -179.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.705 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 4.3 m-85 -125.4 107.6 10.83 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 114.534 -1.212 . . . . 0.0 110.574 -178.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -59.31 104.9 0.29 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.494 179.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 13.8 p -149.25 129.04 6.5 Favored Pre-proline 0 CA--C 1.549 0.919 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.192 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -53.82 144.18 56.15 Favored 'Trans proline' 0 C--N 1.365 1.441 0 C-N-CA 123.298 2.665 . . . . 0.0 115.149 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.769 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.6 p -61.92 142.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 111.796 -2.456 . . . . 0.0 113.362 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.17 2.53 59.16 Favored Glycine 0 N--CA 1.442 -0.963 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.984 178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -88.83 129.45 48.52 Favored Pre-proline 0 N--CA 1.447 -0.623 0 CA-C-O 119.134 -0.46 . . . . 0.0 109.791 179.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.58 126.91 22.69 Favored 'Trans proline' 0 C--N 1.371 1.742 0 C-N-CA 122.152 1.901 . . . . 0.0 112.965 -179.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.595 HG21 HD22 ' A' ' 90' ' ' LEU . 6.2 t -99.93 124.29 53.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.992 0 CA-C-N 115.274 -0.875 . . . . 0.0 108.863 179.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.601 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 11.1 mtp-105 -101.55 153.57 19.62 Favored 'General case' 0 N--CA 1.433 -1.309 0 CA-C-N 113.18 -1.827 . . . . 0.0 111.843 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.33 121.47 20.48 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.61 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 30.4 t -67.76 -14.98 19.03 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.856 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.672 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.75 143.51 2.13 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 123.376 0.67 . . . . 0.0 110.482 179.001 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.562 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.4 OUTLIER -61.74 156.17 21.0 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.078 -0.965 . . . . 0.0 112.156 179.199 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.689 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 168.61 -127.35 1.52 Allowed Glycine 0 C--N 1.333 0.37 0 C-N-CA 120.806 -0.712 . . . . 0.0 113.996 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 20.4 m -149.48 137.08 20.18 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 -177.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 99' ' ' SER . 10.4 t -83.26 113.82 22.99 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 C-N-CA 123.763 0.825 . . . . 0.0 108.956 -179.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.401 ' HD2' ' N ' ' A' ' 78' ' ' GLN . 0.3 OUTLIER -98.84 -17.08 18.62 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.827 179.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -148.78 139.57 22.83 Favored 'General case' 0 N--CA 1.445 -0.695 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.435 178.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -148.95 92.34 1.96 Allowed 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.904 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -94.56 91.27 1.4 Allowed Glycine 0 C--O 1.24 0.482 0 CA-C-N 114.416 -1.265 . . . . 0.0 112.269 179.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.591 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -73.52 122.85 22.84 Favored 'General case' 0 C--N 1.344 0.358 0 C-N-CA 123.924 0.89 . . . . 0.0 112.57 -179.358 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.604 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.34 -0.73 87.32 Favored Glycine 0 C--N 1.32 -0.349 0 CA-C-N 113.265 -1.789 . . . . 0.0 113.378 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.89 -32.91 57.77 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -179.301 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -138.67 22.58 2.69 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-N 115.894 -0.593 . . . . 0.0 112.233 -178.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.604 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.5 113.45 34.5 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -178.619 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.83 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.3 Cg_exo -66.98 162.88 36.07 Favored 'Trans proline' 0 C--N 1.371 1.743 0 C-N-CA 123.675 2.917 . . . . 0.0 111.705 177.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -95.63 8.1 44.37 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.123 -1.065 . . . . 0.0 108.123 176.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 62.0 mtt -74.81 -44.76 47.61 Favored 'General case' 0 CA--C 1.511 -0.556 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.308 -179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.536 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.52 11.74 10.67 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.824 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.83 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.7 OUTLIER -130.65 143.21 50.59 Favored 'General case' 0 C--N 1.361 1.096 0 C-N-CA 120.503 -0.479 . . . . 0.0 111.412 -179.319 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 5.0 ttt -147.22 -19.78 0.39 Allowed 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.212 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -90.85 -29.17 17.69 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 -179.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.63 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 106.48 -127.38 8.87 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 113.8 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.549 HD21 ' HA3' ' A' ' 61' ' ' GLY . 14.8 m-80 -88.61 139.33 30.58 Favored 'General case' 0 C--O 1.236 0.363 0 C-N-CA 122.894 0.478 . . . . 0.0 111.928 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.48 145.67 23.81 Favored 'General case' 0 CA--C 1.521 -0.168 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.143 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.567 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.5 t -138.34 121.24 19.31 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.174 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.121 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.1 126.87 53.51 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 178.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 8.7 mt -139.95 150.69 21.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-N 112.579 -2.1 . . . . 0.0 110.643 -176.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.689 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.7 tt0 -97.23 116.76 30.02 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 113.921 -1.49 . . . . 0.0 108.33 177.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.672 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.4 m-70 -69.55 -176.91 1.08 Allowed 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 114.122 1.156 . . . . 0.0 114.122 -179.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.562 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -64.97 -17.55 64.5 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 113.69 -1.595 . . . . 0.0 113.966 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.61 -12.9 20.67 Favored 'General case' 0 C--O 1.236 0.345 0 O-C-N 123.449 0.468 . . . . 0.0 110.986 -179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 104.59 -6.77 45.38 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.089 -0.959 . . . . 0.0 111.685 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.717 ' HB2' ' O ' ' A' ' 126' ' ' LEU . 18.5 ptp -70.55 168.23 16.76 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 123.352 0.661 . . . . 0.0 110.364 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.463 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 19.0 p80 -118.16 142.11 47.79 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.142 -1.023 . . . . 0.0 111.203 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.544 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.2 OUTLIER -133.85 128.39 34.57 Favored 'General case' 0 N--CA 1.43 -1.448 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.255 -177.347 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.567 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -101.15 154.8 19.13 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 114.719 -1.128 . . . . 0.0 111.471 177.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.516 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 5.4 m-85 -133.44 99.22 4.45 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -111.32 168.92 9.15 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.925 -0.58 . . . . 0.0 112.556 -177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . 0.554 ' CD2' ' HA3' ' A' ' 114' ' ' GLY . 22.1 m80 65.99 37.24 5.44 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 114.836 -1.074 . . . . 0.0 112.042 -179.456 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.595 HD22 HG21 ' A' ' 47' ' ' VAL . 11.5 mt -98.43 169.58 9.44 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.745 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.3 t -107.83 -14.69 14.72 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 111.623 0.231 . . . . 0.0 111.623 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.408 ' HB3' ' HD2' ' A' ' 109' ' ' TYR . 0.7 OUTLIER -167.66 157.95 10.75 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.595 0.712 . . . . 0.0 111.87 -178.544 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.82 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -123.37 149.42 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.844 179.25 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.3 t -113.34 -6.83 13.53 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.837 177.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.82 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -101.54 -175.04 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.419 -2.02 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.28 -177.4 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.5 m -152.64 145.16 24.13 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.256 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.553 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 3.3 m -57.02 126.14 25.85 Favored 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 115.188 -0.915 . . . . 0.0 111.599 -179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.553 ' HB2' ' O ' ' A' ' 97' ' ' THR . 1.6 m-20 85.37 -2.19 0.83 Allowed 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 124.75 1.22 . . . . 0.0 111.939 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.469 ' O ' HG23 ' A' ' 55' ' ' VAL . 8.7 t -80.74 149.28 29.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 178.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 p -82.86 145.17 29.61 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.294 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.52 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.382 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.334 -179.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 70.2 tttt -142.03 148.93 39.28 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.824 179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.787 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.36 137.95 56.85 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.422 -1.263 . . . . 0.0 111.253 -179.75 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.601 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 76.81 -4.55 52.11 Favored Glycine 0 C--N 1.328 0.089 0 CA-C-N 114.477 -1.238 . . . . 0.0 114.083 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.496 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.8 tt0 -74.2 141.94 45.42 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 121.108 0.48 . . . . 0.0 110.086 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.7 mt -72.37 101.44 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.093 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.525 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 47' ' ' VAL . 1.2 pt -93.57 -6.16 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.88 -179.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 168.83 -159.88 33.15 Favored Glycine 0 N--CA 1.44 -1.067 0 C-N-CA 121.435 -0.412 . . . . 0.0 112.702 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.496 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 31.9 m-85 -140.24 138.07 34.76 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 124.674 1.19 . . . . 0.0 108.355 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.421 HG23 HG22 ' A' ' 47' ' ' VAL . 0.7 OUTLIER -60.24 150.17 30.98 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.567 0.747 . . . . 0.0 112.85 -178.654 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.769 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -148.47 -163.71 10.99 Favored Glycine 0 C--N 1.345 1.06 0 C-N-CA 120.616 -0.802 . . . . 0.0 113.02 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.481 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.33 44.4 0.87 Allowed 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.415 0.626 . . . . 0.0 109.81 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.63 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 67.4 p -83.88 -1.1 53.78 Favored 'General case' 0 CA--C 1.54 0.558 0 CA-C-N 115.415 -0.812 . . . . 0.0 112.953 -178.162 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.554 ' HA3' ' CD2' ' A' ' 89' ' ' HIS . . . -92.56 -120.23 2.75 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.396 -0.43 . . . . 0.0 112.326 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -90.92 154.54 19.39 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 122.301 0.24 . . . . 0.0 111.082 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 20.0 m 49.79 167.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 124.99 1.316 . . . . 0.0 114.073 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.4 p -83.92 4.68 28.47 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.913 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -88.37 116.1 4.54 Favored Glycine 0 CA--C 1.53 1.025 0 CA-C-O 118.987 -0.896 . . . . 0.0 112.803 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.481 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 5.0 Cg_exo -73.45 142.95 33.92 Favored 'Trans proline' 0 C--N 1.375 1.929 0 C-N-CA 122.495 2.13 . . . . 0.0 112.202 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 51.9 p-80 -163.29 -171.09 2.47 Favored 'General case' 0 C--N 1.347 0.499 0 CA-C-O 121.371 0.605 . . . . 0.0 111.414 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.743 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 10.4 tp -124.75 131.08 53.48 Favored 'General case' 0 N--CA 1.432 -1.356 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.487 -178.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 23.8 t60 -112.76 109.92 19.7 Favored 'General case' 0 N--CA 1.434 -1.252 0 CA-C-N 114.405 -1.271 . . . . 0.0 109.436 178.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.539 ' O ' HG12 ' A' ' 37' ' ' VAL . 30.1 t80 -114.43 110.16 19.43 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.015 -179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.544 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -115.01 127.13 55.47 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.4 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.2 ttt -121.87 134.68 54.87 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 114.354 -1.294 . . . . 0.0 109.023 -178.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.717 ' O ' ' HB2' ' A' ' 83' ' ' MET . 2.1 mp -143.46 164.77 28.94 Favored Pre-proline 0 C--N 1.313 -1.022 0 CA-C-N 113.355 -1.748 . . . . 0.0 110.358 -177.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.463 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -61.91 -178.5 0.32 Allowed 'Trans proline' 0 C--N 1.369 1.644 0 C-N-CA 123.291 2.661 . . . . 0.0 113.473 177.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . . . . . . . . . . . -68.99 -28.97 67.09 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.077 176.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -158.01 103.93 1.74 Allowed Pre-proline 0 CA--C 1.503 -0.839 0 CA-C-N 113.896 -1.502 . . . . 0.0 108.607 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -73.5 163.13 38.37 Favored 'Trans proline' 0 N--CA 1.444 -1.44 0 C-N-CA 122.511 2.141 . . . . 0.0 116.746 -176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.558 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -118.2 70.53 0.81 Allowed 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 112.281 -2.236 . . . . 0.0 107.412 177.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.444 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.4 m-90 -62.83 12.5 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.391 -1.277 . . . . 0.0 112.427 -178.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.558 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -82.17 34.18 0.41 Allowed 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 124.224 1.01 . . . . 0.0 112.74 -178.565 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 72.54 128.77 0.04 OUTLIER 'General case' 0 CA--C 1.509 -0.62 0 C-N-CA 125.692 1.597 . . . . 0.0 110.748 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.27 -48.6 0.59 Allowed Glycine 0 N--CA 1.439 -1.161 0 CA-C-N 115.135 -0.939 . . . . 0.0 113.043 -179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.55 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -150.48 -20.72 0.23 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 111.756 0.28 . . . . 0.0 111.756 179.301 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.9 t 66.23 17.71 10.78 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 125.081 1.352 . . . . 0.0 107.989 -178.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.651 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 75.29 -11.31 8.95 Favored Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 112.262 -2.245 . . . . 0.0 112.609 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.671 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -79.11 125.72 29.79 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.321 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -129.84 -175.35 1.38 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 115.838 -0.619 . . . . 0.0 112.004 179.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.431 ' HA ' ' HD3' ' A' ' 142' ' ' PRO . 1.9 p30 -79.74 132.96 59.65 Favored Pre-proline 0 CA--C 1.548 0.893 0 N-CA-C 113.439 0.903 . . . . 0.0 113.439 -177.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.591 ' O ' HG12 ' A' ' 146' ' ' ILE . 5.1 Cg_exo -76.68 -1.89 12.05 Favored 'Trans proline' 0 C--N 1.377 2.071 0 C-N-CA 122.667 2.245 . . . . 0.0 112.932 178.016 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -52.75 -23.24 6.41 Favored 'General case' 0 C--N 1.35 0.627 0 N-CA-C 114.278 1.214 . . . . 0.0 114.278 -178.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -67.67 -31.12 75.46 Favored Glycine 0 CA--C 1.518 0.261 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.334 -179.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 45.3 m-85 -103.39 -11.99 17.5 Favored 'General case' 0 C--O 1.236 0.37 0 O-C-N 123.861 0.389 . . . . 0.0 111.919 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.591 HG12 ' O ' ' A' ' 142' ' ' PRO . 24.5 mm -96.2 -8.71 9.34 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.684 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -76.77 -23.87 52.92 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-N 115.773 -0.648 . . . . 0.0 111.412 178.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -100.92 13.6 34.59 Favored 'General case' 0 N--CA 1.433 -1.308 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.013 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.489 ' HB3' ' O ' ' A' ' 146' ' ' ILE . . . -98.52 158.7 32.1 Favored Pre-proline 0 N--CA 1.415 -2.209 0 CA-C-N 113.422 -1.717 . . . . 0.0 112.548 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.446 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 10.1 Cg_endo -55.02 178.74 0.08 OUTLIER 'Trans proline' 0 C--N 1.365 1.434 0 C-N-CA 124.527 3.485 . . . . 0.0 113.977 179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 91.3 t -115.1 132.87 63.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.304 0 C-N-CA 123.43 0.692 . . . . 0.0 111.61 -177.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.59 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 82.4 t80 -98.96 96.69 8.0 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 114.042 -1.435 . . . . 0.0 109.914 178.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 63.24 -30.97 0.1 Allowed 'General case' 0 N--CA 1.489 1.475 0 C-N-CA 124.312 1.045 . . . . 0.0 113.724 179.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 152' ' ' PHE . . . 111.94 64.67 0.49 Allowed Glycine 0 C--N 1.336 0.577 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.0 p -95.38 105.64 17.62 Favored 'General case' 0 N--CA 1.442 -0.829 0 C-N-CA 123.523 0.729 . . . . 0.0 111.55 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 17.9 p -94.04 125.39 52.98 Favored Pre-proline 0 CA--C 1.54 0.581 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.762 178.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.06 -42.09 0.11 Allowed 'Trans proline' 0 C--N 1.374 1.886 0 C-N-CA 122.368 2.046 . . . . 0.0 113.321 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.64 HG23 ' H ' ' A' ' 159' ' ' GLU . 7.9 t -160.78 -63.98 0.06 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.152 -179.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.64 ' H ' HG23 ' A' ' 158' ' ' THR . 35.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-N 114.385 -1.28 . . . . 0.0 111.778 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 mtt . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 120.596 0.236 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.28 -45.31 4.13 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.263 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 118.89 154.03 9.53 Favored Glycine 0 C--N 1.34 0.776 0 O-C-N 123.433 0.458 . . . . 0.0 112.671 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.4 m -116.5 132.24 56.73 Favored 'General case' 0 C--O 1.235 0.32 0 O-C-N 123.663 0.272 . . . . 0.0 110.751 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -110.99 121.31 45.04 Favored 'General case' 0 C--O 1.235 0.335 0 O-C-N 123.647 0.592 . . . . 0.0 111.306 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.9 m-70 -133.7 141.89 47.76 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.831 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 78.7 m-70 -127.95 115.71 18.96 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.619 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -137.06 -43.17 0.57 Allowed 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.363 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -117.93 148.69 41.93 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 123.382 0.426 . . . . 0.0 111.475 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -101.5 140.56 35.62 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.656 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 146.9 59.83 0.01 OUTLIER Glycine 0 C--N 1.338 0.687 0 O-C-N 123.475 0.485 . . . . 0.0 112.585 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.44 164.48 12.99 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -159.16 113.16 2.36 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.444 176.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.3 t -89.93 5.69 45.3 Favored 'General case' 0 CA--C 1.543 0.692 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.5 -179.182 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -101.59 136.02 42.13 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.48 0.657 . . . . 0.0 111.454 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 51.0 p -94.5 -179.08 4.78 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 113.936 -1.484 . . . . 0.0 112.523 -178.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.4 ' H ' ' HB2' ' A' ' 152' ' ' PHE . 1.1 ttp180 -78.04 112.23 23.86 Favored Pre-proline 0 CA--C 1.545 0.751 0 C-N-CA 123.949 0.9 . . . . 0.0 112.451 -179.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.689 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 22.5 Cg_exo -67.41 -23.22 44.37 Favored 'Trans proline' 0 C--N 1.368 1.569 0 C-N-CA 122.617 2.211 . . . . 0.0 112.273 177.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.746 HD12 ' H ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -136.41 -172.02 3.04 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-O 122.561 1.172 . . . . 0.0 110.509 179.978 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.468 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -128.52 -24.83 2.99 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 112.221 -2.263 . . . . 0.0 108.772 177.233 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.746 ' H ' HD12 ' A' ' 19' ' ' LEU . 6.3 t -168.42 -168.51 0.93 Allowed 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.654 -178.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.428 ' O ' ' HD3' ' A' ' 142' ' ' PRO . . . 179.17 110.99 0.29 Allowed Glycine 0 C--N 1.32 -0.356 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.386 177.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.426 ' HB3' ' CG ' ' A' ' 141' ' ' ASP . 0.9 OUTLIER -152.09 124.65 8.35 Favored 'General case' 0 CA--C 1.506 -0.739 0 CA-C-O 121.531 0.682 . . . . 0.0 112.337 -178.434 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -102.93 58.77 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.533 0 CA-C-N 113.924 -1.489 . . . . 0.0 108.978 178.536 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 6.6 t -105.05 -28.64 10.92 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 112.815 -1.993 . . . . 0.0 111.111 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.3 m -114.42 -66.79 1.05 Allowed 'General case' 0 C--O 1.236 0.366 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.981 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.05 121.4 0.94 Allowed Glycine 0 C--N 1.321 -0.257 0 CA-C-N 115.131 -0.94 . . . . 0.0 112.15 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.483 ' CE1' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -74.72 157.49 35.18 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -178.849 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -57.43 31.71 0.0 OUTLIER 'General case' 0 C--O 1.24 0.561 0 N-CA-C 115.87 1.804 . . . . 0.0 115.87 -177.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.691 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.56 -2.05 49.52 Favored Glycine 0 CA--C 1.505 -0.585 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 5.2 m-85 -101.76 85.47 0.67 Allowed Pre-proline 0 CA--C 1.547 0.861 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.245 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.691 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 5.8 Cg_exo -78.12 138.11 15.94 Favored 'Trans proline' 0 C--N 1.375 1.971 0 C-N-CA 122.785 2.323 . . . . 0.0 113.317 -178.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 92.41 4.31 66.27 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.225 179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -76.52 135.89 39.31 Favored 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 123.79 0.836 . . . . 0.0 110.2 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.611 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -104.19 -18.93 6.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.444 -179.019 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -121.22 -149.85 8.22 Favored Glycine 0 C--N 1.337 0.624 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 123' ' ' PHE . 11.2 p -131.08 148.54 32.98 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 O-C-N 123.855 0.385 . . . . 0.0 110.11 179.242 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.788 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 85.6 m-20 -125.21 135.12 52.26 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.456 0.646 . . . . 0.0 112.148 -178.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.689 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 2.1 m-85 -124.56 110.26 14.23 Favored 'General case' 0 C--O 1.239 0.515 0 CA-C-N 114.231 -1.35 . . . . 0.0 109.803 -178.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -55.31 104.25 0.12 Allowed 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.649 179.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.522 ' H ' ' HA ' ' A' ' 120' ' ' HIS . 14.7 p -144.88 120.75 6.0 Favored Pre-proline 0 CA--C 1.551 1.017 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.563 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 71.3 Cg_exo -49.16 144.68 16.11 Favored 'Trans proline' 0 C--N 1.372 1.773 0 C-N-CA 123.191 2.594 . . . . 0.0 115.525 -179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.706 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.7 p -61.03 139.05 20.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 111.628 -2.533 . . . . 0.0 113.437 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 100.52 2.56 55.47 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.358 -0.837 . . . . 0.0 114.181 177.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.4 m -87.41 127.57 58.29 Favored Pre-proline 0 CA--C 1.54 0.578 0 CA-C-O 119.148 -0.453 . . . . 0.0 109.951 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_exo -59.36 127.27 23.31 Favored 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 122.181 1.921 . . . . 0.0 113.378 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.524 HG21 HD22 ' A' ' 90' ' ' LEU . 11.4 t -99.05 123.8 51.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.28 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.584 ' HG2' ' O ' ' A' ' 104' ' ' GLY . 5.9 mtt180 -102.39 152.42 21.13 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.913 -1.949 . . . . 0.0 111.597 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 102' ' ' LYS . . . -73.47 120.82 19.61 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.771 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 37.3 t -65.51 -16.77 20.89 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.671 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -171.27 144.63 2.05 Favored 'General case' 0 CA--C 1.517 -0.313 0 C-N-CA 123.479 0.711 . . . . 0.0 110.391 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.498 HD21 ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -61.15 156.02 19.27 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.071 -0.968 . . . . 0.0 112.512 179.492 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.657 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.71 -125.88 1.38 Allowed Glycine 0 C--N 1.332 0.335 0 CA-C-N 115.72 -0.673 . . . . 0.0 113.701 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 77' ' ' ILE . 14.3 m -148.22 142.95 26.67 Favored 'General case' 0 N--CA 1.439 -1.025 0 C-N-CA 123.624 0.77 . . . . 0.0 109.706 -178.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 99' ' ' SER . 9.4 t -84.89 112.1 21.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 123.805 0.842 . . . . 0.0 108.881 179.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.444 ' HD2' ' N ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -95.14 -14.96 23.71 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.751 -179.861 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 8.1 t80 -154.38 140.37 18.31 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.045 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -147.85 92.31 2.05 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 114.394 -1.275 . . . . 0.0 108.952 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.412 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -94.63 89.99 1.27 Allowed Glycine 0 C--O 1.24 0.499 0 CA-C-N 114.251 -1.341 . . . . 0.0 112.454 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.58 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.1 m-80 -72.09 122.13 20.43 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.951 0.881 . . . . 0.0 112.822 -179.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.627 ' HA2' ' CD2' ' A' ' 64' ' ' HIS . . . -80.63 -0.94 88.59 Favored Glycine 0 N--CA 1.461 0.301 0 CA-C-N 113.197 -1.82 . . . . 0.0 113.693 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.09 -33.44 59.51 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -138.62 26.91 2.52 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.925 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.627 ' CD2' ' HA2' ' A' ' 61' ' ' GLY . 0.0 OUTLIER -78.9 115.26 50.92 Favored Pre-proline 0 N--CA 1.437 -1.119 0 N-CA-C 113.385 0.883 . . . . 0.0 113.385 -178.372 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 37.4 Cg_exo -68.05 162.95 37.76 Favored 'Trans proline' 0 C--N 1.37 1.671 0 C-N-CA 123.845 3.03 . . . . 0.0 111.789 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -96.25 8.58 43.53 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 1.6 mpt? -74.66 -44.6 49.54 Favored 'General case' 0 CA--C 1.51 -0.572 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.312 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.528 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.6 pp -121.97 11.76 10.35 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.913 177.694 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 1.0 OUTLIER -129.03 144.39 51.17 Favored 'General case' 0 C--N 1.361 1.093 0 C-N-CA 120.159 -0.616 . . . . 0.0 112.237 -178.854 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -146.61 -31.16 0.35 Allowed 'General case' 0 N--CA 1.47 0.525 0 CA-C-N 115.155 -0.929 . . . . 0.0 110.689 178.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -85.62 -19.34 31.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.522 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 96.3 -130.28 10.21 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.967 -0.561 . . . . 0.0 114.112 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.579 HD21 ' HA3' ' A' ' 61' ' ' GLY . 10.1 m-80 -81.11 140.95 34.75 Favored 'General case' 0 C--O 1.237 0.398 0 C-N-CA 123.558 0.743 . . . . 0.0 112.35 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 87' ' ' TYR . . . -153.23 146.56 24.83 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.345 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.572 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -139.93 121.35 15.29 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.265 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.89 130.55 56.31 Favored 'General case' 0 CA--C 1.492 -1.273 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 177.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 54' ' ' THR . 8.4 mt -139.4 150.82 22.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 CA-C-N 112.909 -1.951 . . . . 0.0 110.403 -176.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.657 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 tt0 -99.68 116.18 31.2 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 113.865 -1.516 . . . . 0.0 108.281 177.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.671 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 3.8 m-70 -69.21 -175.47 0.77 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 114.246 1.202 . . . . 0.0 114.246 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.498 ' HB2' HD21 ' A' ' 52' ' ' ASN . . . -65.27 -18.1 65.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 113.982 -1.463 . . . . 0.0 114.619 -177.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.22 -9.18 20.66 Favored 'General case' 0 C--O 1.237 0.445 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.49 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.81 -6.14 43.83 Favored Glycine 0 N--CA 1.445 -0.728 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.154 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.507 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 4.0 ptt? -67.43 165.76 15.98 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 123.595 0.758 . . . . 0.0 111.353 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.496 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 61.9 m-70 -111.41 144.37 40.72 Favored 'General case' 0 N--CA 1.44 -0.929 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.826 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.7 127.06 22.96 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 120.99 0.424 . . . . 0.0 110.345 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.572 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -104.24 154.73 17.61 Favored Glycine 0 N--CA 1.44 -1.09 0 CA-C-N 115.023 -0.989 . . . . 0.0 111.628 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.507 ' O ' ' HA ' ' A' ' 74' ' ' ALA . 4.0 m-85 -136.08 99.06 4.03 Favored 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.409 ' HB3' ' CG ' ' A' ' 122' ' ' HIS . . . -113.66 167.78 10.32 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -177.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . . . . . . . . . 82.1 m-70 65.5 42.28 3.82 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.283 1.033 . . . . 0.0 111.383 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 11.2 mt -103.22 168.58 9.08 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.103 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 8.1 t -102.63 -17.81 15.51 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 111.915 0.339 . . . . 0.0 111.915 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 8.3 tttt -167.16 163.64 15.6 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.722 0.772 . . . . 0.0 111.927 -177.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.829 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.7 OUTLIER -127.56 148.18 32.27 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-N 113.509 -1.678 . . . . 0.0 110.893 179.06 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 t -111.51 -6.6 14.41 Favored 'General case' 0 N--CA 1.443 -0.79 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.886 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.829 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -103.35 -175.24 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.099 0 CA-C-N 115.243 -0.89 . . . . 0.0 112.792 -177.118 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.7 m -153.22 143.42 22.35 Favored 'General case' 0 N--CA 1.445 -0.708 0 CA-C-N 114.674 -1.148 . . . . 0.0 108.936 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -55.76 127.88 32.23 Favored 'General case' 0 CA--C 1.541 0.598 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 t70 86.02 -4.43 0.79 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 124.692 1.197 . . . . 0.0 111.719 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.476 ' O ' HG23 ' A' ' 55' ' ' VAL . 39.5 m -80.44 151.61 29.22 Favored 'General case' 0 C--N 1.347 0.463 0 CA-C-O 120.571 0.224 . . . . 0.0 110.552 178.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.1 p -84.7 145.52 27.91 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.608 178.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.89 169.71 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.314 0 CA-C-N 115.197 -0.91 . . . . 0.0 112.196 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.438 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 1.9 tttt -142.42 148.51 37.93 Favored 'General case' 0 N--CA 1.432 -1.361 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.716 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.791 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -58.34 138.41 56.49 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.361 -179.796 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.584 ' O ' ' HG2' ' A' ' 48' ' ' ARG . . . 77.03 -8.44 30.58 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 114.38 -1.282 . . . . 0.0 114.135 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 26.1 tt0 -70.75 141.29 51.48 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.078 0.466 . . . . 0.0 110.214 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 47.8 mt -72.72 102.05 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.069 0 CA-C-N 114.821 -1.081 . . . . 0.0 109.559 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -93.5 -4.97 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 CA-C-N 113.564 -1.653 . . . . 0.0 113.117 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.66 -160.74 34.44 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 121.472 -0.394 . . . . 0.0 112.749 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.524 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 35.4 m-85 -140.16 138.35 35.12 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 124.669 1.188 . . . . 0.0 108.522 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -62.71 150.93 39.84 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 123.631 0.773 . . . . 0.0 112.552 -179.224 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.706 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -161.37 -160.98 11.23 Favored Glycine 0 C--N 1.348 1.241 0 C-N-CA 119.877 -1.154 . . . . 0.0 114.034 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.416 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -150.2 51.94 0.9 Allowed 'General case' 0 N--CA 1.446 -0.645 0 CA-C-N 114.48 -0.86 . . . . 0.0 108.684 178.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.522 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 21.6 p -80.67 2.76 24.53 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 115.196 -0.911 . . . . 0.0 113.33 -177.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -110.6 -162.26 18.25 Favored Glycine 0 C--N 1.337 0.638 0 N-CA-C 111.857 -0.497 . . . . 0.0 111.857 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 52.6 mt-30 -91.57 91.07 7.88 Favored 'General case' 0 C--O 1.238 0.463 0 CA-C-O 121.301 0.572 . . . . 0.0 110.234 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 3.4 m -151.66 159.01 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.746 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.2 t -85.57 -4.21 59.09 Favored 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -179.519 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -166.5 164.04 37.37 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.634 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.417 ' HB3' ' HB ' ' A' ' 43' ' ' VAL . 6.2 Cg_exo -80.25 139.21 13.07 Favored 'Trans proline' 0 C--N 1.374 1.914 0 C-N-CA 123.302 2.668 . . . . 0.0 112.419 179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.522 ' HA ' ' H ' ' A' ' 41' ' ' VAL . 24.0 p-80 -160.94 -166.34 1.57 Allowed 'General case' 0 C--N 1.348 0.5 0 CA-C-O 121.256 0.551 . . . . 0.0 111.411 179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.788 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 13.3 tp -123.03 130.04 52.28 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.64 -1.163 . . . . 0.0 111.261 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.409 ' CG ' ' HB3' ' A' ' 88' ' ' ALA . 22.6 t60 -112.81 113.0 24.9 Favored 'General case' 0 N--CA 1.434 -1.225 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.815 177.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.527 ' O ' HG12 ' A' ' 37' ' ' VAL . 45.2 t80 -118.53 111.31 18.45 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.138 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.461 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.9 tt0 -118.55 127.21 53.4 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.163 179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.505 ' O ' ' HA ' ' A' ' 139' ' ' ARG . 2.0 tpt -117.61 138.41 51.97 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 115.067 -0.969 . . . . 0.0 108.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 2.7 mp -143.65 166.62 18.72 Favored Pre-proline 0 C--N 1.308 -1.237 0 CA-C-N 113.465 -1.698 . . . . 0.0 111.103 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 12.4 Cg_endo -62.52 -178.48 0.38 Allowed 'Trans proline' 0 C--N 1.37 1.708 0 C-N-CA 123.35 2.7 . . . . 0.0 112.703 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -69.98 -28.05 65.22 Favored 'General case' 0 N--CA 1.439 -0.989 0 CA-C-N 115.417 -0.81 . . . . 0.0 109.247 176.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -156.94 101.28 1.95 Allowed Pre-proline 0 CA--C 1.504 -0.793 0 CA-C-N 114.334 -1.303 . . . . 0.0 108.829 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -72.26 163.18 39.46 Favored 'Trans proline' 0 N--CA 1.444 -1.432 0 C-N-CA 122.698 2.265 . . . . 0.0 116.542 -177.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.579 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.5 t-20 -117.08 70.7 0.78 Allowed 'General case' 0 N--CA 1.424 -1.738 0 CA-C-N 112.543 -2.117 . . . . 0.0 107.491 177.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.454 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.07 12.54 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 114.29 -1.323 . . . . 0.0 112.313 -178.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.579 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.1 OUTLIER -81.61 32.29 0.36 Allowed 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 124.378 1.071 . . . . 0.0 112.815 -178.534 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 73.74 129.1 0.04 OUTLIER 'General case' 0 CA--C 1.51 -0.582 0 C-N-CA 125.825 1.65 . . . . 0.0 110.789 178.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.34 -48.6 0.59 Allowed Glycine 0 N--CA 1.44 -1.085 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.121 -179.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -152.2 -19.77 0.18 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.762 0.315 . . . . 0.0 111.757 179.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 22.6 t 66.34 18.03 10.81 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.975 1.31 . . . . 0.0 108.213 -178.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 74.59 -9.71 10.12 Favored Glycine 0 N--CA 1.437 -1.26 0 CA-C-N 112.582 -2.099 . . . . 0.0 112.904 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.611 ' HG2' HG12 ' A' ' 35' ' ' VAL . 1.5 ppt_? -82.73 127.25 33.25 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 112.689 0.626 . . . . 0.0 112.689 -178.561 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.452 HG22 ' H ' ' A' ' 141' ' ' ASP . 0.2 OUTLIER -129.37 -172.86 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.855 -0.612 . . . . 0.0 112.413 178.478 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.452 ' H ' HG22 ' A' ' 140' ' ' ILE . 1.3 m-20 -71.65 134.86 83.83 Favored Pre-proline 0 CA--C 1.549 0.906 0 N-CA-C 114.577 1.325 . . . . 0.0 114.577 -176.278 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.629 ' O ' HG12 ' A' ' 146' ' ' ILE . 1.6 Cg_endo -77.7 2.03 8.24 Favored 'Trans proline' 0 C--N 1.381 2.265 0 C-N-CA 123.296 2.664 . . . . 0.0 113.297 177.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 1.5 p -51.17 -24.04 3.85 Favored 'General case' 0 C--N 1.347 0.467 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 -178.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -70.52 -28.04 71.69 Favored Glycine 0 CA--C 1.52 0.383 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.867 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -102.4 -9.28 20.44 Favored 'General case' 0 C--O 1.237 0.445 0 O-C-N 124.085 0.52 . . . . 0.0 111.496 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.629 HG12 ' O ' ' A' ' 142' ' ' PRO . 19.5 mm -98.53 -11.29 8.63 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.854 -178.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -75.7 -25.51 56.75 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.019 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.29 16.04 27.02 Favored 'General case' 0 N--CA 1.434 -1.238 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.632 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . . . . . . . . . . . -94.55 157.58 36.92 Favored Pre-proline 0 N--CA 1.419 -2.011 0 CA-C-N 114.109 -1.405 . . . . 0.0 113.121 -178.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_exo -55.54 178.87 0.09 OUTLIER 'Trans proline' 0 C--N 1.367 1.551 0 C-N-CA 124.548 3.498 . . . . 0.0 114.904 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 84.2 t -99.84 130.7 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 CA-C-N 114.559 -1.2 . . . . 0.0 111.152 -178.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . 0.4 ' HB2' ' H ' ' A' ' 17' ' ' ARG . 41.1 t80 -107.4 102.35 11.64 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 113.636 -1.62 . . . . 0.0 108.883 178.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 5.9 m-80 72.74 -40.08 0.46 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 124.517 1.127 . . . . 0.0 112.63 179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . 124.09 88.75 0.83 Allowed Glycine 0 C--N 1.339 0.712 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.151 -179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.2 p -95.3 105.09 17.01 Favored 'General case' 0 N--CA 1.443 -0.817 0 CA-C-O 121.337 0.589 . . . . 0.0 111.292 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 12.6 p -103.2 137.72 19.34 Favored Pre-proline 0 CA--C 1.538 0.511 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.506 178.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.63 -41.57 0.11 Allowed 'Trans proline' 0 C--N 1.373 1.86 0 C-N-CA 122.335 2.023 . . . . 0.0 113.231 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.62 HG23 ' H ' ' A' ' 159' ' ' GLU . 8.5 t -161.67 -63.59 0.05 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.986 -1.007 . . . . 0.0 110.204 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.62 ' H ' HG23 ' A' ' 158' ' ' THR . 31.7 mt-10 . . . . . 0 C--O 1.25 1.094 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.609 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 58.9 mtt . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.659 0.266 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -91.35 140.32 29.89 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.357 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 171.99 80.54 0.05 OUTLIER Glycine 0 C--N 1.336 0.536 0 CA-C-N 115.716 -0.675 . . . . 0.0 112.116 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.1 p -112.66 147.73 36.14 Favored 'General case' 0 C--O 1.235 0.293 0 O-C-N 123.624 0.249 . . . . 0.0 111.305 -179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 89.0 m-70 -102.73 -43.63 5.53 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.882 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 m-70 -106.86 149.17 27.7 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -105.57 149.34 26.36 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.158 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 65.9 m80 -129.51 151.38 50.19 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.752 179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -96.96 146.81 24.61 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.3 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 -136.73 152.59 50.52 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.482 179.315 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -99.59 57.38 0.85 Allowed Glycine 0 C--N 1.338 0.673 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.719 -179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.55 163.63 13.74 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -158.87 102.78 1.67 Allowed 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.732 176.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.6 t -92.04 -4.21 54.75 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.569 -179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -94.33 134.42 36.84 Favored 'General case' 0 CA--C 1.505 -0.765 0 CA-C-O 121.793 0.806 . . . . 0.0 112.67 -178.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 10.1 p -88.27 150.85 23.02 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.276 -1.784 . . . . 0.0 112.466 -178.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.734 ' HD3' ' HB1' ' A' ' 149' ' ' ALA . 0.0 OUTLIER -94.64 113.05 60.14 Favored Pre-proline 0 CA--C 1.538 0.49 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.706 179.742 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.667 ' HB2' ' HB3' ' A' ' 39' ' ' TYR . 45.6 Cg_exo -58.08 -31.1 92.31 Favored 'Trans proline' 0 C--N 1.369 1.611 0 C-N-CA 122.948 2.432 . . . . 0.0 113.147 178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.754 HD12 ' O ' ' A' ' 21' ' ' THR . 0.3 OUTLIER -133.37 -172.12 2.87 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-O 122.5 1.143 . . . . 0.0 110.379 -179.985 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.459 ' H ' ' CD1' ' A' ' 19' ' ' LEU . 0.1 OUTLIER -129.78 -25.71 2.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 112.4 -2.182 . . . . 0.0 108.755 177.288 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.754 ' O ' HD12 ' A' ' 19' ' ' LEU . 6.8 t -169.61 -168.32 0.78 Allowed 'General case' 0 CA--C 1.544 0.738 0 CA-C-N 114.02 -1.445 . . . . 0.0 111.234 -178.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -179.24 110.97 0.3 Allowed Glycine 0 C--N 1.316 -0.574 0 CA-C-N 114.793 -1.094 . . . . 0.0 111.289 176.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -151.52 124.98 8.88 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-O 121.851 0.834 . . . . 0.0 113.053 -177.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.808 ' H ' HD12 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -102.85 58.8 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 113.38 -1.736 . . . . 0.0 108.522 178.373 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 4.9 t -100.94 -28.73 12.59 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 112.595 -2.093 . . . . 0.0 110.856 179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 2.6 m -115.55 -66.58 1.07 Allowed 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.422 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -169.46 122.15 0.98 Allowed Glycine 0 C--N 1.323 -0.173 0 CA-C-N 115.084 -0.962 . . . . 0.0 112.037 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.547 ' CD2' HG13 ' A' ' 24' ' ' ILE . 0.2 OUTLIER -70.89 157.35 38.29 Favored 'General case' 0 C--N 1.344 0.34 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -178.909 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 61.3 m-80 -58.67 31.75 0.01 OUTLIER 'General case' 0 C--O 1.24 0.564 0 N-CA-C 115.66 1.726 . . . . 0.0 115.66 -177.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.698 ' O ' ' HD3' ' A' ' 32' ' ' PRO . . . 102.81 -2.03 48.58 Favored Glycine 0 CA--C 1.505 -0.59 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.545 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -102.52 85.35 0.75 Allowed Pre-proline 0 CA--C 1.547 0.864 0 N-CA-C 108.782 -0.821 . . . . 0.0 108.782 178.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.698 ' HD3' ' O ' ' A' ' 30' ' ' GLY . 6.2 Cg_exo -78.6 138.98 15.71 Favored 'Trans proline' 0 C--N 1.374 1.898 0 C-N-CA 122.881 2.388 . . . . 0.0 113.497 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 94.34 3.93 62.89 Favored Glycine 0 C--N 1.336 0.546 0 CA-C-N 115.85 -0.614 . . . . 0.0 113.375 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.507 ' O ' HG12 ' A' ' 24' ' ' ILE . 3.3 t-80 -80.62 135.06 35.98 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 123.724 0.81 . . . . 0.0 109.83 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.658 HG12 ' HG2' ' A' ' 139' ' ' ARG . 0.0 OUTLIER -103.74 -20.1 5.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.144 -179.383 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -120.35 -149.59 8.33 Favored Glycine 0 C--N 1.335 0.49 0 N-CA-C 111.981 -0.448 . . . . 0.0 111.981 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 142' ' ' PRO . 14.7 p -131.69 151.92 36.17 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.778 0 O-C-N 123.939 0.435 . . . . 0.0 110.274 179.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASP . . . . . 0.763 ' HA ' ' O ' ' A' ' 121' ' ' LEU . 82.8 m-20 -128.25 131.71 48.76 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.172 0.51 . . . . 0.0 111.603 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' TYR . . . . . 0.667 ' HB3' ' HB2' ' A' ' 18' ' ' PRO . 1.6 m-85 -119.76 111.17 17.66 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.648 -178.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.21 102.04 0.15 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.227 177.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 119' ' ' PRO . 13.8 p -143.34 133.48 12.06 Favored Pre-proline 0 CA--C 1.548 0.894 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.853 -178.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -48.51 139.35 23.3 Favored 'Trans proline' 0 C--N 1.366 1.486 0 C-N-CA 123.486 2.791 . . . . 0.0 115.653 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.789 HG23 ' HA2' ' A' ' 111' ' ' GLY . 2.5 p -67.57 143.75 15.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 111.793 -2.458 . . . . 0.0 113.222 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.26 2.78 58.98 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.614 -0.721 . . . . 0.0 113.791 177.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.2 m -86.89 126.86 61.91 Favored Pre-proline 0 N--CA 1.447 -0.611 0 CA-C-O 119.253 -0.403 . . . . 0.0 109.978 179.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_exo -60.13 126.18 19.53 Favored 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.022 1.815 . . . . 0.0 112.974 -179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.508 HG21 HD22 ' A' ' 90' ' ' LEU . 5.4 t -99.86 122.34 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.505 ' HA ' ' O ' ' A' ' 105' ' ' GLN . 2.2 mpt_? -101.7 154.78 18.58 Favored 'General case' 0 N--CA 1.434 -1.273 0 CA-C-N 113.389 -1.732 . . . . 0.0 112.052 -178.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -73.35 124.32 25.52 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.265 -178.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 64.2 t -67.29 -18.45 24.06 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 112.946 0.721 . . . . 0.0 112.946 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.66 ' HB3' ' ND1' ' A' ' 79' ' ' HIS . . . -170.26 144.2 2.52 Favored 'General case' 0 CA--C 1.514 -0.439 0 C-N-CA 123.313 0.645 . . . . 0.0 110.388 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.616 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 0.3 OUTLIER -60.03 157.45 12.85 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.978 179.159 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 78' ' ' GLN . . . 166.13 -124.59 1.25 Allowed Glycine 0 C--N 1.333 0.394 0 C-N-CA 120.768 -0.729 . . . . 0.0 113.781 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.2 m -147.83 143.37 27.42 Favored 'General case' 0 N--CA 1.436 -1.141 0 C-N-CA 123.594 0.758 . . . . 0.0 109.938 -177.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 99' ' ' SER . 9.8 t -86.94 113.06 23.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 123.819 0.848 . . . . 0.0 108.826 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.3 mmmt -95.06 -15.02 23.76 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.621 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -154.48 139.6 17.44 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.221 179.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -149.29 92.33 1.94 Allowed 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.041 -1.436 . . . . 0.0 108.894 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . 0.485 ' O ' HD13 ' A' ' 93' ' ' ILE . . . -96.36 92.36 1.38 Allowed Glycine 0 C--O 1.239 0.443 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.488 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.603 ' N ' HD22 ' A' ' 60' ' ' ASN . 1.0 OUTLIER -71.49 122.57 20.67 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 123.914 0.886 . . . . 0.0 112.796 -179.301 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.582 ' HA3' HD21 ' A' ' 73' ' ' ASN . . . -80.59 -0.7 88.01 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-N 113.352 -1.749 . . . . 0.0 113.358 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.41 -32.7 48.81 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 112.898 0.703 . . . . 0.0 112.898 -179.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -138.32 27.62 2.56 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.744 -178.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.573 ' CG ' ' HA2' ' A' ' 61' ' ' GLY . 0.4 OUTLIER -79.58 113.85 40.62 Favored Pre-proline 0 N--CA 1.435 -1.177 0 N-CA-C 113.404 0.891 . . . . 0.0 113.404 -178.69 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.814 ' HD2' ' NE1' ' A' ' 69' ' ' TRP . 31.9 Cg_exo -66.74 162.59 36.71 Favored 'Trans proline' 0 C--N 1.371 1.73 0 C-N-CA 123.371 2.714 . . . . 0.0 111.166 177.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 59.1 m95 -96.41 9.54 40.95 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' MET . . . . . . . . . . . . . 65.5 mtt -76.31 -44.66 35.88 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.239 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.538 ' HG ' ' CD1' ' A' ' 69' ' ' TRP . 3.5 pp -121.19 11.46 10.86 Favored 'General case' 0 N--CA 1.441 -0.891 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.895 177.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' TRP . . . . . 0.814 ' NE1' ' HD2' ' A' ' 65' ' ' PRO . 0.9 OUTLIER -128.53 138.03 52.05 Favored 'General case' 0 C--N 1.359 0.994 0 C-N-CA 120.359 -0.536 . . . . 0.0 110.842 -179.317 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' MET . . . . . . . . . . . . . 11.6 mmt -143.16 -21.21 0.63 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.769 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -96.32 -28.9 14.28 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.97 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.434 ' HA3' ' OG1' ' A' ' 113' ' ' THR . . . 109.01 -131.02 10.32 Favored Glycine 0 CA--C 1.52 0.387 0 O-C-N 123.767 0.667 . . . . 0.0 113.895 179.447 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.582 HD21 ' HA3' ' A' ' 61' ' ' GLY . 12.2 m-80 -79.23 144.13 34.65 Favored 'General case' 0 C--O 1.235 0.339 0 C-N-CA 123.613 0.765 . . . . 0.0 112.448 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -151.22 144.82 24.96 Favored 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.475 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.562 ' O ' ' HA2' ' A' ' 86' ' ' GLY . 1.6 t -140.46 121.55 14.36 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.287 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.975 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.86 129.02 52.26 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 177.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.435 ' CG1' ' HA ' ' A' ' 55' ' ' VAL . 11.1 mt -141.02 151.18 20.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 CA-C-N 113.145 -1.843 . . . . 0.0 110.863 -176.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLN . . . . . 0.679 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 2.0 tt0 -100.37 115.76 30.75 Favored 'General case' 0 N--CA 1.436 -1.128 0 CA-C-N 113.721 -1.582 . . . . 0.0 107.996 177.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.66 ' ND1' ' HB3' ' A' ' 51' ' ' ALA . 2.2 m-70 -70.08 -177.46 1.37 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 114.347 1.24 . . . . 0.0 114.347 -178.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.616 ' HB2' ' ND2' ' A' ' 52' ' ' ASN . . . -63.45 -17.97 63.26 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 113.744 -1.571 . . . . 0.0 114.179 -177.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -99.31 -11.78 20.92 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 123.444 0.465 . . . . 0.0 110.728 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.444 ' O ' ' HA ' ' A' ' 128' ' ' ALA . . . 104.58 -7.43 46.18 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.031 -0.986 . . . . 0.0 111.81 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.477 ' O ' ' HA ' ' A' ' 78' ' ' GLN . 9.2 ptt? -69.0 163.55 24.37 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 123.286 0.635 . . . . 0.0 111.715 179.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.489 ' HD2' ' O ' ' A' ' 127' ' ' PRO . 63.4 m-70 -105.68 144.78 31.94 Favored 'General case' 0 N--CA 1.437 -1.084 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.986 -179.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 124' ' ' GLU . 0.0 OUTLIER -138.22 126.84 23.52 Favored 'General case' 0 N--CA 1.441 -0.916 0 O-C-N 123.633 0.583 . . . . 0.0 109.815 -179.519 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.562 ' HA2' ' O ' ' A' ' 75' ' ' VAL . . . -106.38 154.27 16.86 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.531 178.618 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -140.94 98.48 3.39 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 104.338 -2.467 . . . . 0.0 104.338 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 173.68 6.79 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 113.711 1.004 . . . . 0.0 113.711 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' HIS . . . . . 0.513 ' CE1' ' HA3' ' A' ' 114' ' ' GLY . 86.3 m-70 65.68 24.35 11.58 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 124.577 1.151 . . . . 0.0 111.642 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.575 ' HB3' ' O ' ' A' ' 109' ' ' TYR . 10.2 mt -84.01 170.96 13.4 Favored 'General case' 0 C--O 1.235 0.33 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.577 178.529 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 13.3 t -105.19 -13.82 15.58 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 111.567 0.21 . . . . 0.0 111.567 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.7 tttp -166.82 158.15 12.56 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.749 0.785 . . . . 0.0 112.551 -178.321 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.822 HG23 ' H ' ' A' ' 95' ' ' VAL . 0.8 OUTLIER -126.06 147.43 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 CA-C-N 113.602 -1.635 . . . . 0.0 110.87 179.014 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 t -111.26 -6.63 14.51 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 114.475 -1.239 . . . . 0.0 109.936 177.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.822 ' H ' HG23 ' A' ' 93' ' ' ILE . 0.0 OUTLIER -102.6 -175.24 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.035 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.736 -177.13 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.1 m -151.88 140.48 20.74 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.938 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -55.07 128.99 36.3 Favored 'General case' 0 CA--C 1.54 0.577 0 CA-C-N 115.406 -0.816 . . . . 0.0 111.412 -179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 85.68 -4.92 0.84 Allowed 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.594 1.158 . . . . 0.0 112.001 179.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.481 ' O ' HG23 ' A' ' 55' ' ' VAL . 46.0 m -80.48 152.72 28.59 Favored 'General case' 0 C--N 1.347 0.457 0 CA-C-O 120.514 0.197 . . . . 0.0 110.739 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 p -85.06 145.1 27.84 Favored 'General case' 0 N--CA 1.447 -0.584 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.377 178.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.7 168.2 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.32 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.333 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 74.5 tttt -139.64 148.98 43.2 Favored 'General case' 0 N--CA 1.427 -1.589 0 CA-C-N 114.493 -1.23 . . . . 0.0 109.803 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . 0.79 HE21 ' C ' ' A' ' 103' ' ' GLN . 0.0 OUTLIER -57.94 138.89 55.42 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.231 -1.349 . . . . 0.0 111.421 -179.691 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 76.78 -7.29 34.89 Favored Glycine 0 CA--C 1.517 0.165 0 CA-C-N 114.39 -1.277 . . . . 0.0 114.093 179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 48' ' ' ARG . 24.4 tt0 -71.89 142.92 49.52 Favored 'General case' 0 CA--C 1.51 -0.593 0 C-N-CA 122.971 0.508 . . . . 0.0 110.131 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 32.9 mt -72.65 100.86 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.49 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.491 ' H ' HG13 ' A' ' 107' ' ' ILE . 1.0 OUTLIER -94.25 -3.99 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.947 0 CA-C-N 113.331 -1.759 . . . . 0.0 112.952 -178.902 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 170.71 -168.37 41.46 Favored Glycine 0 N--CA 1.438 -1.212 0 CA-C-O 121.353 0.418 . . . . 0.0 112.752 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.575 ' O ' ' HB3' ' A' ' 90' ' ' LEU . 34.0 m-85 -139.59 134.29 31.92 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 124.718 1.207 . . . . 0.0 108.023 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -56.61 150.49 15.5 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 123.477 0.711 . . . . 0.0 112.459 -178.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.789 ' HA2' HG23 ' A' ' 43' ' ' VAL . . . -146.11 -171.11 15.26 Favored Glycine 0 C--N 1.347 1.152 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.526 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.594 ' HB2' ' HA ' ' A' ' 119' ' ' PRO . . . -143.86 43.1 1.46 Allowed 'General case' 0 N--CA 1.441 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 109.302 179.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.434 ' OG1' ' HA3' ' A' ' 72' ' ' GLY . 36.5 p -81.72 -0.3 42.26 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.109 -0.95 . . . . 0.0 112.868 -178.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.513 ' HA3' ' CE1' ' A' ' 89' ' ' HIS . . . -100.87 179.19 28.78 Favored Glycine 0 C--N 1.338 0.67 0 C-N-CA 121.394 -0.431 . . . . 0.0 112.485 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -85.01 91.76 8.17 Favored 'General case' 0 CA--C 1.54 0.584 0 CA-C-O 121.626 0.727 . . . . 0.0 110.685 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.11 166.12 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.706 -178.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.2 p -78.14 -3.78 44.2 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -170.26 -168.16 31.71 Favored Glycine 0 CA--C 1.528 0.874 0 CA-C-O 119.617 -0.546 . . . . 0.0 113.133 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' PRO . . . . . 0.594 ' HA ' ' HB2' ' A' ' 112' ' ' ALA . 23.0 Cg_exo -68.84 147.34 68.55 Favored 'Trans proline' 0 C--N 1.367 1.55 0 C-N-CA 123.526 2.817 . . . . 0.0 112.268 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 10.4 m80 -149.45 158.44 44.18 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-O 122.313 1.054 . . . . 0.0 113.144 -178.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.763 ' O ' ' HA ' ' A' ' 38' ' ' ASP . 12.0 tp -120.47 125.09 47.02 Favored 'General case' 0 N--CA 1.436 -1.13 0 CA-C-N 112.51 -2.132 . . . . 0.0 109.402 179.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 19.1 t60 -110.88 111.01 21.85 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 114.854 -1.066 . . . . 0.0 109.832 178.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.53 ' O ' HG12 ' A' ' 37' ' ' VAL . 40.4 t80 -115.49 112.59 22.48 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.635 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.446 ' O ' ' HA ' ' A' ' 85' ' ' THR . 17.0 tt0 -119.26 140.04 50.91 Favored 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.349 179.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' MET . . . . . 0.447 ' HA ' ' O ' ' A' ' 84' ' ' HIS . 17.0 tpp -132.72 136.92 46.69 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.819 -179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.581 ' HA ' ' O ' ' A' ' 138' ' ' GLY . 1.8 mp -143.98 165.47 24.03 Favored Pre-proline 0 C--N 1.312 -1.048 0 CA-C-N 113.714 -1.585 . . . . 0.0 110.419 -178.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' O ' ' HD2' ' A' ' 84' ' ' HIS . 13.6 Cg_endo -63.53 -178.55 0.52 Allowed 'Trans proline' 0 C--N 1.367 1.511 0 C-N-CA 122.949 2.433 . . . . 0.0 112.746 176.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ALA . . . . . 0.444 ' HA ' ' O ' ' A' ' 82' ' ' GLY . . . -71.92 -27.46 62.84 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.205 176.245 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -156.75 101.38 1.99 Allowed Pre-proline 0 CA--C 1.504 -0.802 0 CA-C-N 114.25 -1.341 . . . . 0.0 108.741 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -72.34 163.43 38.67 Favored 'Trans proline' 0 N--CA 1.443 -1.441 0 C-N-CA 122.625 2.217 . . . . 0.0 116.633 -177.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.574 ' C ' ' H ' ' A' ' 133' ' ' GLN . 1.4 t-20 -118.18 71.53 0.83 Allowed 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 112.421 -2.172 . . . . 0.0 107.275 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.443 ' N ' ' NE2' ' A' ' 133' ' ' GLN . 2.6 m-90 -63.47 14.91 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 114.266 -1.334 . . . . 0.0 112.421 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.574 ' H ' ' C ' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -81.81 32.94 0.37 Allowed 'General case' 0 N--CA 1.445 -0.71 0 CA-C-O 122.13 0.967 . . . . 0.0 112.833 -178.456 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 9.0 m-80 72.41 128.76 0.03 OUTLIER 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 125.792 1.637 . . . . 0.0 110.96 178.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 149.07 -48.7 0.6 Allowed Glycine 0 N--CA 1.437 -1.287 0 CA-C-N 114.917 -1.038 . . . . 0.0 113.109 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.572 ' O ' ' HG3' ' A' ' 139' ' ' ARG . 0.1 OUTLIER -150.51 -21.09 0.23 Allowed 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 179.558 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' SER . . . . . . . . . . . . . 18.6 t 66.42 18.01 10.77 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 124.806 1.243 . . . . 0.0 108.121 -178.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 126' ' ' LEU . . . 76.97 -11.56 14.63 Favored Glycine 0 N--CA 1.436 -1.315 0 CA-C-N 112.439 -2.164 . . . . 0.0 112.683 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ARG . . . . . 0.658 ' HG2' HG12 ' A' ' 35' ' ' VAL . 0.0 OUTLIER -80.62 125.59 30.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -125.34 -175.79 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.029 179.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 5.0 p30 -76.65 137.85 66.81 Favored Pre-proline 0 CA--C 1.548 0.884 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.584 ' HG3' HG11 ' A' ' 37' ' ' VAL . 76.5 Cg_endo -76.21 20.43 0.57 Allowed 'Trans proline' 0 C--N 1.373 1.856 0 C-N-CA 123.21 2.606 . . . . 0.0 114.559 178.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 5.6 p -56.95 -24.99 56.98 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.154 0.982 . . . . 0.0 113.579 -179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -75.12 -23.71 73.51 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 178.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' TYR . . . . . . . . . . . . . 5.2 t80 -95.53 -10.56 29.33 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 124.607 1.163 . . . . 0.0 110.668 179.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 142' ' ' PRO . 30.0 mm -107.16 -12.27 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.771 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ALA . . . . . . . . . . . . . . . -76.13 -29.27 57.75 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.899 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ASN . . . . . 0.635 ' H ' ' ND2' ' A' ' 148' ' ' ASN . 0.0 OUTLIER -104.1 9.39 36.37 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 114.637 -1.165 . . . . 0.0 109.387 179.648 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ALA . . . . . 0.734 ' HB1' ' HD3' ' A' ' 17' ' ' ARG . . . -103.23 152.96 38.72 Favored Pre-proline 0 N--CA 1.416 -2.173 0 CA-C-N 114.169 -1.378 . . . . 0.0 112.212 -179.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.559 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 77.7 Cg_exo -55.03 178.91 0.08 OUTLIER 'Trans proline' 0 C--N 1.364 1.364 0 C-N-CA 124.605 3.537 . . . . 0.0 114.824 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 93.7 t -110.16 129.75 64.6 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.7 -178.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' PHE . . . . . . . . . . . . . 81.4 t80 -105.15 98.15 7.89 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.79 179.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ASN . . . . . . . . . . . . . 8.3 m-80 53.85 20.67 2.42 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLY . . . . . . . . . . . . . . . -112.83 63.79 0.28 Allowed Glycine 0 C--N 1.339 0.704 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 179.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 22.3 p -102.15 105.14 15.79 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 123.224 0.61 . . . . 0.0 111.609 -179.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' THR . . . . . . . . . . . . . 16.5 p -109.34 140.43 22.03 Favored Pre-proline 0 CA--C 1.537 0.451 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.289 178.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -82.82 -43.0 0.09 OUTLIER 'Trans proline' 0 C--N 1.373 1.855 0 C-N-CA 122.278 1.985 . . . . 0.0 113.108 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.639 HG23 ' H ' ' A' ' 159' ' ' GLU . 9.2 t -160.55 -64.02 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.12 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' GLU . . . . . 0.639 ' H ' HG23 ' A' ' 158' ' ' THR . 31.4 mt-10 . . . . . 0 C--O 1.249 1.078 0 CA-C-N 114.461 -1.245 . . . . 0.0 111.637 179.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' UNL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_